<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002130.pub3" GROUP_ID="VASC" ID="432200012018230932" MERGED_FROM="" MODIFIED="2013-11-07 09:13:42 +0000" MODIFIED_BY="Fiona Taylor" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-10-23 12:16:43 +0530" NOTES_MODIFIED_BY="Fiona Taylor" REVIEW_NO="9819" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-10-23 12:16:43 +0530" MODIFIED_BY="Fiona Taylor">
<TITLE MODIFIED="2009-12-30 16:25:57 +0530" MODIFIED_BY="Xavier Bosch">Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes</TITLE>
<CONTACT>
<PERSON ID="13807" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Xavier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bosch</LAST_NAME>
<SUFFIX>MD, PhD, FESC</SUFFIX>
<POSITION>Director, Coronary Care Unit</POSITION>
<EMAIL_1>xbosch@clinic.ub.es</EMAIL_1>
<EMAIL_2>xbosch@clinic.ub.es</EMAIL_2>
<URL/>
<MOBILE_PHONE>+34 622255809</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Cardiology</DEPARTMENT>
<ORGANISATION>Hospital Clinic, University of Barcelona</ORGANISATION>
<ADDRESS_1>Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)</ADDRESS_1>
<ADDRESS_2>Villarroel 170</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08036</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 2279305</PHONE_1>
<PHONE_2/>
<FAX_1>+34 932275749</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-10-23 12:11:04 +0530" MODIFIED_BY="Fiona Taylor">
<PERSON ID="13807" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Xavier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bosch</LAST_NAME>
<SUFFIX>MD, PhD, FESC</SUFFIX>
<POSITION>Director, Coronary Care Unit</POSITION>
<EMAIL_1>xbosch@clinic.ub.es</EMAIL_1>
<EMAIL_2>xbosch@clinic.ub.es</EMAIL_2>
<URL/>
<MOBILE_PHONE>+34 622255809</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Cardiology</DEPARTMENT>
<ORGANISATION>Hospital Clinic, University of Barcelona</ORGANISATION>
<ADDRESS_1>Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)</ADDRESS_1>
<ADDRESS_2>Villarroel 170</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08036</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 2279305</PHONE_1>
<PHONE_2/>
<FAX_1>+34 932275749</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13895" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jaume</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Marrugat</LAST_NAME>
<SUFFIX>MD, PhD, FESC</SUFFIX>
<POSITION/>
<EMAIL_1>jmarrugat@imim.es</EMAIL_1>
<EMAIL_2/>
<URL>http://www.regicor.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Program of Research in Inflammatory and Cardiovascular Disorders (RICAD) Institut</DEPARTMENT>
<ORGANISATION>Municipal d'Investigacio Medica</ORGANISATION>
<ADDRESS_1>Dr. Aiguader, 88</ADDRESS_1>
<ADDRESS_2/>
<CITY>Barcelona</CITY>
<ZIP>08003</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 3160710</PHONE_1>
<PHONE_2/>
<FAX_1>+34 93 3160796</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="30210230526096559009100104122010" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Juan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sanchis</LAST_NAME>
<SUFFIX>MD, PhD, FESC</SUFFIX>
<POSITION>Professor of Medicine</POSITION>
<EMAIL_1>sanchis_juafor@gva.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiology Department</DEPARTMENT>
<ORGANISATION>Hospital Clinic, Department of Medicine, University of Valencia</ORGANISATION>
<ADDRESS_1>Blasco Ibanez 17</ADDRESS_1>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP>46010</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-10-21 20:38:03 +0530" MODIFIED_BY="Xavier Bosch">
<UP_TO_DATE>
<DATE DAY="9" MONTH="5" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="1" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="9" MONTH="5" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-23 12:16:43 +0530" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-10-23 12:16:43 +0530" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Summary of findings table was replaced with additional tables to summarise risk of bias. Minor correction was made to the 'Implication for practice' section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-10-03 15:38:08 +0530" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Twelve new studies were added, 10 in the PCI group and two in the group of patients with NSTEACS that were treated with IIb/IIIa blockers as initial medical treatment.</P>
<P>Conclusions about IIb/IIIa blockers during PCI were slightly changed: treatment with IIb/IIIa blockers was not associated with a significant reduction in mortality at six months.</P>
<P>Conclusions about IIb/IIIa blockers as initial treatment of NSTEACS were unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-10-23 12:12:27 +0530" MODIFIED_BY="Joey Kwong">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-23 12:12:27 +0530" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Searches re-run in January 2013.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-10-03 15:38:02 +0530" MODIFIED_BY="Xavier Bosch">
<DATE DAY="12" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>Change in authors.</P>
<P>Ten new studies in the PCI group were added, five performed during primary PCI in patients with STEMI, four in patients with stable CAD and one in a mixed population. Four of these 10 studies were performed in patients pre-treated with clopidogrel.</P>
<P>No new studies were added to the group of patients with non-STEACS in which IIb/IIIa blockers were given as initial medical treatment. However, two studies that were previously analysed in the PCI group based on preliminary data from congress reports have been finally included in this group.</P>
<P>Conclusions about IIb/IIIa blockers during PCI were slightly changed to underline that the results were homogeneous for all the subgroups that have been analysed except for patients pretreated with clopidogrel where these drugs seem to be effective only in patients with an ACS.</P>
<P>Conclusions about IIb/IIIa blockers as initial treatment of NSTEACS were unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-10-03 15:39:13 +0530" MODIFIED_BY="Joey Kwong">
<DATE DAY="9" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-10-03 15:39:13 +0530" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="12" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-10-02 16:17:00 +0530" MODIFIED_BY="Xavier Bosch">
<INTERNAL_SOURCES MODIFIED="2013-10-02 16:17:00 +0530" MODIFIED_BY="Xavier Bosch">
<SOURCE>
<NAME>University of Barcelona</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-04-17 21:42:30 +0530" MODIFIED_BY="Xavier Bosch">
<NAME>Institut d&#8217;Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-10-02 16:17:00 +0530" MODIFIED_BY="Xavier Bosch">
<NAME>Institut Municipal d'Investigació Medica, Barcelona</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-10-02 16:16:24 +0530" MODIFIED_BY="Xavier Bosch">
<SOURCE>
<NAME>FIS PI050120, Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-04-17 21:43:59 +0530" MODIFIED_BY="Xavier Bosch">
<NAME>FIS PI07/0640. Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-04-10 21:30:30 +0530" MODIFIED_BY="Xavier Bosch">
<NAME>Red HERACLES RD06/0009, Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-10-02 16:16:24 +0530" MODIFIED_BY="Xavier Bosch">
<NAME>EUPHORIC Project (Ref. 2003/134)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-10-21 21:06:39 +0530" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-10-03 15:40:06 +0530" MODIFIED_BY="Xavier Bosch">
<TITLE MODIFIED="2013-05-09 21:52:41 +0530" MODIFIED_BY="Xavier Bosch">Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial treatment of acute coronary syndromes</TITLE>
<SUMMARY_BODY MODIFIED="2013-10-03 15:40:06 +0530" MODIFIED_BY="Xavier Bosch">
<P>During the last two decades, doctors have been looking for the best treatment to prevent clots in the coronary arteries of patients with coronary heart disease. This review summarises the results of 60 studies which used a potent class of intravenous antiplatelet drugs - glycoprotein IIb-IIIa blockers - in 66,689 participants. This treatment was tested in two different conditions: in patients undergoing coronary angioplasty (inserting a deflated small balloon in the artery and expand it to open the vessel) with or without inserting a stent (a thin metal expandable tube or sleeve to scaffold the artery open); and as the initial treatment of patients hospitalised for unstable angina and non-ST segment elevation acute myocardial infarction (prolonged coronary chest pain with or without small myocardial infarction). The evidence is up to date as January 2013 and the overall quality of the body of evidence was good.</P>
<P>Overall, the use of these drugs during coronary angioplasty with or without inserting a stent reduced the risk of death at 30 days, and the risk of death or myocardial infarction at 30 days and at six months. The results were similar for stable and for unstable patients with coronary artery disease, but there was comparatively less benefit for patients previously treated with clopidogrel, an oral antiplatelet drug. On the other side, these drugs only slightly reduced the risk of death or myocardial infarction when administered as initial medical treatment in patients with unstable angina or non-ST-elevation myocardial infarction. The benefits of glycoprotein IIb/IIIa blockers need to be balanced against the increased risk of bleeding.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-10-02 18:10:44 +0530" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-10-02 18:10:44 +0530" MODIFIED_BY="Xavier Bosch">
<P>During percutaneous coronary intervention (PCI), and in non-ST segment elevation acute coronary syndromes (NSTEACS), the risk of acute vessel occlusion by thrombosis is high. Glycoprotein IIb/IIIa blockers strongly inhibit platelet aggregation and may prevent mortality and myocardial infarction. This is an update of a Cochrane review first published in 2001, and previously updated in 2007 and 2010.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Xavier Bosch">
<P>To assess the efficacy and safety effects of glycoprotein IIb/IIIa blockers when administered during PCI, and as initial medical treatment in patients with NSTEACS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Nicole Ackermann">
<P>We updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL) on <I>The Cochrane Library </I>(Issue 12, 2012), MEDLINE (OVID, 1946 to January Week 1 2013) and EMBASE (OVID, 1947 to Week 1 2013) on 11 January 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-04-29 22:03:07 +0530" MODIFIED_BY="Xavier Bosch">
<P>Randomised controlled trials comparing intravenous IIb/IIIa blockers with placebo or usual care.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Joey Kwong">
<P>Two authors independently selected studies for inclusion, assessed trial quality and extracted data. We collected major bleeding as adverse effect information from the trials. We used odds ratios (OR) and 95% confidence intervals (CI) for effect measures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="[Empty name]">
<P>Sixty trials involving 66,689 patients were included. During PCI (48 trials with 33,513 participants) glycoprotein IIb/IIIa blockers decreased all-cause mortality at 30 days (OR 0.79, 95% CI 0.64 to 0.97) but not at six months (OR 0.90, 95% CI 0.77 to 1.05). All-cause death or myocardial infarction was decreased both at 30 days (OR 0.66, 95% CI 0.60 to 0.72) and at six months (OR 0.75, 95% CI 0.64 to 0.86), although severe bleeding was increased (OR 1.39, 95% CI 1.21 to 1.61; absolute risk increase (ARI) 8.0 per 1000). The efficacy results were homogeneous for every endpoint according to the clinical condition of the patients, but were less marked for patients pre-treated with clopidogrel, especially in patients without acute coronary syndromes.</P>
<P>As initial medical treatment of NSTEACS (12 trials with 33,176 participants), IIb/IIIa blockers did not decrease mortality at 30 days (OR 0.90, 95% CI 0.79 to 1.02) or at six months (OR 1.00, 95% CI 0.87 to 1.15), but slightly decreased death or myocardial infarction at 30 days (OR 0.91, 95% CI 0.85 to 0.98) and at six months (OR 0.88, 95% CI 0.81 to 0.96), although severe bleeding was increased (OR 1.29, 95% CI 1.14 to 1.45; ARI 1.4 per 1000).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="[Empty name]">
<P>When administered during PCI, intravenous glycoprotein IIb/IIIa blockers reduce the risk of all-cause death at 30 days but not at six months, and reduce the risk of death or myocardial infarction at 30 days and at six months, at a price of an increase in the risk of severe bleeding. The efficacy effects are homogeneous but are less marked in patients pre-treated with clopidogrel where they seem to be effective only in patients with acute coronary syndromes. When administered as initial medical treatment in patients with NSTEACS, these agents do not reduce mortality although they slightly reduce the risk of death or myocardial infarction.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-10-21 21:06:39 +0530" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-10-02 18:10:56 +0530" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="[Empty name]">
<P>Cardiovascular diseases were the direct cause of more than four million deaths in Europe around the year 2000 (1.9 million in the European Union), accounting for 43% of all deaths at all ages in men and 55% in women. Coronary artery disease (CAD) accounts for half of this mortality burden and depends mostly on the occurrence of acute coronary syndromes (ACS) (<LINK REF="REF-ESC-Guidelines-CV-Prevention-2012" TYPE="REFERENCE">ESC Guidelines CV Prevention 2012</LINK>).</P>
<P>According to the current European and American guidelines, most patients with an ACS should be referred for coronary angiography, as they recommend percutaneous coronary intervention (PCI) as the preferred treatment option for both patients with ST-segment elevation myocardial infarction (STEMI), and patients with non-ST elevation ACS (NSTEACS) at moderate to high risk of ischaemic events (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). In addition, PCI is the preferred revascularisation technique for patients with stable CAD. As a consequence, the number of PCI procedures is rapidly increasing (<LINK REF="REF-ACCF_x002f_AHA-Guideline-revascularization-2012" TYPE="REFERENCE">ACCF/AHA Guideline revascularization 2012</LINK>; <LINK REF="REF-ESC-Guidelines-revascularization-2010" TYPE="REFERENCE">ESC Guidelines revascularization 2010</LINK>).</P>
<P>The mechanism of PCI using balloon angioplasty, with or without stent implantation, includes profound vessel injury and plaque rupture, all of which triggers an immediate activation of the coagulation cascade, and adhesion, activation and aggregation of platelets (<LINK REF="REF-ACCF_x002f_AHA-Guideline-revascularization-2012" TYPE="REFERENCE">ACCF/AHA Guideline revascularization 2012</LINK>; <LINK REF="REF-ESC-Guidelines-revascularization-2010" TYPE="REFERENCE">ESC Guidelines revascularization 2010</LINK>). Pre-treatment with aspirin, ticlopidine and heparin has been shown to reduce by 70% the risk of acute vessel occlusion and of myocardial infarction in these patients (<LINK REF="REF-ATC-2002" TYPE="REFERENCE">ATC 2002</LINK>). Bivalirudin, a new anticoagulant drug that is a direct thrombin inhibitor, has also been shown to have similar efficacy to unfractionated heparin with less bleeding (<LINK REF="STD-ACUITY-2006" TYPE="STUDY">ACUITY 2006</LINK>; <LINK REF="STD-HORIZONS_x002d_AMI-2008" TYPE="STUDY">HORIZONS-AMI 2008</LINK>). When a stent is implanted, the addition of clopidogrel instead of ticlopidine, before the procedure and during follow-up, has also been shown to be of benefit (<LINK REF="REF-PCI_x002d_CURE-2001" TYPE="REFERENCE">PCI-CURE 2001</LINK>). Thus, treatment with aspirin, clopidogrel and heparin or bivalirudin has been the standard antithrombotic treatment for this procedure (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). Recently, new P2Y<SUB>12</SUB> receptor antagonists, like prasugrel and ticagrelor, have been demonstrated to provide quicker, greater and more consistent inhibition of platelet activation than clopidogrel (<LINK REF="REF-Patrono-2011" TYPE="REFERENCE">Patrono 2011</LINK>), and to decrease the incidence of ischaemic events in patients with ACS submitted for PCI (<LINK REF="REF-PLATO-2009" TYPE="REFERENCE">PLATO 2009</LINK>; <LINK REF="REF-TRITON-TIMI_x002d_38-2007" TYPE="REFERENCE">TRITON TIMI-38 2007</LINK>).</P>
<P>The pathophysiology of non-ST segment elevation ACS (NSTEACS), i.e. unstable angina and non-ST segment elevation myocardial infarction, involves the rupture or erosion of an atherosclerotic coronary plaque (<LINK REF="REF-Falk--1995" TYPE="REFERENCE">Falk 1995</LINK>), activation of the coagulation cascade, and adhesion, activation and platelet aggregation. Treatment with aspirin and fractionated or unfractionated heparin has been shown to reduce the risk of cardiac events by 50% in patients with this syndrome (<LINK REF="REF-ATC-2002" TYPE="REFERENCE">ATC 2002</LINK>; <LINK REF="REF-Mehta-2003" TYPE="REFERENCE">Mehta 2003</LINK>). The addition of clopidogrel has also been shown to decrease further the risk of vascular events by 20% in these patients (<LINK REF="REF-CURE-2001" TYPE="REFERENCE">CURE 2001</LINK>). Finally, fondaparinux, a new anticoagulant, has been shown to have similar efficacy with less bleeding effects than heparin (<LINK REF="REF-OASIS_x002d_5--2006" TYPE="REFERENCE">OASIS-5 2006</LINK>). Thus, the current standard antithrombotic treatment for patients with NSTEACS is the administration of aspirin and clopidogrel with heparin or fondaparinux as recommended in current clinical guidelines (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). Also, ticagrelor has been shown to be more effective than clopidogrel in reducing ischaemic events in patients with ACS treated invasively or conservatively (<LINK REF="REF-PLATO-2009" TYPE="REFERENCE">PLATO 2009</LINK>), while prasugrel has been shown to be effective in patients with NSTEACS treated invasively (<LINK REF="REF-TRITON-TIMI_x002d_38-2007" TYPE="REFERENCE">TRITON TIMI-38 2007</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-10-02 18:10:56 +0530" MODIFIED_BY="Joey Kwong">
<P>The glycoprotein IIb/IIIa integrin present in platelets mediates the final common pathway in platelet aggregation, spawning the development of glycoprotein IIb/IIIa receptor blockers (<LINK REF="REF-Phillips-1988" TYPE="REFERENCE">Phillips 1988</LINK>). Intravenous glycoprotein IIb/IIIa inhibitors rapidly block up to 80% of the glycoprotein IIb/IIIa platelet receptors and inhibit fibrinogen-mediated platelet aggregation (<LINK REF="REF-Gurbel-2005" TYPE="REFERENCE">Gurbel 2005</LINK>; <LINK REF="REF-Patrono-2011" TYPE="REFERENCE">Patrono 2011</LINK>).</P>
<P>The three glycoprotein IIb/IIIa receptor inhibitors approved for clinical use are intravenous agents belonging to different classes: abciximab is a monoclonal antibody fragment; eptifibatide is a cyclic peptide; and tirofiban is a peptidomimetic molecule. All of them have a short half-life and are eliminated by the kidney, which is the reason why they are only indicated in patients without severe renal impairment (glomerular filtration rate &lt; 30) . Glycoprotein IIb/IIIa receptor inhibitors have been shown to be effective in reducing ischaemic events in patients undergoing PCI (<LINK REF="REF-ACCF_x002f_AHA-Guideline-revascularization-2012" TYPE="REFERENCE">ACCF/AHA Guideline revascularization 2012</LINK>; <LINK REF="REF-ESC-Guidelines-revascularization-2010" TYPE="REFERENCE">ESC Guidelines revascularization 2010</LINK>), while tirofiban, lamifiban and eptifibatide have been tested as initial medical treatment in patients with NSTEACS (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). Current guidelines give a class IIa recommendation to these drugs for their administration during PCI with a level of evidence B (data derived from a single randomised clinical trial or large non-randomised studies) (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ACCF_x002f_AHA-Guideline-revascularization-2012" TYPE="REFERENCE">ACCF/AHA Guideline revascularization 2012</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>; <LINK REF="REF-ESC-Guidelines-revascularization-2010" TYPE="REFERENCE">ESC Guidelines revascularization 2010</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Xavier Bosch">
<P>In patients submitted for PCI and also in patients presenting with a NSTEACS, intravenous glycoprotein IIb/IIIa blockade induces strong platelet inhibition (<LINK REF="REF-Gurbel-2005" TYPE="REFERENCE">Gurbel 2005</LINK>; <LINK REF="REF-Patrono-2011" TYPE="REFERENCE">Patrono 2011</LINK>) and may prevent mural and intraluminal thrombus formation. This effect can prevent acute coronary occlusion and embolisation of plaque thrombi to the distal microvasculature resulting in acute myocardial infarction and death.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Joey Kwong">
<P>In spite of their known effects in preventing myocardial infarction, some doubts remain as to the efficacy of these drugs in decreasing mortality, the homogeneity of their effects in different subgroups of patients or PCI techniques used, and their additional benefit when patients are pre-treated with clopidogrel (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). In addition, since glycoprotein IIb/IIIa receptor blockers induce profound platelet inhibition, the risk of bleeding complications is increased, particularly when administered concomitantly with other antiplatelet drugs and with high-dose heparin treatment (<LINK REF="REF-Quinn-2002" TYPE="REFERENCE">Quinn 2002</LINK>). Thus, safety is an important issue in the management of patients with these drugs, especially during PCI.</P>
<P>This is an update of a Cochrane review first published in the year 2001, and previously updated in 2007 and in 2010. In the last update, the main conclusion was that when administered during PCI, intravenous IIb/IIIa blockers reduce the risk of all-cause death and of death or myocardial infarction at 30 days and at six months, but increase the risk of severe bleeding. In contrast, when administered as initial medical treatment in patients with NSTEACS, these drugs do not reduce all-cause mortality, slightly reduce the risk of death or myocardial infarction, and increase the risk of severe bleeding.</P>
<P>In the last three years, several studies have been performed with these drugs in the setting of PCI or in patients presenting with NSTEACS (<LINK REF="STD-ASSIST-2009" TYPE="STUDY">ASSIST 2009</LINK>; <LINK REF="STD-Bhattacharya-2010" TYPE="STUDY">Bhattacharya 2010</LINK>; <LINK REF="STD-INSTANT-2012" TYPE="STUDY">INSTANT 2012</LINK>; <LINK REF="STD-ITTI-2012" TYPE="STUDY">ITTI 2012</LINK>; <LINK REF="STD-Yan-2009" TYPE="STUDY">Yan 2009</LINK>), while information on other small studies has become available (<LINK REF="STD-DANTE-2004" TYPE="STUDY">DANTE 2004</LINK>; <LINK REF="STD-De-Luca-2005" TYPE="STUDY">De Luca 2005</LINK>; <LINK REF="STD-De-Luca-2008" TYPE="STUDY">De Luca 2008</LINK>; <LINK REF="STD-Gasior-2003" TYPE="STUDY">Gasior 2003</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>; <LINK REF="STD-Kurowski-2005" TYPE="STUDY">Kurowski 2005</LINK>; <LINK REF="STD-Prati-2005" TYPE="STUDY">Prati 2005</LINK>). In addition, higher doses of clopidogrel as a loading dose (i.e. 600 mg) to achieve a more rapid and potent antiplatelet effect are being used, and new anticoagulant drugs (i.e. bivalirudin and fondaparinux, <LINK REF="REF-OASIS_x002d_5--2006" TYPE="REFERENCE">OASIS-5 2006</LINK>) have been incorporated in the usual medical treatment of patients with ACS and patients referred for PCI (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). Since the efficacy of intravenous IIb/IIIa blockers and risk of bleeding could be different with higher doses of clopidogrel, and in the presence of these new drugs, an update of this systematic review is justifiable.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Xavier Bosch">
<P>The aim of this systematic review was to assess the efficacy and safety effects of glycoprotein IIb/IIIa blockers given in addition to standard medical treatment when administered:</P>
<OL>
<LI>during PCI;</LI>
<LI>as the initial medical treatment of patients with NSTEACS ('upstream treatment').</LI>
</OL>
<P>The first indication relates to a procedure rather than a health problem, where the studied treatment is administered a few minutes prior to PCI. The second indication relates to a clinical condition that includes a wide range of patient groups at different risk, where the studied treatment is administered at admission in patients with or without coronary angiography and PCI during hospitalisation. Both questions are addressed in the same review to better understand the efficacy of IIb/IIIa antagonists in patients undergoing PCI, including in patients with stable ischaemic heart disease and in patients with acute coronary syndromes with or without ST-segment elevation. The standard medical treatment considered was aspirin and ticlopidine or clopidogrel, plus heparin or bivalirudin during PCI; and aspirin with or without clopidogrel, and heparin or fondaparinux in the initial medical treatment of patients with NSTEACS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-10-03 15:41:22 +0530" MODIFIED_BY="Nicole Ackermann">
<SELECTION_CRITERIA MODIFIED="2013-10-03 15:41:22 +0530" MODIFIED_BY="Joey Kwong">
<CRIT_STUDIES MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Xavier Bosch">
<P>We sought to identify all randomised controlled clinical trials, with or without blinding, studying intravenous glycoprotein IIb/IIIa blockers and in which at least one of the pre-defined primary outcomes was measured. Specifically, we analysed trials performed when IIb/IIIa blockers were administered during PCI in patients with or without an ACS, and trials performed in patients with NSTEACS treated from admission with glycoprotein IIb/IIIa antagonists as the initial medical management.</P>
<P>We did not consider trials:</P>
<UL>
<LI>on oral glycoprotein IIb/IIIa blockers, since clinical research has indicated that their administration is associated with increased mortality, and they are not available for clinical use;</LI>
<LI>performed in patients with ST-segment elevation acute myocardial infarction (STEMI) treated with thrombolytics or with facilitated or rescue PCI after thrombolytic treatment;</LI>
<LI>comparing two different glycoprotein IIb/IIIa blockers;</LI>
<LI>comparing the timing of the glycoprotein IIb/IIIa blockers administration (i.e. pre-hospital administration versus hospital administration or administration in the emergency room versus in the catheterisation laboratory); or</LI>
<LI>comparing the route of administration (i.e. intracoronary versus intravenous).</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-09-09 18:26:50 +0530" MODIFIED_BY="Joey Kwong">
<P>The following participants were considered for each of the two types of studies that we considered in this review:<BR/>
</P>
<OL>
<LI>Studies that randomised adults (18 years and older), male or female, with or without an acute coronary syndrome, who underwent elective or urgent PCI, with or without stent implantation.</LI>
<LI>Studies that included adult patients with NSTEACS in whom glycoprotein IIb/IIIa antagonists were administered at the time of hospital admission as part of the initial medical management.</LI>
</OL>
<P>For both indications there were no exclusion criteria regarding patients' comorbidities, the presence of renal dysfunction or the risk of bleeding.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>Intravenous glycoprotein IIb/IIIa blockers administered as a bolus followed by 12 to 96 hours infusion, at any dose, on top of usual care (aspirin and ticlopidine or clopidogrel, and heparin or bivalirudin).</P>
<SUBSECTION>
<HEADING LEVEL="4">Comparators</HEADING>
<P>A control group with or without placebo, on top of usual care (aspirin and ticlopidine or clopidogrel, and heparin or bivalirudin).</P>
<P>For every major endpoint, two subgroup analyses have been performed in the PCI group:</P>
<UL>
<LI>glycoprotein IIb/IIIa blockers compared with placebo (double-blind studies) on top of usual care;</LI>
<LI>glycoprotein IIb/IIIa blockers compared with usual care (not blinded studies).</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-10-03 15:41:22 +0530" MODIFIED_BY="Joey Kwong">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-03 15:41:22 +0530" MODIFIED_BY="Joey Kwong">
<UL>
<LI>All-cause mortality at 30 days and at six months.</LI>
<LI>All-cause death or non-fatal myocardial infarction at 30 days and at six months.</LI>
</UL>
<P>All-cause mortality was chosen instead of cardiovascular mortality or fatal myocardial infarction because although most deaths occurring early after an ACS or a PCI procedure are due to fatal myocardial infarction, total mortality does not depend on physician interpretation of the cause. In addition, in all of the reviewed studies total mortality was considered.</P>
<P>The combined endpoint of all-cause death or myocardial infarction was chosen because most deaths occurring early after a NSTEACS or a PCI procedure are due to an acute coronary occlusion leading to a myocardial infarction.</P>
<P>Because definitions of myocardial infarction may vary among studies, especially in those performed during PCI, when the data were obtainable we used as a definition of post-procedural myocardial infarction an elevation more than three times the upper limit of normal of the biomarker of necrosis used (creatine kinase-MB fraction (CK-MB) or cardiac troponins) occurring within 48 hours of the procedure. Spontaneous or non-post-procedural myocardial infarction was defined in the presence of signs or symptoms of ischaemia not related to or appearing more than 48 hours after a PCI procedure and with elevation more than two times the upper limit of normal of the biomarker used to assess of necrosis.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="[Empty name]">
<UL>
<LI>Need for an urgent revascularisation procedure at 30 days and at six months for patients who underwent PCI.</LI>
</UL>
<P>Urgent revascularisation was chosen as a secondary endpoint as this is a consequence of refractory ischaemia and because its indication is often clinician-driven and, in consequence, not entirely objective.</P>
<UL>
<LI>All-cause death, non-fatal myocardial infarction or urgent coronary revascularisation at 30 days and at six months.</LI>
</UL>
<P>All of the components of this combined endpoint share the same pathophysiology (i.e. acute vessel occlusion) also as a secondary endpoint.</P>
<UL>
<LI>Safety: severe bleeding at 30 days.</LI>
</UL>
<P>This was the most important safety outcome that was appropriately described in all studies. To decrease definition variability (<LINK REF="REF-Steinhubl-2007" TYPE="REFERENCE">Steinhubl 2007</LINK>) and wherever reported, the Thrombolysis In Myocardial Infarction (TIMI) classification was used to define severe bleeding (<LINK REF="REF-Bovill-1991" TYPE="REFERENCE">Bovill 1991</LINK>); the investigators' definition was used otherwise.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Nicole Ackermann">
<ELECTRONIC_SEARCHES MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Nicole Ackermann">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on <I>The Cochrane Library </I>(2012, Issue 12), MEDLINE OVID (1946 to January Week 1 2013) and EMBASE Classic + EMBASE OVID (1947 to 2013 Week 01) on 11 January 2013. We checked and revised search strategies for the updates. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> for details of the search strategies. We loaded all records into Reference Manager and removed duplicates (see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="[Empty name]">
<P>We carried out handsearches (to January 2013) of abstracts from conferences published in <I>Circulation </I>(American Heart Association Annual Meeting), <I>Journal of the American College of Cardiology</I> (American College of Cardiology Foundation Annual Congress), <I>European Heart Journal </I>(European Society of Cardiology Annual Congress) and online at Theheart.org, TIMI.org. We also searched Clinicaltrials.org. We also examined the references sections of reviews and meta-analysis addressing glycoprotein IIb/IIIa inhibitors.</P>
<P>No language restrictions were applied to the search. English, French and Spanish language papers were read by the authors. The Cochrane Heart Group helped us by translating two Chinese articles (see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>). All published studies could be retrieved from the bibliographic search.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<STUDY_SELECTION MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>Two authors screened and independently extracted results. A paper was rejected only when both review authors agreed that the article did not meet the inclusion criteria. Two review authors scored each manuscript independently using a pre-designed in/out form. Each manuscript was scored 1 (definitely 'in', i.e. the study met the inclusion criteria); 2 (maybe 'in', i.e. small sample size or difficult to determine the type of control or of diagnosis); or 3 (definitely 'out', i.e. definitely did not meet the inclusion criteria). All manuscripts which scored at least one '1' or one '2' were analysed in common by both review authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>Two authors independently extracted data from original reports of trial results and resolved differences by discussion. We abstracted data on characteristics of participants (age, sex, presence of diabetes, prior myocardial infarction, ACS and type), interventions (PCI and type, stent and type, pre-treatment with clopidogrel), outcomes, trial quality characteristics (i.e. sequence generation, allocation concealment, blinding, incomplete outcome report, incomplete data addressing, selective reporting and other) onto this form. In addition, we collected data on potential confounding factors including participants' baseline risk and characteristics, trial duration, intensity of intervention (dosing and duration of treatment), type and dose of concomitant medication used and revascularisation procedures including stent implantation.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>Two authors independently assessed risk of bias in the included studies using The Cochrane Collaboration's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We created a 'Risk of bias' table for each study by adding the degree of bias for the primary and secondary endpoints according to sequence generation, allocation concealment, blinding, incomplete outcome report, incomplete data addressing, selective reporting and other.</P>
<P>In addition, we further analysed the risk of bias by including two tables with the summary assessment of the risk of bias for major and minor endpoints (across key domains) within and across studies. We selected allocation concealment and blinding as the key domains for this analysis.</P>
<P>Only the effect of the intravenous route of administration (i.e. bolus plus infusion) was examined and compared with placebo/control with usual care (i.e. aspirin, ticlopidine/clopidogrel and heparin). To prevent attrition bias, we analysed all patients allocated to active treatment in this group regardless of whether they received it or not (i.e. intention-to-treat analysis). We used intention-to-treat data in the pooled analyses of this review as it was possible to obtain them from the publications of all the studies.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>We calculated pooled odds ratio (OR) of the individual and combined endpoints. Fixed-effect meta-analyses are presented unless a Chi<SUP>2</SUP> test for heterogeneity was statistically significant at a 5% level, in which case random-effects meta-analyses are presented. We calculated risk differences after pooling together the studies for each meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>In the analysis of the effects of glycoprotein IIb/IIIa blockers administered during PCI, we performed six separate subgroup analyses:</P>
<P>1. According to the clinical condition of the patients:</P>
<UL>
<LI>Stable coronary artery disease in which PCI was performed as an elective procedure</LI>
<LI>NSTEACS</LI>
<LI>Primary PCI in patients with STEMI</LI>
</UL>
<P>2.The technique used:</P>
<UL>
<LI>Balloon angioplasty alone</LI>
<LI>PCI with stent implantation</LI>
</UL>
<P>3. Pre-treatment with clopidogrel</P>
<UL>
<LI>Patients with ACS</LI>
<LI>Patients without ACS</LI>
</UL>
<P>For all subgroup analyses we selected studies in which at least two-thirds of patients had the focused condition or procedure. For the analysis of patients pre-treated with clopidogrel and according to the known dose-related onset of action of this drug (<LINK REF="REF-Hochholzer-2005" TYPE="REFERENCE">Hochholzer 2005</LINK>), we selected only trials in which patients were receiving chronic clopidogrel treatment (five days or more), and trials in which a loading dose of 300 mg was administered at least six hours before the procedure or 600 mg at least two hours before the procedure.</P>
<P>We assessed heterogeneity of studies by clinical judgement according to differences in type of patients enrolled, study quality, interventions and outcome. We also evaluated funnel plots for every major endpoint.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Xavier Bosch">
<P>In the PCI meta-analysis, we made two different analyses in the overall group according to the presence or absence of a high risk of bias for the primary endpoint of the review. Group 1 were studies at low to intermediate risk of bias (i.e. comparison with placebo, double-blind and with adequate allocation concealment); and Group 2 were studies at high risk of bias (i.e. comparison with usual care, without placebo and not blinded). We made a sensitivity analysis by comparing the results for each group and for the two groups together.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-10-21 21:06:39 +0530" MODIFIED_BY="Joey Kwong">
<STUDY_DESCRIPTION MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<SEARCH_RESULTS MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Xavier Bosch">
<P>The search strategy was designed to be very sensitive and yielded 4106 documents from the original and the 2007, 2010 and 2013 updates of the review. We screened all references from relevant reviews and meta-analyses (see <LINK TAG="ADDITIONAL_REFERENCES" TYPE="SECTION">Additional references</LINK>) for studies possibly missed by our search strategy. In total 184 articles were retrieved for further examination; 20 of these were from the current update. One hundred and two references to 92 studies were excluded (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Thirteen new RCTs were identified from the current update. The previous version of the review included 48 RCTs so that in total 60 trials (66,689 participants) were included in the review. Of these, 48 trials (33,513 participants) were on glycoprotein IIb/IIIa blockers administered during PCI, and 12 trials (33,176 participants) tested these drugs as initial medical treatment in patients with NSTEACS (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>The three glycoprotein IIb/IIIa receptor inhibitors approved for clinical use are intravenous agents that belong to different classes: abciximab is a monoclonal antibody fragment; eptifibatide is a cyclic peptide; and tirofiban is a peptidomimetic molecule.</P>
<P>Most of the studies were multicentre, international studies and were performed mostly in North America and Europe, Canada, the Netherlands, France, Belgium, Germany, Spain, Poland and Italy. An important number were also performed in south American countries, Australia, New Zealand and the Czech Republic. Only eight studies were performed in low to middle-income countries (<LINK REF="STD-ASIAD-2005" TYPE="STUDY">ASIAD 2005</LINK>; <LINK REF="STD-Bhattacharya-2010" TYPE="STUDY">Bhattacharya 2010</LINK>; <LINK REF="STD-Chen-2000" TYPE="STUDY">Chen 2000</LINK>; <LINK REF="STD-Fu-2008" TYPE="STUDY">Fu 2008</LINK>; <LINK REF="STD-ITTI-2012" TYPE="STUDY">ITTI 2012</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>; <LINK REF="STD-Shen-2008" TYPE="STUDY">Shen 2008</LINK>; <LINK REF="STD-Yan-2009" TYPE="STUDY">Yan 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">During percutaneous coronary intervention</HEADING>
<P>These studies were performed in stable or unstable coronary patients undergoing elective or urgent PCI with or without stent implantation, and IIb/IIIa blockers were administered during the procedure. In all the studies performed during elective PCI, randomisation was performed when the exact coronary anatomy was known and inclusion criteria required the presence of one or more &gt; 70% stenosis in a coronary segment amenable to PCI.</P>
<P>Most of the studies excluded patients with renal dysfunction, since this condition is associated with excess dosing, and those at high risk of bleeding.</P>
<P>PCI was the condition studied in 48 studies with 33,513 patients. Forty-four studies reported outcomes at 30 days while 34 studies reported outcomes at 6 to 12 months.<BR/>Among the 48 studies and according to the clinical condition of the patients, there were 18 studies in patients with stable CAD, seven studies in patients with NSTEACS and 11 studies performed during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI); the other 12 studies were performed in a mixed population. According to the technique used, there were 11 studies performed during balloon angioplasty (10 of them performed before year 2000), 33 during PCI with stent implantation and four with mixed techniques. Finally, 17 studies including 8925 patients were performed in patients pre-treated with clopidogrel, three in patients with NSTEACS (<LINK REF="STD-ISAR_x002d_REACT-2-2006" TYPE="STUDY">ISAR-REACT 2 2006</LINK>; <LINK REF="STD-Kurowski-2005" TYPE="STUDY">Kurowski 2005</LINK>; <LINK REF="STD-Yan-2009" TYPE="STUDY">Yan 2009</LINK>), six in patients with STEMI (<LINK REF="STD-ASSIST-2009" TYPE="STUDY">ASSIST 2009</LINK>; <LINK REF="STD-BRAVE_x002d_3-2009" TYPE="STUDY">BRAVE-3 2009</LINK>; <LINK REF="STD-Fu-2008" TYPE="STUDY">Fu 2008</LINK>; <LINK REF="STD-ITTI-2012" TYPE="STUDY">ITTI 2012</LINK>; <LINK REF="STD-On_x002d_TIME-2004" TYPE="STUDY">On-TIME 2004</LINK>; <LINK REF="STD-Shen-2008" TYPE="STUDY">Shen 2008</LINK>) and eight in patients with stable CAD (<LINK REF="STD-_x0033_T_x002f_2R-2009" TYPE="STUDY">3T/2R 2009</LINK>; <LINK REF="STD-Claeys-2005" TYPE="STUDY">Claeys 2005</LINK>; <LINK REF="STD-Cuisset-2008" TYPE="STUDY">Cuisset 2008</LINK>; <LINK REF="STD-INSTANT-2012" TYPE="STUDY">INSTANT 2012</LINK>; <LINK REF="STD-ISAR_x002d_REACT-2004" TYPE="STUDY">ISAR-REACT 2004</LINK>; <LINK REF="STD-ISAR_x002d_SWEET-2004" TYPE="STUDY">ISAR-SWEET 2004</LINK>; <LINK REF="STD-ISAR_x002d_SMART_x002d_2-2004" TYPE="STUDY">ISAR-SMART-2 2004</LINK>; <LINK REF="STD-OPTIMIZE_x002d_IT-2009" TYPE="STUDY">OPTIMIZE-IT 2009</LINK>; <LINK REF="STD-TOPSTAR-2002" TYPE="STUDY">TOPSTAR 2002</LINK>).</P>
<P>All patients included in trials with stent implantation received heparin, aspirin and ticlopidine or clopidogrel during and after the procedure except for the <LINK REF="STD-ERASER-1999" TYPE="STUDY">ERASER 1999</LINK> study in which ticlopidine was left to the investigator's discretion. In only two studies (<LINK REF="STD-CLEAR-PLATELETS_x002d_2-2009" TYPE="STUDY">CLEAR PLATELETS-2 2009</LINK>; <LINK REF="STD-OPTIMIZE_x002d_IT-2009" TYPE="STUDY">OPTIMIZE-IT 2009</LINK>) a drug-eluting stent was used in most of the patients. Abciximab was used in 28 trials, tirofiban in 13 and eptifibatide in seven. The doses varied among studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">As initial medical treatment of patients with non-ST segment elevation acute coronary syndromes</HEADING>
<P>These studies were performed in patients with a recent (&lt; 24 hours) chest pain at rest associated with ischaemic changes in the admission ECG (ST-segment depression &gt; 0.5 mm or transient elevation &gt; 1 mm, &gt; 1 mm T-wave inversion) or CK-MB or troponin elevation above the upper limits of normality in each participant institution. Most of these trials were performed in patients managed conservatively. All of the studies excluded patients with moderate to severe renal dysfunction and those at high risk of bleeding</P>
<P>Twelve studies with 33,176 patients concerned glycoprotein IIb/IIIa use as initial medical treatment in patients with NSTEACS. All these studies presented 30-day follow-up results and six presented six months follow-up. Abciximab was used in one study, eptifibatide in three, tirofiban in five and lamifiban in three. No subgroup analyses were performed since all of the studies included patients with the same global condition.</P>
<P>
<LINK REF="STD-PRISM-1998" TYPE="STUDY">PRISM 1998</LINK> differed from the other trials in that the glycoprotein IIb/IIIa blocker was given without heparin. <LINK REF="STD-PRISM-Plus-1998" TYPE="STUDY">PRISM Plus 1998</LINK> and <LINK REF="STD-PARAGON-A-1998" TYPE="STUDY">PARAGON A 1998</LINK> also included an arm with glycoprotein IIb/IIIa blocker without heparin. Seven studies were performed following a conservative management while only three (<LINK REF="STD-ELISA_x002d_2-2006" TYPE="STUDY">ELISA-2 2006</LINK>; <LINK REF="STD-PRACTICE-2007" TYPE="STUDY">PRACTICE 2007</LINK>; <LINK REF="STD-PRISM-Plus-1998" TYPE="STUDY">PRISM Plus 1998</LINK>) were performed on an invasive basis with most of the patients scheduled for early coronary angiography.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Variability</HEADING>
<P>The potential sources of heterogeneity among the studies may include the variability in patient characteristics. In the PCI group the mean age ranged from 59 years to 70 years with a median of 61 years, while in the group of studies on initial medical treatment of NSTEACS the mean age ranged from 60 to 65 years. Considering all studies, the proportion of males ranged from 61% to 95%, and the proportion of patients with prior myocardial infarction, which was described in most studies, ranged from 10% to 67% (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
<P>In the PCI analysis, 12 trials were performed in patients with STEMI, 11 of them during primary PCI. The frequency of this diagnosis was of 0% in 26 other studies and ranged from 3% to 41% in the other 11 trials. A specific analysis of those 11 trials has been performed.</P>
<P>In the analysis of glycoprotein IIb/IIIa blockers administered as initial medical treatment in patients with NSTEACS, the prevalence of positive markers of myocardial necrosis ranged from 14% to 100%. Thirty-two to 80% of patients had ST-segment depression at enrolment. Nine studies were performed following a conservative management with less than 14% of patients having in-hospital PCI. In the other three studies, coronary angiography was performed in 60% to 90% of patients, and PCI from 31% to 61% of patients during drug infusion which was administered for 24 to 72 hours after enrolment.</P>
<P>The daily doses of aspirin ranged in the studies from 50 mg to 500 mg and those of heparin were typically aimed at maintaining an activated clotting time of &gt; 200 seconds or an activated partial thromboplastin time between 50 and 85 seconds, or twice that of laboratory control. Only in one study (<LINK REF="STD-Schulman-1996" TYPE="STUDY">Schulman 1996</LINK>) was aspirin not allowed in the treatment group but administered in the placebo group.</P>
<P>Some studies had arms of active treatment with lower heparin doses (<LINK REF="STD-EPILOG-1997" TYPE="STUDY">EPILOG 1997</LINK>) or no heparin at all (<LINK REF="STD-PARAGON-A-1998" TYPE="STUDY">PARAGON A 1998</LINK>; <LINK REF="STD-PRISM-Plus-1998" TYPE="STUDY">PRISM Plus 1998</LINK>; <LINK REF="STD-PRISM-1998" TYPE="STUDY">PRISM 1998</LINK>). All patients from these studies were included in the present update since a prior meta-analysis performed with individual patient data reported similar results by including or excluding those patients (<LINK REF="REF-Boersma-2002" TYPE="REFERENCE">Boersma 2002</LINK>). Patients from the control groups of all studies received heparin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dosing</HEADING>
<P>Where trials had intervention arms with varying doses of glycoprotein IIb/IIIa inhibitor drugs, data from such intervention arms were pooled. In the <LINK REF="STD-EPIC-1994" TYPE="STUDY">EPIC 1994</LINK> study, one intervention arm had glycoprotein IIb/IIIa blocker administered as a bolus alone, i.e. with no subsequent perfusion; the results of that arm were not included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Endpoints</HEADING>
<P>All studies followed more than 95% of patients at 30 days and more than 90% at six months. In general the methodological quality of the 60 selected RCTs was good, but differed in PCI and non-PCI studies. Ten of the 49 PCI trials were considered to be at high risk of bias (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). However, these 10 studies with 3863 participants represented only 11.5% of the total and have been studied separately in this review for each major endpoint. In contrast, among studies on IIb/IIIa blockers administered as initial medical treatment in patients with NSTEACS, only one small study was considered to have a high risk of bias (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>)</P>
<P>We pooled three studies describing endpoints occurring within follow-up periods shorter than 30 days (i.e. in-hospital, seven-day, etc.) with 30-day follow-up studies (<LINK REF="STD-ERASER-1999" TYPE="STUDY">ERASER 1999</LINK>; <LINK REF="STD-Kereiakes-1996" TYPE="STUDY">Kereiakes 1996</LINK>; <LINK REF="STD-Simoons-1994" TYPE="STUDY">Simoons 1994</LINK>) due to the fact that most adverse events occur within the first week after the procedure. Also, one study (<LINK REF="STD-ADVANCE-2004" TYPE="STUDY">ADVANCE 2004</LINK>) that only reported events at six months was also included in the 30-day follow-up analysis in order not to miss important information, on the basis that &gt; 80% of mortality and myocardial infarction and &gt; 95% of severe bleeding occurred during the first 30 days. Finally, we pooled three studies (<LINK REF="STD-ISAR_x002d_REACT-2004" TYPE="STUDY">ISAR-REACT 2004</LINK>; <LINK REF="STD-ISAR_x002d_REACT-2-2006" TYPE="STUDY">ISAR-REACT 2 2006</LINK>; <LINK REF="STD-ISAR_x002d_SMART_x002d_2-2004" TYPE="STUDY">ISAR-SMART-2 2004</LINK>) that reported one-year follow-up alone with the six-month follow-up analysis for the same reason.</P>
<P>The definition of primary and secondary outcomes varied among studies. However, it was possible to obtain or calculate the number of cases with the primary and secondary endpoints of this review in most studies. Myocardial infarction was part of the composite effectiveness endpoint of all trials, but the applied myocardial infarction definition was different, especially regarding the increased levels of the MB fraction of creatine kinase required in studies performed before the year 2005 and of troponin levels thereafter. This point was especially important regarding the definition of post-PCI myocardial infarction. Because of this, and when data were obtainable, we used as a definition of post-procedural myocardial infarction an elevation more than three times the upper limit of normal of the biomarker of necrosis used (creatinine kinase-MB fraction (CK-MB) or cardiac troponins).</P>
<P>The secondary endpoint 'major bleeding' was assessed by the Thrombolysis In Myocardial Infarction (TIMI) classification when described (bleeding was classified as major if it involved intracranial haemorrhage or cardiac tamponade or if it was associated with a decrease in haemoglobin concentration of more than 50 g/L regardless of whether or not a bleeding site had been identified (<LINK REF="REF-Bovill-1991" TYPE="REFERENCE">Bovill 1991</LINK>). Otherwise, we used the 'major' bleeding described in each study. When no description of major bleeding existed at all, we selected intracranial haemorrhages and need for transfusion as 'major' bleeding.</P>
<P>In some instances, it was not specified whether the nature of PCI during follow-up was urgent or not. In such cases, we considered overall revascularisations.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Nicole Ackermann">
<P>Most of the excluded studies were not RCTs, did not compare a IIb/IIIa blocker with placebo or control, did not report clinical events or were performed in conditions other than during PCI or as initial medical treatment of patients with NSTEACS (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="Joey Kwong">
<P>It is important to note that most of the trials excluded patients at high risk of bleeding and patients with renal failure. In addition, the mean age of the studied population was lower (61 years) than what it is usually observed in clinical practice (<LINK REF="REF-CRUSADE-2006" TYPE="REFERENCE">CRUSADE 2006</LINK>; <LINK REF="REF-GRACE-2007" TYPE="REFERENCE">GRACE 2007</LINK>).</P>
<ALLOCATION MODIFIED="2013-09-09 18:26:49 +0530" MODIFIED_BY="[Empty name]">
<P>Reporting of adequate sequence generation was obtained in 70% of the studies and adequate allocation concealment in 54% of them. Only in 10% of the studies was the allocation concealment inadequate (or considered to be at high risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-09-09 18:26:48 +0530" MODIFIED_BY="Joey Kwong">
<P>Patients and clinicians were adequately blinded to treatment (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) in most of the trials. Some studies were performed on an open-label basis while in others (<LINK REF="STD-Claeys-2005" TYPE="STUDY">Claeys 2005</LINK>; <LINK REF="STD-ISAR_x002d_2-2000" TYPE="STUDY">ISAR-2 2000</LINK>) the treatment strategy precluded blinding of the used drugs. Overall, for the primary endpoint of the review, blinding of patients and investigators was adequate in 55% of the studies, unclear in 15% and inadequate in 30% of them. For the secondary endpoints, blinding was adequate in 50%, unclear in 15% and inadequate in 35% (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Regarding allocation concealment and blinding as the two major key domains, the risk of bias across PCI studies was low for mortality and unclear for death or myocardial infarction, and for major bleeding (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In studies performed with the use of IIb/IIIa blockers as initial medical treatment in patients with NSTEACS, the risk of bias across studies was low for every major endpoint (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-09-09 18:26:48 +0530" MODIFIED_BY="Joey Kwong">
<P>Outcome data for the primary endpoint was adequately addressed (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) in 85% of the studies and for the secondary endpoints in 80% of them (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>)</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-09-09 18:26:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>Eighty-five per cent of the studies were free of suggestion of selective outcome reporting (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-09-09 18:26:48 +0530" MODIFIED_BY="Joey Kwong">
<P>Almost all studies were industry funded, enhancing the risk of bias (<LINK REF="REF-Als_x002d_Nielsen-2003" TYPE="REFERENCE">Als-Nielsen 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In fact, only 30% of them were apparently free of other problems that could put them at a risk of bias. We considered 50% of the studies to have an unclear risk of other sources of bias and 20% were at high risk because of the relationship between investigators and industry, premature stopping of the study or other reasons (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-10-21 21:06:39 +0530" MODIFIED_BY="Joey Kwong">
<SUBSECTION>
<HEADING LEVEL="3">1. Glycoprotein IIb/IIIa blockers during percutaneous coronary intervention (PCI)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary endpoints</HEADING>
<P>Of the 48 PCI trials with 33,513 participants, data from 43 trials with 31,744 patients (95%) were available on 30-day mortality, and 44 trials with 31,880 participants on 30-day mortality or myocardial infarction. Twenty-eight of these trials with 27,205 patients (86%) were blinded studies with a placebo group and considered to be at low risk of bias. Six-month data on mortality and on mortality or myocardial infarction were available from 33 trials with 24,845 patients (74%), of which 20 trials (20,329 patients) were blinded and at low risk of bias (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>Mortality occurred in 0.92% of patients in the treatment group versus 1.33% in controls at 30 days, and in 2.44% and 2.94% respectively at six months. Treatment with intravenous glycoprotein IIb/IIIa blockers was associated with a significant reduction in the odds of mortality at 30 days (odds ratio (OR) 0.79, 95% confidence interval (CI) 0.64 to 0.97). The results were homogeneous (I<SUP>2 </SUP>= 0%) and similar for blinded (0.78, 95% CI 0.61 to 1.00) and unblinded studies (0.81, 95% CI 0.54 to 1.21); <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. The absolute risk reduction (ARR) per thousand treated patients was of 4.0 and the number needed to treat (NNT) to save a life was 249. The results were also similar for all the different subgroups that were considered according to the clinical condition of the patients (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and the technique used (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), although they were less marked for patients pre-treated with clopidogrel (OR 0.83, 95% CI 0.57 to 1.20; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>However, at six months treatment with glycoprotein IIb/IIIa inhibitors was not associated with a reduction of mortality in the overall group (OR 0.90, 95% CI 0.77 to 1.05, I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) and in each subgroup; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">All-cause death or myocardial infarction</HEADING>
<P>The rate of death or myocardial infarction at 30 days and six months was of 5.05% versus 7.44% and 7.45% versus 10.05% in the treatment and control groups respectively. Glycoprotein IIb/IIIa blockers were associated with a significant decrease in the odds of death or myocardial infarction at 30 days (OR 0.66, 95% CI 0.60 to 0.72, P &lt; 0.00001; I<SUP>2 </SUP>= 22%) without significant differences between blinded and unblinded studies (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The ARR per thousand treated patients was of 23.9 and the NNT was 42. The results were similar in all subgroups but were less marked in patients pre-treated with clopidogrel (OR 0.81, 95% CI 0.67 to 0.98), especially in patients without ACS (OR 0.91, 95% CI 0.65 to 1.28; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>The results at six months showed marked heterogeneity (I<SUP>2 </SUP>= 47%) but were similar to those obtained at 30 days (OR 0.75, 95% CI 0.64 to 0.86, P &lt; 0.0001; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The ARR per thousand treated patients was of 26.0 and the NNT was 39. Again, the results were similar in all the subgroups of patients considered in the review but were less marked for patients pre-treated with clopidogrel (OR 0.87, 95% CI 0.66 to 1.14; <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary endpoints</HEADING>
<P>Data on urgent coronary revascularisation and the combined endpoint of death, myocardial infarction or urgent revascularisation at 30 days were available from 42 trials with 31,555 patients (94% of patients included in the overall review) and from 32 trials with 21,548 patients (64% of patients included in the overall review) at six months.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="5">Urgent revascularisation</HEADING>
<P>Urgent coronary revascularisation was performed in 2.04% of patients in the treatment group versus 3.44% in controls at 30 days, and in 12.54% and 15.31% respectively at six months. Treatment with intravenous glycoprotein IIb/IIIa blockers was associated with a reduction in the risk of urgent revascularisation at 30 days (OR 0.62, 95% CI 0.54 to 0.71, P &lt; 0.00001; I<SUP>2 </SUP>= 18%) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) and at six months (OR 0.85, 95% CI 0.79 to 0.93, P &lt; 0.0001; I<SUP>2 </SUP>= 9%) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). At 30 days, the results were less marked for patients with stable coronary artery disease (CAD) (OR 0.84, 95% CI 0.54 to 1.32) and for those pre-treated with clopidogrel (OR 0.89, 95% CI 0.62 to 1.28), especially in patients without ACS; while at six months, the results were similar in all subgroups (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Death, myocardial infarction or urgent revascularisation</HEADING>
<P>The combined endpoint of death, myocardial infarction or urgent revascularisation at 30 days and six months was 6.70% versus 9.71% and 19.01% versus 23.22% in the treatment and control groups respectively. IIb/IIIa blockers were also associated with a lower risk of death, myocardial infarction or urgent revascularisation both at 30 days (OR 0.65, 95% CI 0.57 to 0.75) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and at six months (OR 0.80, 95% CI 0.73 to 0.88) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), although the analysis showed a marked heterogeneity of the results both at 30 days (I<SUP>2 </SUP>= 40%) and at six months (I<SUP>2 </SUP>= 35%). Again, the global results were similar to those obtained in all subgroups but were less marked for the subgroup of patients pre-treated with clopidogrel (30-day OR 0.88, 95% CI 0.65 to 1.20; six-month OR 0.88, 95% CI 0.79 to 0.98), especially in patients without ACS (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>Data were available from 40 trials with 31,430 patients (94% of patients included in the overall review). Major bleeding occurred in 3.03% of patients in the treatment group versus 2.23% in controls. Treatment with intravenous glycoprotein IIb/IIIa blockers was associated with an increased risk of severe bleeding (OR 1.39, 95% CI 1.21 to 1.61; P &lt; 0.0001; I<SUP>2 </SUP>= 12%; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The absolute risk increase per thousand treated patients over 30 days was 8.0 and the number needed to harm (NNH) was 125. The results were homogeneous in blinded and in unblinded studies (<LINK REF="CMP-007.09" TYPE="ANALYSIS">Analysis 7.9</LINK>), and in all subgroups (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Glycoprotein IIb/IIIa blockers as initial medical treatment in patients with non-ST segment elevation acute coronary syndromes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary endpoints</HEADING>
<P>Data from 12 trials with 31,490 patients (94% of patients included in this meta-analysis) were available on 30-day mortality and myocardial infarction, while data from only six trials but with 19,396 patients (58% of patients included in the overall review) were available on six-month mortality and myocardial infarction.</P>
<P>Mortality occurred in 3.32% of patients in the treatment group versus 3.62% in controls at 30 days, and in 6.26% and 6.23% respectively at six months. Death or myocardial infarction occurred in 10.50% and 11.89% at 30 days, and 13.25% and 14.53% at six months respectively.</P>
<P>Treatment with intravenous glycoprotein IIb/IIIa blockers was not associated with a reduction in the odds of all-cause mortality at 30 days (OR 0.90, 95% CI 0.79 to 1.02; I<SUP>2 </SUP>= 9%; <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>) or at six months (OR 1.00, 95% CI 0.87 to 1.15; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>). However, these agents reduced the risk of all-cause mortality or myocardial infarction both at 30 days (OR 0.91, 95% CI 0.85 to 0.98; I<SUP>2 </SUP>= 28%; <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>) and at six months (OR 0.88, 95% CI 0.81 to 0.96; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>). The ARR per thousand treated patients was 13.9 at 30 days and 12.7 at six months, and the corresponding NNTs were of 75 and 79 respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>Data were available from 12 trials with 31,099 patients (93.7% of patients included in the overall review). Treatment with intravenous glycoprotein IIb/IIIa blockers was associated with an increase in the incidence of major bleeding at 30 days (OR 1.29, 95% CI 1.14 to 1.45, P &lt; 0.0001; I<SUP>2 </SUP>= 24%; <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>). Major bleeding occurred in 3.76% and in 3.56% of patients in the treatment and control groups, respectively.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-09-09 18:27:14 +0530" MODIFIED_BY="Joey Kwong">
<SUBSECTION>
<HEADING LEVEL="2">Glycoprotein IIb/IIIa blockers during percutaneous coronary intervention (PCI)</HEADING>
<P>This systematic review has identified that glycoprotein IIb/IIIa blockers may be safe and effective when administered during PCI with or without stent implantation. This is based on data from 48 trials including over 33,000 patients. Overall, the administration of IIb/IIIa blockers as a bolus immediately before the intervention followed by a 12 to 24-hour infusion is beneficial. Although associated with an increased risk of severe bleeding (8.0 per 1000), this hazard may be considered to be offset by the reduction of 30-day mortality (4.0 patients per 1000 treated), mortality or non-fatal myocardial infarction (23.9 patients per 1000) and urgent revascularisation (14 patients per 1000 treated). The early benefit of glycoprotein IIb/IIIa blockers on mortality seems to be lost at six months, although the lower number of included studies and enrolled patients with six-month follow-up may account for these different results. The short antiplatelet effects of these intravenous drugs may also account for this apparent decrease in efficacy at six months, although the initial benefit on mortality or myocardial infarction is maintained at six months.</P>
<P>Most of the beneficial effects of these drugs were in the prevention of peri-procedural myocardial infarction, a condition whose definition has varied over the years and between studies partially because troponins have only been included in their diagnosis in studies performed after the year 2005. In addition, their diagnosis is especially difficult in patients presenting with a myocardial infarction. Therefore, no study applied the current third universal definition of a post-procedural myocardial infarction in which an elevation more than five times the upper limit of normal or a 20% increase from a previously abnormal level is required (<LINK REF="REF-Universal-definition-MI-2012" TYPE="REFERENCE">Universal definition MI 2012</LINK>). Although we tried to limit the variability of the definition by using a uniform criteria of an elevation of more than three times the upper limit of normal of the biomarker of necrosis used when the data were obtainable, the variability of the myocardial infarction definition could explain the heterogeneity observed in the analysis of this endpoint.</P>
<P>The beneficial effect of these drugs is homogeneous in different subgroups of patients according to their clinical condition (i.e. stable coronary artery disease (CAD), non-ST segment elevation acute coronary syndromes (NSTEACS) or ST-segment elevation myocardial infarction (STEMI)) and the technique used (i.e. balloon angioplasty or PCI with stent), although 30-day and six-month mortality was only reduced when administered in procedures with stent implantation. The use of drug-eluting stents has been reported to be associated with a higher risk of thrombosis. Since no study on IIb/IIIa blockers has been performed specifically in patients with drug-eluting stents, and since in only four of the 24 reviewed studies (<LINK REF="STD-BRAVE_x002d_3-2009" TYPE="STUDY">BRAVE-3 2009</LINK>; <LINK REF="STD-CLEAR-PLATELETS_x002d_2-2009" TYPE="STUDY">CLEAR PLATELETS-2 2009</LINK>; <LINK REF="STD-ISAR_x002d_REACT-2-2006" TYPE="STUDY">ISAR-REACT 2 2006</LINK>; <LINK REF="STD-OPTIMIZE_x002d_IT-2009" TYPE="STUDY">OPTIMIZE-IT 2009</LINK>) a drug-eluting stent was used in more than 40% of the cases, the results of this meta-analysis only apply to patients in which a bare metal stent was implanted.</P>
<P>The administration of clopidogrel before PCI in addition to aspirin and heparin, and during the first year following PCI, has been shown to reduce the risk of acute coronary occlusion and of mortality, myocardial infarction or recurrent ischaemia (<LINK REF="REF-PCI_x002d_CURE-2001" TYPE="REFERENCE">PCI-CURE 2001</LINK>), and is currently the standard medical treatment for patients subjected to this procedure (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). In recent years, the administration of clopidogrel in addition to aspirin and heparin has also been shown to be of benefit as initial medical treatment of patients with NSTEACS (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-CURE-2001" TYPE="REFERENCE">CURE 2001</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>; <LINK REF="REF-PCI_x002d_CURE-2001" TYPE="REFERENCE">PCI-CURE 2001</LINK>). Controversy currently exists about the effectiveness of glycoprotein IIb/IIIa blockers in patients submitted for PCI on long-term clopidogrel treatment or in patients pre-treated with a loading dose from the time of hospital admission or at least two to six hours before PCI. The results of this systematic review show that IIb/IIIa blockers are less efficacious in decreasing major and minor events in patients pre-treated with clopidogrel, and suggest that they retain a beneficial effect only in patients with ACS. These results are in agreement with the higher risk of thromboembolic events in patients with ACS compared with patients with stable CAD. On the other hand, the risk of severe bleeding is not enhanced in patients pre-treated with clopidogrel.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Glycoprotein IIb/IIIa blockers as initial medical treatment in patients with non-ST segment elevation acute coronary syndromes</HEADING>
<P>This systematic review also identified that glycoprotein IIb/IIIa antagonists are safe but much less effective when administered as an initial medical treatment to patients with NSTEACS than in patients undergoing PCI. This conclusion is based on data from over 33,000 patients. Overall, the administration of intravenous glycoprotein IIb/IIIa blockers as an initial bolus followed by a continuous infusion for 24 to 72 hours resulted in a modest benefit at 30 days (13.9 deaths or myocardial infarctions prevented per 1000 patients treated) and at six months. This benefit was obtained in spite of a very acceptable excess of severe bleeding (2 per 1000). However, the treatment provided no significant benefit on all-cause mortality at 30 days or six months.</P>
<P>These results contrast with those mentioned above in the overall population submitted for PCI, and also in the subgroup of patients with NSTEACS that underwent PCI. It is worth noting that except for two studies (<LINK REF="STD-PRACTICE-2007" TYPE="STUDY">PRACTICE 2007</LINK>; <LINK REF="STD-PRISM-1998" TYPE="STUDY">PRISM 1998</LINK>) the beneficial effect obtained was higher in trials with a high use rate of PCI procedures than in trials with a low frequency of these procedures. In addition, in two trials (<LINK REF="STD-PRISM-Plus-1998" TYPE="STUDY">PRISM Plus 1998</LINK>; <LINK REF="STD-PURSUIT-1998" TYPE="STUDY">PURSUIT 1998</LINK>) patients that underwent PCI 24 to 72 hours after admission obtained greater benefit from glycoprotein IIb/IIIa antagonists after PCI than before the procedure, and in one trial (<LINK REF="STD-PARAGON-B-2002" TYPE="STUDY">PARAGON B 2002</LINK>) a benefit was observed only among patients that underwent PCI during drug infusion. These results strongly suggest the existence of a positive interaction between PCI and the effect of glycoprotein IIb/IIIa blockers. In fact, in previous meta-analysis using individual data, a more marked effect of the intervention was observed among patients that underwent PCI during the administration of IIb/IIIa antagonists that among patients that did not undergo PCI (<LINK REF="REF-Boersma-1999" TYPE="REFERENCE">Boersma 1999</LINK>; <LINK REF="REF-Boersma-2002" TYPE="REFERENCE">Boersma 2002</LINK>). Finally, because the overall treatment effect of glycoprotein IIb/IIIa inhibitors when administered as initial medical management of patients with NSTEACS is small and these drugs are expensive, the best cost-effectiveness ratio may be obtained when they are administered in high-risk patients scheduled for early PCI. In this sense, one trial has shown similar effects but excess bleeding when administering one of these drugs (eptifibatide) since hospital admission (upstream treatment) rather than during early PCI (downstream treatment) (<LINK REF="STD-EARLY_x002d_ACS-2009" TYPE="STUDY">EARLY-ACS 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Characteristics and limitations of the review</HEADING>
<P>Heterogeneity of studies was statistically important only in 19 of the 96 analyses performed, all of them related to PCI and 11 regarding secondary endpoints. Such heterogeneity is likely to be due to the subjective nature of urgent revascularisation, and the inclusion of small studies. Differences in patients' characteristics such as age, gender, history of myocardial infarction and proportion of patients with acute coronary syndromes, although important, did not result in significant statistical heterogeneity. It is unlikely that other factors such as drug dosages or important concomitant treatments may have affected homogeneity, particularly heparin and aspirin.</P>
<P>We did not perform a cost-effectiveness analysis since this was out of the scope of our review. Some of the analysed studies performed a retrospective analysis on cost-effectiveness, most of them with data from a specific country and applying the results of the overall study. It is of note that this kind of analysis is difficult to perform in multicentre trials in which participating countries have major differences in local practices and public health policies and economies.</P>
<P>It should be noted that the studied population may not be representative of all patients undergoing PCI or with NSTEACS. In the group of patients treated during PCI the mean age of patients was lower than what it is usually observed in clinical practice, as well as the proportion of other co-morbidities (<LINK REF="REF-CRUSADE-2006" TYPE="REFERENCE">CRUSADE 2006</LINK>; <LINK REF="REF-GRACE-2007" TYPE="REFERENCE">GRACE 2007</LINK>). However, the subgroup analysis performed on these patients showed similar results to those obtained in the global analysis, and in those obtained for patients with or without stable CAD. In the group of patients with NSTEACS treated medically, the inclusion was limited to patients with ST-segment changes during the admission ECG or with positive biological markers of myocardial necrosis. These features are present in three-quarters of patients and are known to select high-risk patients. In fact, in most centres patients with these characteristics are submitted for coronary angiography within 48 hours as currently recommended (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). In addition, some studies have shown a significant differential treatment effect when glycoprotein IIb/IIIa blockers have been administered in patients with positive or negative troponin levels at admission (<LINK REF="REF-Boersma-2002" TYPE="REFERENCE">Boersma 2002</LINK>). On the other hand, all of these randomised controlled trials excluded patients with significant renal impairment, cerebrovascular disease and also any patient with a moderate to high risk of bleeding complications. For these reasons, the generalisability of the findings of this review is limited to a moderate to high-risk population with a low risk of bleeding complications.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-21 20:42:33 +0530" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-21 20:42:33 +0530" MODIFIED_BY="[Empty name]">
<P>Intravenous IIb/IIIa blockers administered during percutaneous coronary intervention (PCI) reduce the risk of death at 30 days but not at six months, and of death or myocardial infarction at 30 days and at six months, at a price of an increase in the risk of severe bleeding. The efficacy effects are homogeneous for all subgroups of patients, although they are less marked in patients pre-treated with clopidogrel, where they seem to be effective only in patients with acute coronary syndromes.</P>
<P>When administered as initial medical treatment in patients with NSTEACS, these agents do not reduce all-cause mortality, but slightly reduce the risk of death or myocardial infarction at 30 days and at six months, and the risk of severe bleeding.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-09-09 18:27:14 +0530" MODIFIED_BY="[Empty name]">
<P>Since the analysis of patients that underwent PCI after pre-treatment with clopidogrel showed less benefit than in the main analysis, and since new oral antiplatelet agents such as prasugrel and ticagrelor have been shown to be more efficacious than clopidogrel but with a higher risk of bleeding (<LINK REF="REF-PLATO-2009" TYPE="REFERENCE">PLATO 2009</LINK>; <LINK REF="REF-TRITON-TIMI_x002d_38-2007" TYPE="REFERENCE">TRITON TIMI-38 2007</LINK>), further trials are warranted in patients pre-treated with these drugs. Also, further research is needed to analyse whether the favourable effects observed in patients in whom a bare metal stent is implanted will also be observed in patients with drug-eluting stents.</P>
<P>In addition, considering the cost of these drugs, prospective cost-effectiveness analyses in patients managed according to current recommendations (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>) will be desirable. In addition, patient-centred outcomes such as quality of life have not been studied and are particularly warranted.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-09-09 18:27:14 +0530" MODIFIED_BY="[Empty name]">
<P>We would like to thank Margaret Burke and Nicole Martin from the Cochrane Heart Group for updating the bibliographic search and providing help with obtaining difficult to find references; Joey Kwong, Isaac Fung and Aleksandra Mas-Stachurska for their help in translating to English two Chinese and one Polish study; and the Editors of the Cochrane Heart Group for their helpful comments through the review and its updates. We also thank Dr. Pablo Loma-Osorio for his help in calculating absolute risk reductions and NNT in the 2007 update of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-09-09 18:27:13 +0530" MODIFIED_BY="[Empty name]">
<P>Xavier Bosch participated as investigator in the <LINK REF="STD-PRISM-Plus-1998" TYPE="STUDY">PRISM Plus 1998</LINK>, <LINK REF="STD-GUSTO_x002d_IV-2001" TYPE="STUDY">GUSTO-IV 2001</LINK> and <LINK REF="STD-EARLY_x002d_ACS-2009" TYPE="STUDY">EARLY-ACS 2009</LINK> studies. He has no other potential conflicts of interest to declare.</P>
<P>Jaume Marrugat has no potential conflict of interest to declare.</P>
<P>Juan Sanchis participated as investigator in the <LINK REF="STD-EARLY_x002d_ACS-2009" TYPE="STUDY">EARLY-ACS 2009</LINK> study.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-09-09 18:27:14 +0530" MODIFIED_BY="Xavier Bosch">
<P>Xavier Bosch originated and was primarily responsible for planning, designing and carrying out the primary version of the review and the 2007, 2010 and 2013 updates. He was the principal author and prepared the results and the clinical discussion of the findings.<BR/>Juan Sanchis participated in reviewing the studies for the 2010 and 2013 updates and in the discussion of the results.<BR/>Jaume Marrugat participated in the design, the methodology and the discussion of the primary version of the review and in the discussion of the 2007 update.<BR/>In each version, two of the three authors participated in the study selection, review of pre-selected studies, data extraction and in the preparation of the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-05-09 18:42:06 +0530" MODIFIED_BY="Xavier Bosch">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-05-09 18:42:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>None</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-09-05 18:08:55 +0530" MODIFIED_BY="Joey Kwong">
<STUDIES MODIFIED="2013-09-05 18:06:23 +0530" MODIFIED_BY="Joey Kwong">
<INCLUDED_STUDIES MODIFIED="2013-09-05 16:04:44 +0530" MODIFIED_BY="Nicole Ackermann">
<STUDY DATA_SOURCE="PUB" ID="STD-_x0033_T_x002f_2R-2009" MODIFIED="2010-07-09 13:59:42 +0530" MODIFIED_BY="Nicole Ackermann" NAME="3T/2R 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-05 22:24:16 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;19528337&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2009-11-05 22:24:16 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, et al</AU>
<TI>Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>119</VL>
<NO>25</NO>
<PG>3215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-09 13:59:42 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valgimigli M, Campo G, de Cesare N, Vranckx P, Hamon M, Angiolillo DJ, et al</AU>
<TI>Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>4</NO>
<PG>313-20</PG>
<IDENTIFIERS MODIFIED="2010-07-09 13:58:33 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ACE-2003" MODIFIED="2010-07-09 13:59:58 +0530" MODIFIED_BY="Nicole Ackermann" NAME="ACE 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-09 13:59:58 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;One-year results of the ACE trial&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 13:59:58 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antoniucci D, Migliorini A, Parodi G, Valenti R, Rodriguez A, Hempel A, et al</AU>
<TI>Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>109</VL>
<NO>14</NO>
<PG>1704-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;C10. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.[see comment]. Journal of the American College of Cardiology 2003;42:1879-1885.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al</AU>
<TI>A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>42</VL>
<PG>1879-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ADMIRAL-2001" MODIFIED="2010-07-09 14:00:31 +0530" MODIFIED_BY="Nicole Ackermann" NAME="ADMIRAL 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-07-09 14:00:31 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montalescot G, Barragan P, Wittemberg O, Ecollan P, Elhadad S, Villain P, et al</AU>
<TI>Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>25</NO>
<PG>1895-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;1999;138:178-179.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montalescot G</AU>
<TI>The ADMIRAL study: abciximab with percutaneous transluminal coronary angioplasty and stent in acute myocardial infarction</TI>
<SO>American Heart Journal</SO>
<YR>1999</YR>
<VL>138</VL>
<PG>178-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;3-year results of the ADMIRAL study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montalescot G</AU>
<TI>Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study</TI>
<SO>European Heart Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>2520-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ADVANCE-2004" NAME="ADVANCE 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004;44:14-19.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al</AU>
<TI>The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>1</NO>
<PG>14-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ASIAD-2005" MODIFIED="2013-09-05 15:48:35 +0530" MODIFIED_BY="Nicole Ackermann" NAME="ASIAD 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-05 15:48:35 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen WH, Kaul U, Leung SK, Lau YK, Tan HC, Leung AW, et al</AU>
<TI>A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial</TI>
<SO>Journal of Invasive Cardiology</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>10</NO>
<PG>534-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ASSIST-2009" MODIFIED="2013-09-05 15:49:01 +0530" MODIFIED_BY="Xavier Bosch" NAME="ASSIST 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-05 15:49:01 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;INCLUDED&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:49:01 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le May MR, Wells GA, Glover CA, So DY, Froeschl M, Marquis JF, et al</AU>
<TI>Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST)</TI>
<SO>Circulation: Cardiovascular Interventions</SO>
<YR>2009</YR>
<VL>2</VL>
<PG>330-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhattacharya-2010" MODIFIED="2013-09-05 15:49:46 +0530" MODIFIED_BY="Xavier Bosch" NAME="Bhattacharya 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-05 15:49:46 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;New study 2013&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:49:46 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhattacharya R, Pani A, Dutta D, Basak S, Gangopadhyay S, Das Baksi S, et al</AU>
<TI>Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective</TI>
<SO>Singapore Medical Journal</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>7</NO>
<PG>558-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BRAVE_x002d_3-2009" MODIFIED="2013-09-05 15:49:58 +0530" MODIFIED_BY="Nicole Ackermann" NAME="BRAVE-3 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-02-27 21:46:35 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mehilli J, Kastrati A, Schulz S, Früngel S, Nekolla SG, Moshage W, et al</AU>
<TI>Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>119</VL>
<NO>14</NO>
<PG>1933-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-05 15:49:58 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;2013&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:49:58 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz S, Birkmeier KA, Ndrepepa G, Moshage W, Dotzer F, Huber K, et al</AU>
<TI>One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial</TI>
<SO>Clinical Research in Cardiology</SO>
<YR>2010</YR>
<VL>99</VL>
<PG>795-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CADILLAC-2002" MODIFIED="2010-07-29 17:30:32 +0530" MODIFIED_BY="Nicole Ackermann" NAME="CADILLAC 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stone G, Grines CL, Cox DA, García E, Tcheng JE, Griffin JJ, et al</AU>
<TI>Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>13</NO>
<PG>957-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, et al</AU>
<TI>Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>108</VL>
<NO>11</NO>
<PG>1316-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CANADIAN-1996" MODIFIED="2010-07-09 14:03:29 +0530" MODIFIED_BY="Nicole Ackermann" NAME="CANADIAN 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-07-09 14:03:29 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Unstable angina, Events at 30 days.&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:03:29 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al</AU>
<TI>Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>5</NO>
<PG>899-905</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:03:29 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAPTURE-1997" MODIFIED="2010-07-09 14:03:52 +0530" MODIFIED_BY="Nicole Ackermann" NAME="CAPTURE 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-07-09 14:03:52 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Unstable angina, Events at 30 days.&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:03:52 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simoons ML, Rutsch W, Vahanian A, Adgey J, Maseri A, Vassanelli C, et al</AU>
<TI>Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9063</NO>
<PG>1429-35</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:03:52 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2000" NAME="Chen 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;C55. Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chin Med J 2000;63:8-15.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS</AU>
<TI>Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty</TI>
<SO>Chinese Medical Journal (Taipei)</SO>
<YR>2000</YR>
<VL>63</VL>
<NO>1</NO>
<PG>8-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-2005" NAME="Claeys 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claeys MJ, Van Der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, Van Der GP, et al</AU>
<TI>Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis</TI>
<SO>European Heart Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>6</NO>
<PG>567-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CLEAR-PLATELETS_x002d_2-2009" MODIFIED="2009-11-05 21:40:25 +0530" MODIFIED_BY="Xavier Bosch" NAME="CLEAR PLATELETS-2 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-05 21:40:25 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, DiChiara J, Antonino MJ, et al</AU>
<TI>Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>8</NO>
<PG>648-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuisset-2008" MODIFIED="2013-09-05 15:51:20 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Cuisset 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-05 15:51:20 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;19463379&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:51:20 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, et al</AU>
<TI>Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. [see comment]</TI>
<SO>JACC: Cardiovascular Interventions</SO>
<YR>2008</YR>
<VL>1</VL>
<NO>6</NO>
<PG>649-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DANTE-2004" MODIFIED="2013-09-05 15:51:44 +0530" MODIFIED_BY="Xavier Bosch" NAME="DANTE 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-05 15:51:44 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Staico R, Feres F, et al</AU>
<TI>Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>109</VL>
<PG>861-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Luca-2005" MODIFIED="2013-07-31 12:08:33 +0530" MODIFIED_BY="Xavier Bosch" NAME="De Luca 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-04-04 15:49:34 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;This is not a RCT on the effects of abciximab in diabetic patients with or without metabolic control identified retrospectively&lt;/p&gt;" NOTES_MODIFIED="2013-04-04 15:49:34 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Luca L, De Persio G, Minati M, Iacoboni C, Fedele F</AU>
<TI>Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting</TI>
<SO>American Heart Journal</SO>
<YR>2005</YR>
<VL>149</VL>
<PG>1135.e11-1135.e18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Luca-2008" MODIFIED="2013-09-05 15:52:30 +0530" MODIFIED_BY="Xavier Bosch" NAME="De Luca 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-05 15:52:30 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Luca L, Sardella G, De Persio G, Petrolini A, Fedele F</AU>
<TI>Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study</TI>
<SO>Acute Cardiac Care</SO>
<YR>2008</YR>
<VL>10</VL>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ELISA_x002d_2-2006" MODIFIED="2013-09-05 15:52:39 +0530" MODIFIED_BY="[Empty name]" NAME="ELISA-2 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-05 15:52:39 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasoul S, Ottervanger JP, de Boer M, Miedema K, Hoorntje JCA, Gosselink M, et al</AU>
<TI>A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<PG>1401-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EPIC-1994" MODIFIED="2010-07-09 14:05:26 +0530" MODIFIED_BY="Nicole Ackermann" NAME="EPIC 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-07-09 14:05:26 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PTCA-STENT&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:05:26 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The EPIC investigators</AU>
<TI>Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>14</NO>
<PG>956-61</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:05:26 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343(8902):881-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al</AU>
<TI>Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8902</NO>
<PG>881-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al</AU>
<TI>Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>278</VL>
<PG>479-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EPILOG-1997" MODIFIED="2010-07-09 14:06:16 +0530" MODIFIED_BY="Nicole Ackermann" NAME="EPILOG 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, et al</AU>
<TI>Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<PG>1951-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-09 14:06:16 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PTCA-STENT. Events at 30 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:06:16 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Topol EJ, Califf RM, Lincoff AM, Tcheng JE, Cabot CF, Weisman HF, et al</AU>
<TI>Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<NO>24</NO>
<PG>1689-96</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:06:16 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EPISTENT-1998" MODIFIED="2013-09-05 15:53:54 +0530" MODIFIED_BY="Nicole Ackermann" NAME="EPISTENT 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al</AU>
<TI>Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>5</NO>
<PG>319-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-09 14:06:28 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Stent Events at 30 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:06:28 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Topol EJ, Lincoff AM, Califf RM, Tcheng JE, Cohen EA, Kleiman NS, et al</AU>
<TI>Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9122</NO>
<PG>87-92</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:06:28 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-05 15:53:54 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;One-year results of the EPISTENT trial&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:53:54 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al</AU>
<TI>Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9195</NO>
<PG>2019-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ERASER-1999" MODIFIED="2010-07-09 14:06:42 +0530" MODIFIED_BY="Nicole Ackermann" NAME="ERASER 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-07-09 14:06:42 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PTCA-STENT in-hospital and 6-month&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:06:42 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The ERASER Investigators</AU>
<TI>Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>8</NO>
<PG>799-806</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:06:42 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ESPRIT-2000" MODIFIED="2013-09-05 15:54:11 +0530" MODIFIED_BY="[Empty name]" NAME="ESPRIT 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;ESPIT study. Results at 12 months.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, et al</AU>
<TI>Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>5</NO>
<PG>618-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Secondary reference. Events at 6 months&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Shea JE, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kit MM, et al</AU>
<TI>Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>19</NO>
<PG>2468-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-05 15:54:11 +0530" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tcheng JE</AU>
<TI>Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9247</NO>
<PG>2037-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2008" MODIFIED="2010-07-09 14:07:16 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Fu 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-07-09 14:07:16 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, et al</AU>
<TI>Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction</TI>
<SO>Chinese Medical Journal</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>6</NO>
<PG>522-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galassi-1999" NAME="Galassi 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;C99. Galassi AR, Russo G, Nicosia A, et al. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome. Cardiologia 1999;44:639-645.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galassi AR, Russo G, Nicosia A, Tamburino C, Foti R, Rodi G, et al</AU>
<TI>Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome</TI>
<SO>Cardiologia</SO>
<YR>1999</YR>
<VL>44</VL>
<NO>7</NO>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gasior-2003" MODIFIED="2013-09-05 15:54:35 +0530" MODIFIED_BY="Xavier Bosch" NAME="Gasior 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-05 15:54:35 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;Gasior M, Piegza J, Dziobek B, et al. Stenting in chronic total occlusion of left anterior descending artery. Randomised comparison of the impact of adjunctive abciximab therapy on immediate and long-term results. Folia Cardiologica 2003;10:279-287.&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:54:35 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gasior M, Piegza J, Dziobek B, Wasilewski J, Lekston A, Zebik T, et al</AU>
<TI>Stenting in chronic total occlusion of left anterior descending artery. Randomised comparison of the impact of adjunctive abciximab therapy on immediate and long-term results</TI>
<TO>Angioplastyka przewleklego zamkniêcia galêzimiêdzykomorowej przedniej z uzyciem stentu. Badanie porównawcze oceniajace wplyw zastosowania abciximabu na wyniki wczesne i odlegle</TO>
<SO>Folia Cardiologica</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>3</NO>
<PG>279-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GUSTO_x002d_IV-2001" NAME="GUSTO-IV 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;One-year results of the GUSTO-IV trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, et al</AU>
<TI>Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>3</NO>
<PG>437-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simoons ML, The GUSTO IV-ACS Investigators</AU>
<TI>Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9272</NO>
<PG>1915-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IMPACT-1995" MODIFIED="2010-07-09 14:08:03 +0530" MODIFIED_BY="Nicole Ackermann" NAME="IMPACT 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-07-09 14:08:03 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PTCA-Stent Events at 30 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:08:03 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, et al</AU>
<TI>Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>91</VL>
<NO>8</NO>
<PG>2151-7</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:08:03 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IMPACT_x002d_II-1997" MODIFIED="2010-07-09 14:08:21 +0530" MODIFIED_BY="Nicole Ackermann" NAME="IMPACT-II 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Safety endpoints of the IMPACT II trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleiman NS</AU>
<TI>Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>4A</NO>
<PG>29B-33B</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-09 14:08:21 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PTCA-Stent. Events at 30 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:08:21 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tcheng JE, Lincoff AM, Sigmon KN, Lee KL, Kitt MM, Califf RM, et al</AU>
<TI>Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9063</NO>
<PG>1422-8</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:08:21 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-INSTANT-2012" MODIFIED="2013-07-31 12:08:43 +0530" MODIFIED_BY="Xavier Bosch" NAME="INSTANT 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-02-27 18:01:37 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;INCLUDED&lt;/p&gt;" NOTES_MODIFIED="2013-02-27 18:01:37 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biondi-Zoccai G, Valgimigli M, Margheri M, Marzocchi A, Lettieri C, Stabile A, et al</AU>
<TI>Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial</TI>
<SO>American Heart Journal</SO>
<YR>2012</YR>
<VL>163</VL>
<PG>835.e1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISAR_x002d_2-2000" MODIFIED="2013-09-05 15:56:01 +0530" MODIFIED_BY="[Empty name]" NAME="ISAR-2 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-05 15:56:01 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, et al</AU>
<TI>Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic reestenosis after replacement of coronary stent following an acute myocardial infarction</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>35</VL>
<PG>915-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISAR_x002d_REACT-2004" NAME="ISAR-REACT 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, Ten Berg JM, et al</AU>
<TI>A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>3</NO>
<PG>232-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Secondary reference. Outcomes at 1 year&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schömig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Sxhühlen H, et al</AU>
<TI>One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel</TI>
<SO>European Heart Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>1379-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISAR_x002d_REACT-2-2006" MODIFIED="2010-05-25 19:05:16 +0530" MODIFIED_BY="Xavier Bosch" NAME="ISAR-REACT 2 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kastrati A, Mehilli J, Neumann FJ, Dotzer F, Ten Berg J, Bollwein H, et al</AU>
<TI>Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 randomized trial</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>1531-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-25 19:05:16 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ndrepepa G, Kastrati A, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, et al</AU>
<TI>One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial</TI>
<SO>European Heart Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<PG>455-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISAR_x002d_SMART_x002d_2-2004" MODIFIED="2010-07-27 16:54:02 +0530" MODIFIED_BY="Nicole Ackermann" NAME="ISAR-SMART-2 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-07-27 16:54:02 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, et al</AU>
<TI>A randomized trial comparing phosphorylcholine-coated atenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2004</YR>
<VL>256</VL>
<PG>388-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISAR_x002d_SWEET-2004" NAME="ISAR-SWEET 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;E114. Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-3635.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, et al</AU>
<TI>Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>110</VL>
<PG>3627-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ITTI-2012" MODIFIED="2013-09-05 15:59:28 +0530" MODIFIED_BY="Xavier Bosch" NAME="ITTI 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-05 15:59:28 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CP, Lin MS, Chiu YW, Lee JK, Hsu CN, Hung CS, et al</AU>
<TI>Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial</TI>
<SO>International Journal of Cardiology</SO>
<YR>2012</YR>
<VL>156</VL>
<PG>174-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JEPPORT-2009" MODIFIED="2010-07-09 14:09:10 +0530" MODIFIED_BY="Nicole Ackermann" NAME="JEPPORT 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-07-09 14:09:10 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakagawa Y, Nobuyoshi M, Yamaguchi T, Meguro T, Yokoi H, Kimura T, et al</AU>
<TI>Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT)</TI>
<SO>Circulation Journal : Official Journal of the Japanese Circulation Society</SO>
<YR>2009</YR>
<VL>73</VL>
<NO>1</NO>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juergens-2002" MODIFIED="2013-09-05 15:59:47 +0530" MODIFIED_BY="[Empty name]" NAME="Juergens 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-05 15:59:47 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C149. Juergens CP, White HD, Belardi JA, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clinical Therapeutics 2002;24:1332-1344.&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:59:47 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juergens CP, White HD, Belardi JA, Macaya C, Soler-Soler J, Meyer BJ, et al</AU>
<TI>A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1332-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kereiakes-1996" MODIFIED="2010-07-09 14:09:23 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kereiakes 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-07-09 14:09:23 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Dose-ranging study, in-hospital events, low statistical power&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:09:23 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, et al</AU>
<TI>Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>3</NO>
<PG>536-42</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:09:23 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2005" MODIFIED="2013-09-05 16:00:06 +0530" MODIFIED_BY="Xavier Bosch" NAME="Kim 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-05 16:00:06 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim JH, Jeong MH, Rhew JY, Lim JH, Yun KH, Kim KH, et al</AU>
<TI>Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome</TI>
<SO>Circulation Journal</SO>
<YR>2005</YR>
<VL>69</VL>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurowski-2005" MODIFIED="2013-09-05 16:00:32 +0530" MODIFIED_BY="Xavier Bosch" NAME="Kurowski 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-05 16:00:32 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurowski V, Toelg R, Jain D, Richter C, Wiegand UKH, Richardt G, et al</AU>
<TI>Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts</TI>
<SO>American Journal of Cardiology</SO>
<YR>2005</YR>
<VL>96</VL>
<PG>681-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-On_x002d_TIME-2-2008" MODIFIED="2009-11-05 22:15:49 +0530" MODIFIED_BY="Xavier Bosch" NAME="On-TIME 2 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-05 22:15:49 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;Comment in: Lancet. 2008 Aug 16;372(9638):509-10. PMID: 18707968&lt;/p&gt;" NOTES_MODIFIED="2009-11-05 22:15:49 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van't Hof AW, ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, et al</AU>
<TI>Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9638</NO>
<PG>537-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-OPTIMIZE_x002d_IT-2009" MODIFIED="2013-09-05 16:01:01 +0530" MODIFIED_BY="Xavier Bosch" NAME="OPTIMIZE-IT 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-05 16:01:01 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, et al</AU>
<TI>Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study</TI>
<SO>Journal of Cardiovascular Medicine (Hagerstown, Md.)</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>3</NO>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PARAGON-A-1998" MODIFIED="2010-07-09 14:09:30 +0530" MODIFIED_BY="Nicole Ackermann" NAME="PARAGON A 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-09 14:09:30 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Unstable angina. Events at 30 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:09:30 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moliterno DJ</AU>
<TI>International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>24</NO>
<PG>2386-95</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:09:30 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-PARAGON-B-2002" MODIFIED="2009-12-29 20:44:25 +0530" MODIFIED_BY="Xavier Bosch" NAME="PARAGON B 2002" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Global Organization Network (PARAGON-B) Investigators</AU>
<TI>Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>105</VL>
<NO>3</NO>
<PG>316-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Design of the PARAGON B study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moliterno DJ</AU>
<TI>Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee</TI>
<SO>American Heart Journal</SO>
<YR>2000</YR>
<VL>139</VL>
<PG>563-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRACTICE-2007" MODIFIED="2013-09-05 16:01:29 +0530" MODIFIED_BY="Nicole Ackermann" NAME="PRACTICE 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-05 16:01:29 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durand E, Hamm C, Macaya CM, Georges JL, Coste P, Wolf JE, et al</AU>
<TI>A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy</TI>
<SO>Eurointervention</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>2</NO>
<PG>228-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prati-2005" MODIFIED="2013-07-31 12:08:57 +0530" MODIFIED_BY="Xavier Bosch" NAME="Prati 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-04-04 15:57:35 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;Small study on the effects of abciximab on coronary microcirculation&lt;/p&gt;" NOTES_MODIFIED="2013-04-04 15:57:35 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prati F, Kwiatkowski P, Caroselli C, Imola F, Manzoli A, Fouad T, et al</AU>
<TI>Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study</TI>
<SO>Catheterization &amp; Cardiovascular Interventions</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>165-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRIDE-2001" MODIFIED="2013-09-05 16:01:58 +0530" MODIFIED_BY="[Empty name]" NAME="PRIDE 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-05 16:01:58 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, et al</AU>
<TI>Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (The PRIDE Study)</TI>
<SO>American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>88</VL>
<PG>1097-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRISM-1998" MODIFIED="2010-07-09 14:10:10 +0530" MODIFIED_BY="Nicole Ackermann" NAME="PRISM 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-09 14:10:10 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Unstable angina&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:10:10 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bazzino O, Aylward P, Hains A, Slany J, Steinbach K, Van de WF, et al</AU>
<TI>A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>21</NO>
<PG>1498-505</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:10:10 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRISM-Plus-1998" MODIFIED="2010-07-09 14:10:15 +0530" MODIFIED_BY="Nicole Ackermann" NAME="PRISM Plus 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-09 14:10:15 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Bazzino O, Barrero C, Garre L, Sosa A, Aylward P, Slany J et al. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338(21):1488-97.&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:10:15 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bazzino O, Barrero C, Garre L, Sosa A, Aylward P, Slany J, et al</AU>
<TI>Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>21</NO>
<PG>1488-97</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:10:15 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PURSUIT-1998" MODIFIED="2010-07-09 14:10:22 +0530" MODIFIED_BY="Nicole Ackermann" NAME="PURSUIT 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Secondary reference. Events at 6 months.&lt;br&gt;Abstract from the Congress of the American Heart Association&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harrington RA, Lincoff AM, Berdan LG, MacAulay C, Kint PP, Mahaffey KW, et al</AU>
<TI>Glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<PG>I-359</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Design of the PURSUIT trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrington RA</AU>
<TI>Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<PG>34B-38B</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-09 14:10:22 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Primary reference. Events at 30 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:10:22 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Topol E, Califf R, Simoons M, Diaz R, Paolasso E, Klein W, et al</AU>
<TI>Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>7</NO>
<PG>436-43</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:10:22 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RAPPORT-1998" MODIFIED="2010-07-09 14:10:28 +0530" MODIFIED_BY="Nicole Ackermann" NAME="RAPPORT 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-09 14:10:28 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PTCA-STENT&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:10:28 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al</AU>
<TI>Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>8</NO>
<PG>734-41</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:10:28 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RESTORE-1997" MODIFIED="2013-09-05 16:03:08 +0530" MODIFIED_BY="Nicole Ackermann" NAME="RESTORE 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-05 16:03:08 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Secondary publication. Six-minth outcomes&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:03:08 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, et al</AU>
<TI>Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>1</NO>
<PG>28-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-09 14:10:35 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PCI-STENT&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:10:35 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanrath P, vom DJ, Paulus O, Heyndrickx G, Sosa JA, Muller D, et al</AU>
<TI>Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>5</NO>
<PG>1445-53</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:10:35 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-1996" MODIFIED="2010-07-09 14:10:42 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Schulman 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-07-09 14:10:42 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Unstable angina. Events at 30 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:10:42 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, et al</AU>
<TI>Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>9</NO>
<PG>2083-9</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:10:42 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2008" MODIFIED="2009-11-05 22:00:57 +0530" MODIFIED_BY="Xavier Bosch" NAME="Shen 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-05 22:00:57 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, et al</AU>
<TI>Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention</TI>
<SO>Coronary Artery Disease</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>4</NO>
<PG>271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simoons-1994" MODIFIED="2010-07-09 14:11:07 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Simoons 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-07-09 14:11:07 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;PTCA-STENT. EVENTS in-hospital&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:11:07 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simoons ML, de Boer MJ, van Den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, et al</AU>
<TI>Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group</TI>
<SO>Circulation</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>2</NO>
<PG>596-603</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:11:07 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Duplicate publication of Simoons 1994&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Den Brand MJ, Simoons ML, de Boer MJ, van Miltenburg A, van der Wieken LR, de Feyter PJ</AU>
<TI>Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3)</TI>
<SO>European Heart Journal</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>Suppl L</NO>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamburino-2002" NAME="Tamburino 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamburino C, Russo G, Nicosia A, Galassi A, Foti R, Scriffignano V, et al</AU>
<TI>Prophylactic abciximab in elective coronary stenting: results of a randomized trial</TI>
<SO>Journal of Invasive Cardiology</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>2</NO>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOPSTAR-2002" MODIFIED="2013-09-05 16:04:29 +0530" MODIFIED_BY="Xavier Bosch" NAME="TOPSTAR 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, et al</AU>
<TI>Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR Trial)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>4</NO>
<PG>662-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-05 16:04:29 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;2013&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:04:29 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lengenfelder B, Stoerk S, Boes L, Strotmann J, Ertl G, Voelker W, et al</AU>
<TI>Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial</TI>
<SO>Journal of Invasive Cardiology</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>4</NO>
<PG>128-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yan-2009" MODIFIED="2013-09-05 16:04:44 +0530" MODIFIED_BY="Xavier Bosch" NAME="Yan 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-05 16:04:44 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yan Z, Zhou Y, Zhao Y, Li Y, Nie X, Zhou Z, et al</AU>
<TI>Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes</TI>
<SO>Clinical Cardiology</SO>
<YR>2009</YR>
<VL>32</VL>
<PG>E40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-09-05 18:06:23 +0530" MODIFIED_BY="Joey Kwong">
<STUDY DATA_SOURCE="PUB" ID="STD-ACUITY-2006" MODIFIED="2010-07-29 15:55:41 +0530" MODIFIED_BY="Joey Kwong" NAME="ACUITY 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-07-29 15:55:41 +0530" MODIFIED_BY="Joey Kwong" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al</AU>
<TI>Bivalirudin for patients with acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>2203-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ADVANCE-MI-2005" MODIFIED="2013-09-05 16:05:19 +0530" MODIFIED_BY="[Empty name]" NAME="ADVANCE MI 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-05 16:05:19 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Facilitated thombolysis (eptifibatide + tenecteplase) vs. facilitated PCI (eptifibatide) in patients with STEMI&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:05:19 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roe MT</AU>
<TI>Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial</TI>
<SO>American Heart Journal</SO>
<YR>2005</YR>
<VL>150</VL>
<NO>1</NO>
<PG>116-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-1999" NAME="Alexander 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Substudy of the PURSUIT trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, et al</AU>
<TI>Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>8</NO>
<PG>1147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azar-2010" MODIFIED="2013-09-05 16:05:33 +0530" MODIFIED_BY="Xavier Bosch" NAME="Azar 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-05 16:05:33 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;EXCLUDED&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:05:33 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azar RR, Badaoui G, Sarkis A, Kassab R, Salame E, Aboujaoude S, et al</AU>
<TI>Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention</TI>
<SO>Clinical Cardiology</SO>
<YR>2010</YR>
<VL>33</VL>
<PG>E14-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Batyraliev-2009" MODIFIED="2013-09-05 16:05:43 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Batyraliev 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-05 16:05:43 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;19656087&lt;br&gt;Russian&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:05:43 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Batyraliev TA, Fettser DV, Vural A, Pershukov IV, Preobrazhenskii DV, Avsar O, et al</AU>
<TI>Safety and efficacy of the use of glycoprotein IIb/IIIa inhibitors in the invasive treatment of patients with ST-elevation acute coronary syndrome. [Russian]</TI>
<SO>Kardiologiia</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>6</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-07-09 14:11:31 +0530" MODIFIED_BY="Nicole Ackermann"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellandi-2006" NAME="Bellandi 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Comparison of Abciximab administered in the emergency room vs. in the catheterization laboratory&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP</AU>
<TI>Early abciximab administration in acute myocardial infarction treated with primary coronary intervention</TI>
<SO>Internal Journal of Cardiology</SO>
<YR>2006</YR>
<VL>108</VL>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertrand-2006" MODIFIED="2013-09-05 16:06:58 +0530" MODIFIED_BY="Joey Kwong" NAME="Bertrand 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-05 16:06:58 +0530" MODIFIED_BY="Joey Kwong" NOTES="&lt;p&gt;Comment in: Circulation. 2006 Dec 12;114(24):2578-80. PMID: 17159072&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:06:58 +0530" NOTES_MODIFIED_BY="Joey Kwong" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bertrand OF, De Larochellière R, Rodés-Cabau J, Proulx G, Gleeton O, Nguyen CM, et al</AU>
<TI>A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>114</VL>
<NO>24</NO>
<PG>2636-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-29 17:41:41 +0530" MODIFIED_BY="Joey Kwong" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertrand OF, Faurie B, Larose E, Nguyen CM, Gleeton O, Dery JP, et al</AU>
<TI>Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents</TI>
<SO>Journal of Invasive Cardiology</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>3</NO>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blankenship-1998" NAME="Blankenship 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM</AU>
<TI>Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial</TI>
<SO>American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>1</NO>
<PG>36-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BOCHUM-2004" NAME="BOCHUM 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;M214. Open-label study. Pre-hospital Eptifibatide vs Control in even/uneven days. 365 patients with chest pain suggestive of ACS. No ECG performed; 60% had a confirmed MI&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanefeld C, Sirtl C, Spiecker M, Bojara W, Grewe PH, Lawo T, et al</AU>
<TI>Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>3</NO>
<PG>935-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boehrer-1994" NAME="Boehrer 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;A substudy of the EPIC trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ</AU>
<TI>Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications</TI>
<SO>American Journal of Cardiology</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>11</NO>
<PG>1166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brener-1999" NAME="Brener 1999" YEAR="">
<REFERENCE NOTES="&lt;p&gt;A substudy of the RAPPORT trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brener SJ, Barr LA, Burchenal JE, Wolski KE, Effron MB, Topol EJ</AU>
<TI>Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>6</NO>
<PG>728-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cannon-1998" NAME="Cannon 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Trial with an oral GP IIb/IIIa antagonist (TIMI 12)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al</AU>
<TI>Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>4</NO>
<PG>340-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-2002" NAME="Claeys 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;C60&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claeys MJ, Van Der Planken MG, Michiels JJ, Vertessen F, Dilling D, Bosmans JM, et al</AU>
<TI>Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention</TI>
<SO>Blood Coagulation &amp; Fibrinolysis</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>4</NO>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CLEAR-PLATELETS-1b-2006" MODIFIED="2009-11-05 21:35:24 +0530" MODIFIED_BY="Xavier Bosch" NAME="CLEAR PLATELETS 1b 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-05 21:35:24 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gurbel PA, Bliden KP, Tantry US</AU>
<TI>Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2006</YR>
<VL>48</VL>
<NO>11</NO>
<PG>2186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CLOTILDA-2005" NAME="CLOTILDA 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Comparison of Tirofiban vs. provisional abciximab.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leoncini M, Toso A, Maioli M, Bellandi F, Badia T, Politi A, et al</AU>
<TI>Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study</TI>
<SO>American Heart Journal</SO>
<YR>2005</YR>
<VL>150</VL>
<NO>3</NO>
<PG>401.e9-401.e14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costantini-2004" MODIFIED="2013-09-05 16:08:29 +0530" MODIFIED_BY="[Empty name]" NAME="Costantini 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-05 16:08:29 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C68. Substudy of the CADILLAC Trial&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:08:29 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, et al</AU>
<TI>Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>2</NO>
<PG>305-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cutlip-2003" NAME="Cutlip 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;C75. Tirofiban vs Control in the e,ergency room followed by any IIb/IIIa inhibitor during PCI a median of 90 min later&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, et al</AU>
<TI>Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction</TI>
<SO>American Journal of Cardiology</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>8</NO>
<PG>977-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EARLY_x002d_ACS-2009" MODIFIED="2013-09-05 16:08:52 +0530" MODIFIED_BY="Xavier Bosch" NAME="EARLY-ACS 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-05 16:08:52 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;Study design and rationale of the EARLY-ACS trial&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:08:52 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et al</AU>
<TI>Early versus delayed, provisional eptifibatide in acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<PG>2176-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ELISA-2003" MODIFIED="2013-09-05 16:09:07 +0530" MODIFIED_BY="[Empty name]" NAME="ELISA 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-05 16:09:07 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C337. The ELISA pilot study. Early (&amp;lt;6 h) angiography without Tirofiban vs late angiography with Tirofiban&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:09:07 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van 't Hof AW, de Vries ST, Dambrink JH, Miedema K, Suryapranata H, Hoorntje JCA, et al</AU>
<TI>A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes</TI>
<SO>European Heart Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>15</NO>
<PG>1401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-2008" MODIFIED="2013-09-05 16:09:14 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Ellis 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-05 16:09:14 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Comment in: N Engl J Med. 2008 May 22;358(21):2277-9. PMID: 18499572&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:09:14 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis SG, Tendera M, de Belder MA, Van Boven AJ, Widimsky P, Janssens L, et al</AU>
<TI>Facilitated PCI in patients with ST-elevation myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>21</NO>
<PG>2205-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emre-2006" MODIFIED="2009-11-05 21:21:13 +0530" MODIFIED_BY="Xavier Bosch" NAME="Emre 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-05 21:21:13 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emre A, Ucer E, Yesilcimen K, Bilsel T, Oz D, Sayar N, et al</AU>
<TI>Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting</TI>
<SO>Cardiology</SO>
<YR>2006</YR>
<VL>106</VL>
<NO>4</NO>
<PG>264-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ERAMI-2006" MODIFIED="2013-09-05 16:09:38 +0530" MODIFIED_BY="Xavier Bosch" NAME="ERAMI 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-05 16:09:38 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA</AU>
<TI>Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2006</YR>
<VL>68</VL>
<NO>2</NO>
<PG>218-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ercan-2004" NAME="Ercan 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;C93. Small study looking at differences in CRP at 48-72 h. No clinical events reported.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ercan E, Tengiz I, Duman C, Onbasili OA, Baris N</AU>
<TI>Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction</TI>
<SO>American Heart Journal</SO>
<YR>2004</YR>
<VL>147</VL>
<PG>E1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EVEREST-2006" NAME="EVEREST 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Comparison of Tirofiban administered in the CCU vs. in the catheterization laboratory&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, et al</AU>
<TI>Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2006</YR>
<VL>47</VL>
<PG>522-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghaffari-1998" NAME="Ghaffari 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Substudy of the EPILOG trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, et al</AU>
<TI>Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade</TI>
<SO>American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>1</NO>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GRAPE-1999" NAME="GRAPE 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;The GRAPE pilot study performed in 60 patients with STEMI treated with primary PCI without a control group. Not a randomized study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van den Merkhof LF, Zijlstra F, Olsson H, Grip L, Veen G, Bar FW, et al</AU>
<TI>Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>6</NO>
<PG>1528-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunasekara-2006" NAME="Gunasekara 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;A non-randomized comparison of Abciximab vs. high-dose Tirofiban&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunasekara AP, Walters DL, Aroney CN</AU>
<TI>Comparison of abciximab with 'high-dose' tirofiban in patients undergoing percutaneous coronary intervention</TI>
<SO>International Journal of Cardiology</SO>
<YR>2006</YR>
<VL>109</VL>
<PG>16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GUSTO-V-2001" MODIFIED="2013-09-05 16:10:36 +0530" MODIFIED_BY="[Empty name]" NAME="GUSTO V 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-05 16:10:36 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trial comparing the addition of a GP IIb/IIIa antagonist to the fibrinolytic treatment in patients with STEMI&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:10:36 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The GUSTO Investigators</AU>
<TI>Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein iib/IIIa inhibition: the GUSTO V randomised trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1905-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamm-1999" NAME="Hamm 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Substudy of the CAPTURE trial. Differential effects of Abciximab in patients with refractory angina according to basal troponin levels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al</AU>
<TI>Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>21</NO>
<PG>1623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamza-2011" MODIFIED="2013-07-31 12:09:10 +0530" MODIFIED_BY="Xavier Bosch" NAME="Hamza 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-27 21:36:55 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;AsiaPCR/SingLIVE 2011 Singapore Singapore. Conference Start: 20110113 Conference End: 20110115. Conference Publication: (var.pagings)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;NOT FOUND&lt;/p&gt;" NOTES_MODIFIED="2013-02-27 21:36:55 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamza M</AU>
<TI>Effect of high loading dose of clopidogrel vs glycoprotein llb/llla receptor antagonist in management of patients with non-ST-segment elevation acute coronary syndrome</TI>
<SO>EuroIntervention</SO>
<YR>2011</YR>
<VL>7</VL>
<PG>M174</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanefeld-2002" MODIFIED="2013-09-05 16:11:18 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hanefeld 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-05 16:11:18 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;C127. Pilot study of the Bochum trial&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:11:18 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanefeld C, Segbers S, Sirtl C, Lemke B, Mugg A</AU>
<TI>Pre-hospital therapy of acute coronary syndrome with the glycoprotein-IIb/IIIa receptor antagonist eptifibatide - pilot study Bochum</TI>
<TO>Prahospitale Therapie des akuten Koronarsyndroms mit dem Glykoprotein-IIb/IIIa-Rezeptor-Antagonisten Eptifibatide - Pilotstudie Bochum</TO>
<SO>Zeitschrift Für Kardiologie</SO>
<YR>2002</YR>
<VL>91</VL>
<NO>Suppl 5</NO>
<PG>V/10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heeschen-1999" NAME="Heeschen 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Substudy of the PRISM trial. Effects of Tirofiban in patients with US/NSTEMI according to baseline troponon levels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD</AU>
<TI>Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9192</NO>
<PG>1757-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HORIZONS_x002d_AMI-2008" MODIFIED="2013-09-05 16:11:38 +0530" MODIFIED_BY="Nicole Ackermann" NAME="HORIZONS-AMI 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-04-12 14:20:19 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al</AU>
<TI>Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>374</VL>
<PG>1149-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-05 16:11:38 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Comment in: ACP J Club. 2008 Sep 16;149(3):11. PMID: 18783187. Comment in: N Engl J Med. 2008 May 22;358(21):2280-2. PMID: 18499573&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:11:38 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al</AU>
<TI>Bivalirudin during primary PCI in acute myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>21</NO>
<PG>2218-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IMPACT_x002d_AMI-1997" NAME="IMPACT-AMI 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al</AU>
<TI>Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>95</VL>
<PG>846-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-INTAMI-2005" NAME="INTAMI 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Comparison of eptifibatide administered in the emergency room vs. in the cath lab in patients with STEMI submitted to primary PCI&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, et al</AU>
<TI>Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial</TI>
<SO>European Heart Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>1971-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISAR_x002d_REACT-4" MODIFIED="2013-09-05 16:12:39 +0530" MODIFIED_BY="Xavier Bosch" NAME="ISAR-REACT 4" YEAR="2011">
<REFERENCE MODIFIED="2013-09-05 16:12:39 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al, for the ISAR-REACT 4 Trial Investigators</AU>
<TI>Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>365</VL>
<PG>1980-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ji-2012" MODIFIED="2013-09-05 16:13:15 +0530" MODIFIED_BY="Xavier Bosch" NAME="Ji 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-05 16:13:15 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;17th Annual Interventional Vascular Therapeutics Angioplasty Summit-Transcatheter Cardiovascular Therapeutics Asia Pacific Symposium, TCTAP 2012 Seoul South Korea. Conference Start: 20120424 Conference End: 20120427. Conference Publication: (var.pagings). 109 (7 SUPPL&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;NOT FOUND&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:13:15 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ji ZG, Liu HB</AU>
<TI>Clinical efficacy and short-term prognosis of tirofiban treatment in different duration combined with percutaneous coronary intervention in acute st segment elevation myocardial infarction</TI>
<SO>American Journal of Cardiology</SO>
<YR>2012</YR>
<VL>1</VL>
<PG>7S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kereiakes-1997" NAME="Kereiakes 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Study with an oral GP IIb/IIIa antagonist&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, et al</AU>
<TI>Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>4</NO>
<PG>1117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kereiakes-1998a" MODIFIED="2013-09-05 16:13:38 +0530" MODIFIED_BY="[Empty name]" NAME="Kereiakes 1998a" YEAR="1998">
<REFERENCE MODIFIED="2013-09-05 16:13:38 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Study with an oral GP IIb/IIIa antagonist&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:13:38 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, et al</AU>
<TI>Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>13</NO>
<PG>1268-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kereiakes-1998b" MODIFIED="2013-09-05 16:13:47 +0530" MODIFIED_BY="[Empty name]" NAME="Kereiakes 1998b" YEAR="1998">
<REFERENCE MODIFIED="2013-09-05 16:13:47 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Substudy of the EPILOG trial&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:13:47 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, et al</AU>
<TI>Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>9</NO>
<PG>857-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kleiman-1998" NAME="Kleiman 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Substudy of the EPILOG trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, et al</AU>
<TI>Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>19</NO>
<PG>1912-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klootwijk-1998" NAME="Klootwijk 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Substudy of the CAPTURE trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML</AU>
<TI>Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>14</NO>
<PG>1358-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krause-1996" MODIFIED="2010-07-09 14:14:54 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Krause 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-07-09 14:14:54 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;C175. Abstract from a Congress. A phase II RCT with 3 escalating doses of i.v. Fradafiban in 65 patients with stable angina submitted to elective PTCA.&lt;br&gt;Aim: Safety and antiplatelet effects. No clinical events reported&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:14:54 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krause M, Rutsch W, Franke O, Langemann C, Dreysse S, Riess H</AU>
<TI>Fradafiban, a non-peptide GP IIB/IIA antagonist during elective coronary angioplasty: safety and antiplatelet effects</TI>
<SO>Annals of Hematology</SO>
<YR>1996</YR>
<VL>72</VL>
<PG>A53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefkovits-1996" NAME="Lefkovits 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Substudy of the EPIC trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, et al</AU>
<TI>Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators</TI>
<SO>American Journal of Cardiology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>12</NO>
<PG>1045-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenderink-2003" MODIFIED="2013-09-05 16:14:33 +0530" MODIFIED_BY="[Empty name]" NAME="Lenderink 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-05 16:14:33 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C186. Substudy of the CAPTURE trial&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:14:33 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, et al</AU>
<TI>Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. [see comment]</TI>
<SO>European Heart Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>1</NO>
<PG>77-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lincoff-1997" MODIFIED="2013-09-05 16:14:42 +0530" MODIFIED_BY="[Empty name]" NAME="Lincoff 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-05 16:14:42 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al</AU>
<TI>Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>1</NO>
<PG>149-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahaffey-1999" NAME="Mahaffey 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Substudy of the PURSUIT trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, et al</AU>
<TI>Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>18</NO>
<PG>2371-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mak-1997" NAME="Mak 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Substudy of the EPIC trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ</AU>
<TI>Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>8</NO>
<PG>985-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClure-1999" NAME="McClure 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Substudy of the PURSUIT trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, et al</AU>
<TI>Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>22</NO>
<PG>2892-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McElwee-1997" NAME="McElwee 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McElwee NE, Johnson ER</AU>
<TI>Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>4A</NO>
<PG>39B-43B</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1999" NAME="Miller 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JM, Smalling R, Ohman EM, Bode C, Betriu A, Kleiman NS, et al</AU>
<TI>Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>7</NO>
<PG>779-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mockel-2005" MODIFIED="2013-09-05 16:15:34 +0530" MODIFIED_BY="[Empty name]" NAME="Mockel 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-05 16:15:34 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comparison of prehospital tirofiban versus fibrinolysis before direct PCI in patients with STEMI&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:15:34 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mockel M, Bocksch W, Strohm S, Kuhnle Y, Vollert J, Nibbe L, et al</AU>
<TI>Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI</TI>
<SO>International Journal of Cardiology</SO>
<YR>2005</YR>
<VL>103</VL>
<PG>193-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrow-2001" MODIFIED="2013-09-05 16:15:45 +0530" MODIFIED_BY="[Empty name]" NAME="Morrow 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-05 16:15:45 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C229. Substudy of the TACTICS trial&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:15:45 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al</AU>
<TI>Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. [see comment]</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>19</NO>
<PG>2405-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1997" NAME="Muller 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J</AU>
<TI>Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>4</NO>
<PG>1130-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murdock-1997" MODIFIED="2013-09-05 16:16:13 +0530" MODIFIED_BY="[Empty name]" NAME="Murdock 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-05 16:16:13 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murdock DK, Logemann T, Hoffmann MT, Olson KJ, Engelmeier RS</AU>
<TI>Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with abciximab: early and six-month outcome</TI>
<SO>Catheterization &amp; Cardiovascular Diagnosis</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>2</NO>
<PG>173-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narins-1999" NAME="Narins 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Substudy of the EPIC trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Narins CR, Miller DP, Califf RM, Topol EJ</AU>
<TI>The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>3</NO>
<PG>647-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-1998" MODIFIED="2010-07-09 14:46:50 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Neumann 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-09 14:46:50 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Small study on primary PCI with stent implantation. Events at 14 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:46:50 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al</AU>
<TI>Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>24</NO>
<PG>2695-701</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:46:50 +0530" MODIFIED_BY="Nicole Ackermann"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newby-1999" NAME="Newby 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Design of the SYMPHONY trial on an oral GP IIb/IIIa antagonist&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newby LK</AU>
<TI>Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee</TI>
<SO>American Heart Journal</SO>
<YR>1999</YR>
<VL>138</VL>
<NO>2 Pt 1</NO>
<PG>210-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newby-2001" MODIFIED="2013-09-05 18:05:35 +0530" MODIFIED_BY="[Empty name]" NAME="Newby 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-05 18:05:35 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A substudy of the PARAGON-B study&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 18:05:35 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrigton RA, White HD, et al</AU>
<TI>Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin substudy</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<PG>2891-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okmen-2004" MODIFIED="2013-04-04 15:25:15 +0530" MODIFIED_BY="Xavier Bosch" NAME="Okmen 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-04-04 15:25:09 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N</AU>
<TI>Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty</TI>
<SO>Cardiology</SO>
<YR>2004</YR>
<VL>102</VL>
<PG>18-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okmen-2006" MODIFIED="2013-07-31 12:09:21 +0530" MODIFIED_BY="Xavier Bosch" NAME="Okmen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-05 21:52:37 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N</AU>
<TI>Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention</TI>
<SO>Angiology</SO>
<YR>2006</YR>
<VL>57</VL>
<NO>3</NO>
<PG>273-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-On_x002d_TIME-2004" MODIFIED="2013-09-05 16:17:36 +0530" MODIFIED_BY="[Empty name]" NAME="On-TIME 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-05 16:17:36 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C336. Pre-hospital Tirofiban vs hospital (median delay 59 m) Tirofiban during primary PCI in patients with STEMI&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:17:36 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, et al</AU>
<TI>Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. [see comment]</TI>
<SO>European Heart Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>10</NO>
<PG>837-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PARADIGM-1998" MODIFIED="2013-09-05 16:17:46 +0530" MODIFIED_BY="[Empty name]" NAME="PARADIGM 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-05 16:17:46 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trial on GP IIb/IIIa blockers in STEMI patients trerated with thrombolytics&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:17:46 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrington RA, Van de WF, Luyten A, Potkin B, McIntosh-Yellin N, Morgan C, et al</AU>
<TI>Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>7</NO>
<PG>2003-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PARAGON_x002d_B-2001" MODIFIED="2013-09-05 18:05:48 +0530" MODIFIED_BY="[Empty name]" NAME="PARAGON-B 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-05 18:05:48 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A substudy of the PARAGON-B study&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 18:05:48 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrigton RA, White HD, et al</AU>
<TI>Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin substudy</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<PG>2891-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pels-2008" MODIFIED="2013-09-05 16:18:34 +0530" MODIFIED_BY="Xavier Bosch" NAME="Pels 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-05 16:18:34 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pels K, Schröder J, Witzenbichler B, Mller D, Morguet A, Pauschinger M, et al</AU>
<TI>Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention</TI>
<SO>European Journal of Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>6</NO>
<PG>324-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2009" MODIFIED="2013-09-05 16:18:56 +0530" MODIFIED_BY="Xavier Bosch" NAME="Peng 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-05 16:18:56 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng JJ, Ma ZM, Ren LH, Ma ZM, Ren LH, Fu GQ, et al</AU>
<TI>Effect of tirofiban in acute anterior myocardial infarction patients without ST segment resolution after primary percutaneous coronary intervention</TI>
<SO>Zhonghua xin xue guan bing za zhi</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>8</NO>
<PG>725-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petronio-2002" NAME="Petronio 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;C263. Rescue PCI in STEMI after thrombolysis&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, et al</AU>
<TI>Abciximab improves 6-month clinical outcome after rescue coronary angioplasty</TI>
<SO>American Heart Journal</SO>
<YR>2002</YR>
<VL>143</VL>
<PG>334-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PROLOG-1997" NAME="PROLOG 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, et al</AU>
<TI>Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>3</NO>
<PG>286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rakowski-2007" MODIFIED="2009-11-05 21:57:18 +0530" MODIFIED_BY="Xavier Bosch" NAME="Rakowski 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-05 21:57:18 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rakowski T, Zalewski J, Legutko J, Bartus S, Rzeszutko L, Dziewierz A, et al</AU>
<TI>Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study</TI>
<SO>American Heart Journal</SO>
<YR>2007</YR>
<VL>153</VL>
<NO>3</NO>
<PG>360-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RELAx_x002d_AMI-2007" MODIFIED="2009-11-05 21:41:53 +0530" MODIFIED_BY="Xavier Bosch" NAME="RELAx-AMI 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-05 21:41:53 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;Comment in: Nat Clin Pract Cardiovasc Med. 2007 Oct;4(10):536-7. PMID: 17684480&lt;/p&gt;" NOTES_MODIFIED="2009-11-05 21:41:53 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP</AU>
<TI>Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2007</YR>
<VL>49</VL>
<NO>14</NO>
<PG>1517-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2012" MODIFIED="2013-09-05 16:19:34 +0530" MODIFIED_BY="Xavier Bosch" NAME="Ren 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-05 16:19:34 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;EXCLUDED&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:19:34 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren XN, Wang LF, Wang MS, Xu L</AU>
<TI>Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. [Chinese]</TI>
<SO>Chinese Journal of Cardiology</SO>
<YR>2012</YR>
<VL>40</VL>
<PG>131-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ReoPro_x002d_BRIDGING-2004" MODIFIED="2013-09-05 16:19:44 +0530" MODIFIED_BY="[Empty name]" NAME="ReoPro-BRIDGING 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-05 16:19:44 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;E73. Abciximab at admission versus Abciximab immediately before primary PCI (mean difference 62 min) in patients with ST elevation myocardial infarction&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:19:44 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, et al</AU>
<TI>Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study</TI>
<SO>European Heart Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>23</NO>
<PG>2125-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-REPLACE_x002d_2-2003" NAME="REPLACE-2 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al</AU>
<TI>Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>292</VL>
<PG>696-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roe-2003" MODIFIED="2013-09-05 16:20:02 +0530" MODIFIED_BY="[Empty name]" NAME="Roe 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-05 16:20:02 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C275. Treatment with Eptifibatide vs Placebo in the Emergency department followed by open-label Eptifibatide 12-24 h later.&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:20:02 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roe MT, Christenson RH, Ohman EM, Bahr R, Fesmire FM, Storrow A, et al</AU>
<TI>A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes</TI>
<SO>American Heart Journal</SO>
<YR>2003</YR>
<VL>146</VL>
<NO>6</NO>
<PG>993-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2007" MODIFIED="2013-09-05 16:20:18 +0530" MODIFIED_BY="Xavier Bosch" NAME="Shen 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-05 16:20:18 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;18269820&lt;br&gt;Chinese&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:20:18 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shen J, Zhang Q, Zhang RY</AU>
<TI>Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction [Chinese]</TI>
<SO>Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>11</NO>
<PG>1005-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpfendorfer-1997" NAME="Simpfendorfer 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Study on an oral GP IIb/IIIa antagonist&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, et al</AU>
<TI>First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>1</NO>
<PG>76-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPEED-P_x002d_St--2000" NAME="SPEED P-St  2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Thrombolysis in patients with STEMI with or without GP IIb/IIIa antagonist, followed by primary PCI (facilitated PCI)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermann HC, Moliterno DJ, Ohman EM, Sebbins AL, Bode C, Betriu A</AU>
<TI>Facilitation of early percutaneous coronary intervention after Reteplase with or without abciximab in acute myocardial infarction</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>36</VL>
<PG>1489-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steen-2005" NAME="Steen 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Comparison of myocardial tissue perfusion with and without Tirofiban in patients with STEMI. No clinical events reported.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steen H, Lehrke S, Wiegand UK, Merten C, Schuster L, Richardt G, et al</AU>
<TI>Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction</TI>
<SO>American Heart Journal</SO>
<YR>2005</YR>
<VL>149</VL>
<NO>3</NO>
<PG>564</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOPAMI-2000" MODIFIED="2013-09-05 16:21:05 +0530" MODIFIED_BY="[Empty name]" NAME="STOPAMI 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Primary PCI with stent and abciximab vs. thrombolysis in patients with STEMI&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schömic A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, et al</AU>
<TI>Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-05 16:20:54 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schomig A, Schwaiger M, Mehilli J, Neverve J, Pache J, Schricke U, et al</AU>
<TI>1-year mortality after stenting with abciximab or thrombolysis in acute myocardial infarction and prognostic value of myocardial salvage. Results of the STOPAMI study</TI>
<SO>Zeitschrift Fur Kardiologie</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>Suppl 2</NO>
<PG>109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-05 16:21:05 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schricke U, Mehilli J, Neverve J, Ibrahim T, Nekolla S, Blasini R, et al</AU>
<TI>Myocardial salvage and clinical one-year results in patients with acute anterior myocardial infarction and stent placement with abciximab or thrombolysis: a STOPAMI sub-group analysis</TI>
<SO>Zeitschrift Fur Kardiologie</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>Suppl 2</NO>
<PG>74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOPAMI_x002d_2-2002" MODIFIED="2013-09-05 16:21:15 +0530" MODIFIED_BY="[Empty name]" NAME="STOPAMI-2 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-05 16:21:15 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Primary PCI with stent and abciximab vs. thrombolysis and abciximab in patients with STEMI&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:21:15 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, et al</AU>
<TI>Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>920-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svensson-2006" NAME="Svensson 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Thrombolysis vs Facilitated PCI with Abciximab in patients with STEMI&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Summers KM, Holdford DA, Crouch MA</AU>
<TI>Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention</TI>
<SO>Pharmacotherapy</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>609-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SYMPHONY-2-2001" MODIFIED="2013-09-05 18:06:23 +0530" MODIFIED_BY="[Empty name]" NAME="SYMPHONY 2 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-05 18:06:23 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Study on an oral GP IIb/IIIa antagonist&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 18:06:23 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Second SYMPHONY Investigators</AU>
<TI>Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<PG>1727-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TAMI_x002d_8-1993" NAME="TAMI-8 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;TAMI-8 pilot study on the effects of abciximab in patients with STEMI treated with thrombolytics&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al</AU>
<TI>Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>2</NO>
<PG>381-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TARGET-2001" MODIFIED="2010-07-09 14:47:36 +0530" MODIFIED_BY="Nicole Ackermann" NAME="TARGET 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-07-09 14:47:36 +0530" MODIFIED_BY="Nicole Ackermann" NOTES="&lt;p&gt;Trial comparing Abciximab with tirofiban in patients submitted to PCI&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 14:47:36 +0530" NOTES_MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al</AU>
<TI>Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<PG>1888-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiele-2005" NAME="Thiele 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Patients with STEMI were randomized to either pre-hospital facilitated fibrinolysis (half-dose reteplase+abciximab) or pre-hospital facilitated fibrinolysis (half-dose reteplase+abciximab) plus PCI&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiele H, Engelmann L, Elsner K, Kappl MJ, Storch WH, Rahimi K, et al</AU>
<TI>Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction</TI>
<SO>European Heart Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>1956-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TIGER_x002d_PA-2003" MODIFIED="2013-09-05 16:21:51 +0530" MODIFIED_BY="[Empty name]" NAME="TIGER-PA 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-05 16:21:51 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;C183. Open-label randomization of patients (n=100) with ST segment elevation MI to &amp;quot;early&amp;quot; administration of Tirofiban in the emergency room versus &amp;quot;late&amp;quot; administration in the catheterization laboratory immediately before primary PCI.&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:21:51 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, et al</AU>
<TI>Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>11</NO>
<PG>1497-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TIMI-14-1999" NAME="TIMI 14 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Thrombolysis with or without abciximab in patients with STEMI&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al</AU>
<TI>Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>21</NO>
<PG>2720-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TIMI-15A-2000" MODIFIED="2013-09-05 16:22:29 +0530" MODIFIED_BY="[Empty name]" NAME="TIMI 15A 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-05 16:22:29 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Study on an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with acute coronary syndromes&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:22:29 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, et al</AU>
<TI>First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials</TI>
<SO>American Heart Journal</SO>
<YR>2000</YR>
<VL>140</VL>
<PG>81-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TITAN_x002d_TIMI-34-2006" MODIFIED="2009-11-05 21:25:51 +0530" MODIFIED_BY="Xavier Bosch" NAME="TITAN-TIMI 34 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-05 21:25:51 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, et al</AU>
<TI>Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial</TI>
<SO>American Heart Journal</SO>
<YR>2006</YR>
<VL>152</VL>
<NO>4</NO>
<PG>668-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valgimigli-2005" NAME="Valgimigli 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Comparison of Tirofiban and an eluting stent vs. Abciximab + bare metal stent durinf primary PCI in patients with STEMI&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al</AU>
<TI>Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<PG>2109-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-den-Brand-1999" MODIFIED="2013-09-05 16:23:20 +0530" MODIFIED_BY="[Empty name]" NAME="van den Brand 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-05 16:23:20 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Substudy of the CAPTURE trial&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:23:20 +0530" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van den Brand M, Laarman GJ, Steg PG, De Scheerder I, Heyndrickx G, Beatt K, et al</AU>
<TI>Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial</TI>
<SO>European Heart Journal</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>21</NO>
<PG>1572-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-den-Merkhof-1999" NAME="van den Merkhof 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Study on the TIMI perffusion grade of 60 patients with STEMI treated with Abciximab in the emergency department. Not a RCT&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van den Merkhof LF, Zijlstra F, Olsson H, Grip L, Veen G, Bar FW, et al</AU>
<TI>Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>6</NO>
<PG>1528-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2003" NAME="Wong 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;M528. Small study (n=32) on the coronary flow reserve before and after stenting in patients receiving Tirofiban vs. control. No data on clinical events&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong P, Harding S, Inglessis I, Choi CJ, Walters D, Chang Y, et al</AU>
<TI>The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study</TI>
<SO>Journal of Thrombosis &amp; Thrombolysis</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>163-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zajdel-2002" NAME="Zajdel 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;C351. Abstract from a congress&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zajdel W, Zalewski J, Czunko P, et al</AU>
<TI>Randomised trial assessing efficacy and safety of cornaroplasty in coronary arteries of reference size of &lt; 2,9 mm with the use of integrillin - eptifibatide -- preliminary results</TI>
<SO>Kardiologia Polska</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>II-166</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeymer-2008" MODIFIED="2013-09-05 16:25:12 +0530" MODIFIED_BY="Xavier Bosch" NAME="Zeymer 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-05 16:25:12 +0530" MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeymer U</AU>
<TI>Eptifibatide versus abciximab in primary PCI for acute St-elevation myocardial infarction: EVA-AMI Study</TI>
<SO>Clinical Research in Cardiology</SO>
<YR>2008</YR>
<VL>97</VL>
<NO>1</NO>
<PG>2-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2011" MODIFIED="2013-09-05 16:25:25 +0530" MODIFIED_BY="Xavier Bosch" NAME="Zhang 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-05 16:25:25 +0530" MODIFIED_BY="Xavier Bosch" NOTES="&lt;p&gt;NOT FOUND&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:25:25 +0530" NOTES_MODIFIED_BY="Xavier Bosch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YX, Lu CY, Zhou SH, Xue Q, Gao L, Tian JW, et al</AU>
<TI>Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention</TI>
<SO>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue</SO>
<YR>2011</YR>
<VL>23</VL>
<PG>727-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-1999" NAME="Zhao 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Substudy of the PRISM PLUS trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao XQ, Theroux P, Snapinn SM, Sax FL</AU>
<TI>Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>15</NO>
<PG>1609-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-04-17 20:02:48 +0530" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-12-15 23:25:14 +0530" MODIFIED_BY="Xavier Bosch"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-05 18:08:55 +0530" MODIFIED_BY="Joey Kwong">
<ADDITIONAL_REFERENCES MODIFIED="2013-09-05 18:08:55 +0530" MODIFIED_BY="Joey Kwong">
<REFERENCE ID="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" MODIFIED="2013-09-05 16:27:25 +0530" MODIFIED_BY="Karen Hovhannisyan" NAME="ACCF/AHA Guideline NSTEACS 2013" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al</AU>
<TI>2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non&#8211;ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2013</YR>
<VL>61</VL>
<NO>23</NO>
<PG>e179-347</PG>
<IDENTIFIERS MODIFIED="2013-09-05 16:27:19 +0530" MODIFIED_BY="Xavier Bosch">
<IDENTIFIER MODIFIED="2013-09-05 16:27:19 +0530" MODIFIED_BY="Xavier Bosch" TYPE="DOI" VALUE="10.1016/j.jacc.2013.01.014"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ACCF_x002f_AHA-Guideline-revascularization-2012" MODIFIED="2013-09-05 16:28:25 +0530" MODIFIED_BY="Xavier Bosch" NAME="ACCF/AHA Guideline revascularization 2012" TYPE="JOURNAL_ARTICLE">
<AU>Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA</AU>
<TI>ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2012</YR>
<VL>59</VL>
<NO>9</NO>
<PG>857-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2003" MODIFIED="2010-05-20 16:11:28 +0530" MODIFIED_BY="Xavier Bosch" NAME="Als-Nielsen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Als-Nielsen B, Chen W, Gluud C, Kjaergard LL</AU>
<TI>Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<PG>921-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATC-2002" MODIFIED="2008-09-09 14:27:20 +0530" MODIFIED_BY="Karen Hovhannisyan" NAME="ATC 2002" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists' Collaboration</AU>
<TI>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>324</VL>
<PG>71-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boersma-1999" MODIFIED="2010-06-15 18:07:01 +0530" MODIFIED_BY="Joey Kwong" NAME="Boersma 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML</AU>
<TI>Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>20</NO>
<PG>2045-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boersma-2002" MODIFIED="2010-06-15 18:07:11 +0530" MODIFIED_BY="Joey Kwong" NAME="Boersma 2002" TYPE="JOURNAL_ARTICLE">
<AU>Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al</AU>
<TI>Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bovill-1991" MODIFIED="2010-06-15 18:06:57 +0530" MODIFIED_BY="Joey Kwong" NAME="Bovill 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bovill EG, Terrin ML, Stump DC</AU>
<TI>Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<PG>256-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CRUSADE-2006" MODIFIED="2010-07-29 15:56:26 +0530" MODIFIED_BY="Joey Kwong" NAME="CRUSADE 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV, Brindis RG, et al</AU>
<TI>Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes. Insights from the CRUSADE initiative</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<PG>2027-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CURE-2001" MODIFIED="2010-07-29 15:56:32 +0530" MODIFIED_BY="Joey Kwong" NAME="CURE 2001" TYPE="JOURNAL_ARTICLE">
<AU>The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE)</AU>
<TI>Effects of clopidogrel in addition to aspirin patients with acute coronary syndromes without ST-segment elevation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<PG>494-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESC-Guidelines-CV-Prevention-2012" MODIFIED="2013-09-05 16:30:08 +0530" MODIFIED_BY="Nicole Ackermann" NAME="ESC Guidelines CV Prevention 2012" TYPE="JOURNAL_ARTICLE">
<AU>Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al</AU>
<TI>European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice</TI>
<SO>European Heart Journal</SO>
<YR>2012</YR>
<VL>33</VL>
<NO>13</NO>
<PG>1635-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESC-Guidelines-NSTEACS-2011" MODIFIED="2013-09-05 16:30:35 +0530" MODIFIED_BY="Xavier Bosch" NAME="ESC Guidelines NSTEACS 2011" TYPE="JOURNAL_ARTICLE">
<AU>Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al</AU>
<TI>ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)</TI>
<SO>European Heart Journal</SO>
<YR>2011</YR>
<VL>32</VL>
<NO>23</NO>
<PG>2999-3054</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESC-Guidelines-revascularization-2010" MODIFIED="2013-09-05 16:30:53 +0530" MODIFIED_BY="Xavier Bosch" NAME="ESC Guidelines revascularization 2010" TYPE="JOURNAL_ARTICLE">
<AU>Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al</AU>
<TI>Guidelines on myocardial revascularization</TI>
<SO>European Heart Journal</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>20</NO>
<PG>2501-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falk--1995" MODIFIED="2008-09-09 14:27:20 +0530" MODIFIED_BY="Karen Hovhannisyan" NAME="Falk  1995" TYPE="JOURNAL_ARTICLE">
<AU>Falk E, Shah P, Fuster V</AU>
<TI>Coronary plaque disruption</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<PG>657-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRACE-2007" MODIFIED="2013-09-05 16:31:20 +0530" MODIFIED_BY="Joey Kwong" NAME="GRACE 2007" TYPE="JOURNAL_ARTICLE">
<AU>Fox KAA, Anderson FA Jr, Dabbous OH, Steg PG, López-Sendón J, Van de Werf F, et al</AU>
<TI>Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)</TI>
<SO>Heart</SO>
<YR>2007</YR>
<VL>97</VL>
<PG>147-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gurbel-2005" MODIFIED="2008-09-09 14:27:20 +0530" MODIFIED_BY="Karen Hovhannisyan" NAME="Gurbel 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US</AU>
<TI>Clopidogrel loading with eptifibatide to arrest the reactivity of platelets. Results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>111</VL>
<PG>1153-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-09-05 16:32:06 +0530" MODIFIED_BY="Xavier Bosch" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2013-07-23 20:26:57 +0530" MODIFIED_BY="Xavier Bosch"/>
</REFERENCE>
<REFERENCE ID="REF-Hochholzer-2005" MODIFIED="2010-07-09 14:54:24 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hochholzer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al</AU>
<TI>Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>111</VL>
<NO>20</NO>
<PG>2560-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mehta-2003" MODIFIED="2008-09-09 14:27:20 +0530" MODIFIED_BY="Karen Hovhannisyan" NAME="Mehta 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mehta SR, Yusuf S</AU>
<TI>Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>4 Suppl S</NO>
<PG>79S-88S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2013-05-09 20:52:37 +0530" MODIFIED_BY="Karen Hovhannisyan" NAME="NICE 2010" TYPE="OTHER">
<AU>Robinson M, Ginnelly L, Sculpher MJ, Jones L, Riemsma R, Palmer S, et al</AU>
<TI>Guidance of the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes</TI>
<SO>National Institute for Health and Clinical Excellence</SO>
<YR>2002; re-issued March 2010</YR>
<IDENTIFIERS MODIFIED="2013-05-09 20:49:49 +0530" MODIFIED_BY="Xavier Bosch">
<IDENTIFIER MODIFIED="2013-05-09 20:49:49 +0530" MODIFIED_BY="Xavier Bosch" TYPE="OTHER" VALUE="www.nice.org.uk/guidance/TA47"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-OASIS_x002d_5--2006" MODIFIED="2010-07-09 14:55:00 +0530" MODIFIED_BY="Nicole Ackermann" NAME="OASIS-5  2006" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al</AU>
<TI>Comparison of fondaparinux and enoxaparin in acute coronary syndromes. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>14</NO>
<PG>1464-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patrono-2011" MODIFIED="2013-09-05 16:32:43 +0530" MODIFIED_BY="Xavier Bosch" NAME="Patrono 2011" TYPE="JOURNAL_ARTICLE">
<AU>Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al</AU>
<TI>Antiplatelet agents for the treatment and prevention of atherothrombosis</TI>
<SO>European Heart Journal</SO>
<YR>2011</YR>
<VL>32</VL>
<NO>23</NO>
<PG>2922-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PCI_x002d_CURE-2001" MODIFIED="2010-07-29 15:57:12 +0530" MODIFIED_BY="Joey Kwong" NAME="PCI-CURE 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al</AU>
<TI>Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients in patients undergoing percutaneous coronary intervention: the PCI-CURE study</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<PG>527-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phillips-1988" MODIFIED="2010-07-29 15:57:27 +0530" MODIFIED_BY="Joey Kwong" NAME="Phillips 1988" TYPE="JOURNAL_ARTICLE">
<AU>Phillips DR, Charo IF, Parise LV, Fitzgerald LA</AU>
<TI>The platelet membrane glycoprotein IIb-IIIa complex</TI>
<SO>Blood</SO>
<YR>1988</YR>
<VL>71</VL>
<PG>831-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PLATO-2009" MODIFIED="2010-07-09 14:55:38 +0530" MODIFIED_BY="Nicole Ackermann" NAME="PLATO 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wallentin L, Becker RC, Budaj A, Christopher P, Cannon CP, Emanuelsson H, et al</AU>
<TI>Ticagrelor versus clopidogrel in patients with acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>361</VL>
<NO>11</NO>
<PG>1045-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quinn-2002" MODIFIED="2013-09-05 18:08:55 +0530" MODIFIED_BY="Karen Hovhannisyan" NAME="Quinn 2002" TYPE="JOURNAL_ARTICLE">
<AU>Quinn MJ, Plow EF, Topol EJ</AU>
<TI>Platelet glycoprotein IIb/IIIa inhibitors. Recognition of a two-edge sword?</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>106</VL>
<PG>379-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinhubl-2007" MODIFIED="2013-08-15 22:09:23 +0530" MODIFIED_BY="Xavier Bosch" NAME="Steinhubl 2007" TYPE="JOURNAL_ARTICLE">
<AU>Steinhubl SR, Kastrati A, Berger PB</AU>
<TI>Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs</TI>
<SO>American Heart Journal</SO>
<YR>2007</YR>
<VL>154</VL>
<PG>3211</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TRITON-TIMI_x002d_38-2007" MODIFIED="2013-09-05 16:34:48 +0530" MODIFIED_BY="Nicole Ackermann" NAME="TRITON TIMI-38 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al; TRITON-TIMI 38 Investigators</AU>
<TI>Prasugrel versus clopidogrel in patients with acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<PG>2001-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Universal-definition-MI-2012" MODIFIED="2013-09-05 16:34:58 +0530" MODIFIED_BY="Xavier Bosch" NAME="Universal definition MI 2012" TYPE="JOURNAL_ARTICLE">
<AU>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction</AU>
<TI>Third universal definition of myocardial infarction</TI>
<SO>Circulation</SO>
<YR>2012</YR>
<VL>126</VL>
<PG>2020-3035</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-07-12 16:56:48 +0530" MODIFIED_BY="Joey Kwong"/>
<PENDING_REFERENCES MODIFIED="2013-02-27 21:50:47 +0530" MODIFIED_BY="Xavier Bosch"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-10-03 16:31:18 +0530" MODIFIED_BY="Joey Kwong">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-10-03 16:31:18 +0530" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-10-03 15:44:29 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<CHAR_METHODS MODIFIED="2013-09-09 18:27:20 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: an independent study nurse at each site performed assignments of study treatments via a procedure using sealed envelopes, in preselected blocks of 6</P>
<P>Double-blinded?: yes</P>
<P>Stratification: yes, according to the presence of stable or unstable coronary artery disease and poor responsiveness to aspirin, clopidogrel, or both</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: partially supported by a research grant from Merck, USA and Iroko, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:27:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 10 centres in Italy, Belgium, France and Spain</P>
<P>Timeframe: from February 2006 to June 2008</P>
<P>Follow-up: 30 days</P>
<P>Eligibility criteria: 263 patients &gt; 18 ys scheduled for coronary angiography, PCI or both who presented with stable or troponin-negative NSTEACS, and showed poor ex-vivo response to aspirin or clopidogrel</P>
<P>Exclusion criteria: any evidence of myocardial damage as witnessed by a rise of cardiac specific injury markers and ongoing MI, defined as the presence of ST-segment elevation at ECG or new or presumably new left bundle-branch block</P>
<P>Mean age: 68 y, 74% male, 26% diabetes, 43% prior MI</P>
<P>ACS: 32% (unstable angina: 32%, non-STEMI: 0%, STEMI: 0%)</P>
<P>PCI: 100% (balloon angioplasty: 7%, stent: 93%, drug-eluting stents: ?%), pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:11:35 +0530" MODIFIED_BY="[Empty name]">
<P>Tirofiban (bolus of 25 µg/kg plus a 14 to 24-h infusion of 0.15 µg/kg/min) for 14 to 24 hours versus placebo (bolus and infusion)</P>
<P>93 patients were low-responders to aspirin, 147 to clopidogrel and 23 to both. Screening for clopidogrel response was undertaken in patients at steady state for aspirin provided at least 1 of the following 2 requirements was fulfilled: the patient received a 600 or 300 mg loading dose &#8805; 2 or 6 hours before, respectively, or the patient received a 75 mg maintenance clopidogrel dose for &#8805; 7 consecutive days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:27:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary:<B> </B>rate of periprocedural MI</P>
<P>Secondary: 30-day occurrence of minor myocardial injury, the composite of death, MI, or urgent target vessel revascularisation, and the incidence of stent thrombosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 15:44:29 +0530" MODIFIED_BY="[Empty name]">
<P>Screening for clopidogrel response was undertaken in patients at steady state for aspirin provided at least 1 of the following 2 requirements was fulfilled: the patient received a 600 or 300 mg loading dose &gt;2 or 6 h before, respectively, or the patient received a 75 mg maintenance clopidogrel dose for &#8805; 7 consecutive days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:37:56 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACE-2003">
<CHAR_METHODS MODIFIED="2013-09-09 18:27:34 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: by means of a computer-generated sequence, and assignments were made using a centralised telephone system</P>
<P>Double-blinded?: no (study not blinded, without a placebo group)</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: SORIN Biomedica and the ARCARD ONLUS Foundation<B> </B>
</P>
<P>Follow-up: 30 days and 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:37:56 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 4 centres in Italy, Argentina and Germany</P>
<P>Timeframe: from January 2001 to August 2002</P>
<P>Eligibility criteria: 400 patients with ST-segment elevation acute myocardial infarction of less than 6 hours or between 6 and 24 hours if there was evidence of continuing ischaemia, including patients with cardiogenic shock</P>
<P>Exclusion criteria: previous administration of fibrinolytic or abciximab therapy, a history of bleeding diathesis or allergy to the study drug, major surgery within 15 days, active bleeding, participation in another study, and inability to obtain informed consent. Angiographic criteria: IRA reference diameter &lt; 2.5 mm, a previously stented IRA; 3) &lt; 70% stenosis of the IRA associated with Thrombolysis In Myocardial Infarction (TIMI) trial flow grade 3 (9); and 4) an inability to identify the IRA</P>
<P>Mean age: 66 y, male: 78%, diabetes: 18%, prior myocardial infarction: 11%<BR/>Acute coronary syndrome: 100% (unstable angina: 0%, non-STEMI: 0%, STEMI: 100%)<BR/>PCI: atherectomy: ?%, balloon angioplasty: 0%, stent: 99%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:27:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Unblinded abciximab versus placebo. Patients randomised to abciximab received the drug immediately before the procedure as a bolus of 0.25 mg/kg body weight, followed by a 12-h infusion at a rate of 0.125 µg/kg/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:27:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary:<B> </B>a composite of death from any cause, reinfarction, target vessel revascularisation, and stroke within 1 month of the index procedure</P>
<P>Secondary: ST-segment reduction, postprocedural corrected TIMI frame count, infarct size at 1 month, death from any cause at 6 months, reinfarction at 6 months, 6-month composite of death and reinfarction, TVR at 6 months, and angiographic restenosis of the IRA at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:27:34 +0530" MODIFIED_BY="[Empty name]">
<P>All patients treated with 325 mg of aspirin and heparin. Immediately after the procedure patients received 500 mg of ticlopidine or 300 mg of clopidogrel. Aspirin and clopidogrel 75 mg or ticlopidine 500 mg were maintained for 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:27:46 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ADMIRAL-2001">
<CHAR_METHODS MODIFIED="2013-09-09 18:27:45 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: not stated (all the patients were randomly assigned,<SUP> </SUP>in the order in which they were enrolled, to receive either abciximab or placebo)</P>
<P>Double-blinded?: yes</P>
<P>Stratification: none stated</P>
<P>Placebo. yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: supported by Eli Lilly, Saint-Cloud, France and Indianapolis,<SUP> </SUP>and by Saint-Côme-Chirurgie, Marseilles, France</P>
<P>Follow-up: 30 days and 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:27:46 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 26 centres in France</P>
<P>Timeframe: from 12 July 1997 to 22 December 1998</P>
<P>Eligibility criteria: 300 patients with ST-segment elevation acute myocardial infarction of less than 12 h with coronary anatomy suitable for stent implantation</P>
<P>Exclusion criteria: bleeding diathesis, administration of<SUP> </SUP>thrombolytic agents for the current episode, neoplasm, recent<SUP> </SUP>stroke, uncontrolled hypertension, recent surgery, oral anticoagulant<SUP> </SUP>therapy, a limited life expectancy, childbearing potential<SUP> </SUP>and known contraindications to therapy with aspirin, ticlopidine<SUP> </SUP>or heparin</P>
<P>Mean age: 61 y, male: 82%, prior myocardial infarction: 11%<BR/>Acute coronary syndrome: 100% (unstable angina: 0%, NSTEMI: 0%, STEMI: 100%)<BR/>PCI: atherectomy: ?%, balloon angioplasty: 13%, stent: 87%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:27:45 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab as a bolus of 0.25 mg per kilogram of body weight, followed by a 12-h infusion of 0.125 µg per kilogram per minute (maximum, 10 µg per minute) versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:27:46 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: a composite of death, myocardial infarction or urgent revascularisation at 30 days<BR/>Secondary: a composite of death, myocardial infarction or any revascularisation at 30 days and at 6 months; death or myocardial infarction, death, myocardial infarction or urgent revascularisation at 6 months; TIMI flow grade; ejection fraction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:27:46 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients treated with aspirin, heparin and ticlopidine</P>
<P>The data were retained by Eli Lilly, where the analyses were performed. Independent statistical advice was provided by E. Vicant (Paris VII University)</P>
<P>One of the authors, Dr. Pinton, was an employee of and stockholder in Eli Lilly. Dr.<SUP> </SUP>Montalescot has served as a consultant to Eli Lilly</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:28:02 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ADVANCE-2004">
<CHAR_METHODS MODIFIED="2013-09-09 18:28:01 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: by the use of computer-based 1:1 randomisation scheme by an independent study nurse</P>
<P>Double-blinded?:  yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: supported by a grant from Cassa dei Risparmi di Ferrara, Italy</P>
<P>Follow-up: 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:28:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 hospital in<SUP> </SUP>Italy (Arcispedale S. Anna Hospital, University of Ferrara)</P>
<P>Timeframe: from March 2002 to August 2003</P>
<P>Eligibility criteria: 202 coronary patients undergoing elective or urgent PCI + stent with clinical or angiographic high-risk features. Inclusion criteria were the presence of &gt; 1 stenosis &gt; 70% amenable to coronary stenting and the presence of diabetes mellitus, or a planned multivessel intervention, or the presence of non-ST-segment elevation ACS</P>
<P>Exclusion criteria: ST-segment elevation myocardial infarction, administration of any GP IIb/IIIa inhibitors during the previous 2 weeks, serum creatinine ?2.5 mg/dl, ongoing bleeding or bleeding diathesis, previous stroke in the last 6 months, major surgery within the previous 6 weeks, and platelet count &lt; 100,000 per mm<SUP>3</SUP>
</P>
<P>Mean age: 69 y, male: 68%, diabetes: 49%, prior myocardial infarction: 48%<BR/>Acute coronary syndrome: 56% (unstable angina: ?, NSTEMI: ?, STEMI: 0%)<BR/>ST-segment depression: ?, CK-MB elevation: ?, Troponin elevation: ?</P>
<P>PCI: atherectomy: ?, balloon angioplasty: 2%, stent: 98%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:28:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>High-dose bolus tirofiban (25 µg/kg per 3 min) and infusion (0.15 µg/kg/min for 24 to 48 h) versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:28:02 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: a composite of death, nonfatal MI, urgent TVR and thrombotic bailout GP IIb/IIIa inhibitor therapy<BR/>Secondary: each component of the primary endpoint, the effects on troponin I release after the procedure and the effects on pre-specified subgroups: diabetes and ACS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:28:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients were pre-treated with aspirin and a thienopyridine (clopidogrel 300 mg orally 6 h before the procedure (63%) or ticlopidine 500 mg 48 h before (37%))</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:28:23 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ASIAD-2005">
<CHAR_METHODS MODIFIED="2013-09-09 18:28:23 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by means of a computer-generated randomisation numbers at each centre</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Guidant, Corporation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:28:23 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 7 centres in China (5 in Hong Kong), India and Singapore</P>
<P>N: 254 patients</P>
<P>Timeframe: from January 2001 to October 2002</P>
<P>Follow-up: 6 months</P>
<P>Eligibility criteria: type 2 diabetic patients undergoing PCI with planned use of stents to treat de novo ?50% coronary lesions</P>
<P>Exclusion criteria: platelet count &lt; 100,000/L, concurrent warfarin therapy, INR ?1.5, uncontrolled hypertension, stroke in previous 2 y, transient ischaemic attack in previous 6 months, intracranial neoplasm, major surgery within 6 weeks, gastrointestinal bleeding within 3 months, PCI within 3 months, myocardial infarction within 5 days, and target lesion or target vessel proximal to target lesion containing thrombus</P>
<P>Mean age: 61 y, 74% male, 100% diabetes, 41% prior MI</P>
<P>ACS: 46% (non-STEACS: 31%, STEMI: 15%).</P>
<P>PCI: 100% (balloon angioplasty: 0%, stent: 100%, drug-eluting stents: 0%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:28:23 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg/kg up to 60 minutes before the intervention followed by a continuous infusion of 0.125 µg/kg/ min for 12 h) versus placebo (bolus and infusion)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:28:23 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: incidence of angiographic restenosis at 6 months follow-up</P>
<P>Secondary: major cardiac events (death, MI or target lesion revascularisation) at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:28:23 +0530" MODIFIED_BY="[Empty name]">
<P>Clopidogrel pre-treatment was administered as a 300 mg loading dose at least 12 h before the procedure, or a 75 mg daily dose 5 days before the intervention</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:38:20 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ASSIST-2009">
<CHAR_METHODS MODIFIED="2013-10-02 17:38:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Schering-Plough Canada Inc. provided an unrestricted grant and free distribution of eptifibatide, and Medtronic Canada Ltd provided free stents for the study</P>
<P>Follow-up: 30 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:28:30 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 3 centres in Ottawa, Canada</P>
<P>Timeframe: August 2005 to March 2008</P>
<P>Eligibility criteria: 400 patients with STEMI referred for primary PCI after pre-treatment with 160 mg of aspirin, 600 mg of clopidogrel and 60 U/kg of IV unfractionated heparin</P>
<P>Exclusion criteria: active bleeding, stroke within 90 days, intracranial bleeding at any time, major surgery or trauma within 6 weeks, systolic blood pressure &gt; 200 mm Hg or diastolic blood pressure &gt; 110 mm Hg, prolonged cardiopulmonary resuscitation, PCI within 30 days, fibrinolytic agents within 7 days, any glycoprotein IIb/IIIa inhibitors within 7 days, low-molecular-weight heparin within 12 h, coagulation disorder, current warfarin treatment, intolerance to aspirin or clopidogrel, other illness likely to result in death within 12 months, pregnancy, creatinine &gt; 200 µmol/L, cardiogenic shock and severe contrast allergy</P>
<P>Mean age: 60 y, male: 77%, prior myocardial infarction: 13%<BR/>Acute coronary syndrome: 100%<BR/>ST-segment depression: 0%, CK-MB elevation: 100%, troponin elevation: ?%<BR/>PCI: balloon PCI: 1%, stent: 93%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:38:20 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomly assigned in a 1:1 ratio to PCI with heparin plus eptifibatide or to PCI with heparin alone, in blocks of 10 at each site. Immediately after randomisation, patients assigned to the eptifibatide group received open-label drug, 180 µg/kg of body weight bolus, followed by a continuous infusion of 2.0 µg/kg per minute with a second bolus of 180 µg/kg administered 10 minutes after the first bolus. The infusion was reduced to 1.0 µg/kg per minute in patients with a creatinine clearance of &lt; 50 mL/min. Eptifibatide was to be initiated before cardiac catheterisation and the infusion continued for 18 hours after PCI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:28:30 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of death from any cause, recurrent myocardial infarction or recurrent severe ischaemia during the first 30 days after randomisation<BR/>Secondary: stroke, congestive heart failure and cardiogenic shock. Episodes of bleeding were classified by an independent adjudicator as major or minor according to the TIMI criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:28:30 +0530" MODIFIED_BY="Xavier Bosch">
<P>STEMI patients referred for primary PCI<BR/>All patients pre-treated with high-dose clopidogrel before the procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:38:27 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Bhattacharya-2010">
<CHAR_METHODS MODIFIED="2013-09-09 18:28:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by a computer-generated randomised table</P>
<P>Double-blinded?: yes</P>
<P>Placebo: yes, normal saline</P>
<P>Sample size calculation: not stated</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: not stated</P>
<P>Follow-up: 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:28:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 1 clinical centre from Kolkata, India</P>
<P>Timeframe: June 2007 to May 2009</P>
<P>Eligibility criteria: 301 patients with angina at rest within the last 48 h of presentation and a new ST depression of &gt; 1 mm, or a positive biomarker (cardiac troponin T &gt; 0.04 &#956;g/L or creatine kinase myocardial band (CK-MB) elevation &gt; the upper limit of normal), and with a TIMI score &gt; 4</P>
<P>Exclusion criteria: age &gt; 80 years, persistent ST-segment elevation, prior treatment with tirofiban within 3 months of presentation, PCI within the last 6 months, cardiogenic shock, contraindications for the use of anti-platelet drugs or LMWH, ACE inhibitors and beta blockers, or presence of valvular or congenital heart disease</P>
<P>Mean age: 62 y, 54% males, 45% diabetics, 26% with prior MI</P>
<P>Acute coronary syndrome: 100% (unstable angina: 55%, non-ST elevation myocardial infarction: 45%, STEMI: 0%)</P>
<P>ST-segment depression: 95%, troponin elevation: 45%</P>
<P>Coronary angiography: 0%, PCI: 0% (balloon angioplasty: 0%, stent: 0%, drug-eluting stent: 0%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:38:27 +0530" MODIFIED_BY="Xavier Bosch">
<P>Tirofiban was initially administered at the rate of 0.4 &#956;g/kg/min for 30 minutes and thereafter, the infusion rate was reduced to 0.1 &#956;g/kg/min. This was continued for the next 47 h and 30 minutes. The placebo was administered in bottles similar to those of tirofiban and consisted of 0.9% normal saline</P>
<P>Conventional therapy was defined as aspirin (375 mg started during admission followed by 75 mg once daily) and clopidogrel (300 mg loading dose, followed by 70 mg daily), with low-molecular weight heparin (LMWH) (enoxaparin 1 U/kg sc twice daily)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:28:37 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of total death, MI or refractory ischaemia at 1 and 3 months</P>
<P>Secondary: major bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:28:37 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study performed in Kolkata, India</P>
<P>No patient underwent coronary angiography or PCI</P>
<P>Complete outcome assessment available only for the first 7 days of follow-up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:28:55 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BRAVE_x002d_3-2009">
<CHAR_METHODS MODIFIED="2013-09-09 18:28:55 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: according to a computer-generated random sequence enclosed in sealed envelopes in the emergency room or intensive care unit of the 5 participating PCI centres. The size of the block was preselected by the statistician and was unknown to the investigators and medical staff caring for the patients</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: grants from Deutsches Herzzentrum, Munich, Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:28:55 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 5 centres in Germany and 1 in Austria</P>
<P>Timeframe: from June 2003 to January 2008</P>
<P>Follow-up: 30 days</P>
<P>Eligibility criteria: 800 patients with acute STEMI presenting &lt; 24 h after the onset of symptoms, or presumed new left bundle-branch block on surface ECG, who gave informed consent</P>
<P>Exclusion criteria: thrombolytic therapy for the index infarction; those with previous stroke within the last 3 months, active bleeding or bleeding diatheses, recent trauma or major surgery during the last month, suspected aortic dissection, oral anticoagulation therapy with coumarin derivatives within the last 7 days, recent use of glycoprotein IIb/IIIa inhibitors within the last 14 days, severe uncontrolled hypertension, haemoglobin &lt; 100 g/L or haematocrit &lt; 4%, platelet count &lt; 100,000/L or &gt; 600,000/L), malignancies, prolonged cardiopulmonary resuscitation, or cardiogenic shock; those &gt; 80 or &lt; 18 years of age; those with known or suspected pregnancy; and those who were allergic to study drugs</P>
<P>Mean age: 62 y, 74% male, 18% diabetes, 10% prior MI</P>
<P>ACS: 100% (non-STEACS: 0%, STEMI: 100%)</P>
<P>PCI: 100% (balloon angioplasty: 4%, stent: 96%, drug-eluting stents: 44%), pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:28:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg/kg followed by a continuous infusion of 0.125 µg/kg/ min (up to a maximal dose of 10 µg/min) for 12 h) versus placebo (bolus and infusion)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:28:55 +0530" MODIFIED_BY="[Empty name]">
<P>Primary:<B> </B>infarct size in a SPECT study</P>
<P>Secondary: total death resulting from any cause, recurrent MI, stroke, urgent IRA revascularisation at 30 days, and in-hospital incidence of major and minor bleeding complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-09 23:16:13 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients received 600 mg clopidogrel orally at the emergency room or intensive care unit of the admitting hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:29:08 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CADILLAC-2002">
<CHAR_METHODS MODIFIED="2013-09-09 18:29:08 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: not stated (patients were randomly assigned in a balanced fashion to 1 of 4 interventional strategies of reperfusion with the use of a 2 by 2 factorial design: PTCA alone, PTCA plus abciximab, stenting alone or stenting plus abciximab)</P>
<P>Double-blinded?: no, open-label study</P>
<P>Stratification: none stated</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: supported in part by Guidant, Lilly Research Laboratories and Mallinkrodt</P>
<P>Follow-up: 30 days and 1 year<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:29:08 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 76 centres in USA and 8 European countries</P>
<P>Timeframe: from November 1997 to September 1999</P>
<P>Eligibility criteria: 2082 patients with ST-segment elevation acute myocardial infarction of less than 12 h with a coronary stenosis no longer than 64 mm and with a reference diameter of 2.5 to 4 mm. Patients were randomised using a 2 by 2 factorial design to undergo PTCA alone, PTCA plus abciximab, stenting alone or stenting plus abciximab</P>
<P>Exclusion criteria: cardiogenic shock, history of bleeding diathesis or allergy to the study drug; major surgery within the preceding 6 weeks; gastrointestinal or genitourinary bleeding within the preceding 6 months; cerebrovascular event within the preceding 2 years or any permanent residual neurologic defect; history of leukopenia, thrombocytopenia, or hepatic or renal dysfunction; recent treatment with a thrombolytic agent; a non-cardiac illness associated with a life expectancy of less than 1 year; and participation in another study</P>
<P>Mean age: 60 y, male: 73%, diabetes: 16%, prior myocardial infarction: 14%<BR/>Acute coronary syndrome: 100% (unstable angina: 0%, NSTEMI: 12%, STEMI: 88%)<BR/>ST-segment depression: 0%, CK-MB elevation: 100%, troponin elevation: ?%</P>
<P>PCI: balloon angioplasty: 50%, stent: 50%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:29:08 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg per kilogram of body weight, followed by a 12-h infusion at a rate of 0.125 µg per kilogram per minute (maximum, 10 µg/minute)) versus control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:29:08 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: a composite of death, reinfarction, repeated intervention or revascularisation of the target vessel as a result of ischaemia or disabling stroke during the first 6 months after the index procedure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:29:08 +0530" MODIFIED_BY="Xavier Bosch">
<P>Al patients received 324 mg of aspirin before the procedure, 500 mg ticlopidine or 300 mg clopidogrel orally, a 5000 U bolus of heparin and a beta-blocker IV</P>
<P>All but 2 of the authors have received research support from, or have served as consultants to, companies manufacturing interventional devices or pharmaceutical agents relevant to this study. These companies include, but are not limited to, Guidant and Lilly Research Laboratories, 2 of the sponsors of the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:29:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CANADIAN-1996">
<CHAR_METHODS MODIFIED="2013-09-09 18:29:14 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by sequential numbers generated<SUP> </SUP>centrally and incorporated into double-blind labelling</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: F. Hoffmann-La Roche</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:29:14 +0530" MODIFIED_BY="[Empty name]">
<P>Institutions: 15 Canadian centres</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 365 patients with unstable angina or myocardial infarction without ST-segment elevation</P>
<P>Exclusion criteria: age &gt; 75 years (380 patients); unstable angina precipitated by identifiable factors (67 patients) or occurring within 6 months of coronary angioplasty or 2 months after bypass surgery (198 patients); a previous stroke (22 patients); a high bleeding risk including trauma, surgery or active bleeding within the previous month (89 patients); shock, congestive heart failure, left bundle-branch block, uncontrolled hypertension, a life-threatening concomitant illness, platelet count &lt; 100 000/mm<SUP>3</SUP>, use of oral anticoagulants or of an investigational drug, potential for pregnancy, or the inability to obtain informed consent (270 patients)</P>
<P>Mean age: 60 y, male: 72%, prior myocardial infarction: 55%<BR/>ACS: 100% (unstable angina: 86%, non-STEMI: 14%, STEMI: 0%), ST-segment depression: 65%, CK-MB elevation: 14%, Troponin elevation: ?<BR/>PCI: in-hospital: not stated, during drug-infusion: not stated<BR/>Treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:29:14 +0530" MODIFIED_BY="Xavier Bosch">
<P>Dose-ranging study in which patients were randomly assigned to 1 of 5 parallel study arms: 1 with placebo and 4 with different bolus plus infusion doses of lamifiban: 150 µg plus 1 µg/min, 300 µg plus 2 µg/min, 600 µg plus 4 µg/min, and 750 µg plus 5 µg/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:29:14 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study designed to obtain a first evaluation of lamifiban in patients with unstable angina and to determine an optimal dose of the drug for a subsequent pivotal trial on a large scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:29:14 +0530" MODIFIED_BY="Xavier Bosch">
<P>Dose-ranging trial: all 4 lamifiban arms were grouped for the analysis<BR/>All patients were treated with aspirin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:29:34 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CAPTURE-1997">
<CHAR_METHODS MODIFIED="2013-09-09 18:29:33 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: randomisation was obtained by telephone call to an independent service organised by the Department of Clinical Epidemiology of the University of Amsterdam</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: not stated</P>
<P>Follow-up: 30 days and 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:29:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 69 centres in 12 countries (Netherlands, Germany, France, Belgium, Spain, UK, Italy, Israel, Switzerland, Canada, Portugal, Austria)</P>
<P>Timeframe: from May 1993 to December 1995</P>
<P>Eligibility criteria: 1265 patients with refractory unstable angina who underwent percutaneous transluminal coronary angioplasty</P>
<P>Exclusion criteria: recent myocardial infarction, persisting ischaemia that would require immediate intervention; a greater than 50% occlusion of the left main coronary artery or a culprit lesion located in a bypass graft; bleeding risk factors such as surgery, gastrointestinal or genitourinary bleeding during the 6 weeks before enrolment, or a cerebrovascular accident within the previous 2 years; planned administration of oral anticoagulants or a thrombolytic agent before or during PTCA; underlying medical conditions such as persistent hypertension despite treatment; history of haemorrhagic diathesis; history of autoimmune disease, or a platelet count below 100 x 109/L</P>
<P>Mean age: 61 y, male: 72%, prior myocardial infarction: 50%<BR/>Acute coronary syndrome: 100% (unstable angina: 100%, NSTEMI: 0%, STEMI: 0%)<BR/>ST-segment depression: ?, CK-MB elevation: 0%, troponin elevation: ?<BR/>PCI: balloon angioplasty: 98%, stent: 1%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:29:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (0.25 mg/kg bolus followed by a continuous infusion of 10 µg/min) versus matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:29:33 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary:<B> </B>30-day incidence of death (from any cause), myocardial infarction or an urgent intervention for treatment of recurrent ischaemia</P>
<P>Secondary: each component of the composite endpoint and bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:29:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Intervention began 18 to 24 h before percutaneous transluminal coronary angioplasty and continued until 1 h after it. Permits assessment of the effect of GP IIb/IIIa blockers as initial medical treatment of unstable angina and also during percutaneous transluminal coronary angioplasty</P>
<P>The trial was discontinued on the recommendation of the Safety and Efficacy Monitoring Committee after interim analysis of 1050 patients (planned 1400 patients)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:39:06 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2000">
<CHAR_METHODS MODIFIED="2013-09-09 18:29:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded ?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: not stated</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:29:59 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 1 centre in Taiwan (The Veterans General Hospital, Taipei)</P>
<P>Timeframe: from January 1997 to July 1997</P>
<P>Eligibility criteria: 42 coronary patients scheduled to undergo coronary angioplasty. They were eligible if they had early postinfarction angina or unstable angina with &gt;= 2 episodes of angina at rest associated with ECG changes during the previous 24 h; or clinical or angiographic characteristics indicating high risk according to the AHA/ACC criteria</P>
<P>Exclusion criteria: patients &gt; 80 y old, bleeding diatheses, major surgery within prior 6 weeks, stroke within prior 2 y, planned stent implantation or atherectomy</P>
<P>Mean age: 70 y, male: 95%, diabetes:35%, prior myocardial infarction: 46%<BR/>Acute coronary syndrome: 29% (unstable angina: 29%, NSTEMI: ?%, STEMI: 0%)<BR/>PCI: balloon angioplasty: 100%, stent: 0%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:39:06 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg/kg, followed by an infusion of 10 µg/min for 12 hours) versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:29:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: 30-day incidence of the composite endpoint of death, nonfatal myocardial infarction, unplanned surgical or repeated percutaneous revascularisation, or insertion of an intra-aortic balloon pump for refractory ischaemia</P>
<P>Secondary: each component of the composite endpoint and bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:29:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>Small study performed in 42 Chinese patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:39:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Claeys-2005">
<CHAR_METHODS MODIFIED="2013-09-09 18:30:15 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded ?: no</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: Sanofi-Synthelabo, Belgium and Dade Behring, Belgium</P>
<P>Follow-up: 30 days and 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:30:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Belgium: Antwerp University Hospital, Antwerp, Belgium</P>
<P>Timeframe: from October 2001 to November 2003</P>
<P>Eligibility criteria: 200 patients scheduled for elective PCI with stent implantation and pre-treated with aspirin and a loading dose of clopidogrel (450 mg) were randomised just before coronary intervention to treatment with or without abciximab</P>
<P>Exclusion criteria: acute coronary syndromes requiring urgent coronary intervention or early treatment with GP IIb/IIIa receptor antagonists, recent myocardial infarction, intervention of lesions located in bypass grafts or near major side branches, presence of an angiographically visible intracoronary thrombus, patients with creatinine value &gt; 2.0 mg/dL, with haemostatic disorders, or with a history of intolerance to thienopyridine or to abciximab</P>
<P>Mean age: 67 y, male: 70%, prior myocardial infarction: 19%<BR/>Acute coronary syndrome: 33% (unstable angina: 31%, NSTEMI: 0%, STEMI: 0%)<BR/>PCI: balloon angioplasty: 2%, stent: 98%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:39:13 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg/kg, followed by an infusion of 0.125 µg/kg/min for 12 h) versus placebo. All patients treated with 160 mg ASA, unfractionated heparin and clopidogrel at randomisation</P>
<P>Abciximab was administered just before intervention as an intravenous bolus (0.25 mg/kg) followed by a 12-h infusion (10 µg/min)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:30:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: level of platelet aggregation inhibition and of peri-procedural myonecrosis<BR/>Secondary: a composite endpoint of death, MI or urgent target-vessel revascularisation within 30 days of randomisation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:30:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Low-risk patients scheduled for elective PCI with stent placement<BR/>All patients pre-treated with high-dose clopidogrel (300 mg) in the evening preceding PCI and 150 mg in the morning of the intervention</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:30:35 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<CHAR_METHODS MODIFIED="2013-09-09 18:30:35 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by a computer-generated assignment</P>
<P>Double-blinded?: no, open-label study</P>
<P>Stratification: yes, according to clopidogrel therapy before PCI</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: a research grant from Integrated Therapeutics Group, Inc., a subsidiary of Schering-Plough Corporation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:30:35 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 2 centres in USA</P>
<P>Timeframe: from March 2006 to December 2007</P>
<P>Follow-up: 30 days and 6 months</P>
<P>Eligibility criteria: 200 consecutive stable patients undergoing PCI</P>
<P>Exclusion criteria: age &lt; 18 y, history of bleeding diathesis, MI within 48 h, elevated cardiac markers of necrosis, cerebrovascular event within 3 months, chronic vessel occlusion, visible thrombus, illicit drug or alcohol abuse, prothrombin time &gt; 1.5 times control, platelet count &lt; 100,000/mm<SUP>3</SUP>, haematocrit &lt; 30%, creatinine &gt; 2.0 mg/dl, and anticoagulation therapy or GP IIb/IIIa blocker use before the procedure</P>
<P>Mean age: 64 y, 61% male, 41% diabetes, 36% prior MI</P>
<P>ACS: 0%</P>
<P>PCI: 100% (balloon angioplasty: 3%, stent: 97%, drug-eluting stents: 72%), pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:30:35 +0530" MODIFIED_BY="[Empty name]">
<P>Eptifibatide plus bivalirudin (n = 98) versus bivalirudin alone (n = 102) stratified by prior clopidogrel treatment, thus providing 4 treatment groups: 1) 600 mg clopidogrel plus bivalirudin; 2) 75 mg clopidogrel plus bivalirudin; 3) 600 mg clopidogrel plus bivalirudin plus eptifibatide; and 4) 75 mg clopidogrel plus bivalirudin plus eptifibatide. Clopidogrel-naive patients (n = 128) received treatment with 600 mg clopidogrel in the catheterisation laboratory immediately after stenting, whereas patients currently on 75 mg (n = 72) did not receive a load. Eptifibatide was administered as a double bolus (180 µg/kg) followed by an infusion (2 µg/kg/min) for 18 h after the procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:30:35 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary:<B> </B>effects on platelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-fibrin clot strength measured by thrombelastography in PCI patients</P>
<P>Secondary: to study the relation of platelet aggregation and thrombin-induced platelet-fibrin clot strength to the occurrence of periprocedural infarction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:30:35 +0530" MODIFIED_BY="[Empty name]">
<P>All patients received clopidogrel therapy. Clopidogrel-naive patients received treatment with 600 mg clopidogrel in the catheterisation laboratory immediately after stenting</P>
<P>72% received a drug-eluting stent</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:30:48 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Cuisset-2008">
<CHAR_METHODS MODIFIED="2013-09-09 18:30:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: no, open-label study</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: the Assistance Publique Hôpitaux de Marseille</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:30:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in France</P>
<P>Timeframe: not stated</P>
<P>Follow-up: 30 days</P>
<P>Eligibility criteria: 149 patients older than 18 years with stable angina or a positive functional study with a planned PCI with stent implantation of a de novo lesion in a native coronary artery</P>
<P>Exclusion criteria: left ventricular ejection fraction &lt; 30%, ACS in the previous month, prior MI in the target vessel related territory, positive biomarkers pre-PCI, platelet count &lt; 100 g/l and history of bleeding diathesis</P>
<P>Mean age: 65 y, 75% male, 38% diabetes, ?% prior MI</P>
<P>ACS: 0%</P>
<P>PCI: 100% (balloon angioplasty: 0%, stent: 100%, drug-eluting stents: ?%), pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:30:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 &#956;g/kg/min (maximum, 10 mg/min) infusion for 12 h) versus control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:30:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: death from any cause, periprocedural myonecrosis, acute or subacute definite or probable stent thrombosis and recurrent ACS</P>
<P>Secondary: major bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:30:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study on patients non-responders to clopidogrel therapy. Antiplatelet therapy was administered with loading doses of 600 mg of clopidogrel and 250 mg of aspirin the day before the procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:30:59 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-DANTE-2004">
<CHAR_METHODS MODIFIED="2013-09-09 18:30:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by use of sealed envelope</P>
<P>Double-blinded?: no, single-blinded</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Losses to follow-up: no</P>
<P>Funding: research grant from Sociedade Brasileira de Cardiologia (SBC/FUNCOR)</P>
<P>Follow-up: 30 days and 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:30:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Brazil (Instituto Dante Pazzanese de Cardiologia, Sao Paulo)</P>
<P>Timeframe: from February 2001 to March 2002</P>
<P>Eligibility criteria: 96 patients with diabetes mellitus and a symptomatic or ischaemia-provoking de novo stenosis in a native coronary artery</P>
<P>Exclusion criteria: myocardial infarction within &lt; 7 days, renal dysfunction (serum creatinine &gt; 2.0 mg/dL) or standard contraindications to abciximab. Angiographic exclusions included target vessel &lt; 2.5 mm or &gt; 4.0 mm in reference diameter, target lesion &gt; 18 mm in length, impaired left ventricular function (ejection fraction &lt; 30%), unprotected left main coronary lesion &gt; 50%, ostial lesion, total occlusion, or evidence of thrombus</P>
<P>Mean age: 60 y, male: 49%, diabetes mellitus: 100%, prior myocardial infarction: 50%<BR/>Acute coronary syndrome: 24% (none with acute myocardial infarction)<BR/>PCI: 100% (balloon PCI: 0%, stent: 100%, drug-eluting stents: ?%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:30:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomly assigned, by use of sealed envelopes, to stenting with versus without abciximab. Abciximab was administered as a bolus of 0.25 mg/kg, followed by a 12-h infusion (0.125 µg/kg per minute, maximum 10 µg/min). Patients received 200 mg of aspirin and 500 mg of ticlopidine started &gt; 24 h before the procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:30:58 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: the primary endpoint was the in-stent per cent volume obstruction as measured by IVUS at 6-month follow-up</P>
<P>Secondary: secondary angiographic endpoints included MLD, late loss and binary restenosis. Secondary clinical endpoints were the composite major adverse cardiac events (MACE) of death of any cause, nonfatal myocardial infarction and target lesion revascularisation (TLR) within 30 days and 1 year after the procedure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-05 17:02:22 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study on diabetic patients undergoing PCI with stent implantation. All patients pre-treated with 500 mg of ticlopidine started &gt; 24 h before the procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:39:29 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-De-Luca-2005">
<CHAR_METHODS MODIFIED="2013-09-09 18:31:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated, but number of patients different in the 2 groups</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: not stated</P>
<P>Losses to follow-up: no, but number of patients different in the 2 groups</P>
<P>Funding: not stated</P>
<P>Follow-up: 30 days and 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:31:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Rome, Italy</P>
<P>Timeframe: January 2002 to May 2003</P>
<P>Eligibility criteria: 122 patients with DM undergoing elective PCI with stenting of de novo coronary artery lesions</P>
<P>Exclusion criteria: if they require urgent procedures for an acute MI or haemodynamic instability, they are undergoing interventions in previously instrumented vessels, had a chronic occlusion (present for &gt; 3 months), had a target lesion with angiographically visible thrombus, had trauma or major surgery in the preceding month, or had a stroke in the prior 3 months</P>
<P>Mean age: 62 y, male: 66%, diabetes: 100%, prior myocardial infarction: 12%<BR/>Acute coronary syndrome: 0%<BR/>PCI: balloon PCI: 0%, stent: 100% (10% DES), pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:39:29 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab or placebo was administered in a double-blind manner. Abciximab was given as 0.25 mg/kg bolus and 0.125 µg/Kg/min infusion immediately before revascularisation, and continued for 12 hs. All patients were treated with aspirin before the procedure.</P>
<P>Heparin was dosed to achieve an activated clotting time of &gt; 250 seconds. After stent implantation, all patients received either clopidogrel (loading dose of 300 mg, followed by 75 mg/d for at least 4 weeks) or ticlopidine (250 mg orally twice a day for at least 4 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:31:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: MACE at 1 year. The diagnosis of MI was based on either the development of new pathological Q waves in &#8805; 2 contiguous electrocardiogram leads or an elevation of creatine kinase or its MB isoenzyme to &#8805; 3 times the upper limit of normal in &#8805; 2 samples<BR/>Secondary: need for TVR (surgical or percutaneous) at 30 and 180 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:31:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Diabetic patients undergoing elective PCI<BR/>Clopidogrel (300 mg) or ticlopidine (250 mg) after PCI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:40:06 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-De-Luca-2008">
<CHAR_METHODS MODIFIED="2013-09-09 18:31:22 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: not stated.</P>
<P>Losses to follow-up: 4 (3%) of the 132 patients</P>
<P>Funding: not stated</P>
<P>Follow-up: 30 days and 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:31:22 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Rome, Italy</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 132 patients diabetic patients undergoing elective PCI with stenting of de novo coronary artery lesions</P>
<P>Exclusion criteria: need for urgent procedures for an acute MI or haemodynamic instability, undergoing interventions in previously instrumented vessels, had a chronic occlusion (present for longer than 3 months), target lesion with angiographically visible thrombus, trauma or major surgery in the preceding month or a stroke in the previous 3 months</P>
<P>Mean age: 63 y, male: 62%, diabetes: 100%, prior myocardial infarction: 12%<BR/>Acute coronary syndrome: 27% (unstable angina 11%, NSTEMI 16%)<BR/>PCI: balloon PCI: 0%, stent: 100% (10% DES), pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:40:06 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab or placebo was administered in a double-blind manner. Abciximab was given as 0.25 mg/kg bolus and 0.125 mµg/Kg/min infusion immediately before revascularisation and continued for 12 hs. All patients were treated with aspirin before the procedure</P>
<P>Heparin was dosed to achieve an activated clotting time of &gt; 250 seconds. Before or immediately after stent implantation, all patients received clopidogrel (loading dose of 300 mg, followed by 75 mg/d for at 9 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:31:22 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: MACE at 30 days year: target-lesion revascularisation (TLR), death for every cause and MI. Periprocedural MI was defined as a raise in creatine kinase (CK)-MB of more than 3 times the upper limit of normal. The diagnosis of re-MI during follow-up required the development of new, pathologic Q-waves in 2 or more contiguous leads, with creatine kinase or creatine kinase MB levels elevated above the upper limit of the normal range</P>
<P>Secondary: bleeding complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:31:22 +0530" MODIFIED_BY="Xavier Bosch">
<P>Diabetic patients undergoing elective PCI<BR/>Clopidogrel (300 mg) immediately before or after PCI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 15:54:02 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ELISA_x002d_2-2006">
<CHAR_METHODS MODIFIED="2013-09-09 18:44:45 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by a computerised randomisation procedure</P>
<P>Double-blinded ?: no, open-label study</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: not stated</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:44:45 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 3 centres in The Netherlands</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 328 patients with NSTEACS who underwent coronary angiography a median of 23 h after admission</P>
<P>Exclusion criteria: age &gt; 80 y, persistent ST-segment elevation, previous PCI within the preceding 6 months, cardiogenic shock, or a contraindication for the use of triple antiplatelet therapy or invasive therapy</P>
<P>Mean age: 63 y, male: 71%, diabetes:18%, prior myocardial infarction: 21%<BR/>Acute coronary syndrome: 100% (unstable angina: 22%, NSTEMI: 78%, STEMI: 0%)<BR/>ST-segment depression: 61%, CK-MB elevation: ?, troponin elevation: 78%<BR/>PCI: in-hospital: 59%, balloon angioplasty: 10%, stent: 49%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 15:54:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomised to pre-treatment with either dual (aspirin, clopidogrel 600 mg) or triple antiplatelet therapy (aspirin, clopidogrel 300 mg and tirofiban 10 µg/kg bolus, 0.15 µg/kg/min maintenance)<BR/>Study medication was given in an open-label manner. All patients were scheduled for coronary angiography within 48 h after admission</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:44:45 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: enzymatic infarct size<BR/>Secondary: initial TIMI flow of the culprit vessel</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:44:45 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of dual versus triple antiplatelet pre-treatment in patients with NSTEACS who were planned for early catheterisation.</P>
<P>All patients were pre-treated with 300 to 600 mg of clopidogrel<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:31:48 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-EPIC-1994">
<CHAR_METHODS MODIFIED="2013-09-09 18:31:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by telephone (patients were randomly assigned to 1 of the 3<SUP> </SUP>treatment groups according to a double-blind study design)</P>
<P>Double-blinded ?: yes</P>
<P>Stratification: according to their study centre and whether they were having an acute evolving myocardial infarction</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: supported by a grant from Centocor, Inc., Malvern, Pa</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:31:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 56 institutions in the United States</P>
<P>Timeframe: from November 1991 to November 1992</P>
<P>Eligibility criteria: 2099 patients with unstable angina, angina post myocardial infarction or clinically or angiographically high-risk patients undergoing percutaneous transluminal coronary angioplasty or atherectomy</P>
<P>Exclusion criteria: age &gt; 80 years old, bleeding<SUP> </SUP>diathesis, major surgery within the preceding<SUP> </SUP>6 weeks, stroke within the preceding 2 years</P>
<P>Mean age: 61 y, male: 72%, prior myocardial infarction: 56%<BR/>Acute coronary syndrome: 100% (unstable angina: 43%, NSTEMI: ?%, STEMI: 41%)<BR/>ST-segment depression: ?, CK-MB elevation: ?, troponin elevation: ?<BR/>PCI: atherectomy: 10%, balloon angioplasty: 90%, stent: 0%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:31:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab bolus (0.25 mg/kg) + placebo infusion versus abciximab bolus + infusion (10 µg per minute) versus placebo bolus and infusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:31:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: the 30-day incidence of the composite endpoint of  death from any cause, nonfatal myocardial infarction, coronary-artery bypass grafting or repeat percutaneous intervention for acute ischaemia, and insertion of a coronary endovascular stent because of procedural failure or placement of an intra-aortic counterpulsation balloon pump to relieve refractory ischaemia.</P>
<P>Secondary endpoint: unplanned repeat angioplasty to treat recurrent ischaemia, urgent coronary surgery to treat recurrent ischaemia or failure of an angioplasty, placement of an intracoronary stent to treat imminent or complete abrupt closure of the vessel undergoing angioplasty, and placement of an intra-aortic balloon pump for recurrent ischaemia when a repeat revascularisation procedure was contraindicated<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:31:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>Excluded bolus-alone arm from analysis. This was the only study using the bolus-alone arm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:40:53 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-EPILOG-1997">
<CHAR_METHODS MODIFIED="2013-09-09 18:32:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by means of a central telephone hot line</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Centocor, Malvern, Pa. and Eli Lilly and Company, Indianapolis</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:40:43 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 69 clinical sites in the United States and Canada</P>
<P>Timeframe: from 27 February 1995 to December 1995</P>
<P>Eligibility criteria: 2792 patients with ST-segment elevation acute myocardial infarction, unstable or stable angina undergoing percutaneous transluminal coronary angioplasty<BR/>
</P>
<P>Exclusion criteria: acute myocardial infarction or unstable angina, planned stent implantation or rotational atherectomy; percutaneous coronary intervention performed within the previous 3 months; a left-main coronary artery stenosis of more than 50% not protected by collateral vessels; concurrent warfarin therapy or a baseline prothrombin time more than 1.2 times the control value; cerebrovascular accident within the previous 2 years or a residual neurologic deficit; intracranial neoplasm, aneurysm, or arteriovenous malformation; history of vasculitis, known haemorrhagic diathesis, or active internal bleeding; hypertension, with a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 100 mm Hg; and major surgery, gastrointestinal bleeding, or genitourinary bleeding within the previous 6 weeks</P>
<P>Mean age: 60 y, male: 72%, prior myocardial infarction: %<BR/>Acute coronary syndrome: 69% (unstable angina: 48%, NSTEMI: ?, STEMI: ?<BR/>ST-segment depression: ?, CK-MB elevation: ?, troponin elevation: ?<BR/>PCI: atherectomy: 5%, balloon angioplasty: 95%, stent: 11%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:40:53 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab + low-dose heparin versus abciximab + standard dose heparin versus placebo + standard dose heparin. For those receiving abciximab, a bolus of 0.25 mg per kilogram of body weight was administered followed by an infusion of 0.125 mg per kilogram per minute (maximum, 10 mg per minute) for 12 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:32:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: a composite of death from any cause, myocardial infarction or reinfarction, or severe myocardial ischaemia requiring urgent coronary bypass surgery or repeated percutaneous coronary revascularisation within 30 days after randomisation</P>
<P>Secondary endpoints: a composite of death, myocardial infarction, or coronary bypass surgery or repeated percutaneous revascularisation (urgent or non-urgent) within 6 months after randomisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:32:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>The 2 abciximab groups have been grouped together for the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:41:16 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-EPISTENT-1998">
<CHAR_METHODS MODIFIED="2013-09-09 18:32:20 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by a telephone hotline</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Centocor, Malvern PA, USA</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:32:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 63 centres in the USA and Canada</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 2399 patients scheduled to elective or urgent coronary angioplasty or stent</P>
<P>Exclusion criteria: unprotected left-main stenosis, bleeding diathesis, intracranial neoplasm, a history of stroke in the previous 2 years, uncontrolled hypertension (systolic blood pressure &gt; 180 mm Hg, diastolic &gt; 100 mm Hg), recent surgery, or percutaneous coronary intervention within the previous 3 months, concurrent warfarin therapy or an INR &gt; 1.5 at baseline</P>
<P>Mean age: 59 y, male: 75%, prior myocardial infarction: 35%<BR/>Acute coronary syndrome: 52% (unstable angina: 36%, NSTEMI: ?, STEMI: ?)</P>
<P>ST-segment depression: ?, CK-MB elevation: ?, troponin elevation: ?</P>
<P>PCI: balloon angioplasty: 29%, stent: 71%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:41:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab + stent versus abciximab + balloon coronary angioplasty versus placebo + stent</P>
<P>Patients were randomly assigned stent plus placebo (n = 809), stent plus abciximab (n = 794) or balloon angioplasty plus abciximab (n = 796). Patients received abciximab 0.25 mg/kg body weight, followed by an infusion of 0.125 &#956;g/kg every min (maximum 10 &#956;g/min) for 12 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:32:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: a combination of death from any cause, myocardial infarction or reinfarction, or severe myocardial ischaemia requiring urgent coronary artery bypass surgery or revascularisation within 30 days of intervention</P>
<P>Secondary endpoints: death or myocardial infarction, and death or large myocardial infarction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients treated with aspirin and heparin. The stent group received also ticlopidine 250 mg twice daily starting at the discretion of the investigator before the start of the study agent</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:41:31 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ERASER-1999">
<CHAR_METHODS MODIFIED="2013-09-09 18:32:31 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: into 1 of 3<SUP> </SUP>groups by sealed envelopes provided by the co-ordinating centre</P>
<P>Double-blinded ?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: not stated.</P>
<P>Follow-up: hospitalisation and 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:32:31 +0530" MODIFIED_BY="[Empty name]">
<P>Institutions: 17 centres from 9 countries (USA, Canada, Israel, Italy, Germany, France, Belgium, UK, Netherlands)</P>
<P>Timeframe: from May 1996 to February 1997</P>
<P>Eligibility criteria: 215 angina patients with 1 lesion suitable for stent implantation (&gt;/ = 50% reduction in intraluminal diameter) in an artery with an intraluminal diameter from 2.75 to 3 mm. Excluded were patients with acute coronary syndrome &lt; 72 h</P>
<P>Exclusion criteria: myocardial infarction within 72 h before randomisation, evident intracoronary thrombus, previous coronary intervention on a non-target lesion within the past 6 months, planned debulking before stent placement, expected inability to access the target lesion by IVUS, or standard contraindications to the use of abciximab</P>
<P>Mean age: 60 y, male: 79%, prior myocardial infarction: ?<BR/>Acute coronary syndrome: 56% (see exclusions) (unstable angina: 56%, NSTEMI: 0%, STEMI: 0%). ST-segment depression: ?, CK-MB elevation: ?, Troponin elevation: ?<BR/>PCI: balloon angioplasty: 0%, stent: 100%, pre-treatment with clopidogrel: 0%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:41:31 +0530" MODIFIED_BY="Xavier Bosch">
<P>3 different treatment regimens: placebo bolus + 2 consecutive 12-h placebo infusions; abciximab 0.25 mg/kg bolus + 0.125 µg/kg/min (up to 10 µg/min maximum) continuous infusion for 12 hours followed by 12-h placebo infusion; or abciximab 0.25 mg/kg bolus + 2 consecutive 12-h 0.125 µg/kg//min (up to 10 µg/min maximum) infusions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:32:32 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary efficacy criterion: per cent in-stent volume obstruction of the target lesion, measured at 6 months by IVUS. Primary safety objectives: major bleeding not associated with bypass surgery, and mortality and intracranial haemorrhage through 6 months</P>
<P>Secondary efficacy objectives: target lesion mean and minimum lumen diameter, late loss and loss index by QCA at 6 months, and a composite of death, myocardial infarction and TLR within 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:32:32 +0530" MODIFIED_BY="Xavier Bosch">
<P>The 12-h and 24-h infusion groups were grouped together for the analysis. In-hospital was considered 30-day in this review.<BR/>All patients treated with aspirin and heparin. Ticlopidine use was left to the investigator's discretion</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:41:40 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ESPRIT-2000">
<CHAR_METHODS MODIFIED="2013-09-09 18:32:58 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: generated with random permuted blocks within each investigative site, with 1 to 1 allocation of treatments</P>
<P>Double-blinded?:  yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: COR Therapeutics, South San Francisco, CA, USA and Schering-Plough Corporation, Kenilworth, NJ, USA</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:32:58 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 92 centres in USA and Canada</P>
<P>Timeframe: from 3 June 1999 to 4 February 2000</P>
<P>Eligibility criteria: 2064 patients with coronary artery disease undergoing stent implantation on a native coronary artery</P>
<P>Exclusion criteria: acute myocardial infarction; continuing chest pain precipitating urgent referral for PCI; PCI within the previous 90 days; previous stent implantation at the target lesion; anticipated staged PCI, treatment with a glycoprotein IIb/IIIa inhibitor or a thienopyridine, stroke or transient ischaemic attack within 30 days before randomisation; any history of haemorrhagic stroke; history of bleeding diathesis or evidence of abnormal bleeding within the previous 30 days; major surgery within the previous 6 weeks; uncontrolled hypertension; documented thrombocytopenia; or a serum creatinine greater than 350 mmol/L</P>
<P>Mean age: 62 y, male: 73%, prior myocardial infarction: 32%<BR/>Acute coronary syndrome: 18% (unstable angina: 14%, NSTEMI: ?, STEMI: 5%)<BR/>ST-segment depression: ?, CK-MB elevation: ?, Troponin elevation: ?<BR/>PCI: balloon angioplasty: 3%, stent: 96%, pre-treatment with clopidogrel: 1% (all patients pre-treated with a thienopyridine, either ticlopidine or clopidogrel, with use of a loading dose) on the day of randomisation<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:41:40 +0530" MODIFIED_BY="Xavier Bosch">
<P>Eptifibatide was delivered as 2 boluses and an infusion. The first bolus of 180 &#956;g/kg was immediately followed by initiation of a 2.0 µg/kg/min (or 1 µg/kg/min in patients with serum creatinine values greater than 177 (mol/L) continuous infusion. A second bolus of 180 µg/kg was given 10 min after the first. The infusion was continued until hospital discharge or up to 18-24 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:32:57 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: the composite of death, myocardial infarction, urgent target vessel revascularisation and thrombotic bailout glycoprotein IIb/IIIa inhibitor therapy within 48 h after randomisation</P>
<P>Secondary endpoint: the composite of death, myocardial infarction and urgent target vessel revascularisation within 30 days after randomisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:32:52 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients treated with aspirin, heparin and clopidogrel or ticlopidine</P>
<P>Sample size calculation was based on a predicted reduction in the rate of the key 30-day secondary composite efficacy endpoint, rather than the primary endpoint</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-01 22:08:38 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Fu-2008">
<CHAR_METHODS MODIFIED="2013-09-09 18:33:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: a grant from the Natural Science Foundation of Hebei Province (no C2004000615)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-01 22:08:38 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in China</P>
<P>Timeframe: from January 2005 to May 2007</P>
<P>Follow-up: 6 months</P>
<P>Eligibility criteria: 150 patients with acute STEMI (or documented new left bundle-branch block) presenting &lt; 12 hs after the onset of symptoms and with coronary anatomy suitable for PCI</P>
<P>Exclusion criteria: bleeding diathesis, administration of thrombolytic agents, neoplasm, recent stroke, uncontrolled hypertension, recent surgery, oral anticoagulant therapy and known contraindications to therapy with aspirin, clopidogrel, tirofiban or heparin</P>
<P>Mean age: 53 y, 68% male, 19% diabetes,?% prior MI</P>
<P>ACS: 100% (non-STEACS: 0%, STEMI: 100%)</P>
<P>PCI: 100% (balloon angioplasty: ?%, stent: ?%, drug-eluting stents: ?%), pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:33:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Tirofiban (bolus of 10 µg/kg over 3 minutes followed by continuous infusion of 0.15 µg/kg/min for 24 h) versus placebo (bolus and infusion). All patients treated with 300 mg of clopidogrel at enrolment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:33:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: not clear (&#8220;to evaluate the effect and safety of tirofiban in STEMI patients undergoing PCI via transradial approach&#8221;)</P>
<P>Secondary: not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:33:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Chinese study. All patients treated with 300 mg of clopidogrel at enrolment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:33:32 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galassi-1999">
<CHAR_METHODS MODIFIED="2013-09-09 18:33:31 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: with a standard list of random numbers</P>
<P>Double-blinded?: no, open-label study</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: not stated</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:33:31 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Italy</P>
<P>Timeframe: from October 1996 to February 1998</P>
<P>Eligibility criteria: 106 patients with CAD, demonstrable ischaemia and a target de novo complex lesion stenosis &gt; 70% in a native vessel scheduled for elective implantation of a &gt; 20 mm stent or multiple stents</P>
<P>Exclusion criteria: acute myocardial infarction; bleeding diathesis, thrombocytopenia, history of stroke, active internal bleeding, severe uncontrolled hypertension, major surgery or trauma within 6 weeks</P>
<P>Male: 88%, mean age: 62 y, diabetes: 27%, previous MI: 67%, ACS: 0%</P>
<P>Balloon angioplasty: 0%, stent: 100%, drug-eluting stents: 0%</P>
<P>Pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:33:31 +0530" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned, in an open-label fashion, to receive either a combination of abciximab (bolus and a 12-h infusion) and weight-adjusted low-dose heparin or weight-adjusted heparin alone. All patients received 325 mg of aspirin the day before the procedure and daily thereafter. Ticlopidine 250 mg twice daily was started the day before the intervention and was given to all patients for the first 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:33:31 +0530" MODIFIED_BY="[Empty name]">
<P>No primary outcome was specified<BR/>Outcomes: mortality, MI, urgent revascularisation, target lesion revascularisation, acute or subacute stent thrombosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:33:32 +0530" MODIFIED_BY="[Empty name]">
<P>Patients were 'randomly allocated'. There is no description of the allocation concealment or the primary outcome of the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-01 22:09:48 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Gasior-2003">
<CHAR_METHODS MODIFIED="2013-09-09 18:33:43 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Stratification (yes/no): not stated</P>
<P>Placebo (yes/no): no</P>
<P>Sample size calculation (yes/no): no</P>
<P>Intention-to-treat analyses (yes/no): not stated.</P>
<P>Losses to follow-up (yes/no, and n (%)): yes, 1 patient in the control group</P>
<P>Funding: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:33:43 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Poland (Zabrze)</P>
<P>Time frame: from October 1998 to May 2000</P>
<P>Inclusion criteria: patients with all of the following characteristics: proximal or medial LAD chronic total occlusion with TIMI coronary blood flow  0 or 1, myocardial viability in LAD territory on a dobutamine stress echocardiography in patients with CCS II or III angina, angina at rest or during exercise, and no contraindication for abciximab</P>
<P>Exclusion criteria: LAD occlusion &lt; 2 weeks or &gt; 6 months (according to the last severe chest pain), contraindication for abciximab, previous revascularisation, failed attempt of recanalisation of the coronary vessel, or no indirect signs of viability in LAD territory</P>
<P>Male: 84%, mean age: 54 y, diabetes: 8%, previous MI: 72%, ACS: 15% (unstable angina 15%, AMI 0%)</P>
<P>Balloon angioplasty: 0%, stent: 100%, drug-eluting stents: 0%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-01 22:09:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab group: AAS 75 to 150 mg/24 hs and ticlopidine 500 mg/24 hs at least 48 hs before PCI, and 500 mg/24 hs during 6 to 8 weeks. During PCI: abciximab bolus of 0.25 mg/kg + infusion of 0.125 &#956;g/kg/min during 12 h</P>
<P>Control group: AAS 75 to 150 mg/24 h and ticlopidine 500 mg/24 h at least 48 h before PCI, and 500 mg/24 h during 6 to 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:33:43 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: recurrent ischaemia, urgent revascularisation, myocardial infarction, death</P>
<P>Secondary endpoints: coronary restenosis (&gt; 50%), reocclusion, percent luminal diameter and of stenosis, improvement in left ventricular ejection fraction</P>
<P>Safety endpoints: severe bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:33:43 +0530" MODIFIED_BY="Xavier Bosch">
<P>55 patients were eligible but only 41 patients were randomised because of failure to cross the vessel complete occlusion with the guidewire. 2 patients (1 in each group) were  excluded after randomisation because of failure in stent implantation, resulting in 39 analysable patients, 20 in the abciximab group and 19 in the control group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:47:50 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<CHAR_METHODS MODIFIED="2013-09-09 18:33:56 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: via a centralised interactive voice-response system</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Centocor Inc, Malvern, Pa</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:33:56 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 458 hospitals in 24 countries: Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, UK, USA</P>
<P>Timeframe: from 17 July 1998 to 21 April 2000</P>
<P>Eligibility criteria: 7800 average-risk patients with unstable angina or non-ST segment elevation myocardial infarction<BR/>Last episode of chest pain: &lt; 24 h<BR/>Indicator of myocardial ischaemia: &gt; 0.5 mm ST depression or &gt; 0.5 mm transient ST elevation or troponin T or I elevation above ULN</P>
<P>Exclusion criteria: myocardial ischaemia precipitated by a disorder other than atherosclerotic CAD, STEMI, new left-bundle branch block; PCI within previous 14 days; planned PCI or coronary bypass surgery within 30 days after enrolment; active internal bleeding or history of haemorrhagic diathesis; major surgery, serious trauma or gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks; intracranial neoplasm or aneurysm, history of stroke within 2 years, or prior stroke with a residual neurological deficit; oral anticoagulation within the previous 7 days; platelet count of less than 100,000/mL; confirmed hypertension; history of vasculitis; puncture of non-compressible vessel within 24 h before enrolment; allergy to abciximab; weight more than 120 kg; a coexisting disorder associated with limited life expectancy; and participation in another investigational trial within 7 days</P>
<P>Mean age: 65 y, male: 62%, prior myocardial infarction: 31%, diabetes: 22%<BR/>Acute coronary syndrome: 100% (unstable angina: 72%, non-STEMI: 28%, STEMI: 0%), ST-segment depression: 80%, CK-MB elevation: 28%, troponin elevation: 59%<BR/>PCI: in-hospital: 19%, during drug-infusion: 1.6%, CABG: 11%<BR/>
</P>
<P>Treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:47:50 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab bolus + 48-h infusion versus abciximab bolus + 24-h infusion versus placebo<BR/>Dose:<BR/>a) 0.25 mg/kg bolus + 0.125 µg/kg/min infusion (maximum 0.10 µg/min) for 24 hs + heparin<BR/>b) 0.25 mg/kg bolus + 0.125 µg/kg/min infusion (maximum 0.10 µg/min) for 48 hs + heparin<BR/>c) placebo + heparin<BR/>Duration: 24 or 48 hs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-01 22:12:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: death or myocardial infarction at 30 days<BR/>Secondary: death or myocardial infarction in patients with positive troponin levels; death, myocardial infarction, revascularisation or coronary angiography at 48 hs, 7 days and 30 days; death or myocardial infarction within 30 days<BR/>
</P>
<P>Required level of CK or CK-MB elevation in MI definition: 3 x ULN<BR/>Safety: intracranial haemorrhage; bleeding leading to decrease in haemoglobin concentration &gt; 50 g/L</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:33:56 +0530" MODIFIED_BY="Xavier Bosch">
<P>GUSTO-IV Study<BR/>Both abciximab groups were analysed together in this review<BR/>All patients treated with 150 to 325 mg aspirin<BR/>Heparin was part of study regimen; initial dose weight-adjusted (maximum 5000 U bolus + 800 U/h infusion aiming for a PTT of 50 to 70 s; a subgroup treated with dalteparin (maximum dose 10,000 U)<BR/>Angiography was discouraged during infusion period<BR/>PCI was not scheduled (just 1.6% had PCI within 48 h)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:13:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IMPACT-1995">
<CHAR_METHODS MODIFIED="2013-09-09 18:34:11 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded ?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: COR Therapeutics, Inc, South San Francisco, USA</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:34:11 +0530" MODIFIED_BY="[Empty name]">
<P>Institutions: 11 centres in USA</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 150 patients with coronary artery disease scheduled for elective percutaneous coronary revascularisation</P>
<P>Exclusion criteria: known history of bleeding disorder, recent gastrointestinal bleeding, major surgery within 6 weeks, history of stroke or other central nervous system structural abnormality, severe hypertension, pregnancy, elevation of baseline prothrombin time (&gt; 1.2 times control), haematocrit &lt; 30%, platelet count &lt; 100,000/µL or creatinine &gt; 4.0 mg/dl</P>
<P>Mean age: 62 y, male: 75%, prior myocardial infarction: 45%<BR/>Acute coronary syndrome: 75% (unstable angina: 58%, non-STEMI: ?%, STEMI: 17%)<BR/>ST-segment depression: ?%, CK-MB elevation: ?%, troponin elevation: ?%</P>
<P>PCI: atherectomy: 13%, balloon angioplasty: 100%, stent: 0%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:13:13 +0530" MODIFIED_BY="Xavier Bosch">
<P>Eptifibatide bolus (90 µg/kg) + 12-h infusion (1.0 µg/kg/min for 4 hs) versus eptifibatide bolus + 4-h infusion versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:34:12 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of total death, myocardial infarction and urgent coronary revascularisation</P>
<P>Secondary: safety and bleeding complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:34:12 +0530" MODIFIED_BY="Xavier Bosch">
<P>A phase II study. The 2 eptifibatide groups were grouped together for the meta-analysis. All patients treated with aspirin and heparin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:34:26 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-IMPACT_x002d_II-1997">
<CHAR_METHODS MODIFIED="2013-09-09 18:34:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: generated by computer in blocks of 9. Assignment was done at the same time as registration and enrolment by telephone call to the Duke Coordinating Center</P>
<P>Double-blinded?: yes</P>
<P>Stratification: yes, patients were stratified according to the perceived risk of ischaemic complications into high-risk and low-risk categories</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: COR Therapeutics, Inc (South San Francisco, California) and Schering-Plough, Inc (Kenilworth, New Jersey)</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:34:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 82 centres in the USA</P>
<P>Timeframe: from 30 November 1993 to9 November 1994</P>
<P>Eligibility criteria: 4010 patients with coronary artery disease undergoing percutaneous revascularisation</P>
<P>Exclusion criteria: history of bleeding diathesis, severe hypertension, major surgery within the previous 6 weeks, history of stroke or other disorders of the central nervous system, pregnancy, gastrointestinal or genitourinary bleeding within the previous 30 days, or other major illness</P>
<P>Mean age: 61 y, male: 75%, prior myocardial infarction: 41%<BR/>Acute coronary syndrome: 42% (unstable angina: 38%, non-STEMI: ? %, STEMI: 4%)<BR/>ST-segment depression: ?%, CK-MB elevation: ?%, troponin elevation: ?%</P>
<P>PCI: atherectomy: 23%, balloon angioplasty: 92%, stent: 4%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:34:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Bolus of 135 &#956;g/kg eptifibatide followed by an infusion of 0.5 mg/kg/min for 20 to 24 h versus a 135 mg/kg eptifibatide bolus followed by an infusion of 0.75 mg/kg/min for 20 to 24 h versus placebo bolus plus placebo infusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:34:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: the occurrence within 30 days of death, myocardial infarction, urgent or emergency repeat coronary revascularisation, or index placement of an intracoronary stent for abrupt closure</P>
<P>Secondary endpoint: the occurrence of the composite endpoint at the completion of drug infusion (24 h) and at 6 months, the composite endpoint as determined by the site principal investigators (rather than the Clinical Events Committee), outcomes by risk stratification and actual treatment received, and the frequency of angiographically documented abrupt closure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:34:26 +0530" MODIFIED_BY="Xavier Bosch">
<P>2 arms with different doses of eptifibatide and a placebo arm. The 2 active treatment arms were grouped in our analysis. All patients received aspirin and heparin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:34:36 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-INSTANT-2012">
<CHAR_METHODS MODIFIED="2013-09-09 18:34:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: an online randomisation system</P>
<P>Double-blinded?: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: GlaxoSmithKline, Verona, Italy</P>
<P>Follow-up: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:34:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Verona, Italy</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 91 patients with stable coronary disease and diffuse disease involving a major epicardial coronary vessel undergoing PCI on a native coronary vessel with planned implantation of N33 mm of DES with a reference vessel diameter 2.25 to 4.0 mm</P>
<P>Exclusion criteria: 1) Clinical: women with childbearing potential, aged less than 18 years, ongoing or recent episode (&lt; 48 h) of ACS, administration of any GP IIb/IIIa inhibitors during the previous 2 weeks, serum creatinine greater than 2.5 mg/dl, ongoing serious bleeding or bleeding diathesis, previous stroke in the last 6 months, major surgery within the previous 6 weeks, platelet count higher than 100,000 per mm<SUP>3</SUP>, ejection fraction below 30%, known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or sensitivity to contrast that cannot be adequately premedicated, haemodynamic instability requiring balloon counterpulsation or inotropic support, positive clinical history for intracranial neoplasia, arteriovenous malformation, aneurysm, international normalised ratio (INR) at least 2.0 or prothrombin time 1.2 times upper limit of normality, clinically manifested reduced liver function and programmed surgery within 1 month</P>
<P>2) Angiographical: DES implantation in a chronic total occlusion, vessel size less than 2.25 mm or greater than 5 mm, and previous implantation of a BMS or a DES in the target lesion</P>
<P>Mean age: 66 y, male: 81%, prior myocardial infarction: 30%<BR/>Acute coronary syndrome: 40%<BR/>ST-segment depression: ?, CK-MB elevation: ?%, troponin elevation: ?%<BR/>PCI: balloon PCI: 0%, stent: 100%, drug-eluting stent: 100%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:34:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Enrolled patients were randomised to intravenous normal saline or intravenous eptifibatide (double bolus (180 &#956;g/kg) followed by infusion (2 &#956;g/kg per minute) for 18 to 24 h after the procedure). Concomitantly to study drug administration, an intravenous bolus of unfractionated heparin (60 IU/kg) was administered, and during the procedure, patients received intravenous boluses of heparin in sufficient doses to prolong the activated clotting time (&#8805; 250 seconds)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-28 15:25:29 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: the rate of elevated postprocedural peak CK-MB mass ratio values</P>
<P>Secondary: in-hospital 1- and 6-month major adverse cardiovascular events (MACEs), defined as the composite of cardiac death, nonfatal MI, or urgent TVR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:34:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Owing to difficulties in enrolling patients and funding issues due to the inability to meet enrolment milestones originally agreed upon with the sponsor, the study was prematurely stopped before any statistical analysis. Only 91 of the 320 planned patients were enrolled in the study<BR/>Pre-treatment with 600 mg of clopidogrel recommended in all patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 15:56:32 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISAR_x002d_2-2000">
<CHAR_METHODS MODIFIED="2013-10-03 15:56:32 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: sealed envelopes</P>
<P>Double-blinded?: no, patients but not physicians were blinded to the assignment of treatment</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Lilly, Deutschland</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:50:25 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 1 hospital in<SUP> </SUP>Germany</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 401 patients with ST-segment elevation acute myocardial infarction undergoing angioplasty with stent implantation within 48 h after onset of chest pain</P>
<P>Exclusion criteria were inability to give informed consent and contraindications to 1 of the study drugs. All eligible patients who gave written, informed consent were randomised by means of sealed envelopes. Patients, but not physicians, were blinded to the assignment of treatment</P>
<P>Mean age: 61 y, male: 76%, prior myocardial infarction: ?%<BR/>Acute coronary syndrome: 100% (unstable angina: 0%, non-STEMI: 0%, STEMI: 100%)<BR/>ST-segment depression: 0%, CK-MB elevation: 100%, troponin elevation: ?%</P>
<P>PCI: balloon angioplasty: 0%, stent: 100%, pre-treatment with clopidogrel: 0%, but 100% with ticlopidine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:50:29 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomised to 1 of 2 treatment regimens: 1) a bolus of abciximab 0.25 mg/kg of body weight, followed by continuous infusion, 10 µg/min for 12 h plus an additional dose of heparin (2500 U intra-arterially) or heparin (10,000 U intra-arterially), followed by IV heparin infusion (1000 U/h), for the first 12 h after sheath removal</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 17:50:33 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: angiographic restenosis at 6 months<BR/>Secondary: clinical restenosis and a composite of death, myocardial infarction and target lesion revascularisation at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 17:50:37 +0530" MODIFIED_BY="Xavier Bosch">
<P>Not placebo-controlled. All patients treated with aspirin, heparin and ticlopidine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:35:01 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<CHAR_METHODS MODIFIED="2013-09-09 18:35:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: using sealed envelopes containing the block randomisation sequence for each participating centre</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: supported in part by the grant KKF 04-03 from Deutsches Herzzentrum, Munich, Germany</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:35:01 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 5 centres in Germany, 1 in Netherlands and 1 in Brazil</P>
<P>Timeframe: from March 2003 through December 2005</P>
<P>Eligibility criteria: an episode of angina (with an accelerating pattern or prolonged or recurrent episodes at rest or with minimal effort) within the preceding 48 h, accompanied by an elevated troponin T level or a new finding of ST-segment depression of at least 0.1 mV or transient  ST-segment elevation of at least 0.1 mV or new or presumed new bundle-branch block; significant angiographic lesions in a native coronary vessel or venous bypass graft amenable to and requiring a PCI; and written informed consent from the patient</P>
<P>Exclusion criteria: ST-segment elevation acute MI; haemodynamic instability; pericarditis; malignancies with life expectancy less than 1 year; increased risk of bleeding (stroke within the previous 3 months, active bleeding or bleeding diathesis, recent trauma or major surgery in the last month, suspected aortic dissection); oral anticoagulation with a coumarin derivative within the previous 7 days; receipt of a GP IIb/IIIa inhibitor within the previous 14 days; uncontrolled hypertension; a haemoglobin level less than 100 g/L or haematocrit less than 34%, or platelet count less than 100,000 cells/?L or greater than 600,000 cells/?L; known allergy to the study medication; and pregnancy (present or suspected)</P>
<P>2022 patients with NSTEACS that underwent PCI in native coronary vessels within 6 h from diagnosis of ACS and after pre-treatment with 600 mg of clopidogrel &gt; 2 h before PCI. Coronary stenting was the target PCI</P>
<P>Mean age: 66 y, male: 74%, diabetes 27%, prior myocardial infarction: 24%</P>
<P>ACS: 100% (unstable angina: 48%, NSTEMI: 52%, STEMI: 0%)</P>
<P>PCI: balloon angioplasty: 3%, stent: 97% (BMS: 48%, DES: 49%), pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:35:01 +0530" MODIFIED_BY="[Empty name]">
<P>Abciximab (bolus of 0.25 mg/kg, followed by an infusion of 0.125 µg/kg/min) versus placebo. All patients treated with ASA, heparin and 600 mg of clopidogrel &gt; 2 h before the procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:35:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: all-cause death, MI or urgent target-vessel revascularisation within 30 days of randomisation<BR/>Safety: major and minor bleeding, and thrombocytopenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:35:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>High-risk patients with NSTEACS treated with early (&lt; 6 h) PCI after diagnosis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:50:57 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<CHAR_METHODS MODIFIED="2013-09-09 18:35:13 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: patients underwent randomisation in a double-blind manner with the use of sealed envelopes containing the block randomisation sequence for each participating centre</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: supported by research grants from Deutsches Herzzentrum, Klinik an der Technischen Universität, Munich, Germany (67-00 and 04-01), and by an unrestricted educational grant from Bristol-Myers Squibb GmbH, Munich, Germany</P>
<P>Follow-up: 30 days and 1 y<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:35:13 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 4 institutions in Germany, 1 in The Netherlands and 1 in the USA</P>
<P>Timeframe: from May 2000 and February 2003</P>
<P>Eligibility criteria: 2159 patients with CAD that underwent elective PCI in native coronary vessels and had been pre-treated with 600 mg of clopidogrel &gt; 2 h before the intervention. Coronary stenting was the target PCI</P>
<P>Exclusion criteria: recent myocardial infarction or unstable angina, a target lesion in a venous bypass graft; a chronic occlusion; a target lesion with angiographically visible thrombus; a left ventricular ejection fraction &lt; 30%; haemodynamic instability,  insulin-dependent diabetes mellitus, pericarditis or cancer; stroke in the prior 3 months; active bleeding or bleeding diathesis; trauma or major surgery in the preceding month; suspected aortic dissection; oral anticoagulation therapy or glycoprotein IIb/IIIa inhibitor within the preceding 14 days; severe, uncontrolled hypertension; haemoglobin &lt; 10 g/dl or a haematocrit &lt; 34%; a platelet count &lt; 100,000 or &gt; 600,000; a known allergic reaction to the study medication; or child-bearing potential</P>
<P>Mean age: 66 y, male: 76%, prior myocardial infarction: 33%<BR/>Acute coronary syndrome: 0% (unstable angina: 0%, NSTEMI: 0%, STEMI: 0%)<BR/>ST-segment depression: ?, CK-MB elevation: 0%, troponin elevation: 0%<BR/>PCI: balloon angioplasty: 10%, stent: 90%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:50:57 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg/kg, followed by an infusion of 0.125 µg/kg/min (maximum, 10 µg per minute) for 12 hours versus placebo. All patients treated with ASA and heparin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:35:13 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: all-cause death, MI or urgent target-vessel revascularisation within 30 days of randomisation<BR/>Secondary: major and minor bleeding, and thrombocytopenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:35:13 +0530" MODIFIED_BY="[Empty name]">
<P>Low-risk patients scheduled for elective PCI with stent placement<BR/>All patients pre-treated with high-dose clopidogrel</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:51:07 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<CHAR_METHODS MODIFIED="2013-09-09 18:35:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: sealed envelopes containing the randomisation sequence generated by computer before initiation of the trial</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: supported in part by an unrestricted research grant from Krauth medical KG, Hamburg, Germany</P>
<P>Follow-up: 1 year<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:35:25 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 3 centres in Germany</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: 502 patients with stable angina pectoris or a positive exercise test that underwent elective PCI in native coronary vessels &lt; 2.5 mm in size and after pre-treatment with 600 mg of clopidogrel &gt; 2 h before PCI</P>
<P>Exclusion criteria: acute coronary syndrome, left main coronary artery, in-stent restenosis and contraindications to the antithrombotic medication used in the study</P>
<P>Mean age: 66 y, male: 73%, prior myocardial infarction: 37%<BR/>Acute coronary syndrome: 0%<BR/>ST-segment depression: ?, CK-MB elevation: 0%, troponin elevation: 0%<BR/>PCI: balloon angioplasty: 50%, stent: 50%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:51:07 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomly assigned to be treated with either PC-coated stents (n = 253) or PTCA (n = 249) and with either abciximab (n = 251) or placebo (n = 251) with the use of a 2 x 2 factorial design. Patients randomised to abciximab received a bolus of 0.25 mg/kg, followed by an infusion of 0.125 µg/kg/min (maximum, 10 µg per minute) for 12 hours</P>
<P>All patients treated with ASA, heparin and 600 mg of clopidogrel &gt; 2 h before the procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:35:26 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: angiographic restenosis at follow-up angiography<BR/>Secondary: combined incidence of all-cause death and MI as well as target vessel revascularisation during 1-year follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:35:26 +0530" MODIFIED_BY="Xavier Bosch">
<P>Low-risk patients scheduled for elective PCI with stent placement<BR/>All patients pre-treated with high-dose clopidogrel &gt; 2 h before the procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:40:27 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<CHAR_METHODS MODIFIED="2013-09-09 18:40:27 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: with the use of sealed envelopes containing the randomisation sequence for each participating centre</P>
<P>Double-blinded ?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: research grants by Deutsches Herzzentrum, Klinik an der Technischen Universität, Munich, Germany (H04-01)</P>
<P>Follow-up: 30 days and 1 y<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:40:27 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 3 German hospitals</P>
<P>Timeframe: between January 2001 and October 2003</P>
<P>Eligibility criteria: 701 diabetic patients with CAD scheduled for elective PCI in native coronary vessels and had been pre-treated with 600 mg clopidogrel at least 2 h before intervention. Coronary stenting was the target PCI</P>
<P>Exclusion criteria: myocardial infarction within the prior 14 days; ACS; target lesion with thrombus or  in a venous bypass graft; chronic coronary occlusion; a left ventricular ejection fraction &lt; 30%, haemodynamic instability, pericarditis, malignancy, a stroke in the prior 3 months, active bleeding or bleeding diathesis, recent trauma or major surgery in the last month, a suspected aortic dissection, oral anticoagulation therapy, severe uncontrolled hypertension, haemoglobin &lt; 100 g/L or haematocrit &lt; 34%, thrombocytopenia, known allergic reaction to the study medication, had received a glycoprotein IIb/IIIa inhibitor within 14 days, or were pregnant (present or suspected)</P>
<P>Mean age: 67 y, male: 74%, prior myocardial infarction: 34%<BR/>Acute coronary syndrome: 0%<BR/>ST-segment depression: ?, CK-MB elevation: 0%, troponin elevation: 0%<BR/>PCI: balloon angioplasty: 10%, stent: 90%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:40:27 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg/kg, followed by an infusion for 12 h of 0.125 µg/kg/min) versus placebo. All patients treated with ASA and heparin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:40:27 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint:<B> </B>the cumulative incidence of death from any cause and MI during the first 12 months after randomisation</P>
<P>Secondary endpoints: incidence of binary angiographic restenosis, and of target lesion revascularisation due to angiographic restenosis and symptoms or signs of ischaemia<BR/>Safety: major and minor bleeding, and thrombocytopenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:40:27 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients with diabetes mellitus (29% treated with insulin) scheduled for elective PCI with stent</P>
<P>Patients of both study groups received clopidogrel 600 mg at least 2 h before the percutaneous coronary intervention</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:40:16 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ITTI-2012">
<CHAR_METHODS MODIFIED="2013-09-09 18:40:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Stratification: yes, by the performance of thrombosuction procedure</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analyses (yes/no): yes</P>
<P>Losses to follow-up: no</P>
<P>Funding: not stated</P>
<P>Follow-up: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:40:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 5 centres in Taiwan</P>
<P>Time frame: not stated</P>
<P>Eligibility criteria: age &#8807; 18 years, continuous chest pain &#8807; 30 min, ST-segment elevation &gt; 0.1 mV in &#8807; 2 contiguous leads on a 12-lead electrocardiogram (ECG)</P>
<P>Exclusion criteria: cardiogenic shock (systolic BP &lt; 80 mm Hg or need for inotropic agent), history of bleeding tendency, major operation within 6 weeks, hepatic or renal insufficiency, and contraindication to tirofiban use</P>
<P>Total recruited: a total of 100 STEMI patients undergoing primary PCI within 12 h of symptom onset were randomly allocated to 1 of the 4 intervention groups: standard PCI, initial thrombus aspiration (IT), tirofiban infusion (TI) and PCI with both treatments (IT + TI).</P>
<P>Mean age: 59 y, male: 74%, diabetes 26%, prior myocardial infarction: ?%<BR/>Acute coronary syndrome: 100% (STEMI 100%)<BR/>PCI: balloon angioplasty: 0%, stent: 100%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:40:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Active group: tirofiban was administered with 10 &#956;g/kg over 3 min as a bolus at cath lab before PCI procedure, followed by 0.15 &#956;g/kg/min infusion for 24 h</P>
<P>Control group: all patients received aspirin (300 mg loading followed by 100 mg daily) and clopidogrel (300 mg loading followed by 75 mg daily) and unfractionated heparin 100 IU/kg before the procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:40:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: occurrence of MBG 3 myocardial reperfusion</P>
<P>Secondary endpoints: complete ST-segment resolution, procedure time, occurrence of no-reflow, peak CK-MB level and time to peak, TIMI flow and corrected TIMI frame count, 6 months major adverse events including death, reinfarction, target lesion revascularisation and stroke</P>
<P>Safety endpoints: severe bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:40:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study performed in Taiwan. All patients received 300 mg of clopidogrel before the procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:40:05 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-JEPPORT-2009">
<CHAR_METHODS MODIFIED="2013-09-09 18:40:05 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:40:05 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 88 centres in Japan</P>
<P>Timeframe: from May 1997 to April 2000</P>
<P>Follow-up: 30 days and 6 months</P>
<P>Eligibility criteria: 973 patients with ACS</P>
<P>Exclusion criteria: age &gt; 75 y; &gt; 100 kg of body weight; scheduled for primary stent placement, directional coronary atherectomy or rotablator; history of thrombocytopenia; bleeding symptoms or bleeding diathesis; undergone surgery in the previous 6 weeks; cerebrovascular disorder in the previous 2 y; ?50% stenosis in the left main trunk of the coronary artery; 3-vessel disease; uncontrolled hypertension or pulmonary hypertension; cardiogenic shock requiring cardiopulmonary resuscitation</P>
<P>Mean age: 61 y, 81% male, 31% diabetes, ?% prior MI</P>
<P>ACS: 100% (non-STEACS: 23%, STEMI: 77%)</P>
<P>PCI: 100% (balloon angioplasty: 75%, stent: 25%, drug-eluting stents: 0%), pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:40:05 +0530" MODIFIED_BY="Xavier Bosch">
<P>Low-dose abciximab (0.20 mg/kg bolus + 0.125 µg/kg/min infusion for 12 h) versus high-dose abciximab (0.25 mg/kg bolus + 0.125 µg/kg/min infusion for 12 h) versus placebo (bolus and infusion)</P>
<P>Thrombolytic drugs, antiplatelet drugs other than aspirin, anticoagulant drugs other than heparin, PGE1 and its derivatives, dextran and low-molecular-weight dextran, were prohibited during the 6 months from the start of the investigation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:40:05 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: 30-day occurrence of death, MI and/or urgent revascularisation for recurrence of ischaemia</P>
<P>Secondary: 6-month incidence of major coronary events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:40:05 +0530" MODIFIED_BY="[Empty name]">
<P>Aspirin administered before the procedure. Clopidogrel and ticlopidine were not allowed before and during the 6 month follow-up.</P>
<P>After the first 223 patients were enrolled in the study, &#8220;overseas authorities&#8221; stipulated that the approved intravenous drip infusion dose of abciximab be adjusted according to body weight. The study was resumed 1 year later with the new standard dose</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 16:01:31 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Juergens-2002">
<CHAR_METHODS MODIFIED="2013-10-02 17:51:20 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: the patient received the next consecutive ascending number allocated to the investigator</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Merck &amp; Co, Inc</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:39:51 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 59 centres in 24 countries (Argentina, Australia, Austria, Brazil, China, Colombia, Costa Rica, Ecuador, Greece, Lebanon, Malaysia, Mexico, New Zealand, Poland, Portugal, Singapore, Slovenia, South Africa, Spain, Switzerland, Taiwan, Turkey, United Kingdom and Venezuela)</P>
<P>Timeframe: from May 1998 to June 1999</P>
<P>Eligibility criteria: 894 patients scheduled to undergo PTCA with intracoronary stent placement</P>
<P>Exclusion criteria: thrombolytic therapy within 24 h of AMI, allergy to or unable to tolerate aspirin or heparin, prior treatment with abciximab within 14 days, ticlopidine, clopidogrel or low-molecular-weight heparin within 12 to 24 h, PTCA within 14 days or planned repeat PTCA as a staged procedure; unprotected left main stenosis; bleeding disorder within 3 months; persistent hypertension; history of stroke or other intracranial pathology within 1 year; recent major surgery, trauma, or cardiopulmonary resuscitation; active peptic ulcer disease, pericarditis, significant retinopathy, suspected aortic dissection, uncontrolled cardiac arrhythmia, other haemodynamically significant cardiac disease, or other clinically important medical illness that would make survival for the duration of the study unlikely; serum creatinine level &gt; 2.5 mg/dL, haemoglobin &lt; 11 g/dL, international normalised ratio &gt; 1.5, or a platelet count &lt; 150,000/mm<SUP>3</SUP>; or unable to give informed consent</P>
<P>Mean age: 59 y, male: 83%, prior myocardial infarction: 46%<BR/>Acute coronary syndrome: 46% (unstable angina: 46%, NSTEMI: ?, STEMI: 0%)<BR/>ST-segment depression: ?, CK-MB elevation: 0%, troponin elevation: 0%</P>
<P>PCI: balloon angioplasty: 2%, stent: 98%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 16:01:31 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomised in a 3:2 ratio to receive tirofiban as an intravenous bolus (10 µg/kg over 3 minutes) and maintenance infusion (0.10 µg/kg per minute for 36 h) or a bolus and infusion of placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:39:51 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint:<B> </B>proportion of patients with bleeding</P>
<P>Secondary endpoints: death, MI, urgent coronary artery bypass grafting for recurrent ischaemia and urgent repeat percutaneous intervention for recurrent ischaemia in the target vessel</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:39:51 +0530" MODIFIED_BY="Xavier Bosch">
<P>This was primarily a tolerability study. 3 employees of Merck &amp; Co, Inc, assisted in the preparation of the manuscript</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-09 18:40:42 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kereiakes-1996">
<CHAR_METHODS MODIFIED="2013-09-09 18:39:39 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: 3 dose regimens of tirofiban were studied in 3 sequential panels. Patients within each panel were randomised to receive either tirofiban or placebo in a 3:1 randomisation design</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: not stated</P>
<P>Follow-up: hospitalisation<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:40:42 +0530" MODIFIED_BY="[Empty name]">
<P>Institutions: 9 centres in USA</P>
<P>Timeframe: not stated</P>
<P>Eligibility criteria: men and women &gt; 18 and &lt; 75 years of age who were scheduled to undergo coronary angioplasty for treatment of 1) rest angina pectoris, 2) recurrent angina, or 3) complex coronary lesion morphology associated with a moderate to high risk of procedural failure; 93 patients were enrolled</P>
<P>Exclusion criteria: women of childbearing potential, thrombolytic therapy within 24 h of angioplasty, severed diffuse multivessel coronary atherosclerosis, uncontrolled cardiac arrhythmia, increased bleeding risk, history of stroke or other intracranial pathology, severe congestive heart failure or haemodynamic instability and allergy or intolerance to aspirin or heparin</P>
<P>Mean age: 59 y, male: 82%, prior myocardial infarction: 47%<BR/>Acute coronary syndrome: 52% (unstable angina: 39%, non-STEMI: 0%, STEMI: 13%)<BR/>ST-segment depression: ?%, CK-MB elevation: ?%, troponin elevation: ?%<BR/>PCI: atherectomy: 0%, balloon angioplasty: 100%, stent: 0%, pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-09 18:40:42 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients received 1 of 3 graduated regimens of tirofiban intravenously with a bolus dose of 5, 10 and 10 µg/kg and continuous infusion doses of 0.05, 0.10 and 0.15 µg/kg per min, respectively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:40:42 +0530" MODIFIED_BY="[Empty name]">
<P>Primary composite: death, myocardial infarction and need for urgent revascularisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dose-ranging study<BR/>All tirofiban groups were grouped together for the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:53:48 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Kim-2005">
<CHAR_METHODS MODIFIED="2013-10-02 17:52:56 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated.</P>
<P>Double-blinded?: not stated.</P>
<P>Placebo: not stated.</P>
<P>Sample size calculation: not stated.</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: not stated.</P>
<P>Follow-up: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:53:10 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 1 One clinical centre from Korea (Chonnam National University Hospital).</P>
<P>Timeframe: March 2001 to December 2002.</P>
<P>Eligibility criteria: One hundred and sixty160 patients who had ST-segment depression more than 1 mm in 2 or more consecutive leads, or T wave inversions, or ST-segment elevation less than 20 min on ECG, and elevated troponin concentration.</P>
<P>Exclusion criteria: ST elevation greater than 20 min, thrombolytic therapy within 20 min, percutaneous coronary intervention within the past 6 months or previous coronary artery bypass graft, cerebrovascular accident within the past year, active bleeding or a high risk for bleeding, secondary angina, contra-indication for antithrombotic or anti-platelet therapy, previous history of thrombocytopenia, elevated creatinine (&#8805; 2.5 mg/dl) and thrombocytopenia (&lt; 150,000/mm<SUP>3</SUP>).</P>
<P>Mean age: 61 ys, 65% males, 23% diabetics, ¿?% with prior MI.</P>
<P>Acute coronary syndrome: 100% (Uunstable angina: 50%, Nnon-ST elevation myocardial infarction: 50%, STEMI: 0%)</P>
<P>ST-segment depression: 14%, Ttroponin elevation: 100%.</P>
<P>Coronary angiography: 100%, PCI:¬71% (balloon angioplasty: ?%, stent: ?%, drug-eluting stent: ?%).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:53:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>Aspirin was administered as an oral loading dose of 300 mg followed by 100 mg daily for all patients. The patients were randomised into 4 groups; group I (n = 40): standard heparin alone; group II (n = 40): LMW heparin (dalteparin) alone; group III (n = 40): standard heparin + tirofiban (n = 40); group IV (n = 40): dalteparin + tirofiban</P>
<P>Tirofiban was administered as a bolus injection dose of 0.4 µg/kg//min for 30 min and then a maintenance dose of 0.1 µg/kg/min<SUP>.</SUP>
</P>
<P>Unfractionated heparin was administered as a bolus injection of 5000 units and the 12 U/kg//h, keeping the activated partial thromboplastin time at 1.5 to 2.0-fold the normal control value. Dalteparin was injected at 120 U/kg twice daily. All therapeutic agents were administered between 48 and 96 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 17:53:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of cardiac death, MI or revasculariszation at 7, 30 and 180 days.</P>
<P>Secondary: Mmajor bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 17:53:39 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients underwent 1 month of combined therapy with aspirin and clopidogrel after stenting.</P>
<P>Study performed in Korea.</P>
<P>Unfractionated heparin or dDalteparin used as anticoagulant agent.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:53:55 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Kurowski-2005">
<CHAR_METHODS MODIFIED="2013-09-09 18:39:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: no</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: not stated</P>
<P>Losses to follow-up: no</P>
<P>Funding: a restricted educational grant from MSD GMBH, Germany</P>
<P>Follow-up: 30 days and a mean of 2 y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:39:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Lubeck, Germany</P>
<P>Timeframe: June 2000 to February 2003</P>
<P>Eligibility criteria: 50 patients with stable angina or cardiac troponin T negative unstable angina. The culprit lesion was a critical saphenous vein graft stenosis determined by being the only significant lesion explaining the anginal symptoms or by appropriate objective evidence of ischaemia. All lesions had &gt; 90% diameter stenosis and the SVGs were &gt; 3 mm in diameter</P>
<P>Exclusion criteria: not stated</P>
<P>Mean age: 68 y, male: 84%, diabetes: 20%, prior myocardial infarction: 72%<BR/>Acute coronary syndrome: 68% (unstable angina); none had acute MI<BR/>PCI: balloon PCI: 0%, stent: 100%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:53:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients randomised to tirofiban therapy received a bolus of 10 µg/kg body weight 4 to 6 h before PCI and a maintenance infusion of 0.15 µg/kg body weight per minute or 12 to 14 h. Immediately after inclusion, all patients received a clopidogrel loading dose of 300 mg with an oral maintenance dose of 75 mg/day for 4 weeks, an intravenous aspirin dose of 500 mg with an oral maintenance dose of 100 mg/day indefinitely, and a continuous heparin infusion to maintain the activated partial thromboplastin time at 1.5 to 2 times the upper normal range. The index procedure was performed on the following day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:39:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: occurrence of myocardial necrosis as evidenced by an increase in the cTnT above the limit of detection (0.1 ng/ml) estimated quantitatively every 12 h for 72 h after the procedure<BR/>Secondary: the major adverse cardiac event rate (death, Q-wave myocardial infarction, or emergency revascularisation) at hospital discharge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:39:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients with stenosis in saphenous vein grafts referred for PCI<BR/>All patients pre-treated with 300 mg of clopidogrel 24 h before the procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:36:02 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-On_x002d_TIME-2-2008">
<CHAR_METHODS MODIFIED="2013-10-02 17:35:24 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: Bby blinded sealed kits with study drug. All staff and study personnel were blinded to treatment. Kits were distributed among the ambulance services or referring centres in blocks of 4four.</P>
<P>Double-blinded? yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Merck (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:35:16 +0530" MODIFIED_BY="[Empty name]">
<P>ocation: 24 centres in The Netherlands, Germany, and Belgium.</P>
<P>Timeframe: from 29 June 29,2006 to 13 November 13, 2007.</P>
<P>Follow-up: 30 days.</P>
<P>Eligibility criteria: 984 patients aged 21- to 85 y with acute STEMI presenting &lt; 24 h after the onset of symptoms whio were candidates to undergo primary PCI.</P>
<P>Exclusion criteria: known severe renal dysfunction (glomerular filtration rate &lt; 30 mL/min or serum creatinine &gt; 2·.5 mg/dL), therapy- resistant cardiogenic shock (systolic blood pressure ?80 mm Hg for &gt; 30 min), persistent severe hypertension, contraindication to anticoagulation or increased risk of bleeding, left bundle branch block, pregnant women or women who were breastfeeding, and patients with a life expectancy of less than 1 one year.</P>
<P>Mean age: 62 y, 76% male, 12% diabetes, 9% prior MI.</P>
<P>ACS: 100% (Nnon-STEACS: 0%, STEMI: 100%).</P>
<P>PCI: 100% (balloon angioplasty: 10%, stent: 90%, drug-eluting stents: 24%), pre-treatment with Cclopidogrel: 100%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:35:40 +0530" MODIFIED_BY="Xavier Bosch">
<P>Pre-hospital treatment with tirofiban (25 &#956;g/kg bolus and 0.15 &#956;g/kg/min maintenance infusion for 18 h) or placebo (bolus plus infusion). All patients received at enrolment aspirin and a 600 mg loading dose of clopidogrel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:39:04 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary:<B> </B>extent of residual ST-segment deviation at 1 h after PCI</P>
<P>Secondary: the composite of death, recurrent myocardial infarction, urgent target vessel revascularisation or blinded bail-out use of tirofiban at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 17:36:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients received 600 mg clopidogrel orally at enrolment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:54:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<CHAR_METHODS MODIFIED="2013-09-09 18:38:52 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not clear (&#8220;by the use of computer-based 1:1 randomisation)</P>
<P>Double-blinded?: no, open randomised study</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: yes, but for an alpha error of 0.10</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:38:52 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 1 centre in Italy</P>
<P>Timeframe: not stated</P>
<P>Follow-up: 6 months</P>
<P>Eligibility criteria: 46 diabetic patients with CAD undergoing elective PCI</P>
<P>Exclusion criteria: pre-menopause, severe renal failure (creatinine &gt; 2 mg/dl), known haemorrhagic diathesis or thrombocytopenia, life expectancy &lt; 1 year or raised troponin levels</P>
<P>Mean age: 66 y, 72% male, 100% diabetes, 17% prior MI</P>
<P>ACS: 0%</P>
<P>PCI: 100% (balloon angioplasty: 0%, stent: 100%, drug-eluting stents: 67%), pre-treatment with clopidogrel: ?%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:54:12 +0530" MODIFIED_BY="Xavier Bosch">
<P>Tirofiban (25 µg/kg bolus plus 0.15 µg/kg/min infusion for 8 hours versus placebo (bolus and infusion). Ticlopidine or clopidogrel (loading dose 300 mg) were administered &gt; 24 hours before the procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:38:51 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: incidence of MI and TIMI flow grade after PCI</P>
<P>Secondary: peak troponin levels and myocardial blush grade</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:38:52 +0530" MODIFIED_BY="Xavier Bosch">
<P>Ticlopidine (?%) or 300 mg loading dose of clopidogrel (?%) were administered &gt; 24 h before the procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:56:02 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PARAGON-A-1998">
<CHAR_METHODS MODIFIED="2013-10-02 17:54:55 +0530" MODIFIED_BY="[Empty name]">
<P>Method of treatment allocation: not stated.</P>
<P>Double-blinded?:¬ yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Hoffman La-Roche (Basel, Switzerland).<B> </B>
</P>
<P>Follow-up: 30 days and 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:55:16 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 389 centres in 29 countries.</P>
<P>Timeframe: from February 1998 to June 1999.</P>
<P>Eligibility criteria: 5,225 patients with NSTEACS.</P>
<P>Exclusion criteria: active bleeding (particularly gastrointestinal bleeding within 1 month or history of active ulcer), impaired haemostasis (oral anticoagulation with international normalizsed ratio &gt; 1.5, bleeding disorder such as von Willebrand disease, or thrombocytopenia [(&lt; 100 000 platelets/µL)]), increased bleeding risk (stroke within 12 months, any prior intracranial haemorrhage, tumour or aneurysm, trauma or major surgery within 1 one month, blood pressure &gt; 180/100 mm Hg despite treatment), contraindication to aspirin or heparin, planned fibrinolysis or GP IIb/IIIa inhibition, GP IIb/IIIa inhibition within 1 one week, left bundle-branch block or pacemaker use, estimated creatinine clearance &lt; 30 ml/min, serious co-morbid disease likely to limit survival, and current enrolment in trials of other investigational drugs or devices.</P>
<P>Mean age: 64 y, male: 66%, prior myocardial infarction: 30%.<BR/>Acute coronary syndrome: 100% (unstable angina: 43%, Nnon-STEMI: 57%, STEMI: 0%). ST-segment depression: 44%, CK-MB elevation: 57%, tTroponin elevation: ?%.<BR/>PCI: Iin-hospital: 28%, during drug-infusion: 12%<BR/>Atherectomy: 4%, balloon angioplasty: 28%, stent: 21%.</P>
<P>Treatment with clopidogrel: 0%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:55:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Low-dose lamifiban versus low-dose lamifiban + heparin versus high-dose lamifiban versus high-dose lamifiban + heparin versus placebo + heparin<BR/>Dose:<BR/>a) 300 µg bolus + 1 µg/min infusion + random assignment to heparin or heparin-placebo<BR/>b) 750 µg bolus + 5 µg/min infusion + random assignment to heparin or heparin-placebo<BR/>c) placebo + heparin<BR/>Duration: 72 to 120 hours; median: 72 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 17:55:51 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: a composite of death, myocardial infarction or severe recurrent ischaemia at 30 days.<BR/>Secondary: death or myocardial infarction.<BR/>Required level of CK or CK-MB elevation in MI definition: 2 x ULN in spontaneous MI; 3 x ULN in relation to PCI; 5 x ULN in relation to CABG.<BR/>Safety: Iintracranial haemorrhage; or bleeding leading to haemodynamic compromise requiring intervention.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 17:56:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>The dose of lamifiban used was the one that had the best results in the previous PARAGON A study.<BR/>Performance of angiography and PCI at the discretion of treating physician.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:56:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PARAGON-B-2002">
<CHAR_METHODS MODIFIED="2013-09-09 18:38:32 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Hoffman La-Roche (Basel, Switzerland)</P>
<P>Follow-up: 30 days and 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:38:33 +0530" MODIFIED_BY="[Empty name]">
<P>Institutions: 389 centres in 29 countries</P>
<P>Timeframe: from February 1998 to June 1999</P>
<P>Eligibility criteria: 5225 patients with NSTEACS</P>
<P>Exclusion criteria: active bleeding (particularly gastrointestinal bleeding within 1 month or history of active ulcer), impaired haemostasis (oral anticoagulation with international normalised ratio &gt; 1.5, bleeding disorder such as von Willebrand disease, or thrombocytopenia (&lt; 100 000 platelets/µL)), increased bleeding risk (stroke within 12 months, any prior intracranial haemorrhage, tumour or aneurysm, trauma or major surgery within 1 month, blood pressure &gt; 180/100 mm Hg despite treatment), contraindication to aspirin or heparin, planned fibrinolysis or GP IIb/IIIa inhibition, GP IIb/IIIa inhibition within 1 week, left bundle-branch block or pacemaker use, estimated creatinine clearance &lt; 30 ml/min, serious co-morbid disease likely to limit survival and current enrolment in trials of other investigational drugs or devices</P>
<P>Mean age: 64 y, male: 66%, prior myocardial infarction: 30%<BR/>Acute coronary syndrome: 100% (unstable angina: 43%, non-STEMI: 57%, STEMI: 0%). ST-segment depression: 44%, CK-MB elevation: 57%, troponin elevation: ?%<BR/>PCI: in-hospital: 28%, during drug-infusion: 12%<BR/>Atherectomy: 4%, balloon angioplasty: 28%, stent: 21%</P>
<P>Treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:56:11 +0530" MODIFIED_BY="Xavier Bosch">
<P>Lamifiban (72 h infusion) versus placebo<BR/>Dose:<BR/>a) 500 µg bolus + 1 to 2 µg/min infusion depending on creatinine clearance + heparin<BR/>b) placebo + heparin<BR/>Duration: 72 to 120 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:38:33 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of death, myocardial infarction or severe recurrent ischaemia at 30 days<BR/>Secondary: death or myocardial infarction<BR/>Required level of CK or CK-MB elevation in MI definition: 2 x ULN in spontaneous MI; 3 x ULN in relation to PCI; 5 x ULN in relation to CABG<BR/>Safety: intracranial haemorrhage; or bleeding leading to haemodynamic compromise requiring intervention</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:38:33 +0530" MODIFIED_BY="Xavier Bosch">
<P>The dose of lamifiban used was the one that had the best results in the previous PARAGON A study<BR/>Performance of angiography and PCI at the discretion of treating physician<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 16:03:20 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PRACTICE-2007">
<CHAR_METHODS MODIFIED="2013-10-03 16:03:20 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated (&#8220;using a prospective randomisation schedule&#8221;)..</P>
<P>Double-blinded?: yes</P>
<P>Stratification: yes</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis:?</P>
<P>Funding: Schering Plough.</P>
<P>Follow-up: 30 days and 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>Institutions: 46 hospitals (34 in France, 5 in Israel, 4 in Spain, 2 in Denmark, and 1 in Germany).</P>
<P>Timeframe: September 2001 to July 2004.</P>
<P>Eligibility criteria: 393 patients with ischaemic chest pain at rest within last 24 h associated with ECG changes and elevated Tn I or T.</P>
<P>Exclusion criteria: Ppersistent ST-segment elevation, recent MI, prothrombin time &gt; 1.2 times control, INR &gt; 2, active bleeding within the previous 30 days, uncontrolled hypertension, major surgery or severe trauma within past 6six weeks, history of stroke, thrombocytopenia, creatinine clearance &lt; 30 ml/min, concomitant use of other GP IIib/IIIa blocker, concomitant severe disease associated with shortened life expectancy or pregnancy.</P>
<P>Mean age: 63 y, 73% males, 22% diabetics, 19% with prior MI.</P>
<P>Acute coronary syndrome: 100% (unstable angina: 0%, Nnon-ST elevation myocardial infarction: 100%, STEMI: 0%)</P>
<P>ST-segment depression: 0%, Ttroponin elevation: 100%.</P>
<P>Coronary angiography: 94%, PCI:¬ 61% (balloon angioplasty: ?%, stent: 45%, drug-eluting stent: ?%).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:58:06 +0530" MODIFIED_BY="Xavier Bosch">
<P>Eptifibatide 180 mg/kg bolus + 2 &#956;g/kg/min infusion for 72 h versus placebo. All patients received aspirin + clopidogrel (loading dose: 300 mg) from randomisation. An invasive strategy was planned within 6 to 48 hours after randomisation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 17:57:43 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: a composite of death, MI or urgent revascularizsation at 30 days.</P>
<P>Secondary: Iincidence of death, non -fatal MI, and recurrent ischaemia requiring urgent revasculariszation at hospital discharge and at 6six months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 17:58:00 +0530" MODIFIED_BY="Xavier Bosch">
<P>First study to evaluate the efficacy of upstream administration of a IIb/IIIa antagonist in patients with NSTEACS pre-treated with aspirin and clopidogrel from the time of hospital admission.</P>
<P>Study stopped by the promoter because of low enrolment when 49% of planned patients were included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 17:59:33 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Prati-2005">
<CHAR_METHODS MODIFIED="2013-10-02 17:58:37 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated.</P>
<P>Double-blinded?: no (open-label study).</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: yes</P>
<P>Losses to follow-up: yes, n = 4 (2.9%), all of them in the intervention group.</P>
<P>Funding: not stated.</P>
<P>Follow-up: 30 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 17:58:53 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in Rome, Italy.</P>
<P>Timeframe: not stated.</P>
<P>Eligibility criteria: 140 patients with non-ST elevation unstable anginaUA scheduled for target lesion PTCA.</P>
<P>Exclusion criteria: Ppre-procedural levels of troponin and/or the MB fraction of creatinine kinase (CK-MB) above the upper reference limit, previous coronary artery bypass grafts, congestive heart failure, myocardial infarction in the territory of the treated artery.</P>
<P>Mean age: 62 y, male: 83%, prior myocardial infarction: ?%.<BR/>Acute coronary syndrome: 100% (all of them with unstable angina).<BR/>PCI: balloon PCI: 0%, stent: 98%%. D, drug-eluting stent: 0%, pre-treatment with clopidogrel: 0%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 17:59:18 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomised to receive abciximab administered as a bolus of 0.25 mg/kg followed by an infusion of 10 mg/min, or not to receive a GP IIb/IIIa inhibitor. After the insertion of the arterial sheath, they were all given 70&#8211; to 100 IU/kg of heparin and an additional bolus in order to maintain an activated clotting time of more than 250 sec.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:38:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: coronary microcirculatory impairment as assessed by angiographic myocardial blush grade immediately after PCI</P>
<P>Secondary: in-hospital troponin I and CK-MB plasma levels after PCI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 17:59:33 +0530" MODIFIED_BY="Xavier Bosch">
<P>Ticlopidine 500 mg administered before the procedure. 4Four of the patients randomised to the abciximab group did not complete the study (2two withdrew their informed consent before the intervention and 2two experienced a large groin haematoma after sheath insertion that was interpreted as contraindicating the use of a GP IIb/IIIa inhibitor).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:00:55 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-PRIDE-2001">
<CHAR_METHODS MODIFIED="2013-10-02 17:59:57 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated.</P>
<P>Double-blinded?:¬ yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: COR Therapeutics, Inc., South San Francisco, California; and Schering-Plough Corp., Kenilworth, New Jersey.</P>
<P>Follow-up: 30 d.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 18:00:09 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 14<SUP> </SUP>centres in USA.</P>
<P>Timeframe: from September 1996 to June 1997.</P>
<P>Eligibility criteria: 127 coronary patients scheduled to undergo elective PCI.</P>
<P>Exclusion criteria: hHistory of a bleeding diathesis, severe hypertension (systolic blood pressure &gt; 200 mm Hg or diastolic blood pressure &gt; 100 mm Hg on therapy), major surgery within 6 weeks, history of stroke or other central nervous system disease, pregnancy, gastrointestinal or genitourinary bleeding within 30 days, and any other major co-morbid illness</P>
<P>Mean age: 59 y, male: ?, prior myocardial infarction: 51%.<BR/>Acute coronary syndrome: 0%.<BR/>ST-segment depression: 0%.<BR/>PCI: atherectomy: 0%, balloon angioplasty: 55%, stent: 45%, pre-treatment with clopidogrel: 0%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:00:23 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients randomised to 4 treatment regiments: 1) placebo bolus and infusion; 2) bolus of 135 µg/kg eptifibatide with a 0.75 µg/kg/min infusion; 3) bolus of 180 µg/kg eptifibatide with a 2 µg/kg/min infusion; 4) bolus of 250 µg/kg eptifibatide with a 3 µg/kg/min infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 18:00:42 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: to explore the pharmacodynamics of high doses of eptifibatide.<BR/>Secondary: Ssafety and the composite incidence at 30 days of death, myocardial infarction, or urgent revascularizsation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 18:00:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Dose-ranging study.<BR/>45% of patients underwent stent implantation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:01:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PRISM-1998">
<CHAR_METHODS MODIFIED="2013-09-09 18:37:41 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?:  yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Merck Co.</P>
<P>Follow-up: 30 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-01 22:31:15 +0530" MODIFIED_BY="[Empty name]">
<P>Institutions: 128 sites in 25 countries (Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Costa Rica, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Portugal, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States)</P>
<P>Timeframe: from March 1994 to October 1996</P>
<P>Eligibility criteria: 3232 patients with unstable angina or non-ST segment elevation myocardial infarction</P>
<P>Exclusion criteria: prior thrombolytic therapy within the previous 48 h, allergy to or intolerance of heparin; serum creatinine &gt; 2.5 mg/dL; active bleeding disorder; history of gastrointestinal bleeding; haematuria; a positive fecal occult blood test; known coagulopathy; a platelet disorder or a history of thrombocytopenia; persistent systolic blood pressure &gt; 180 mm Hg, diastolic blood pressure &gt; 110 mm Hg, or both; a history of haemorrhagic cerebrovascular disease or an active intracranial pathologic process; a history of cerebrovascular disease or transient ischaemic attack within the previous year; a major surgical procedure within the previous month; active peptic ulceration within the previous 3 months; or an invasive procedure within 14 days before enrolment that would substantially increase the risk of haemorrhage<BR/>
</P>
<P>Mean age: 62 y, male: 68%, prior myocardial infarction: 47%<BR/>Acute coronary syndrome: 100% (unstable angina: 75%, non-STEMI: 25%, STEMI: 0%)<BR/>ST-segment depression: 32%, CK-MB elevation: 24%, troponin elevation: ?%</P>
<P>PCI: in-hospital: 21%, during drug-infusion: 2%<BR/>Atherectomy: 0%, balloon angioplasty: 13%, stent: 8%</P>
<P>Treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:01:12 +0530" MODIFIED_BY="Xavier Bosch">
<P>Tirofiban (0.6 µg/kg/min for 30 minutes + 0.15 µg/kg/min infusion for a mean of 47.5 hours + placebo heparin) versus placebo + heparin bolus and infusion<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 18:01:09 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of death, myocardial infarction or refractory ischaemia at 48 hours<BR/>Secondary: a composite of death, myocardial infarction and refractory ischaemia at 7 days<BR/>Required level of CK or CK-MB elevation in MI definition: 2 x ULN<BR/>Safety: intracranial haemorrhage; bleeding leading to decrease in haemoglobin concentration &gt; 50 g/L; or cardiac tamponade</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:48:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>Angiography was discouraged during the infusion period<BR/>PCI was not scheduled</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:02:51 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-PRISM-Plus-1998">
<CHAR_METHODS MODIFIED="2013-10-02 18:01:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: locally by means of sealed envelopes.</P>
<P>Double-blinded?:¬ yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Merck COo.</P>
<P>Follow-up: 30 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 18:02:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>Institutions: 72 hospitals in 14 countries (Argentina, Australia, Austria, Canada, Chile, Colombia, Denmark, Finland, France, South Africa, Spain, Switzerland, United States),</P>
<P>Timeframe: from November 1994 to September 1996.</P>
<P>Eligibility criteria: 1,915 Hhigh- risk patients with unstable angina or non-ST elevation MI.</P>
<P>Exclusion criteria: ST-segment elevation lasting more than 20 minutes, coronary angioplasty within the previous 6 months or bypass surgery within the previous month, angina caused by identifiable factors, prior thrombolytic therapy in the previous 48 h, serum creatinine &gt; 2.5 mg, an active bleeding disorder or a high risk of bleeding, a history of gastrointestinal bleeding, haematuria, known coagulopathy, a platelet disorder or a history of thrombocytopenia, stroke within the previous year, a history of haemorrhagic cerebrovascular disease or an active intracranial pathologic process.</P>
<P>Mean age: 63 y, Mmale: 67%, Pprior myocardial infarction: 43%.<BR/>Acute coronary syndrome: 100% (unstable angina: 55%, Nnon-STEMI: 45%, STEMI: 0%)<BR/>ST-segment depression: 58%, CK-MB elevation: 45%, Ttroponin elevation: ?%.</P>
<P>PCI: Iin-hospital: 31%, during drug- infusion: 25%.<BR/>Atherectomy: ?%, balloon angioplasty: ?%, stent: ?%.</P>
<P>Treatment with clopidogrel: 0%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:02:24 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients were randomised to receive one of three regimens: High-dose tirofiban (0.6 µg/kg/minfor 30 min + 0.15 µg/kg/min infusion) + placebo heparin; versus regular dose tirofiban (0.4 µg/kg/min for 30 min + 0.1 µg/kg/min infusion) + adjusted-dose heparin; versus placebo + heparin<BR/>Duration of infusion: 48 to 96 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 18:02:37 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of death, myocardial infarction and refractory ischaemia at 7 days.<BR/>Secondary: the same composite endpoint at 48 h and 30 days; the components of the primary endpoint as separate measures, and a composite of death or myocardial infarction.<BR/>Required level of CK or CK-MB elevation in MI definition: 2 x ULN in spontaneous MI; 3 x ULN in relation to PCI.<BR/>Safety: Iintracranial haemorrhage; bleeding leading to decrease in haemoglobin concentration &gt; 40 g/L or transfusion of &gt; = 2 U blood; or requiring corrective surgery.</P>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 18:02:51 +0530" MODIFIED_BY="Xavier Bosch">
<P>Angiography was recommended after the first 48 h of randomisation and during the infusion period (48- to 96 h). PCI performed if indicated by angiography.<BR/>The study in the tirofiban-only group was stopped prematurely on the recommendation of the data and safety monitoring board at the time of the first interim efficacy analysis. This effect disappeared at 6-month follow-up. Both tirofiban groups were grouped together for the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 16:27:59 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PURSUIT-1998">
<CHAR_METHODS MODIFIED="2013-10-03 16:26:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: in a double-blind manner, by co-ordinating centres in the United States or the Netherlands.<BR/>Double-blinded?: yes<BR/>Stratification: no<BR/>Placebo: yes<BR/>Sample size calculation: yes<BR/>Intention-to-treat analysis: yes<BR/>Funding: COR Therapeutics and Schering-Plough Research Institute.<BR/>Follow-up: 30 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 16:26:35 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 726 participating hospitals in 28 countries (United States, Argentina, Uruguay, Austria, Belgium, Canada, Chile, Colombia, Czech Republic, El Salvador, Finland, France, Germany, Greece, Guatemala, Hungary, Italy, Mexico, Norway, Poland, Portugal, Spain, Switzerland, the Netherlands, United Kingdom, Venezuela)<BR/>
<BR/>Timeframe: from November 1995 to January 1997.<BR/>
<BR/>Eligibility criteria: 10,948 patients with unstable angina or non-ST segment elevation myocardial infarction<BR/>
<BR/>Exclusion criteria: Ppersistent ST-segment elevation of more than 1 mm, active bleeding or a history of bleeding diathesis, gastrointestinal or genitourinary bleeding within 30 days before enrolment, systolic blood pressure &gt; 200 mm Hg or diastolic blood pressure &gt; 110 mm Hg, a history of major surgery within the previous 6six weeks, a history of non-haemorrhagic stroke within the previous 30 days or any history of haemorrhagic stroke, renal failure, pregnancy, the planned administration of a platelet glycoprotein IIb/IIIa receptor inhibitor or thrombolytic agent, or the receipt of thrombolytic therapy within the previous 24 h.<BR/>
<BR/>Mean age: 64 y, Mmale: 65%, pPrior myocardial infarction: 32%.<BR/>Acute coronary syndrome: 100% (unstable angina: 54%, Nnon-STEMI: 46%, STEMI: 0%)<BR/>ST-segment depression: 50%, CK-MB elevation: 46%, Ttroponin elevation: ?%.<BR/>
<BR/>PCI: Iin-hospital: 24%, during drug-infusion: 11%<BR/>Atherectomy: ?%, balloon angioplasty: 12%, stent: 12%.<BR/>
<BR/>Treatment with clopidogrel: 0%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:14:13 +0530" MODIFIED_BY="Xavier Bosch">
<P>Regular dose eptifibatide (180 µg/kg bolus + 1.3 µg/kg/min infusion) + heparin versus high-dose eptifibatide (180 µg/kg bolus + 2.0 µg/kg/min infusion) + heparin, versus placebo + heparin<BR/>Duration of infusion: 72 to 96 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 16:27:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of death or non-fatal myocardial infarction at 30 days.<BR/>Secondary: Mmortality at 30 days; myocardial infarction at 30 days; death or myocardial infarction at 96 h and 7 d; bleeding complications.<BR/>Required level of CK or CK-MB elevation in MI definition: 1 x ULN in spontaneous MI; 3 x ULN in relation to PCI; 5 x ULN in relation to CABG.<BR/>Safety: Iintracranial haemorrhage; or bleeding leading to haemodynamic compromise requiring intervention.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 16:27:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>Angiography and PCI at the discretion of treating physician.<BR/>
<BR/>After 3218 patients had been randomly assigned to treatment groups, the independent data safety and monitoring committee recommended dropping the lower dose .</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:14:30 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RAPPORT-1998">
<CHAR_METHODS MODIFIED="2013-09-09 18:37:03 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes<BR/>Funding: this study was supported by Centocor, Malvern, Pa, and Eli Lilly and Company, Indianapolis, Ind</P>
<P>Follow-up: 30 days and 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:37:03 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 36 centres in the USA</P>
<P>Timeframe: from 16 November 1995 to 2 February 1997</P>
<P>Eligibility criteria: 483 patients with myocardial infarction (&lt; 12 h) candidates for primary percutaneous transluminal coronary angioplasty</P>
<P>Exclusion criteria: severe thrombocytopenia, baseline prothrombin time &gt; 1.2 times control, ongoing internal bleeding or recent major surgery, previous stroke, severe uncontrolled hypertension, PTCA of the infarct artery within 3 months, cardiogenic shock or prolonged resuscitation, vasculitis, prior administration of abciximab or fibrinolytic therapy, or inability to give written informed consent</P>
<P>Mean age: 61 y, male: 72%, prior myocardial infarction: 21%<BR/>Acute coronary syndrome: 100% (unstable angina: 0%, non-STEMI: 0%, STEMI: 100%)<BR/>ST-segment depression: 0%, CK-MB elevation: 100%, troponin elevation: ?</P>
<P>PCI: atherectomy: 0%, balloon angioplasty: 85%, stent: 7% (unplanned), pre-treatment with clopidogrel: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:14:30 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (0.25 mg/kg bolus followed by a 12-h infusion of 0.125 µg/kg/min infusion (maximum, 10 µg/min) versus placebo (bolus and infusion)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:37:03 +0530" MODIFIED_BY="[Empty name]">
<P>Primary: a composite of total death, myocardial infarction and any repeat target vessel revascularisation within 6 months</P>
<P>Secondary: major bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 18:14:30 +0530" MODIFIED_BY="Xavier Bosch"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:14:39 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-RESTORE-1997">
<CHAR_METHODS MODIFIED="2013-10-02 18:03:30 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated.</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: yes</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Merck &amp; Co., Inc., Whitehouse Station, New Jersey.</P>
<P>Follow-up: 30 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 18:03:44 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 104 centres in USA and Europe.</P>
<P>Timeframe: from 9 January 9 to 1 December 1, 1995.</P>
<P>Eligibility criteria: 2,141 patients who were undergoing coronary interventions (balloon angioplasty or DCA) within 72 h of presentation with an acute coronary syndrome.</P>
<P>Exclusion criteria: thrombolytic therapy within 24 hours, contraindication to anticoagulation, history of a platelet disorder or thrombocytopenia, history of stroke or other intracranial pathology likely to predispose to bleeding, patients scheduled for elective stent placement or angioplasty using a rotablator or transluminal extraction catheter.</P>
<P>Mean age: 59 y, male: 72%, prior myocardial infarction: 35%.<BR/>Acute coronary syndrome: 100% (unstable angina: 67%, Nnon-STEMI: ?, STEMI: 32%).<BR/>ST-Ssegment depression: ?, CK-MB elevation: ?, Ttroponin elevation: ?.</P>
<P>PCI: atherectomy: 8%, balloon angioplasty: 92%, stent: 0%, pre-treatment with clopidogrel: 0%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:14:39 +0530" MODIFIED_BY="Xavier Bosch">
<P>Tirofiban (10 mg/kg bolus + 0.15 mg/kg/min infusion for 36 hours versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 18:04:11 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary endpoint: 30-day incidence of a composite endpoint of death from any cause, MI, CABG surgery owing to angioplasty failure or recurrent ischaemia, repeat target-vessel angioplasty for recurrent ischaemia or insertion of a stent owing to actual or threatened abrupt closure of the target artery.</P>
<P>Secondary endpoints: the incidence of all individual endpoints.</P>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-01 00:20:01 +0530" MODIFIED_BY="Xavier Bosch"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:05:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulman-1996">
<CHAR_METHODS MODIFIED="2013-10-02 18:04:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated.</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: no</P>
<P>Funding: COR Therapeutics, Inc, San Francisco, California.</P>
<P>Follow-up: 30 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 18:04:46 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 15 centres in USA.</P>
<P>Timeframe: not stated.</P>
<P>Eligibility criteria: 227 patients with unstable angina and ST-T changes on admission ECG, or known coronary artery disease.</P>
<P>Exclusion criteria: Ssuspected myocardial infarction in evolution, prior coronary artery bypass graft surgery within 6six months, coronary angioplasty within 72 h, thrombolytic therapy within 7 days, major surgery within 6six weeks, a history of cerebral vascular disease, major gastrointestinal or genitourinary bleeding within 30 days, significant thrombocytopenia (&lt; 100 ,000/mm<SUP>3</SUP>), coagulopathy (receiving coumarin or bleeding time &gt; 20 minutes), and if they presented with severe hypertension¬ or had renal insufficiency with a creatinine level &gt; 4 mg/dL.</P>
<P>Mean age: 62 y, male: 63%, prior myocardial infarction: 55%.</P>
<P>ACS: 100% (unstable angina: 100%, Nnon-STEMI: 0%, STEMI: 0%).</P>
<P>ST-segment depression: 33%, CK-MB or Tn elevation: 0%.</P>
<P>PCI: not stated (Aatherectomy: ?%, balloon angioplasty: ?%, stent: ?%).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:05:13 +0530" MODIFIED_BY="[Empty name]">
<P>Low-dose eptifibatide (45 µg/kg bolus over 3 minutes followed by a continuous 0.5 µg/kg//min infusion for 24 to 72 h) versus high-dose eptifibatide (90 µg/kg bolus<SUP> </SUP>plus infusion of 1 µg/kg/min) versus placebo bolus and infusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 18:04:57 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: number and duration of ischaemic episodes on continuous monitoring over the first 24 hours as well as for the entire duration of drug infusion.</P>
<P>Secondary: number and duration of symptomatic ischaemic episodes, ECG episodes of ischaemia after study drug withdrawal, and clinical events of death, myocardial infarction and refractory ischaemia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 18:05:09 +0530" MODIFIED_BY="[Empty name]">
<P>The placebo group received aspirin and heparin while the eptifibatide group received only heparin.<BR/>Both active treatment groups have been grouped in our analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 16:08:41 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shen-2008">
<CHAR_METHODS MODIFIED="2013-09-09 18:36:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: by a 24-h computer-generated random-allocation system</P>
<P>Double-blinded?: no</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: a grant from the Shanghai Science and Technology Committee (no 05DZ19503)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:36:34 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 1 centre in China</P>
<P>Timeframe: from January 2005 to June 2006</P>
<P>Follow-up: 30 days and 6 months</P>
<P>Eligibility criteria: 172 patients with STEMI presenting &lt; 12 h after the onset of symptoms</P>
<P>Exclusion criteria: cardiogenic shock and known bleeding diathesis</P>
<P>Mean age: 66 y, 81% male, 27% diabetes, ?% prior MI</P>
<P>ACS: 100% (non-STEACS: 0%, STEMI: 100%)</P>
<P>PCI: 100% (balloon angioplasty: 0%, stent: 100%, drug-eluting stents: 100%), pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 16:08:41 +0530" MODIFIED_BY="Xavier Bosch">
<P>Tirofiban (bolus of 10 µg/kg plus a 36-h infusion of 0.15 µg/kg/min) in the emergency room versus tirofiban (bolus of 10 &#956;g/kg plus a 36-h infusion of 0.15 &#956;g/kg/min)  in the catheterisation laboratory versus placebo (bolus and infusion). Upon admission, loading doses of aspirin (300 mg) and clopidogrel (450 mg) were given for all patients in the emergency room</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:36:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary:<B> </B>occurrence rate of major adverse cardiac events including death, nonfatal MI and target vessel revascularisation (either by PCI or coronary artery bypass surgery) at 30-day and 6-month follow-up</P>
<P>Secondary: haemorrhagic complications and thrombocytopenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:36:34 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients treated with drug-eluting stents</P>
<P>Upon admission, loading doses of aspirin (300 mg) and clopidogrel (450 mg) were given for all patients in the emergency room</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:07:29 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simoons-1994">
<CHAR_METHODS MODIFIED="2013-09-09 18:36:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: yes</P>
<P>Funding: Centocor, Inc, Malvern, Pa</P>
<P>Follow-up: hospitalisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:36:25 +0530" MODIFIED_BY="[Empty name]">
<P>Location: 7 centres in Europe</P>
<P>Timeframe: from September 1991 to July 1992</P>
<P>Eligibility criteria: 60 refractory unstable angina patients with chest pain at rest despite optimal treatment and a recent (&lt; 24 h) coronary angiography showing a single culprit lesion suitable for PCI were enrolled, provided that a second coronary angiogram, followed by PCI, could be performed 18 to 24 h after the first (diagnostic) angiogram</P>
<P>Exclusion criteria: features of ongoing ischaemia requiring immediate intervention, prior PCI of the same coronary segment within 6 months, a previous myocardial Q-wave infarction within 7 days, female sex with childbearing potential, recent major trauma including resuscitation, surgery or gastrointestinal or genitourinary bleeding within the past 6 weeks, known hepatic or renal disorder, history of bleeding diathesis or a platelet count of &lt; 100,000/mm<SUP>3</SUP>, and known autoimmune disorders</P>
<P>Mean age: 60 y, male: 73%, prior myocardial infarction: 18%</P>
<P>ACS: 100% (NSTEACS: 100%)</P>
<P>Transient ST-segment depression or elevation: 67%; CK-MB or Tn elevation: ?%</P>
<P>PCI: atherectomy: 0%, balloon angioplasty: 100%, stent: 0%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:07:29 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (0.25 mg/kg bolus + 10 µg/min infusion) versus placebo. The infusion started &lt; 4 h after first coronary angiography and was continued until 1 h after PCI, which was scheduled between 18 and 24 h after the start of the infusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:36:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a composite of death, myocardial infarction and recurrent ischaemia requiring urgent intervention (PCI, CABG or intra-aortic balloon pump)</P>
<P>Secondary: occurrence of all recurrent ischaemic episodes and angiographic endpoints</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 18:36:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients treated with IV nitroglycerin infusion, aspirin and heparin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-02 18:08:31 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Tamburino-2002">
<CHAR_METHODS MODIFIED="2013-10-02 18:08:08 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: Bby a &#8220;standard list of random numbers&#8221; with the use of closed envelopes.</P>
<P>Double-blinded?: no</P>
<P>Stratification: no</P>
<P>Placebo: no</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: not stated.</P>
<P>Funding: not stated.</P>
<P>Follow-up: 30 days and 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 18:08:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: Hospital of Catania (Italy).</P>
<P>Timeframe: from October 1996 to February 1998.</P>
<P>Eligibility criteria: 107 patients with demonstrable reversible ischaemia and &gt; 70% de novo native coronary stenoses requiring implantation of either a stent longer than 20 mm or of multiple overlapping stents.</P>
<P>Exclusion criteria: Ppatients with saphenous graft lesion, bleeding diathesis, thrombocytopenia, history of stroke, active bleeding, severe uncontrolled hypertension, major surgery or trauma within 6 weeks.</P>
<P>Mean age: 62 y, male: 88%, diabetes: 27%, prior myocardial infarction: 67%.<BR/>Acute Ccoronary Ssyndrome: 48% (unstable angina: 48%, Nnon-STEMI: ?%, STEMI: 0%).<BR/>ST-segment depression: ?%, CK-MB elevation: ?%, Ttroponin elevation: ?%.<BR/>PCI: atherectomy: 0%, balloon angioplasty: 0%, stent: 100%, pre-treatment with clopidogrel: 0%, but 100% with ticlopidine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 18:08:31 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab (bolus of 0.25 mg/Kkg, followed by an infusion of 0.125 µg/Kkg/min for 12 h) versus placebo. All patients treated with ASA and heparin. Ticlopidine 250 mg twice daily was started the day before the intervention and was prescribed to all patients for 4 weeks following the procedure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:36:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: safety (bleeding and vascular complications) and efficacy in reducing major in-hospital adverse cardiac events related to the procedure (death, MI and urgent revascularisation)<BR/>Secondary: reduction in death, MI, target lesion revascularisation and angiographic binary restenosis at 6 months<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 16:11:01 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-TOPSTAR-2002">
<CHAR_METHODS MODIFIED="2013-10-03 16:10:49 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: Nnot stated (&#8220;The patients were randomised by an independent study nurse&#8221;).</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes (0.9% NaCl solution).</P>
<P>Sample size calculation: no</P>
<P>Intention-to-treat analysis: not stated.</P>
<P>Funding: Ssupported by a grant from MSD (Merck, Sharp and Dohme) GmbH, Germany.</P>
<P>Follow-up: 30 days and 9 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-02 18:10:09 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: University of Würzburg, Würzburg, Germany.</P>
<P>Eligibility criteria: 96 of 109 patients with stable CAD, a target lesion &gt; 70% suitable for PCI, and thatwho underwent elective PCI after pre-treatment with 375 mg of clopidogrel at least 1 one day before PCI.</P>
<P>Exclusion criteria: acute coronary syndromes, stenosis located in venous or arterial bypass grafts; renal insufficiency; recent peptic ulcers or a history of bleeding, thrombocytopenia or thrombolytic therapy within the previous 24 hours; stroke during the past 2 years; severe hypertension; neoplasms; and previous or planned administration of a GP IIb/IIIa receptor antagonist.</P>
<P>Mean age: 65 years, male: 75%, prior myocardial infarction: 38%.<BR/>Acute coronary syndrome: 0%<BR/>ST-segment depression: ?, CK-MB elevation: ?, Ttroponin elevation: ?.<BR/>PCI: atherectomy: 0%, balloon angioplasty: 8%, stent: 92%, pre-treatment with clopidogrel: 100%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 16:11:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>Tirofiban bolus of 10 µg/kg + infusion of 0.15 µg/kg/min.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-02 18:10:14 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: presence of post interventional release of troponin T after 24 hours<BR/>Secondary: incidence of death, MI or target vessel revascularisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-02 18:09:46 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients pre-treated with clopidogrel 375 mg and ASA 500 mg at least 1 one day before PCI.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 16:25:02 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Yan-2009">
<CHAR_METHODS MODIFIED="2013-09-09 18:35:54 +0530" MODIFIED_BY="Xavier Bosch">
<P>Method of treatment allocation: not stated</P>
<P>Double-blinded?: yes</P>
<P>Stratification: no</P>
<P>Placebo: yes</P>
<P>Sample size calculation: not stated</P>
<P>Intention-to-treat analysis: not stated</P>
<P>Funding: not stated</P>
<P>Follow-up: 30 days and 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-09 18:35:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Location: 1 centre in China (Beijing Anzhen Hospital, Capital Medical University, Beijing, China)</P>
<P>Timeframe: from June 2005 to June 2006</P>
<P>Eligibility criteria: 240 high-risk patients with NSTEACS</P>
<P>Exclusion criteria: acute Q wave myocardial infarction, coronary artery bypass grafting within 1 month, drug allergy and/or anticoagulation contraindication</P>
<P>Mean age: 63 y, male: 73%, prior myocardial infarction: 15%<BR/>Acute coronary syndrome: 100%<BR/>ST-segment depression: ?, CK-MB elevation: ?%, troponin elevation:?%<BR/>PCI: balloon PCI: ?%, stent: ?%, pre-treatment with clopidogrel: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 16:12:18 +0530" MODIFIED_BY="Xavier Bosch">
<P>All patients orally took 300 mg of aspirin and 300 mg of clopidogrel before PCI, then took aspirin 100 mg/d and clopidogrel 75 mg/d.</P>
<P>During PCI, heparin was given in intravenous bolus of 5000 IU, then followed by continuous infusion at a rate of 1000 IU/h, to maintain the activated clotting time (ACT) in 300 to 400 seconds</P>
<P>Tirofiban (Wuhan Yuanda Co., Wuhan, China) was given as intravenous bolus of 10 &#956;g/kg over 3 minutes immediately after PCI, then followed by continuous infusion at a rate of 0.15 &#956;g/kg/min for 24 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 18:35:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Primary: a combined endpoint of death from any cause; new myocardial infarction or repeat target vessel revascularisation</P>
<P>Secondary: platelet aggregation rate, ECG changes, CK-MB and Tn levels, and safety results (bleeding and thrombocytopenia)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 16:25:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>High-risk patients with NSTEACS scheduled for PCI<BR/>All patients pre-treated with 300 mg of clopidogrel &gt; 2 h before the procedure</P>
<P>Tirofiban was given as intravenous bolus of 10 &#956;g/kg over 3 minutes immediately after PCI</P>
<P>Study performed in Beijing, China</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACE; Angiotensin converting enzyme</P>
<P>AMI: Acute myocardial infarction</P>
<P>ASA: Acetyl salicylic acid</P>
<P>ACS: acute coronary syndrome<BR/>AHA/ACC: American Heart Association/American College of Cardiology<BR/>BP: blood pressure</P>
<P>CABG: coronary artery bypass graft</P>
<P>CCS: Canadian cardiovascular society<BR/>CK: creatinine kinase<BR/>CK-MB: creatinine kinase-MB fraction<BR/>d: day/s</P>
<P>DES: drug-eluted stent</P>
<P>DM: diabetes mellitus<BR/>ECG: electrocardiogram<BR/>GP: glycoprotein<BR/>h: hour/s<BR/>INR: international normalised ratio</P>
<P>IRA: Infarct-related artery<BR/>IV: intravenous</P>
<P>IVUS: intravascular ultrasound</P>
<P>LAD: left anterior descending<BR/>LMW: low molecular weight<BR/>MACE: major adverse cardiovascular event<BR/>MI: myocardial infarction</P>
<P>MLD: minimal lumen diameter<BR/>NSTEACS: non-ST segment elevation acute coronary syndromes<BR/>NSTEMI: non ST-segment elevation myocardial infarction<BR/>PCI: percutaneous coronary intervention</P>
<P>PTCA: percutaneous transluminal coronary artery</P>
<P>PTT: Prothrombin time<BR/>s: second/s<BR/>sc: subcutaneous<BR/>STEMI: ST-segment elevation myocardial infarction</P>
<P>SVG: single vein graft<BR/>TIMI: thrombolysis in myocardial infarction<BR/>TLR: target lesion revascularisation</P>
<P>TVR: target vessel revascularisation</P>
<P>ULN: upper limit of normal<BR/>y: year/s</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-10-03 16:14:03 +0530" MODIFIED_BY="Joey Kwong" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:06:47 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ACUITY-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:06:47 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of unfractionated heparin or enoxaparin plus any GP IIb/IIIa inhibitor versus bivalirudin plus any GP IIb/IIIa inhibitor versus bivalirudin alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:24 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ADVANCE-MI-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:24 +0530" MODIFIED_BY="Xavier Bosch">
<P>Facilitated thrombolysis (eptifibatide + tenecteplase) versus facilitated PCI (eptifibatide) in patients with STEMI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:17 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alexander-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:17 +0530" MODIFIED_BY="[Empty name]">
<P>Sub-study of the PURSUIT trial on the effect of prior use of aspirin in GP IIb/IIIa inhibitors use in unstable angina</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:29 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Azar-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:29 +0530" MODIFIED_BY="Xavier Bosch">
<P>The aim was to assess the anti-inflammatory effect of tirofiban. No clinical events were reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-06 17:12:46 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Batyraliev-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-06 17:12:46 +0530" MODIFIED_BY="[Empty name]">
<P>Study on rescue coronary angioplasty after unsuccessful thrombolysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:33 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellandi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:33 +0530" MODIFIED_BY="[Empty name]">
<P>Comparison of abciximab administered in the emergency room versus in the catheterisation laboratory</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:37 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Bertrand-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:37 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study comparing bolus abciximab versus bolus + infusion abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:54 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Blankenship-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:54 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPIC sub-study on local bleeding after GP IIb/IIIa inhibitors use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:40 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-BOCHUM-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:40 +0530" MODIFIED_BY="Xavier Bosch">
<P>Open-label pilot study to assess the practical application and safety of pre-hospital eptifibatide versus control in patients with suspected ACS. Patients were assigned eptifibatide or control in even/uneven days<BR/>Of the 356 patients included, 42% had a NSTEACS, 32% had a STEMI and 42% had a non-specific chest pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:11:30 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Boehrer-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:11:30 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPIC sub-study on the effect of abciximab in coronary artery bypass surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:11:33 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Brener-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:11:33 +0530" MODIFIED_BY="Xavier Bosch">
<P>RAPPORT sub-study on the pattern of reperfusion in myocardial infarction patients treated with abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cannon-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial with an oral GP IIb/IIIa antagonist (TIMI 12)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:44 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Claeys-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:44 +0530" MODIFIED_BY="Xavier Bosch">
<P>Open-label, non-randomised study. Comparison of the degree of inhibition of platelet aggregation after the administration of a loading dose of clopidogrel versus abciximab. 39 patients that underwent PCI with stent implantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:55 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-CLEAR-PLATELETS-1b-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study on the effects of eptifibatide on top of aspirin and clopidogrel on platelet aggregation and clinical markers of inflammation and necrosis. No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:57 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-CLOTILDA-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:57 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of tirofiban versus provisional abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:15:59 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Costantini-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:15:59 +0530" MODIFIED_BY="[Empty name]">
<P>Sub-study of the CADILLAC trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:06:33 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cutlip-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:06:33 +0530" MODIFIED_BY="[Empty name]">
<P>Tirofiban versus control in the emergency room followed by any IIb/IIIa inhibitor during PCI a median of 90 min later</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:04 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-EARLY_x002d_ACS-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:04 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study comparing eptifibatide administered at admission versus at the catheterisation laboratory (a mean of 12 h later) in 9492 patients with NSTEACS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:09 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ELISA-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:09 +0530" MODIFIED_BY="Xavier Bosch">
<P>The ELISA pilot study. This study compared 2 different PCI strategies in patients with UA/NSTEMI rather than 2 different treatments: immediate (median 6 h) PCI after randomisation without pre-treatment with tirofiban versus delayed (median 50 h) PCI after prolonged pre-treatment with tirofiban<BR/>Thus, although tirofiban administration was randomised, the basal conditions were different because of differences in timing of administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:13:39 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Ellis-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:13:39 +0530" MODIFIED_BY="Xavier Bosch">
<P>RCT on facilitated PCI in patients with STEMI comparing PCI after abciximab plus half-dose reteplase versus abciximab alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:12 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Emre-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:12 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of tirofiban administered in the emergency room versus in the catheterisation laboratory</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:15 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ERAMI-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of abciximab administered in the emergency room versus in the catheterisation laboratory</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:17 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Ercan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>Small study looking at differences in CRP at 48 to 72 h. No clinical events reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:25 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-EVEREST-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of tirofiban administered in the CCU versus in the catheterisation laboratory</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:28 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Ghaffari-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:28 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPILOG and EPIC joined sub-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-06 17:14:27 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-GRAPE-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-06 17:14:27 +0530" MODIFIED_BY="Xavier Bosch">
<P>Pilot study performed in 60 patients with STEMI treated with primary PCI without a control group. Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:14:22 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Gunasekara-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:14:22 +0530" MODIFIED_BY="Xavier Bosch">
<P>A non-randomised comparison of abciximab versus high-dose tirofiban</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-GUSTO-V-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial comparing the addition of a GP IIb/IIIa antagonist to the fibrinolytic treatment in patients with ST-segment elevation acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:14:33 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamm-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:14:33 +0530" MODIFIED_BY="[Empty name]">
<P>Sub-study of the CAPTURE trial. Differential effects of abciximab in patients with refractory angina according to basal troponin levels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:32 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Hamza-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:32 +0530" MODIFIED_BY="Xavier Bosch">
<P>Small study performed with 50 patients comparing tirofiban + clopidogrel 300 mg versus clopidogrel 600 mg. Just the Abstract from a Congress is available and there is not enough information. In addition, there were no deaths, MI, target-vessel revascularisation or major bleeding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanefeld-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study of the BOCHUM trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:36 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Heeschen-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:36 +0530" MODIFIED_BY="Xavier Bosch">
<P>Sub-study of the PRISM trial. Effects of tirofiban in patients with UA/NSTEMI according to baseline troponin levels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:39 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-HORIZONS_x002d_AMI-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:39 +0530" MODIFIED_BY="Xavier Bosch">
<P>RCT comparing bivalirudin versus any GP IIb/IIIa inhibitor plus heparin in patients with STEMI submitted to primary PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-IMPACT_x002d_AMI-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT on the effect of GP IIb/IIIa inhibitors in patients with ST-segment elevation acute myocardial infarction treated with thrombolytics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:45 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-INTAMI-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:45 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of eptifibatide administered in the emergency room versus in the catheterisation laboratory in patients with STEMI submitted to primary PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:48 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-ISAR_x002d_REACT-4">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>RCT comparing abciximab plus unfractionated heparin with bivalirudin alone. Excluded because of no appropriate control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:16:23 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Ji-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:16:23 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abstract from a congress. Only 41 patients studied and not enough information on clinical events is available (mortality 0%, severe bleeding 0%)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:50 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Kereiakes-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:50 +0530" MODIFIED_BY="Xavier Bosch">
<P>Oral GP IIb/IIIa inhibitor xemilofiban. It is not a randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:53 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Kereiakes-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:53 +0530" MODIFIED_BY="Xavier Bosch">
<P>Oral GP IIb/IIIa inhibitor xemilofiban</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:20:44 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kereiakes-1998b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:20:44 +0530" MODIFIED_BY="[Empty name]">
<P>Sub-study of the EPILOG trial. Sub-analysis in unplanned stent patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:20:50 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Kleiman-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:20:50 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPILOG sub-analysis in patients with diabetes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:16:59 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Klootwijk-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:16:59 +0530" MODIFIED_BY="Xavier Bosch">
<P>CAPTURE sub-study on silent ischaemia in GP IIb/IIIa inhibitors in unstable angina</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:02 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Krause-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:02 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abstract from a congress. A phase II RCT with 3 escalating doses of IV fradafiban in 65 patients with stable angina submitted to elective PTCA<BR/>Aim: safety and antiplatelet effects. No clinical events reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:25:54 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Lefkovits-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:25:54 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPIC sub-study on the effects of abciximab on outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:25:57 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lenderink-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:25:57 +0530" MODIFIED_BY="[Empty name]">
<P>Sub-study of the CAPTURE trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:26:00 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Lincoff-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:26:00 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPIC sub-study of prevention of ischaemic complications in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:05 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahaffey-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:05 +0530" MODIFIED_BY="[Empty name]">
<P>PURSUIT sub-study on stroke after GP IIb/IIIa inhibitors in unstable angina</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:11 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Mak-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:11 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPIC sub-study on distal embolisation during coronary artery bypass surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:26:17 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-McClure-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:26:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>PURSUIT sub-study on the significance of thrombocytopenia after non-ST-elevation in acute coronary syndromes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:18 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McElwee-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:18 +0530" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness analysis review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:26:28 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Miller-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:26:28 +0530" MODIFIED_BY="Xavier Bosch">
<P>GUSTO-III trial sub-analysis on effectiveness of GP IIb/IIIa inhibitors in patients in whom thrombolysis failed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:15 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Mockel-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:15 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of pre-hospital tirofiban versus fibrinolysis before primary PCI in patients with STEMI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:26:38 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morrow-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:26:38 +0530" MODIFIED_BY="[Empty name]">
<P>Sub-study of the TACTICS trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:27:26 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Muller-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:27:26 +0530" MODIFIED_BY="Xavier Bosch">
<P>Analysis of the degree of platelet inhibition by an oral GP IIb/IIIa inhibitor fradafiban (ledrafiban is the active prodrug). Not a randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:28:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murdock-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:28:13 +0530" MODIFIED_BY="[Empty name]">
<P>Non-randomised study of patients with ST-segment elevation acute myocardial infarction treated with GP IIb/IIIa inhibitors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:28:01 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Narins-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:28:01 +0530" MODIFIED_BY="Xavier Bosch">
<P>EPIC sub-analysis on periprocedural myocardial infarction during percutaneous transluminal coronary angioplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:28:32 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:28:32 +0530" MODIFIED_BY="[Empty name]">
<P>Sub-study on coronary flow and left ventricular ejection fraction after GP IIb/IIIa inhibitors in patients with ST-segment elevation acute myocardial infarction who underwent stent implantation<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:28:39 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Newby-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:28:39 +0530" MODIFIED_BY="Xavier Bosch">
<P>Design description of the SYMPHONY trial with oral GP IIb/IIIa inhibitor sibrafiban</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:28:57 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Newby-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:28:57 +0530" MODIFIED_BY="Xavier Bosch">
<P>A sub-study of the PARAGON-B study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:29:04 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Okmen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:29:04 +0530" MODIFIED_BY="Xavier Bosch">
<P>No data on the randomisation procedure. Patients with failed PCI were retrospectively excluded from the analysis (8 of 119 patients). No useful data on clinical events</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:28 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Okmen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:28 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of tirofiban versus no tirofiban on QT dispersion in patients that underwent PCI. Patients with failed PCI were excluded and no clinical outcomes were reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:37 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-On_x002d_TIME-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:37 +0530" MODIFIED_BY="Xavier Bosch">
<P>Pre-hospital tirofiban versus hospital (median delay 59 min) tirofiban during primary PCI in patients with ST-segment elevation acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-PARADIGM-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial on GP IIb/IIIa blockers in patients with ST-segment elevation acute myocardial infarction treated with thrombolytics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:39 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-PARAGON_x002d_B-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:39 +0530" MODIFIED_BY="Xavier Bosch">
<P>PARAGON-B sub study on the effects of lamifiban according to baseline troponin levels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-06 17:17:21 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Pels-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-06 17:17:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab administered in the ambulance versus in the catheterization laboratory in patients with ST-segment elevation myocardial infarction undergoing primary PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:42 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Peng-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:42 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study performed to analyse the effect of tirofiban not before or during PCI but after primary PCI in patients with STEMI that had no ST-segment resolution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petronio-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rescue PCI in STEMI after thrombolysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:45 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PROLOG-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:45 +0530" MODIFIED_BY="[Empty name]">
<P>Study on the effect of different doses of heparin in patients treated with abciximab during percutaneous revascularisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:48 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Rakowski-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:48 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab administered in the emergency room versus in the catheterisation laboratory in patients with ST-segment elevation myocardial infarction undergoing primary PCI. No clinical outcomes were reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-03 16:13:49 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-RELAx_x002d_AMI-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-03 16:13:49 +0530" MODIFIED_BY="Xavier Bosch">
<P>Abciximab administered in the emergency room versus in the catheterisation laboratory in patients with ST-segment elevation myocardial infarction undergoing primary PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-03 16:13:32 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Ren-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-03 16:13:32 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study comparing high-dose tirofiban versus regular dose tirofiban versus control on platelet activity in patients with STEMI that underwent primary PCI. Paper in Chinese. In the English abstract no clinical events are reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 17:14:02 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ReoPro_x002d_BRIDGING-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 17:14:02 +0530" MODIFIED_BY="[Empty name]">
<P>Abciximab at admission versus abciximab immediately before primary PCI (mean difference 62 min) in patients with ST-segment elevation myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:17:55 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-REPLACE_x002d_2-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:17:55 +0530" MODIFIED_BY="Xavier Bosch">
<P>A comparison of planned treatment with heparin plus any GP IIb/IIIa inhibitor versus provisional treatment with bivalirudin plus any GP IIb/IIIa inhibitor only in case of complications during PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-03 16:14:03 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Roe-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-03 16:14:03 +0530" MODIFIED_BY="Xavier Bosch">
<P>Treatment with eptifibatide versus placebo in the emergency department followed by open-label eptifibatide 12 to 24 h later</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:06 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Shen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:06 +0530" MODIFIED_BY="Xavier Bosch">
<P>RCT comparing tirofiban versus control in 160 patients with STEMI that underwent primary PCI. The study was performed during the same dates as the Shen 2008 study performed with the same drug and the same type of patients. The authors were contacted to clarify if one study included the patients of the other study. Since they have not responded, this study was excluded from the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:17 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Simpfendorfer-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:17 +0530" MODIFIED_BY="Xavier Bosch">
<P>Controlled clinical trial with oral GP IIb/IIIa blockade with xemilofiban in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:19 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SPEED-P_x002d_St--2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:19 +0530" MODIFIED_BY="[Empty name]">
<P>Primary PCI with or without GP IIb/IIIa antagonist in patients with ST-segment elevation acute myocardial infarction treated with a thrombolytic (facilitated PCI)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:21 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:21 +0530" MODIFIED_BY="[Empty name]">
<P>Comparison of myocardial tissue perfusion with and without tirofiban in patients with STEMI. No clinical events reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:06:23 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-STOPAMI-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:06:23 +0530" MODIFIED_BY="[Empty name]">
<P>Primary PCI with stent and abciximab versus thrombolysis in patients with STEMI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:24 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-STOPAMI_x002d_2-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:24 +0530" MODIFIED_BY="Xavier Bosch">
<P>Controlled clinical trial with GP IIb/IIIa blockade in patients with ST-segment elevation acute myocardial infarction, comparing primary PCI with stenting and abciximab versus fibrinolysis and abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:06:36 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svensson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:06:36 +0530" MODIFIED_BY="[Empty name]">
<P>Thrombolysis versus facilitated PCI with abciximab in patients with STEMI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:32:04 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-SYMPHONY-2-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:32:04 +0530" MODIFIED_BY="Xavier Bosch">
<P>Controlled clinical trial with oral GP IIb/IIIa blockade with sibrafiban in patients with acute coronary syndromes 7 days or more after admission</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TAMI_x002d_8-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study on the effects of abciximab in patients with STEMI treated with thrombolytics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:32 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-TARGET-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:32 +0530" MODIFIED_BY="Xavier Bosch">
<P>RCT comparing abciximab with tirofiban in patients submitted to PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:32:25 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Thiele-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:32:25 +0530" MODIFIED_BY="Xavier Bosch">
<P>Patients with STEMI were randomised to either pre-hospital facilitated fibrinolysis (half-dose reteplase + abciximab) or pre-hospital facilitated fibrinolysis (half-dose reteplase + abciximab) plus PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:29 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-TIGER_x002d_PA-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:29 +0530" MODIFIED_BY="Xavier Bosch">
<P>Open-label randomisation of patients (n = 100) with ST-segment elevation MI to "early" administration of tirofiban in the emergency room versus "late" administration in the catheterisation laboratory immediately before primary PCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TIMI-14-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Thrombolysis with or without abciximab in patients with STEMI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:38 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-TIMI-15A-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:38 +0530" MODIFIED_BY="Xavier Bosch">
<P>A randomised open-label study of a new drug (RPR 109891) administered IV for 24 to 96 h in 91 patients. Patients were assigned to 1 of 9 regimens. No placebo group was included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:41 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-TITAN_x002d_TIMI-34-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:41 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison on the administration of eptifibatide in the emergency room versus provisional eptifibatide in the catheterisation laboratory</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:45 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Valgimigli-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:45 +0530" MODIFIED_BY="Xavier Bosch">
<P>Comparison of tirofiban and an drug eluting stent versus abciximab + bare metal stent during primary PCI in patients with STEMI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:33:21 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-van-den-Brand-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:33:21 +0530" MODIFIED_BY="Xavier Bosch">
<P>CAPTURE sub-study on angiographic assessment of GP IIb/IIIa inhibitor use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-15 17:55:20 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-den-Merkhof-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-15 17:55:20 +0530" MODIFIED_BY="[Empty name]">
<P>Study on the TIMI perfusion grade of 60 patients with STEMI treated with abciximab in the emergency department. Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:49 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Wong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:49 +0530" MODIFIED_BY="Xavier Bosch">
<P>Small study (n = 32) on the coronary flow reserve before and after stenting in patients receiving tirofiban versus control. No data on clinical events</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:59 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zajdel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:59 +0530" MODIFIED_BY="[Empty name]">
<P>Abstract from a congress, written in Polish, with preliminary data. No clinical events</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:18:56 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Zeymer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:18:56 +0530" MODIFIED_BY="Xavier Bosch">
<P>Study comparing 2 IIb/IIIa receptor blockers: eptifibatide versus abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:19:03 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Zhang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:19:03 +0530" MODIFIED_BY="Xavier Bosch">
<P>The text of the published article does not mention if this is really a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 18:19:06 +0530" MODIFIED_BY="Xavier Bosch" STUDY_ID="STD-Zhao-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 18:19:06 +0530" MODIFIED_BY="Xavier Bosch">
<P>PRISM plus sub-study on angiographic results with tirofiban</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ACS: acute coronary syndrome<BR/>CCU: coronary care unit</P>
<P>CRP: C-reactive protein<BR/>GP: glycoprotein<BR/>h: hour/s<BR/>IV: intravenous<BR/>MI: myocardial infarction<BR/>NSTEACS: non-ST segment elevation acute coronary syndromes<BR/>NSTEMI: non ST-segment elevation myocardial infarction<BR/>PCI: percutaneous coronary intervention<BR/>RCT: randomised controlled trial<BR/>STEMI: ST-segment elevation myocardial infarction<BR/>UA: unstable angina<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-04-17 20:02:48 +0530" MODIFIED_BY="Joey Kwong" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-12-15 23:25:14 +0530" MODIFIED_BY="Xavier Bosch" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-10-03 16:31:18 +0530" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-10-03 16:30:09 +0530" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:27:25 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>Refers to a random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:27:38 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>By means of a computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:19:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>"All the patients were randomly assigned,<SUP> </SUP>in the order in which they were enrolled, to receive either<SUP> </SUP>abciximab or placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:28:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>Using computer random number generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 16:30:09 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>"By means of a computer-generated randomisation numbers at each centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-12 19:42:37 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>No information provided, but probably done: "Patients were randomly assigned in a 1:1 ratio to PCI with heparin plus Eptifibatide or to PCI with heparin alone, in blocks of 10 at each site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:06:55 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>"according to a computer-generated random sequence"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:28:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>"By a computer-generated randomised table." An imbalance occurred in the number of patients allocated to the intervention (n = 136) and the control groups (n = 165). However, no differences were observed in the baseline characteristics of both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 15:43:05 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>"Patients were randomly assigned in a balanced fashion to one of four interventional strategies of reperfusion with the use of a 2-by-2 factorial design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:44:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>"sequential numbers generated<SUP> </SUP>centrally"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:37:49 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>Using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>By computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:58:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:53 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:20:25 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>No information provided but probably done: &#8220;Patients were randomly assigned&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-04 15:41:00 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>No information provided. &#8220;Abciximab or placebo was administered in a double-blind manner&#8221;, but probably not done since the number of patients allocated to each group were markedly different (69 versus 53)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:39:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>No information provided (&#8220;Abciximab or placebo was administered in a double-blind manner&#8221;)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:31:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>By a computerised randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:31:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>Randomisation by telephone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:41:00 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>Not specified "by a central telephone", but probably correct</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:12:25 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>By computer generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:21:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>Computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:26:32 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>Computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:45:28 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>Not stated and probably not done since the number of patients in each group were different.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>Using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:33:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>Patients were "randomly allocated. . . with a standard list of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-17 20:52:15 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-04 14:30:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>No information provided, but probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:48:47 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>No information provided, but probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-04 15:45:50 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>"An online randomisation system". Comment: the number of implanted stents per patient was much lower in the intervention group than in the control group, and the stent type was also different</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:06:57 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>Not stated, but probably correct since all the trials from this group have a very good design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:35:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:35:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:35:29 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:40:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:40:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>Not stated but probably yes because the baseline data were well balanced in the 3 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:45 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>The patient received the next consecutive ascending number allocated to the investigator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 21:11:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>Not stated but probably correct</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>Not described. "The patients were randomised into one of 4 groups and analysed prospectively". More patients in the intervention group than in the control group had a NSTEMI at baseline (61% versus 39%, P = 0.04)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:08 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>No information provided, but probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 21:32:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>"by the use of computer-based 1:1 randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>Not stated (&#8220;using a prospective randomisation schedule&#8221;) but probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>Not stated, but probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>Using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>Using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:01:17 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>Using a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicentre, double-blind, placebo-controlled trial and the same investigators have performed other well-designed and performed trials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicentre, double-blind, placebo-controlled trial and the same investigators have performed other well-designed and performed trials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:05:39 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicenter, double-blind, placebo- controlled trial and the same investigators have performed other well- designed and performed trials.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>By a 24-h computer-generated random list of numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicentre, double-blind, placebo-controlled trial and the same investigators have performed other well-designed and performed trials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:01 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>Not stated ("The patients were randomised by an independent study nurse")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:09:52 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>By a "standard list of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>Not explained. "All patients were divided into the study group and the control group according to the principle of randomised, double-blind, placebo-controlled trials"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-10-03 16:30:25 +0530" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 15:44:50 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>An independent study nurse at each site performed assignments of study treatments via a procedure using sealed envelopes, in preselected blocks of 6.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:27:38 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>Using a centralised telephone system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 19:29:40 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:28:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>"by an independent study nurse"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 16:30:25 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>Not specifically stated but probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-12 19:42:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>No information provided, but probably done: "Patients were randomly assigned in a 1:1 ratio to PCI with heparin plus Eptifibatide or to PCI with heparin alone, in blocks of 10 at each site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-04 15:12:16 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>"enclosed in sealed envelopes in the emergency room or intensive care unit of the 5 participating PCI centres"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:28:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-14 22:27:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:45:00 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>"sequential numbers incorporated into double-blind labelling"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:29:39 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>"Randomisation was obtained by telephone call to an independent service organised by the Department of Clinical Epidemiology of the University of Amsterdam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>By computer-generated assignment. Details previously published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>Not stated: "Patients were randomly assigned in a double-blind fashion to one of the two treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 15:51:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:53 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:31:07 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>Not enough information was provided, just that it was performed &#8220;By use of sealed envelopes&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:22:32 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:40:28 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:25:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:26:46 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>Not specified but probably correct</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:41:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>By means of a central telephone hot line</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:32:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>Randomisation by telephone. "The study drug allocation was concealed from patients and investigators". "The masking of the study drug allocation was maintained through the 1-year follow-up"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:32:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>By sealed envelopes provided by the co-ordinating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:28:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>Study drugs were packaged to be indistinguishable, irrespective of content</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:45:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>Via a centralised interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:33:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>There is no description of the allocation concealment; probably not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-17 20:52:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:48:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>The method of concealment is not described. Comment: the number of implanted stents per patient was much lower in the intervention group than in the control group, and the stent type was also different</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:35:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>Using sealed envelopes containing the block randomisation sequence for each participating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:35:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>Patients underwent randomisation<SUP> </SUP>in a double-blind manner with the use of sealed envelopes containing<SUP> </SUP>the block randomisation sequence for each participating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:35:29 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>Sealed envelopes containing the randomisation sequence generated by computer before initiation of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:40:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>With the use of sealed envelopes containing the randomisation sequence for each participating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:40:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>Not stated but probably yes because the baseline data were well balanced in the 3 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:45 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>Patients and investigators were blinded to treatment assignment through the use of identical-appearing active treatment and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 21:11:46 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>Not stated but probably correct</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>Not described. More patients in the intervention group than in the control group had a NSTEMI at baseline (61% versus 39%, P = 0.04)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:08 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:46 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>Not stated and probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>By blinded sealed kits with study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 21:54:00 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>By a central telephone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 22:05:24 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>A central telephone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:48:28 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>Locally by means of sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:14:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>Centrally by co-ordinating<SUP> </SUP>centres</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicentre, double-blind, placebo-controlled trial and the same investigators have performed other well-designed and performed trials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicentre, double-blind, placebo-controlled trial and the same investigators have performed other well-designed and performed trials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:05:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicenter, double-blind, placebo- controlled trial and the same investigators have performed other well- designed and performed trials.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>Using an open random allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>Not stated but probably yes because this was a multicentre, double-blind, placebo-controlled trial and the same investigators have performed other well-designed and performed trials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>Not stated ("The patients were randomised by an independent study nurse")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>With the use of closed envelopes but it remains unclear whether envelopes were sequentially numbered, opaque and sealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>Not explained. "All patients were divided into the study group and the control group according to the principle of randomised, double-blind, placebo-controlled trials". No baseline differences were observed between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-10-03 16:30:38 +0530" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Primary</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Secondary</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-04 14:46:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>Double-blinded study with a placebo group. Mortality and myocardial infarction adjudicated by an independent clinical events committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 19:02:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>Major bleeding assessed by TIMI criteria and adjudicated by an independent clinical events committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-03 19:17:13 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>Study not blinded and without a placebo group. Events were not adjudicated by an independent clinical events committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 19:17:15 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>Study not blinded and without a placebo group. Events were not adjudicated by an independent clinical events committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-10 22:19:39 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>Double-blinded study with a placebo group. "The patients, investigators, and sponsors of the study were blinded to the treatment assignments during the entire study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-10 22:19:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>Double-blinded study with a placebo group. "The patients, investigators, and sponsors of the study were blinded to the treatment assignments during the entire study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-10 22:20:50 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study, but the preparation of the placebo was not stated. Some key study personnel were not blinded, and this condition could bias the assessment of myocardial infarction, since no clinical events committee adjudicated the endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 15:47:40 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>Some key study personnel were not blinded, and this condition could bias the assessment of subjective endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 16:30:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study.: "patients and investigators were blinded to treatment allocation".<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-02 18:11:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study: "patients and investigators were blinded to treatment allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-02 18:12:08 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>Open-label study, but the outcome measurement is not likely to be influenced by lack of blinding. A blinded off-site independent Clinical Event Committee adjudicated all primary events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-02-27 22:19:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>Open-label study, but the outcome measurement is not likely to be influenced by lack of blinding. Episodes of bleeding were classified by an independent adjudicator. In addition, an independent Data Safety Monitoring Committee reviewed the data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-03 20:10:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 20:10:12 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:28:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>"The patients, the investigators that administered the drugs and the person who evaluated the patients were blinded to the treatment administered"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-02-27 22:40:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>"The patients, the investigators that administered the drugs and the person who evaluated the patients were blinded to the treatment administered"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 15:43:05 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>In spite of the existence of a clinical events adjudication committee, the open-label nature of the study could bias the assignment of myocardial infarction</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-02 18:12:28 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>The open-label nature of the study could certainly bias the assignment of subjective outcomes such as revascularisation and major bleeding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:44:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial. "Events were all classified by a Critical Event Committee before the study was unblinded. Relevant data and documents without patient/centre identifiers were reviewed independently by a panel of two for all patients with any complication or event."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:44:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial. "Events were all classified by a Critical Event Committee before the study was unblinded. Relevant data and documents without patient/centre identifiers were reviewed independently by a panel of two for all patients with any complication or event".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:29:39 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:29:39 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:30:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:30:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:30:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>"Double-blinded, placebo-controlled study", but no specific methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:30:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>"Double-blinded, placebo-controlled study", but no specific methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 15:51:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>The open-label nature of the study could influence the diagnosis of myocardial infarction</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 21:01:16 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-03 21:14:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 21:17:49 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:31:07 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>Open-label study. Mortality and myocardial infarction adjudicated by the investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:31:07 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-04 16:22:46 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>Not enough information provided, just that &#8220;Abciximab or placebo was administered in a double-blind manner &#8220;. No data provided on the placebo used and the method of administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-04-04 16:22:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>Not enough information provided, just that &#8220;Abciximab or placebo was administered in a double-blind manner &#8220;. No data provided on the placebo used and the method of administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:31:31 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>Not enough information provided, just that "Abciximab or placebo was administered in a double-blind manner". No data on the placebo used and the method of administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:31:31 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>Not enough information provided, just that "Abciximab or placebo was administered in a double-blind manner". No data on the placebo used and the method of administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:31:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:31:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-03 21:54:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial with Clinical Events Committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 21:54:27 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial with Clinical Events Committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-03 21:58:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial with Clinical Events Committee. "To preserve the blinding of all investigators and personnel involved in patient care, a heparin coordinator at each clinical site performed all measurements of activated clotting time and directed the administration of heparin"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 21:59:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial with Clinical Events Committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:32:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial with Clinical Events Committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-03 22:15:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial with Clinical Events Committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:32:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:32:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:33:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:33:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-02 17:45:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>Patients were blinded with use of placebo (infusion of saline). Unclear information about blinding of investigators.</P>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:33:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>Patients were blinded with use of placebo (infusion of saline). Unclear information about blinding of investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:34:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>Double-blind, placebo-controlled study. A clinical endpoint committee, the members of which were unaware of treatment assignment, adjudicated all possible cases of myocardial infarction and the cause of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-04 19:03:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>Double-blind, placebo-controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:33:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:33:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-17 20:52:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-04-17 20:52:37 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-04 19:50:31 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>Double-blind, placebo-controlled<SUP> </SUP>phase II clinical trial. "All clinical end<SUP> </SUP>points were adjudicated by blinded review"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-14 22:19:40 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>Uncertain since the proportion of major bleeding was 4 times higher in patients in the placebo group than in the intervention group and inversely correlated with minor bleeding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-02 17:49:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled<SUP> </SUP>phase II clinical trial. "All clinical end<SUP> </SUP>points were adjudicated by blinded review"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:34:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial. Study drugs were packaged to be indistinguishable irrespective of content. All efficacy and safety events were adjudicated by consensus of the Clinical Events Committee, from which treatment assignment was concealed throughout the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-28 15:33:07 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>Single-blinded study, without placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-02-28 15:33:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>Single-blinded study, without placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:34:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>Patients, but not physicians, were blinded to the assignment of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:34:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>Patients, but not physicians, were blinded to the assignment of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:35:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial. Double-blinding was achieved by using vials of similar appearance in the<BR/>2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:35:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial. Double-blinding was achieved by using vials of similar appearance in the<BR/>2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:35:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial. Double-blinding was achieved by using vials of similar appearance in the<BR/>2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:35:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled trial. Double-blinding was achieved by using vials of similar appearance in the<BR/>2 groups. All events were adjudicated and classified by an event-adjudication committee whose members were unaware of the patients&#8217; assigned treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-17 20:33:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>Double-blind, placebo-controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-17 20:33:31 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>Double-blind, placebo-controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:40:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>Double-blinding was achieved with the use of vials that appeared similar in the 2 groups. All events were adjudicated and classified by an event adjudication committee blinded to the assigned treatment. All analyses were performed in a blinded manner regarding the randomly assigned treatment. Unblinding of the study groups was done after completion of the statistical analyses. No patient required unblinding because of clinical needs, and no cross-overs occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:40:21 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>Double-blinding was achieved with the use of vials that appeared similar in the 2 groups. All events were adjudicated and classified by an event adjudication committee blinded to the assigned treatment. All analyses were performed in a blinded manner regarding the randomly assigned treatment. Unblinding of the study groups was done after completion of the statistical analyses. No patient required unblinding because of clinical needs, and no cross-overs occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-09 21:59:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>Open study without placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-04-09 21:59:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>Open study without placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-04 20:38:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-04 20:38:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>Double-blind, placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:40:46 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>Patients and investigators were blinded to treatment assignment through the use of identical-appearing active treatment and placebo. Cardiac events were reviewed and adjudicated by an external Event Classification Committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:40:46 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>There was no central adjudication of bleeding incidents despite bleeding being the primary endpoint. In addition, the number of major bleedings was 3 times lower in the intervention group than in the placebo group and was inversely correlated with minor bleedings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:39:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>Double-blind, placebo-controlled dose-ranging study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:39:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>Double-blind, placebo-controlled dose-ranging study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-04 20:18:29 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>Not described, probably the study was single-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-04-04 20:18:39 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>Not described, probably the study was single-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:39:08 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>Open-label study. Mortality and myocardial infarction adjudicated by the investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:39:08 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:38:46 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:38:46 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:38:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study. All staff and study personnel were blinded to treatment. Kits were distributed among the ambulance services or referring centres in blocks of 4. A blinded, independent clinical endpoint committee adjudicated all clinical endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:38:57 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study. All staff and study personnel were blinded to treatment. Kits were distributed among the ambulance services or referring centres in blocks of 4. An independent Data Safety<BR/>Monitoring Committee was responsible for identification of safety issues</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:38:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study. Matching heparin-placebo vials were supplied by the same manufacturer. "Systematic blinding of heparin administration and careful control of anticoagulation was achieved by use of a bedside aPTT device that produced encrypted results". A Clinical Events Committee, which consisted of practising cardiologists, was blinded to treatment assignment and adjudicated all clinical primary and main secondary endpoint events according to published predefined criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:38:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>Double-blinded, placebo-controlled study. Matching heparin-placebo vials were supplied by the same manufacturer. "Systematic blinding of heparin administration and careful control of anticoagulation was achieved by use of a bedside aPTT device that produced encrypted results". A Clinical Events Committee, which consisted of practising cardiologists, was blinded to treatment assignment and adjudicated all clinical primary and main secondary endpoint events according to published predefined criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-02 17:56:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>Randomised, double-blind, placebo-controlled trial. All suspected MIs and severe, recurrent ischaemic episodes were independently adjudicated by a clinical events committee (CEC)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-02 17:56:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>Randomised, double-blind, placebo-controlled trial. Revascularisation and bleeding outcomes were not adjudicated by a clinical events committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:48:28 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>Double-blind randomised study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-02 17:56:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>Double-blind randomised study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>A randomised, double-blind, placebo-controlled small dose-ranging study. The primary endpoints (eptifibatide pharmacokinetics and its effect on the pharmacodynamics of platelet function) were blinded. However, no clinical events committee adjudicated the events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>A randomised, double-blind, placebo-controlled small dose-ranging study. The primary endpoints (eptifibatide pharmacokinetics and its effect on the pharmacodynamics of platelet function) were blinded. However, no clinical events committee adjudicated the events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:37:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:37:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-02 18:14:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-02 18:14:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:37:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>Open-label study. Mortality and myocardial infarction adjudicated by the investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:37:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-02 18:06:04 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:36:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-10 22:06:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-10 22:06:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:36:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured during the study period (first 48 h after PCI) but likely that the blinding could have been broken afterwards</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:36:01 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured during the study period (first 48 h after PCI) but likely that the blinding could have been broken afterwards</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-09 18:36:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-09-09 18:36:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-02 18:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>Not explained. "All patients were divided into the study group and the control group according to the principle of randomised, double-blind, placebo-controlled trials"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-02 18:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>Not explained. "All patients were divided into the study group and the control group according to the principle of randomised, double-blind, placebo-controlled trials"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-10-03 16:31:01 +0530" MODIFIED_BY="Xavier Bosch" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Primary</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Secondary</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 19:04:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 19:05:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 19:18:13 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 19:18:14 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-10 22:20:01 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-10 22:20:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 19:50:17 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 19:50:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 16:30:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 16:31:01 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-27 22:22:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-02-27 22:22:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 20:10:13 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 20:10:15 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:28:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>An imbalance occurred in the number of patients allocated to the intervention (n = 136) and the control groups (n = 165). 9 patients were lost of follow-up but, in fact, complete outcome assessment is available only for the first 7 days of follow-up. The incidence of the secondary endpoint (bleeding events) was 0% in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:28:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>An imbalance occurred in the number of patients allocated to the intervention (n = 136) and the control groups (n =1 65). 9 patients were lost of follow-up but, in fact, complete outcome assessment is available only for the first 7 days of follow-up. The incidence of the secondary endpoint (bleeding events) was 0% in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 20:23:57 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 20:23:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 20:31:50 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 20:31:51 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 20:46:00 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 20:46:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:30:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:30:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:30:07 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:30:07 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:30:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:30:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:30:53 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:30:53 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-04 16:21:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-04 16:21:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-04 16:23:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-04 16:23:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-04 16:25:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-04 16:25:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:31:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:31:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-03 21:54:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-03 21:52:31 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:32:14 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:32:14 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:32:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:32:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:32:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:32:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:33:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:33:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-02 17:46:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>No missing outcome data seem to be missing present although the extremely good results obtained in the intervention arm raises serious doubts on about the methods used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-02 17:46:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>No missing outcome data seem to be missing present although the extremely good results obtained in the intervention arm raises serious doubts on about the methods used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 19:08:32 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 19:08:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:33:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:33:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:33:47 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>2 patients (1 in each group) were excluded after randomisation because of failure in stent implantation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:33:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>2 patients (1 in each group) were excluded after randomisation because of failure in stent implantation. The incidence of major and minor bleeding was unusually low (0% and 2.5% respectively)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 19:52:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 19:52:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-02 17:49:27 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-02 17:49:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:34:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>Only 91 of the 320 planned patients were enrolled in the study; 5 patients were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:34:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>Only 91 of the 320 planned patients were enrolled in the study; 5 patients were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 20:08:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 20:08:28 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 20:14:25 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 20:14:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 20:20:32 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 20:20:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 20:23:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 20:23:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 20:29:01 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 20:29:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-09 22:00:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>All data are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:40:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>All data are reported, but 2 patients in the tirofiban group crossed over to the tirofiban plus thrombectomy group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:39:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>3.6% of the patients excluded because of exclusion criteria or because they did not underwent PCI. However, excluded patients were well balanced in the placebo and intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:39:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>3.6% of the patients excluded because of exclusion criteria or because they did not underwent PCI. However, excluded patients were well balanced in the placebo and intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 21:07:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 21:07:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 21:12:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 21:12:35 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:39:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>The outcome data are reported only for the patients that underwent in-hospital revascularisation (75% of the patients)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:39:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>The outcome data are reported only for the patients that underwent in-hospital revascularisation (75% of the patients)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-04 16:30:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-04-04 16:30:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 21:39:16 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 21:39:17 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:38:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>8% of the patients in the intervention group and 8% in the placebo group were excluded. In addition, 3.6% in both groups were lost to follow-up. However, these incomplete data were well balanced in the 2 groups and are expected in this kind of study in which patients with a presumed STEMI are randomised in the ambulance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:38:58 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>8% of the patients in the intervention group and 8% in the placebo group were excluded. In addition, 3.6% in both groups were lost to follow-up. However, these incomplete data were well balanced in the 2 groups and are expected in this kind of study in which patients with a presumed STEMI are randomised in the ambulance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:38:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>Study drug was given to 98.4% of the treatment group and 99.1% of the control group. Drug was terminated early in 13% of the control group and in 19% of the lamifiban-treated patients, most commonly for bleeding or planned surgical revascularisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:38:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>Study drug was given to 98.4% of the treatment group and 99.1% of the control group. Drug was terminated early in 13% of the control group and in 19% of the lamifiban-treated patients, most commonly for bleeding or planned surgical revascularisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 16:03:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>Follow-up data were 99.8% complete for the primary endpoint (99.9% for placebo, 99.7% for lamifiban)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-02 17:56:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>Follow-up data were 99.8% complete for the primary endpoint (99.9% for placebo, 99.7% for lamifiban)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-04 22:17:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-04 22:17:12 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:37:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:37:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-02 18:14:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-02 18:14:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:37:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>4 patients (5.7%) from the intervention group did not complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:37:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>4 patients (5.7%) from the intervention group did not complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-02 18:06:32 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-02 18:06:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-10 22:06:25 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-10 22:06:27 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:36:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:36:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 18:36:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-09-09 18:36:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-02 18:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-02 18:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-10-03 16:31:18 +0530" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 19:07:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>The published reports include all the prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-05 17:09:52 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>The published report includes all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-05 17:09:57 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>The published report includes all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:28:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>The published report includes all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 16:31:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>The published report includes all pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-05 17:10:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:11:15 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-01 15:46:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>The study protocol is not available and the incidence of bleeding events was 0% in both groups. Complete outcome assessment is available only for the first 7 days of follow-up. The incidence of the secondary endpoint (bleeding events) was 0% in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:24:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:31:53 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:46:19 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:12:47 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:55:06 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:04:16 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:18:25 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:21:52 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>The published reports include all the prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:23:47 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:31:31 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>Insufficient information provided, but it seems that all the planned outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:26:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:54:35 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:56:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:15:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:22:08 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:34:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:46:55 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 19:08:37 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:55:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-17 20:53:17 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>The published reports include all pre-specified and expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:50:00 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>Probably correct for the primary endpoint. The incidence of bleeding was very low: 0% for major bleeding and just 2% for any bleeding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:56 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:14:49 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:20:35 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:24:29 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:29:04 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-09 22:01:40 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>All data are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:34:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:40:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>The study protocol is not available. The outcome data are reported only for the patients that underwent in-hospital revascularisation (75% of the patients)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:30:51 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>The published reports include all the prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:47 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 21:30:52 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>Follow-up was completed on 96.8% and 93.3% of patients at 6 months and 1 year, respectively, and were well balanced in the placebo and lamifiban groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:56:21 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:48:35 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>Because of slow enrolment, the study was stopped by the promoter when 51% of the planned patients were enrolled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>The study protocol is not available but the published report includes all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 21:58:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-15 17:54:44 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>The study protocol is available and all of the studies pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:42:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:06:52 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:06:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 16:25:12 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>The study protocol is not available but the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-10-03 15:57:14 +0530" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 15:45:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-_x0033_T_x002f_2R-2009">
<DESCRIPTION>
<P>The study was partially supported by a research grant from Merck, USA and Iroko, USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:03:01 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ACE-2003">
<DESCRIPTION>
<P>The study was supported by SORIN Biomedica and the ARCARD ONLUS Foundation<B> </B>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:27:55 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ADMIRAL-2001">
<DESCRIPTION>
<P>The data were retained by Eli Lilly, where the<SUP> </SUP>analyses were performed. Independent statistical advice was<SUP> </SUP>provided by E. Vicant (Paris VII University)</P>
<P>One of the authors, Dr. Pinton, was an employee of and stockholder in Eli Lilly. The principal investigator has served as a consultant to Eli Lilly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 19:52:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ADVANCE-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:12:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ASIAD-2005">
<DESCRIPTION>
<P>The study was supported by Guidant, Corporation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 15:49:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ASSIST-2009">
<DESCRIPTION>
<P>Funding: Schering-Plough Canada Inc provided an unrestricted grant and free distribution of Eptifibatide, and Medtronic Canada Ltd provided free stents for the study. However, the study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:11:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-BRAVE_x002d_3-2009">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-27 22:47:28 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Bhattacharya-2010">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 15:50:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-CADILLAC-2002">
<DESCRIPTION>
<P>"Supported in part by Guidant, Lilly Research Laboratories, and Mallinkrodt"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:29:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-CANADIAN-1996">
<DESCRIPTION>
<P>Probably yes because the trial sponsor (F. Hoffmann-La Roche) and the investigators<SUP> </SUP>remained blinded to randomisation code and study results until<SUP> </SUP>all study endpoints had been agreed on by the Critical Event<SUP> </SUP>Committee<SUP> </SUP>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 20:45:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-CAPTURE-1997">
<DESCRIPTION>
<P>The trial was discontinued after the third interim analysis of 1050 patients (1400 planned) by the Safety and Efficacy Monitoring Committee<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:41 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009">
<DESCRIPTION>
<P>Funding: a research grant from Integrated Therapeutics Group, Inc., a subsidiary of Schering-Plough Corporation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:24:35 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2000">
<DESCRIPTION>
<P>To few explanations in the study report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:30:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Claeys-2005">
<DESCRIPTION>
<P>Funding: Sanofi-Synthelabo, Belgium and Dade Behring, Belgium</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 21:20:04 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Cuisset-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:21:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-DANTE-2004">
<DESCRIPTION>
<P>The published reports include all the prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:24:01 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-De-Luca-2005">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:25:50 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-De-Luca-2008">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:31:42 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ELISA_x002d_2-2006">
<DESCRIPTION>
<P>44% of the patients in the control group received the intervention before (5%), during (22%) or after (17%) PCI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:31:54 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-EPIC-1994">
<DESCRIPTION>
<P>Supported by a grant from Centocor, Inc., Malvern, Pa</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:41:05 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-EPILOG-1997">
<DESCRIPTION>
<P>The study was stopped after enrolment of 2792 of the planned 4800 patients after the recommendation of the Data and Safety Monitoring Committee</P>
<P>Funding: Centocor, Malvern, Pa. and Eli Lilly and Company, Indianapolis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:32:27 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-EPISTENT-1998">
<DESCRIPTION>
<P>Study sponsored by Centocor, Malvern PA, USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-03 22:22:09 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ERASER-1999">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:33:10 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-ESPRIT-2000">
<DESCRIPTION>
<P>The data and safety monitoring board recommended to stop the trial after 2064 patients were enrolled (2400 planned)</P>
<P>Funding: COR Therapeutics, South San Francisco, CA, USA and Schering-Plough Corporation, Kenilworth, NJ, USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:47:16 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Fu-2008">
<DESCRIPTION>
<P>The extremely good results obtained in the intervention arm raises serious doubts about the methods used in this trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:03 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-GUSTO_x002d_IV-2001">
<DESCRIPTION>
<P>This study was supported by Centocor Inc, Malvern, Pa. "Full independence of the analyses and control over publication remain with the authors, along with the responsibility for any errors"</P>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:33:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Galassi-1999">
<DESCRIPTION>
<P>No primary outcome was specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-17 20:56:14 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Gasior-2003">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias although the incidence of major and minor bleeding was unusually low (0% and 2.5% respectively)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-IMPACT-1995">
<DESCRIPTION>
<P>Funding: COR Therapeutics, Inc, South<SUP> </SUP>San Francisco, USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:50:12 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-IMPACT_x002d_II-1997">
<DESCRIPTION>
<P>Funding: COR Therapeutics, Inc, South<SUP> </SUP>San Francisco, USA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:34:43 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-INSTANT-2012">
<DESCRIPTION>
<P>Funding: GlaxoSmithKline, Verona, Italy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 15:57:14 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ISAR_x002d_2-2000">
<DESCRIPTION>
<P>Funding: Lilly, Deutschland</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_REACT-2-2006">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:17:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ISAR_x002d_REACT-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:24:32 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-04 20:29:05 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-ISAR_x002d_SWEET-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:44:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-ITTI-2012">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:59 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-JEPPORT-2009">
<DESCRIPTION>
<P>The study was stopped for 1 year and resumed with the dose of abciximab adjusted according to body weight. In total, the study took 8 years to be completed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:40:36 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Juergens-2002">
<DESCRIPTION>
<P>4 employees of Merck &amp; Co assisted the authors in the preparation of the manuscript.</P>
<P>Funding: Merck &amp; Co, Inc.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:33 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Kereiakes-1996">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:39:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kim-2005">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:31:05 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Kurowski-2005">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:47 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 22:36:07 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-On_x002d_TIME-2-2008">
<DESCRIPTION>
<P>Funding: Merck (USA). "The study was investigator initiated. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:38 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PARAGON-A-1998">
<DESCRIPTION>
<P>Funding: Hoffman La-Roche (Basel, Switzerland)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:38:22 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PARAGON-B-2002">
<DESCRIPTION>
<P>Following the Data and Safety Monitoring Board recommendation when 1639 patients were accrued, it was decided to augment the original sample by 1200 patients</P>
<P>This study was supported by F. Hoffman-La Roche Ltd, Basel, Switzerland</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:48:35 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PRACTICE-2007">
<DESCRIPTION>
<P>Funding: Schering Plough</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PRIDE-2001">
<DESCRIPTION>
<P>Supported by COR Therapeutics, Inc., South San Francisco, California and Schering-Plough Corp., Kenilworth, New Jersey</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:34 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PRISM-1998">
<DESCRIPTION>
<P>At the time of the second interim analysis, after 1350 patients had completed the study, the combined rate of clinical events comprised by the primary endpoint was lower than expected. Because of this, the steering committee and the data and safety monitoring committee recommended an increase in the sample size from the initial 2000 planned to 3200</P>
<P>Funding: Merck Co.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:37:23 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-PRISM-Plus-1998">
<DESCRIPTION>
<P>The study in the tirofiban-only group was stopped prematurely on the recommendation of the data and safety monitoring board at the time of the first interim efficacy analysis because of an apparent mortality excess. At that time the sample size of the other 2 arms was increased to 735 patients per group<BR/>Funding: Merck Co.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:14:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-PURSUIT-1998">
<DESCRIPTION>
<P>After 3218 patients had been randomly assigned to treatment groups, the committee recommended dropping the lower dose of the intervention arm</P>
<P>Funding: COR Therapeutics and Schering-Plough Research Institute</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 16:42:44 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Prati-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:59 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-RAPPORT-1998">
<DESCRIPTION>
<P>Funding: this study was supported by Centocor, Malvern, Pa and Eli Lilly and Company, Indianapolis, Ind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:48 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-RESTORE-1997">
<DESCRIPTION>
<P>Funding: Merck &amp; Co., Inc., Whitehouse Station, New Jersey</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:07:18 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Schulman-1996">
<DESCRIPTION>
<P>Funding: COR Therapeutics, Inc, San<SUP> </SUP>Francisco, California</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:30 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Shen-2008">
<DESCRIPTION>
<P>There may be a risk of bias, but there is insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:20 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-Simoons-1994">
<DESCRIPTION>
<P>Funding: Centocor, Inc, Malvern, Pa</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:02 +0530" MODIFIED_BY="Xavier Bosch" RESULT="UNKNOWN" STUDY_ID="STD-TOPSTAR-2002">
<DESCRIPTION>
<P>Funding: supported by a grant from MSD (Merck, Sharp and Dohme) GmbH, Germany</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-09 18:36:11 +0530" MODIFIED_BY="Xavier Bosch" RESULT="NO" STUDY_ID="STD-Tamburino-2002">
<DESCRIPTION>
<P>The commercial name of the drug and the pharmaceutical company are listed in the Abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 18:10:26 +0530" MODIFIED_BY="Xavier Bosch" RESULT="YES" STUDY_ID="STD-Yan-2009">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-10-21 21:00:21 +0530" MODIFIED_BY="Xavier Bosch"/>
<ADDITIONAL_TABLES MODIFIED="2013-10-21 21:00:21 +0530" MODIFIED_BY="Joey Kwong">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-09-09 18:43:02 +0530" MODIFIED_BY="Joey Kwong" NO="1">
<TITLE MODIFIED="2010-05-11 21:24:51 +0530" MODIFIED_BY="Xavier Bosch">Summary assessment of the risk of bias (allocation concealment and blinding) for major endpoints within and across PCI studies</TITLE>
<TABLE COLS="8" ROWS="50">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day mortality</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>6-month mortality</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day death or MI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>6-month death or MI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Major bleeding</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Within study</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EPIC 1994</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2099</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simoons 1994</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IMPACT 1995</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>150</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Kereiakes 1996</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>93</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RESTORE 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2141</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IMPACT-II 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EPILOG 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2792</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CAPTURE 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1265</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EPISTENT 1998</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2399</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RAPPORT 1998</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>483</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ERASER 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>215</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Galassi 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chen 2000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ESPRIT 2000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2064</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ISAR-2 2000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>401</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRIDE 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>127</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ADMIRAL 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>300</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Tamburino 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>107</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TOPSTAR 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Juergens 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>894</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CADILLAC 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2082</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ACE 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>400</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gasior 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ADVANCE 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>202</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DANTE 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ISAR SMART-2 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>502</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ISAR-REACT 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2159</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ISAR-SWEET 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>701</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Claeys 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>200</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ASIAD 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>254</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>De Luca 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>122</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Kurowski 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Prati 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>140</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ISAR-REACT 2 2006</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2022</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FU 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>150</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cuisset 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>149</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Shen 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>172</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>On-TIME 2 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>984</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>De Luca 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>132</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OPTIMIZE-IT 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>JEPPORT 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>973</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CLEAR PLATELETS-2 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>200</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BRAVE-3 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>800</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3T/2R 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>263</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ASSIST 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>400</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yan 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>240</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>INSTANT 2012</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>91</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ITTI 2012</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ACROSS STUDIES</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33,474</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Allocation concealment and blinding were the 2 selected key domains.</P>
<P>Bias for each endpoint: NA: Not applicable; Low: Plausible bias unlikely to seriously alter the results; Unclear: Plausible bias that raises some doubt about the results; High: Plausible bias that seriously weakens confidence in the results.</P>
<P>Bias within a study: Low: Low risk of bias for all key domains; Unclear: Unclear risk of bias for one or more key domains; High: High risk of bias for one or more key domains.</P>
<P>Bias across studies: Low: Most information is from studies at low risk of bias; Unclear: Most information is from studies at low or unclear risk of bias; High: The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of the results.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-09-05 15:45:55 +0530" MODIFIED_BY="Joey Kwong" NO="2">
<TITLE MODIFIED="2010-05-11 22:02:01 +0530" MODIFIED_BY="Xavier Bosch">Summary assessment of the risk of bias (allocation concealment and blinding) for major endpoints within and across studies on initial treatment of patients with NSTEACS</TITLE>
<TABLE COLS="8" ROWS="14">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day mortality</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>6-month mortality</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day death or MI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>6-month death or MI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Major bleeding</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Within study</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CANADIAN 1996</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>365</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Schulman 1996</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>227</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PURSUIT 1998</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10,948</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRISM 1998</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3232</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PARAGON A 1998</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2282</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRISM Plus 1998</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1915</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GUSTO-IV 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7800</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PARAGON B 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5225</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Kim 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>160</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ELISA-2 2006</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>328</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRACTICE 2007</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>393</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bhattacharya 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>301</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ACROSS STUDIES</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33,176</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Allocation concealment and blinding were the 2 selected key domains.</P>
<P>Bias for each endpoint: NA: Not applicable; Low: Plausible bias unlikely to seriously alter the results; Unclear: Plausible bias that raises some doubt about the results; High: Plausible bias that seriously weakens confidence in the results.</P>
<P>Bias within a study: Low: Low risk of bias for all key domains; Unclear: Unclear risk of bias for one or more key domains; High: High risk of bias for one or more key domains.</P>
<P>Bias across studies: Low: Most information is from studies at low risk of bias; Unclear: Most information is from studies at low or unclear risk of bias; High: The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of the results.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-10-21 21:00:03 +0530" MODIFIED_BY="Xavier Bosch" NO="3">
<TITLE MODIFIED="2013-10-21 21:00:03 +0530" MODIFIED_BY="Xavier Bosch">Main results for the primary outcomes</TITLE>
<TABLE COLS="5" ROWS="18">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day mortality</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>6-month mortality </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day death or non-fatal MI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>6-month death or non-fatal MI</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>1. During PCI (all patients)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.79 (0.64 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.90 (0.77 to 1.05)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.66 (0.60 to 0.72)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.75 (0.64 to 0.86)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>1.1. Subgroup analysis by patient's condition</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with stable CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.71 (0.34 to 1.46)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0.63 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.68 (0.55 to 0.84)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.64 to 0.92)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with NSTEACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.46 to 1.28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.01 (0.74 to 1.38)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.68 (0.56 to 0.83)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.65 to 0.92)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary PCI in patients with STEMI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0.64 to 1.21)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0.68 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.78 (0.61 to 1.00)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.51 to 1.16)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>1.2. Subgroup analysis by technique</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Balloon angioplasty</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.79 (0.55 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.06 (0.75 to 1.50)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.65 (0.56 to 0.75)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.78 (0.65 to 0.94)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI with stent placement</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.78 (0.58 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.87 (0.71 to 1.07)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.67 (0.59 to 0.76)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.72 (0.60 to 0.87)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.3. Subgroup analysis by pre-treatment with clopidogrel</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.83 (0.57 to 1.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.95 (0.75 to 1.21)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.81 (0.67 to 0.98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.87 (0.66 to 1.14)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with ACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.84 (0.56 to 1.25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.97 (0.72 to 1.31)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.61 to 0.96)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.46 to 1.27)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients without ACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.78 (0.29 to 2.09)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.92 (0.63 to 1.35)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.91 (0.65 to 1.28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.94 (0.73 to 1.21)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>2. As initial medical treatment of NSTEACS</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.90 (0.79 to 1.02)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.00 (0.87 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.91 (0.85 to 0.98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0.81 to 0.96)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>MI, myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease; NSTEACS, non-ST segment elevation acute coronary syndrome; STEMI, ST-segment elevation acute myocardial infarction; ACS, acute coronary syndromes; OR, odds ratio; CI, confidence interval</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2013-10-21 21:00:13 +0530" MODIFIED_BY="Xavier Bosch" NO="4">
<TITLE MODIFIED="2013-10-21 21:00:13 +0530" MODIFIED_BY="Xavier Bosch">Main results for the secondary outcomes</TITLE>
<TABLE COLS="5" ROWS="16">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day urgent revasc</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>6-month revasc </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day death, MI or revasc</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>6-month death, MI or revasc</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR (95% CI)</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>1. During PCI (all patients)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.62 (0.54 to 0.71)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.85 (0.79 to 0.93)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.65 (0.57 to 0.75)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.80 (0.73 to 0.88)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>1.1. Subgroup analysis by patient's condition</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with stable CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.84 (0.54 to 1.32)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.93 (0.81 to 1.08)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.74 (0.60 to 0.91)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.87 (0.77 to 0.98)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with NSTEACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.68 (0.52 to 0.89)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.91 (0.79 to 1.05)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.69 (0.58 to 0.81)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.85 (0.76 to 0.96)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary PCI in patients with STEMI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.61 (0.45 to 0.83)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.75 (0.63 to 0.90)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.69 (0.49 to 0.98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.84 (0.73 to 0.97)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>1.2. Subgroup analysis by technique</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Balloon angioplasty</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.58 (0.49 to 0.70)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.81 (0.60 to 1.10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.63 (0.51 to 0.76)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.84 (0.75 to 0.94)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI with stent placement</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.75 (0.58 to 0.98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.87 (0.78 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.69 (0.57 to 0.84)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.78 [0.69 to 0.89)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.3. Subgroup analysis by pre-treatment with clopidogrel</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.89 (0.62 to 1.28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.87 (0.76 to 0.98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0.65 to 1.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0.79 to 0.98)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with ACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.82 (0.54 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.64 to 0.94)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.80 (0.50 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.81 (0.69 to 0.95)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients without ACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.17 (0.54 to 2.53)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.94 (0.80 to 1.11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.08 (0.76 to 1.52)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.94 (0.81 to 1.10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>revasc, revascularisation; MI, myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease; NSTEACS, non-ST segment elevation acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; ACS, acute coronary syndromes; OR, odds ratio; CI, confidence interval</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2013-10-21 21:00:21 +0530" MODIFIED_BY="Xavier Bosch" NO="5">
<TITLE MODIFIED="2013-10-21 21:00:21 +0530" MODIFIED_BY="Xavier Bosch">Main results for safety outcomes</TITLE>
<TABLE COLS="2" ROWS="17">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>30-day major bleeding (OR, 95% CI)</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>1. PCI (all patients)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.39 (1.21 to 1.61)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>1.1. Subgroup analysis by patient's condition</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with stable CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.83 (1.10 to 3.03)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with NSTEACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.41 (1.03 to 1.93)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary PCI in patients with STEMI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.54 (1.12 to 2.11)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>1.2. Subgroup analysis by technique</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Balloon angioplasty</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.38 (1.02 to 1.86)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI with stent placement</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.38 (1.05 to 1.82)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.3. Subgroup analysis by pre-treatment with clopidogrel</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.30 (0.93 to 1.83)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients with ACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.27 (0.87 to 1.86)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Patients without ACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.41 (0.67 to 2.97)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>2. As initial medical treatment of patients with NSTEACS</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.29 (1.14 to 1.45)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>d, day; PCI, percutaneous coronary intervention; NSTEACS, non-ST elevation acute coronary syndrome; STEMI, ST elevation myocardial infarction; CAD, coronary artery disease; OR, odds ratio; CI, confidence interval</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-09-05 16:36:37 +0530" MODIFIED_BY="Xavier Bosch">
<COMPARISON ID="CMP-001" MODIFIED="2013-09-05 16:36:37 +0530" MODIFIED_BY="Xavier Bosch" NO="1">
<NAME>During PCI (all patients)</NAME>
<DICH_OUTCOME CHI2="12.544596353712024" CI_END="0.9728182814718136" CI_START="0.638533553303392" CI_STUDY="95" CI_TOTAL="95" DF="30" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7881479010862723" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="183" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.011968276611915732" LOG_CI_START="-0.19481627673784854" LOG_EFFECT_SIZE="-0.10339227667488214" METHOD="MH" MODIFIED="2013-09-05 16:35:47 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.9978718926399698" P_Q="0.8922624183163835" P_Z="0.026654402815379938" Q="0.018344537709894138" RANDOM="NO" SCALE="19.71" SORT_BY="YEAR" STUDIES="43" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17845" TOTAL_2="13899" WEIGHT="99.99999999999999" Z="2.2165420286008266">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.924397422270822" CI_END="0.9996141081876582" CI_START="0.6104408399466259" DF="21" EFFECT_SIZE="0.7811563709172265" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="132" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-1.6762302896942077E-4" LOG_CI_START="-0.21435641874560968" LOG_EFFECT_SIZE="-0.10726202088728955" MODIFIED="2013-04-05 18:29:13 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.9897964588267154" P_Z="0.04964249077799184" STUDIES="28" TAU2="0.0" TOTAL_1="15537" TOTAL_2="11668" WEIGHT="73.08655584638588" Z="1.9630316996244062">
<NAME>Blinded studies with a placebo group</NAME>
<DICH_DATA CI_END="8.235307327498598" CI_START="0.012621821467408088" EFFECT_SIZE="0.3224043715846995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9156798109309462" LOG_CI_START="-1.8988779671075169" LOG_EFFECT_SIZE="-0.49159907808828524" ORDER="2196" O_E="0.0" SE="1.6532851711054914" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.733351856997314" WEIGHT="0.756762807714835"/>
<DICH_DATA CI_END="2.202710344178457" CI_START="0.43846641438461686" EFFECT_SIZE="0.9827586206896551" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3429573912970908" LOG_CI_START="-0.35806366707798265" LOG_EFFECT_SIZE="-0.007553137890445899" ORDER="2178" O_E="0.0" SE="0.4117832397997223" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.1695654365799556" WEIGHT="6.100757307647576"/>
<DICH_DATA CI_END="7.839090119459458" CI_START="0.029391166128842395" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8942656571959335" LOG_CI_START="-1.5317831824447592" LOG_EFFECT_SIZE="-0.3187587626244128" ORDER="2184" O_E="0.0" SE="1.42507309754038" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="2.0308333333333333" WEIGHT="0.6837055603398144"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2191" O_E="0.0" SE="0.0" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1845324933014454" CI_START="0.25997400229081025" EFFECT_SIZE="0.7536057692307693" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3393585089021063" LOG_CI_START="-0.5850700798221213" LOG_EFFECT_SIZE="-0.12285578546000747" ORDER="2174" O_E="0.0" SE="0.5430139290119261" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.29486412710096915" WEIGHT="4.047104534248641"/>
<DICH_DATA CI_END="1.4436250602245138" CI_START="0.17656882170682706" EFFECT_SIZE="0.504875406283857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.1594544124722273" LOG_CI_START="-0.7530859811440511" LOG_EFFECT_SIZE="-0.2968157843359119" ORDER="2179" O_E="0.0" SE="0.536030744358002" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.2873289588969937" WEIGHT="4.746513207760253"/>
<DICH_DATA CI_END="2.9269030729044214" CI_START="0.43241097107602416" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.46640834060948216" LOG_CI_START="-0.36410329571471955" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="2195" O_E="0.0" SE="0.48784664627573887" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.2379943502824859" WEIGHT="4.069660747767677"/>
<DICH_DATA CI_END="1.1772678121099514" CI_START="0.2971311837935988" EFFECT_SIZE="0.5914414414414414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.07087527005767102" LOG_CI_START="-0.5270517667799897" LOG_EFFECT_SIZE="-0.22808824836115932" ORDER="2185" O_E="0.0" SE="0.35122530122500906" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.12335921222059834" WEIGHT="10.219778375752739"/>
<DICH_DATA CI_END="4.0198731872551905" CI_START="0.3643435677348885" EFFECT_SIZE="1.2102127659574469" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.604212352849646" LOG_CI_START="-0.4384888932776613" LOG_EFFECT_SIZE="0.08286172978599245" ORDER="2194" O_E="0.0" SE="0.6124878734295915" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.3751413950983033" WEIGHT="2.4948883024822424"/>
<DICH_DATA CI_END="2.493604260075294" CI_START="0.26516217536299935" EFFECT_SIZE="0.8131479140328698" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.39682753121841946" LOG_CI_START="-0.5764884267329828" LOG_EFFECT_SIZE="-0.0898304477572817" ORDER="2180" O_E="0.0" SE="0.5717306116923492" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.3268758923461077" WEIGHT="3.3814783132271358"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2181" O_E="0.0" SE="0.0" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3282392489212675" CI_START="0.18431722399516723" EFFECT_SIZE="0.6550836550836551" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.36702760619586355" LOG_CI_START="-0.7344340791241746" LOG_EFFECT_SIZE="-0.18370323646415554" ORDER="2182" O_E="0.0" SE="0.6470040462802666" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.4186142359030375" WEIGHT="3.0886001185118364"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2175" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4683555293054376" CI_START="0.16323828629647819" EFFECT_SIZE="0.4895833333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16683122296507713" LOG_CI_START="-0.787177973172779" LOG_EFFECT_SIZE="-0.31017337510385096" ORDER="2171" O_E="0.0" SE="0.5603897242330598" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.31403664302600476" WEIGHT="4.922680034446664"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2193" O_E="0.0" SE="0.0" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="49.439081904863905" CI_START="0.08158897589607542" EFFECT_SIZE="2.008403361344538" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6940703972071016" LOG_CI_START="-1.0883685180958877" LOG_EFFECT_SIZE="0.30285093955560694" ORDER="2190" O_E="0.0" SE="1.6344183921437394" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="2.671323480577726" WEIGHT="0.3064656759726317"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2198" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.970205306279777" CI_START="0.201573081602601" EFFECT_SIZE="1.0009293680297398" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6963743286815872" LOG_CI_START="-0.6955674647463649" LOG_EFFECT_SIZE="4.0343196761120383E-4" ORDER="2187" O_E="0.0" SE="0.8176334996825806" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.6685245398031845" WEIGHT="1.5333498486175923"/>
<DICH_DATA CI_END="22.63921752989657" CI_START="0.18027196377431381" EFFECT_SIZE="2.0202020202020203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3548614124313982" LOG_CI_START="-0.7440718102985355" LOG_EFFECT_SIZE="0.3053948010664313" ORDER="2172" O_E="0.0" SE="1.2329237649185816" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="1.52010101010101" WEIGHT="0.502625127279517"/>
<DICH_DATA CI_END="4.9744715717384125" CI_START="0.19987271343101215" EFFECT_SIZE="0.9971264367816092" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6967469532893872" LOG_CI_START="-0.6992464916008017" LOG_EFFECT_SIZE="-0.001249769155707207" ORDER="2189" O_E="0.0" SE="0.8200134598074966" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.672422074265461" WEIGHT="1.5273650606164757"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-10 19:19:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="639" O_E="0.0" SE="0.0" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4783959943434857" CI_START="0.3152530098603363" EFFECT_SIZE="0.6826923076923077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16979077717359825" LOG_CI_START="-0.5013407583330084" LOG_EFFECT_SIZE="-0.16577499057970504" MODIFIED="2010-05-17 22:41:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2188" O_E="0.0" SE="0.3942259861112605" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.15541412812539573" WEIGHT="8.123314728785214"/>
<DICH_DATA CI_END="76.13490374800293" CI_START="0.12184827829900997" EFFECT_SIZE="3.045801526717557" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.881583803024787" LOG_CI_START="-0.9141806029628191" LOG_EFFECT_SIZE="0.48370160003098395" MODIFIED="2013-04-04 18:18:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="940" O_E="0.0" SE="1.642245851334126" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.6969714362241484" WEIGHT="0.2506495197887566"/>
<DICH_DATA CI_END="1.2195597139842589" CI_START="0.27009845721495546" EFFECT_SIZE="0.5739348370927319" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.08620306977393853" LOG_CI_START="-0.5684778964676589" LOG_EFFECT_SIZE="-0.24113741334686023" MODIFIED="2009-12-10 21:50:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="644" O_E="0.0" SE="0.384562840293363" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.14788857813449863" WEIGHT="9.47615906630983"/>
<DICH_DATA CI_END="50.04906970284203" CI_START="0.11464844051728294" EFFECT_SIZE="2.3954222573007105" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.6993960093542557" LOG_CI_START="-0.9406318482985855" LOG_EFFECT_SIZE="0.37938208052783506" MODIFIED="2009-12-10 21:47:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="643" O_E="0.0" SE="1.550765431933938" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="2.4048734248812527" WEIGHT="0.3455804301664408"/>
<DICH_DATA CI_END="8.132763947030567" CI_START="0.013252828875088381" EFFECT_SIZE="0.3283018867924528" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910238167112663" LOG_CI_START="-1.877691409749042" LOG_EFFECT_SIZE="-0.48372662131818933" MODIFIED="2009-12-10 19:14:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="638" O_E="0.0" SE="1.6376436339225422" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="2.6818766717270295" WEIGHT="0.7691687553822912"/>
<DICH_DATA CI_END="8.196019479828836" CI_START="0.013332642230707504" EFFECT_SIZE="0.330567081604426" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9136029819365901" LOG_CI_START="-1.8750837746293763" LOG_EFFECT_SIZE="-0.48074039634639315" MODIFIED="2013-04-05 18:29:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1031" O_E="0.0" SE="1.6380884050289253" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="2.6833336226902085" WEIGHT="0.7659903720955876"/>
<DICH_DATA CI_END="3.0079258897057595" CI_START="0.5647488097940576" EFFECT_SIZE="1.3033505154639176" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.47826713175725805" LOG_CI_START="-0.24814467568058352" LOG_EFFECT_SIZE="0.11506122803833728" MODIFIED="2009-12-16 23:28:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="640" O_E="0.0" SE="0.4266978914854272" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.18207109059810941" WEIGHT="4.97395795147215"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.586260377780415" CI_END="1.209065563883198" CI_START="0.5388174522092954" DF="8" EFFECT_SIZE="0.8071342061178797" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="51" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.0824498519448428" LOG_CI_START="-0.2685583459938832" LOG_EFFECT_SIZE="-0.09305424702452017" MODIFIED="2013-09-05 16:35:47 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8923929103120877" P_Z="0.2987140950478493" STUDIES="15" TAU2="0.0" TOTAL_1="2308" TOTAL_2="2231" WEIGHT="26.91344415361411" Z="1.0391949467139847">
<NAME>Non-blinded studies and without placebo</NAME>
<DICH_DATA CI_END="7.908679956389632" CI_START="0.01254512355454697" EFFECT_SIZE="0.3149847094801223" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8981040011339438" LOG_CI_START="-1.9015250570441715" LOG_EFFECT_SIZE="-0.501710527955114" MODIFIED="2010-04-22 21:11:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="838" O_E="0.0" SE="1.6445159671611682" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="2.7044327662480327" WEIGHT="0.7762906883024977"/>
<DICH_DATA CI_END="1.4228034224634079" CI_START="0.130504156735544" EFFECT_SIZE="0.43090806542583193" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15314490118283527" LOG_CI_START="-0.8843756552332911" LOG_EFFECT_SIZE="-0.36561537702522784" MODIFIED="2010-04-22 21:11:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="839" O_E="0.0" SE="0.6094447106484161" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.37142285533733166" WEIGHT="4.534451216268669"/>
<DICH_DATA CI_END="8.060469765718873" CI_START="0.01279153723938795" EFFECT_SIZE="0.3211009174311927" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9063603533081072" LOG_CI_START="-1.893077260488803" LOG_EFFECT_SIZE="-0.49335845359034797" MODIFIED="2010-04-22 21:11:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="843" O_E="0.0" SE="1.6444035117839833" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="2.7040629095674964" WEIGHT="0.7691687553822912"/>
<DICH_DATA CI_END="1.55459457609585" CI_START="0.4631127285849624" EFFECT_SIZE="0.848500168520391" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.19161714813998693" LOG_CI_START="-0.3343132823223593" LOG_EFFECT_SIZE="-0.0713480670911862" MODIFIED="2010-04-22 21:12:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="833" O_E="0.0" SE="0.3089341382512" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.09544030177701154" WEIGHT="11.691956181718902"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:07:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1059" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.4476717815124527" CI_START="0.3095642243140261" EFFECT_SIZE="0.8704663212435233" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3887531810247094" LOG_CI_START="-0.5092492355885312" LOG_EFFECT_SIZE="-0.060248027281910914" MODIFIED="2010-04-22 21:11:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="832" O_E="0.0" SE="0.5274910647022708" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.2782468233407352" WEIGHT="3.958655194367526"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:43:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="967" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:12:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="834" O_E="0.0" SE="0.0" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:26:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="999" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2010-05-17 22:45:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2167" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="1.9497533566667384"/>
<DICH_DATA CI_END="8.315037261213861" CI_START="0.013362671461425384" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9198641997134829" LOG_CI_START="-1.8741067091528076" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-04-22 21:14:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="836" O_E="0.0" SE="1.6411923422471113" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="2.6935123042505595" WEIGHT="0.7589810897480888"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:15:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="842" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:15:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="835" O_E="0.0" SE="0.0" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.10558003083999" CI_START="0.5067747078702879" EFFECT_SIZE="1.759020618556701" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7857269282689927" LOG_CI_START="-0.2951850680318199" LOG_EFFECT_SIZE="0.2452709301185864" MODIFIED="2013-02-28 20:15:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="836" O_E="0.0" SE="0.6349330572277724" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.40313998716060573" WEIGHT="1.9895831805888602"/>
<DICH_DATA CI_END="17.641513452415772" CI_START="0.0648698527340903" EFFECT_SIZE="1.069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2465358401970499" LOG_CI_START="-1.1879570879930745" LOG_EFFECT_SIZE="0.029289376101987508" MODIFIED="2013-04-05 18:38:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1034" O_E="0.0" SE="1.4300331969532285" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="2.044994944388271" WEIGHT="0.48460449057052785"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.86183673843934" CI_END="1.054023369205925" CI_START="0.7725254861592745" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9023635163940549" ESTIMABLE="YES" EVENTS_1="327" EVENTS_2="332" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.022850239913215352" LOG_CI_START="-0.11208718398629014" LOG_EFFECT_SIZE="-0.044618472036537404" METHOD="MH" MODIFIED="2013-09-05 16:35:59 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8826035965129573" P_Q="0.962841808331575" P_Z="0.1949185672887493" Q="0.0021704183152580336" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="34" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13167" TOTAL_2="11264" WEIGHT="100.0" Z="1.2961652254744325">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.410000358510338" CI_END="1.0811090882350987" CI_START="0.7563367906197" DF="19" EFFECT_SIZE="0.9042580262875882" ESTIMABLE="YES" EVENTS_1="249" EVENTS_2="250" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.033869518216241304" LOG_CI_START="-0.1212847736294029" LOG_EFFECT_SIZE="-0.043707627706580814" MODIFIED="2013-04-05 18:41:27 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.6297715842962359" P_Z="0.2694801796886819" STUDIES="20" TAU2="0.0" TOTAL_1="11066" TOTAL_2="9263" WEIGHT="75.5405325290574" Z="1.1042604769168471">
<NAME>Blinded studies with a placebo group</NAME>
<DICH_DATA CI_END="1.6170078930196432" CI_START="0.49865600472596355" EFFECT_SIZE="0.8979591836734694" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.20871213981147868" LOG_CI_START="-0.30219894689613114" LOG_EFFECT_SIZE="-0.04674340354232623" ORDER="2234" O_E="0.0" SE="0.3001117013827172" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.09006703330682922" WEIGHT="7.004271316120811"/>
<DICH_DATA CI_END="1.3790622888152348" CI_START="0.38118258130019855" EFFECT_SIZE="0.7250341530054645" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.13958388262095694" LOG_CI_START="-0.4188669533066557" LOG_EFFECT_SIZE="-0.13964153534284932" ORDER="2235" O_E="0.0" SE="0.3280367854001008" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.10760813257563179" WEIGHT="6.263980099303412"/>
<DICH_DATA CI_END="2.5132396804314543" CI_START="0.6420466222174387" EFFECT_SIZE="1.2702822708531558" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.40023390798182035" LOG_CI_START="-0.1924334344909537" LOG_EFFECT_SIZE="0.10390023674543333" ORDER="2243" O_E="0.0" SE="0.34813573071916765" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.12119848700336881" WEIGHT="4.402282429441505"/>
<DICH_DATA CI_END="2.5174088912697563" CI_START="0.6011048899796547" EFFECT_SIZE="1.2301328361687252" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.40095376175403624" LOG_CI_START="-0.22104973903763422" LOG_EFFECT_SIZE="0.08995201135820102" ORDER="2232" O_E="0.0" SE="0.3653679353320131" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.13349372816877814" WEIGHT="4.052217012692593"/>
<DICH_DATA CI_END="2.1820465687753776" CI_START="0.37874823242455313" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.33886401497201135" LOG_CI_START="-0.4216493852884615" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="2242" O_E="0.0" SE="0.44672933591504776" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.1995670995670996" WEIGHT="3.142333281224564"/>
<DICH_DATA CI_END="1.9912052108508034" CI_START="0.4203562076702034" EFFECT_SIZE="0.9148854961832061" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.29911602012162397" LOG_CI_START="-0.37638253469380717" LOG_EFFECT_SIZE="-0.03863325728609161" ORDER="2236" O_E="0.0" SE="0.39679119487035824" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.15744325232664663" WEIGHT="3.9139656026083642"/>
<DICH_DATA CI_END="1.8988064215731146" CI_START="0.004262770397576661" EFFECT_SIZE="0.08996763754045307" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.27848069178924056" LOG_CI_START="-2.3703080588027574" LOG_EFFECT_SIZE="-1.0459136835067584" ORDER="2237" O_E="0.0" SE="1.555911623813518" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="2.420860981118018" WEIGHT="1.0163360864702633"/>
<DICH_DATA CI_END="1.3388595129904626" CI_START="0.23359968181134735" EFFECT_SIZE="0.5592469545957918" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1267350087267564" LOG_CI_START="-0.6315277531164453" LOG_EFFECT_SIZE="-0.25239637219484445" ORDER="2238" O_E="0.0" SE="0.44540729976790283" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.19838766268653443" WEIGHT="4.181121142786403"/>
<DICH_DATA CI_END="1.3044622028586013" CI_START="0.14971117734078232" EFFECT_SIZE="0.44191919191919193" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.11543149981971623" LOG_CI_START="-0.8247457742981519" LOG_EFFECT_SIZE="-0.3546571372392179" ORDER="2229" O_E="0.0" SE="0.5522647847694007" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.3049963924963925" WEIGHT="3.153759947701744"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2245" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.46169085505258023"/>
<DICH_DATA CI_END="2.7941731204946523" CI_START="0.44551088293209834" EFFECT_SIZE="1.11572153065929" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4462533104919537" LOG_CI_START="-0.3511416825594777" LOG_EFFECT_SIZE="0.04755581396623803" MODIFIED="2010-05-17 22:54:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2240" O_E="0.0" SE="0.46839376608728556" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.21939272010943078" WEIGHT="2.5807773929151137"/>
<DICH_DATA CI_END="1.5573678239082727" CI_START="0.500577314151068" EFFECT_SIZE="0.8829399766899767" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.19239119768551802" LOG_CI_START="-0.3005288362344995" LOG_EFFECT_SIZE="-0.05406881927449073" ORDER="2239" O_E="0.0" SE="0.2895436679181379" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.08383553563148893" WEIGHT="7.595901680430324"/>
<DICH_DATA CI_END="22.63921752989657" CI_START="0.18027196377431381" EFFECT_SIZE="2.0202020202020203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3548614124313982" LOG_CI_START="-0.7440718102985355" LOG_EFFECT_SIZE="0.3053948010664313" ORDER="2230" O_E="0.0" SE="1.2329237649185816" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="1.52010101010101" WEIGHT="0.2927376189079589"/>
<DICH_DATA CI_END="1.853129240597719" CI_START="0.4755874190312977" EFFECT_SIZE="0.9387890884896873" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.26790570886079224" LOG_CI_START="-0.32276964252591284" LOG_EFFECT_SIZE="-0.0274319668325603" ORDER="2241" O_E="0.0" SE="0.3469656252946958" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12038514513613925" WEIGHT="5.122661567236979"/>
<DICH_DATA CI_END="15.909437532889589" CI_START="0.060891652234792946" EFFECT_SIZE="0.984251968503937" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2016548257383248" LOG_CI_START="-1.2154422416341257" LOG_EFFECT_SIZE="-0.006893707947900438" MODIFIED="2009-12-15 22:40:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="686" O_E="0.0" SE="1.4198147821980271" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="2.0158740157480315" WEIGHT="0.2986515101990288"/>
<DICH_DATA CI_END="1.381299390738275" CI_START="0.6030299390679948" EFFECT_SIZE="0.9126691007323302" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="49" LOG_CI_END="0.1402878202538681" LOG_CI_START="-0.21966112558912065" LOG_EFFECT_SIZE="-0.039686652667626277" MODIFIED="2010-05-17 22:55:29 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2246" O_E="0.0" SE="0.21143579256418962" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.04470509437724702" WEIGHT="13.997037099664276"/>
<DICH_DATA CI_END="16.330717844801725" CI_START="0.061234295363097754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213005275317456" LOG_CI_START="-1.213005275317456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:24:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="945" O_E="0.0" SE="1.4250506063888506" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.0307692307692307" WEIGHT="0.29412648731722535"/>
<DICH_DATA CI_END="0.8834563410491986" CI_START="0.002881385072286747" EFFECT_SIZE="0.05045372050816697" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.053814907741730686" LOG_CI_START="-2.5403986981256867" LOG_EFFECT_SIZE="-1.2971068029337087" MODIFIED="2009-12-15 22:41:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="688" O_E="0.0" SE="1.4606316272598117" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="2.1334447505516456" WEIGHT="2.7065293111786985"/>
<DICH_DATA CI_END="3.2595498269126137" CI_START="0.91618733147098" EFFECT_SIZE="1.7281082887700534" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.5131576242434559" LOG_CI_START="-0.03801571770104572" LOG_EFFECT_SIZE="0.2375709532712051" MODIFIED="2013-03-04 21:54:42 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1558" O_E="0.0" SE="0.32376194941024516" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.10482179988592213" WEIGHT="4.467826592577471"/>
<DICH_DATA CI_END="5.541897364276366" CI_START="0.04435592312350596" EFFECT_SIZE="0.4957983193277311" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7436584784037782" LOG_CI_START="-1.3530483779045512" LOG_EFFECT_SIZE="-0.3046949497503866" MODIFIED="2013-04-05 18:41:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1036" O_E="0.0" SE="1.2316159862618397" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="1.5168779376157242" WEIGHT="0.5923254952280738"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.434674650490487" CI_END="1.228154002254845" CI_START="0.6544250108882419" DF="12" EFFECT_SIZE="0.896512518762602" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="82" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.08925282782795613" LOG_CI_START="-0.184140111104484" LOG_EFFECT_SIZE="-0.04744364163826395" MODIFIED="2013-09-05 16:35:59 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8926062363761714" P_Z="0.49634592517666265" STUDIES="14" TAU2="0.0" TOTAL_1="2101" TOTAL_2="2001" WEIGHT="24.459467470942606" Z="0.6802504063896181">
<NAME>Non-blinded studies and without placebo</NAME>
<DICH_DATA CI_END="8.060469765718873" CI_START="0.01279153723938795" EFFECT_SIZE="0.3211009174311927" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9063603533081072" LOG_CI_START="-1.893077260488803" LOG_EFFECT_SIZE="-0.49335845359034797" MODIFIED="2010-04-22 22:01:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="903" O_E="0.0" SE="1.6444035117839833" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="2.7040629095674964" WEIGHT="0.4479772652985432"/>
<DICH_DATA CI_END="1.429833630659547" CI_START="0.6085783583833501" EFFECT_SIZE="0.9328267811914988" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" LOG_CI_END="0.15528550775184805" LOG_CI_START="-0.21568349562195988" LOG_EFFECT_SIZE="-0.030198993935055932" MODIFIED="2010-04-22 21:58:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="893" O_E="0.0" SE="0.21790902890795738" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.04748434487960901" WEIGHT="13.026197714300578"/>
<DICH_DATA CI_END="1.2569296091459647" CI_START="0.23361622838048451" EFFECT_SIZE="0.5418848167539267" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.09931095690992588" LOG_CI_START="-0.6314969918195077" LOG_EFFECT_SIZE="-0.26609301745479097" MODIFIED="2010-04-22 21:58:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="892" O_E="0.0" SE="0.4292802066413587" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.1842814958140476" WEIGHT="4.56339507584116"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:13:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1062" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="41.50906567302496" CI_START="0.48031106126703915" EFFECT_SIZE="4.465116279069767" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6181429579601554" LOG_CI_START="-0.3184774117122293" LOG_EFFECT_SIZE="0.649832773123963" MODIFIED="2013-04-04 18:45:37 +0530" MODIFIED_BY="Xavier Bosch" ORDER="971" O_E="0.0" SE="1.1375803915709966" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="1.2940891472868217" WEIGHT="0.26754197788663"/>
<DICH_DATA CI_END="5.651593953590671" CI_START="0.0406258298685047" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.752170951823081" LOG_CI_START="-1.3911977545390697" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-04-04 19:27:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1001" O_E="0.0" SE="1.2590253879633373" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.585144927536232" WEIGHT="0.5734108995821353"/>
<DICH_DATA CI_END="5.547508069852916" CI_START="0.044159467542199585" EFFECT_SIZE="0.494949494949495" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7440979426643058" LOG_CI_START="-1.3549761718023785" LOG_EFFECT_SIZE="-0.3054391145690362" MODIFIED="2010-04-22 21:59:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="894" O_E="0.0" SE="1.2330065254221743" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="1.5203050917336631" WEIGHT="0.5913299901940771"/>
<DICH_DATA CI_END="8.909425101380505" CI_START="0.27639103298809176" EFFECT_SIZE="1.5692307692307692" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9498496812138301" LOG_CI_START="-0.5584760509757061" LOG_EFFECT_SIZE="0.19568681511906197" MODIFIED="2013-04-04 19:23:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="995" O_E="0.0" SE="0.8859980014209232" STUDY_ID="STD-De-Luca-2005" TOTAL_1="69" TOTAL_2="53" VAR="0.7849924585218703" WEIGHT="0.6364704315717008"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2010-05-17 22:59:17 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2168" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="1.1355702771521212"/>
<DICH_DATA CI_END="4.318001687357362" CI_START="0.5265163609854081" EFFECT_SIZE="1.5078125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6352828077086909" LOG_CI_START="-0.27858812898888013" LOG_EFFECT_SIZE="0.1783473393599054" MODIFIED="2013-02-28 20:16:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="839" O_E="0.0" SE="0.5368123119502478" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.2881674582613702" WEIGHT="1.7202326987464058"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2010-04-22 22:01:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="902" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="0.2986515101990288"/>
<DICH_DATA CI_END="8.533335321744723" CI_START="0.013826055703629716" EFFECT_SIZE="0.34348561759729274" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9311188117901551" LOG_CI_START="-1.8593016977262402" LOG_EFFECT_SIZE="-0.46409144296804244" MODIFIED="2010-04-22 21:59:31 +0530" MODIFIED_BY="Xavier Bosch" ORDER="895" O_E="0.0" SE="1.6391068200942227" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.6866711676793944" WEIGHT="0.43688871912778715"/>
<DICH_DATA CI_END="16.508125798938536" CI_START="0.06057622846951526" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2176977697266207" LOG_CI_START="-1.2176977697266207" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-28 20:17:36 +0530" MODIFIED_BY="Xavier Bosch" ORDER="840" O_E="0.0" SE="1.4305633952771812" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="44" VAR="2.046511627906977" WEIGHT="0.2918639758763236"/>
<DICH_DATA CI_END="7.28486338926983" CI_START="0.011522173759729045" EFFECT_SIZE="0.2897196261682243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8624214119958415" LOG_CI_START="-1.9384655796977155" LOG_EFFECT_SIZE="-0.538022083850937" MODIFIED="2013-04-10 20:41:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1024" O_E="0.0" SE="1.6452548835350098" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="2.706863631795799" WEIGHT="0.46993693516611884"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.43658203686068" CI_END="0.7248919979049842" CI_START="0.6017361009794538" CI_STUDY="95" CI_TOTAL="95" DF="39" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6604496078055854" ESTIMABLE="YES" EVENTS_1="915" EVENTS_2="1044" I2="21.111050980585592" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.13972669440542923" LOG_CI_START="-0.22059393235769348" LOG_EFFECT_SIZE="-0.18016031338156138" METHOD="MH" MODIFIED="2013-09-05 16:36:09 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.12216501487819809" P_Q="0.8038789599259408" P_Z="2.479545816949048E-18" Q="0.061667873771959064" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17911" TOTAL_2="13969" WEIGHT="100.00000000000003" Z="8.73302302917156">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="35.690033291700196" CI_END="0.7320189154647796" CI_START="0.6009274656174812" DF="26" EFFECT_SIZE="0.6632422420611547" ESTIMABLE="YES" EVENTS_1="827" EVENTS_2="915" I2="27.15053026849834" ID="CMP-001.03.01" LOG_CI_END="-0.1354776965702438" LOG_CI_START="-0.2211779459393003" LOG_EFFECT_SIZE="-0.17832782125477203" MODIFIED="2013-04-05 18:45:31 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.09751872205631562" P_Z="3.4426924391376596E-16" STUDIES="28" TAU2="0.0" TOTAL_1="15537" TOTAL_2="11668" WEIGHT="88.64471560349904" Z="8.156711553911729">
<NAME>Blinded studies with a placebo group</NAME>
<DICH_DATA CI_END="0.9414881500085304" CI_START="0.44107318857244265" EFFECT_SIZE="0.6444107233181589" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="72" LOG_CI_END="-0.026185141837749826" LOG_CI_START="-0.3554893407909315" LOG_EFFECT_SIZE="-0.19083724131434066" ORDER="2207" O_E="0.0" SE="0.19343491654717335" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.03741706693961192" WEIGHT="6.231232664496453"/>
<DICH_DATA CI_END="3.167699031428313" CI_START="0.03040500724782702" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5007439118066108" LOG_CI_START="-1.5170548887258732" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="2225" O_E="0.0" SE="1.1852650036979324" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.40485312899106" WEIGHT="0.2673567581011187"/>
<DICH_DATA CI_END="4.451856159984327" CI_START="0.11624785788060497" EFFECT_SIZE="0.7193877551020408" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6485411237816595" LOG_CI_START="-0.9346150411838517" LOG_EFFECT_SIZE="-0.14303695870109617" ORDER="2213" O_E="0.0" SE="0.9299537680501474" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.8648140107106673" WEIGHT="0.24092838890951385"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2220" O_E="0.0" SE="0.0" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0558572080524815" CI_START="0.6489885600172458" EFFECT_SIZE="0.8277917908736528" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="112" LOG_CI_END="0.023605189080383865" LOG_CI_START="-0.18776295861592085" LOG_EFFECT_SIZE="-0.08207888476776852" ORDER="2214" O_E="0.0" SE="0.12415869624601483" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.015415381853510178" WEIGHT="12.833492237175102"/>
<DICH_DATA CI_END="1.1114459902280995" CI_START="0.5338598055112013" EFFECT_SIZE="0.7702962677953059" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" LOG_CI_END="0.04588836337705915" LOG_CI_START="-0.2725727760924846" LOG_EFFECT_SIZE="-0.11334220635771275" ORDER="2224" O_E="0.0" SE="0.1870656497324744" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.0349935573098328" WEIGHT="6.043333210787677"/>
<DICH_DATA CI_END="0.8004339095848543" CI_START="0.32115929460659554" EFFECT_SIZE="0.5070175438596491" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="57" LOG_CI_END="-0.09667452119319817" LOG_CI_START="-0.49327950463868886" LOG_EFFECT_SIZE="-0.2949770129159435" ORDER="2203" O_E="0.0" SE="0.23296773050221178" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.054273963455351175" WEIGHT="4.9849263334105265"/>
<DICH_DATA CI_END="0.5692663034659291" CI_START="0.29824153653584085" EFFECT_SIZE="0.4120423000660939" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="85" LOG_CI_END="-0.2446845225856398" LOG_CI_START="-0.5254318718418116" LOG_EFFECT_SIZE="-0.38505819721372575" ORDER="2208" O_E="0.0" SE="0.16491238267486727" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.02719609395950186" WEIGHT="9.991867775096152"/>
<DICH_DATA CI_END="0.6848823617309" CI_START="0.3652601599581652" EFFECT_SIZE="0.5001602153294027" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="83" LOG_CI_END="-0.1643840183448971" LOG_CI_START="-0.4373976950311747" LOG_EFFECT_SIZE="-0.30089085668803595" ORDER="2209" O_E="0.0" SE="0.16036958512501479" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.02571840383316936" WEIGHT="9.594422626461844"/>
<DICH_DATA CI_END="1.7520048352522535" CI_START="0.3462645412651205" EFFECT_SIZE="0.7788819875776397" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.24353530041680768" LOG_CI_START="-0.4605919794911118" LOG_EFFECT_SIZE="-0.1085283395371521" ORDER="2223" O_E="0.0" SE="0.41360784970416065" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.17107145333689955" WEIGHT="1.229226474028132"/>
<DICH_DATA CI_END="1.5784964664456438" CI_START="0.23247208260974708" EFFECT_SIZE="0.6057692307692307" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.19824361403636032" LOG_CI_START="-0.6336291937267576" LOG_EFFECT_SIZE="-0.2176927898451987" ORDER="2210" O_E="0.0" SE="0.4886462051168655" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.2387751137751138" WEIGHT="0.9374900575254552"/>
<DICH_DATA CI_END="2.2958317839925195" CI_START="0.005377431873896343" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3609400640568862" LOG_CI_START="-2.269425082935536" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="2204" O_E="0.0" SE="1.5450895078608187" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.387301587301587" WEIGHT="0.33000540282857516"/>
<DICH_DATA CI_END="0.8388568957696354" CI_START="0.44232860120015605" EFFECT_SIZE="0.6091390623764724" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="104" LOG_CI_END="-0.07631212102880706" LOG_CI_START="-0.3542549780126941" LOG_EFFECT_SIZE="-0.21528354952075057" ORDER="2211" O_E="0.0" SE="0.16326501003166657" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.026655463500640183" WEIGHT="9.039817249989442"/>
<DICH_DATA CI_END="1.4928490993582744" CI_START="0.2184090295750719" EFFECT_SIZE="0.5710093896713615" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.17401591045232867" LOG_CI_START="-0.6607294107769874" LOG_EFFECT_SIZE="-0.2433567501623294" ORDER="2200" O_E="0.0" SE="0.49033353374608135" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.24042697431591947" WEIGHT="1.0473009558719684"/>
<DICH_DATA CI_END="2.4881828163165496" CI_START="0.008820844535940005" EFFECT_SIZE="0.14814814814814814" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.39588228646919893" LOG_CI_START="-2.0544898321312486" LOG_EFFECT_SIZE="-0.829303772831025" ORDER="2222" O_E="0.0" SE="1.4393607120035128" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="2.0717592592592595" WEIGHT="0.15804340380361695"/>
<DICH_DATA CI_END="2.000690280803328" CI_START="0.47544221316172913" EFFECT_SIZE="0.9753012944502306" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.30117986237486477" LOG_CI_START="-0.3229022611242171" LOG_EFFECT_SIZE="-0.010861199374676195" ORDER="2219" O_E="0.0" SE="0.3665889285996949" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="0.13438744257187218" WEIGHT="1.3861797201246768"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2227" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.14252128378719028"/>
<DICH_DATA CI_END="2.6510797996207787" CI_START="0.6348282227549744" EFFECT_SIZE="1.2972972972972974" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.4234228005408498" LOG_CI_START="-0.19734377392366526" LOG_EFFECT_SIZE="0.11303951330859224" ORDER="2218" O_E="0.0" SE="0.36464135868455794" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.13296332046332043" WEIGHT="1.2262454683136557"/>
<DICH_DATA CI_END="1.3012920474593934" CI_START="0.16861571003746822" EFFECT_SIZE="0.46842105263157896" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.11437477570557761" LOG_CI_START="-0.77310196432141" LOG_EFFECT_SIZE="-0.3293635943079162" ORDER="2201" O_E="0.0" SE="0.5213082301725663" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.2717622708456534" WEIGHT="1.0405828072218344"/>
<DICH_DATA CI_END="1.5829481218694044" CI_START="0.6647323957684306" EFFECT_SIZE="1.0257859900717043" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.19946668191539413" LOG_CI_START="-0.17735315534557233" LOG_EFFECT_SIZE="0.011056763284910887" ORDER="2216" O_E="0.0" SE="0.2213458376953691" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.04899397986506469" WEIGHT="3.7160330480253876"/>
<DICH_DATA CI_END="1.3662645739289538" CI_START="0.09172161994922402" EFFECT_SIZE="0.354" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.13553480759685635" LOG_CI_START="-1.0375282835452808" LOG_EFFECT_SIZE="-0.4509967379742122" MODIFIED="2009-12-10 19:20:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="648" O_E="0.0" SE="0.6890630664928427" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.47480790960451974" WEIGHT="0.7259211460796055"/>
<DICH_DATA CI_END="0.9714269034686553" CI_START="0.5408837972671123" EFFECT_SIZE="0.7248648648648649" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="116" LOG_CI_END="-0.012589872999912627" LOG_CI_START="-0.26689602810291707" LOG_EFFECT_SIZE="-0.13974295055141486" MODIFIED="2010-05-25 19:07:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2217" O_E="0.0" SE="0.14938069434327483" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.022314591842478904" WEIGHT="9.784569782137874"/>
<DICH_DATA CI_END="2.4006588745471547" CI_START="0.1733828554084815" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3803304526738385" LOG_CI_START="-0.7609938490144215" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2013-04-04 18:19:45 +0530" MODIFIED_BY="Xavier Bosch" ORDER="941" O_E="0.0" SE="0.6704195444580936" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.4494623655913978" WEIGHT="0.519627554930074"/>
<DICH_DATA CI_END="1.2364778498688138" CI_START="0.41829389011617946" EFFECT_SIZE="0.7191739218465276" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" LOG_CI_END="0.09218634086237065" LOG_CI_START="-0.37851847897234026" LOG_EFFECT_SIZE="-0.14316606905498483" MODIFIED="2009-12-10 21:51:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="654" O_E="0.0" SE="0.27649434119734556" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.07644912071415413" WEIGHT="2.8758076840539206"/>
<DICH_DATA CI_END="0.9416889999817076" CI_START="0.11495840288142405" EFFECT_SIZE="0.32902137232845896" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.026092502613264228" LOG_CI_START="-0.9394592784907644" LOG_EFFECT_SIZE="-0.4827758905520144" MODIFIED="2009-12-10 19:15:33 +0530" MODIFIED_BY="Xavier Bosch" ORDER="647" O_E="0.0" SE="0.5365161653889019" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.2878495957236115" WEIGHT="1.2465197742330905"/>
<DICH_DATA CI_END="1.7209680322803378" CI_START="0.31514448379462257" EFFECT_SIZE="0.7364465915190553" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.23577280319612934" LOG_CI_START="-0.5014902902471488" LOG_EFFECT_SIZE="-0.13285874352550972" MODIFIED="2009-12-10 21:47:41 +0530" MODIFIED_BY="Xavier Bosch" ORDER="653" O_E="0.0" SE="0.43307199059975265" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.18755134904203224" WEIGHT="1.0986375421124566"/>
<DICH_DATA CI_END="2.350045571117705" CI_START="0.6032006136699485" EFFECT_SIZE="1.1906086387434556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.3710762840134639" LOG_CI_START="-0.2195382253058275" LOG_EFFECT_SIZE="0.07576902935381821" MODIFIED="2009-12-10 19:22:56 +0530" MODIFIED_BY="Xavier Bosch" ORDER="649" O_E="0.0" SE="0.34692988636312394" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12036034605193009" WEIGHT="1.408693539236239"/>
<DICH_DATA CI_END="1.6286850888993347" CI_START="0.06367457549921701" EFFECT_SIZE="0.3220338983050847" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21183712029725427" LOG_CI_START="-1.1960339416758847" LOG_EFFECT_SIZE="-0.49209841068931526" MODIFIED="2013-04-05 18:45:31 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1037" O_E="0.0" SE="0.8269904308771744" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6839131727624145" WEIGHT="0.5439327147574484"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.765607844305736" CI_END="0.8462237214148108" CI_START="0.48199136471032217" DF="12" EFFECT_SIZE="0.6386489852297365" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="129" I2="12.826225069575077" ID="CMP-001.03.02" LOG_CI_END="-0.07251480465450014" LOG_CI_START="-0.316960742450468" LOG_EFFECT_SIZE="-0.1947377735524841" MODIFIED="2013-09-05 16:36:09 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.31592605008346786" P_Z="0.001791337806069988" STUDIES="16" TAU2="0.0" TOTAL_1="2374" TOTAL_2="2301" WEIGHT="11.355284396500988" Z="3.122809288906754">
<NAME>Non-blinded studies and without placebo</NAME>
<DICH_DATA CI_END="1.5334642240539935" CI_START="0.05670127417843977" EFFECT_SIZE="0.2948717948717949" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1856736482825227" LOG_CI_START="-1.2464071816282978" LOG_EFFECT_SIZE="-0.5303667666728875" MODIFIED="2010-04-22 21:31:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="862" O_E="0.0" SE="0.8412113684040525" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.7076365663322185" WEIGHT="0.5427150847595903"/>
<DICH_DATA CI_END="1.1562036362510264" CI_START="0.13814868059653734" EFFECT_SIZE="0.39965986394557823" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.06303433089385553" LOG_CI_START="-0.8596532585026601" LOG_EFFECT_SIZE="-0.39830946380440224" MODIFIED="2010-04-22 21:32:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="863" O_E="0.0" SE="0.5419912573887424" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.29375452308583005" WEIGHT="1.0814740649304861"/>
<DICH_DATA CI_END="1.426718784819025" CI_START="0.5097284757657291" EFFECT_SIZE="0.852783203125" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.15433837939576345" LOG_CI_START="-0.29266110405601875" LOG_EFFECT_SIZE="-0.0691613623301276" MODIFIED="2010-04-22 21:31:29 +0530" MODIFIED_BY="Xavier Bosch" ORDER="857" O_E="0.0" SE="0.2625697092627056" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.06894285222230175" WEIGHT="2.901966361740189"/>
<DICH_DATA CI_END="1.993245780616303" CI_START="0.06839666350859779" EFFECT_SIZE="0.36923076923076925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2995608534341538" LOG_CI_START="-1.1649650832966527" LOG_EFFECT_SIZE="-0.43270211493124955" MODIFIED="2010-04-22 21:32:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="867" O_E="0.0" SE="0.8602697847559815" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.7400641025641027" WEIGHT="0.44803581763642186"/>
<DICH_DATA CI_END="1.0645979234953766" CI_START="0.1889714687376683" EFFECT_SIZE="0.4485294117647059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.027185614743575174" LOG_CI_START="-0.723603761462476" LOG_EFFECT_SIZE="-0.34820907335945045" MODIFIED="2010-04-22 21:31:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="856" O_E="0.0" SE="0.44101739605078505" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.19449634361941498" WEIGHT="1.5045732042104334"/>
<DICH_DATA CI_END="16.3090734852818" CI_START="0.055031141163090325" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.212429289571308" LOG_CI_START="-1.2593914812703537" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-17 21:09:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1060" O_E="0.0" SE="1.4519597565025428" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.1081871345029235" WEIGHT="0.08982808848667118"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:43:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="968" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.862838331323726" CI_START="0.2939412325783307" EFFECT_SIZE="1.0655737704918034" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5869065323013709" LOG_CI_START="-0.5317394890371939" LOG_EFFECT_SIZE="0.02758352163208857" MODIFIED="2013-04-04 19:43:33 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1024" O_E="0.0" SE="0.6570982103213844" STUDY_ID="STD-Prati-2005" TOTAL_1="66" TOTAL_2="70" VAR="0.43177805800756625" WEIGHT="0.41350817049108113"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:27:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1000" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.293535365340421" CI_START="0.3454473074383324" EFFECT_SIZE="0.8901098901098901" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.360505441155937" LOG_CI_START="-0.46161818804082483" LOG_EFFECT_SIZE="-0.050556373442443875" MODIFIED="2010-04-22 21:32:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="858" O_E="0.0" SE="0.4829194893677757" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.2332112332112332" WEIGHT="0.8389470685242"/>
<DICH_DATA CI_END="1.1038931784097734" CI_START="0.10118222733826397" EFFECT_SIZE="0.33420707732634336" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.042927049596310406" LOG_CI_START="-0.9948957646381609" LOG_EFFECT_SIZE="-0.4759843575209253" MODIFIED="2010-05-17 23:07:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2170" O_E="0.0" SE="0.6096222583871124" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.37163929792100325" WEIGHT="0.817935871816975"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-04-22 21:33:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="860" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="0.1806715421558127"/>
<DICH_DATA CI_END="6.053764570656634" CI_START="0.6816653038207906" EFFECT_SIZE="2.031413612565445" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7820255273485307" LOG_CI_START="-0.16642881065557125" LOG_EFFECT_SIZE="0.30779835834647973" MODIFIED="2013-02-28 20:18:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="842" O_E="0.0" SE="0.5571267730683014" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.31039024126949855" WEIGHT="0.44021673101132475"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:33:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="866" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7175025470338756" CI_START="0.03402644715468491" EFFECT_SIZE="0.15625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.14417655290645223" LOG_CI_START="-1.4681833950613221" LOG_EFFECT_SIZE="-0.8061799739838872" MODIFIED="2010-04-22 21:34:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="859" O_E="0.0" SE="0.7777281730213398" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.6048611111111111" WEIGHT="1.0620516735603058"/>
<DICH_DATA CI_END="1.5974377473368826" CI_START="0.24645388119281297" EFFECT_SIZE="0.6274509803921569" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.20342394256447882" LOG_CI_START="-0.6082643381205396" LOG_EFFECT_SIZE="-0.2024201977780304" MODIFIED="2013-04-05 18:47:33 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1038" O_E="0.0" SE="0.47678971399616943" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.22732843137254904" WEIGHT="1.0333607171774954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="60.091509942711006" CI_END="0.8640524800129729" CI_START="0.6449956297223136" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7465320311005377" ESTIMABLE="YES" EVENTS_1="1011" EVENTS_2="1158" I2="45.08375637180533" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.06345987894717456" LOG_CI_START="-0.19044322799095492" LOG_EFFECT_SIZE="-0.12695155346906478" METHOD="MH" MODIFIED="2013-09-05 16:36:21 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.0027026908279987882" P_Q="0.5306907340335123" P_Z="8.8936868975288E-5" Q="0.3930694762101469" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="33" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06135559197561226" TOTALS="YES" TOTAL_1="13374" TOTAL_2="11471" WEIGHT="99.99999999999999" Z="3.918946451711418">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="34.87334232970402" CI_END="0.8383419438054831" CI_START="0.618876673453167" DF="19" EFFECT_SIZE="0.7202987389955637" ESTIMABLE="YES" EVENTS_1="848" EVENTS_2="981" I2="45.51712359438403" ID="CMP-001.04.01" LOG_CI_END="-0.07657880473765179" LOG_CI_START="-0.20839588631912476" LOG_EFFECT_SIZE="-0.14248734552838827" MODIFIED="2013-04-05 18:48:50 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.0144654364177359" P_Z="2.2628788604103674E-5" STUDIES="20" TAU2="0.043446765824299335" TOTAL_1="11066" TOTAL_2="9263" WEIGHT="76.4651670835423" Z="4.2372363602321945">
<NAME>Blinded studies with a placebo group</NAME>
<DICH_DATA CI_END="0.9533908483014176" CI_START="0.4969091916449878" EFFECT_SIZE="0.6882940329184807" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="97" LOG_CI_END="-0.02072902122717514" LOG_CI_START="-0.30372296975924196" LOG_EFFECT_SIZE="-0.1622259954932086" ORDER="2253" O_E="0.0" SE="0.1662320462103738" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.02763309318728785" WEIGHT="6.252215919292026"/>
<DICH_DATA CI_END="1.200758503518926" CI_START="0.6534829323577985" EFFECT_SIZE="0.8858189363143631" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="96" LOG_CI_END="0.07945567090397891" LOG_CI_START="-0.1847657508219595" LOG_EFFECT_SIZE="-0.0526550399589903" ORDER="2262" O_E="0.0" SE="0.1552049710389476" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.024088583035200558" WEIGHT="6.5115787464966655"/>
<DICH_DATA CI_END="1.1232459971740139" CI_START="0.5425202595202663" EFFECT_SIZE="0.780630328575534" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="73" LOG_CI_END="0.050474879605739334" LOG_CI_START="-0.26558403916870277" LOG_EFFECT_SIZE="-0.10755457978148174" ORDER="2251" O_E="0.0" SE="0.18565457340498742" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.03446762062618786" WEIGHT="5.806280742479491"/>
<DICH_DATA CI_END="0.6805885608995557" CI_START="0.39407927896643186" EFFECT_SIZE="0.5178859424159903" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="109" LOG_CI_END="-0.16711535465241978" LOG_CI_START="-0.40441640011821395" LOG_EFFECT_SIZE="-0.28576587738531684" ORDER="2254" O_E="0.0" SE="0.13939180876572724" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.01943007635098107" WEIGHT="6.887069025202335"/>
<DICH_DATA CI_END="1.3856074448955416" CI_START="0.41696769722548055" EFFECT_SIZE="0.76010101010101" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.14164020815217282" LOG_CI_START="-0.3798975888155107" LOG_EFFECT_SIZE="-0.11912869033166898" ORDER="2261" O_E="0.0" SE="0.30635388359254867" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.09385270199223687" WEIGHT="3.5847083927589702"/>
<DICH_DATA CI_END="0.7463113737976644" CI_START="0.4152278981061628" EFFECT_SIZE="0.5566770186335404" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="92" LOG_CI_END="-0.12707993967409198" LOG_CI_START="-0.3817134750378945" LOG_EFFECT_SIZE="-0.2543967073559932" ORDER="2255" O_E="0.0" SE="0.149572999129026" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.022372082068451614" WEIGHT="6.6450726162480365"/>
<DICH_DATA CI_END="1.1859413013483808" CI_START="0.21325656803794923" EFFECT_SIZE="0.5029013539651838" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.07406319397650363" LOG_CI_START="-0.6710975842227527" LOG_EFFECT_SIZE="-0.2985171951231245" ORDER="2256" O_E="0.0" SE="0.4377111297195843" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.19159103308039477" WEIGHT="2.1995805395274926"/>
<DICH_DATA CI_END="0.8403905395532184" CI_START="0.46115857362075363" EFFECT_SIZE="0.6225377920293175" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="118" LOG_CI_END="-0.07551884517964914" LOG_CI_START="-0.3361497127736406" LOG_EFFECT_SIZE="-0.20583427897664486" ORDER="2257" O_E="0.0" SE="0.15309586176831233" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.0234383428905822" WEIGHT="6.561512623400683"/>
<DICH_DATA CI_END="1.2524491230418444" CI_START="0.21128903242115818" EFFECT_SIZE="0.5144208037825059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.09776009299759868" LOG_CI_START="-0.6751230456953988" LOG_EFFECT_SIZE="-0.28868147634890007" ORDER="2248" O_E="0.0" SE="0.45399538150150553" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.20611180642469754" WEIGHT="2.080165572851012"/>
<DICH_DATA CI_END="1.490417290079542" CI_START="0.018790038269107676" EFFECT_SIZE="0.1673469387755102" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.17330788009442707" LOG_CI_START="-1.7260723353840213" LOG_EFFECT_SIZE="-0.7763822276447969" ORDER="2264" O_E="0.0" SE="1.115705340655742" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2447984071677451" WEIGHT="0.4259654484672178"/>
<DICH_DATA CI_END="1.3012920474593934" CI_START="0.16861571003746822" EFFECT_SIZE="0.46842105263157896" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.11437477570557761" LOG_CI_START="-0.77310196432141" LOG_EFFECT_SIZE="-0.3293635943079162" ORDER="2249" O_E="0.0" SE="0.5213082301725663" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.2717622708456534" WEIGHT="1.6702090644441783"/>
<DICH_DATA CI_END="1.3325825657155022" CI_START="0.662004293235404" EFFECT_SIZE="0.9392419175027871" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="69" LOG_CI_END="0.12469412705977545" LOG_CI_START="-0.17913919406120712" LOG_EFFECT_SIZE="-0.027222533500715847" ORDER="2258" O_E="0.0" SE="0.17847319682566087" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.03185268198517109" WEIGHT="5.969174734921507"/>
<DICH_DATA CI_END="2.55497240607456" CI_START="0.684418996161148" EFFECT_SIZE="1.3223734908810685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.40738621407767245" LOG_CI_START="-0.16467794504929822" LOG_EFFECT_SIZE="0.12135413451418711" MODIFIED="2010-05-17 23:09:51 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2259" O_E="0.0" SE="0.3360333188344404" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.11291839136688867" WEIGHT="3.1925389168324836"/>
<DICH_DATA CI_END="1.6375543683499472" CI_START="0.5635675410031722" EFFECT_SIZE="0.9606625258799172" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.21419572788971358" LOG_CI_START="-0.24905402828297613" LOG_EFFECT_SIZE="-0.017429150196631278" ORDER="2260" O_E="0.0" SE="0.27211519989911404" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.07404668201613479" WEIGHT="4.1090629987961815"/>
<DICH_DATA CI_END="1.885203763539329" CI_START="0.19070212319783858" EFFECT_SIZE="0.5995934959349594" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2753582980952003" LOG_CI_START="-0.719644471673595" LOG_EFFECT_SIZE="-0.2221430867891973" MODIFIED="2009-12-15 22:46:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="691" O_E="0.0" SE="0.5844695523053356" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.3416046575719994" WEIGHT="1.3807229736356705"/>
<DICH_DATA CI_END="0.9404987851447159" CI_START="0.5614014133321323" EFFECT_SIZE="0.7266342595951535" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="154" LOG_CI_END="-0.02664176109742685" LOG_CI_START="-0.2507264983606934" LOG_EFFECT_SIZE="-0.13868412972906016" MODIFIED="2010-05-17 23:11:29 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2265" O_E="0.0" SE="0.13162848390578177" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.017326057775334653" WEIGHT="7.071235488496534"/>
<DICH_DATA CI_END="4.0612089439834165" CI_START="0.10604331578113421" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6086553339580679" LOG_CI_START="-0.9745167011300413" LOG_EFFECT_SIZE="-0.18293068358598671" MODIFIED="2013-04-04 18:25:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="946" O_E="0.0" SE="0.9299630902387197" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.8648313492063491" WEIGHT="0.6007172518566563"/>
<DICH_DATA CI_END="0.6122631719676019" CI_START="0.009801003503232143" EFFECT_SIZE="0.07746478873239436" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.21306186287730208" LOG_CI_START="-2.008729455572361" LOG_EFFECT_SIZE="-1.1108956592248316" MODIFIED="2009-12-15 22:47:37 +0530" MODIFIED_BY="Xavier Bosch" ORDER="693" O_E="0.0" SE="1.0547840326470164" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="1.112569355527102" WEIGHT="0.47394552368609905"/>
<DICH_DATA CI_END="1.6286850888993347" CI_START="0.06367457549921701" EFFECT_SIZE="0.3220338983050847" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21183712029725427" LOG_CI_START="-1.1960339416758847" LOG_EFFECT_SIZE="-0.49209841068931526" MODIFIED="2013-04-05 18:48:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1039" O_E="0.0" SE="0.8269904308771744" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6839131727624145" WEIGHT="0.7465447370626421"/>
<DICH_DATA CI_END="2.475775806656468" CI_START="0.8899366852164702" EFFECT_SIZE="1.4843462246777164" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="27" LOG_CI_END="0.39371131468559334" LOG_CI_START="-0.05064089025310598" LOG_EFFECT_SIZE="0.17153521221624368" MODIFIED="2013-03-04 22:05:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1559" O_E="0.0" SE="0.26101468475988077" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.06812866566029994" WEIGHT="4.296865767086426"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.204866458570606" CI_END="1.1808448202266248" CI_START="0.566541008272025" DF="13" EFFECT_SIZE="0.8179223771630106" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="177" I2="41.45427524072195" ID="CMP-001.04.02" LOG_CI_END="0.07219282890281913" LOG_CI_START="-0.24676864886912145" LOG_EFFECT_SIZE="-0.08728790998315114" MODIFIED="2013-09-05 16:36:21 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.05226772572685279" P_Z="0.28338838946413014" STUDIES="14" TAU2="0.16434106516860222" TOTAL_1="2308" TOTAL_2="2208" WEIGHT="23.534832916457688" Z="1.0727386958940206">
<NAME>Non-blinded studies and without placebo</NAME>
<DICH_DATA CI_END="1.404259604736001" CI_START="0.702224635685269" EFFECT_SIZE="0.9930285440727664" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="68" LOG_CI_END="0.1474474030089811" LOG_CI_START="-0.15352393853558846" LOG_EFFECT_SIZE="-0.003038267763303675" MODIFIED="2010-04-22 21:49:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="881" O_E="0.0" SE="0.17679205585544852" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.031255431013596034" WEIGHT="6.0076701029118675"/>
<DICH_DATA CI_END="1.565956242562915" CI_START="0.057965141015792906" EFFECT_SIZE="0.30128205128205127" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19477962242245186" LOG_CI_START="-1.2368331032599402" LOG_EFFECT_SIZE="-0.5210267404187442" MODIFIED="2010-04-22 21:49:43 +0530" MODIFIED_BY="Xavier Bosch" ORDER="891" O_E="0.0" SE="0.8409364016631203" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.7071740316421168" WEIGHT="0.7239492882438258"/>
<DICH_DATA CI_END="117.25632331883436" CI_START="0.2368806042653152" EFFECT_SIZE="5.27027027027027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.069136272354529" LOG_CI_START="-0.6254704977634833" LOG_EFFECT_SIZE="0.721832887295523" MODIFIED="2013-04-17 21:11:30 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1061" O_E="0.0" SE="1.5828253552859535" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.505336105336105" WEIGHT="0.21676794084583034"/>
<DICH_DATA CI_END="0.7744334863035875" CI_START="0.17957352853781652" EFFECT_SIZE="0.37291789143640997" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.11101587651261872" LOG_CI_START="-0.7457576835778034" LOG_EFFECT_SIZE="-0.42838678004521097" MODIFIED="2010-04-22 21:50:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="880" O_E="0.0" SE="0.3728504794927083" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.13901748005794248" WEIGHT="2.7767028192250236"/>
<DICH_DATA CI_END="6.744525616085399" CI_START="0.30165103303213875" EFFECT_SIZE="1.426356589147287" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8289514084835862" LOG_CI_START="-0.520495183063011" LOG_EFFECT_SIZE="0.15422811271028752" MODIFIED="2013-04-04 18:46:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="972" O_E="0.0" SE="0.7926716077428309" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.6283282777216043" WEIGHT="0.8067123191624148"/>
<DICH_DATA CI_END="2.55497240607456" CI_START="0.684418996161148" EFFECT_SIZE="1.3223734908810685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.40738621407767245" LOG_CI_START="-0.16467794504929822" LOG_EFFECT_SIZE="0.12135413451418711" MODIFIED="2010-04-22 21:50:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="889" O_E="0.0" SE="0.3360333188344404" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.11291839136688867" WEIGHT="3.1925389168324836"/>
<DICH_DATA CI_END="1.7846508327367492" CI_START="0.30982290576356214" EFFECT_SIZE="0.7435897435897436" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.25155325896414527" LOG_CI_START="-0.5088864772192315" LOG_EFFECT_SIZE="-0.1286666091275431" MODIFIED="2010-04-22 21:50:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="882" O_E="0.0" SE="0.44668606527151844" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.19952844090775124" WEIGHT="2.1326582077987735"/>
<DICH_DATA CI_END="4.01950720127219" CI_START="0.6073894454592059" EFFECT_SIZE="1.5625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6041728110727181" LOG_CI_START="-0.21653275904049243" LOG_EFFECT_SIZE="0.19382002601611284" MODIFIED="2013-04-04 19:23:47 +0530" MODIFIED_BY="Xavier Bosch" ORDER="996" O_E="0.0" SE="0.482086514442592" STUDY_ID="STD-De-Luca-2005" TOTAL_1="69" TOTAL_2="53" VAR="0.23240740740740742" WEIGHT="1.8939637571133483"/>
<DICH_DATA CI_END="3.159193437595083" CI_START="0.029553175319944055" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4995762185952884" LOG_CI_START="-1.5293958498134126" LOG_EFFECT_SIZE="-0.5149098156090622" MODIFIED="2013-04-04 19:28:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1002" O_E="0.0" SE="1.1918282365569903" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.4204545454545454" WEIGHT="0.3754708244723248"/>
<DICH_DATA CI_END="1.4311007059550747" CI_START="0.15874593051244992" EFFECT_SIZE="0.4766355140186916" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.15567019595523704" LOG_CI_START="-0.7992973991297837" LOG_EFFECT_SIZE="-0.3218136015872733" MODIFIED="2010-05-17 23:10:43 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2171" O_E="0.0" SE="0.5609526925187756" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.31466792324406395" WEIGHT="1.4796321280261162"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2010-04-22 21:52:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="890" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="0.25848485413657835"/>
<DICH_DATA CI_END="0.6497708921999872" CI_START="0.03130765804115496" EFFECT_SIZE="0.14262820512820512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.1872397476541158" LOG_CI_START="-1.5043494184209065" LOG_EFFECT_SIZE="-0.8457945830375112" MODIFIED="2010-04-22 21:52:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="883" O_E="0.0" SE="0.7736767404064332" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.5985756986459234" WEIGHT="0.8430824267907413"/>
<DICH_DATA CI_END="4.858291695424427" CI_START="0.7404466913695666" EFFECT_SIZE="1.8966565349544073" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6864835866136397" LOG_CI_START="-0.1305062031487403" LOG_EFFECT_SIZE="0.2779886917324497" MODIFIED="2013-02-28 20:20:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="845" O_E="0.0" SE="0.47990384667110486" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.2303077020497233" WEIGHT="1.9075985405418214"/>
<DICH_DATA CI_END="3.723005569583228" CI_START="0.20684787573541472" EFFECT_SIZE="0.8775510204081632" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5708936859195615" LOG_CI_START="-0.6843489348174159" LOG_EFFECT_SIZE="-0.05672762444892715" MODIFIED="2013-04-10 20:40:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1025" O_E="0.0" SE="0.737335728972084" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.5436639772187946" WEIGHT="0.9196007903565407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="38.925673586525974" CI_END="0.7084138429587237" CI_START="0.5352219477453662" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6157585864916121" ESTIMABLE="YES" EVENTS_1="366" EVENTS_2="476" I2="17.79204557920169" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.1497129609463224" LOG_CI_START="-0.2714660858432489" LOG_EFFECT_SIZE="-0.21058952339478562" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.18615020488097" P_Q="1.0" P_Z="1.201104771046971E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="42" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17757" TOTAL_2="13798" WEIGHT="99.99999999999994" Z="6.780078650542365">
<NAME>30-day urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.607065820519196" CI_START="0.0063638162757009495" EFFECT_SIZE="0.1288056206088993" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41615199592760443" LOG_CI_START="-2.1962823669891645" LOG_EFFECT_SIZE="-0.89006518553078" ORDER="2291" O_E="0.0" SE="1.5345568765359672" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.3548648073238234" WEIGHT="0.6894379112360185"/>
<DICH_DATA CI_END="0.6703290654766458" CI_START="0.26348566009098934" EFFECT_SIZE="0.42026431718061674" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="60" LOG_CI_END="-0.17371194918384947" LOG_CI_START="-0.5792430157942057" LOG_EFFECT_SIZE="-0.3764774824890276" ORDER="2273" O_E="0.0" SE="0.23821095593807806" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.056744459528932964" WEIGHT="11.653334729761273"/>
<DICH_DATA CI_END="1.9391125998376293" CI_START="0.1109886402355104" EFFECT_SIZE="0.4639175257731959" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.2876030282990867" LOG_CI_START="-0.954721469280889" LOG_EFFECT_SIZE="-0.33355922049090114" ORDER="2279" O_E="0.0" SE="0.7297475594839202" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.5325315005727377" WEIGHT="1.035760711487504"/>
<DICH_DATA CI_END="8.27984505730735" CI_START="0.08008135658343192" EFFECT_SIZE="0.8142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9180222098058899" LOG_CI_START="-1.0964685784894206" LOG_EFFECT_SIZE="-0.08922318434176543" ORDER="2286" O_E="0.0" SE="1.1833218609348921" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="1.400250626566416" WEIGHT="0.30139362239825945"/>
<DICH_DATA CI_END="1.245765473204795" CI_START="0.5581523046855739" EFFECT_SIZE="0.8338626205598683" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="39" LOG_CI_END="0.0954362900921226" LOG_CI_START="-0.25324727765903693" LOG_EFFECT_SIZE="-0.07890549378345717" ORDER="2280" O_E="0.0" SE="0.20481845370852822" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.041950598979552514" WEIGHT="10.187718605753766"/>
<DICH_DATA CI_END="0.5707657474647189" CI_START="0.2369791719849716" EFFECT_SIZE="0.3677765547605944" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="48" LOG_CI_END="-0.24354209745895225" LOG_CI_START="-0.6252898222999667" LOG_EFFECT_SIZE="-0.43441595987945947" ORDER="2274" O_E="0.0" SE="0.22424050325332628" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.05028380329930504" WEIGHT="12.50834114772336"/>
<DICH_DATA CI_END="1.1718197603392158" CI_START="0.46175543970194177" EFFECT_SIZE="0.7355910199879132" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" LOG_CI_END="0.06886081721982046" LOG_CI_START="-0.33558797965897996" LOG_EFFECT_SIZE="-0.13336358121957978" MODIFIED="2009-11-30 20:45:31 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2290" O_E="0.0" SE="0.23757522534044068" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.05644198769556117" WEIGHT="8.355766642513474"/>
<DICH_DATA CI_END="1.0156963059996749" CI_START="0.47120588217630355" EFFECT_SIZE="0.6918107211454514" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="69" LOG_CI_END="0.006763872963093745" LOG_CI_START="-0.3267892967846956" LOG_EFFECT_SIZE="-0.16001271191080094" ORDER="2270" O_E="0.0" SE="0.19593078302467057" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.038388871736660536" WEIGHT="12.689767479775444"/>
<DICH_DATA CI_END="0.7238898464461551" CI_START="0.0785104955386949" EFFECT_SIZE="0.23839662447257384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.14032751490813414" LOG_CI_START="-1.1050722814731966" LOG_EFFECT_SIZE="-0.6226998981906653" ORDER="2289" O_E="0.0" SE="0.5666958514439314" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.3211441880437624" WEIGHT="3.1436932653203367"/>
<DICH_DATA CI_END="4.573998534878749" CI_START="0.12719783310210436" EFFECT_SIZE="0.7627599243856332" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6602960211596286" LOG_CI_START="-0.8955202871138216" LOG_EFFECT_SIZE="-0.11761213297709656" ORDER="2275" O_E="0.0" SE="0.9138942008947574" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.8352026104290671" WEIGHT="0.5297801003201514"/>
<DICH_DATA CI_END="3.7802369099058293" CI_START="0.006120117198123009" EFFECT_SIZE="0.15210355987055016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.577519018207779" LOG_CI_START="-2.213240261186013" LOG_EFFECT_SIZE="-0.8178606214891172" ORDER="2276" O_E="0.0" SE="1.6393058151971438" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="2.687323555739172" WEIGHT="0.4088018499146687"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2278" O_E="0.0" SE="0.0" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.3122791004773" CI_START="0.11010644244117765" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.871060580987677" LOG_CI_START="-0.9581872692680543" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="2271" O_E="0.0" SE="1.6619141922429452" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.7619587823785214" WEIGHT="0.09783060843917529"/>
<DICH_DATA CI_END="1.4883382224710782" CI_START="0.44847220223636175" EFFECT_SIZE="0.8169934640522876" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.17270163514906156" LOG_CI_START="-0.3482644707681463" LOG_EFFECT_SIZE="-0.08778141780954239" ORDER="2277" O_E="0.0" SE="0.306018069439583" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.09364705882352942" WEIGHT="4.749202495132706"/>
<DICH_DATA CI_END="1.6402545667807582" CI_START="0.2083671369376391" EFFECT_SIZE="0.5846153846153846" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.21491125558947877" LOG_CI_START="-0.6811707756415695" LOG_EFFECT_SIZE="-0.23312976002604538" ORDER="2281" O_E="0.0" SE="0.52636302082271" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.2770580296896087" WEIGHT="1.9471939231180744"/>
<DICH_DATA CI_END="0.6175945891362937" CI_START="0.0012977518806351123" EFFECT_SIZE="0.028310502283105023" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="-0.20929651759224244" LOG_CI_START="-2.8868083330914867" LOG_EFFECT_SIZE="-1.5480524253418644" ORDER="2288" O_E="0.0" SE="1.5727836943214988" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="2.473648549123582" WEIGHT="0.8563733129722866"/>
<DICH_DATA CI_END="0.8909646983457026" CI_START="0.041305040307814664" EFFECT_SIZE="0.19183673469387755" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.05013950316557952" LOG_CI_START="-1.3839969496920503" LOG_EFFECT_SIZE="-0.717068226428815" ORDER="2267" O_E="0.0" SE="0.7835144667904963" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.6138949196699957" WEIGHT="1.9620724818126691"/>
<DICH_DATA CI_END="0.906036103183183" CI_START="0.33958922692973154" EFFECT_SIZE="0.5546891921160927" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="45" LOG_CI_END="-0.042854496472370794" LOG_CI_START="-0.46904609569305217" LOG_EFFECT_SIZE="-0.25595029608271147" ORDER="2269" O_E="0.0" SE="0.25034705506466887" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.06267364797955234" WEIGHT="8.87969637566811"/>
<DICH_DATA CI_END="1.2974108780885616" CI_START="0.10955629481726407" EFFECT_SIZE="0.3770139634801289" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.11307753493383373" LOG_CI_START="-0.9603626639648709" LOG_EFFECT_SIZE="-0.42364256451551857" ORDER="2285" O_E="0.0" SE="0.6305440864477805" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="0.397585844954266" WEIGHT="1.6679810807356021"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2292" O_E="0.0" SE="0.0" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-30 16:54:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2293" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:14:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1063" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.199564624588795" CI_START="0.03403242558921244" EFFECT_SIZE="0.32998324958123953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5050908864441218" LOG_CI_START="-1.4681070963796743" LOG_EFFECT_SIZE="-0.48150810496777613" ORDER="2266" O_E="0.0" SE="1.1590662625982406" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="1.3434346010934535" WEIGHT="0.5976312610419201"/>
<DICH_DATA CI_END="2.987023368566935" CI_START="0.21179738528757835" EFFECT_SIZE="0.7953890489913544" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47523862026063" LOG_CI_START="-0.674079405711942" LOG_EFFECT_SIZE="-0.09942039272565603" ORDER="2284" O_E="0.0" SE="0.6751150976722718" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.45578039510504115" WEIGHT="0.9910610952123733"/>
<DICH_DATA CI_END="3.781031937907338" CI_START="0.5437980021108695" EFFECT_SIZE="1.4339168782573835" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.577610345809597" LOG_CI_START="-0.2645623923237646" LOG_EFFECT_SIZE="0.15652397674291624" ORDER="2282" O_E="0.0" SE="0.4946964352018243" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.24472456300139275" WEIGHT="1.3878485297808132"/>
<DICH_DATA CI_END="1.4752159173430712" CI_START="0.3269508564054051" EFFECT_SIZE="0.6944948578342408" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.16885558970261824" LOG_CI_START="-0.48551752072160365" LOG_EFFECT_SIZE="-0.15833096550949274" ORDER="2268" O_E="0.0" SE="0.3843820042623257" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.1477495252007226" WEIGHT="3.2767284425503553"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:44:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="969" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0769114050515256" CI_START="0.06438201903313293" EFFECT_SIZE="0.3656716417910448" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.31741797120150345" LOG_CI_START="-1.1912354078740914" LOG_EFFECT_SIZE="-0.43690871833629397" MODIFIED="2013-04-04 19:22:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="994" O_E="0.0" SE="0.8861904628236723" STUDY_ID="STD-De-Luca-2005" TOTAL_1="69" TOTAL_2="53" VAR="0.7853335363996345" WEIGHT="0.8796176398892528"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2272" O_E="0.0" SE="0.0" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.75751323740641" CI_START="0.12011491133267621" EFFECT_SIZE="2.976470588235294" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8678062658888743" LOG_CI_START="-0.9204030749658237" LOG_EFFECT_SIZE="0.4737015954615252" MODIFIED="2009-12-10 19:20:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="659" O_E="0.0" SE="1.6378079686768805" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="2.6824149422614894" WEIGHT="0.09971470082554022"/>
<DICH_DATA CI_END="1.9298648416669453" CI_START="0.35697372673348626" EFFECT_SIZE="0.8300066533599467" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.28552689420276856" LOG_CI_START="-0.4473637467857298" LOG_EFFECT_SIZE="-0.08091842629148066" ORDER="2283" O_E="0.0" SE="0.4305035903838263" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.18533334133336532" WEIGHT="2.3811501565751763"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:20:31 +0530" MODIFIED_BY="Xavier Bosch" ORDER="942" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-10 21:42:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="662" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0902129935917557" CI_START="0.0046596722490235415" EFFECT_SIZE="0.09868995633187773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32019054315814804" LOG_CI_START="-2.3316446295431223" LOG_EFFECT_SIZE="-1.0057270431924872" MODIFIED="2009-12-10 21:56:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="667" O_E="0.0" SE="1.5577011072405373" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="2.426432739498396" WEIGHT="0.6587417873784618"/>
<DICH_DATA CI_END="1.7313461317694077" CI_START="0.4719660121165727" EFFECT_SIZE="0.903956043956044" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.2383839009719388" LOG_CI_START="-0.3260892752678133" LOG_EFFECT_SIZE="-0.04385268714793728" MODIFIED="2009-12-10 21:51:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="665" O_E="0.0" SE="0.3315743379105168" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.10994154156079758" WEIGHT="3.8356304155736387"/>
<DICH_DATA CI_END="3.3473104987492195" CI_START="0.16552156130414566" EFFECT_SIZE="0.7443467336683417" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5246959996714731" LOG_CI_START="-0.7811454257825281" LOG_EFFECT_SIZE="-0.12822471305552757" MODIFIED="2009-12-10 19:23:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="660" O_E="0.0" SE="0.7670577173309867" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.5883775417170239" WEIGHT="0.7968416813892268"/>
<DICH_DATA CI_END="1.3450633984541422" CI_START="0.05565626122334936" EFFECT_SIZE="0.2736077481840194" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12874275493314666" LOG_CI_START="-1.254485971279109" LOG_EFFECT_SIZE="-0.5628716081729812" MODIFIED="2013-02-28 20:26:57 +0530" MODIFIED_BY="Xavier Bosch" ORDER="850" O_E="0.0" SE="0.8125154008697023" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6601812766504531" WEIGHT="1.3781223384160415"/>
<DICH_DATA CI_END="8.533335321744723" CI_START="0.013826055703629716" EFFECT_SIZE="0.34348561759729274" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9311188117901551" LOG_CI_START="-1.8593016977262402" LOG_EFFECT_SIZE="-0.46409144296804244" MODIFIED="2009-12-10 19:25:57 +0530" MODIFIED_BY="Xavier Bosch" ORDER="661" O_E="0.0" SE="1.6391068200942227" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.6866711676793944" WEIGHT="0.2928836221335844"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-10 21:54:09 +0530" MODIFIED_BY="Xavier Bosch" ORDER="666" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.890840025883355" CI_START="0.6047914710086019" EFFECT_SIZE="2.0414507772020727" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8382721676795183" LOG_CI_START="-0.21839434204391756" LOG_EFFECT_SIZE="0.3099389128178004" MODIFIED="2013-02-28 20:26:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="848" O_E="0.0" SE="0.6206911383951271" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3852574892822388" WEIGHT="0.7689714468267745"/>
<DICH_DATA CI_END="5.34902962456593" CI_START="0.38642155987492577" EFFECT_SIZE="1.4376996805111821" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7282750031576615" LOG_CI_START="-0.412938650699871" LOG_EFFECT_SIZE="0.1576681762288952" MODIFIED="2009-12-10 21:48:12 +0530" MODIFIED_BY="Xavier Bosch" ORDER="664" O_E="0.0" SE="0.6703545493746086" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.4493752218672346" WEIGHT="0.8016996912327994"/>
<DICH_DATA CI_END="17.641513452415772" CI_START="0.0648698527340903" EFFECT_SIZE="1.069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2465358401970499" LOG_CI_START="-1.1879570879930745" LOG_EFFECT_SIZE="0.029289376101987508" MODIFIED="2013-04-05 18:54:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1040" O_E="0.0" SE="1.4300331969532285" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="2.044994944388271" WEIGHT="0.18921084709115218"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.805473910188052" CI_END="0.9251435699588941" CI_START="0.7900714559654035" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8549441661854034" ESTIMABLE="YES" EVENTS_1="1438" EVENTS_2="1586" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.0337908653122188" LOG_CI_START="-0.10233362829426114" LOG_EFFECT_SIZE="-0.06806224680323998" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="6" P_CHI2="0.47604543085527395" P_Q="1.0" P_Z="9.92379883078729E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="32" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11264" TOTAL_2="10284" WEIGHT="100.0" Z="3.892447477676861">
<NAME>6-month urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8958944107333983" CI_START="0.5547221842685097" EFFECT_SIZE="0.704962768092032" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="205" LOG_CI_END="-0.04774317285801856" LOG_CI_START="-0.25592446561071513" LOG_EFFECT_SIZE="-0.15183381923436687" ORDER="2354" O_E="0.0" SE="0.12228672187695304" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.014954042347411265" WEIGHT="11.963795214725412"/>
<DICH_DATA CI_END="1.5411131987860613" CI_START="0.888944331963629" EFFECT_SIZE="1.1704545454545454" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="120" LOG_CI_END="0.18783453995305668" LOG_CI_START="-0.0511254348430495" LOG_EFFECT_SIZE="0.06835455255500357" ORDER="2352" O_E="0.0" SE="0.1403662720661851" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.019702690333758297" WEIGHT="7.033812876944691"/>
<DICH_DATA CI_END="1.0822977170775834" CI_START="0.6895569249655266" EFFECT_SIZE="0.8638899731361789" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="194" LOG_CI_END="0.0343467423776864" LOG_CI_START="-0.16142987571302295" LOG_EFFECT_SIZE="-0.06354156666766828" ORDER="2362" O_E="0.0" SE="0.11500015457637185" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.013225035552589418" WEIGHT="12.200065799664362"/>
<DICH_DATA CI_END="0.8326811201833133" CI_START="0.15679614180968204" EFFECT_SIZE="0.3613325158389536" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.07952128221711992" LOG_CI_START="-0.8046646279486479" LOG_EFFECT_SIZE="-0.442092955082884" ORDER="2361" O_E="0.0" SE="0.42595279080015186" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.18143577999043792" WEIGHT="1.5174800003038083"/>
<DICH_DATA CI_END="1.2686127424011306" CI_START="0.41046685041319086" EFFECT_SIZE="0.7216117216117216" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.10332906929280598" LOG_CI_START="-0.3867219110511323" LOG_EFFECT_SIZE="-0.14169642087916312" ORDER="2355" O_E="0.0" SE="0.2878583716455047" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.08286244212640151" WEIGHT="2.0455426360212923"/>
<DICH_DATA CI_END="1.8988120315378625" CI_START="0.3906343799083346" EFFECT_SIZE="0.861244019138756" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.27848197489693755" LOG_CI_START="-0.40822953691243336" LOG_EFFECT_SIZE="-0.0648737810077479" ORDER="2356" O_E="0.0" SE="0.40337774131363074" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.1627136021872864" WEIGHT="0.9739949361988145"/>
<DICH_DATA CI_END="1.2239193649618252" CI_START="0.6686820411735788" EFFECT_SIZE="0.9046617595513494" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="96" LOG_CI_END="0.08775280628528935" LOG_CI_START="-0.17478034051170438" LOG_EFFECT_SIZE="-0.043513767113207515" ORDER="2357" O_E="0.0" SE="0.1542132699885898" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.023781732640573695" WEIGHT="6.62577902917361"/>
<DICH_DATA CI_END="1.0746307700612487" CI_START="0.07811163916943659" EFFECT_SIZE="0.2897260273972603" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03125927162862725" LOG_CI_START="-1.1072842484474166" LOG_EFFECT_SIZE="-0.5380124884093948" ORDER="2349" O_E="0.0" SE="0.6687860995739869" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.4472748469833867" WEIGHT="0.7289982605179096"/>
<DICH_DATA CI_END="1.064204034826217" CI_START="0.6404199246336706" EFFECT_SIZE="0.8255528255528255" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="148" LOG_CI_END="0.02702490117716406" LOG_CI_START="-0.19353516484791605" LOG_EFFECT_SIZE="-0.08325513183537601" ORDER="2351" O_E="0.0" SE="0.12955807457306703" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.0167852946870804" WEIGHT="9.838929584535272"/>
<DICH_DATA CI_END="1.4018762394893192" CI_START="0.16248884871700733" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.14670967491501172" LOG_CI_START="-0.789176438419548" LOG_EFFECT_SIZE="-0.3212333817522681" ORDER="2363" O_E="0.0" SE="0.5497441356836967" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.3022186147186148" WEIGHT="0.7391711974525469"/>
<DICH_DATA CI_END="1.5771801567298585" CI_START="0.5483507361248292" EFFECT_SIZE="0.9299719887955182" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.19788130436559231" LOG_CI_START="-0.26094156918190614" LOG_EFFECT_SIZE="-0.03153013240815689" ORDER="2348" O_E="0.0" SE="0.26951482713165426" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.07263824204380548" WEIGHT="2.139060649355291"/>
<DICH_DATA CI_END="78.27196626944439" CI_START="0.11498369632134046" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8936062438651577" LOG_CI_START="-0.9393637344258329" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-04-17 21:15:04 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1064" O_E="0.0" SE="1.6641005886756874" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.769230769230769" WEIGHT="0.03562178269319889"/>
<DICH_DATA CI_END="1.1688860250620519" CI_START="0.5927735955328928" EFFECT_SIZE="0.8323970037453183" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="96" LOG_CI_END="0.06777216633738355" LOG_CI_START="-0.2271111497820314" LOG_EFFECT_SIZE="-0.07966949172232393" ORDER="2360" O_E="0.0" SE="0.17321591958450078" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.030003754797504244" WEIGHT="5.4772096848714344"/>
<DICH_DATA CI_END="1.269607706872106" CI_START="0.5309487402340985" EFFECT_SIZE="0.8210338680926916" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="55" LOG_CI_END="0.10366955004316035" LOG_CI_START="-0.27494740529905853" LOG_EFFECT_SIZE="-0.08563892762794909" MODIFIED="2009-12-15 23:08:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2359" O_E="0.0" SE="0.22240147375217478" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.049462415527139286" WEIGHT="3.347989064158822"/>
<DICH_DATA CI_END="1.4752159173430712" CI_START="0.3269508564054051" EFFECT_SIZE="0.6944948578342408" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.16885558970261824" LOG_CI_START="-0.48551752072160365" LOG_EFFECT_SIZE="-0.15833096550949274" ORDER="2350" O_E="0.0" SE="0.3843820042623257" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.1477495252007226" WEIGHT="1.22579084969087"/>
<DICH_DATA CI_END="2.0202926025166335" CI_START="0.18425313828495743" EFFECT_SIZE="0.6101190476190477" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.305414273632577" LOG_CI_START="-0.7345851063007564" LOG_EFFECT_SIZE="-0.2145854163340897" MODIFIED="2013-04-04 18:46:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="973" O_E="0.0" SE="0.6109007838527979" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.37319976771196284" WEIGHT="0.5242795709204144"/>
<DICH_DATA CI_END="1.2710449219595512" CI_START="0.8273272660180548" EFFECT_SIZE="1.025460930640913" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="204" LOG_CI_END="0.10416089989656532" LOG_CI_START="-0.08232266250200475" LOG_EFFECT_SIZE="0.010919118697280301" ORDER="2358" O_E="0.0" SE="0.10954136766144161" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.011999311229139125" WEIGHT="12.327941676625809"/>
<DICH_DATA CI_END="2.421188444141164" CI_START="0.7107482377070651" EFFECT_SIZE="1.3118137900746596" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="0.38402859244285104" LOG_CI_START="-0.14828420846488005" LOG_EFFECT_SIZE="0.11787219198898548" MODIFIED="2009-12-15 22:49:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="696" O_E="0.0" SE="0.31268317424406233" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.09777076745534263" WEIGHT="1.3428398008838962"/>
<DICH_DATA CI_END="3.5672413705482016" CI_START="0.28032866187754585" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5523324960360485" LOG_CI_START="-0.5523324960360485" LOG_EFFECT_SIZE="0.0" ORDER="2353" O_E="0.0" SE="0.6488856845230502" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.4210526315789474" WEIGHT="0.35576113741028126"/>
<DICH_DATA CI_END="5.77937573192896" CI_START="0.418687622791419" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7618809299740814" LOG_CI_START="-0.378109877496255" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2013-04-04 19:28:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1003" O_E="0.0" SE="0.6696362433535825" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.44841269841269843" WEIGHT="0.2696294936162132"/>
<DICH_DATA CI_END="1.7363754549278496" CI_START="0.41332663151848936" EFFECT_SIZE="0.847165991902834" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.2396436381061147" LOG_CI_START="-0.38370661129485095" LOG_EFFECT_SIZE="-0.07203148659436812" MODIFIED="2013-04-04 19:24:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="997" O_E="0.0" SE="0.3661590221316262" STUDY_ID="STD-De-Luca-2005" TOTAL_1="69" TOTAL_2="53" VAR="0.13407242948838874" WEIGHT="1.213087157071123"/>
<DICH_DATA CI_END="1.032685386096504" CI_START="0.6316987638578053" EFFECT_SIZE="0.8076794425087108" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="164" LOG_CI_END="0.013968031206493012" LOG_CI_START="-0.1994899729556546" LOG_EFFECT_SIZE="-0.09276097087458082" ORDER="2364" O_E="0.0" SE="0.12538628827900727" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.015721721288386316" WEIGHT="10.630792486516812"/>
<DICH_DATA CI_END="3.464326476266973" CI_START="0.03578858328997774" EFFECT_SIZE="0.352112676056338" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5396188129527141" LOG_CI_START="-1.4462554930467892" LOG_EFFECT_SIZE="-0.4533183400470377" MODIFIED="2009-12-15 22:50:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="698" O_E="0.0" SE="1.166512397580463" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="1.3607511737089202" WEIGHT="0.21270771163056815"/>
<DICH_DATA CI_END="2.0166422415625695" CI_START="0.053146902198584145" EFFECT_SIZE="0.3273809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.3046288598904091" LOG_CI_START="-1.2745220443536471" LOG_EFFECT_SIZE="-0.484946592231619" MODIFIED="2009-12-15 22:51:15 +0530" MODIFIED_BY="Xavier Bosch" ORDER="700" O_E="0.0" SE="0.9276010580760043" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.8604437229437228" WEIGHT="0.2926211558625569"/>
<DICH_DATA CI_END="5.767582946099541" CI_START="0.4165523101188767" EFFECT_SIZE="1.55" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7609938490144217" LOG_CI_START="-0.3803304526738386" LOG_EFFECT_SIZE="0.1903316981702915" MODIFIED="2013-04-04 18:26:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="947" O_E="0.0" SE="0.6704195444580937" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.44946236559139785" WEIGHT="0.27235302385476073"/>
<DICH_DATA CI_END="1.387435875521921" CI_START="0.0928782314732757" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.14221292004658065" LOG_CI_START="-1.0320860627431032" LOG_EFFECT_SIZE="-0.4449365713482612" MODIFIED="2013-02-28 20:29:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="853" O_E="0.0" SE="0.6897890353643739" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.47580891330891334" WEIGHT="0.5841972361684619"/>
<DICH_DATA CI_END="3.955226875555563" CI_START="0.4588393732155589" EFFECT_SIZE="1.3471502590673574" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.597171400090559" LOG_CI_START="-0.3383393221644707" LOG_EFFECT_SIZE="0.12941603896304418" MODIFIED="2013-02-28 20:27:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="851" O_E="0.0" SE="0.5495236291053651" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3019762189451308" WEIGHT="0.43149661913705756"/>
<DICH_DATA CI_END="0.9484297050211324" CI_START="0.44173922377133823" EFFECT_SIZE="0.6472701149425287" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="76" LOG_CI_END="-0.02299485228480921" LOG_CI_START="-0.35483403630615146" LOG_EFFECT_SIZE="-0.18891444429548035" MODIFIED="2013-03-04 22:07:17 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1560" O_E="0.0" SE="0.19492397932458935" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.03799535771573294" WEIGHT="4.952195032751115"/>
<DICH_DATA CI_END="5.034588321726299" CI_START="0.16259404980062087" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7019639640828441" LOG_CI_START="-0.7888953516450247" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2009-12-15 22:50:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="699" O_E="0.0" SE="0.875738141931184" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.7669172932330826" WEIGHT="0.20515287557755352"/>
<DICH_DATA CI_END="5.7774576728618765" CI_START="0.045989614345266244" EFFECT_SIZE="0.5154639175257731" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7617367724099338" LOG_CI_START="-1.337340232270386" LOG_EFFECT_SIZE="-0.28780172993022607" MODIFIED="2009-12-15 22:50:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="697" O_E="0.0" SE="1.2330082231479704" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="1.5203092783505154" WEIGHT="0.14530033822651486"/>
<DICH_DATA CI_END="17.641513452415772" CI_START="0.0648698527340903" EFFECT_SIZE="1.069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2465358401970499" LOG_CI_START="-1.1879570879930745" LOG_EFFECT_SIZE="0.029289376101987508" MODIFIED="2013-02-28 20:28:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="852" O_E="0.0" SE="1.4300331969532285" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="2.044994944388271" WEIGHT="0.07078185729851749"/>
<DICH_DATA CI_END="5.984006774904314" CI_START="0.4472035769791267" EFFECT_SIZE="1.6358695652173914" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.77699207655124" LOG_CI_START="-0.3494947313826262" LOG_EFFECT_SIZE="0.2137486725843069" MODIFIED="2013-04-10 20:41:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1026" O_E="0.0" SE="0.6617039271799842" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.4378520872454138" WEIGHT="0.2756212601410179"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="63.434751635342366" CI_END="0.7454044540228177" CI_START="0.5734275159878611" CI_STUDY="95" CI_TOTAL="95" DF="38" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6537854575291441" ESTIMABLE="YES" EVENTS_1="1185" EVENTS_2="1334" I2="40.095926884927714" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.12760801653018986" LOG_CI_START="-0.24152147121692263" LOG_EFFECT_SIZE="-0.18456474387355623" METHOD="MH" MODIFIED="2013-04-17 21:15:44 +0530" MODIFIED_BY="Xavier Bosch" NO="7" P_CHI2="0.005954252374132829" P_Q="1.0" P_Z="2.1372260833361804E-10" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="41" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05025971952017493" TOTALS="YES" TOTAL_1="17688" TOTAL_2="13745" WEIGHT="100.0" Z="6.351141782203551">
<NAME>30-day mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8773550134563916" CI_START="0.4381639433212762" EFFECT_SIZE="0.6200204290091931" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="89" LOG_CI_END="-0.056824637891562176" LOG_CI_START="-0.3583633635641983" LOG_EFFECT_SIZE="-0.20759400072788023" ORDER="2301" O_E="0.0" SE="0.17712534010087153" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.0313733861058494" WEIGHT="5.484776449184272"/>
<DICH_DATA CI_END="0.9879383279139586" CI_START="0.012993727708655546" EFFECT_SIZE="0.11330049261083744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.005270165415032944" LOG_CI_START="-1.886266238376207" LOG_EFFECT_SIZE="-0.94576820189562" ORDER="2319" O_E="0.0" SE="1.104906404338122" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.2208181623473977" WEIGHT="0.35225169251905697"/>
<DICH_DATA CI_END="1.6830902987408398" CI_START="0.1692261080684414" EFFECT_SIZE="0.5336879432624113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.22610741674401394" LOG_CI_START="-0.7715326335230119" LOG_EFFECT_SIZE="-0.27271260838949896" ORDER="2307" O_E="0.0" SE="0.5860187039247453" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.3434179213496383" WEIGHT="1.1373247772520945"/>
<DICH_DATA CI_END="8.27984505730735" CI_START="0.08008135658343192" EFFECT_SIZE="0.8142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9180222098058899" LOG_CI_START="-1.0964685784894206" LOG_EFFECT_SIZE="-0.08922318434176543" ORDER="2314" O_E="0.0" SE="1.1833218609348921" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="1.400250626566416" WEIGHT="0.30867710555761985"/>
<DICH_DATA CI_END="1.0175972998729885" CI_START="0.6648465549874352" EFFECT_SIZE="0.822524199756501" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="151" LOG_CI_END="0.00757594593423518" LOG_CI_START="-0.1772785772711139" LOG_EFFECT_SIZE="-0.08485131566843937" ORDER="2308" O_E="0.0" SE="0.10858446197546959" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.0117905853825022" WEIGHT="7.21574754408778"/>
<DICH_DATA CI_END="0.9302489014033002" CI_START="0.4847677080446522" EFFECT_SIZE="0.6715315538709506" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="101" LOG_CI_END="-0.031400834195185426" LOG_CI_START="-0.31446631764768285" LOG_EFFECT_SIZE="-0.17293357592143413" ORDER="2298" O_E="0.0" SE="0.1662740661767383" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.02764706508294634" WEIGHT="5.747116088698802"/>
<DICH_DATA CI_END="1.0028070258903052" CI_START="0.5561629400415707" EFFECT_SIZE="0.7468092820884699" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="112" LOG_CI_END="0.0012173680611100304" LOG_CI_START="-0.25479795375247255" LOG_EFFECT_SIZE="-0.12679029284568125" ORDER="2318" O_E="0.0" SE="0.15038466732958006" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.022615548167828462" WEIGHT="6.143913421056242"/>
<DICH_DATA CI_END="0.5597636840042857" CI_START="0.31607701488665507" EFFECT_SIZE="0.42062861800171364" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="109" LOG_CI_END="-0.25199528083975664" LOG_CI_START="-0.5002070848970208" LOG_EFFECT_SIZE="-0.3761011828683887" ORDER="2302" O_E="0.0" SE="0.14580084237148275" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.021257885636233955" WEIGHT="6.260547095112947"/>
<DICH_DATA CI_END="0.9615712027823643" CI_START="0.25082585419205716" EFFECT_SIZE="0.4911078479360418" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" LOG_CI_END="-0.017018551435328988" LOG_CI_START="-0.6006277000812044" LOG_EFFECT_SIZE="-0.30882312575826665" ORDER="2317" O_E="0.0" SE="0.34281490282646476" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.11752205759991848" WEIGHT="2.66858143295807"/>
<DICH_DATA CI_END="0.72980656649569" CI_START="0.39833821814291026" EFFECT_SIZE="0.5391751545526634" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="87" LOG_CI_END="-0.1367922333528258" LOG_CI_START="-0.399748023662694" LOG_EFFECT_SIZE="-0.26827012850775994" ORDER="2303" O_E="0.0" SE="0.1544615328801714" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.023858365139692264" WEIGHT="6.040891872288604"/>
<DICH_DATA CI_END="1.5784964664456438" CI_START="0.23247208260974708" EFFECT_SIZE="0.6057692307692307" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.19824361403636032" LOG_CI_START="-0.6336291937267576" LOG_EFFECT_SIZE="-0.2176927898451987" ORDER="2304" O_E="0.0" SE="0.4886462051168655" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.2387751137751138" WEIGHT="1.5490843442871924"/>
<DICH_DATA CI_END="1.5334642240539935" CI_START="0.05670127417843977" EFFECT_SIZE="0.2948717948717949" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1856736482825227" LOG_CI_START="-1.2464071816282978" LOG_EFFECT_SIZE="-0.5303667666728875" ORDER="2306" O_E="0.0" SE="0.8412113684040525" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.7076365663322185" WEIGHT="0.5907659709769197"/>
<DICH_DATA CI_END="0.9736848337437168" CI_START="0.20454192202130164" EFFECT_SIZE="0.4462727499376714" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.011581594574893973" LOG_CI_START="-0.6892176674286133" LOG_EFFECT_SIZE="-0.35039963100175364" ORDER="2309" O_E="0.0" SE="0.3980467835469336" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.1584412418920594" WEIGHT="2.145363069636263"/>
<DICH_DATA CI_END="0.8844972494574412" CI_START="0.48308376408692294" EFFECT_SIZE="0.6536713704855298" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="113" LOG_CI_END="-0.05330351328824661" LOG_CI_START="-0.31597755842726144" LOG_EFFECT_SIZE="-0.184640535857754" ORDER="2305" O_E="0.0" SE="0.154296034372151" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.023807266222972003" WEIGHT="6.045059492012844"/>
<DICH_DATA CI_END="2.8344626813240428" CI_START="0.025688929118493718" EFFECT_SIZE="0.2698412698412698" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45247074342198523" LOG_CI_START="-1.5902539995726008" LOG_EFFECT_SIZE="-0.5688916280753078" ORDER="2299" O_E="0.0" SE="1.1999066256855764" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="1.4397759103641457" WEIGHT="0.30048901263263805"/>
<DICH_DATA CI_END="0.8486823956007047" CI_START="0.16742403825503982" EFFECT_SIZE="0.3769480519480519" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.07125480639264883" LOG_CI_START="-0.7761821871310922" LOG_EFFECT_SIZE="-0.42371849676187046" ORDER="2295" O_E="0.0" SE="0.41407783289257327" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.17146045169300983" WEIGHT="2.0193892723494575"/>
<DICH_DATA CI_END="0.8132066598279538" CI_START="0.005930264842171622" EFFECT_SIZE="0.06944444444444445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="-0.0897990733263167" LOG_CI_START="-2.2269259108641823" LOG_EFFECT_SIZE="-1.1583624920952496" ORDER="2316" O_E="0.0" SE="1.2553588833182032" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="1.575925925925926" WEIGHT="0.2753310093870402"/>
<DICH_DATA CI_END="1.9973591253099527" CI_START="0.5026072942057845" EFFECT_SIZE="1.0019417475728156" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3004561580696121" LOG_CI_START="-0.2987712128975713" LOG_EFFECT_SIZE="8.424725860203823E-4" ORDER="2313" O_E="0.0" SE="0.3519891239294485" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="0.12389634336462063" WEIGHT="2.570908688419136"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2321" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.16230046702327577"/>
<DICH_DATA CI_END="1.565956242562915" CI_START="0.057965141015792906" EFFECT_SIZE="0.30128205128205127" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19477962242245186" LOG_CI_START="-1.2368331032599402" LOG_EFFECT_SIZE="-0.5210267404187442" ORDER="2320" O_E="0.0" SE="0.8409364016631203" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.7071740316421168" WEIGHT="0.5911267282773294"/>
<DICH_DATA CI_END="0.9262861126575417" CI_START="0.4368536025279076" EFFECT_SIZE="0.6361221779548473" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="72" LOG_CI_END="-0.033254847058855334" LOG_CI_START="-0.3596640785134194" LOG_EFFECT_SIZE="-0.19645946278613735" ORDER="2297" O_E="0.0" SE="0.19173439830816513" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.03676207949459411" WEIGHT="5.1451399566607625"/>
<DICH_DATA CI_END="0.9558047000345323" CI_START="0.18816296222446746" EFFECT_SIZE="0.42408376963350786" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.019630838228236497" LOG_CI_START="-0.7254658585099191" LOG_EFFECT_SIZE="-0.3725483483690778" ORDER="2294" O_E="0.0" SE="0.4146109848531603" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.1719022687609075" WEIGHT="2.0153732808913483"/>
<DICH_DATA CI_END="16.3090734852818" CI_START="0.055031141163090325" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.212429289571308" LOG_CI_START="-1.2593914812703537" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-17 21:15:44 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1065" O_E="0.0" SE="1.4519597565025428" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.1081871345029235" WEIGHT="0.20743588584396014"/>
<DICH_DATA CI_END="1.6082015976438466" CI_START="0.6849581893064272" EFFECT_SIZE="1.0495479285682157" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.2063404892236446" LOG_CI_START="-0.16433593756989562" LOG_EFFECT_SIZE="0.02100227582687446" ORDER="2310" O_E="0.0" SE="0.2177371679764307" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.0474094743183964" WEIGHT="4.584243174479546"/>
<DICH_DATA CI_END="1.0645455176230145" CI_START="0.292010461245386" EFFECT_SIZE="0.5575467941059339" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="0.02716423564740791" LOG_CI_START="-0.5346015897167767" LOG_EFFECT_SIZE="-0.2537186770346844" ORDER="2296" O_E="0.0" SE="0.3299840266046055" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.108889457814189" WEIGHT="2.8133311319022023"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:44:51 +0530" MODIFIED_BY="Xavier Bosch" ORDER="970" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6809347848852267" CI_START="0.6792424973440371" EFFECT_SIZE="1.34944612286002" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.42828624967517337" LOG_CI_START="-0.1679751499363205" LOG_EFFECT_SIZE="0.13015554986942643" ORDER="2312" O_E="0.0" SE="0.35024689767332146" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12267288932978612" WEIGHT="2.5890972106935353"/>
<DICH_DATA CI_END="2.634116880616915" CI_START="0.37963387553470984" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.42063504149925784" LOG_CI_START="-0.42063504149925784" LOG_EFFECT_SIZE="0.0" ORDER="2300" O_E="0.0" SE="0.4941662111074008" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.2442002442002442" WEIGHT="1.5205440140463558"/>
<DICH_DATA CI_END="1.3662645739289538" CI_START="0.09172161994922402" EFFECT_SIZE="0.354" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.13553480759685635" LOG_CI_START="-1.0375282835452808" LOG_EFFECT_SIZE="-0.4509967379742122" MODIFIED="2009-12-10 19:21:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="669" O_E="0.0" SE="0.6890630664928427" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.47480790960451974" WEIGHT="0.852726982917966"/>
<DICH_DATA CI_END="0.9659913924620098" CI_START="0.542584572743223" EFFECT_SIZE="0.7239696312364425" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="120" LOG_CI_END="-0.015026743380476264" LOG_CI_START="-0.2655325586535567" LOG_EFFECT_SIZE="-0.1402796510170165" ORDER="2311" O_E="0.0" SE="0.14714835591519188" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.021652638648543984" WEIGHT="6.226180681780953"/>
<DICH_DATA CI_END="2.4006588745471547" CI_START="0.1733828554084815" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3803304526738385" LOG_CI_START="-0.7609938490144215" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2013-04-04 18:21:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="943" O_E="0.0" SE="0.6704195444580936" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.4494623655913978" WEIGHT="0.8959766809414154"/>
<DICH_DATA CI_END="0.7840334509694098" CI_START="0.07955354949249081" EFFECT_SIZE="0.24974515800203873" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="-0.10566540764526376" LOG_CI_START="-1.0993404383855683" LOG_EFFECT_SIZE="-0.6025029230154161" MODIFIED="2009-12-10 21:56:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="677" O_E="0.0" SE="0.5836896318275859" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.34069358630302277" WEIGHT="1.1452501578637968"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-12-10 21:43:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="672" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="0.2838001802329752"/>
<DICH_DATA CI_END="1.3640756923992228" CI_START="0.5201194130751116" EFFECT_SIZE="0.8423076923076923" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.1348384699386668" LOG_CI_START="-0.283896936200066" LOG_EFFECT_SIZE="-0.07452923313069962" MODIFIED="2009-12-10 21:51:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="675" O_E="0.0" SE="0.24596725033958133" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.06049988823961427" WEIGHT="4.042442405379664"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-10 21:54:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="676" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.660740130594438" CI_START="0.36112149071683597" EFFECT_SIZE="0.7744216885221747" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.2203016802067009" LOG_CI_START="-0.44234666548618556" LOG_EFFECT_SIZE="-0.11102249263974236" MODIFIED="2009-12-10 21:48:43 +0530" MODIFIED_BY="Xavier Bosch" ORDER="674" O_E="0.0" SE="0.38924291842221453" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.15151004954184277" WEIGHT="2.219060552494211"/>
<DICH_DATA CI_END="4.79000015643427" CI_START="0.9192311686322996" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6803355275979743" LOG_CI_START="-0.03657525832377156" LOG_EFFECT_SIZE="0.32188013463710136" MODIFIED="2013-02-28 20:32:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="854" O_E="0.0" SE="0.4211169444160576" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.17733948087431695" WEIGHT="1.9672271890030157"/>
<DICH_DATA CI_END="0.6497708921999872" CI_START="0.03130765804115496" EFFECT_SIZE="0.14262820512820512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.1872397476541158" LOG_CI_START="-1.5043494184209065" LOG_EFFECT_SIZE="-0.8457945830375112" MODIFIED="2009-12-10 19:26:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="671" O_E="0.0" SE="0.7736767404064332" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.5985756986459234" WEIGHT="0.6900661133402732"/>
<DICH_DATA CI_END="2.767396850752258" CI_START="0.676043157306895" EFFECT_SIZE="1.367801047120419" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.44207144238401824" LOG_CI_START="-0.17002557864125237" LOG_EFFECT_SIZE="0.1360229318713829" MODIFIED="2009-12-10 19:23:57 +0530" MODIFIED_BY="Xavier Bosch" ORDER="670" O_E="0.0" SE="0.359548820079364" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12927535402046286" WEIGHT="2.493882261451518"/>
<DICH_DATA CI_END="0.8972843645247331" CI_START="0.08977486378926258" EFFECT_SIZE="0.2838196286472148" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.04706989990731927" LOG_CI_START="-1.046845245133847" LOG_EFFECT_SIZE="-0.5469575725205833" MODIFIED="2013-02-28 20:33:44 +0530" MODIFIED_BY="Xavier Bosch" ORDER="855" O_E="0.0" SE="0.5872729867538373" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.3448895609707727" WEIGHT="1.133089081308975"/>
<DICH_DATA CI_END="1.9922639043227777" CI_START="0.2970068247722938" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2993468665172843" LOG_CI_START="-0.5272335711309577" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2013-04-05 18:57:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1041" O_E="0.0" SE="0.48553744071373284" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.23574660633484165" WEIGHT="1.5654875250499185"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.325066791346174" CI_END="0.8844731108998903" CI_START="0.7295816334790093" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8033027679639869" ESTIMABLE="YES" EVENTS_1="2258" EVENTS_2="2451" I2="35.1242642298576" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.05331536565455081" LOG_CI_START="-0.1369261074909304" LOG_EFFECT_SIZE="-0.09512073657274057" METHOD="MH" MODIFIED="2013-04-17 21:16:53 +0530" MODIFIED_BY="Xavier Bosch" NO="8" P_CHI2="0.02586498681872873" P_Q="1.0" P_Z="8.213121563016874E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="33" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.021205327620113797" TOTALS="YES" TOTAL_1="11877" TOTAL_2="10555" WEIGHT="100.0" Z="4.459551817643967">
<NAME>6-month mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8592528544555702" CI_START="0.5450820514021844" EFFECT_SIZE="0.6843707391318135" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="244" LOG_CI_END="-0.0658790164531824" LOG_CI_START="-0.263538118293942" LOG_EFFECT_SIZE="-0.16470856737356226" ORDER="2371" O_E="0.0" SE="0.11610593484959623" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.013480588107298686" WEIGHT="6.954184247157964"/>
<DICH_DATA CI_END="1.2849616530516683" CI_START="0.7961437635626567" EFFECT_SIZE="1.011441647597254" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="193" LOG_CI_END="0.10889016726532466" LOG_CI_START="-0.09900850250798449" LOG_EFFECT_SIZE="0.004940832378670084" ORDER="2369" O_E="0.0" SE="0.12212070773985452" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.014913467258882965" WEIGHT="6.678302793820138"/>
<DICH_DATA CI_END="1.0366623011375466" CI_START="0.7026984046560227" EFFECT_SIZE="0.853499235603873" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="290" LOG_CI_END="0.015637305436564705" LOG_CI_START="-0.15323103244523825" LOG_EFFECT_SIZE="-0.06879686350433677" ORDER="2379" O_E="0.0" SE="0.09919409758352499" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.009839468995409877" WEIGHT="7.769812498278844"/>
<DICH_DATA CI_END="1.0168400969205984" CI_START="0.3639765750973116" EFFECT_SIZE="0.6083633584452451" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="43" LOG_CI_END="0.007252663360284221" LOG_CI_START="-0.43892656589308093" LOG_EFFECT_SIZE="-0.21583695126639835" ORDER="2378" O_E="0.0" SE="0.2620878878862317" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.06869006097666595" WEIGHT="2.683254975755912"/>
<DICH_DATA CI_END="0.8116700530689275" CI_START="0.4639625823779702" EFFECT_SIZE="0.6136648383773701" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="98" LOG_CI_END="-0.09062047722722606" LOG_CI_START="-0.33351704298397916" LOG_EFFECT_SIZE="-0.2120687601056026" ORDER="2372" O_E="0.0" SE="0.14267864508290862" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.0203571957626946" WEIGHT="5.803599712369575"/>
<DICH_DATA CI_END="1.5518721055795837" CI_START="0.41553531716075454" EFFECT_SIZE="0.803030303030303" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" LOG_CI_END="0.1908559268901096" LOG_CI_START="-0.3813920587722689" LOG_EFFECT_SIZE="-0.09526806594107966" ORDER="2373" O_E="0.0" SE="0.3361412994512949" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.1129909731968051" WEIGHT="1.7974582554171983"/>
<DICH_DATA CI_END="0.9397155381936182" CI_START="0.5869012263377732" EFFECT_SIZE="0.7426440612934941" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="187" LOG_CI_END="-0.027003592027319622" LOG_CI_START="-0.2314349830214897" LOG_EFFECT_SIZE="-0.12921928752440467" ORDER="2374" O_E="0.0" SE="0.12008401102168147" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.014420169703055315" WEIGHT="6.770775620666149"/>
<DICH_DATA CI_END="0.8958463513146007" CI_START="0.19859971768922444" EFFECT_SIZE="0.42179951690821255" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.04776647080472422" LOG_CI_START="-0.702021373192597" LOG_EFFECT_SIZE="-0.3748939219986606" ORDER="2366" O_E="0.0" SE="0.38431256827663507" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.1476961501353833" WEIGHT="1.4281239688086154"/>
<DICH_DATA CI_END="1.1771634974207843" CI_START="0.015724923278181254" EFFECT_SIZE="0.1360544217687075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07083678662964918" LOG_CI_START="-1.8034114647980388" LOG_EFFECT_SIZE="-0.8662873390841949" ORDER="2381" O_E="0.0" SE="1.100942700567097" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2120748299319728" WEIGHT="0.19558593177125136"/>
<DICH_DATA CI_END="0.7946895041905886" CI_START="0.12187579613009114" EFFECT_SIZE="0.3112128146453089" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.09980252286106286" LOG_CI_START="-0.9140825343393459" LOG_EFFECT_SIZE="-0.5069425286002043" ORDER="2380" O_E="0.0" SE="0.4783121094934074" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.22878247408803337" WEIGHT="0.9648960753350205"/>
<DICH_DATA CI_END="1.12794595413546" CI_START="0.7187539075452365" EFFECT_SIZE="0.9003974467060099" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="190" LOG_CI_END="0.05228829079709292" LOG_CI_START="-0.14341978123000562" LOG_EFFECT_SIZE="-0.04556574521645637" ORDER="2368" O_E="0.0" SE="0.11495989027929837" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.013215776373028319" WEIGHT="7.007684843515723"/>
<DICH_DATA CI_END="117.25632331883436" CI_START="0.2368806042653152" EFFECT_SIZE="5.27027027027027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.069136272354529" LOG_CI_START="-0.6254704977634833" LOG_EFFECT_SIZE="0.721832887295523" MODIFIED="2013-04-17 21:16:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1066" O_E="0.0" SE="1.5828253552859535" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.505336105336105" WEIGHT="0.09547132123124791"/>
<DICH_DATA CI_END="0.9808629342255492" CI_START="0.39709938413492707" EFFECT_SIZE="0.6240994048240577" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="61" LOG_CI_END="-0.008391676685752695" LOG_CI_START="-0.4011007864868856" LOG_EFFECT_SIZE="-0.20474623158631913" ORDER="2365" O_E="0.0" SE="0.23067927503863042" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.053212927932348095" WEIGHT="3.2413047975812272"/>
<DICH_DATA CI_END="1.0645455176230145" CI_START="0.292010461245386" EFFECT_SIZE="0.5575467941059339" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="0.02716423564740791" LOG_CI_START="-0.5346015897167767" LOG_EFFECT_SIZE="-0.2537186770346844" ORDER="2367" O_E="0.0" SE="0.3299840266046055" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.108889457814189" WEIGHT="1.85412695785283"/>
<DICH_DATA CI_END="1.249540537688291" CI_START="0.6583788979122845" EFFECT_SIZE="0.9070121951219512" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="112" LOG_CI_END="0.09675035010532974" LOG_CI_START="-0.18152409739955114" LOG_EFFECT_SIZE="-0.042386873647110725" ORDER="2377" O_E="0.0" SE="0.16345978794509788" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.026719102275056365" WEIGHT="5.033179304948392"/>
<DICH_DATA CI_END="2.524097051528937" CI_START="0.33801890472429086" EFFECT_SIZE="0.9236842105263158" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.40210604951550155" LOG_CI_START="-0.47105900981747373" LOG_EFFECT_SIZE="-0.03447648015098608" MODIFIED="2013-04-04 18:47:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="974" O_E="0.0" SE="0.5129014780889415" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.263067926225821" WEIGHT="0.8485224884383544"/>
<DICH_DATA CI_END="1.3912058332074704" CI_START="0.638564961241306" EFFECT_SIZE="0.94253663003663" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="72" LOG_CI_END="0.1433913899582164" LOG_CI_START="-0.19479491535660595" LOG_EFFECT_SIZE="-0.025701762699194778" ORDER="2376" O_E="0.0" SE="0.19865230979113668" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.039462740185353735" WEIGHT="3.975934251330846"/>
<DICH_DATA CI_END="1.2205425601562463" CI_START="0.8213024295341018" EFFECT_SIZE="1.0012165450121655" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="257" LOG_CI_END="0.08655292780789149" LOG_CI_START="-0.08549689246345253" LOG_EFFECT_SIZE="5.280176722194622E-4" ORDER="2375" O_E="0.0" SE="0.1010629160877332" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.010213713008156202" WEIGHT="7.677263338613347"/>
<DICH_DATA CI_END="2.028553799857179" CI_START="0.48440753721661234" EFFECT_SIZE="0.9912854030501089" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.30718653024160836" LOG_CI_START="-0.314789108001906" LOG_EFFECT_SIZE="-0.0038012888801488382" MODIFIED="2013-04-04 19:25:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="998" O_E="0.0" SE="0.3653515687333043" STUDY_ID="STD-De-Luca-2005" TOTAL_1="69" TOTAL_2="53" VAR="0.1334817687758864" WEIGHT="1.5593559797147867"/>
<DICH_DATA CI_END="1.8488542874945328" CI_START="0.5685373626502128" EFFECT_SIZE="1.0252525252525253" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.26690268474991974" LOG_CI_START="-0.2452409894465561" LOG_EFFECT_SIZE="0.01083084765168183" MODIFIED="2009-12-15 22:52:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="701" O_E="0.0" SE="0.30083572937508357" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.09050213606863854" WEIGHT="2.1593207900763383"/>
<DICH_DATA CI_END="3.2818350259814215" CI_START="0.3047075773411107" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5161167457887658" LOG_CI_START="-0.5161167457887657" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:29:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1004" O_E="0.0" SE="0.6063390625908325" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.36764705882352944" WEIGHT="0.620318293416928"/>
<DICH_DATA CI_END="1.7300298892594128" CI_START="0.35572402673145254" EFFECT_SIZE="0.7844827586206896" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.23805360638214693" LOG_CI_START="-0.4488868001937967" LOG_EFFECT_SIZE="-0.1054165969058249" ORDER="2370" O_E="0.0" SE="0.403512195232563" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.16282209170140205" WEIGHT="1.310740810468013"/>
<DICH_DATA CI_END="0.953751578729526" CI_START="0.6383805812228086" EFFECT_SIZE="0.7802925651135771" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="281" LOG_CI_END="-0.020564730155853063" LOG_CI_START="-0.19492033217744956" LOG_EFFECT_SIZE="-0.10774253116665135" ORDER="2382" O_E="0.0" SE="0.10241734370163527" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.01048931229089889" WEIGHT="7.610506048564018"/>
<DICH_DATA CI_END="3.1749472983095473" CI_START="0.4127383274584887" EFFECT_SIZE="1.144736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5017365207324632" LOG_CI_START="-0.384325200056809" LOG_EFFECT_SIZE="0.058705660337827134" MODIFIED="2013-04-04 18:27:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="948" O_E="0.0" SE="0.5204770408678742" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.2708963500705787" WEIGHT="0.8257817985052488"/>
<DICH_DATA CI_END="1.0778788344356367" CI_START="0.15704313321671678" EFFECT_SIZE="0.4114285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.03256994406638623" LOG_CI_START="-0.8039810485764382" LOG_EFFECT_SIZE="-0.385705552255026" MODIFIED="2009-12-15 22:53:47 +0530" MODIFIED_BY="Xavier Bosch" ORDER="705" O_E="0.0" SE="0.49139419407259377" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.24146825396825397" WEIGHT="0.9182965690391393"/>
<DICH_DATA CI_END="3.4705248704498204" CI_START="0.8202144425463485" EFFECT_SIZE="1.6871794871794872" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.5403951609874541" LOG_CI_START="-0.08607258781254147" LOG_EFFECT_SIZE="0.2271612865874563" MODIFIED="2013-02-28 20:35:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="856" O_E="0.0" SE="0.3679902567104873" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.13541682903385033" WEIGHT="1.5400902011759872"/>
<DICH_DATA CI_END="1.5702368125140274" CI_START="0.7206166975148911" EFFECT_SIZE="1.0637381567614126" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="43" LOG_CI_END="0.1959651547101257" LOG_CI_START="-0.14229567899590428" LOG_EFFECT_SIZE="0.026834737857110703" MODIFIED="2009-12-15 22:53:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="703" O_E="0.0" SE="0.19869608813705356" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.039480135440967755" WEIGHT="3.9747945650020653"/>
<DICH_DATA CI_END="0.6543236827184337" CI_START="0.05126944857789578" EFFECT_SIZE="0.1831578947368421" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.1842073604783508" LOG_CI_START="-1.2901413535341453" LOG_EFFECT_SIZE="-0.737174357006248" MODIFIED="2009-12-15 22:52:37 +0530" MODIFIED_BY="Xavier Bosch" ORDER="702" O_E="0.0" SE="0.6496311019825304" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.42202056866303683" WEIGHT="0.5442196648991025"/>
<DICH_DATA CI_END="1.198304705792229" CI_START="0.6271970198850383" EFFECT_SIZE="0.8669331810394061" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="102" LOG_CI_END="0.07856726481289066" LOG_CI_START="-0.20259601386085985" LOG_EFFECT_SIZE="-0.06201437452398457" MODIFIED="2013-03-04 22:09:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1561" O_E="0.0" SE="0.16515670167363683" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.027276736107714677" WEIGHT="4.97528838920621"/>
<DICH_DATA CI_END="0.9071379885371758" CI_START="0.1290167676353862" EFFECT_SIZE="0.34210526315789475" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.042326645572642096" LOG_CI_START="-0.8893538430473046" LOG_EFFECT_SIZE="-0.4658402443099734" MODIFIED="2013-02-28 20:37:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="858" O_E="0.0" SE="0.49754796864886575" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.24755398110661267" WEIGHT="0.8975028619197868"/>
<DICH_DATA CI_END="4.136431592337159" CI_START="0.195820958697962" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6166258464281339" LOG_CI_START="-0.7081408275494842" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2009-12-15 22:53:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="704" O_E="0.0" SE="0.7781745019952502" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.6055555555555556" WEIGHT="0.38485530163855686"/>
<DICH_DATA CI_END="1.6058163716198053" CI_START="0.25974370533021174" EFFECT_SIZE="0.6458333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.20569588132137684" LOG_CI_START="-0.5854549684040059" LOG_EFFECT_SIZE="-0.1898795435413145" MODIFIED="2013-02-28 20:36:29 +0530" MODIFIED_BY="Xavier Bosch" ORDER="857" O_E="0.0" SE="0.46472592538855656" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.21597018572825025" WEIGHT="1.0170200344228932"/>
<DICH_DATA CI_END="2.95874555117806" CI_START="0.41329613692164313" EFFECT_SIZE="1.1058201058201058" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4711076179247954" LOG_CI_START="-0.38373865404917573" LOG_EFFECT_SIZE="0.043684481937809855" MODIFIED="2013-04-10 20:42:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1027" O_E="0.0" SE="0.5021409317148026" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.25214551530341" WEIGHT="0.8824273090582905"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.8808942357875" CI_END="1.6089626284626561" CI_START="1.2080947987665183" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="OR" EFFECT_SIZE="1.394194886970771" ESTIMABLE="YES" EVENTS_1="541" EVENTS_2="311" I2="11.802885310715011" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.20654595681441917" LOG_CI_START="0.08210101455483776" LOG_EFFECT_SIZE="0.14432348568462847" METHOD="MH" MODIFIED="2013-09-05 16:36:37 +0530" MODIFIED_BY="Xavier Bosch" NO="9" P_CHI2="0.28256910889637643" P_Q="0.6626464553581235" P_Z="5.4652173690073315E-6" Q="0.19032477482540888" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="40" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17618" TOTAL_2="13812" WEIGHT="99.99999999999997" Z="4.546088076044326">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="28.712081356416824" CI_END="1.604687423272118" CI_START="1.185024507949399" DF="22" EFFECT_SIZE="1.3789829310675425" ESTIMABLE="YES" EVENTS_1="488" EVENTS_2="277" I2="23.377202345927287" ID="CMP-001.09.01" LOG_CI_END="0.20539044884766774" LOG_CI_START="0.07372733225086792" LOG_EFFECT_SIZE="0.13955889054926784" MODIFIED="2013-04-05 18:58:45 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.15326612751312219" P_Z="3.252816108444593E-5" STUDIES="27" TAU2="0.0" TOTAL_1="15382" TOTAL_2="11655" WEIGHT="89.85449335391851" Z="4.155004169263006">
<NAME>Blinded studies with a placebo group</NAME>
<DICH_DATA CI_END="3.314863102592244" CI_START="1.5917734487238189" EFFECT_SIZE="2.2970657528378666" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="46" LOG_CI_END="0.5204655975925502" LOG_CI_START="0.20188125625936182" LOG_EFFECT_SIZE="0.36117342692595605" ORDER="2330" O_E="0.0" SE="0.1871380191170383" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.03502063819904899" WEIGHT="12.249780544183118"/>
<DICH_DATA CI_END="3.167699031428313" CI_START="0.03040500724782702" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5007439118066108" LOG_CI_START="-1.5170548887258732" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="2345" O_E="0.0" SE="1.1852650036979324" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.40485312899106" WEIGHT="0.8902014432729346"/>
<DICH_DATA CI_END="2.2866509402138306" CI_START="0.15014217861959508" EFFECT_SIZE="0.5859375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.35919987413497284" LOG_CI_START="-0.8234972866473095" LOG_EFFECT_SIZE="-0.23214870625616832" ORDER="2335" O_E="0.0" SE="0.6947221666888778" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.4826388888888889" WEIGHT="1.5716659963991122"/>
<DICH_DATA CI_END="1.4106838314975623" CI_START="0.5590979231770411" EFFECT_SIZE="0.8880936890045543" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="29" LOG_CI_END="0.14942968872097434" LOG_CI_START="-0.25251212096691494" LOG_EFFECT_SIZE="-0.051541216122970294" ORDER="2331" O_E="0.0" SE="0.2361026086547127" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.05574444181356042" WEIGHT="11.490995707577566"/>
<DICH_DATA CI_END="2.1886542810760448" CI_START="0.957306708003668" EFFECT_SIZE="1.4474852071005917" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="40" LOG_CI_END="0.34017716600892445" LOG_CI_START="-0.018948897904156315" LOG_EFFECT_SIZE="0.16061413405238403" ORDER="2344" O_E="0.0" SE="0.21095242764523042" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.044500926729416176" WEIGHT="11.630585301470544"/>
<DICH_DATA CI_END="1.495281509701739" CI_START="0.8003510976705752" EFFECT_SIZE="1.0939607843137256" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="60" LOG_CI_END="0.17472296296202838" LOG_CI_START="-0.09671945509409843" LOG_EFFECT_SIZE="0.03900175393396498" ORDER="2336" O_E="0.0" SE="0.15944662002780857" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.025423224638292368" WEIGHT="23.42433929327698"/>
<DICH_DATA CI_END="4.14843312209715" CI_START="1.0190763976070794" EFFECT_SIZE="2.056105610561056" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.6178840931164504" LOG_CI_START="0.00820674319727878" LOG_EFFECT_SIZE="0.3130454181568646" ORDER="2326" O_E="0.0" SE="0.3581274932940764" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.12825530145309874" WEIGHT="3.5292598585148047"/>
<DICH_DATA CI_END="3.6142617822240544" CI_START="0.07145398719235442" EFFECT_SIZE="0.5081863979848866" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.558019605462861" LOG_CI_START="-1.145973532200875" LOG_EFFECT_SIZE="-0.2939769633690071" ORDER="2332" O_E="0.0" SE="1.0009340039657464" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="1.0018688802949007" WEIGHT="0.8127753758993951"/>
<DICH_DATA CI_END="3.2759534767807224" CI_START="1.0960306519268834" EFFECT_SIZE="1.8948734587929916" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="23" LOG_CI_END="0.5153377255301146" LOG_CI_START="0.039822699929883416" LOG_EFFECT_SIZE="0.277580212729999" ORDER="2343" O_E="0.0" SE="0.2793198798749147" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.07801959529333677" WEIGHT="5.876206571358288"/>
<DICH_DATA CI_END="9.932499875628727" CI_START="1.048980971085676" EFFECT_SIZE="3.2278481012658227" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9970585682893176" LOG_CI_START="0.02076760999770986" LOG_EFFECT_SIZE="0.5089130891435137" ORDER="2333" O_E="0.0" SE="0.5734781416186749" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.328877178914409" WEIGHT="1.2219151059092541"/>
<DICH_DATA CI_END="7.506992811000863" CI_START="0.011117206613167119" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87546599996867" LOG_CI_START="-1.9540043229056838" LOG_EFFECT_SIZE="-0.5392691614685069" ORDER="2327" O_E="0.0" SE="1.6620448737603812" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.762393162393162" WEIGHT="0.4709137728912468"/>
<DICH_DATA CI_END="75.7329305966302" CI_START="0.12368872278442308" EFFECT_SIZE="3.0606060606060606" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8792847628106097" LOG_CI_START="-0.9076698950010998" LOG_EFFECT_SIZE="0.4858074339047551" ORDER="2323" O_E="0.0" SE="1.6370709616466477" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="2.68000133346668" WEIGHT="0.1509418980658036"/>
<DICH_DATA CI_END="2.4881828163165496" CI_START="0.008820844535940005" EFFECT_SIZE="0.14814814814814814" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.39588228646919893" LOG_CI_START="-2.0544898321312486" LOG_EFFECT_SIZE="-0.829303772831025" ORDER="2342" O_E="0.0" SE="1.4393607120035128" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="2.0717592592592595" WEIGHT="0.5262274541514884"/>
<DICH_DATA CI_END="15.120249715113221" CI_START="0.0557794083969631" EFFECT_SIZE="0.9183673469387755" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1795589637181094" LOG_CI_START="-1.2535260962244492" LOG_EFFECT_SIZE="-0.036983566253169974" ORDER="2347" O_E="0.0" SE="1.429206208175548" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.042630385487528" WEIGHT="0.3133611402325704"/>
<DICH_DATA CI_END="3.682945930385523" CI_START="0.030056409395846417" EFFECT_SIZE="0.33271028037383177" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5661953429907868" LOG_CI_START="-1.5220629024154557" LOG_EFFECT_SIZE="-0.47793377971233447" ORDER="2341" O_E="0.0" SE="1.2266532303966553" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="1.5046781476425497" WEIGHT="0.7347956061884133"/>
<DICH_DATA CI_END="3.7015192534081667" CI_START="0.6135687571429665" EFFECT_SIZE="1.507029053420806" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.568380012701654" LOG_CI_START="-0.21213676272572884" LOG_EFFECT_SIZE="0.17812162498796255" ORDER="2338" O_E="0.0" SE="0.4584794175063947" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.21020337627700297" WEIGHT="2.427292175425331"/>
<DICH_DATA CI_END="6.001482304785" CI_START="0.2962231141397101" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7782585299305445" LOG_CI_START="-0.5283810567139446" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="2340" O_E="0.0" SE="0.7675265611652409" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.5890970220941403" WEIGHT="0.9117022012367799"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2324" O_E="0.0" SE="0.0" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-10 19:21:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="679" O_E="0.0" SE="0.0" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1042808924914613" CI_START="0.47331893929655383" EFFECT_SIZE="0.9979959919839679" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32310371167784774" LOG_CI_START="-0.32484611740519254" LOG_EFFECT_SIZE="-8.712028636723787E-4" MODIFIED="2010-05-17 23:17:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2339" O_E="0.0" SE="0.3806089370067602" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.14486316292941592" WEIGHT="4.242264253695366"/>
<DICH_DATA CI_END="8.887695683575577" CI_START="0.014285508586923415" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9487891758600732" LOG_CI_START="-1.8451042934287647" LOG_EFFECT_SIZE="-0.4481575587843458" MODIFIED="2009-12-16 23:39:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="734" O_E="0.0" SE="1.6411468538559837" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="2.693362995921394" WEIGHT="0.4392441331938823"/>
<DICH_DATA CI_END="16.330717844801725" CI_START="0.061234295363097754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213005275317456" LOG_CI_START="-1.213005275317456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:22:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="944" O_E="0.0" SE="1.4250506063888506" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.0307692307692307" WEIGHT="0.3023150146956152"/>
<DICH_DATA CI_END="2.793753964807843" CI_START="0.6856670030823098" EFFECT_SIZE="1.3840465701699183" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.4461881568135316" LOG_CI_START="-0.16388674994265123" LOG_EFFECT_SIZE="0.14115070343544017" MODIFIED="2009-12-10 21:52:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="685" O_E="0.0" SE="0.35836102014807486" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.1284226207615689" WEIGHT="4.107528401773338"/>
<DICH_DATA CI_END="13.83872288303058" CI_START="0.14849992216190167" EFFECT_SIZE="1.4335443037974684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1410960127764698" LOG_CI_START="-0.8282737739876136" LOG_EFFECT_SIZE="0.1564111193944281" MODIFIED="2009-12-10 21:49:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="684" O_E="0.0" SE="1.1568175612828895" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="1.3382268700924915" WEIGHT="0.41365143162156803"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-05 18:58:45 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1042" O_E="0.0" SE="0.0" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-10 19:18:09 +0530" MODIFIED_BY="Xavier Bosch" ORDER="678" O_E="0.0" SE="0.0" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.862927770247001" CI_START="0.34575566077574593" EFFECT_SIZE="0.9949238578680203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.45681039120048" LOG_CI_START="-0.4612307008107137" LOG_EFFECT_SIZE="-0.002210154805116882" MODIFIED="2009-12-10 19:24:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="680" O_E="0.0" SE="0.5392618818240714" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.2908033771884388" WEIGHT="2.1165306728851325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.0597520049835" CI_END="2.369780783136273" CI_START="0.9864198463421663" DF="6" EFFECT_SIZE="1.5289207945364276" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="34" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.37470817340352963" LOG_CI_START="-0.005938198506625928" LOG_EFFECT_SIZE="0.18438498744845183" MODIFIED="2013-09-05 16:36:37 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.6685904937447404" P_Z="0.05758920900360068" STUDIES="13" TAU2="0.0" TOTAL_1="2236" TOTAL_2="2157" WEIGHT="10.145506646081454" Z="1.8988119228633258">
<NAME>Non-blinded studies and without placebo</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:40:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="874" O_E="0.0" SE="0.0" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0976802499127216" CI_START="0.2795342622396157" EFFECT_SIZE="0.7657502863688431" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.32173928925237827" LOG_CI_START="-0.5535649534675113" LOG_EFFECT_SIZE="-0.11591283210756652" MODIFIED="2010-04-22 21:40:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="875" O_E="0.0" SE="0.5141580449995434" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.2643584952377525" WEIGHT="2.673130484056314"/>
<DICH_DATA CI_END="5.2290966529281615" CI_START="0.41398747442575456" EFFECT_SIZE="1.47131931166348" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7184266692623242" LOG_CI_START="-0.3830127986618777" LOG_EFFECT_SIZE="0.1677069353002233" MODIFIED="2010-04-22 21:41:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="869" O_E="0.0" SE="0.6469909956719746" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.41859734848061303" WEIGHT="1.2337615815873193"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:41:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="879" O_E="0.0" SE="0.0" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:23:42 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1076" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.553023019892206" CI_START="0.387065443325746" EFFECT_SIZE="1.1727115716753023" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5505980212747973" LOG_CI_START="-0.4122156001686663" LOG_EFFECT_SIZE="0.0691912105530655" MODIFIED="2010-04-22 21:41:41 +0530" MODIFIED_BY="Xavier Bosch" ORDER="868" O_E="0.0" SE="0.5655614872401817" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.3198597958493263" WEIGHT="1.7773332263966524"/>
<DICH_DATA CI_END="10.924023369377402" CI_START="0.723640154774154" EFFECT_SIZE="2.8115942028985508" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.038382620539537" LOG_CI_START="-0.14047734215359553" LOG_EFFECT_SIZE="0.44895263919297074" MODIFIED="2010-04-22 21:42:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="870" O_E="0.0" SE="0.6924681775368743" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.4795121769012401" WEIGHT="0.8472262011838964"/>
<DICH_DATA CI_END="15.145884842133626" CI_START="0.1566937278201711" EFFECT_SIZE="1.5405405405405406" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1802946504539946" LOG_CI_START="-0.8049483872430017" LOG_EFFECT_SIZE="0.18767313160549642" MODIFIED="2010-05-17 23:20:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2173" O_E="0.0" SE="1.1661415874547418" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="1.3598862019914653" WEIGHT="0.39620032158498697"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:43:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="872" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-22 21:43:43 +0530" MODIFIED_BY="Xavier Bosch" ORDER="878" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="147.36553289489572" CI_START="0.38303737170923763" EFFECT_SIZE="7.513089005235602" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.168395918910134" LOG_CI_START="-0.41675885126556694" LOG_EFFECT_SIZE="0.8758185338222836" MODIFIED="2010-04-22 21:43:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="871" O_E="0.0" SE="1.518532708723702" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.3059415874637432" WEIGHT="0.145125021906052"/>
<DICH_DATA CI_END="3.853603594794696" CI_START="0.8260906671731362" EFFECT_SIZE="1.7842157842157842" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5858670384337318" LOG_CI_START="-0.08297228428731374" LOG_EFFECT_SIZE="0.25144737707320897" MODIFIED="2013-02-28 20:38:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="859" O_E="0.0" SE="0.39287952897438555" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.15435432428713505" WEIGHT="3.072729809366233"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-28 20:38:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="860" O_E="0.0" SE="0.0" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-04-17 21:25:09 +0530" MODIFIED_BY="Xavier Bosch" NO="2">
<NAME>Subgroup of PCI in patients with stable CAD</NAME>
<DICH_OUTCOME CHI2="1.100611461537064" CI_END="1.4648262716835834" CI_START="0.3414755150114101" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7072498183282873" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" I2_Q="99.99999999999999" ID="CMP-002.01" LOG_CI_END="0.16578612044225682" LOG_CI_START="-0.46664043129917343" LOG_EFFECT_SIZE="-0.1504271554284583" METHOD="MH" MODIFIED="2013-04-17 21:17:32 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.9815091827549275" P_Q="0.0" P_Z="0.3511387621521963" Q="2.2328784086089138E-32" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3266" TOTAL_2="3153" WEIGHT="100.00000000000001" Z="0.9323827600999591">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.908679956389632" CI_START="0.01254512355454697" EFFECT_SIZE="0.3149847094801223" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8981040011339438" LOG_CI_START="-1.9015250570441715" LOG_EFFECT_SIZE="-0.501710527955114" ORDER="2492" O_E="0.0" SE="1.6445159671611682" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="2.7044327662480327" WEIGHT="8.665152596018894"/>
<DICH_DATA CI_END="2.3282392489212675" CI_START="0.18431722399516723" EFFECT_SIZE="0.6550836550836551" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.36702760619586355" LOG_CI_START="-0.7344340791241746" LOG_EFFECT_SIZE="-0.18370323646415554" ORDER="2491" O_E="0.0" SE="0.6470040462802666" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.4186142359030375" WEIGHT="34.47573407522089"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2489" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2495" O_E="0.0" SE="0.0" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2496" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:17:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1067" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.9744715717384125" CI_START="0.19987271343101215" EFFECT_SIZE="0.9971264367816092" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6967469532893872" LOG_CI_START="-0.6992464916008017" LOG_EFFECT_SIZE="-0.001249769155707207" ORDER="2494" O_E="0.0" SE="0.8200134598074966" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.672422074265461" WEIGHT="17.04883430845969"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:47:59 +0530" MODIFIED_BY="Xavier Bosch" ORDER="975" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.970205306279777" CI_START="0.201573081602601" EFFECT_SIZE="1.0009293680297398" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6963743286815872" LOG_CI_START="-0.6955674647463649" LOG_EFFECT_SIZE="4.0343196761120383E-4" ORDER="2493" O_E="0.0" SE="0.8176334996825806" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.6685245398031845" WEIGHT="17.11563802266873"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2490" O_E="0.0" SE="0.0" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.315037261213861" CI_START="0.013362671461425384" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9198641997134829" LOG_CI_START="-1.8741067091528076" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-12-17 20:17:49 +0530" MODIFIED_BY="Xavier Bosch" ORDER="734" O_E="0.0" SE="1.6411923422471113" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="2.6935123042505595" WEIGHT="8.471938488069508"/>
<DICH_DATA CI_END="16.330717844801725" CI_START="0.061234295363097754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213005275317456" LOG_CI_START="-1.213005275317456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:28:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="949" O_E="0.0" SE="1.4250506063888506" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.0307692307692307" WEIGHT="5.637046726350907"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:17:30 +0530" MODIFIED_BY="Xavier Bosch" ORDER="733" O_E="0.0" SE="0.0" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.132763947030567" CI_START="0.013252828875088381" EFFECT_SIZE="0.3283018867924528" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910238167112663" LOG_CI_START="-1.877691409749042" LOG_EFFECT_SIZE="-0.48372662131818933" MODIFIED="2009-12-17 20:17:09 +0530" MODIFIED_BY="Xavier Bosch" ORDER="732" O_E="0.0" SE="1.6376436339225422" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="2.6818766717270295" WEIGHT="8.585655783211381"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:18:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="735" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.353740367387777" CI_END="1.2217955347721505" CI_START="0.6273501711043491" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8754962237461897" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.08699853360712262" LOG_CI_START="-0.20248997922102874" LOG_EFFECT_SIZE="-0.05774572280695306" METHOD="MH" MODIFIED="2013-04-17 21:25:09 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.9299815178993666" P_Q="1.0" P_Z="0.43425709820869374" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3170" TOTAL_2="3153" WEIGHT="100.0" Z="0.7819276547947019">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3388595129904626" CI_START="0.23359968181134735" EFFECT_SIZE="0.5592469545957918" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1267350087267564" LOG_CI_START="-0.6315277531164453" LOG_EFFECT_SIZE="-0.25239637219484445" ORDER="2506" O_E="0.0" SE="0.44540729976790283" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.19838766268653443" WEIGHT="18.899811013111826"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2510" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="2.086968927468252"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:25:09 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1068" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5573678239082727" CI_START="0.500577314151068" EFFECT_SIZE="0.8829399766899767" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.19239119768551802" LOG_CI_START="-0.3005288362344995" LOG_EFFECT_SIZE="-0.05406881927449073" ORDER="2507" O_E="0.0" SE="0.2895436679181379" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.08383553563148893" WEIGHT="34.33555291312104"/>
<DICH_DATA CI_END="41.50906567302496" CI_START="0.48031106126703915" EFFECT_SIZE="4.465116279069767" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6181429579601554" LOG_CI_START="-0.3184774117122293" LOG_EFFECT_SIZE="0.649832773123963" MODIFIED="2013-04-04 18:50:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="980" O_E="0.0" SE="1.1375803915709966" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="1.2940891472868217" WEIGHT="1.2093629070890008"/>
<DICH_DATA CI_END="2.7941731204946523" CI_START="0.44551088293209834" EFFECT_SIZE="1.11572153065929" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4462533104919537" LOG_CI_START="-0.3511416825594777" LOG_EFFECT_SIZE="0.04755581396623803" ORDER="2508" O_E="0.0" SE="0.46839376608728556" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.21939272010943078" WEIGHT="11.665819603710744"/>
<DICH_DATA CI_END="1.853129240597719" CI_START="0.4755874190312977" EFFECT_SIZE="0.9387890884896873" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.26790570886079224" LOG_CI_START="-0.32276964252591284" LOG_EFFECT_SIZE="-0.0274319668325603" ORDER="2509" O_E="0.0" SE="0.3469656252946958" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12038514513613925" WEIGHT="23.15583122291182"/>
<DICH_DATA CI_END="5.547508069852916" CI_START="0.044159467542199585" EFFECT_SIZE="0.494949494949495" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7440979426643058" LOG_CI_START="-1.3549761718023785" LOG_EFFECT_SIZE="-0.3054391145690362" ORDER="2505" O_E="0.0" SE="1.2330065254221743" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="1.5203050917336631" WEIGHT="2.672973271854387"/>
<DICH_DATA CI_END="16.330717844801725" CI_START="0.061234295363097754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213005275317456" LOG_CI_START="-1.213005275317456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:31:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="954" O_E="0.0" SE="1.4250506063888506" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.0307692307692307" WEIGHT="1.329532160013278"/>
<DICH_DATA CI_END="8.533335321744723" CI_START="0.013826055703629716" EFFECT_SIZE="0.34348561759729274" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9311188117901551" LOG_CI_START="-1.8593016977262402" LOG_EFFECT_SIZE="-0.46409144296804244" MODIFIED="2009-12-17 20:27:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="752" O_E="0.0" SE="1.6391068200942227" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.6866711676793944" WEIGHT="1.9748564902314514"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2009-12-17 20:27:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="753" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="1.349986500936559"/>
<DICH_DATA CI_END="16.508125798938536" CI_START="0.06057622846951526" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2176977697266207" LOG_CI_START="-1.2176977697266207" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-28 20:45:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="862" O_E="0.0" SE="1.4305633952771812" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="44" VAR="2.046511627906977" WEIGHT="1.3193049895516373"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.601310337860397" CI_END="0.8431007781865615" CI_START="0.550340261246271" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6811698044717827" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="216" I2="27.716549141104853" I2_Q="100.0" ID="CMP-002.03" LOG_CI_END="-0.0741205098421671" LOG_CI_START="-0.25936871434223135" LOG_EFFECT_SIZE="-0.16674461209219923" METHOD="MH" MODIFIED="2013-04-17 21:18:47 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.16522006023918456" P_Q="0.0" P_Z="4.1810457302983146E-4" Q="2.6024191713962627E-31" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3266" TOTAL_2="3153" WEIGHT="99.99999999999999" Z="3.528384366248463">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5334642240539935" CI_START="0.05670127417843977" EFFECT_SIZE="0.2948717948717949" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1856736482825227" LOG_CI_START="-1.2464071816282978" LOG_EFFECT_SIZE="-0.5303667666728875" ORDER="2500" O_E="0.0" SE="0.8412113684040525" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.7076365663322185" WEIGHT="2.8424780151200473"/>
<DICH_DATA CI_END="2.2958317839925195" CI_START="0.005377431873896343" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3609400640568862" LOG_CI_START="-2.269425082935536" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="2497" O_E="0.0" SE="1.5450895078608187" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.387301587301587" WEIGHT="1.7284080150943033"/>
<DICH_DATA CI_END="0.8388568957696354" CI_START="0.44232860120015605" EFFECT_SIZE="0.6091390623764724" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="104" LOG_CI_END="-0.07631212102880706" LOG_CI_START="-0.3542549780126941" LOG_EFFECT_SIZE="-0.21528354952075057" ORDER="2499" O_E="0.0" SE="0.16326501003166657" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.026655463500640183" WEIGHT="47.346172080660764"/>
<DICH_DATA CI_END="2.4881828163165496" CI_START="0.008820844535940005" EFFECT_SIZE="0.14814814814814814" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.39588228646919893" LOG_CI_START="-2.0544898321312486" LOG_EFFECT_SIZE="-0.829303772831025" ORDER="2503" O_E="0.0" SE="1.4393607120035128" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="2.0717592592592595" WEIGHT="0.827754586820673"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2504" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.7464572613293571"/>
<DICH_DATA CI_END="16.3090734852818" CI_START="0.055031141163090325" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.212429289571308" LOG_CI_START="-1.2593914812703537" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-17 21:18:47 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1069" O_E="0.0" SE="1.4519597565025428" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.1081871345029235" WEIGHT="0.4704758976373911"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:48:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="976" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5829481218694044" CI_START="0.6647323957684306" EFFECT_SIZE="1.0257859900717043" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.19946668191539413" LOG_CI_START="-0.17735315534557233" LOG_EFFECT_SIZE="0.011056763284910887" ORDER="2501" O_E="0.0" SE="0.2213458376953691" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.04899397986506469" WEIGHT="19.46277621369368"/>
<DICH_DATA CI_END="2.6510797996207787" CI_START="0.6348282227549744" EFFECT_SIZE="1.2972972972972974" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.4234228005408498" LOG_CI_START="-0.19734377392366526" LOG_EFFECT_SIZE="0.11303951330859224" ORDER="2502" O_E="0.0" SE="0.36464135868455794" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.13296332046332043" WEIGHT="6.422478170781228"/>
<DICH_DATA CI_END="2.293535365340421" CI_START="0.3454473074383324" EFFECT_SIZE="0.8901098901098901" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.360505441155937" LOG_CI_START="-0.46161818804082483" LOG_EFFECT_SIZE="-0.050556373442443875" ORDER="2498" O_E="0.0" SE="0.4829194893677757" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.2332112332112332" WEIGHT="4.39399726503974"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-12-17 20:19:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="738" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="0.9462697849337002"/>
<DICH_DATA CI_END="2.4006588745471547" CI_START="0.1733828554084815" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3803304526738385" LOG_CI_START="-0.7609938490144215" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2013-04-04 18:29:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="950" O_E="0.0" SE="0.6704195444580936" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.4494623655913978" WEIGHT="2.7215567475770617"/>
<DICH_DATA CI_END="0.9416889999817076" CI_START="0.11495840288142405" EFFECT_SIZE="0.32902137232845896" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.026092502613264228" LOG_CI_START="-0.9394592784907644" LOG_EFFECT_SIZE="-0.4827758905520144" MODIFIED="2009-12-17 20:19:26 +0530" MODIFIED_BY="Xavier Bosch" ORDER="736" O_E="0.0" SE="0.5365161653889019" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.2878495957236115" WEIGHT="6.528665137877121"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:20:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="739" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7175025470338756" CI_START="0.03402644715468491" EFFECT_SIZE="0.15625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.14417655290645223" LOG_CI_START="-1.4681833950613221" LOG_EFFECT_SIZE="-0.8061799739838872" MODIFIED="2009-12-17 20:19:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="737" O_E="0.0" SE="0.7777281730213398" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.6048611111111111" WEIGHT="5.562510823434923"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.365431928616486" CI_END="0.9210754184576263" CI_START="0.6397114481528967" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7676082919038613" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="287" I2="28.410733579746186" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.03570480793671405" LOG_CI_START="-0.19401587716247026" LOG_EFFECT_SIZE="-0.11486034254959214" METHOD="MH" MODIFIED="2013-04-17 21:19:22 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.1663710634161788" P_Q="1.0" P_Z="0.004454434612391772" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3170" TOTAL_2="3156" WEIGHT="100.0" Z="2.8440479336047377">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8403905395532184" CI_START="0.46115857362075363" EFFECT_SIZE="0.6225377920293175" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="118" LOG_CI_END="-0.07551884517964914" LOG_CI_START="-0.3361497127736406" LOG_EFFECT_SIZE="-0.20583427897664486" ORDER="2512" O_E="0.0" SE="0.15309586176831233" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.0234383428905822" WEIGHT="41.44216123188654"/>
<DICH_DATA CI_END="1.490417290079542" CI_START="0.018790038269107676" EFFECT_SIZE="0.1673469387755102" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.17330788009442707" LOG_CI_START="-1.7260723353840213" LOG_EFFECT_SIZE="-0.7763822276447969" ORDER="2516" O_E="0.0" SE="1.115705340655742" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2447984071677451" WEIGHT="1.9230468329483277"/>
<DICH_DATA CI_END="117.25632331883436" CI_START="0.2368806042653152" EFFECT_SIZE="5.27027027027027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.069136272354529" LOG_CI_START="-0.6254704977634833" LOG_EFFECT_SIZE="0.721832887295523" MODIFIED="2013-04-17 21:19:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1070" O_E="0.0" SE="1.5828253552859535" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.505336105336105" WEIGHT="0.17000155178278895"/>
<DICH_DATA CI_END="1.6375543683499472" CI_START="0.5635675410031722" EFFECT_SIZE="0.9606625258799172" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.21419572788971358" LOG_CI_START="-0.24905402828297613" LOG_EFFECT_SIZE="-0.017429150196631278" ORDER="2515" O_E="0.0" SE="0.27211519989911404" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.07404668201613479" WEIGHT="10.38374748029323"/>
<DICH_DATA CI_END="2.55497240607456" CI_START="0.684418996161148" EFFECT_SIZE="1.3223734908810685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.40738621407767245" LOG_CI_START="-0.16467794504929822" LOG_EFFECT_SIZE="0.12135413451418711" ORDER="2514" O_E="0.0" SE="0.3360333188344404" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.11291839136688867" WEIGHT="5.8435356271575944"/>
<DICH_DATA CI_END="1.3325825657155022" CI_START="0.662004293235404" EFFECT_SIZE="0.9392419175027871" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="69" LOG_CI_END="0.12469412705977545" LOG_CI_START="-0.17913919406120712" LOG_EFFECT_SIZE="-0.027222533500715847" ORDER="2513" O_E="0.0" SE="0.17847319682566087" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.03185268198517109" WEIGHT="24.41908648665769"/>
<DICH_DATA CI_END="6.744525616085399" CI_START="0.30165103303213875" EFFECT_SIZE="1.426356589147287" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8289514084835862" LOG_CI_START="-0.520495183063011" LOG_EFFECT_SIZE="0.15422811271028752" MODIFIED="2013-04-04 18:50:47 +0530" MODIFIED_BY="Xavier Bosch" ORDER="981" O_E="0.0" SE="0.7926716077428309" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.6283282777216043" WEIGHT="1.012543026327895"/>
<DICH_DATA CI_END="1.7846508327367492" CI_START="0.30982290576356214" EFFECT_SIZE="0.7435897435897436" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.25155325896414527" LOG_CI_START="-0.5088864772192315" LOG_EFFECT_SIZE="-0.1286666091275431" ORDER="2511" O_E="0.0" SE="0.44668606527151844" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.19952844090775124" WEIGHT="4.40809429136237"/>
<DICH_DATA CI_END="4.0612089439834165" CI_START="0.10604331578113421" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6086553339580679" LOG_CI_START="-0.9745167011300413" LOG_EFFECT_SIZE="-0.18293068358598671" MODIFIED="2013-04-04 18:32:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="955" O_E="0.0" SE="0.9299630902387197" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.8648313492063491" WEIGHT="1.0960296606340003"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2009-12-17 20:28:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="755" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="0.37676019584293763"/>
<DICH_DATA CI_END="0.6497708921999872" CI_START="0.03130765804115496" EFFECT_SIZE="0.14262820512820512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.1872397476541158" LOG_CI_START="-1.5043494184209065" LOG_EFFECT_SIZE="-0.8457945830375112" MODIFIED="2009-12-17 20:28:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="754" O_E="0.0" SE="0.7736767404064332" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.5985756986459234" WEIGHT="4.701967244119862"/>
<DICH_DATA CI_END="1.5974377473368826" CI_START="0.24645388119281297" EFFECT_SIZE="0.6274509803921569" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.20342394256447882" LOG_CI_START="-0.6082643381205396" LOG_EFFECT_SIZE="-0.2024201977780304" MODIFIED="2013-02-28 20:46:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="863" O_E="0.0" SE="0.47678971399616943" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.22732843137254904" WEIGHT="4.223026370986773"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.66710809124812" CI_END="1.318847156782725" CI_START="0.5392684398786173" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8433342449329152" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="25.00496569774419" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.12019446740982978" LOG_CI_START="-0.2681949955984181" LOG_EFFECT_SIZE="-0.07400026409429417" METHOD="MH" MODIFIED="2013-04-17 21:19:44 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.2465983259498591" P_Q="1.0" P_Z="0.45514318211042726" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3134" TOTAL_2="3022" WEIGHT="99.99999999999997" Z="0.7468681119610553">
<NAME>30-day urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2520" O_E="0.0" SE="0.0" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.3122791004773" CI_START="0.11010644244117765" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.871060580987677" LOG_CI_START="-0.9581872692680543" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="2517" O_E="0.0" SE="1.6619141922429452" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.7619587823785214" WEIGHT="1.1680988199425815"/>
<DICH_DATA CI_END="1.4883382224710782" CI_START="0.44847220223636175" EFFECT_SIZE="0.8169934640522876" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.17270163514906156" LOG_CI_START="-0.3482644707681463" LOG_EFFECT_SIZE="-0.08778141780954239" ORDER="2519" O_E="0.0" SE="0.306018069439583" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.09364705882352942" WEIGHT="56.70554357925695"/>
<DICH_DATA CI_END="0.6175945891362937" CI_START="0.0012977518806351123" EFFECT_SIZE="0.028310502283105023" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="-0.20929651759224244" LOG_CI_START="-2.8868083330914867" LOG_EFFECT_SIZE="-1.5480524253418644" ORDER="2523" O_E="0.0" SE="1.5727836943214988" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="2.473648549123582" WEIGHT="10.225109219628193"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2524" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:19:44 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1071" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.987023368566935" CI_START="0.21179738528757835" EFFECT_SIZE="0.7953890489913544" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47523862026063" LOG_CI_START="-0.674079405711942" LOG_EFFECT_SIZE="-0.09942039272565603" ORDER="2522" O_E="0.0" SE="0.6751150976722718" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.45578039510504115" WEIGHT="11.833283205310243"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:48:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="977" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.781031937907338" CI_START="0.5437980021108695" EFFECT_SIZE="1.4339168782573835" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.577610345809597" LOG_CI_START="-0.2645623923237646" LOG_EFFECT_SIZE="0.15652397674291624" ORDER="2521" O_E="0.0" SE="0.4946964352018243" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.24472456300139275" WEIGHT="16.570930670475555"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2518" O_E="0.0" SE="0.0" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:22:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="742" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:29:59 +0530" MODIFIED_BY="Xavier Bosch" ORDER="951" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:22:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="743" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.533335321744723" CI_START="0.013826055703629716" EFFECT_SIZE="0.34348561759729274" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9311188117901551" LOG_CI_START="-1.8593016977262402" LOG_EFFECT_SIZE="-0.46409144296804244" MODIFIED="2009-12-17 20:22:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="741" O_E="0.0" SE="1.6391068200942227" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.6866711676793944" WEIGHT="3.4970345053864706"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.825471978413598" CI_END="1.0751874850975098" CI_START="0.809168953206091" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9327423716207179" ESTIMABLE="YES" EVENTS_1="450" EVENTS_2="475" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.03148420066443306" LOG_CI_START="-0.09196078891401556" LOG_EFFECT_SIZE="-0.03023829412479126" METHOD="MH" MODIFIED="2013-04-17 21:20:26 +0530" MODIFIED_BY="Xavier Bosch" NO="6" P_CHI2="0.9747469169423534" P_Q="1.0" P_Z="0.33695435105550153" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3170" TOTAL_2="3156" WEIGHT="100.00000000000001" Z="0.9602004527021621">
<NAME>6-month urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2239193649618252" CI_START="0.6686820411735788" EFFECT_SIZE="0.9046617595513494" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="96" LOG_CI_END="0.08775280628528935" LOG_CI_START="-0.17478034051170438" LOG_EFFECT_SIZE="-0.043513767113207515" ORDER="2542" O_E="0.0" SE="0.1542132699885898" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.023781732640573695" WEIGHT="22.457257241451302"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2546" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.3924381486175522"/>
<DICH_DATA CI_END="78.27196626944439" CI_START="0.11498369632134046" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8936062438651577" LOG_CI_START="-0.9393637344258329" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-04-17 21:20:26 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1072" O_E="0.0" SE="1.6641005886756874" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.769230769230769" WEIGHT="0.12073561973889435"/>
<DICH_DATA CI_END="1.1688860250620519" CI_START="0.5927735955328928" EFFECT_SIZE="0.8323970037453183" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="96" LOG_CI_END="0.06777216633738355" LOG_CI_START="-0.2271111497820314" LOG_EFFECT_SIZE="-0.07966949172232393" ORDER="2545" O_E="0.0" SE="0.17321591958450078" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.030003754797504244" WEIGHT="18.56432372962302"/>
<DICH_DATA CI_END="2.0202926025166335" CI_START="0.18425313828495743" EFFECT_SIZE="0.6101190476190477" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.305414273632577" LOG_CI_START="-0.7345851063007564" LOG_EFFECT_SIZE="-0.2145854163340897" MODIFIED="2013-04-04 18:51:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="982" O_E="0.0" SE="0.6109007838527979" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.37319976771196284" WEIGHT="1.776980659746804"/>
<DICH_DATA CI_END="1.269607706872106" CI_START="0.5309487402340985" EFFECT_SIZE="0.8210338680926916" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="55" LOG_CI_END="0.10366955004316035" LOG_CI_START="-0.27494740529905853" LOG_EFFECT_SIZE="-0.08563892762794909" ORDER="2544" O_E="0.0" SE="0.22240147375217478" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.049462415527139286" WEIGHT="11.34759419599268"/>
<DICH_DATA CI_END="1.2710449219595512" CI_START="0.8273272660180548" EFFECT_SIZE="1.025460930640913" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="204" LOG_CI_END="0.10416089989656532" LOG_CI_START="-0.08232266250200475" LOG_EFFECT_SIZE="0.010919118697280301" ORDER="2543" O_E="0.0" SE="0.10954136766144161" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.011999311229139125" WEIGHT="41.78403117136917"/>
<DICH_DATA CI_END="3.5672413705482016" CI_START="0.28032866187754585" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5523324960360485" LOG_CI_START="-0.5523324960360485" LOG_EFFECT_SIZE="0.0" ORDER="2541" O_E="0.0" SE="0.6488856845230502" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.4210526315789474" WEIGHT="1.2058083048281885"/>
<DICH_DATA CI_END="5.767582946099541" CI_START="0.4165523101188767" EFFECT_SIZE="1.55" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7609938490144217" LOG_CI_START="-0.3803304526738386" LOG_EFFECT_SIZE="0.1903316981702915" MODIFIED="2013-04-04 18:32:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="956" O_E="0.0" SE="0.6704195444580937" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.44946236559139785" WEIGHT="0.923106836232106"/>
<DICH_DATA CI_END="5.034588321726299" CI_START="0.16259404980062087" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7019639640828441" LOG_CI_START="-0.7888953516450247" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2009-12-17 20:29:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="757" O_E="0.0" SE="0.875738141931184" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.7669172932330826" WEIGHT="0.6953402581617929"/>
<DICH_DATA CI_END="5.7774576728618765" CI_START="0.045989614345266244" EFFECT_SIZE="0.5154639175257731" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7617367724099338" LOG_CI_START="-1.337340232270386" LOG_EFFECT_SIZE="-0.28780172993022607" MODIFIED="2009-12-17 20:29:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="756" O_E="0.0" SE="1.2330082231479704" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="1.5203092783505154" WEIGHT="0.4924774971298285"/>
<DICH_DATA CI_END="17.641513452415772" CI_START="0.0648698527340903" EFFECT_SIZE="1.069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2465358401970499" LOG_CI_START="-1.1879570879930745" LOG_EFFECT_SIZE="0.029289376101987508" MODIFIED="2013-02-28 20:47:26 +0530" MODIFIED_BY="Xavier Bosch" ORDER="864" O_E="0.0" SE="1.4300331969532285" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="2.044994944388271" WEIGHT="0.23990633710867368"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.008884774054206" CI_END="0.9080885204603286" CI_START="0.5962538346822357" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7358337193655838" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="214" I2="35.32791746123364" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.04187181439341098" LOG_CI_START="-0.22456881486842584" LOG_EFFECT_SIZE="-0.1332203146309184" METHOD="MH" MODIFIED="2013-04-17 21:21:02 +0530" MODIFIED_BY="Xavier Bosch" NO="7" P_CHI2="0.10761310506285404" P_Q="1.0" P_Z="0.004258352147763415" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3134" TOTAL_2="3022" WEIGHT="100.00000000000001" Z="2.858361308689387">
<NAME>30-day mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5334642240539935" CI_START="0.05670127417843977" EFFECT_SIZE="0.2948717948717949" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1856736482825227" LOG_CI_START="-1.2464071816282978" LOG_EFFECT_SIZE="-0.5303667666728875" ORDER="2528" O_E="0.0" SE="0.8412113684040525" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.7076365663322185" WEIGHT="2.888655164553237"/>
<DICH_DATA CI_END="2.8344626813240428" CI_START="0.025688929118493718" EFFECT_SIZE="0.2698412698412698" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45247074342198523" LOG_CI_START="-1.5902539995726008" LOG_EFFECT_SIZE="-0.5688916280753078" ORDER="2525" O_E="0.0" SE="1.1999066256855764" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="1.4397759103641457" WEIGHT="1.472103112705015"/>
<DICH_DATA CI_END="0.8844972494574412" CI_START="0.48308376408692294" EFFECT_SIZE="0.6536713704855298" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="113" LOG_CI_END="-0.05330351328824661" LOG_CI_START="-0.31597755842726144" LOG_EFFECT_SIZE="-0.184640535857754" ORDER="2527" O_E="0.0" SE="0.154296034372151" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.023807266222972003" WEIGHT="51.68812692820134"/>
<DICH_DATA CI_END="0.8132066598279538" CI_START="0.005930264842171622" EFFECT_SIZE="0.06944444444444445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="-0.0897990733263167" LOG_CI_START="-2.2269259108641823" LOG_EFFECT_SIZE="-1.1583624920952496" ORDER="2531" O_E="0.0" SE="1.2553588833182032" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="1.575925925925926" WEIGHT="1.6824035573771599"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2532" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.7585837468530945"/>
<DICH_DATA CI_END="16.3090734852818" CI_START="0.055031141163090325" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.212429289571308" LOG_CI_START="-1.2593914812703537" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-17 21:21:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1073" O_E="0.0" SE="1.4519597565025428" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.1081871345029235" WEIGHT="0.47811895968197066"/>
<DICH_DATA CI_END="2.6809347848852267" CI_START="0.6792424973440371" EFFECT_SIZE="1.34944612286002" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.42828624967517337" LOG_CI_START="-0.1679751499363205" LOG_EFFECT_SIZE="0.13015554986942643" ORDER="2530" O_E="0.0" SE="0.35024689767332146" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12267288932978612" WEIGHT="6.951014697651354"/>
<DICH_DATA CI_END="1.6082015976438466" CI_START="0.6849581893064272" EFFECT_SIZE="1.0495479285682157" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.2063404892236446" LOG_CI_START="-0.16433593756989562" LOG_EFFECT_SIZE="0.02100227582687446" ORDER="2529" O_E="0.0" SE="0.2177371679764307" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.0474094743183964" WEIGHT="20.21079160015142"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:49:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="978" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.634116880616915" CI_START="0.37963387553470984" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.42063504149925784" LOG_CI_START="-0.42063504149925784" LOG_EFFECT_SIZE="0.0" ORDER="2526" O_E="0.0" SE="0.4941662111074008" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.2442002442002442" WEIGHT="4.018841497684691"/>
<DICH_DATA CI_END="2.4006588745471547" CI_START="0.1733828554084815" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3803304526738385" LOG_CI_START="-0.7609938490144215" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2013-04-04 18:30:37 +0530" MODIFIED_BY="Xavier Bosch" ORDER="952" O_E="0.0" SE="0.6704195444580936" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.4494623655913978" WEIGHT="2.7657694844760887"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-12-17 20:24:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="746" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="0.9616423018117771"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:24:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="747" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6497708921999872" CI_START="0.03130765804115496" EFFECT_SIZE="0.14262820512820512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.1872397476541158" LOG_CI_START="-1.5043494184209065" LOG_EFFECT_SIZE="-0.8457945830375112" MODIFIED="2009-12-17 20:24:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="745" O_E="0.0" SE="0.7736767404064332" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.5985756986459234" WEIGHT="6.1239489488528625"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.568263677280344" CI_END="0.9793076350166663" CI_START="0.7668896392720885" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8666146080896244" ESTIMABLE="YES" EVENTS_1="631" EVENTS_2="703" I2="24.4934039932649" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.009080859572663991" LOG_CI_START="-0.11526712953686881" LOG_EFFECT_SIZE="-0.0621739945547664" METHOD="MH" MODIFIED="2013-04-17 21:21:32 +0530" MODIFIED_BY="Xavier Bosch" NO="8" P_CHI2="0.20312728362657373" P_Q="1.0" P_Z="0.021722283750240157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3170" TOTAL_2="3156" WEIGHT="99.99999999999997" Z="2.2951892018320246">
<NAME>6-month mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9397155381936182" CI_START="0.5869012263377732" EFFECT_SIZE="0.7426440612934941" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="187" LOG_CI_END="-0.027003592027319622" LOG_CI_START="-0.2314349830214897" LOG_EFFECT_SIZE="-0.12921928752440467" ORDER="2548" O_E="0.0" SE="0.12008401102168147" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.014420169703055315" WEIGHT="29.238880154303992"/>
<DICH_DATA CI_END="1.1771634974207843" CI_START="0.015724923278181254" EFFECT_SIZE="0.1360544217687075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07083678662964918" LOG_CI_START="-1.8034114647980388" LOG_EFFECT_SIZE="-0.8662873390841949" ORDER="2552" O_E="0.0" SE="1.100942700567097" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2120748299319728" WEIGHT="1.108000776092633"/>
<DICH_DATA CI_END="117.25632331883436" CI_START="0.2368806042653152" EFFECT_SIZE="5.27027027027027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.069136272354529" LOG_CI_START="-0.6254704977634833" LOG_EFFECT_SIZE="0.721832887295523" MODIFIED="2013-04-17 21:21:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1074" O_E="0.0" SE="1.5828253552859535" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.505336105336105" WEIGHT="0.08162474607352398"/>
<DICH_DATA CI_END="1.2205425601562463" CI_START="0.8213024295341018" EFFECT_SIZE="1.0012165450121655" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="257" LOG_CI_END="0.08655292780789149" LOG_CI_START="-0.08549689246345253" LOG_EFFECT_SIZE="5.280176722194622E-4" ORDER="2549" O_E="0.0" SE="0.1010629160877332" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.010213713008156202" WEIGHT="35.4010599695888"/>
<DICH_DATA CI_END="1.3912058332074704" CI_START="0.638564961241306" EFFECT_SIZE="0.94253663003663" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="72" LOG_CI_END="0.1433913899582164" LOG_CI_START="-0.19479491535660595" LOG_EFFECT_SIZE="-0.025701762699194778" ORDER="2550" O_E="0.0" SE="0.19865230979113668" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.039462740185353735" WEIGHT="9.44417736070761"/>
<DICH_DATA CI_END="2.524097051528937" CI_START="0.33801890472429086" EFFECT_SIZE="0.9236842105263158" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.40210604951550155" LOG_CI_START="-0.47105900981747373" LOG_EFFECT_SIZE="-0.03447648015098608" MODIFIED="2013-04-04 18:52:56 +0530" MODIFIED_BY="Xavier Bosch" ORDER="983" O_E="0.0" SE="0.5129014780889415" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.263067926225821" WEIGHT="1.432109846650342"/>
<DICH_DATA CI_END="1.249540537688291" CI_START="0.6583788979122845" EFFECT_SIZE="0.9070121951219512" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="112" LOG_CI_END="0.09675035010532974" LOG_CI_START="-0.18152409739955114" LOG_EFFECT_SIZE="-0.042386873647110725" ORDER="2551" O_E="0.0" SE="0.16345978794509788" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.026719102275056365" WEIGHT="14.219983059957132"/>
<DICH_DATA CI_END="1.7300298892594128" CI_START="0.35572402673145254" EFFECT_SIZE="0.7844827586206896" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.23805360638214693" LOG_CI_START="-0.4488868001937967" LOG_EFFECT_SIZE="-0.1054165969058249" ORDER="2547" O_E="0.0" SE="0.403512195232563" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.16282209170140205" WEIGHT="2.5181013556260328"/>
<DICH_DATA CI_END="3.1749472983095473" CI_START="0.4127383274584887" EFFECT_SIZE="1.144736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5017365207324632" LOG_CI_START="-0.384325200056809" LOG_EFFECT_SIZE="0.058705660337827134" MODIFIED="2013-04-04 18:33:04 +0530" MODIFIED_BY="Xavier Bosch" ORDER="957" O_E="0.0" SE="0.5204770408678742" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.2708963500705787" WEIGHT="1.2498413207130257"/>
<DICH_DATA CI_END="4.136431592337159" CI_START="0.195820958697962" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6166258464281339" LOG_CI_START="-0.7081408275494842" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2009-12-17 20:30:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="759" O_E="0.0" SE="0.7781745019952502" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.6055555555555556" WEIGHT="0.6292107335397382"/>
<DICH_DATA CI_END="0.6543236827184337" CI_START="0.05126944857789578" EFFECT_SIZE="0.1831578947368421" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.1842073604783508" LOG_CI_START="-1.2901413535341453" LOG_EFFECT_SIZE="-0.737174357006248" MODIFIED="2009-12-17 20:30:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="758" O_E="0.0" SE="0.6496311019825304" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.42202056866303683" WEIGHT="2.5777977239706154"/>
<DICH_DATA CI_END="1.6058163716198053" CI_START="0.25974370533021174" EFFECT_SIZE="0.6458333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.20569588132137684" LOG_CI_START="-0.5854549684040059" LOG_EFFECT_SIZE="-0.1898795435413145" MODIFIED="2013-02-28 20:48:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="865" O_E="0.0" SE="0.46472592538855656" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.21597018572825025" WEIGHT="2.0992129527765333"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.272724657820248" CI_END="3.0314091068552846" CI_START="1.1014216500549876" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8272546676542556" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.48164455097013326" LOG_CI_START="0.041953608923004315" LOG_EFFECT_SIZE="0.2617990799465688" METHOD="MH" MODIFIED="2013-04-17 21:22:22 +0530" MODIFIED_BY="Xavier Bosch" NO="9" P_CHI2="0.50751404989906" P_Q="1.0" P_Z="0.019596332016873535" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3310" TOTAL_2="3200" WEIGHT="99.99999999999999" Z="2.3339883486887847">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2536" O_E="0.0" SE="0.0" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.932499875628727" CI_START="1.048980971085676" EFFECT_SIZE="3.2278481012658227" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9970585682893176" LOG_CI_START="0.02076760999770986" LOG_EFFECT_SIZE="0.5089130891435137" ORDER="2535" O_E="0.0" SE="0.5734781416186749" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.328877178914409" WEIGHT="17.05137860579734"/>
<DICH_DATA CI_END="7.506992811000863" CI_START="0.011117206613167119" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87546599996867" LOG_CI_START="-1.9540043229056838" LOG_EFFECT_SIZE="-0.5392691614685069" ORDER="2533" O_E="0.0" SE="1.6620448737603812" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.762393162393162" WEIGHT="6.571429548109248"/>
<DICH_DATA CI_END="2.4881828163165496" CI_START="0.008820844535940005" EFFECT_SIZE="0.14814814814814814" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.39588228646919893" LOG_CI_START="-2.0544898321312486" LOG_EFFECT_SIZE="-0.829303772831025" ORDER="2539" O_E="0.0" SE="1.4393607120035128" STUDY_ID="STD-PRIDE-2001" TOTAL_1="109" TOTAL_2="17" VAR="2.0717592592592595" WEIGHT="7.3433117489982696"/>
<DICH_DATA CI_END="15.120249715113221" CI_START="0.0557794083969631" EFFECT_SIZE="0.9183673469387755" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1795589637181094" LOG_CI_START="-1.2535260962244492" LOG_EFFECT_SIZE="-0.036983566253169974" ORDER="2540" O_E="0.0" SE="1.429206208175548" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.042630385487528" WEIGHT="4.372840156087511"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:22:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1075" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7015192534081667" CI_START="0.6135687571429665" EFFECT_SIZE="1.507029053420806" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.568380012701654" LOG_CI_START="-0.21213676272572884" LOG_EFFECT_SIZE="0.17812162498796255" ORDER="2537" O_E="0.0" SE="0.4584794175063947" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.21020337627700297" WEIGHT="33.87197495956034"/>
<DICH_DATA CI_END="6.001482304785" CI_START="0.2962231141397101" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7782585299305445" LOG_CI_START="-0.5283810567139446" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="2538" O_E="0.0" SE="0.7675265611652409" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.5890970220941403" WEIGHT="12.722470926046219"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:50:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="979" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.924023369377402" CI_START="0.723640154774154" EFFECT_SIZE="2.8115942028985508" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.038382620539537" LOG_CI_START="-0.14047734215359553" LOG_EFFECT_SIZE="0.44895263919297074" ORDER="2534" O_E="0.0" SE="0.6924681775368743" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.4795121769012401" WEIGHT="11.822731915887214"/>
<DICH_DATA CI_END="16.330717844801725" CI_START="0.061234295363097754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213005275317456" LOG_CI_START="-1.213005275317456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:31:05 +0530" MODIFIED_BY="Xavier Bosch" ORDER="953" O_E="0.0" SE="1.4250506063888506" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.0307692307692307" WEIGHT="4.2186955123664305"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:25:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="750" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:25:42 +0530" MODIFIED_BY="Xavier Bosch" ORDER="748" O_E="0.0" SE="0.0" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="147.36553289489572" CI_START="0.38303737170923763" EFFECT_SIZE="7.513089005235602" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.168395918910134" LOG_CI_START="-0.41675885126556694" LOG_EFFECT_SIZE="0.8758185338222836" MODIFIED="2009-12-17 20:25:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="749" O_E="0.0" SE="1.518532708723702" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.3059415874637432" WEIGHT="2.025166627147419"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:26:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="751" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-05 16:21:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1028" O_E="0.0" SE="0.0" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="3">
<NAME>Subgroup of PCI in patients with NSTEACS</NAME>
<DICH_OUTCOME CHI2="1.242631752279698" CI_END="1.2751014731885892" CI_START="0.4645630048097952" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7696525006922849" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.10554474750902733" LOG_CI_START="-0.33295537793371943" LOG_EFFECT_SIZE="-0.11370531521234603" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.871030955663673" P_Q="1.0" P_Z="0.3094116942477454" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2888" TOTAL_2="2890" WEIGHT="99.99999999999999" Z="1.0164572812468686">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.235307327498598" CI_START="0.012621821467408088" EFFECT_SIZE="0.3224043715846995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9156798109309462" LOG_CI_START="-1.8988779671075169" LOG_EFFECT_SIZE="-0.49159907808828524" ORDER="2419" O_E="0.0" SE="1.6532851711054914" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.733351856997314" WEIGHT="4.260372202981676"/>
<DICH_DATA CI_END="2.1845324933014454" CI_START="0.25997400229081025" EFFECT_SIZE="0.7536057692307693" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3393585089021063" LOG_CI_START="-0.5850700798221213" LOG_EFFECT_SIZE="-0.12285578546000747" ORDER="2414" O_E="0.0" SE="0.5430139290119261" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.29486412710096915" WEIGHT="22.78411608564575"/>
<DICH_DATA CI_END="2.9269030729044214" CI_START="0.43241097107602416" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.46640834060948216" LOG_CI_START="-0.36410329571471955" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="2418" O_E="0.0" SE="0.48784664627573887" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.2379943502824859" WEIGHT="22.911101534853017"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:30:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1005" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4783959943434857" CI_START="0.3152530098603363" EFFECT_SIZE="0.6826923076923077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16979077717359825" LOG_CI_START="-0.5013407583330084" LOG_EFFECT_SIZE="-0.16577499057970504" ORDER="2416" O_E="0.0" SE="0.3942259861112605" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.15541412812539573" WEIGHT="45.7320892540868"/>
<DICH_DATA CI_END="8.196019479828836" CI_START="0.013332642230707504" EFFECT_SIZE="0.330567081604426" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9136029819365901" LOG_CI_START="-1.8750837746293763" LOG_EFFECT_SIZE="-0.48074039634639315" MODIFIED="2013-02-28 21:21:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="866" O_E="0.0" SE="1.6380884050289253" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="2.6833336226902085" WEIGHT="4.312320922432747"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.638617886637895" CI_END="1.381881228084422" CI_START="0.7423218619729959" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0128181703826005" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.1404707172753731" LOG_CI_START="-0.12940774893886384" LOG_EFFECT_SIZE="0.00553148416825465" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.801835187973459" P_Q="1.0" P_Z="0.9359639472323443" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2857" TOTAL_2="2859" WEIGHT="100.0" Z="0.08034364432934286">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5132396804314543" CI_START="0.6420466222174387" EFFECT_SIZE="1.2702822708531558" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.40023390798182035" LOG_CI_START="-0.1924334344909537" LOG_EFFECT_SIZE="0.10390023674543333" ORDER="2427" O_E="0.0" SE="0.34813573071916765" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.12119848700336881" WEIGHT="18.64009634498329"/>
<DICH_DATA CI_END="2.5174088912697563" CI_START="0.6011048899796547" EFFECT_SIZE="1.2301328361687252" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.40095376175403624" LOG_CI_START="-0.22104973903763422" LOG_EFFECT_SIZE="0.08995201135820102" ORDER="2426" O_E="0.0" SE="0.3653679353320131" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.13349372816877814" WEIGHT="17.15785316776073"/>
<DICH_DATA CI_END="5.651593953590671" CI_START="0.0406258298685047" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.752170951823081" LOG_CI_START="-1.3911977545390697" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-04-04 19:31:04 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1007" O_E="0.0" SE="1.2590253879633373" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.585144927536232" WEIGHT="2.4279301895745315"/>
<DICH_DATA CI_END="1.381299390738275" CI_START="0.6030299390679948" EFFECT_SIZE="0.9126691007323302" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="49" LOG_CI_END="0.1402878202538681" LOG_CI_START="-0.21966112558912065" LOG_EFFECT_SIZE="-0.039686652667626277" ORDER="2428" O_E="0.0" SE="0.21143579256418962" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.04470509437724702" WEIGHT="59.26610213310359"/>
<DICH_DATA CI_END="5.541897364276366" CI_START="0.04435592312350596" EFFECT_SIZE="0.4957983193277311" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7436584784037782" LOG_CI_START="-1.3530483779045512" LOG_EFFECT_SIZE="-0.3046949497503866" MODIFIED="2013-02-28 21:21:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="867" O_E="0.0" SE="1.2316159862618397" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="1.5168779376157242" WEIGHT="2.5080181645778583"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9376796695217977" CI_END="0.8289150248756528" CI_START="0.5569645087392405" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6794676221987648" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="256" I2="0.0" I2_Q="100.00000000000001" ID="CMP-003.03" LOG_CI_END="-0.08148998829065812" LOG_CI_START="-0.2541724783447502" LOG_EFFECT_SIZE="-0.16783123331770416" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.5584231306779103" P_Q="0.0" P_Z="1.3907731531866857E-4" Q="2.994943675885913E-31" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2954" TOTAL_2="2960" WEIGHT="100.00000000000001" Z="3.8098034453938996">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.167699031428313" CI_START="0.03040500724782702" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5007439118066108" LOG_CI_START="-1.5170548887258732" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="2425" O_E="0.0" SE="1.1852650036979324" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.40485312899106" WEIGHT="1.2131830639881795"/>
<DICH_DATA CI_END="1.1114459902280995" CI_START="0.5338598055112013" EFFECT_SIZE="0.7702962677953059" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" LOG_CI_END="0.04588836337705915" LOG_CI_START="-0.2725727760924846" LOG_EFFECT_SIZE="-0.11334220635771275" ORDER="2424" O_E="0.0" SE="0.1870656497324744" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.0349935573098328" WEIGHT="27.422794746007355"/>
<DICH_DATA CI_END="0.8004339095848543" CI_START="0.32115929460659554" EFFECT_SIZE="0.5070175438596491" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="57" LOG_CI_END="-0.09667452119319817" LOG_CI_START="-0.49327950463868886" LOG_EFFECT_SIZE="-0.2949770129159435" ORDER="2420" O_E="0.0" SE="0.23296773050221178" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.054273963455351175" WEIGHT="22.62006857756344"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:30:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1006" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.862838331323726" CI_START="0.2939412325783307" EFFECT_SIZE="1.0655737704918034" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5869065323013709" LOG_CI_START="-0.5317394890371939" LOG_EFFECT_SIZE="0.02758352163208857" MODIFIED="2013-04-04 19:44:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1025" O_E="0.0" SE="0.6570982103213844" STUDY_ID="STD-Prati-2005" TOTAL_1="66" TOTAL_2="70" VAR="0.43177805800756625" WEIGHT="1.8763734001845578"/>
<DICH_DATA CI_END="0.9714269034686553" CI_START="0.5408837972671123" EFFECT_SIZE="0.7248648648648649" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="116" LOG_CI_END="-0.012589872999912627" LOG_CI_START="-0.26689602810291707" LOG_EFFECT_SIZE="-0.13974295055141486" MODIFIED="2010-05-25 19:09:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2422" O_E="0.0" SE="0.14938069434327483" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.022314591842478904" WEIGHT="44.399380185521906"/>
<DICH_DATA CI_END="1.6286850888993347" CI_START="0.06367457549921701" EFFECT_SIZE="0.3220338983050847" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21183712029725427" LOG_CI_START="-1.1960339416758847" LOG_EFFECT_SIZE="-0.49209841068931526" MODIFIED="2013-02-28 21:22:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="868" O_E="0.0" SE="0.8269904308771744" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6839131727624145" WEIGHT="2.4682000267345723"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.721156273901891" CI_END="0.9179242363868405" CI_START="0.6517473060020421" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7734692289801224" ESTIMABLE="YES" EVENTS_1="264" EVENTS_2="332" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.037193163109204334" LOG_CI_START="-0.1859207553124765" LOG_EFFECT_SIZE="-0.11155695921084041" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.6055178594654305" P_Q="1.0" P_Z="0.0032795505975747345" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2857" TOTAL_2="2859" WEIGHT="100.00000000000003" Z="2.9402428835022927">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.200758503518926" CI_START="0.6534829323577985" EFFECT_SIZE="0.8858189363143631" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="96" LOG_CI_END="0.07945567090397891" LOG_CI_START="-0.1847657508219595" LOG_EFFECT_SIZE="-0.0526550399589903" ORDER="2430" O_E="0.0" SE="0.1552049710389476" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.024088583035200558" WEIGHT="29.495561414845046"/>
<DICH_DATA CI_END="1.1232459971740139" CI_START="0.5425202595202663" EFFECT_SIZE="0.780630328575534" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="73" LOG_CI_END="0.050474879605739334" LOG_CI_START="-0.26558403916870277" LOG_EFFECT_SIZE="-0.10755457978148174" ORDER="2429" O_E="0.0" SE="0.18565457340498742" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.03446762062618786" WEIGHT="22.045983771934104"/>
<DICH_DATA CI_END="3.159193437595083" CI_START="0.029553175319944055" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4995762185952884" LOG_CI_START="-1.5293958498134126" LOG_EFFECT_SIZE="-0.5149098156090622" MODIFIED="2013-04-04 19:31:33 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1008" O_E="0.0" SE="1.1918282365569903" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.4204545454545454" WEIGHT="0.961753138206609"/>
<DICH_DATA CI_END="0.9404987851447159" CI_START="0.5614014133321323" EFFECT_SIZE="0.7266342595951535" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="154" LOG_CI_END="-0.02664176109742685" LOG_CI_START="-0.2507264983606934" LOG_EFFECT_SIZE="-0.13868412972906016" MODIFIED="2010-05-25 19:10:15 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2431" O_E="0.0" SE="0.13162848390578177" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.017326057775334653" WEIGHT="45.526443509938225"/>
<DICH_DATA CI_END="1.6286850888993347" CI_START="0.06367457549921701" EFFECT_SIZE="0.3220338983050847" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21183712029725427" LOG_CI_START="-1.1960339416758847" LOG_EFFECT_SIZE="-0.49209841068931526" MODIFIED="2013-02-28 21:23:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="869" O_E="0.0" SE="0.8269904308771744" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6839131727624145" WEIGHT="1.9702581650760396"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7596568911426456" CI_END="0.8944625082068102" CI_START="0.5188386615920794" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6812354443232645" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="134" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.048437858361155876" LOG_CI_START="-0.2849676696532849" LOG_EFFECT_SIZE="-0.16670276400722042" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.598816763251601" P_Q="1.0" P_Z="0.005732400543384358" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2863" TOTAL_2="2865" WEIGHT="100.00000000000001" Z="2.7627081067924957">
<NAME>30-day urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.607065820519196" CI_START="0.0063638162757009495" EFFECT_SIZE="0.1288056206088993" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41615199592760443" LOG_CI_START="-2.1962823669891645" LOG_EFFECT_SIZE="-0.89006518553078" ORDER="2436" O_E="0.0" SE="1.5345568765359672" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.3548648073238234" WEIGHT="2.7042884540660124"/>
<DICH_DATA CI_END="1.0156963059996749" CI_START="0.47120588217630355" EFFECT_SIZE="0.6918107211454514" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="69" LOG_CI_END="0.006763872963093745" LOG_CI_START="-0.3267892967846956" LOG_EFFECT_SIZE="-0.16001271191080094" ORDER="2432" O_E="0.0" SE="0.19593078302467057" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.038388871736660536" WEIGHT="49.77502849939923"/>
<DICH_DATA CI_END="1.1718197603392158" CI_START="0.46175543970194177" EFFECT_SIZE="0.7355910199879132" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" LOG_CI_END="0.06886081721982046" LOG_CI_START="-0.33558797965897996" LOG_EFFECT_SIZE="-0.13336358121957978" ORDER="2435" O_E="0.0" SE="0.23757522534044068" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.05644198769556117" WEIGHT="32.775109822012084"/>
<DICH_DATA CI_END="1.9298648416669453" CI_START="0.35697372673348626" EFFECT_SIZE="0.8300066533599467" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.28552689420276856" LOG_CI_START="-0.4473637467857298" LOG_EFFECT_SIZE="-0.08091842629148066" ORDER="2433" O_E="0.0" SE="0.4305035903838263" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.18533334133336532" WEIGHT="9.339951822897836"/>
<DICH_DATA CI_END="1.3450633984541422" CI_START="0.05565626122334936" EFFECT_SIZE="0.2736077481840194" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12874275493314666" LOG_CI_START="-1.254485971279109" LOG_EFFECT_SIZE="-0.5628716081729812" MODIFIED="2013-02-28 21:23:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="870" O_E="0.0" SE="0.8125154008697023" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6601812766504531" WEIGHT="5.40562140162485"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.783556838172346" CI_END="1.0481567306684227" CI_START="0.7919680225939772" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9111018677162498" ESTIMABLE="YES" EVENTS_1="454" EVENTS_2="491" I2="41.03388391335869" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.02042622747131953" LOG_CI_START="-0.10129235362685564" LOG_EFFECT_SIZE="-0.040433063077768054" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="6" P_CHI2="0.14777811567253962" P_Q="1.0" P_Z="0.1928683583588021" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2857" TOTAL_2="2859" WEIGHT="100.0" Z="1.3021405064382525">
<NAME>6-month urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0822977170775834" CI_START="0.6895569249655266" EFFECT_SIZE="0.8638899731361789" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="194" LOG_CI_END="0.0343467423776864" LOG_CI_START="-0.16142987571302295" LOG_EFFECT_SIZE="-0.06354156666766828" ORDER="2448" O_E="0.0" SE="0.11500015457637185" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.013225035552589418" WEIGHT="39.71569782544605"/>
<DICH_DATA CI_END="1.5411131987860613" CI_START="0.888944331963629" EFFECT_SIZE="1.1704545454545454" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="120" LOG_CI_END="0.18783453995305668" LOG_CI_START="-0.0511254348430495" LOG_EFFECT_SIZE="0.06835455255500357" ORDER="2447" O_E="0.0" SE="0.1403662720661851" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.019702690333758297" WEIGHT="22.897645911807462"/>
<DICH_DATA CI_END="5.77937573192896" CI_START="0.418687622791419" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7618809299740814" LOG_CI_START="-0.378109877496255" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2013-04-04 19:31:59 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1009" O_E="0.0" SE="0.6696362433535825" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.44841269841269843" WEIGHT="0.8777430932859527"/>
<DICH_DATA CI_END="1.032685386096504" CI_START="0.6316987638578053" EFFECT_SIZE="0.8076794425087108" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="164" LOG_CI_END="0.013968031206493012" LOG_CI_START="-0.1994899729556546" LOG_EFFECT_SIZE="-0.09276097087458082" ORDER="2449" O_E="0.0" SE="0.12538628827900727" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.015721721288386316" WEIGHT="34.60713646734098"/>
<DICH_DATA CI_END="1.387435875521921" CI_START="0.0928782314732757" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.14221292004658065" LOG_CI_START="-1.0320860627431032" LOG_EFFECT_SIZE="-0.4449365713482612" MODIFIED="2013-02-28 21:24:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="871" O_E="0.0" SE="0.6897890353643739" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.47580891330891334" WEIGHT="1.901776702119564"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.381661660188301" CI_END="0.8145641917153033" CI_START="0.5787827197231017" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6866263017610331" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="353" I2="25.673514007938532" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-0.08907468543865857" LOG_CI_START="-0.23748444376055558" LOG_EFFECT_SIZE="-0.16327956459960705" METHOD="MH" MODIFIED="2013-02-28 21:24:42 +0530" MODIFIED_BY="Xavier Bosch" NO="7" P_CHI2="0.250329171168319" P_Q="1.0" P_Z="1.6128582688461282E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2863" TOTAL_2="2865" WEIGHT="99.99999999999999" Z="4.312682260859039">
<NAME>30-day mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9879383279139586" CI_START="0.012993727708655546" EFFECT_SIZE="0.11330049261083744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.005270165415032944" LOG_CI_START="-1.886266238376207" LOG_EFFECT_SIZE="-0.94576820189562" ORDER="2441" O_E="0.0" SE="1.104906404338122" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.2208181623473977" WEIGHT="2.107421895005743"/>
<DICH_DATA CI_END="1.0028070258903052" CI_START="0.5561629400415707" EFFECT_SIZE="0.7468092820884699" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="112" LOG_CI_END="0.0012173680611100304" LOG_CI_START="-0.25479795375247255" LOG_EFFECT_SIZE="-0.12679029284568125" ORDER="2440" O_E="0.0" SE="0.15038466732958006" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.022615548167828462" WEIGHT="32.09551037893073"/>
<DICH_DATA CI_END="0.9302489014033002" CI_START="0.4847677080446522" EFFECT_SIZE="0.6715315538709506" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="101" LOG_CI_END="-0.031400834195185426" LOG_CI_START="-0.31446631764768285" LOG_EFFECT_SIZE="-0.17293357592143413" ORDER="2437" O_E="0.0" SE="0.1662740661767383" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.02764706508294634" WEIGHT="27.80029193016902"/>
<DICH_DATA CI_END="0.9659913924620098" CI_START="0.542584572743223" EFFECT_SIZE="0.7239696312364425" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="120" LOG_CI_END="-0.015026743380476264" LOG_CI_START="-0.2655325586535567" LOG_EFFECT_SIZE="-0.1402796510170165" ORDER="2438" O_E="0.0" SE="0.14714835591519188" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.021652638648543984" WEIGHT="34.08299227659812"/>
<DICH_DATA CI_END="0.8972843645247331" CI_START="0.08977486378926258" EFFECT_SIZE="0.2838196286472148" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.04706989990731927" LOG_CI_START="-1.046845245133847" LOG_EFFECT_SIZE="-0.5469575725205833" MODIFIED="2013-02-28 21:24:42 +0530" MODIFIED_BY="Xavier Bosch" ORDER="872" O_E="0.0" SE="0.5872729867538373" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.3448895609707727" WEIGHT="3.9137835192963792"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.144486916615833" CI_END="0.9578755850148333" CI_START="0.7552369741120086" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.850542802216545" ESTIMABLE="YES" EVENTS_1="699" EVENTS_2="788" I2="34.90099247858665" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-0.01869089619330367" LOG_CI_START="-0.12191675644867228" LOG_EFFECT_SIZE="-0.07030382632098797" METHOD="MH" MODIFIED="2013-04-04 19:32:53 +0530" MODIFIED_BY="Xavier Bosch" NO="8" P_CHI2="0.18861478991575376" P_Q="1.0" P_Z="0.007591059964835047" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2857" TOTAL_2="2859" WEIGHT="100.0" Z="2.66973735503123">
<NAME>6-month mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0366623011375466" CI_START="0.7026984046560227" EFFECT_SIZE="0.853499235603873" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="290" LOG_CI_END="0.015637305436564705" LOG_CI_START="-0.15323103244523825" LOG_EFFECT_SIZE="-0.06879686350433677" ORDER="2451" O_E="0.0" SE="0.09919409758352499" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.009839468995409877" WEIGHT="37.29280661492273"/>
<DICH_DATA CI_END="1.2849616530516683" CI_START="0.7961437635626567" EFFECT_SIZE="1.011441647597254" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="193" LOG_CI_END="0.10889016726532466" LOG_CI_START="-0.09900850250798449" LOG_EFFECT_SIZE="0.004940832378670084" ORDER="2450" O_E="0.0" SE="0.12212070773985452" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.014913467258882965" WEIGHT="22.5855175542378"/>
<DICH_DATA CI_END="3.2818350259814215" CI_START="0.3047075773411107" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5161167457887658" LOG_CI_START="-0.5161167457887657" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:32:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1010" O_E="0.0" SE="0.6063390625908325" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.36764705882352944" WEIGHT="0.9214053520899851"/>
<DICH_DATA CI_END="0.953751578729526" CI_START="0.6383805812228086" EFFECT_SIZE="0.7802925651135771" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="281" LOG_CI_END="-0.020564730155853063" LOG_CI_START="-0.19492033217744956" LOG_EFFECT_SIZE="-0.10774253116665135" ORDER="2452" O_E="0.0" SE="0.10241734370163527" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.01048931229089889" WEIGHT="36.62575552438041"/>
<DICH_DATA CI_END="0.9071379885371758" CI_START="0.1290167676353862" EFFECT_SIZE="0.34210526315789475" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.042326645572642096" LOG_CI_START="-0.8893538430473046" LOG_EFFECT_SIZE="-0.4658402443099734" MODIFIED="2013-02-28 21:25:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="873" O_E="0.0" SE="0.49754796864886575" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.24755398110661267" WEIGHT="2.5745149543690755"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5803881747252353" CI_END="1.9310902694065353" CI_START="1.0287669199293656" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4094828088923008" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="69" I2="16.21020253676196" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.28580257548257376" LOG_CI_START="0.012316991035908163" LOG_EFFECT_SIZE="0.14905978325924096" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="9" P_CHI2="0.3104848950739194" P_Q="1.0" P_Z="0.03263818608045034" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2863" TOTAL_2="2865" WEIGHT="100.0" Z="2.1365060781727125">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.167699031428313" CI_START="0.03040500724782702" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5007439118066108" LOG_CI_START="-1.5170548887258732" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="2446" O_E="0.0" SE="1.1852650036979324" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.40485312899106" WEIGHT="4.38689043129795"/>
<DICH_DATA CI_END="4.14843312209715" CI_START="1.0190763976070794" EFFECT_SIZE="2.056105610561056" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.6178840931164504" LOG_CI_START="0.00820674319727878" LOG_EFFECT_SIZE="0.3130454181568646" ORDER="2442" O_E="0.0" SE="0.3581274932940764" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.12825530145309874" WEIGHT="17.392104247729968"/>
<DICH_DATA CI_END="2.1886542810760448" CI_START="0.957306708003668" EFFECT_SIZE="1.4474852071005917" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="40" LOG_CI_END="0.34017716600892445" LOG_CI_START="-0.018948897904156315" LOG_EFFECT_SIZE="0.16061413405238403" ORDER="2445" O_E="0.0" SE="0.21095242764523042" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.044500926729416176" WEIGHT="57.315233259818925"/>
<DICH_DATA CI_END="2.1042808924914613" CI_START="0.47331893929655383" EFFECT_SIZE="0.9979959919839679" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32310371167784774" LOG_CI_START="-0.32484611740519254" LOG_EFFECT_SIZE="-8.712028636723787E-4" ORDER="2444" O_E="0.0" SE="0.3806089370067602" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.14486316292941592" WEIGHT="20.905772061153165"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-28 21:25:41 +0530" MODIFIED_BY="Xavier Bosch" ORDER="874" O_E="0.0" SE="0.0" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-04-10 21:11:29 +0530" MODIFIED_BY="Xavier Bosch" NO="4">
<NAME>Subgroup of primary PCI in patients with STEMI</NAME>
<DICH_OUTCOME CHI2="5.072512745403724" CI_END="1.2051817480235818" CI_START="0.6389940948860697" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8775557077767427" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.08105254584178959" LOG_CI_START="-0.1945031552535635" LOG_EFFECT_SIZE="-0.05672530470588698" METHOD="MH" MODIFIED="2013-02-28 21:31:17 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.7497985902885663" P_Q="1.0" P_Z="0.4196964781671322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3466" TOTAL_2="3059" WEIGHT="99.99999999999997" Z="0.806947951311858">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.0198731872551905" CI_START="0.3643435677348885" EFFECT_SIZE="1.2102127659574469" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.604212352849646" LOG_CI_START="-0.4384888932776613" LOG_EFFECT_SIZE="0.08286172978599245" ORDER="2456" O_E="0.0" SE="0.6124878734295915" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.3751413950983033" WEIGHT="5.968173453105864"/>
<DICH_DATA CI_END="1.4683555293054376" CI_START="0.16323828629647819" EFFECT_SIZE="0.4895833333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16683122296507713" LOG_CI_START="-0.787177973172779" LOG_EFFECT_SIZE="-0.31017337510385096" ORDER="2454" O_E="0.0" SE="0.5603897242330598" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.31403664302600476" WEIGHT="11.775841135047349"/>
<DICH_DATA CI_END="1.55459457609585" CI_START="0.4631127285849624" EFFECT_SIZE="0.848500168520391" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.19161714813998693" LOG_CI_START="-0.3343132823223593" LOG_EFFECT_SIZE="-0.0713480670911862" ORDER="2455" O_E="0.0" SE="0.3089341382512" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.09544030177701154" WEIGHT="27.96903670163744"/>
<DICH_DATA CI_END="2.4476717815124527" CI_START="0.3095642243140261" EFFECT_SIZE="0.8704663212435233" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3887531810247094" LOG_CI_START="-0.5092492355885312" LOG_EFFECT_SIZE="-0.060248027281910914" ORDER="2453" O_E="0.0" SE="0.5274910647022708" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.2782468233407352" WEIGHT="9.469738912767244"/>
<DICH_DATA CI_END="1.2195597139842589" CI_START="0.27009845721495546" EFFECT_SIZE="0.5739348370927319" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.08620306977393853" LOG_CI_START="-0.5684778964676589" LOG_EFFECT_SIZE="-0.24113741334686023" MODIFIED="2009-12-16 23:29:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="705" O_E="0.0" SE="0.384562840293363" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.14788857813449863" WEIGHT="22.66849418496615"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2009-12-16 23:30:05 +0530" MODIFIED_BY="Xavier Bosch" ORDER="706" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="4.664123123983144"/>
<DICH_DATA CI_END="6.10558003083999" CI_START="0.5067747078702879" EFFECT_SIZE="1.759020618556701" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7857269282689927" LOG_CI_START="-0.2951850680318199" LOG_EFFECT_SIZE="0.2452709301185864" MODIFIED="2013-02-28 21:31:17 +0530" MODIFIED_BY="Xavier Bosch" ORDER="875" O_E="0.0" SE="0.6349330572277724" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.40313998716060573" WEIGHT="4.759402458748304"/>
<DICH_DATA CI_END="50.04906970284203" CI_START="0.11464844051728294" EFFECT_SIZE="2.3954222573007105" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.6993960093542557" LOG_CI_START="-0.9406318482985855" LOG_EFFECT_SIZE="0.37938208052783506" MODIFIED="2009-12-16 23:29:36 +0530" MODIFIED_BY="Xavier Bosch" ORDER="704" O_E="0.0" SE="1.550765431933938" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="2.4048734248812527" WEIGHT="0.8266838828737252"/>
<DICH_DATA CI_END="3.0079258897057595" CI_START="0.5647488097940576" EFFECT_SIZE="1.3033505154639176" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.47826713175725805" LOG_CI_START="-0.24814467568058352" LOG_EFFECT_SIZE="0.11506122803833728" MODIFIED="2009-12-16 23:29:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="702" O_E="0.0" SE="0.4266978914854272" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.18207109059810941" WEIGHT="11.898506146870758"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.520430529003642" CI_END="1.1546592441082912" CI_START="0.677664001353639" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8845739107403027" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="118" I2="36.1044336177741" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.062453836835948115" LOG_CI_START="-0.16898558419724133" LOG_EFFECT_SIZE="-0.053265873680646586" METHOD="MH" MODIFIED="2013-04-10 20:44:08 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.12945012401449085" P_Q="1.0" P_Z="0.366965005348345" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2483" TOTAL_2="2404" WEIGHT="100.0" Z="0.9021729621779168">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1820465687753776" CI_START="0.37874823242455313" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.33886401497201135" LOG_CI_START="-0.4216493852884615" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="2464" O_E="0.0" SE="0.44672933591504776" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.1995670995670996" WEIGHT="9.138466871000855"/>
<DICH_DATA CI_END="1.3044622028586013" CI_START="0.14971117734078232" EFFECT_SIZE="0.44191919191919193" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.11543149981971623" LOG_CI_START="-0.8247457742981519" LOG_EFFECT_SIZE="-0.3546571372392179" ORDER="2462" O_E="0.0" SE="0.5522647847694007" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.3049963924963925" WEIGHT="9.171697659622676"/>
<DICH_DATA CI_END="1.429833630659547" CI_START="0.6085783583833501" EFFECT_SIZE="0.9328267811914988" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" LOG_CI_END="0.15528550775184805" LOG_CI_START="-0.21568349562195988" LOG_EFFECT_SIZE="-0.030198993935055932" ORDER="2463" O_E="0.0" SE="0.21790902890795738" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.04748434487960901" WEIGHT="37.882511374112845"/>
<DICH_DATA CI_END="1.2569296091459647" CI_START="0.23361622838048451" EFFECT_SIZE="0.5418848167539267" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.09931095690992588" LOG_CI_START="-0.6314969918195077" LOG_EFFECT_SIZE="-0.26609301745479097" ORDER="2461" O_E="0.0" SE="0.4292802066413587" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.1842814958140476" WEIGHT="13.2711685832419"/>
<DICH_DATA CI_END="0.8834563410491986" CI_START="0.002881385072286747" EFFECT_SIZE="0.05045372050816697" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.053814907741730686" LOG_CI_START="-2.5403986981256867" LOG_EFFECT_SIZE="-1.2971068029337087" MODIFIED="2009-12-16 23:33:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="725" O_E="0.0" SE="1.4606316272598117" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="2.1334447505516456" WEIGHT="7.871071026546448"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2009-12-16 23:33:17 +0530" MODIFIED_BY="Xavier Bosch" ORDER="726" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="3.3024413481067376"/>
<DICH_DATA CI_END="3.2595498269126137" CI_START="0.91618733147098" EFFECT_SIZE="1.7281082887700534" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.5131576242434559" LOG_CI_START="-0.03801571770104572" LOG_EFFECT_SIZE="0.2375709532712051" MODIFIED="2013-03-04 22:12:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1562" O_E="0.0" SE="0.32376194941024516" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.10482179988592213" WEIGHT="12.993238351132124"/>
<DICH_DATA CI_END="4.318001687357362" CI_START="0.5265163609854081" EFFECT_SIZE="1.5078125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6352828077086909" LOG_CI_START="-0.27858812898888013" LOG_EFFECT_SIZE="0.1783473393599054" MODIFIED="2013-02-28 21:31:51 +0530" MODIFIED_BY="Xavier Bosch" ORDER="876" O_E="0.0" SE="0.5368123119502478" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.2881674582613702" WEIGHT="5.0027441779760045"/>
<DICH_DATA CI_END="7.28486338926983" CI_START="0.011522173759729045" EFFECT_SIZE="0.2897196261682243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8624214119958415" LOG_CI_START="-1.9384655796977155" LOG_EFFECT_SIZE="-0.538022083850937" MODIFIED="2013-04-10 20:44:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1028" O_E="0.0" SE="1.6452548835350098" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="2.706863631795799" WEIGHT="1.3666606082603976"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.568806199478525" CI_END="1.0000641023787609" CI_START="0.612365990232124" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7825632526184514" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="145" I2="6.638103211076717" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="2.7838417127869338E-5" LOG_CI_START="-0.2129889372825114" LOG_EFFECT_SIZE="-0.10648054943269175" METHOD="MH" MODIFIED="2013-02-28 21:32:26 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.37996498766533926" P_Q="1.0" P_Z="0.05005991074716175" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3466" TOTAL_2="3059" WEIGHT="100.0" Z="1.9594517028685474">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7520048352522535" CI_START="0.3462645412651205" EFFECT_SIZE="0.7788819875776397" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.24353530041680768" LOG_CI_START="-0.4605919794911118" LOG_EFFECT_SIZE="-0.1085283395371521" ORDER="2460" O_E="0.0" SE="0.41360784970416065" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.17107145333689955" WEIGHT="9.225408386956534"/>
<DICH_DATA CI_END="1.4928490993582744" CI_START="0.2184090295750719" EFFECT_SIZE="0.5710093896713615" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.17401591045232867" LOG_CI_START="-0.6607294107769874" LOG_EFFECT_SIZE="-0.2433567501623294" ORDER="2458" O_E="0.0" SE="0.49033353374608135" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.24042697431591947" WEIGHT="7.860047945686966"/>
<DICH_DATA CI_END="1.426718784819025" CI_START="0.5097284757657291" EFFECT_SIZE="0.852783203125" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.15433837939576345" LOG_CI_START="-0.29266110405601875" LOG_EFFECT_SIZE="-0.0691613623301276" ORDER="2459" O_E="0.0" SE="0.2625697092627056" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.06894285222230175" WEIGHT="21.779407926786146"/>
<DICH_DATA CI_END="1.0645979234953766" CI_START="0.1889714687376683" EFFECT_SIZE="0.4485294117647059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.027185614743575174" LOG_CI_START="-0.723603761462476" LOG_EFFECT_SIZE="-0.34820907335945045" ORDER="2457" O_E="0.0" SE="0.44101739605078505" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.19449634361941498" WEIGHT="11.291899865634797"/>
<DICH_DATA CI_END="1.2364778498688138" CI_START="0.41829389011617946" EFFECT_SIZE="0.7191739218465276" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" LOG_CI_END="0.09218634086237065" LOG_CI_START="-0.37851847897234026" LOG_EFFECT_SIZE="-0.14316606905498483" MODIFIED="2009-12-16 23:31:42 +0530" MODIFIED_BY="Xavier Bosch" ORDER="710" O_E="0.0" SE="0.27649434119734556" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.07644912071415413" WEIGHT="21.58308569518973"/>
<DICH_DATA CI_END="1.1038931784097734" CI_START="0.10118222733826397" EFFECT_SIZE="0.33420707732634336" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.042927049596310406" LOG_CI_START="-0.9948957646381609" LOG_EFFECT_SIZE="-0.4759843575209253" MODIFIED="2009-12-16 23:32:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="711" O_E="0.0" SE="0.6096222583871124" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.37163929792100325" WEIGHT="6.138651103995206"/>
<DICH_DATA CI_END="1.7209680322803378" CI_START="0.31514448379462257" EFFECT_SIZE="0.7364465915190553" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.23577280319612934" LOG_CI_START="-0.5014902902471488" LOG_EFFECT_SIZE="-0.13285874352550972" MODIFIED="2009-12-16 23:31:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="709" O_E="0.0" SE="0.43307199059975265" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.18755134904203224" WEIGHT="8.245331685719627"/>
<DICH_DATA CI_END="6.053764570656634" CI_START="0.6816653038207906" EFFECT_SIZE="2.031413612565445" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7820255273485307" LOG_CI_START="-0.16642881065557125" LOG_EFFECT_SIZE="0.30779835834647973" MODIFIED="2013-02-28 21:32:26 +0530" MODIFIED_BY="Xavier Bosch" ORDER="877" O_E="0.0" SE="0.5571267730683014" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.31039024126949855" WEIGHT="3.303849378578809"/>
<DICH_DATA CI_END="2.350045571117705" CI_START="0.6032006136699485" EFFECT_SIZE="1.1906086387434556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.3710762840134639" LOG_CI_START="-0.2195382253058275" LOG_EFFECT_SIZE="0.07576902935381821" MODIFIED="2009-12-16 23:31:09 +0530" MODIFIED_BY="Xavier Bosch" ORDER="707" O_E="0.0" SE="0.34692988636312394" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12036034605193009" WEIGHT="10.572318011452188"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.574333982865237" CI_END="1.1561857536730384" CI_START="0.5095017683132798" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7675146161442368" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="194" I2="61.11660281852828" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.0630276137682915" LOG_CI_START="-0.2928543043614469" LOG_EFFECT_SIZE="-0.1149133452965777" METHOD="MH" MODIFIED="2013-04-10 20:44:30 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.00836839879351936" P_Q="1.0" P_Z="0.20560816269496818" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2051846562455198" TOTALS="YES" TOTAL_1="2483" TOTAL_2="2404" WEIGHT="100.00000000000001" Z="1.2657345408720675">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3856074448955416" CI_START="0.41696769722548055" EFFECT_SIZE="0.76010101010101" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.14164020815217282" LOG_CI_START="-0.3798975888155107" LOG_EFFECT_SIZE="-0.11912869033166898" ORDER="2468" O_E="0.0" SE="0.30635388359254867" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.09385270199223687" WEIGHT="14.613747591768567"/>
<DICH_DATA CI_END="1.2524491230418444" CI_START="0.21128903242115818" EFFECT_SIZE="0.5144208037825059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.09776009299759868" LOG_CI_START="-0.6751230456953988" LOG_EFFECT_SIZE="-0.28868147634890007" ORDER="2466" O_E="0.0" SE="0.45399538150150553" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.20611180642469754" WEIGHT="10.625076727926581"/>
<DICH_DATA CI_END="1.404259604736001" CI_START="0.702224635685269" EFFECT_SIZE="0.9930285440727664" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="68" LOG_CI_END="0.1474474030089811" LOG_CI_START="-0.15352393853558846" LOG_EFFECT_SIZE="-0.003038267763303675" ORDER="1030" O_E="0.0" SE="0.17679205585544852" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.031255431013596034" WEIGHT="18.482722301682642"/>
<DICH_DATA CI_END="0.7744334863035875" CI_START="0.17957352853781652" EFFECT_SIZE="0.37291789143640997" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.11101587651261872" LOG_CI_START="-0.7457576835778034" LOG_EFFECT_SIZE="-0.42838678004521097" ORDER="2465" O_E="0.0" SE="0.3728504794927083" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.13901748005794248" WEIGHT="12.696192187322843"/>
<DICH_DATA CI_END="0.6122631719676019" CI_START="0.009801003503232143" EFFECT_SIZE="0.07746478873239436" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.21306186287730208" LOG_CI_START="-2.008729455572361" LOG_EFFECT_SIZE="-1.1108956592248316" MODIFIED="2009-12-16 23:33:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="727" O_E="0.0" SE="1.0547840326470164" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="1.112569355527102" WEIGHT="3.316291534500677"/>
<DICH_DATA CI_END="1.4311007059550747" CI_START="0.15874593051244992" EFFECT_SIZE="0.4766355140186916" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.15567019595523704" LOG_CI_START="-0.7992973991297837" LOG_EFFECT_SIZE="-0.3218136015872733" MODIFIED="2009-12-16 23:34:15 +0530" MODIFIED_BY="Xavier Bosch" ORDER="728" O_E="0.0" SE="0.5609526925187756" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.31466792324406395" WEIGHT="8.40633796236345"/>
<DICH_DATA CI_END="4.858291695424427" CI_START="0.7404466913695666" EFFECT_SIZE="1.8966565349544073" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6864835866136397" LOG_CI_START="-0.1305062031487403" LOG_EFFECT_SIZE="0.2779886917324497" MODIFIED="2013-02-28 21:33:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="878" O_E="0.0" SE="0.47990384667110486" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.2303077020497233" WEIGHT="10.034748923959672"/>
<DICH_DATA CI_END="2.475775806656468" CI_START="0.8899366852164702" EFFECT_SIZE="1.4843462246777164" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="27" LOG_CI_END="0.39371131468559334" LOG_CI_START="-0.05064089025310598" LOG_EFFECT_SIZE="0.17153521221624368" MODIFIED="2013-03-04 22:13:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1563" O_E="0.0" SE="0.26101468475988077" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.06812866566029994" WEIGHT="15.989182098125886"/>
<DICH_DATA CI_END="3.723005569583228" CI_START="0.20684787573541472" EFFECT_SIZE="0.8775510204081632" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5708936859195615" LOG_CI_START="-0.6843489348174159" LOG_EFFECT_SIZE="-0.05672762444892715" MODIFIED="2013-04-10 20:44:30 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1029" O_E="0.0" SE="0.737335728972084" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.5436639772187946" WEIGHT="5.835700672349696"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.615455198495923" CI_END="0.8291973940403702" CI_START="0.44976909148195826" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6106941612433712" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="107" I2="41.24324245227036" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.08134207145476348" LOG_CI_START="-0.34701039296453184" LOG_EFFECT_SIZE="-0.21417623220964765" METHOD="MH" MODIFIED="2013-02-28 21:33:37 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.09235567982089887" P_Q="1.0" P_Z="0.0015768048425859227" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3466" TOTAL_2="3061" WEIGHT="100.0" Z="3.1601637642744858">
<NAME>30-day urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7238898464461551" CI_START="0.0785104955386949" EFFECT_SIZE="0.23839662447257384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.14032751490813414" LOG_CI_START="-1.1050722814731966" LOG_EFFECT_SIZE="-0.6226998981906653" ORDER="2472" O_E="0.0" SE="0.5666958514439314" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.3211441880437624" WEIGHT="14.659344513049339"/>
<DICH_DATA CI_END="0.8909646983457026" CI_START="0.041305040307814664" EFFECT_SIZE="0.19183673469387755" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.05013950316557952" LOG_CI_START="-1.3839969496920503" LOG_EFFECT_SIZE="-0.717068226428815" ORDER="2470" O_E="0.0" SE="0.7835144667904963" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.6138949196699957" WEIGHT="9.149332979703026"/>
<DICH_DATA CI_END="0.906036103183183" CI_START="0.33958922692973154" EFFECT_SIZE="0.5546891921160927" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="45" LOG_CI_END="-0.042854496472370794" LOG_CI_START="-0.46904609569305217" LOG_EFFECT_SIZE="-0.25595029608271147" ORDER="2471" O_E="0.0" SE="0.25034705506466887" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.06267364797955234" WEIGHT="41.40687953820784"/>
<DICH_DATA CI_END="3.199564624588795" CI_START="0.03403242558921244" EFFECT_SIZE="0.32998324958123953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5050908864441218" LOG_CI_START="-1.4681070963796743" LOG_EFFECT_SIZE="-0.48150810496777613" ORDER="2469" O_E="0.0" SE="1.1590662625982406" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="1.3434346010934535" WEIGHT="2.7868121371850543"/>
<DICH_DATA CI_END="1.7313461317694077" CI_START="0.4719660121165727" EFFECT_SIZE="0.903956043956044" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.2383839009719388" LOG_CI_START="-0.3260892752678133" LOG_EFFECT_SIZE="-0.04385268714793728" MODIFIED="2009-12-16 23:35:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="714" O_E="0.0" SE="0.3315743379105168" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.10994154156079758" WEIGHT="17.885914095660052"/>
<DICH_DATA CI_END="2.0902129935917557" CI_START="0.0046596722490235415" EFFECT_SIZE="0.09868995633187773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32019054315814804" LOG_CI_START="-2.3316446295431223" LOG_EFFECT_SIZE="-1.0057270431924872" MODIFIED="2009-12-16 23:35:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="715" O_E="0.0" SE="1.5577011072405373" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="2.426432739498396" WEIGHT="3.0717764079755936"/>
<DICH_DATA CI_END="5.34902962456593" CI_START="0.38642155987492577" EFFECT_SIZE="1.4376996805111821" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7282750031576615" LOG_CI_START="-0.412938650699871" LOG_EFFECT_SIZE="0.1576681762288952" MODIFIED="2009-12-16 23:35:04 +0530" MODIFIED_BY="Xavier Bosch" ORDER="713" O_E="0.0" SE="0.6703545493746086" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.4493752218672346" WEIGHT="3.738402884096054"/>
<DICH_DATA CI_END="3.3473104987492195" CI_START="0.16552156130414566" EFFECT_SIZE="0.7443467336683417" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5246959996714731" LOG_CI_START="-0.7811454257825281" LOG_EFFECT_SIZE="-0.12822471305552757" MODIFIED="2009-12-16 23:34:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="712" O_E="0.0" SE="0.7670577173309867" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.5883775417170239" WEIGHT="3.715749516246739"/>
<DICH_DATA CI_END="6.890840025883355" CI_START="0.6047914710086019" EFFECT_SIZE="2.0414507772020727" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8382721676795183" LOG_CI_START="-0.21839434204391756" LOG_EFFECT_SIZE="0.3099389128178004" MODIFIED="2013-02-28 21:33:37 +0530" MODIFIED_BY="Xavier Bosch" ORDER="879" O_E="0.0" SE="0.6206911383951271" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3852574892822388" WEIGHT="3.5857879278763"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.463836426274195" CI_END="0.8981098364868755" CI_START="0.6253155333708587" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7494011151769159" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="305" I2="23.546205482413882" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-0.04667054700400337" LOG_CI_START="-0.20390078294021796" LOG_EFFECT_SIZE="-0.1252856649721107" METHOD="MH" MODIFIED="2013-04-10 20:44:49 +0530" MODIFIED_BY="Xavier Bosch" NO="6" P_CHI2="0.2339671303059957" P_Q="1.0" P_Z="0.001787055986486943" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2483" TOTAL_2="2406" WEIGHT="99.99999999999999" Z="3.1235136125357674">
<NAME>6-month urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8326811201833133" CI_START="0.15679614180968204" EFFECT_SIZE="0.3613325158389536" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.07952128221711992" LOG_CI_START="-0.8046646279486479" LOG_EFFECT_SIZE="-0.442092955082884" ORDER="2484" O_E="0.0" SE="0.42595279080015186" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.18143577999043792" WEIGHT="7.442600387626646"/>
<DICH_DATA CI_END="1.0746307700612487" CI_START="0.07811163916943659" EFFECT_SIZE="0.2897260273972603" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03125927162862725" LOG_CI_START="-1.1072842484474166" LOG_EFFECT_SIZE="-0.5380124884093948" ORDER="2482" O_E="0.0" SE="0.6687860995739869" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.4472748469833867" WEIGHT="3.5754294852146318"/>
<DICH_DATA CI_END="1.064204034826217" CI_START="0.6404199246336706" EFFECT_SIZE="0.8255528255528255" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="148" LOG_CI_END="0.02702490117716406" LOG_CI_START="-0.19353516484791605" LOG_EFFECT_SIZE="-0.08325513183537601" ORDER="2483" O_E="0.0" SE="0.12955807457306703" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.0167852946870804" WEIGHT="48.25580641921671"/>
<DICH_DATA CI_END="1.5771801567298585" CI_START="0.5483507361248292" EFFECT_SIZE="0.9299719887955182" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.19788130436559231" LOG_CI_START="-0.26094156918190614" LOG_EFFECT_SIZE="-0.03153013240815689" ORDER="2481" O_E="0.0" SE="0.26951482713165426" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.07263824204380548" WEIGHT="10.491191722369509"/>
<DICH_DATA CI_END="3.464326476266973" CI_START="0.03578858328997774" EFFECT_SIZE="0.352112676056338" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5396188129527141" LOG_CI_START="-1.4462554930467892" LOG_EFFECT_SIZE="-0.4533183400470377" MODIFIED="2009-12-16 23:39:44 +0530" MODIFIED_BY="Xavier Bosch" ORDER="729" O_E="0.0" SE="1.166512397580463" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="1.3607511737089202" WEIGHT="1.043241753905091"/>
<DICH_DATA CI_END="2.0166422415625695" CI_START="0.053146902198584145" EFFECT_SIZE="0.3273809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.3046288598904091" LOG_CI_START="-1.2745220443536471" LOG_EFFECT_SIZE="-0.484946592231619" MODIFIED="2009-12-16 23:39:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="730" O_E="0.0" SE="0.9276010580760043" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.8604437229437228" WEIGHT="1.4351835461517797"/>
<DICH_DATA CI_END="0.9484297050211324" CI_START="0.44173922377133823" EFFECT_SIZE="0.6472701149425287" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="76" LOG_CI_END="-0.02299485228480921" LOG_CI_START="-0.35483403630615146" LOG_EFFECT_SIZE="-0.18891444429548035" MODIFIED="2013-03-04 22:13:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1564" O_E="0.0" SE="0.19492397932458935" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.03799535771573294" WEIGHT="24.288431256410085"/>
<DICH_DATA CI_END="3.955226875555563" CI_START="0.4588393732155589" EFFECT_SIZE="1.3471502590673574" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.597171400090559" LOG_CI_START="-0.3383393221644707" LOG_EFFECT_SIZE="0.12941603896304418" MODIFIED="2013-02-28 21:34:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="880" O_E="0.0" SE="0.5495236291053651" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3019762189451308" WEIGHT="2.116309212777829"/>
<DICH_DATA CI_END="5.984006774904314" CI_START="0.4472035769791267" EFFECT_SIZE="1.6358695652173914" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.77699207655124" LOG_CI_START="-0.3494947313826262" LOG_EFFECT_SIZE="0.2137486725843069" MODIFIED="2013-04-10 20:44:49 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1030" O_E="0.0" SE="0.6617039271799842" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.4378520872454138" WEIGHT="1.351806216327724"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.03202273442367" CI_END="0.9776245747936658" CI_START="0.4869146893070686" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6899418570391369" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="223" I2="57.9655819476812" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="-0.009827889995198642" LOG_CI_START="-0.3125471234028152" LOG_EFFECT_SIZE="-0.16118750669900694" METHOD="MH" MODIFIED="2013-04-10 21:11:29 +0530" MODIFIED_BY="Xavier Bosch" NO="7" P_CHI2="0.014689351981356014" P_Q="1.0" P_Z="0.03686772189764347" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.15353371450930914" TOTALS="YES" TOTAL_1="3466" TOTAL_2="3061" WEIGHT="100.00000000000001" Z="2.0872258715221332">
<NAME>30-day mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9615712027823643" CI_START="0.25082585419205716" EFFECT_SIZE="0.4911078479360418" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" LOG_CI_END="-0.017018551435328988" LOG_CI_START="-0.6006277000812044" LOG_EFFECT_SIZE="-0.30882312575826665" ORDER="2476" O_E="0.0" SE="0.34281490282646476" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.11752205759991848" WEIGHT="11.66531777536124"/>
<DICH_DATA CI_END="0.8486823956007047" CI_START="0.16742403825503982" EFFECT_SIZE="0.3769480519480519" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.07125480639264883" LOG_CI_START="-0.7761821871310922" LOG_EFFECT_SIZE="-0.42371849676187046" ORDER="2474" O_E="0.0" SE="0.41407783289257327" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.17146045169300983" WEIGHT="9.72925684620328"/>
<DICH_DATA CI_END="0.9262861126575417" CI_START="0.4368536025279076" EFFECT_SIZE="0.6361221779548473" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="72" LOG_CI_END="-0.033254847058855334" LOG_CI_START="-0.3596640785134194" LOG_EFFECT_SIZE="-0.19645946278613735" ORDER="2475" O_E="0.0" SE="0.19173439830816513" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.03676207949459411" WEIGHT="16.61598320157923"/>
<DICH_DATA CI_END="0.9558047000345323" CI_START="0.18816296222446746" EFFECT_SIZE="0.42408376963350786" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.019630838228236497" LOG_CI_START="-0.7254658585099191" LOG_EFFECT_SIZE="-0.3725483483690778" ORDER="2473" O_E="0.0" SE="0.4146109848531603" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.1719022687609075" WEIGHT="9.716048252336622"/>
<DICH_DATA CI_END="0.7840334509694098" CI_START="0.07955354949249081" EFFECT_SIZE="0.24974515800203873" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="-0.10566540764526376" LOG_CI_START="-1.0993404383855683" LOG_EFFECT_SIZE="-0.6025029230154161" MODIFIED="2009-12-16 23:36:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="719" O_E="0.0" SE="0.5836896318275859" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.34069358630302277" WEIGHT="6.397768215764137"/>
<DICH_DATA CI_END="1.3640756923992228" CI_START="0.5201194130751116" EFFECT_SIZE="0.8423076923076923" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.1348384699386668" LOG_CI_START="-0.283896936200066" LOG_EFFECT_SIZE="-0.07452923313069962" MODIFIED="2009-12-16 23:36:43 +0530" MODIFIED_BY="Xavier Bosch" ORDER="718" O_E="0.0" SE="0.24596725033958133" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.06049988823961427" WEIGHT="14.773155597484529"/>
<DICH_DATA CI_END="2.767396850752258" CI_START="0.676043157306895" EFFECT_SIZE="1.367801047120419" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.44207144238401824" LOG_CI_START="-0.17002557864125237" LOG_EFFECT_SIZE="0.1360229318713829" MODIFIED="2009-12-16 23:36:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="716" O_E="0.0" SE="0.359548820079364" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12927535402046286" WEIGHT="11.180517417415036"/>
<DICH_DATA CI_END="1.660740130594438" CI_START="0.36112149071683597" EFFECT_SIZE="0.7744216885221747" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.2203016802067009" LOG_CI_START="-0.44234666548618556" LOG_EFFECT_SIZE="-0.11102249263974236" MODIFIED="2009-12-16 23:36:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="717" O_E="0.0" SE="0.38924291842221453" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.15151004954184277" WEIGHT="10.36556746647612"/>
<DICH_DATA CI_END="4.79000015643427" CI_START="0.9192311686322996" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6803355275979743" LOG_CI_START="-0.03657525832377156" LOG_EFFECT_SIZE="0.32188013463710136" MODIFIED="2013-02-28 21:34:33 +0530" MODIFIED_BY="Xavier Bosch" ORDER="881" O_E="0.0" SE="0.4211169444160576" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.17733948087431695" WEIGHT="9.556385227379812"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.19948955635855" CI_END="0.9690745643594753" CI_START="0.7326560400683624" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.842613988048256" ESTIMABLE="YES" EVENTS_1="488" EVENTS_2="495" I2="43.65994658999844" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="-0.013642805359965156" LOG_CI_START="-0.13509986568561258" LOG_EFFECT_SIZE="-0.07437133552278885" METHOD="MH" MODIFIED="2013-04-10 20:45:10 +0530" MODIFIED_BY="Xavier Bosch" NO="8" P_CHI2="0.07671174102159983" P_Q="1.0" P_Z="0.016382783707511228" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3046" TOTAL_2="2631" WEIGHT="100.0" Z="2.400274446227974">
<NAME>6-month mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0168400969205984" CI_START="0.3639765750973116" EFFECT_SIZE="0.6083633584452451" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="43" LOG_CI_END="0.007252663360284221" LOG_CI_START="-0.43892656589308093" LOG_EFFECT_SIZE="-0.21583695126639835" ORDER="2488" O_E="0.0" SE="0.2620878878862317" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.06869006097666595" WEIGHT="8.879225205400223"/>
<DICH_DATA CI_END="0.8958463513146007" CI_START="0.19859971768922444" EFFECT_SIZE="0.42179951690821255" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.04776647080472422" LOG_CI_START="-0.702021373192597" LOG_EFFECT_SIZE="-0.3748939219986606" ORDER="2486" O_E="0.0" SE="0.38431256827663507" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.1476961501353833" WEIGHT="5.169436635796453"/>
<DICH_DATA CI_END="1.12794595413546" CI_START="0.7187539075452365" EFFECT_SIZE="0.9003974467060099" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="190" LOG_CI_END="0.05228829079709292" LOG_CI_START="-0.14341978123000562" LOG_EFFECT_SIZE="-0.04556574521645637" ORDER="2487" O_E="0.0" SE="0.11495989027929837" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.013215776373028319" WEIGHT="37.347234740684435"/>
<DICH_DATA CI_END="0.9808629342255492" CI_START="0.39709938413492707" EFFECT_SIZE="0.6240994048240577" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="61" LOG_CI_END="-0.008391676685752695" LOG_CI_START="-0.4011007864868856" LOG_EFFECT_SIZE="-0.20474623158631913" ORDER="2485" O_E="0.0" SE="0.23067927503863042" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.053212927932348095" WEIGHT="11.210981580847516"/>
<DICH_DATA CI_END="1.0778788344356367" CI_START="0.15704313321671678" EFFECT_SIZE="0.4114285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.03256994406638623" LOG_CI_START="-0.8039810485764382" LOG_EFFECT_SIZE="-0.385705552255026" MODIFIED="2009-12-16 23:42:49 +0530" MODIFIED_BY="Xavier Bosch" ORDER="733" O_E="0.0" SE="0.49139419407259377" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.24146825396825397" WEIGHT="2.858478928413737"/>
<DICH_DATA CI_END="3.4705248704498204" CI_START="0.8202144425463485" EFFECT_SIZE="1.6871794871794872" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.5403951609874541" LOG_CI_START="-0.08607258781254147" LOG_EFFECT_SIZE="0.2271612865874563" MODIFIED="2013-02-28 21:35:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="882" O_E="0.0" SE="0.3679902567104873" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.13541682903385033" WEIGHT="2.725611464363802"/>
<DICH_DATA CI_END="1.5702368125140274" CI_START="0.7206166975148911" EFFECT_SIZE="1.0637381567614126" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="43" LOG_CI_END="0.1959651547101257" LOG_CI_START="-0.14229567899590428" LOG_EFFECT_SIZE="0.026834737857110703" MODIFIED="2009-12-16 23:42:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="732" O_E="0.0" SE="0.19869608813705356" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.039480135440967755" WEIGHT="11.591336667129575"/>
<DICH_DATA CI_END="1.198304705792229" CI_START="0.6271970198850383" EFFECT_SIZE="0.8669331810394061" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="102" LOG_CI_END="0.07856726481289066" LOG_CI_START="-0.20259601386085985" LOG_EFFECT_SIZE="-0.06201437452398457" MODIFIED="2013-03-04 22:13:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1565" O_E="0.0" SE="0.16515670167363683" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.027276736107714677" WEIGHT="18.44772462489047"/>
<DICH_DATA CI_END="2.95874555117806" CI_START="0.41329613692164313" EFFECT_SIZE="1.1058201058201058" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4711076179247954" LOG_CI_START="-0.38373865404917573" LOG_EFFECT_SIZE="0.043684481937809855" MODIFIED="2013-04-10 20:45:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1031" O_E="0.0" SE="0.5021409317148026" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.25214551530341" WEIGHT="1.7699701524737856"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.648977220589459" CI_END="2.107084742742736" CI_START="1.1232767460106936" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="1.538453539563948" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.3236820024165786" LOG_CI_START="0.05048676824575984" LOG_EFFECT_SIZE="0.18708438533116922" METHOD="MH" MODIFIED="2013-02-28 21:35:48 +0530" MODIFIED_BY="Xavier Bosch" NO="9" P_CHI2="0.9766049084458959" P_Q="1.0" P_Z="0.007266645910058322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3538" TOTAL_2="3137" WEIGHT="100.0" Z="2.684370819511697">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2759534767807224" CI_START="1.0960306519268834" EFFECT_SIZE="1.8948734587929916" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="23" LOG_CI_END="0.5153377255301146" LOG_CI_START="0.039822699929883416" LOG_EFFECT_SIZE="0.277580212729999" ORDER="2480" O_E="0.0" SE="0.2793198798749147" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.07801959529333677" WEIGHT="30.004943579851815"/>
<DICH_DATA CI_END="75.7329305966302" CI_START="0.12368872278442308" EFFECT_SIZE="3.0606060606060606" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8792847628106097" LOG_CI_START="-0.9076698950010998" LOG_EFFECT_SIZE="0.4858074339047551" ORDER="2478" O_E="0.0" SE="1.6370709616466477" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="2.68000133346668" WEIGHT="0.7707358616995148"/>
<DICH_DATA CI_END="5.2290966529281615" CI_START="0.41398747442575456" EFFECT_SIZE="1.47131931166348" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7184266692623242" LOG_CI_START="-0.3830127986618777" LOG_EFFECT_SIZE="0.1677069353002233" ORDER="2479" O_E="0.0" SE="0.6469909956719746" STUDY_ID="STD-CADILLAC-2002" TOTAL_1="1052" TOTAL_2="1030" VAR="0.41859734848061303" WEIGHT="6.299803486649605"/>
<DICH_DATA CI_END="3.553023019892206" CI_START="0.387065443325746" EFFECT_SIZE="1.1727115716753023" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5505980212747973" LOG_CI_START="-0.4122156001686663" LOG_EFFECT_SIZE="0.0691912105530655" ORDER="2477" O_E="0.0" SE="0.5655614872401817" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.3198597958493263" WEIGHT="9.075375845458165"/>
<DICH_DATA CI_END="2.793753964807843" CI_START="0.6856670030823098" EFFECT_SIZE="1.3840465701699183" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.4461881568135316" LOG_CI_START="-0.16388674994265123" LOG_EFFECT_SIZE="0.14115070343544017" MODIFIED="2009-12-30 16:59:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="723" O_E="0.0" SE="0.35836102014807486" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.1284226207615689" WEIGHT="20.97376197572297"/>
<DICH_DATA CI_END="15.145884842133626" CI_START="0.1566937278201711" EFFECT_SIZE="1.5405405405405406" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1802946504539946" LOG_CI_START="-0.8049483872430017" LOG_EFFECT_SIZE="0.18767313160549642" MODIFIED="2009-12-30 16:58:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="724" O_E="0.0" SE="1.1661415874547418" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="1.3598862019914653" WEIGHT="2.0230684798286065"/>
<DICH_DATA CI_END="8.887695683575577" CI_START="0.014285508586923415" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9487891758600732" LOG_CI_START="-1.8451042934287647" LOG_EFFECT_SIZE="-0.4481575587843458" MODIFIED="2009-12-16 23:38:36 +0530" MODIFIED_BY="Xavier Bosch" ORDER="721" O_E="0.0" SE="1.6411468538559837" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="2.693362995921394" WEIGHT="2.242857747462902"/>
<DICH_DATA CI_END="2.862927770247001" CI_START="0.34575566077574593" EFFECT_SIZE="0.9949238578680203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.45681039120048" LOG_CI_START="-0.4612307008107137" LOG_EFFECT_SIZE="-0.002210154805116882" MODIFIED="2009-12-16 23:37:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="720" O_E="0.0" SE="0.5392618818240714" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.2908033771884388" WEIGHT="10.807377625981701"/>
<DICH_DATA CI_END="13.83872288303058" CI_START="0.14849992216190167" EFFECT_SIZE="1.4335443037974684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1410960127764698" LOG_CI_START="-0.8282737739876136" LOG_EFFECT_SIZE="0.1564111193944281" MODIFIED="2009-12-30 17:00:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="722" O_E="0.0" SE="1.1568175612828895" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="1.3382268700924915" WEIGHT="2.11217691495504"/>
<DICH_DATA CI_END="3.853603594794696" CI_START="0.8260906671731362" EFFECT_SIZE="1.7842157842157842" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5858670384337318" LOG_CI_START="-0.08297228428731374" LOG_EFFECT_SIZE="0.25144737707320897" MODIFIED="2013-02-28 21:35:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="883" O_E="0.0" SE="0.39287952897438555" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.15435432428713505" WEIGHT="15.689898482389678"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-05-25 20:58:32 +0530" MODIFIED_BY="Xavier Bosch" NO="5">
<NAME>Subgroup of balloon angioplasty</NAME>
<DICH_OUTCOME CHI2="3.6043907923338567" CI_END="1.1365917975151754" CI_START="0.5510445885988923" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.791399241512541" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.05560451753067945" LOG_CI_START="-0.2588132581373684" LOG_EFFECT_SIZE="-0.10160437030334446" METHOD="MH" MODIFIED="2009-12-23 20:59:18 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.8909386760778572" P_Q="1.0" P_Z="0.2052525751151909" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8046" TOTAL_2="5332" WEIGHT="100.0" Z="1.266728040698772">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.235307327498598" CI_START="0.012621821467408088" EFFECT_SIZE="0.3224043715846995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9156798109309462" LOG_CI_START="-1.8988779671075169" LOG_EFFECT_SIZE="-0.49159907808828524" ORDER="2562" O_E="0.0" SE="1.6532851711054914" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.733351856997314" WEIGHT="2.261372874166558"/>
<DICH_DATA CI_END="2.202710344178457" CI_START="0.43846641438461686" EFFECT_SIZE="0.9827586206896551" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3429573912970908" LOG_CI_START="-0.35806366707798265" LOG_EFFECT_SIZE="-0.007553137890445899" ORDER="2555" O_E="0.0" SE="0.4117832397997223" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.1695654365799556" WEIGHT="18.230397882590317"/>
<DICH_DATA CI_END="7.839090119459458" CI_START="0.029391166128842395" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8942656571959335" LOG_CI_START="-1.5317831824447592" LOG_EFFECT_SIZE="-0.3187587626244128" ORDER="2557" O_E="0.0" SE="1.42507309754038" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="2.0308333333333333" WEIGHT="2.043061831669604"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2559" O_E="0.0" SE="0.0" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.9269030729044214" CI_START="0.43241097107602416" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.46640834060948216" LOG_CI_START="-0.36410329571471955" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="2561" O_E="0.0" SE="0.48784664627573887" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.2379943502824859" WEIGHT="12.161036890610667"/>
<DICH_DATA CI_END="2.1845324933014454" CI_START="0.25997400229081025" EFFECT_SIZE="0.7536057692307693" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3393585089021063" LOG_CI_START="-0.5850700798221213" LOG_EFFECT_SIZE="-0.12285578546000747" ORDER="2553" O_E="0.0" SE="0.5430139290119261" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.29486412710096915" WEIGHT="12.09363398857075"/>
<DICH_DATA CI_END="1.4436250602245138" CI_START="0.17656882170682706" EFFECT_SIZE="0.504875406283857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.1594544124722273" LOG_CI_START="-0.7530859811440511" LOG_EFFECT_SIZE="-0.2968157843359119" ORDER="2556" O_E="0.0" SE="0.536030744358002" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.2873289588969937" WEIGHT="14.18362015875786"/>
<DICH_DATA CI_END="1.1772678121099514" CI_START="0.2971311837935988" EFFECT_SIZE="0.5914414414414414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.07087527005767102" LOG_CI_START="-0.5270517667799897" LOG_EFFECT_SIZE="-0.22808824836115932" ORDER="2558" O_E="0.0" SE="0.35122530122500906" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.12335921222059834" WEIGHT="30.538934212038928"/>
<DICH_DATA CI_END="4.0198731872551905" CI_START="0.3643435677348885" EFFECT_SIZE="1.2102127659574469" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.604212352849646" LOG_CI_START="-0.4384888932776613" LOG_EFFECT_SIZE="0.08286172978599245" ORDER="2560" O_E="0.0" SE="0.6124878734295915" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.3751413950983033" WEIGHT="7.455272211837841"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2554" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="50.04906970284203" CI_START="0.11464844051728294" EFFECT_SIZE="2.3954222573007105" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.6993960093542557" LOG_CI_START="-0.9406318482985855" LOG_EFFECT_SIZE="0.37938208052783506" MODIFIED="2009-12-17 20:35:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="760" O_E="0.0" SE="1.550765431933938" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="2.4048734248812527" WEIGHT="1.032669949757469"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8599729622813179" CI_END="1.4989489540240686" CI_START="0.7500445759943487" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.060320014268407" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.17578684341322737" LOG_CI_START="-0.12491292523084291" LOG_EFFECT_SIZE="0.025436959091192216" METHOD="MH" MODIFIED="2010-05-25 19:32:21 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8350749851857774" P_Q="1.0" P_Z="0.7401938213014821" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2649" TOTAL_2="2642" WEIGHT="100.00000000000001" Z="0.3315966880837079">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6170078930196432" CI_START="0.49865600472596355" EFFECT_SIZE="0.8979591836734694" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.20871213981147868" LOG_CI_START="-0.30219894689613114" LOG_EFFECT_SIZE="-0.04674340354232623" ORDER="2574" O_E="0.0" SE="0.3001117013827172" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.09006703330682922" WEIGHT="37.655137572773974"/>
<DICH_DATA CI_END="2.5132396804314543" CI_START="0.6420466222174387" EFFECT_SIZE="1.2702822708531558" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.40023390798182035" LOG_CI_START="-0.1924334344909537" LOG_EFFECT_SIZE="0.10390023674543333" ORDER="2576" O_E="0.0" SE="0.34813573071916765" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.12119848700336881" WEIGHT="23.666780316361784"/>
<DICH_DATA CI_END="2.5174088912697563" CI_START="0.6011048899796547" EFFECT_SIZE="1.2301328361687252" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.40095376175403624" LOG_CI_START="-0.22104973903763422" LOG_EFFECT_SIZE="0.08995201135820102" ORDER="2573" O_E="0.0" SE="0.3653679353320131" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.13349372816877814" WEIGHT="21.7848198907552"/>
<DICH_DATA CI_END="2.1820465687753776" CI_START="0.37874823242455313" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.33886401497201135" LOG_CI_START="-0.4216493852884615" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="2575" O_E="0.0" SE="0.44672933591504776" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.1995670995670996" WEIGHT="16.89326222010905"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.377965843428887" CI_END="0.7456573505031641" CI_START="0.5619849666735104" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6473393401241567" ESTIMABLE="YES" EVENTS_1="425" EVENTS_2="426" I2="41.47470418627726" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.12746069661812862" LOG_CI_START="-0.2502753018296285" LOG_EFFECT_SIZE="-0.1888679992238786" METHOD="MH" MODIFIED="2009-12-23 20:59:38 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.08106357927844055" P_Q="1.0" P_Z="1.658129287519262E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8046" TOTAL_2="5332" WEIGHT="100.00000000000003" Z="6.02818330398833">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.167699031428313" CI_START="0.03040500724782702" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5007439118066108" LOG_CI_START="-1.5170548887258732" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="2572" O_E="0.0" SE="1.1852650036979324" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.40485312899106" WEIGHT="0.6181515251612918"/>
<DICH_DATA CI_END="0.9414881500085304" CI_START="0.44107318857244265" EFFECT_SIZE="0.6444107233181589" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="72" LOG_CI_END="-0.026185141837749826" LOG_CI_START="-0.3554893407909315" LOG_EFFECT_SIZE="-0.19083724131434066" ORDER="2565" O_E="0.0" SE="0.19343491654717335" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.03741706693961192" WEIGHT="14.407138994917464"/>
<DICH_DATA CI_END="4.451856159984327" CI_START="0.11624785788060497" EFFECT_SIZE="0.7193877551020408" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6485411237816595" LOG_CI_START="-0.9346150411838517" LOG_EFFECT_SIZE="-0.14303695870109617" ORDER="2567" O_E="0.0" SE="0.9299537680501474" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.8648140107106673" WEIGHT="0.5570468916396009"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2569" O_E="0.0" SE="0.0" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.5692663034659291" CI_START="0.29824153653584085" EFFECT_SIZE="0.4120423000660939" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="85" LOG_CI_END="-0.2446845225856398" LOG_CI_START="-0.5254318718418116" LOG_EFFECT_SIZE="-0.38505819721372575" ORDER="2566" O_E="0.0" SE="0.16491238267486727" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.02719609395950186" WEIGHT="23.102046674464837"/>
<DICH_DATA CI_END="1.0558572080524815" CI_START="0.6489885600172458" EFFECT_SIZE="0.8277917908736528" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="112" LOG_CI_END="0.023605189080383865" LOG_CI_START="-0.18776295861592085" LOG_EFFECT_SIZE="-0.08207888476776852" ORDER="2568" O_E="0.0" SE="0.12415869624601483" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.015415381853510178" WEIGHT="29.672123704293956"/>
<DICH_DATA CI_END="1.1114459902280995" CI_START="0.5338598055112013" EFFECT_SIZE="0.7702962677953059" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" LOG_CI_END="0.04588836337705915" LOG_CI_START="-0.2725727760924846" LOG_EFFECT_SIZE="-0.11334220635771275" ORDER="2571" O_E="0.0" SE="0.1870656497324744" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.0349935573098328" WEIGHT="13.972699503984066"/>
<DICH_DATA CI_END="0.8004339095848543" CI_START="0.32115929460659554" EFFECT_SIZE="0.5070175438596491" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="57" LOG_CI_END="-0.09667452119319817" LOG_CI_START="-0.49327950463868886" LOG_EFFECT_SIZE="-0.2949770129159435" ORDER="2563" O_E="0.0" SE="0.23296773050221178" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.054273963455351175" WEIGHT="11.525572937449192"/>
<DICH_DATA CI_END="1.7520048352522535" CI_START="0.3462645412651205" EFFECT_SIZE="0.7788819875776397" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.24353530041680768" LOG_CI_START="-0.4605919794911118" LOG_EFFECT_SIZE="-0.1085283395371521" ORDER="2570" O_E="0.0" SE="0.41360784970416065" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.17107145333689955" WEIGHT="2.842075977753066"/>
<DICH_DATA CI_END="2.2958317839925195" CI_START="0.005377431873896343" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3609400640568862" LOG_CI_START="-2.269425082935536" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="2564" O_E="0.0" SE="1.5450895078608187" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.387301587301587" WEIGHT="0.7630005110729111"/>
<DICH_DATA CI_END="1.7209680322803378" CI_START="0.31514448379462257" EFFECT_SIZE="0.7364465915190553" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.23577280319612934" LOG_CI_START="-0.5014902902471488" LOG_EFFECT_SIZE="-0.13285874352550972" MODIFIED="2009-12-17 20:36:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="761" O_E="0.0" SE="0.43307199059975265" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.18755134904203224" WEIGHT="2.5401432792636274"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2430184921572633" CI_END="0.9382330743856946" CI_START="0.6536130435133048" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.783097296173393" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="293" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-0.027689261465584133" LOG_CI_START="-0.18467928960090121" LOG_EFFECT_SIZE="-0.1061842755332427" METHOD="MH" MODIFIED="2010-05-25 19:32:57 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.742706338522791" P_Q="1.0" P_Z="0.008017192406908139" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2649" TOTAL_2="2642" WEIGHT="100.0" Z="2.6513449069548196">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9533908483014176" CI_START="0.4969091916449878" EFFECT_SIZE="0.6882940329184807" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="97" LOG_CI_END="-0.02072902122717514" LOG_CI_START="-0.30372296975924196" LOG_EFFECT_SIZE="-0.1622259954932086" ORDER="2578" O_E="0.0" SE="0.1662320462103738" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.02763309318728785" WEIGHT="32.97097696506197"/>
<DICH_DATA CI_END="1.200758503518926" CI_START="0.6534829323577985" EFFECT_SIZE="0.8858189363143631" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="96" LOG_CI_END="0.07945567090397891" LOG_CI_START="-0.1847657508219595" LOG_EFFECT_SIZE="-0.0526550399589903" ORDER="2580" O_E="0.0" SE="0.1552049710389476" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.024088583035200558" WEIGHT="33.085926759180985"/>
<DICH_DATA CI_END="1.1232459971740139" CI_START="0.5425202595202663" EFFECT_SIZE="0.780630328575534" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="73" LOG_CI_END="0.050474879605739334" LOG_CI_START="-0.26558403916870277" LOG_EFFECT_SIZE="-0.10755457978148174" ORDER="2577" O_E="0.0" SE="0.18565457340498742" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.03446762062618786" WEIGHT="24.72954469838276"/>
<DICH_DATA CI_END="1.3856074448955416" CI_START="0.41696769722548055" EFFECT_SIZE="0.76010101010101" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.14164020815217282" LOG_CI_START="-0.3798975888155107" LOG_EFFECT_SIZE="-0.11912869033166898" ORDER="2579" O_E="0.0" SE="0.30635388359254867" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.09385270199223687" WEIGHT="9.213551577374279"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.242905482302707" CI_END="0.6998193620806757" CI_START="0.48787740171502497" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5843167394844908" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="286" I2="42.00513358805149" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-0.1550140459507549" LOG_CI_START="-0.3116892977675433" LOG_EFFECT_SIZE="-0.23335167185914912" METHOD="MH" MODIFIED="2010-05-25 19:33:23 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.06915898517997066" P_Q="1.0" P_Z="5.2726801512077185E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8046" TOTAL_2="5332" WEIGHT="99.99999999999999" Z="5.838329503512988">
<NAME>30-day urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6703290654766458" CI_START="0.26348566009098934" EFFECT_SIZE="0.42026431718061674" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="60" LOG_CI_END="-0.17371194918384947" LOG_CI_START="-0.5792430157942057" LOG_EFFECT_SIZE="-0.3764774824890276" ORDER="2583" O_E="0.0" SE="0.23821095593807806" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.056744459528932964" WEIGHT="18.95938043922909"/>
<DICH_DATA CI_END="2.607065820519196" CI_START="0.0063638162757009495" EFFECT_SIZE="0.1288056206088993" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41615199592760443" LOG_CI_START="-2.1962823669891645" LOG_EFFECT_SIZE="-0.89006518553078" ORDER="2590" O_E="0.0" SE="1.5345568765359672" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="2.3548648073238234" WEIGHT="1.1216802701949766"/>
<DICH_DATA CI_END="1.9391125998376293" CI_START="0.1109886402355104" EFFECT_SIZE="0.4639175257731959" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.2876030282990867" LOG_CI_START="-0.954721469280889" LOG_EFFECT_SIZE="-0.33355922049090114" ORDER="2585" O_E="0.0" SE="0.7297475594839202" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.5325315005727377" WEIGHT="1.685129778598617"/>
<DICH_DATA CI_END="8.27984505730735" CI_START="0.08008135658343192" EFFECT_SIZE="0.8142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9180222098058899" LOG_CI_START="-1.0964685784894206" LOG_EFFECT_SIZE="-0.08922318434176543" ORDER="2587" O_E="0.0" SE="1.1833218609348921" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="1.400250626566416" WEIGHT="0.4903520306863286"/>
<DICH_DATA CI_END="0.5707657474647189" CI_START="0.2369791719849716" EFFECT_SIZE="0.3677765547605944" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="48" LOG_CI_END="-0.24354209745895225" LOG_CI_START="-0.6252898222999667" LOG_EFFECT_SIZE="-0.43441595987945947" ORDER="2584" O_E="0.0" SE="0.22424050325332628" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.05028380329930504" WEIGHT="20.350432213853416"/>
<DICH_DATA CI_END="1.1718197603392158" CI_START="0.46175543970194177" EFFECT_SIZE="0.7355910199879132" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" LOG_CI_END="0.06886081721982046" LOG_CI_START="-0.33558797965897996" LOG_EFFECT_SIZE="-0.13336358121957978" ORDER="2589" O_E="0.0" SE="0.23757522534044068" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.05644198769556117" WEIGHT="13.594405576649754"/>
<DICH_DATA CI_END="1.245765473204795" CI_START="0.5581523046855739" EFFECT_SIZE="0.8338626205598683" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="39" LOG_CI_END="0.0954362900921226" LOG_CI_START="-0.25324727765903693" LOG_EFFECT_SIZE="-0.07890549378345717" ORDER="2586" O_E="0.0" SE="0.20481845370852822" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.041950598979552514" WEIGHT="16.57489785829357"/>
<DICH_DATA CI_END="1.0156963059996749" CI_START="0.47120588217630355" EFFECT_SIZE="0.6918107211454514" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="69" LOG_CI_END="0.006763872963093745" LOG_CI_START="-0.3267892967846956" LOG_EFFECT_SIZE="-0.16001271191080094" ORDER="2581" O_E="0.0" SE="0.19593078302467057" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.038388871736660536" WEIGHT="20.64560359018784"/>
<DICH_DATA CI_END="0.7238898464461551" CI_START="0.0785104955386949" EFFECT_SIZE="0.23839662447257384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.14032751490813414" LOG_CI_START="-1.1050722814731966" LOG_EFFECT_SIZE="-0.6226998981906653" ORDER="2588" O_E="0.0" SE="0.5666958514439314" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.3211441880437624" WEIGHT="5.114628386090444"/>
<DICH_DATA CI_END="74.3122791004773" CI_START="0.11010644244117765" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.871060580987677" LOG_CI_START="-0.9581872692680543" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="2582" O_E="0.0" SE="1.6619141922429452" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.7619587823785214" WEIGHT="0.15916540346709643"/>
<DICH_DATA CI_END="5.34902962456593" CI_START="0.38642155987492577" EFFECT_SIZE="1.4376996805111821" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7282750031576615" LOG_CI_START="-0.412938650699871" LOG_EFFECT_SIZE="0.1576681762288952" MODIFIED="2009-12-17 20:37:51 +0530" MODIFIED_BY="Xavier Bosch" ORDER="763" O_E="0.0" SE="0.6703545493746086" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.4493752218672346" WEIGHT="1.3043244527488584"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.589831678822343" CI_END="1.1022519570036207" CI_START="0.6005698886677215" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8136211250339083" ESTIMABLE="YES" EVENTS_1="476" EVENTS_2="540" I2="74.11524098765139" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.0422808785712738" LOG_CI_START="-0.22143644621841857" LOG_EFFECT_SIZE="-0.0895777838235724" METHOD="MH" MODIFIED="2010-05-25 19:33:56 +0530" MODIFIED_BY="Xavier Bosch" NO="6" P_CHI2="0.008928842322767583" P_Q="1.0" P_Z="0.1830259885615742" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06392599958384472" TOTALS="YES" TOTAL_1="2649" TOTAL_2="2642" WEIGHT="100.00000000000001" Z="1.3314956099234545">
<NAME>6-month urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8958944107333983" CI_START="0.5547221842685097" EFFECT_SIZE="0.704962768092032" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="205" LOG_CI_END="-0.04774317285801856" LOG_CI_START="-0.25592446561071513" LOG_EFFECT_SIZE="-0.15183381923436687" ORDER="2611" O_E="0.0" SE="0.12228672187695304" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.014954042347411265" WEIGHT="30.421834141598683"/>
<DICH_DATA CI_END="1.5411131987860613" CI_START="0.888944331963629" EFFECT_SIZE="1.1704545454545454" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="120" LOG_CI_END="0.18783453995305668" LOG_CI_START="-0.0511254348430495" LOG_EFFECT_SIZE="0.06835455255500357" ORDER="2610" O_E="0.0" SE="0.1403662720661851" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.019702690333758297" WEIGHT="28.694405652884818"/>
<DICH_DATA CI_END="1.0822977170775834" CI_START="0.6895569249655266" EFFECT_SIZE="0.8638899731361789" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="194" LOG_CI_END="0.0343467423776864" LOG_CI_START="-0.16142987571302295" LOG_EFFECT_SIZE="-0.06354156666766828" ORDER="2613" O_E="0.0" SE="0.11500015457637185" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.013225035552589418" WEIGHT="31.103607987519876"/>
<DICH_DATA CI_END="0.8326811201833133" CI_START="0.15679614180968204" EFFECT_SIZE="0.3613325158389536" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.07952128221711992" LOG_CI_START="-0.8046646279486479" LOG_EFFECT_SIZE="-0.442092955082884" ORDER="2612" O_E="0.0" SE="0.42595279080015186" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.18143577999043792" WEIGHT="9.780152217996626"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.620234826505925" CI_END="0.7638199402637214" CI_START="0.5118184981600444" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6252496898763508" ESTIMABLE="YES" EVENTS_1="613" EVENTS_2="617" I2="46.294984498450106" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-0.11700900813412972" LOG_CI_START="-0.29088402188053575" LOG_EFFECT_SIZE="-0.20394651500733266" METHOD="MH" MODIFIED="2010-05-25 19:35:02 +0530" MODIFIED_BY="Xavier Bosch" NO="7" P_CHI2="0.04536004608970523" P_Q="1.0" P_Z="4.2682111343348635E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.040638354761332866" TOTALS="YES" TOTAL_1="8046" TOTAL_2="5332" WEIGHT="100.0" Z="4.597875399967778">
<NAME>30-day mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8773550134563916" CI_START="0.4381639433212762" EFFECT_SIZE="0.6200204290091931" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="89" LOG_CI_END="-0.056824637891562176" LOG_CI_START="-0.3583633635641983" LOG_EFFECT_SIZE="-0.20759400072788023" ORDER="2593" O_E="0.0" SE="0.17712534010087153" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.0313733861058494" WEIGHT="14.485925545261589"/>
<DICH_DATA CI_END="0.9879383279139586" CI_START="0.012993727708655546" EFFECT_SIZE="0.11330049261083744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.005270165415032944" LOG_CI_START="-1.886266238376207" LOG_EFFECT_SIZE="-0.94576820189562" ORDER="2600" O_E="0.0" SE="1.104906404338122" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.2208181623473977" WEIGHT="0.8269462343241111"/>
<DICH_DATA CI_END="1.6830902987408398" CI_START="0.1692261080684414" EFFECT_SIZE="0.5336879432624113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.22610741674401394" LOG_CI_START="-0.7715326335230119" LOG_EFFECT_SIZE="-0.27271260838949896" ORDER="2595" O_E="0.0" SE="0.5860187039247453" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.3434179213496383" WEIGHT="2.716155890355138"/>
<DICH_DATA CI_END="8.27984505730735" CI_START="0.08008135658343192" EFFECT_SIZE="0.8142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9180222098058899" LOG_CI_START="-1.0964685784894206" LOG_EFFECT_SIZE="-0.08922318434176543" ORDER="2597" O_E="0.0" SE="1.1833218609348921" STUDY_ID="STD-Kereiakes-1996" TOTAL_1="73" TOTAL_2="20" VAR="1.400250626566416" WEIGHT="0.7239674465588781"/>
<DICH_DATA CI_END="1.0175972998729885" CI_START="0.6648465549874352" EFFECT_SIZE="0.822524199756501" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="151" LOG_CI_END="0.00757594593423518" LOG_CI_START="-0.1772785772711139" LOG_EFFECT_SIZE="-0.08485131566843937" ORDER="2596" O_E="0.0" SE="0.10858446197546959" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.0117905853825022" WEIGHT="19.896582187716312"/>
<DICH_DATA CI_END="0.9302489014033002" CI_START="0.4847677080446522" EFFECT_SIZE="0.6715315538709506" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="101" LOG_CI_END="-0.031400834195185426" LOG_CI_START="-0.31446631764768285" LOG_EFFECT_SIZE="-0.17293357592143413" ORDER="2591" O_E="0.0" SE="0.1662740661767383" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.02764706508294634" WEIGHT="15.276419460633466"/>
<DICH_DATA CI_END="1.0028070258903052" CI_START="0.5561629400415707" EFFECT_SIZE="0.7468092820884699" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="112" LOG_CI_END="0.0012173680611100304" LOG_CI_START="-0.25479795375247255" LOG_EFFECT_SIZE="-0.12679029284568125" ORDER="2599" O_E="0.0" SE="0.15038466732958006" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.022615548167828462" WEIGHT="16.49157867388697"/>
<DICH_DATA CI_END="0.5597636840042857" CI_START="0.31607701488665507" EFFECT_SIZE="0.42062861800171364" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="109" LOG_CI_END="-0.25199528083975664" LOG_CI_START="-0.5002070848970208" LOG_EFFECT_SIZE="-0.3761011828683887" ORDER="2594" O_E="0.0" SE="0.14580084237148275" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.021257885636233955" WEIGHT="16.85331305886037"/>
<DICH_DATA CI_END="0.9615712027823643" CI_START="0.25082585419205716" EFFECT_SIZE="0.4911078479360418" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" LOG_CI_END="-0.017018551435328988" LOG_CI_START="-0.6006277000812044" LOG_EFFECT_SIZE="-0.30882312575826665" ORDER="2598" O_E="0.0" SE="0.34281490282646476" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.11752205759991848" WEIGHT="6.595561436726772"/>
<DICH_DATA CI_END="2.8344626813240428" CI_START="0.025688929118493718" EFFECT_SIZE="0.2698412698412698" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45247074342198523" LOG_CI_START="-1.5902539995726008" LOG_EFFECT_SIZE="-0.5688916280753078" ORDER="2592" O_E="0.0" SE="1.1999066256855764" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="1.4397759103641457" WEIGHT="0.704638384782287"/>
<DICH_DATA CI_END="1.660740130594438" CI_START="0.36112149071683597" EFFECT_SIZE="0.7744216885221747" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.2203016802067009" LOG_CI_START="-0.44234666548618556" LOG_EFFECT_SIZE="-0.11102249263974236" MODIFIED="2009-12-17 20:38:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="764" O_E="0.0" SE="0.38924291842221453" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.15151004954184277" WEIGHT="5.428911680894106"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.381080365105452" CI_END="0.9437352309737845" CI_START="0.748123971110227" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8402564779117951" ESTIMABLE="YES" EVENTS_1="765" EVENTS_2="813" I2="52.27345609697335" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-0.025149831820267525" LOG_CI_START="-0.12602642953132956" LOG_EFFECT_SIZE="-0.0755881306757985" METHOD="MH" MODIFIED="2010-05-25 19:35:24 +0530" MODIFIED_BY="Xavier Bosch" NO="8" P_CHI2="0.07857504840407037" P_Q="1.0" P_Z="0.0033113448927730637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3284" TOTAL_2="2945" WEIGHT="100.0" Z="2.937252388460093">
<NAME>6-month mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8592528544555702" CI_START="0.5450820514021844" EFFECT_SIZE="0.6843707391318135" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="244" LOG_CI_END="-0.0658790164531824" LOG_CI_START="-0.263538118293942" LOG_EFFECT_SIZE="-0.16470856737356226" ORDER="2615" O_E="0.0" SE="0.11610593484959623" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.013480588107298686" WEIGHT="28.9529071335216"/>
<DICH_DATA CI_END="1.0366623011375466" CI_START="0.7026984046560227" EFFECT_SIZE="0.853499235603873" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="290" LOG_CI_END="0.015637305436564705" LOG_CI_START="-0.15323103244523825" LOG_EFFECT_SIZE="-0.06879686350433677" ORDER="2617" O_E="0.0" SE="0.09919409758352499" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1070" TOTAL_2="1069" VAR="0.009839468995409877" WEIGHT="35.474979917433295"/>
<DICH_DATA CI_END="1.2849616530516683" CI_START="0.7961437635626567" EFFECT_SIZE="1.011441647597254" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="193" LOG_CI_END="0.10889016726532466" LOG_CI_START="-0.09900850250798449" LOG_EFFECT_SIZE="0.004940832378670084" ORDER="2614" O_E="0.0" SE="0.12212070773985452" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.014913467258882965" WEIGHT="21.48459326042825"/>
<DICH_DATA CI_END="1.0168400969205984" CI_START="0.3639765750973116" EFFECT_SIZE="0.6083633584452451" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="43" LOG_CI_END="0.007252663360284221" LOG_CI_START="-0.43892656589308093" LOG_EFFECT_SIZE="-0.21583695126639835" ORDER="2616" O_E="0.0" SE="0.2620878878862317" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.06869006097666595" WEIGHT="6.110543554185323"/>
<DICH_DATA CI_END="1.5702368125140274" CI_START="0.7206166975148911" EFFECT_SIZE="1.0637381567614126" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="43" LOG_CI_END="0.1959651547101257" LOG_CI_START="-0.14229567899590428" LOG_EFFECT_SIZE="0.026834737857110703" MODIFIED="2009-12-17 20:40:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="766" O_E="0.0" SE="0.19869608813705356" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="0.039480135440967755" WEIGHT="7.976976134431544"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.554341931031697" CI_END="1.8632320023806919" CI_START="1.0213785651895324" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3795163026245143" ESTIMABLE="YES" EVENTS_1="412" EVENTS_2="219" I2="53.97441636367481" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.2702669349179851" LOG_CI_START="0.009186739443168892" LOG_EFFECT_SIZE="0.139726837180577" METHOD="MH" MODIFIED="2010-05-25 19:36:51 +0530" MODIFIED_BY="Xavier Bosch" NO="9" P_CHI2="0.020871001179132542" P_Q="1.0" P_Z="0.03591432013950188" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09858748966561713" TOTALS="YES" TOTAL_1="7973" TOTAL_2="5312" WEIGHT="100.0" Z="2.097896150641113">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.167699031428313" CI_START="0.03040500724782702" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5007439118066108" LOG_CI_START="-1.5170548887258732" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="2609" O_E="0.0" SE="1.1852650036979324" STUDY_ID="STD-Simoons-1994" TOTAL_1="30" TOTAL_2="30" VAR="1.40485312899106" WEIGHT="1.564360289036553"/>
<DICH_DATA CI_END="3.314863102592244" CI_START="1.5917734487238189" EFFECT_SIZE="2.2970657528378666" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="46" LOG_CI_END="0.5204655975925502" LOG_CI_START="0.20188125625936182" LOG_EFFECT_SIZE="0.36117342692595605" ORDER="2603" O_E="0.0" SE="0.1871380191170383" STUDY_ID="STD-EPIC-1994" TOTAL_1="708" TOTAL_2="696" VAR="0.03502063819904899" WEIGHT="17.603141652679653"/>
<DICH_DATA CI_END="2.2866509402138306" CI_START="0.15014217861959508" EFFECT_SIZE="0.5859375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.35919987413497284" LOG_CI_START="-0.8234972866473095" LOG_EFFECT_SIZE="-0.23214870625616832" ORDER="2605" O_E="0.0" SE="0.6947221666888778" STUDY_ID="STD-IMPACT-1995" TOTAL_1="101" TOTAL_2="49" VAR="0.4826388888888889" WEIGHT="4.046483242209724"/>
<DICH_DATA CI_END="1.4106838314975623" CI_START="0.5590979231770411" EFFECT_SIZE="0.8880936890045543" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="29" LOG_CI_END="0.14942968872097434" LOG_CI_START="-0.25251212096691494" LOG_EFFECT_SIZE="-0.051541216122970294" ORDER="2604" O_E="0.0" SE="0.2361026086547127" STUDY_ID="STD-EPILOG-1997" TOTAL_1="1853" TOTAL_2="939" VAR="0.05574444181356042" WEIGHT="15.239379033290817"/>
<DICH_DATA CI_END="1.495281509701739" CI_START="0.8003510976705752" EFFECT_SIZE="1.0939607843137256" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="60" LOG_CI_END="0.17472296296202838" LOG_CI_START="-0.09671945509409843" LOG_EFFECT_SIZE="0.03900175393396498" ORDER="2606" O_E="0.0" SE="0.15944662002780857" STUDY_ID="STD-IMPACT_x002d_II-1997" TOTAL_1="2682" TOTAL_2="1328" VAR="0.025423224638292368" WEIGHT="18.96548063570752"/>
<DICH_DATA CI_END="4.14843312209715" CI_START="1.0190763976070794" EFFECT_SIZE="2.056105610561056" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.6178840931164504" LOG_CI_START="0.00820674319727878" LOG_EFFECT_SIZE="0.3130454181568646" ORDER="2601" O_E="0.0" SE="0.3581274932940764" STUDY_ID="STD-CAPTURE-1997" TOTAL_1="630" TOTAL_2="635" VAR="0.12825530145309874" WEIGHT="10.368073806322542"/>
<DICH_DATA CI_END="2.1886542810760448" CI_START="0.957306708003668" EFFECT_SIZE="1.4474852071005917" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="40" LOG_CI_END="0.34017716600892445" LOG_CI_START="-0.018948897904156315" LOG_EFFECT_SIZE="0.16061413405238403" ORDER="2608" O_E="0.0" SE="0.21095242764523042" STUDY_ID="STD-RESTORE-1997" TOTAL_1="1071" TOTAL_2="1070" VAR="0.044500926729416176" WEIGHT="16.43684974650883"/>
<DICH_DATA CI_END="3.2759534767807224" CI_START="1.0960306519268834" EFFECT_SIZE="1.8948734587929916" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="23" LOG_CI_END="0.5153377255301146" LOG_CI_START="0.039822699929883416" LOG_EFFECT_SIZE="0.277580212729999" ORDER="2607" O_E="0.0" SE="0.2793198798749147" STUDY_ID="STD-RAPPORT-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.07801959529333677" WEIGHT="13.317261882770307"/>
<DICH_DATA CI_END="7.506992811000863" CI_START="0.011117206613167119" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87546599996867" LOG_CI_START="-1.9540043229056838" LOG_EFFECT_SIZE="-0.5392691614685069" ORDER="2602" O_E="0.0" SE="1.6620448737603812" STUDY_ID="STD-Chen-2000" TOTAL_1="22" TOTAL_2="20" VAR="2.762393162393162" WEIGHT="0.8220687543128248"/>
<DICH_DATA CI_END="13.83872288303058" CI_START="0.14849992216190167" EFFECT_SIZE="1.4335443037974684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1410960127764698" LOG_CI_START="-0.8282737739876136" LOG_EFFECT_SIZE="0.1564111193944281" MODIFIED="2009-12-17 20:39:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="765" O_E="0.0" SE="1.1568175612828895" STUDY_ID="STD-JEPPORT-2009" TOTAL_1="635" TOTAL_2="303" VAR="1.3382268700924915" WEIGHT="1.6369009571612338"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="6">
<NAME>Subgroup of stent implantation</NAME>
<DICH_OUTCOME CHI2="8.55382909044744" CI_END="1.0374862413542434" CI_START="0.5818322695399891" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="OR" EFFECT_SIZE="0.776944640514144" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="101" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.01598234601685206" LOG_CI_START="-0.23520219561128944" LOG_EFFECT_SIZE="-0.10960992479721864" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.9692006779635989" P_Q="1.0" P_Z="0.08716473638607146" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="28" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8474" TOTAL_2="7353" WEIGHT="100.0" Z="1.7105471822285396">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.493604260075294" CI_START="0.26516217536299935" EFFECT_SIZE="0.8131479140328698" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.39682753121841946" LOG_CI_START="-0.5764884267329828" LOG_EFFECT_SIZE="-0.0898304477572817" ORDER="2622" O_E="0.0" SE="0.5717306116923492" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.3268758923461077" WEIGHT="6.309587797405461"/>
<DICH_DATA CI_END="7.908679956389632" CI_START="0.01254512355454697" EFFECT_SIZE="0.3149847094801223" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8981040011339438" LOG_CI_START="-1.9015250570441715" LOG_EFFECT_SIZE="-0.501710527955114" ORDER="2625" O_E="0.0" SE="1.6445159671611682" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="2.7044327662480327" WEIGHT="1.4485008627715896"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2623" O_E="0.0" SE="0.0" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3282392489212675" CI_START="0.18431722399516723" EFFECT_SIZE="0.6550836550836551" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.36702760619586355" LOG_CI_START="-0.7344340791241746" LOG_EFFECT_SIZE="-0.18370323646415554" ORDER="2624" O_E="0.0" SE="0.6470040462802666" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.4186142359030375" WEIGHT="5.76309880285142"/>
<DICH_DATA CI_END="1.4228034224634079" CI_START="0.130504156735544" EFFECT_SIZE="0.43090806542583193" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15314490118283527" LOG_CI_START="-0.8843756552332911" LOG_EFFECT_SIZE="-0.36561537702522784" ORDER="2626" O_E="0.0" SE="0.6094447106484161" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.37142285533733166" WEIGHT="8.46094974206548"/>
<DICH_DATA CI_END="1.4683555293054376" CI_START="0.16323828629647819" EFFECT_SIZE="0.4895833333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16683122296507713" LOG_CI_START="-0.787177973172779" LOG_EFFECT_SIZE="-0.31017337510385096" ORDER="2619" O_E="0.0" SE="0.5603897242330598" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.31403664302600476" WEIGHT="9.185355929795621"/>
<DICH_DATA CI_END="8.060469765718873" CI_START="0.01279153723938795" EFFECT_SIZE="0.3211009174311927" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9063603533081072" LOG_CI_START="-1.893077260488803" LOG_EFFECT_SIZE="-0.49335845359034797" ORDER="2632" O_E="0.0" SE="1.6444035117839833" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="2.7040629095674964" WEIGHT="1.435211864030566"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2633" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="49.439081904863905" CI_START="0.08158897589607542" EFFECT_SIZE="2.008403361344538" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6940703972071016" LOG_CI_START="-1.0883685180958877" LOG_EFFECT_SIZE="0.30285093955560694" ORDER="2630" O_E="0.0" SE="1.6344183921437394" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="2.671323480577726" WEIGHT="0.5718422270746786"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:25:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1077" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.4476717815124527" CI_START="0.3095642243140261" EFFECT_SIZE="0.8704663212435233" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3887531810247094" LOG_CI_START="-0.5092492355885312" LOG_EFFECT_SIZE="-0.060248027281910914" ORDER="2618" O_E="0.0" SE="0.5274910647022708" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.2782468233407352" WEIGHT="7.386557060210646"/>
<DICH_DATA CI_END="22.63921752989657" CI_START="0.18027196377431381" EFFECT_SIZE="2.0202020202020203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3548614124313982" LOG_CI_START="-0.7440718102985355" LOG_EFFECT_SIZE="0.3053948010664313" ORDER="2620" O_E="0.0" SE="1.2329237649185816" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="1.52010101010101" WEIGHT="0.9378612180793797"/>
<DICH_DATA CI_END="4.9744715717384125" CI_START="0.19987271343101215" EFFECT_SIZE="0.9971264367816092" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6967469532893872" LOG_CI_START="-0.6992464916008017" LOG_EFFECT_SIZE="-0.001249769155707207" ORDER="2629" O_E="0.0" SE="0.8200134598074966" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.672422074265461" WEIGHT="2.849949949686944"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:17:09 +0530" MODIFIED_BY="Xavier Bosch" ORDER="984" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.970205306279777" CI_START="0.201573081602601" EFFECT_SIZE="1.0009293680297398" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6963743286815872" LOG_CI_START="-0.6955674647463649" LOG_EFFECT_SIZE="4.0343196761120383E-4" ORDER="2627" O_E="0.0" SE="0.8176334996825806" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.6685245398031845" WEIGHT="2.861117120327724"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2621" O_E="0.0" SE="0.0" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:34:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1011" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:43:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="768" O_E="0.0" SE="0.0" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4783959943434857" CI_START="0.3152530098603363" EFFECT_SIZE="0.6826923076923077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16979077717359825" LOG_CI_START="-0.5013407583330084" LOG_EFFECT_SIZE="-0.16577499057970504" ORDER="2628" O_E="0.0" SE="0.3942259861112605" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.15541412812539573" WEIGHT="15.157502943826934"/>
<DICH_DATA CI_END="8.315037261213861" CI_START="0.013362671461425384" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9198641997134829" LOG_CI_START="-1.8741067091528076" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-12-17 20:43:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="771" O_E="0.0" SE="1.6411923422471113" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="2.6935123042505595" WEIGHT="1.4162024353679092"/>
<DICH_DATA CI_END="76.13490374800293" CI_START="0.12184827829900997" EFFECT_SIZE="3.045801526717557" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.881583803024787" LOG_CI_START="-0.9141806029628191" LOG_EFFECT_SIZE="0.48370160003098395" MODIFIED="2013-04-04 18:34:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="958" O_E="0.0" SE="1.642245851334126" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.6969714362241484" WEIGHT="0.4676934183781198"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2009-12-17 20:44:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="774" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="3.638095190217016"/>
<DICH_DATA CI_END="1.2195597139842589" CI_START="0.27009845721495546" EFFECT_SIZE="0.5739348370927319" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.08620306977393853" LOG_CI_START="-0.5684778964676589" LOG_EFFECT_SIZE="-0.24113741334686023" MODIFIED="2009-12-17 20:44:12 +0530" MODIFIED_BY="Xavier Bosch" ORDER="772" O_E="0.0" SE="0.384562840293363" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.14788857813449863" WEIGHT="17.68181016485657"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:44:12 +0530" MODIFIED_BY="Xavier Bosch" ORDER="773" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.132763947030567" CI_START="0.013252828875088381" EFFECT_SIZE="0.3283018867924528" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910238167112663" LOG_CI_START="-1.877691409749042" LOG_EFFECT_SIZE="-0.48372662131818933" MODIFIED="2009-12-17 20:42:31 +0530" MODIFIED_BY="Xavier Bosch" ORDER="767" O_E="0.0" SE="1.6376436339225422" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="2.6818766717270295" WEIGHT="1.435211864030566"/>
<DICH_DATA CI_END="6.10558003083999" CI_START="0.5067747078702879" EFFECT_SIZE="1.759020618556701" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7857269282689927" LOG_CI_START="-0.2951850680318199" LOG_EFFECT_SIZE="0.2452709301185864" MODIFIED="2013-02-28 21:39:31 +0530" MODIFIED_BY="Xavier Bosch" ORDER="884" O_E="0.0" SE="0.6349330572277724" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.40313998716060573" WEIGHT="3.712414688292397"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:43:30 +0530" MODIFIED_BY="Xavier Bosch" ORDER="770" O_E="0.0" SE="0.0" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0079258897057595" CI_START="0.5647488097940576" EFFECT_SIZE="1.3033505154639176" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.47826713175725805" LOG_CI_START="-0.24814467568058352" LOG_EFFECT_SIZE="0.11506122803833728" MODIFIED="2009-12-17 20:43:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="769" O_E="0.0" SE="0.4266978914854272" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.18207109059810941" WEIGHT="9.281036720730992"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.897585781760075" CI_END="1.0652345689346794" CI_START="0.7134116466943705" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8717515402564296" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="205" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.027445251696655574" LOG_CI_START="-0.1466598049306481" LOG_EFFECT_SIZE="-0.059607276616996274" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.7071527257325478" P_Q="1.0" P_Z="0.17958250394665248" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="25" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7352" TOTAL_2="6402" WEIGHT="100.00000000000001" Z="1.3420416115301723">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9912052108508034" CI_START="0.4203562076702034" EFFECT_SIZE="0.9148854961832061" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.29911602012162397" LOG_CI_START="-0.37638253469380717" LOG_EFFECT_SIZE="-0.03863325728609161" ORDER="2654" O_E="0.0" SE="0.39679119487035824" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.15744325232664663" WEIGHT="6.400394408535029"/>
<DICH_DATA CI_END="1.8988064215731146" CI_START="0.004262770397576661" EFFECT_SIZE="0.08996763754045307" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.27848069178924056" LOG_CI_START="-2.3703080588027574" LOG_EFFECT_SIZE="-1.0459136835067584" ORDER="2655" O_E="0.0" SE="1.555911623813518" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="2.420860981118018" WEIGHT="1.661984919004292"/>
<DICH_DATA CI_END="1.3388595129904626" CI_START="0.23359968181134735" EFFECT_SIZE="0.5592469545957918" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1267350087267564" LOG_CI_START="-0.6315277531164453" LOG_EFFECT_SIZE="-0.25239637219484445" ORDER="2656" O_E="0.0" SE="0.44540729976790283" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.19838766268653443" WEIGHT="6.837266113392413"/>
<DICH_DATA CI_END="0.8486823956007047" CI_START="0.16742403825503982" EFFECT_SIZE="0.3769480519480519" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.07125480639264883" LOG_CI_START="-0.7761821871310922" LOG_EFFECT_SIZE="-0.42371849676187046" ORDER="2651" O_E="0.0" SE="0.41407783289257327" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.17146045169300983" WEIGHT="10.027990299642207"/>
<DICH_DATA CI_END="8.060469765718873" CI_START="0.01279153723938795" EFFECT_SIZE="0.3211009174311927" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9063603533081072" LOG_CI_START="-1.893077260488803" LOG_EFFECT_SIZE="-0.49335845359034797" ORDER="2659" O_E="0.0" SE="1.6444035117839833" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="2.7040629095674964" WEIGHT="0.7325642264349015"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2660" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.7549896619380106"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:26:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1078" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2569296091459647" CI_START="0.23361622838048451" EFFECT_SIZE="0.5418848167539267" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.09931095690992588" LOG_CI_START="-0.6314969918195077" LOG_EFFECT_SIZE="-0.26609301745479097" ORDER="2650" O_E="0.0" SE="0.4292802066413587" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.1842814958140476" WEIGHT="7.462387586616862"/>
<DICH_DATA CI_END="1.853129240597719" CI_START="0.4755874190312977" EFFECT_SIZE="0.9387890884896873" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.26790570886079224" LOG_CI_START="-0.32276964252591284" LOG_EFFECT_SIZE="-0.0274319668325603" ORDER="2658" O_E="0.0" SE="0.3469656252946958" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12038514513613925" WEIGHT="8.376939856065864"/>
<DICH_DATA CI_END="2.7941731204946523" CI_START="0.44551088293209834" EFFECT_SIZE="1.11572153065929" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4462533104919537" LOG_CI_START="-0.3511416825594777" LOG_EFFECT_SIZE="0.04755581396623803" MODIFIED="2009-12-22 21:18:07 +0530" MODIFIED_BY="Xavier Bosch" ORDER="843" O_E="0.0" SE="0.46839376608728556" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.21939272010943078" WEIGHT="4.220270404083138"/>
<DICH_DATA CI_END="22.63921752989657" CI_START="0.18027196377431381" EFFECT_SIZE="2.0202020202020203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3548614124313982" LOG_CI_START="-0.7440718102985355" LOG_EFFECT_SIZE="0.3053948010664313" ORDER="2652" O_E="0.0" SE="1.2329237649185816" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="1.52010101010101" WEIGHT="0.4787053360861732"/>
<DICH_DATA CI_END="41.50906567302496" CI_START="0.48031106126703915" EFFECT_SIZE="4.465116279069767" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6181429579601554" LOG_CI_START="-0.3184774117122293" LOG_EFFECT_SIZE="0.649832773123963" MODIFIED="2013-04-04 19:18:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="989" O_E="0.0" SE="1.1375803915709966" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="1.2940891472868217" WEIGHT="0.43750363523195507"/>
<DICH_DATA CI_END="1.5573678239082727" CI_START="0.500577314151068" EFFECT_SIZE="0.8829399766899767" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.19239119768551802" LOG_CI_START="-0.3005288362344995" LOG_EFFECT_SIZE="-0.05406881927449073" ORDER="2657" O_E="0.0" SE="0.2895436679181379" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.08383553563148893" WEIGHT="12.421357666201423"/>
<DICH_DATA CI_END="5.547508069852916" CI_START="0.044159467542199585" EFFECT_SIZE="0.494949494949495" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7440979426643058" LOG_CI_START="-1.3549761718023785" LOG_EFFECT_SIZE="-0.3054391145690362" ORDER="2653" O_E="0.0" SE="1.2330065254221743" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="1.5203050917336631" WEIGHT="0.96698477889407"/>
<DICH_DATA CI_END="5.651593953590671" CI_START="0.0406258298685047" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.752170951823081" LOG_CI_START="-1.3911977545390697" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-04-04 19:34:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1013" O_E="0.0" SE="1.2590253879633373" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.585144927536232" WEIGHT="0.9376822098366738"/>
<DICH_DATA CI_END="15.909437532889589" CI_START="0.060891652234792946" EFFECT_SIZE="0.984251968503937" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2016548257383248" LOG_CI_START="-1.2154422416341257" LOG_EFFECT_SIZE="-0.006893707947900438" MODIFIED="2009-12-17 20:54:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="807" O_E="0.0" SE="1.4198147821980271" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="2.0158740157480315" WEIGHT="0.488376150956601"/>
<DICH_DATA CI_END="1.381299390738275" CI_START="0.6030299390679948" EFFECT_SIZE="0.9126691007323302" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="49" LOG_CI_END="0.1402878202538681" LOG_CI_START="-0.21966112558912065" LOG_EFFECT_SIZE="-0.039686652667626277" ORDER="2661" O_E="0.0" SE="0.21143579256418962" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.04470509437724702" WEIGHT="22.888948724803782"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2009-12-17 20:55:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="810" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="1.8569651321256806"/>
<DICH_DATA CI_END="16.330717844801725" CI_START="0.061234295363097754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213005275317456" LOG_CI_START="-1.213005275317456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:36:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="963" O_E="0.0" SE="1.4250506063888506" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.0307692307692307" WEIGHT="0.4809765123057434"/>
<DICH_DATA CI_END="4.318001687357362" CI_START="0.5265163609854081" EFFECT_SIZE="1.5078125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6352828077086909" LOG_CI_START="-0.27858812898888013" LOG_EFFECT_SIZE="0.1783473393599054" MODIFIED="2013-02-28 21:40:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="885" O_E="0.0" SE="0.5368123119502478" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.2881674582613702" WEIGHT="2.8130466295100214"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2009-12-17 20:55:29 +0530" MODIFIED_BY="Xavier Bosch" ORDER="809" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="0.488376150956601"/>
<DICH_DATA CI_END="3.2595498269126137" CI_START="0.91618733147098" EFFECT_SIZE="1.7281082887700534" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.5131576242434559" LOG_CI_START="-0.03801571770104572" LOG_EFFECT_SIZE="0.2375709532712051" MODIFIED="2013-03-04 22:15:04 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1566" O_E="0.0" SE="0.32376194941024516" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.10482179988592213" WEIGHT="7.306107218310751"/>
<DICH_DATA CI_END="8.533335321744723" CI_START="0.013826055703629716" EFFECT_SIZE="0.34348561759729274" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9311188117901551" LOG_CI_START="-1.8593016977262402" LOG_EFFECT_SIZE="-0.46409144296804244" MODIFIED="2009-12-17 20:55:09 +0530" MODIFIED_BY="Xavier Bosch" ORDER="808" O_E="0.0" SE="1.6391068200942227" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.6866711676793944" WEIGHT="0.7144314485528495"/>
<DICH_DATA CI_END="7.28486338926983" CI_START="0.011522173759729045" EFFECT_SIZE="0.2897196261682243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8624214119958415" LOG_CI_START="-1.9384655796977155" LOG_EFFECT_SIZE="-0.538022083850937" MODIFIED="2013-04-10 20:46:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1032" O_E="0.0" SE="1.6452548835350098" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="2.706863631795799" WEIGHT="0.7684742375346515"/>
<DICH_DATA CI_END="16.508125798938536" CI_START="0.06057622846951526" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2176977697266207" LOG_CI_START="-1.2176977697266207" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-28 21:40:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="886" O_E="0.0" SE="1.4305633952771812" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="44" VAR="2.046511627906977" WEIGHT="0.4772766929803146"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.16533402613996" CI_END="0.7582654665959586" CI_START="0.5855948291659341" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6663605153171125" ESTIMABLE="YES" EVENTS_1="449" EVENTS_2="564" I2="19.782666282250588" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.1201787224762199" LOG_CI_START="-0.23240276677653665" LOG_EFFECT_SIZE="-0.17629074462637825" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.18360248171693616" P_Q="1.0" P_Z="7.378815154113249E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="29" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8540" TOTAL_2="7423" WEIGHT="99.99999999999999" Z="6.157744758348084">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6848823617309" CI_START="0.3652601599581652" EFFECT_SIZE="0.5001602153294027" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="83" LOG_CI_END="-0.1643840183448971" LOG_CI_START="-0.4373976950311747" LOG_EFFECT_SIZE="-0.30089085668803595" ORDER="2638" O_E="0.0" SE="0.16036958512501479" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.02571840383316936" WEIGHT="18.411267459555013"/>
<DICH_DATA CI_END="1.5334642240539935" CI_START="0.05670127417843977" EFFECT_SIZE="0.2948717948717949" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1856736482825227" LOG_CI_START="-1.2464071816282978" LOG_EFFECT_SIZE="-0.5303667666728875" ORDER="2641" O_E="0.0" SE="0.8412113684040525" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.7076365663322185" WEIGHT="1.0414459492627837"/>
<DICH_DATA CI_END="1.5784964664456438" CI_START="0.23247208260974708" EFFECT_SIZE="0.6057692307692307" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.19824361403636032" LOG_CI_START="-0.6336291937267576" LOG_EFFECT_SIZE="-0.2176927898451987" ORDER="2639" O_E="0.0" SE="0.4886462051168655" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.2387751137751138" WEIGHT="1.7990014471709714"/>
<DICH_DATA CI_END="0.8388568957696354" CI_START="0.44232860120015605" EFFECT_SIZE="0.6091390623764724" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="104" LOG_CI_END="-0.07631212102880706" LOG_CI_START="-0.3542549780126941" LOG_EFFECT_SIZE="-0.21528354952075057" ORDER="2640" O_E="0.0" SE="0.16326501003166657" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.026655463500640183" WEIGHT="17.347004572846412"/>
<DICH_DATA CI_END="1.1562036362510264" CI_START="0.13814868059653734" EFFECT_SIZE="0.39965986394557823" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.06303433089385553" LOG_CI_START="-0.8596532585026601" LOG_EFFECT_SIZE="-0.39830946380440224" ORDER="2642" O_E="0.0" SE="0.5419912573887424" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.29375452308583005" WEIGHT="2.075300310942221"/>
<DICH_DATA CI_END="1.4928490993582744" CI_START="0.2184090295750719" EFFECT_SIZE="0.5710093896713615" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.17401591045232867" LOG_CI_START="-0.6607294107769874" LOG_EFFECT_SIZE="-0.2433567501623294" ORDER="2635" O_E="0.0" SE="0.49033353374608135" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.24042697431591947" WEIGHT="2.0097236446542843"/>
<DICH_DATA CI_END="2.000690280803328" CI_START="0.47544221316172913" EFFECT_SIZE="0.9753012944502306" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.30117986237486477" LOG_CI_START="-0.3229022611242171" LOG_EFFECT_SIZE="-0.010861199374676195" ORDER="2646" O_E="0.0" SE="0.3665889285996949" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="0.13438744257187218" WEIGHT="2.660016821005736"/>
<DICH_DATA CI_END="1.993245780616303" CI_START="0.06839666350859779" EFFECT_SIZE="0.36923076923076925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2995608534341538" LOG_CI_START="-1.1649650832966527" LOG_EFFECT_SIZE="-0.43270211493124955" ORDER="2648" O_E="0.0" SE="0.8602697847559815" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.7400641025641027" WEIGHT="0.8597606746250394"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2649" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.2734919626375432"/>
<DICH_DATA CI_END="1.0645979234953766" CI_START="0.1889714687376683" EFFECT_SIZE="0.4485294117647059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.027185614743575174" LOG_CI_START="-0.723603761462476" LOG_EFFECT_SIZE="-0.34820907335945045" ORDER="2634" O_E="0.0" SE="0.44101739605078505" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.19449634361941498" WEIGHT="2.887208616263902"/>
<DICH_DATA CI_END="16.3090734852818" CI_START="0.055031141163090325" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.212429289571308" LOG_CI_START="-1.2593914812703537" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-17 21:29:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1079" O_E="0.0" SE="1.4519597565025428" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.1081871345029235" WEIGHT="0.1723760800308388"/>
<DICH_DATA CI_END="2.6510797996207787" CI_START="0.6348282227549744" EFFECT_SIZE="1.2972972972972974" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.4234228005408498" LOG_CI_START="-0.19734377392366526" LOG_EFFECT_SIZE="0.11303951330859224" ORDER="2645" O_E="0.0" SE="0.36464135868455794" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.13296332046332043" WEIGHT="2.353110152342296"/>
<DICH_DATA CI_END="1.5829481218694044" CI_START="0.6647323957684306" EFFECT_SIZE="1.0257859900717043" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.19946668191539413" LOG_CI_START="-0.17735315534557233" LOG_EFFECT_SIZE="0.011056763284910887" ORDER="2643" O_E="0.0" SE="0.2213458376953691" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.04899397986506469" WEIGHT="7.130901045263949"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:17:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="985" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3012920474593934" CI_START="0.16861571003746822" EFFECT_SIZE="0.46842105263157896" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.11437477570557761" LOG_CI_START="-0.77310196432141" LOG_EFFECT_SIZE="-0.3293635943079162" ORDER="2636" O_E="0.0" SE="0.5213082301725663" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.2717622708456534" WEIGHT="1.9968318181790234"/>
<DICH_DATA CI_END="3.862838331323726" CI_START="0.2939412325783307" EFFECT_SIZE="1.0655737704918034" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5869065323013709" LOG_CI_START="-0.5317394890371939" LOG_EFFECT_SIZE="0.02758352163208857" MODIFIED="2013-04-04 19:45:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1026" O_E="0.0" SE="0.6570982103213844" STUDY_ID="STD-Prati-2005" TOTAL_1="66" TOTAL_2="70" VAR="0.43177805800756625" WEIGHT="0.7935036656218372"/>
<DICH_DATA CI_END="1.3662645739289538" CI_START="0.09172161994922402" EFFECT_SIZE="0.354" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.13553480759685635" LOG_CI_START="-1.0375282835452808" LOG_EFFECT_SIZE="-0.4509967379742122" MODIFIED="2009-12-17 20:52:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="776" O_E="0.0" SE="0.6890630664928427" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.47480790960451974" WEIGHT="1.3930101784506244"/>
<DICH_DATA CI_END="2.293535365340421" CI_START="0.3454473074383324" EFFECT_SIZE="0.8901098901098901" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.360505441155937" LOG_CI_START="-0.46161818804082483" LOG_EFFECT_SIZE="-0.050556373442443875" ORDER="2637" O_E="0.0" SE="0.4829194893677757" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.2332112332112332" WEIGHT="1.6099018632353863"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:34:17 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1012" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9714269034686553" CI_START="0.5408837972671123" EFFECT_SIZE="0.7248648648648649" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="116" LOG_CI_END="-0.012589872999912627" LOG_CI_START="-0.26689602810291707" LOG_EFFECT_SIZE="-0.13974295055141486" ORDER="2644" O_E="0.0" SE="0.14938069434327483" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.022314591842478904" WEIGHT="18.776151338045995"/>
<DICH_DATA CI_END="1.2364778498688138" CI_START="0.41829389011617946" EFFECT_SIZE="0.7191739218465276" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" LOG_CI_END="0.09218634086237065" LOG_CI_START="-0.37851847897234026" LOG_EFFECT_SIZE="-0.14316606905498483" MODIFIED="2009-12-17 20:53:41 +0530" MODIFIED_BY="Xavier Bosch" ORDER="780" O_E="0.0" SE="0.27649434119734556" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.07644912071415413" WEIGHT="5.518546190296986"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-12-17 20:53:15 +0530" MODIFIED_BY="Xavier Bosch" ORDER="779" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="0.3467006003869997"/>
<DICH_DATA CI_END="1.1038931784097734" CI_START="0.10118222733826397" EFFECT_SIZE="0.33420707732634336" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.042927049596310406" LOG_CI_START="-0.9948957646381609" LOG_EFFECT_SIZE="-0.4759843575209253" MODIFIED="2009-12-17 20:53:56 +0530" MODIFIED_BY="Xavier Bosch" ORDER="782" O_E="0.0" SE="0.6096222583871124" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.37163929792100325" WEIGHT="1.5695823174656274"/>
<DICH_DATA CI_END="2.4006588745471547" CI_START="0.1733828554084815" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3803304526738385" LOG_CI_START="-0.7609938490144215" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2013-04-04 18:34:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="959" O_E="0.0" SE="0.6704195444580936" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.4494623655913978" WEIGHT="0.9971420131927469"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:53:41 +0530" MODIFIED_BY="Xavier Bosch" ORDER="781" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.053764570656634" CI_START="0.6816653038207906" EFFECT_SIZE="2.031413612565445" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7820255273485307" LOG_CI_START="-0.16642881065557125" LOG_EFFECT_SIZE="0.30779835834647973" MODIFIED="2013-02-28 21:41:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="887" O_E="0.0" SE="0.5571267730683014" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.31039024126949855" WEIGHT="0.8447561974669199"/>
<DICH_DATA CI_END="2.350045571117705" CI_START="0.6032006136699485" EFFECT_SIZE="1.1906086387434556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.3710762840134639" LOG_CI_START="-0.2195382253058275" LOG_EFFECT_SIZE="0.07576902935381821" MODIFIED="2009-12-17 20:52:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="777" O_E="0.0" SE="0.34692988636312394" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12036034605193009" WEIGHT="2.703219831894143"/>
<DICH_DATA CI_END="0.9416889999817076" CI_START="0.11495840288142405" EFFECT_SIZE="0.32902137232845896" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.026092502613264228" LOG_CI_START="-0.9394592784907644" LOG_EFFECT_SIZE="-0.4827758905520144" MODIFIED="2009-12-17 20:52:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="775" O_E="0.0" SE="0.5365161653889019" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.2878495957236115" WEIGHT="2.392015637682294"/>
<DICH_DATA CI_END="0.7175025470338756" CI_START="0.03402644715468491" EFFECT_SIZE="0.15625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.14417655290645223" LOG_CI_START="-1.4681833950613221" LOG_EFFECT_SIZE="-0.8061799739838872" MODIFIED="2009-12-17 20:53:15 +0530" MODIFIED_BY="Xavier Bosch" ORDER="778" O_E="0.0" SE="0.7777281730213398" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.6048611111111111" WEIGHT="2.0380296114804013"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="37.4836351715044" CI_END="0.8668832464939785" CI_START="0.5969479608136591" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="OR" EFFECT_SIZE="0.719363737102521" ESTIMABLE="YES" EVENTS_1="555" EVENTS_2="658" I2="35.97205849915767" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.062039390202919376" LOG_CI_START="-0.22406352702228688" LOG_EFFECT_SIZE="-0.14305145861260318" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.039130577167689085" P_Q="1.0" P_Z="5.383471042176125E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="25" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.058683348775003856" TOTALS="YES" TOTAL_1="7352" TOTAL_2="6405" WEIGHT="100.00000000000001" Z="3.460912828428779">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7463113737976644" CI_START="0.4152278981061628" EFFECT_SIZE="0.5566770186335404" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="92" LOG_CI_END="-0.12707993967409198" LOG_CI_START="-0.3817134750378945" LOG_EFFECT_SIZE="-0.2543967073559932" ORDER="2666" O_E="0.0" SE="0.149572999129026" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.022372082068451614" WEIGHT="11.17512831065342"/>
<DICH_DATA CI_END="1.1859413013483808" CI_START="0.21325656803794923" EFFECT_SIZE="0.5029013539651838" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.07406319397650363" LOG_CI_START="-0.6710975842227527" LOG_EFFECT_SIZE="-0.2985171951231245" ORDER="2667" O_E="0.0" SE="0.4377111297195843" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.19159103308039477" WEIGHT="3.6192471368254453"/>
<DICH_DATA CI_END="0.8403905395532184" CI_START="0.46115857362075363" EFFECT_SIZE="0.6225377920293175" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="118" LOG_CI_END="-0.07551884517964914" LOG_CI_START="-0.3361497127736406" LOG_EFFECT_SIZE="-0.20583427897664486" ORDER="2668" O_E="0.0" SE="0.15309586176831233" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.0234383428905822" WEIGHT="11.030031427500374"/>
<DICH_DATA CI_END="1.2524491230418444" CI_START="0.21128903242115818" EFFECT_SIZE="0.5144208037825059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.09776009299759868" LOG_CI_START="-0.6751230456953988" LOG_EFFECT_SIZE="-0.28868147634890007" ORDER="2663" O_E="0.0" SE="0.45399538150150553" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.20611180642469754" WEIGHT="3.420775728573191"/>
<DICH_DATA CI_END="1.565956242562915" CI_START="0.057965141015792906" EFFECT_SIZE="0.30128205128205127" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19477962242245186" LOG_CI_START="-1.2368331032599402" LOG_EFFECT_SIZE="-0.5210267404187442" ORDER="2671" O_E="0.0" SE="0.8409364016631203" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.7071740316421168" WEIGHT="1.182733055934732"/>
<DICH_DATA CI_END="1.490417290079542" CI_START="0.018790038269107676" EFFECT_SIZE="0.1673469387755102" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.17330788009442707" LOG_CI_START="-1.7260723353840213" LOG_EFFECT_SIZE="-0.7763822276447969" ORDER="2672" O_E="0.0" SE="1.115705340655742" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2447984071677451" WEIGHT="0.6949117897670783"/>
<DICH_DATA CI_END="117.25632331883436" CI_START="0.2368806042653152" EFFECT_SIZE="5.27027027027027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.069136272354529" LOG_CI_START="-0.6254704977634833" LOG_EFFECT_SIZE="0.721832887295523" MODIFIED="2013-04-17 21:30:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1080" O_E="0.0" SE="1.5828253552859535" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.505336105336105" WEIGHT="0.3532753382578889"/>
<DICH_DATA CI_END="0.7744334863035875" CI_START="0.17957352853781652" EFFECT_SIZE="0.37291789143640997" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.11101587651261872" LOG_CI_START="-0.7457576835778034" LOG_EFFECT_SIZE="-0.42838678004521097" ORDER="2662" O_E="0.0" SE="0.3728504794927083" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.13901748005794248" WEIGHT="4.581694701524486"/>
<DICH_DATA CI_END="2.55497240607456" CI_START="0.684418996161148" EFFECT_SIZE="1.3223734908810685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.40738621407767245" LOG_CI_START="-0.16467794504929822" LOG_EFFECT_SIZE="0.12135413451418711" MODIFIED="2009-12-22 21:20:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="844" O_E="0.0" SE="0.3360333188344404" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.11291839136688867" WEIGHT="5.278529455481779"/>
<DICH_DATA CI_END="1.6375543683499472" CI_START="0.5635675410031722" EFFECT_SIZE="0.9606625258799172" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.21419572788971358" LOG_CI_START="-0.24905402828297613" LOG_EFFECT_SIZE="-0.017429150196631278" ORDER="2670" O_E="0.0" SE="0.27211519989911404" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.07404668201613479" WEIGHT="6.824415202436487"/>
<DICH_DATA CI_END="6.744525616085399" CI_START="0.30165103303213875" EFFECT_SIZE="1.426356589147287" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8289514084835862" LOG_CI_START="-0.520495183063011" LOG_EFFECT_SIZE="0.15422811271028752" MODIFIED="2013-04-04 19:19:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="990" O_E="0.0" SE="0.7926716077428309" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.6283282777216043" WEIGHT="1.3184709035712103"/>
<DICH_DATA CI_END="1.3325825657155022" CI_START="0.662004293235404" EFFECT_SIZE="0.9392419175027871" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="69" LOG_CI_END="0.12469412705977545" LOG_CI_START="-0.17913919406120712" LOG_EFFECT_SIZE="-0.027222533500715847" ORDER="2669" O_E="0.0" SE="0.17847319682566087" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.03185268198517109" WEIGHT="10.004910004839264"/>
<DICH_DATA CI_END="1.3012920474593934" CI_START="0.16861571003746822" EFFECT_SIZE="0.46842105263157896" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.11437477570557761" LOG_CI_START="-0.77310196432141" LOG_EFFECT_SIZE="-0.3293635943079162" ORDER="2664" O_E="0.0" SE="0.5213082301725663" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.2717622708456534" WEIGHT="2.7411615895854493"/>
<DICH_DATA CI_END="3.159193437595083" CI_START="0.029553175319944055" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4995762185952884" LOG_CI_START="-1.5293958498134126" LOG_EFFECT_SIZE="-0.5149098156090622" MODIFIED="2013-04-04 19:35:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1014" O_E="0.0" SE="1.1918282365569903" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.4204545454545454" WEIGHT="0.6123870150880854"/>
<DICH_DATA CI_END="1.885203763539329" CI_START="0.19070212319783858" EFFECT_SIZE="0.5995934959349594" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2753582980952003" LOG_CI_START="-0.719644471673595" LOG_EFFECT_SIZE="-0.2221430867891973" MODIFIED="2009-12-17 20:56:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="811" O_E="0.0" SE="0.5844695523053356" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.3416046575719994" WEIGHT="2.2628827883633416"/>
<DICH_DATA CI_END="1.7846508327367492" CI_START="0.30982290576356214" EFFECT_SIZE="0.7435897435897436" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.25155325896414527" LOG_CI_START="-0.5088864772192315" LOG_EFFECT_SIZE="-0.1286666091275431" ORDER="2665" O_E="0.0" SE="0.44668606527151844" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.19952844090775124" WEIGHT="3.5079917964388927"/>
<DICH_DATA CI_END="0.9404987851447159" CI_START="0.5614014133321323" EFFECT_SIZE="0.7266342595951535" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="154" LOG_CI_END="-0.02664176109742685" LOG_CI_START="-0.2507264983606934" LOG_EFFECT_SIZE="-0.13868412972906016" MODIFIED="2010-05-25 19:10:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2673" O_E="0.0" SE="0.13162848390578177" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.017326057775334653" WEIGHT="11.917009763140634"/>
<DICH_DATA CI_END="4.0612089439834165" CI_START="0.10604331578113421" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6086553339580679" LOG_CI_START="-0.9745167011300413" LOG_EFFECT_SIZE="-0.18293068358598671" MODIFIED="2013-04-04 18:37:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="964" O_E="0.0" SE="0.9299630902387197" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.8648313492063491" WEIGHT="0.9808234150802863"/>
<DICH_DATA CI_END="1.4311007059550747" CI_START="0.15874593051244992" EFFECT_SIZE="0.4766355140186916" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.15567019595523704" LOG_CI_START="-0.7992973991297837" LOG_EFFECT_SIZE="-0.3218136015872733" MODIFIED="2009-12-17 20:57:36 +0530" MODIFIED_BY="Xavier Bosch" ORDER="814" O_E="0.0" SE="0.5609526925187756" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.31466792324406395" WEIGHT="2.4261463876963796"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2009-12-17 20:57:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="813" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="0.4213475625480221"/>
<DICH_DATA CI_END="2.475775806656468" CI_START="0.8899366852164702" EFFECT_SIZE="1.4843462246777164" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="27" LOG_CI_END="0.39371131468559334" LOG_CI_START="-0.05064089025310598" LOG_EFFECT_SIZE="0.17153521221624368" MODIFIED="2013-03-04 22:15:57 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1567" O_E="0.0" SE="0.26101468475988077" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.06812866566029994" WEIGHT="7.14289449611281"/>
<DICH_DATA CI_END="6.053764570656634" CI_START="0.6816653038207906" EFFECT_SIZE="2.031413612565445" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7820255273485307" LOG_CI_START="-0.16642881065557125" LOG_EFFECT_SIZE="0.30779835834647973" MODIFIED="2013-02-28 21:42:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="888" O_E="0.0" SE="0.5571267730683014" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.31039024126949855" WEIGHT="2.4542662070230734"/>
<DICH_DATA CI_END="0.6497708921999872" CI_START="0.03130765804115496" EFFECT_SIZE="0.14262820512820512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.1872397476541158" LOG_CI_START="-1.5043494184209065" LOG_EFFECT_SIZE="-0.8457945830375112" MODIFIED="2009-12-17 20:56:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="812" O_E="0.0" SE="0.7736767404064332" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.5985756986459234" WEIGHT="1.378154996124088"/>
<DICH_DATA CI_END="3.723005569583228" CI_START="0.20684787573541472" EFFECT_SIZE="0.8775510204081632" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5708936859195615" LOG_CI_START="-0.6843489348174159" LOG_EFFECT_SIZE="-0.05672762444892715" MODIFIED="2013-04-10 20:47:17 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1033" O_E="0.0" SE="0.737335728972084" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.5436639772187946" WEIGHT="1.5037915847911236"/>
<DICH_DATA CI_END="1.5974377473368826" CI_START="0.24645388119281297" EFFECT_SIZE="0.6274509803921569" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.20342394256447882" LOG_CI_START="-0.6082643381205396" LOG_EFFECT_SIZE="-0.2024201977780304" MODIFIED="2013-02-28 21:43:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="889" O_E="0.0" SE="0.47678971399616943" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.22732843137254904" WEIGHT="3.167019342642484"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.33309218657028" CI_END="0.9750791971441878" CI_START="0.5795622699622086" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7517440474588498" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="131" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-0.01096010893134229" LOG_CI_START="-0.2368998952515417" LOG_EFFECT_SIZE="-0.12393000209144198" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.6482651260711334" P_Q="1.0" P_Z="0.03154606418666772" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="26" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8317" TOTAL_2="7199" WEIGHT="100.00000000000003" Z="2.1501156981618723">
<NAME>30-day urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.573998534878749" CI_START="0.12719783310210436" EFFECT_SIZE="0.7627599243856332" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6602960211596286" LOG_CI_START="-0.8955202871138216" LOG_EFFECT_SIZE="-0.11761213297709656" ORDER="2678" O_E="0.0" SE="0.9138942008947574" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.8352026104290671" WEIGHT="2.0103801400769887"/>
<DICH_DATA CI_END="3.7802369099058293" CI_START="0.006120117198123009" EFFECT_SIZE="0.15210355987055016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.577519018207779" LOG_CI_START="-2.213240261186013" LOG_EFFECT_SIZE="-0.8178606214891172" ORDER="2679" O_E="0.0" SE="1.6393058151971438" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="2.687323555739172" WEIGHT="1.5512985855801937"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2681" O_E="0.0" SE="0.0" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6402545667807582" CI_START="0.2083671369376391" EFFECT_SIZE="0.5846153846153846" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.21491125558947877" LOG_CI_START="-0.6811707756415695" LOG_EFFECT_SIZE="-0.23312976002604538" ORDER="2682" O_E="0.0" SE="0.52636302082271" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.2770580296896087" WEIGHT="7.389103496997234"/>
<DICH_DATA CI_END="1.4883382224710782" CI_START="0.44847220223636175" EFFECT_SIZE="0.8169934640522876" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.17270163514906156" LOG_CI_START="-0.3482644707681463" LOG_EFFECT_SIZE="-0.08778141780954239" ORDER="2680" O_E="0.0" SE="0.306018069439583" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.09364705882352942" WEIGHT="18.022010210744238"/>
<DICH_DATA CI_END="0.8909646983457026" CI_START="0.041305040307814664" EFFECT_SIZE="0.19183673469387755" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.05013950316557952" LOG_CI_START="-1.3839969496920503" LOG_EFFECT_SIZE="-0.717068226428815" ORDER="2675" O_E="0.0" SE="0.7835144667904963" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.6138949196699957" WEIGHT="7.445563826281983"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2689" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2974108780885616" CI_START="0.10955629481726407" EFFECT_SIZE="0.3770139634801289" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.11307753493383373" LOG_CI_START="-0.9603626639648709" LOG_EFFECT_SIZE="-0.42364256451551857" ORDER="2686" O_E="0.0" SE="0.6305440864477805" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="0.397585844954266" WEIGHT="6.329562089456719"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2688" O_E="0.0" SE="0.0" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:31:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1081" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.199564624588795" CI_START="0.03403242558921244" EFFECT_SIZE="0.32998324958123953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5050908864441218" LOG_CI_START="-1.4681070963796743" LOG_EFFECT_SIZE="-0.48150810496777613" ORDER="2674" O_E="0.0" SE="1.1590662625982406" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="1.3434346010934535" WEIGHT="2.267857961372624"/>
<DICH_DATA CI_END="2.987023368566935" CI_START="0.21179738528757835" EFFECT_SIZE="0.7953890489913544" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47523862026063" LOG_CI_START="-0.674079405711942" LOG_EFFECT_SIZE="-0.09942039272565603" ORDER="2685" O_E="0.0" SE="0.6751150976722718" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.45578039510504115" WEIGHT="3.7608236742261028"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:17:41 +0530" MODIFIED_BY="Xavier Bosch" ORDER="986" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.781031937907338" CI_START="0.5437980021108695" EFFECT_SIZE="1.4339168782573835" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.577610345809597" LOG_CI_START="-0.2645623923237646" LOG_EFFECT_SIZE="0.15652397674291624" ORDER="2683" O_E="0.0" SE="0.4946964352018243" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.24472456300139275" WEIGHT="5.2665306228382445"/>
<DICH_DATA CI_END="1.4752159173430712" CI_START="0.3269508564054051" EFFECT_SIZE="0.6944948578342408" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.16885558970261824" LOG_CI_START="-0.48551752072160365" LOG_EFFECT_SIZE="-0.15833096550949274" ORDER="2676" O_E="0.0" SE="0.3843820042623257" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.1477495252007226" WEIGHT="12.43434734779159"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2677" O_E="0.0" SE="0.0" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.75751323740641" CI_START="0.12011491133267621" EFFECT_SIZE="2.976470588235294" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8678062658888743" LOG_CI_START="-0.9204030749658237" LOG_EFFECT_SIZE="0.4737015954615252" MODIFIED="2009-12-17 20:58:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="784" O_E="0.0" SE="1.6378079686768805" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="2.6824149422614894" WEIGHT="0.3783918159482433"/>
<DICH_DATA CI_END="1.9298648416669453" CI_START="0.35697372673348626" EFFECT_SIZE="0.8300066533599467" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.28552689420276856" LOG_CI_START="-0.4473637467857298" LOG_EFFECT_SIZE="-0.08091842629148066" ORDER="2684" O_E="0.0" SE="0.4305035903838263" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.18533334133336532" WEIGHT="9.035856542039054"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:59:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="787" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0902129935917557" CI_START="0.0046596722490235415" EFFECT_SIZE="0.09868995633187773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32019054315814804" LOG_CI_START="-2.3316446295431223" LOG_EFFECT_SIZE="-1.0057270431924872" MODIFIED="2009-12-17 20:59:56 +0530" MODIFIED_BY="Xavier Bosch" ORDER="790" O_E="0.0" SE="1.5577011072405373" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="2.426432739498396" WEIGHT="2.4997567971771257"/>
<DICH_DATA CI_END="1.7313461317694077" CI_START="0.4719660121165727" EFFECT_SIZE="0.903956043956044" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.2383839009719388" LOG_CI_START="-0.3260892752678133" LOG_EFFECT_SIZE="-0.04385268714793728" MODIFIED="2009-12-17 20:59:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="788" O_E="0.0" SE="0.3315743379105168" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.10994154156079758" WEIGHT="14.55523755513771"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:35:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="960" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 20:59:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="789" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.890840025883355" CI_START="0.6047914710086019" EFFECT_SIZE="2.0414507772020727" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8382721676795183" LOG_CI_START="-0.21839434204391756" LOG_EFFECT_SIZE="0.3099389128178004" MODIFIED="2013-02-28 21:43:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="890" O_E="0.0" SE="0.6206911383951271" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3852574892822388" WEIGHT="2.9180501948876487"/>
<DICH_DATA CI_END="3.3473104987492195" CI_START="0.16552156130414566" EFFECT_SIZE="0.7443467336683417" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5246959996714731" LOG_CI_START="-0.7811454257825281" LOG_EFFECT_SIZE="-0.12822471305552757" MODIFIED="2009-12-17 20:58:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="785" O_E="0.0" SE="0.7670577173309867" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.5883775417170239" WEIGHT="3.023810615163499"/>
<DICH_DATA CI_END="8.533335321744723" CI_START="0.013826055703629716" EFFECT_SIZE="0.34348561759729274" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9311188117901551" LOG_CI_START="-1.8593016977262402" LOG_EFFECT_SIZE="-0.46409144296804244" MODIFIED="2009-12-17 20:59:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="786" O_E="0.0" SE="1.6391068200942227" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.6866711676793944" WEIGHT="1.1114185242808272"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.837714594275354" CI_END="0.9682731553240307" CI_START="0.7841565072971217" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8713654202390955" ESTIMABLE="YES" EVENTS_1="799" EVENTS_2="861" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="-0.014002108481606256" LOG_CI_START="-0.10559724921341493" LOG_EFFECT_SIZE="-0.059799678847510564" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="6" P_CHI2="0.817138563083952" P_Q="1.0" P_Z="0.010491287141487223" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="24" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7302" TOTAL_2="6361" WEIGHT="100.0" Z="2.5592016321337456">
<NAME>6-month urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2686127424011306" CI_START="0.41046685041319086" EFFECT_SIZE="0.7216117216117216" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.10332906929280598" LOG_CI_START="-0.3867219110511323" LOG_EFFECT_SIZE="-0.14169642087916312" ORDER="2724" O_E="0.0" SE="0.2878583716455047" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.08286244212640151" WEIGHT="3.6899224779984348"/>
<DICH_DATA CI_END="1.8988120315378625" CI_START="0.3906343799083346" EFFECT_SIZE="0.861244019138756" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.27848197489693755" LOG_CI_START="-0.40822953691243336" LOG_EFFECT_SIZE="-0.0648737810077479" ORDER="2725" O_E="0.0" SE="0.40337774131363074" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.1627136021872864" WEIGHT="1.7569742841083695"/>
<DICH_DATA CI_END="1.2239193649618252" CI_START="0.6686820411735788" EFFECT_SIZE="0.9046617595513494" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="96" LOG_CI_END="0.08775280628528935" LOG_CI_START="-0.17478034051170438" LOG_EFFECT_SIZE="-0.043513767113207515" ORDER="2726" O_E="0.0" SE="0.1542132699885898" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.023781732640573695" WEIGHT="11.95213951714662"/>
<DICH_DATA CI_END="1.0746307700612487" CI_START="0.07811163916943659" EFFECT_SIZE="0.2897260273972603" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03125927162862725" LOG_CI_START="-1.1072842484474166" LOG_EFFECT_SIZE="-0.5380124884093948" ORDER="2721" O_E="0.0" SE="0.6687860995739869" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.4472748469833867" WEIGHT="1.3150285995206181"/>
<DICH_DATA CI_END="1.4018762394893192" CI_START="0.16248884871700733" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.14670967491501172" LOG_CI_START="-0.789176438419548" LOG_EFFECT_SIZE="-0.3212333817522681" ORDER="2729" O_E="0.0" SE="0.5497441356836967" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.3022186147186148" WEIGHT="1.333379401895186"/>
<DICH_DATA CI_END="78.27196626944439" CI_START="0.11498369632134046" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8936062438651577" LOG_CI_START="-0.9393637344258329" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-04-17 21:32:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1082" O_E="0.0" SE="1.6641005886756874" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.769230769230769" WEIGHT="0.06425757857664231"/>
<DICH_DATA CI_END="1.5771801567298585" CI_START="0.5483507361248292" EFFECT_SIZE="0.9299719887955182" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.19788130436559231" LOG_CI_START="-0.26094156918190614" LOG_EFFECT_SIZE="-0.03153013240815689" ORDER="2720" O_E="0.0" SE="0.26951482713165426" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.07263824204380548" WEIGHT="3.858618164620773"/>
<DICH_DATA CI_END="1.4752159173430712" CI_START="0.3269508564054051" EFFECT_SIZE="0.6944948578342408" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.16885558970261824" LOG_CI_START="-0.48551752072160365" LOG_EFFECT_SIZE="-0.15833096550949274" ORDER="2722" O_E="0.0" SE="0.3843820042623257" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.1477495252007226" WEIGHT="2.2111850078064377"/>
<DICH_DATA CI_END="2.0202926025166335" CI_START="0.18425313828495743" EFFECT_SIZE="0.6101190476190477" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.305414273632577" LOG_CI_START="-0.7345851063007564" LOG_EFFECT_SIZE="-0.2145854163340897" MODIFIED="2013-04-04 19:19:36 +0530" MODIFIED_BY="Xavier Bosch" ORDER="991" O_E="0.0" SE="0.6109007838527979" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.37319976771196284" WEIGHT="0.9457397462305817"/>
<DICH_DATA CI_END="1.2710449219595512" CI_START="0.8273272660180548" EFFECT_SIZE="1.025460930640913" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="204" LOG_CI_END="0.10416089989656532" LOG_CI_START="-0.08232266250200475" LOG_EFFECT_SIZE="0.010919118697280301" ORDER="2727" O_E="0.0" SE="0.10954136766144161" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.011999311229139125" WEIGHT="22.23818183937467"/>
<DICH_DATA CI_END="1.269607706872106" CI_START="0.5309487402340985" EFFECT_SIZE="0.8210338680926916" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="55" LOG_CI_END="0.10366955004316035" LOG_CI_START="-0.27494740529905853" LOG_EFFECT_SIZE="-0.08563892762794909" MODIFIED="2009-12-22 21:20:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="845" O_E="0.0" SE="0.22240147375217478" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.049462415527139286" WEIGHT="6.0393852889625075"/>
<DICH_DATA CI_END="1.1688860250620519" CI_START="0.5927735955328928" EFFECT_SIZE="0.8323970037453183" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="96" LOG_CI_END="0.06777216633738355" LOG_CI_START="-0.2271111497820314" LOG_EFFECT_SIZE="-0.07966949172232393" ORDER="2728" O_E="0.0" SE="0.17321591958450078" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.030003754797504244" WEIGHT="9.880253179287658"/>
<DICH_DATA CI_END="2.421188444141164" CI_START="0.7107482377070651" EFFECT_SIZE="1.3118137900746596" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="0.38402859244285104" LOG_CI_START="-0.14828420846488005" LOG_EFFECT_SIZE="0.11787219198898548" MODIFIED="2009-12-17 21:05:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="815" O_E="0.0" SE="0.31268317424406233" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.09777076745534263" WEIGHT="2.4223277864646056"/>
<DICH_DATA CI_END="3.5672413705482016" CI_START="0.28032866187754585" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5523324960360485" LOG_CI_START="-0.5523324960360485" LOG_EFFECT_SIZE="0.0" ORDER="2723" O_E="0.0" SE="0.6488856845230502" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.4210526315789474" WEIGHT="0.6417519706564662"/>
<DICH_DATA CI_END="5.77937573192896" CI_START="0.418687622791419" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7618809299740814" LOG_CI_START="-0.378109877496255" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2013-04-04 19:35:45 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1015" O_E="0.0" SE="0.6696362433535825" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.44841269841269843" WEIGHT="0.4863804409185849"/>
<DICH_DATA CI_END="1.032685386096504" CI_START="0.6316987638578053" EFFECT_SIZE="0.8076794425087108" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="164" LOG_CI_END="0.013968031206493012" LOG_CI_START="-0.1994899729556546" LOG_EFFECT_SIZE="-0.09276097087458082" ORDER="2730" O_E="0.0" SE="0.12538628827900727" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.015721721288386316" WEIGHT="19.17672086817698"/>
<DICH_DATA CI_END="2.0166422415625695" CI_START="0.053146902198584145" EFFECT_SIZE="0.3273809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.3046288598904091" LOG_CI_START="-1.2745220443536471" LOG_EFFECT_SIZE="-0.484946592231619" MODIFIED="2009-12-17 21:07:05 +0530" MODIFIED_BY="Xavier Bosch" ORDER="818" O_E="0.0" SE="0.9276010580760043" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.8604437229437228" WEIGHT="0.5278547420821851"/>
<DICH_DATA CI_END="5.767582946099541" CI_START="0.4165523101188767" EFFECT_SIZE="1.55" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7609938490144217" LOG_CI_START="-0.3803304526738386" LOG_EFFECT_SIZE="0.1903316981702915" MODIFIED="2013-04-04 18:37:35 +0530" MODIFIED_BY="Xavier Bosch" ORDER="965" O_E="0.0" SE="0.6704195444580937" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.44946236559139785" WEIGHT="0.4912933746652372"/>
<DICH_DATA CI_END="5.7774576728618765" CI_START="0.045989614345266244" EFFECT_SIZE="0.5154639175257731" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7617367724099338" LOG_CI_START="-1.337340232270386" LOG_EFFECT_SIZE="-0.28780172993022607" MODIFIED="2009-12-17 21:05:45 +0530" MODIFIED_BY="Xavier Bosch" ORDER="816" O_E="0.0" SE="1.2330082231479704" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="1.5203092783505154" WEIGHT="0.26210501538390407"/>
<DICH_DATA CI_END="3.955226875555563" CI_START="0.4588393732155589" EFFECT_SIZE="1.3471502590673574" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.597171400090559" LOG_CI_START="-0.3383393221644707" LOG_EFFECT_SIZE="0.12941603896304418" MODIFIED="2013-02-28 21:44:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="891" O_E="0.0" SE="0.5495236291053651" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3019762189451308" WEIGHT="0.7783700256823125"/>
<DICH_DATA CI_END="5.034588321726299" CI_START="0.16259404980062087" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7019639640828441" LOG_CI_START="-0.7888953516450247" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2009-12-17 21:06:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="817" O_E="0.0" SE="0.875738141931184" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.7669172932330826" WEIGHT="0.3700720746119668"/>
<DICH_DATA CI_END="0.9484297050211324" CI_START="0.44173922377133823" EFFECT_SIZE="0.6472701149425287" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="76" LOG_CI_END="-0.02299485228480921" LOG_CI_START="-0.35483403630615146" LOG_EFFECT_SIZE="-0.18891444429548035" MODIFIED="2013-03-04 22:16:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1568" O_E="0.0" SE="0.19492397932458935" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.03799535771573294" WEIGHT="8.933187431538009"/>
<DICH_DATA CI_END="5.984006774904314" CI_START="0.4472035769791267" EFFECT_SIZE="1.6358695652173914" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.77699207655124" LOG_CI_START="-0.3494947313826262" LOG_EFFECT_SIZE="0.2137486725843069" MODIFIED="2013-04-10 20:48:03 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1034" O_E="0.0" SE="0.6617039271799842" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.4378520872454138" WEIGHT="0.4971888951612201"/>
<DICH_DATA CI_END="17.641513452415772" CI_START="0.0648698527340903" EFFECT_SIZE="1.069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2465358401970499" LOG_CI_START="-1.1879570879930745" LOG_EFFECT_SIZE="0.029289376101987508" MODIFIED="2013-02-28 21:45:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="892" O_E="0.0" SE="1.4300331969532285" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="2.044994944388271" WEIGHT="0.12768228913003143"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="38.785129395243466" CI_END="0.8383599745856946" CI_START="0.5693048191633234" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6908562612622666" ESTIMABLE="YES" EVENTS_1="509" EVENTS_2="617" I2="40.69892157477067" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="-0.07656946417656021" LOG_CI_START="-0.2446551398716065" LOG_EFFECT_SIZE="-0.1606123020240834" METHOD="MH" MODIFIED="2013-04-17 21:32:41 +0530" MODIFIED_BY="Xavier Bosch" NO="7" P_CHI2="0.02094475078063629" P_Q="1.0" P_Z="1.799335098841011E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="26" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07234995344047472" TOTALS="YES" TOTAL_1="8317" TOTAL_2="7199" WEIGHT="99.99999999999999" Z="3.745641336057649">
<NAME>30-day mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.72980656649569" CI_START="0.39833821814291026" EFFECT_SIZE="0.5391751545526634" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="87" LOG_CI_END="-0.1367922333528258" LOG_CI_START="-0.399748023662694" LOG_EFFECT_SIZE="-0.26827012850775994" ORDER="2694" O_E="0.0" SE="0.1544615328801714" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.023858365139692264" WEIGHT="10.132672082670032"/>
<DICH_DATA CI_END="1.5784964664456438" CI_START="0.23247208260974708" EFFECT_SIZE="0.6057692307692307" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.19824361403636032" LOG_CI_START="-0.6336291937267576" LOG_EFFECT_SIZE="-0.2176927898451987" ORDER="2695" O_E="0.0" SE="0.4886462051168655" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.2387751137751138" WEIGHT="3.1332973344843977"/>
<DICH_DATA CI_END="1.5334642240539935" CI_START="0.05670127417843977" EFFECT_SIZE="0.2948717948717949" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1856736482825227" LOG_CI_START="-1.2464071816282978" LOG_EFFECT_SIZE="-0.5303667666728875" ORDER="2697" O_E="0.0" SE="0.8412113684040525" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.7076365663322185" WEIGHT="1.2498258868396555"/>
<DICH_DATA CI_END="0.9736848337437168" CI_START="0.20454192202130164" EFFECT_SIZE="0.4462727499376714" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.011581594574893973" LOG_CI_START="-0.6892176674286133" LOG_EFFECT_SIZE="-0.35039963100175364" ORDER="2698" O_E="0.0" SE="0.3980467835469336" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.1584412418920594" WEIGHT="4.223936456472179"/>
<DICH_DATA CI_END="0.8844972494574412" CI_START="0.48308376408692294" EFFECT_SIZE="0.6536713704855298" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="113" LOG_CI_END="-0.05330351328824661" LOG_CI_START="-0.31597755842726144" LOG_EFFECT_SIZE="-0.184640535857754" ORDER="2696" O_E="0.0" SE="0.154296034372151" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.023807266222972003" WEIGHT="10.138056686849712"/>
<DICH_DATA CI_END="0.8486823956007047" CI_START="0.16742403825503982" EFFECT_SIZE="0.3769480519480519" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.07125480639264883" LOG_CI_START="-0.7761821871310922" LOG_EFFECT_SIZE="-0.42371849676187046" ORDER="2691" O_E="0.0" SE="0.41407783289257327" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.17146045169300983" WEIGHT="3.9983828551704357"/>
<DICH_DATA CI_END="1.565956242562915" CI_START="0.057965141015792906" EFFECT_SIZE="0.30128205128205127" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19477962242245186" LOG_CI_START="-1.2368331032599402" LOG_EFFECT_SIZE="-0.5210267404187442" ORDER="2704" O_E="0.0" SE="0.8409364016631203" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.7071740316421168" WEIGHT="1.2505674776570173"/>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2705" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.35056405635212573"/>
<DICH_DATA CI_END="1.9973591253099527" CI_START="0.5026072942057845" EFFECT_SIZE="1.0019417475728156" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3004561580696121" LOG_CI_START="-0.2987712128975713" LOG_EFFECT_SIZE="8.424725860203823E-4" ORDER="2702" O_E="0.0" SE="0.3519891239294485" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="0.12389634336462063" WEIGHT="4.9674687353008515"/>
<DICH_DATA CI_END="16.3090734852818" CI_START="0.055031141163090325" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.212429289571308" LOG_CI_START="-1.2593914812703537" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2013-04-17 21:32:41 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1083" O_E="0.0" SE="1.4519597565025428" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.1081871345029235" WEIGHT="0.4470675363368034"/>
<DICH_DATA CI_END="0.9558047000345323" CI_START="0.18816296222446746" EFFECT_SIZE="0.42408376963350786" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.019630838228236497" LOG_CI_START="-0.7254658585099191" LOG_EFFECT_SIZE="-0.3725483483690778" ORDER="2690" O_E="0.0" SE="0.4146109848531603" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.1719022687609075" WEIGHT="3.99115035683948"/>
<DICH_DATA CI_END="2.6809347848852267" CI_START="0.6792424973440371" EFFECT_SIZE="1.34944612286002" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.42828624967517337" LOG_CI_START="-0.1679751499363205" LOG_EFFECT_SIZE="0.13015554986942643" ORDER="2701" O_E="0.0" SE="0.35024689767332146" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12267288932978612" WEIGHT="4.998631595921633"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:17:59 +0530" MODIFIED_BY="Xavier Bosch" ORDER="987" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0645455176230145" CI_START="0.292010461245386" EFFECT_SIZE="0.5575467941059339" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="0.02716423564740791" LOG_CI_START="-0.5346015897167767" LOG_EFFECT_SIZE="-0.2537186770346844" ORDER="2692" O_E="0.0" SE="0.3299840266046055" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.108889457814189" WEIGHT="5.378782335747615"/>
<DICH_DATA CI_END="1.6082015976438466" CI_START="0.6849581893064272" EFFECT_SIZE="1.0495479285682157" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.2063404892236446" LOG_CI_START="-0.16433593756989562" LOG_EFFECT_SIZE="0.02100227582687446" ORDER="2699" O_E="0.0" SE="0.2177371679764307" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.0474094743183964" WEIGHT="8.140046775780217"/>
<DICH_DATA CI_END="1.3662645739289538" CI_START="0.09172161994922402" EFFECT_SIZE="0.354" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.13553480759685635" LOG_CI_START="-1.0375282835452808" LOG_EFFECT_SIZE="-0.4509967379742122" MODIFIED="2009-12-17 21:02:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="792" O_E="0.0" SE="0.6890630664928427" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.47480790960451974" WEIGHT="1.7816564645032211"/>
<DICH_DATA CI_END="2.634116880616915" CI_START="0.37963387553470984" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.42063504149925784" LOG_CI_START="-0.42063504149925784" LOG_EFFECT_SIZE="0.0" ORDER="2693" O_E="0.0" SE="0.4941662111074008" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.2442002442002442" WEIGHT="3.0795979628618775"/>
<DICH_DATA CI_END="0.9659913924620098" CI_START="0.542584572743223" EFFECT_SIZE="0.7239696312364425" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="120" LOG_CI_END="-0.015026743380476264" LOG_CI_START="-0.2655325586535567" LOG_EFFECT_SIZE="-0.1402796510170165" ORDER="2700" O_E="0.0" SE="0.14714835591519188" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.021652638648543984" WEIGHT="10.37043045445726"/>
<DICH_DATA CI_END="0.7840334509694098" CI_START="0.07955354949249081" EFFECT_SIZE="0.24974515800203873" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="-0.10566540764526376" LOG_CI_START="-1.0993404383855683" LOG_EFFECT_SIZE="-0.6025029230154161" MODIFIED="2009-12-17 21:02:50 +0530" MODIFIED_BY="Xavier Bosch" ORDER="798" O_E="0.0" SE="0.5836896318275859" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.34069358630302277" WEIGHT="2.360156375774013"/>
<DICH_DATA CI_END="1.3640756923992228" CI_START="0.5201194130751116" EFFECT_SIZE="0.8423076923076923" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.1348384699386668" LOG_CI_START="-0.283896936200066" LOG_EFFECT_SIZE="-0.07452923313069962" MODIFIED="2009-12-17 21:02:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="796" O_E="0.0" SE="0.24596725033958133" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.06049988823961427" WEIGHT="7.337963910754054"/>
<DICH_DATA CI_END="2.4006588745471547" CI_START="0.1733828554084815" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3803304526738385" LOG_CI_START="-0.7609938490144215" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2013-04-04 18:35:42 +0530" MODIFIED_BY="Xavier Bosch" ORDER="961" O_E="0.0" SE="0.6704195444580936" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.4494623655913978" WEIGHT="1.8681953419699517"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-12-17 21:02:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="795" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="0.6093758660372272"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 21:02:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="797" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6497708921999872" CI_START="0.03130765804115496" EFFECT_SIZE="0.14262820512820512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.1872397476541158" LOG_CI_START="-1.5043494184209065" LOG_EFFECT_SIZE="-0.8457945830375112" MODIFIED="2009-12-17 21:02:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="794" O_E="0.0" SE="0.7736767404064332" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.5985756986459234" WEIGHT="1.4529886296139818"/>
<DICH_DATA CI_END="4.79000015643427" CI_START="0.9192311686322996" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6803355275979743" LOG_CI_START="-0.03657525832377156" LOG_EFFECT_SIZE="0.32188013463710136" MODIFIED="2013-02-28 21:46:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="893" O_E="0.0" SE="0.4211169444160576" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.17733948087431695" WEIGHT="3.9042394664119446"/>
<DICH_DATA CI_END="2.767396850752258" CI_START="0.676043157306895" EFFECT_SIZE="1.367801047120419" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.44207144238401824" LOG_CI_START="-0.17002557864125237" LOG_EFFECT_SIZE="0.1360229318713829" MODIFIED="2009-12-17 21:02:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="793" O_E="0.0" SE="0.359548820079364" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12927535402046286" WEIGHT="4.834945355194298"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.43175067003785" CI_END="0.8867488190067545" CI_START="0.6853357860005403" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7795644289339048" ESTIMABLE="YES" EVENTS_1="1274" EVENTS_2="1405" I2="34.12339632709979" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-0.052199381259392885" LOG_CI_START="-0.164096590148475" LOG_EFFECT_SIZE="-0.10814798570393393" METHOD="MH" MODIFIED="2013-04-17 21:33:17 +0530" MODIFIED_BY="Xavier Bosch" NO="8" P_CHI2="0.049811356039064836" P_Q="1.0" P_Z="1.5150652075040594E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="25" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.027448328468897235" TOTALS="YES" TOTAL_1="7352" TOTAL_2="6406" WEIGHT="99.99999999999997" Z="3.788587027052197">
<NAME>6-month mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8116700530689275" CI_START="0.4639625823779702" EFFECT_SIZE="0.6136648383773701" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="98" LOG_CI_END="-0.09062047722722606" LOG_CI_START="-0.33351704298397916" LOG_EFFECT_SIZE="-0.2120687601056026" ORDER="2735" O_E="0.0" SE="0.14267864508290862" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="0.0203571957626946" WEIGHT="9.03723606282814"/>
<DICH_DATA CI_END="1.5518721055795837" CI_START="0.41553531716075454" EFFECT_SIZE="0.803030303030303" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" LOG_CI_END="0.1908559268901096" LOG_CI_START="-0.3813920587722689" LOG_EFFECT_SIZE="-0.09526806594107966" ORDER="2736" O_E="0.0" SE="0.3361412994512949" STUDY_ID="STD-ERASER-1999" TOTAL_1="154" TOTAL_2="71" VAR="0.1129909731968051" WEIGHT="3.076274251324159"/>
<DICH_DATA CI_END="0.9397155381936182" CI_START="0.5869012263377732" EFFECT_SIZE="0.7426440612934941" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="187" LOG_CI_END="-0.027003592027319622" LOG_CI_START="-0.2314349830214897" LOG_EFFECT_SIZE="-0.12921928752440467" ORDER="2737" O_E="0.0" SE="0.12008401102168147" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.014420169703055315" WEIGHT="10.318731897519081"/>
<DICH_DATA CI_END="0.8958463513146007" CI_START="0.19859971768922444" EFFECT_SIZE="0.42179951690821255" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.04776647080472422" LOG_CI_START="-0.702021373192597" LOG_EFFECT_SIZE="-0.3748939219986606" ORDER="2732" O_E="0.0" SE="0.38431256827663507" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="0.1476961501353833" WEIGHT="2.4667052654526986"/>
<DICH_DATA CI_END="0.7946895041905886" CI_START="0.12187579613009114" EFFECT_SIZE="0.3112128146453089" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.09980252286106286" LOG_CI_START="-0.9140825343393459" LOG_EFFECT_SIZE="-0.5069425286002043" ORDER="2740" O_E="0.0" SE="0.4783121094934074" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.22878247408803337" WEIGHT="1.6860962978569125"/>
<DICH_DATA CI_END="1.1771634974207843" CI_START="0.015724923278181254" EFFECT_SIZE="0.1360544217687075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07083678662964918" LOG_CI_START="-1.8034114647980388" LOG_EFFECT_SIZE="-0.8662873390841949" ORDER="2741" O_E="0.0" SE="1.100942700567097" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2120748299319728" WEIGHT="0.3485451680834388"/>
<DICH_DATA CI_END="0.9808629342255492" CI_START="0.39709938413492707" EFFECT_SIZE="0.6240994048240577" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="61" LOG_CI_END="-0.008391676685752695" LOG_CI_START="-0.4011007864868856" LOG_EFFECT_SIZE="-0.20474623158631913" ORDER="2731" O_E="0.0" SE="0.23067927503863042" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.053212927932348095" WEIGHT="5.356100646871105"/>
<DICH_DATA CI_END="117.25632331883436" CI_START="0.2368806042653152" EFFECT_SIZE="5.27027027027027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.069136272354529" LOG_CI_START="-0.6254704977634833" LOG_EFFECT_SIZE="0.721832887295523" MODIFIED="2013-04-17 21:33:17 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1084" O_E="0.0" SE="1.5828253552859535" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="2.505336105336105" WEIGHT="0.17057504058452688"/>
<DICH_DATA CI_END="1.219076992356302" CI_START="0.8202927348068005" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="257" LOG_CI_END="0.08603113490433693" LOG_CI_START="-0.08603113490433689" LOG_EFFECT_SIZE="0.0" ORDER="2738" O_E="0.0" SE="0.10107022900758697" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1079" VAR="0.010215191191646076" WEIGHT="11.470776270565734"/>
<DICH_DATA CI_END="1.3912058332074704" CI_START="0.638564961241306" EFFECT_SIZE="0.94253663003663" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="72" LOG_CI_END="0.1433913899582164" LOG_CI_START="-0.19479491535660595" LOG_EFFECT_SIZE="-0.025701762699194778" MODIFIED="2009-12-22 21:21:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="846" O_E="0.0" SE="0.19865230979113668" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.039462740185353735" WEIGHT="6.456776379115544"/>
<DICH_DATA CI_END="1.249540537688291" CI_START="0.6583788979122845" EFFECT_SIZE="0.9070121951219512" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="112" LOG_CI_END="0.09675035010532974" LOG_CI_START="-0.18152409739955114" LOG_EFFECT_SIZE="-0.042386873647110725" ORDER="2739" O_E="0.0" SE="0.16345978794509788" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.026719102275056365" WEIGHT="7.975822402032079"/>
<DICH_DATA CI_END="2.524097051528937" CI_START="0.33801890472429086" EFFECT_SIZE="0.9236842105263158" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.40210604951550155" LOG_CI_START="-0.47105900981747373" LOG_EFFECT_SIZE="-0.03447648015098608" MODIFIED="2013-04-04 19:20:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="992" O_E="0.0" SE="0.5129014780889415" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.263067926225821" WEIGHT="1.4871106198244708"/>
<DICH_DATA CI_END="1.0645455176230145" CI_START="0.292010461245386" EFFECT_SIZE="0.5575467941059339" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="0.02716423564740791" LOG_CI_START="-0.5346015897167767" LOG_EFFECT_SIZE="-0.2537186770346844" ORDER="2733" O_E="0.0" SE="0.3299840266046055" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.108889457814189" WEIGHT="3.168819293362275"/>
<DICH_DATA CI_END="1.8488542874945328" CI_START="0.5685373626502128" EFFECT_SIZE="1.0252525252525253" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.26690268474991974" LOG_CI_START="-0.2452409894465561" LOG_EFFECT_SIZE="0.01083084765168183" MODIFIED="2009-12-17 21:07:37 +0530" MODIFIED_BY="Xavier Bosch" ORDER="819" O_E="0.0" SE="0.30083572937508357" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.09050213606863854" WEIGHT="3.6628071731812457"/>
<DICH_DATA CI_END="3.2818350259814215" CI_START="0.3047075773411107" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5161167457887658" LOG_CI_START="-0.5161167457887657" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:36:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1016" O_E="0.0" SE="0.6063390625908325" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.36764705882352944" WEIGHT="1.0934822867683414"/>
<DICH_DATA CI_END="1.7300298892594128" CI_START="0.35572402673145254" EFFECT_SIZE="0.7844827586206896" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.23805360638214693" LOG_CI_START="-0.4488868001937967" LOG_EFFECT_SIZE="-0.1054165969058249" ORDER="2734" O_E="0.0" SE="0.403512195232563" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.16282209170140205" WEIGHT="2.27060941580653"/>
<DICH_DATA CI_END="0.953751578729526" CI_START="0.6383805812228086" EFFECT_SIZE="0.7802925651135771" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="281" LOG_CI_END="-0.020564730155853063" LOG_CI_START="-0.19492033217744956" LOG_EFFECT_SIZE="-0.10774253116665135" ORDER="2742" O_E="0.0" SE="0.10241734370163527" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.01048931229089889" WEIGHT="11.387893367528104"/>
<DICH_DATA CI_END="3.1749472983095473" CI_START="0.4127383274584887" EFFECT_SIZE="1.144736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5017365207324632" LOG_CI_START="-0.384325200056809" LOG_EFFECT_SIZE="0.058705660337827134" MODIFIED="2013-04-04 18:37:56 +0530" MODIFIED_BY="Xavier Bosch" ORDER="966" O_E="0.0" SE="0.5204770408678742" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="0.2708963500705787" WEIGHT="1.4480895375882545"/>
<DICH_DATA CI_END="1.0778788344356367" CI_START="0.15704313321671678" EFFECT_SIZE="0.4114285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.03256994406638623" LOG_CI_START="-0.8039810485764382" LOG_EFFECT_SIZE="-0.385705552255026" MODIFIED="2009-12-17 21:08:12 +0530" MODIFIED_BY="Xavier Bosch" ORDER="822" O_E="0.0" SE="0.49139419407259377" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.24146825396825397" WEIGHT="1.6065569615407274"/>
<DICH_DATA CI_END="4.136431592337159" CI_START="0.195820958697962" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6166258464281339" LOG_CI_START="-0.7081408275494842" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2009-12-17 21:08:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="821" O_E="0.0" SE="0.7781745019952502" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.6055555555555556" WEIGHT="0.682507356576436"/>
<DICH_DATA CI_END="1.198304705792229" CI_START="0.6271970198850383" EFFECT_SIZE="0.8669331810394061" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="102" LOG_CI_END="0.07856726481289066" LOG_CI_START="-0.20259601386085985" LOG_EFFECT_SIZE="-0.06201437452398457" MODIFIED="2013-03-04 22:16:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1569" O_E="0.0" SE="0.16515670167363683" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.027276736107714677" WEIGHT="7.894550896021868"/>
<DICH_DATA CI_END="0.6543236827184337" CI_START="0.05126944857789578" EFFECT_SIZE="0.1831578947368421" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.1842073604783508" LOG_CI_START="-1.2901413535341453" LOG_EFFECT_SIZE="-0.737174357006248" MODIFIED="2009-12-17 21:07:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="820" O_E="0.0" SE="0.6496311019825304" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="0.42202056866303683" WEIGHT="0.9612006756083304"/>
<DICH_DATA CI_END="3.4705248704498204" CI_START="0.8202144425463485" EFFECT_SIZE="1.6871794871794872" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.5403951609874541" LOG_CI_START="-0.08607258781254147" LOG_EFFECT_SIZE="0.2271612865874563" MODIFIED="2013-02-28 21:47:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="894" O_E="0.0" SE="0.3679902567104873" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.13541682903385033" WEIGHT="2.6526840621564975"/>
<DICH_DATA CI_END="1.6058163716198053" CI_START="0.25974370533021174" EFFECT_SIZE="0.6458333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.20569588132137684" LOG_CI_START="-0.5854549684040059" LOG_EFFECT_SIZE="-0.1898795435413145" MODIFIED="2013-02-28 21:47:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="895" O_E="0.0" SE="0.46472592538855656" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.21597018572825025" WEIGHT="1.7748436638563991"/>
<DICH_DATA CI_END="2.95874555117806" CI_START="0.41329613692164313" EFFECT_SIZE="1.1058201058201058" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4711076179247954" LOG_CI_START="-0.38373865404917573" LOG_EFFECT_SIZE="0.043684481937809855" MODIFIED="2013-04-10 20:48:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1035" O_E="0.0" SE="0.5021409317148026" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.25214551530341" WEIGHT="1.5452050079470927"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.171929789990353" CI_END="1.8239886139977164" CI_START="1.0451781307885537" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3807219163023878" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.26102212297628086" LOG_CI_START="0.019190314012407932" LOG_EFFECT_SIZE="0.1401062184943444" METHOD="MH" MODIFIED="2013-05-14 19:44:47 +0530" MODIFIED_BY="Xavier Bosch" NO="9" P_CHI2="0.8574967545626738" P_Q="1.0" P_Z="0.023145414379638966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8339" TOTAL_2="7304" WEIGHT="100.0" Z="2.2710258293609127">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6142617822240544" CI_START="0.07145398719235442" EFFECT_SIZE="0.5081863979848866" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.558019605462861" LOG_CI_START="-1.145973532200875" LOG_EFFECT_SIZE="-0.2939769633690071" ORDER="2710" O_E="0.0" SE="1.0009340039657464" STUDY_ID="STD-EPISTENT-1998" TOTAL_1="1590" TOTAL_2="809" VAR="1.0018688802949007" WEIGHT="3.095913642229155"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2712" O_E="0.0" SE="0.0" STUDY_ID="STD-Galassi-1999" TOTAL_1="54" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0976802499127216" CI_START="0.2795342622396157" EFFECT_SIZE="0.7657502863688431" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.32173928925237827" LOG_CI_START="-0.5535649534675113" LOG_EFFECT_SIZE="-0.11591283210756652" ORDER="2713" O_E="0.0" SE="0.5141580449995434" STUDY_ID="STD-ISAR_x002d_2-2000" TOTAL_1="201" TOTAL_2="200" VAR="0.2643584952377525" WEIGHT="10.182125810456322"/>
<DICH_DATA CI_END="9.932499875628727" CI_START="1.048980971085676" EFFECT_SIZE="3.2278481012658227" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9970585682893176" LOG_CI_START="0.02076760999770986" LOG_EFFECT_SIZE="0.5089130891435137" ORDER="2711" O_E="0.0" SE="0.5734781416186749" STUDY_ID="STD-ESPRIT-2000" TOTAL_1="1040" TOTAL_2="1024" VAR="0.328877178914409" WEIGHT="4.654353168419061"/>
<DICH_DATA CI_END="75.7329305966302" CI_START="0.12368872278442308" EFFECT_SIZE="3.0606060606060606" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8792847628106097" LOG_CI_START="-0.9076698950010998" LOG_EFFECT_SIZE="0.4858074339047551" ORDER="2707" O_E="0.0" SE="1.6370709616466477" STUDY_ID="STD-ADMIRAL-2001" TOTAL_1="149" TOTAL_2="151" VAR="2.68000133346668" WEIGHT="0.5749473904629296"/>
<DICH_DATA CI_END="3.682945930385523" CI_START="0.030056409395846417" EFFECT_SIZE="0.33271028037383177" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5661953429907868" LOG_CI_START="-1.5220629024154557" LOG_EFFECT_SIZE="-0.47793377971233447" ORDER="2717" O_E="0.0" SE="1.2266532303966553" STUDY_ID="STD-Juergens-2002" TOTAL_1="536" TOTAL_2="358" VAR="1.5046781476425497" WEIGHT="2.7988836877980567"/>
<DICH_DATA CI_END="15.120249715113221" CI_START="0.0557794083969631" EFFECT_SIZE="0.9183673469387755" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1795589637181094" LOG_CI_START="-1.2535260962244492" LOG_EFFECT_SIZE="-0.036983566253169974" ORDER="2719" O_E="0.0" SE="1.429206208175548" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.042630385487528" WEIGHT="1.1936127222321034"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2718" O_E="0.0" SE="0.0" STUDY_ID="STD-Tamburino-2002" TOTAL_1="54" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.553023019892206" CI_START="0.387065443325746" EFFECT_SIZE="1.1727115716753023" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5505980212747973" LOG_CI_START="-0.4122156001686663" LOG_EFFECT_SIZE="0.0691912105530655" ORDER="2706" O_E="0.0" SE="0.5655614872401817" STUDY_ID="STD-ACE-2003" TOTAL_1="200" TOTAL_2="200" VAR="0.3198597958493263" WEIGHT="6.769976484954004"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-17 21:34:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1085" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasior-2003" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:18:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="988" O_E="0.0" SE="0.0" STUDY_ID="STD-DANTE-2004" TOTAL_1="47" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.001482304785" CI_START="0.2962231141397101" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7782585299305445" LOG_CI_START="-0.5283810567139446" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="2716" O_E="0.0" SE="0.7675265611652409" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.5890970220941403" WEIGHT="3.472732277766092"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2708" O_E="0.0" SE="0.0" STUDY_ID="STD-ADVANCE-2004" TOTAL_1="101" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7015192534081667" CI_START="0.6135687571429665" EFFECT_SIZE="1.507029053420806" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.568380012701654" LOG_CI_START="-0.21213676272572884" LOG_EFFECT_SIZE="0.17812162498796255" ORDER="2714" O_E="0.0" SE="0.4584794175063947" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.21020337627700297" WEIGHT="9.245711893350386"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 21:03:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="800" O_E="0.0" SE="0.0" STUDY_ID="STD-ASIAD-2005" TOTAL_1="128" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.924023369377402" CI_START="0.723640154774154" EFFECT_SIZE="2.8115942028985508" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.038382620539537" LOG_CI_START="-0.14047734215359553" LOG_EFFECT_SIZE="0.44895263919297074" ORDER="2709" O_E="0.0" SE="0.6924681775368743" STUDY_ID="STD-Claeys-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.4795121769012401" WEIGHT="3.2271390498226338"/>
<DICH_DATA CI_END="2.1042808924914613" CI_START="0.47331893929655383" EFFECT_SIZE="0.9979959919839679" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32310371167784774" LOG_CI_START="-0.32484611740519254" LOG_EFFECT_SIZE="-8.712028636723787E-4" ORDER="2715" O_E="0.0" SE="0.3806089370067602" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.14486316292941592" WEIGHT="16.15905718406293"/>
<DICH_DATA CI_END="16.330717844801725" CI_START="0.061234295363097754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213005275317456" LOG_CI_START="-1.213005275317456" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 18:36:04 +0530" MODIFIED_BY="Xavier Bosch" ORDER="962" O_E="0.0" SE="1.4250506063888506" STUDY_ID="STD-De-Luca-2008" TOTAL_1="66" TOTAL_2="66" VAR="2.0307692307692307" WEIGHT="1.15153732014971"/>
<DICH_DATA CI_END="2.793753964807843" CI_START="0.6856670030823098" EFFECT_SIZE="1.3840465701699183" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.4461881568135316" LOG_CI_START="-0.16388674994265123" LOG_EFFECT_SIZE="0.14115070343544017" MODIFIED="2009-12-17 21:04:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="804" O_E="0.0" SE="0.35836102014807486" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.1284226207615689" WEIGHT="15.645839664891428"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 21:04:05 +0530" MODIFIED_BY="Xavier Bosch" ORDER="803" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.145884842133626" CI_START="0.1566937278201711" EFFECT_SIZE="1.5405405405405406" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1802946504539946" LOG_CI_START="-0.8049483872430017" LOG_EFFECT_SIZE="0.18767313160549642" MODIFIED="2009-12-17 21:04:42 +0530" MODIFIED_BY="Xavier Bosch" ORDER="806" O_E="0.0" SE="1.1661415874547418" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="1.3598862019914653" WEIGHT="1.509152487909978"/>
<DICH_DATA CI_END="3.853603594794696" CI_START="0.8260906671731362" EFFECT_SIZE="1.7842157842157842" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5858670384337318" LOG_CI_START="-0.08297228428731374" LOG_EFFECT_SIZE="0.25144737707320897" MODIFIED="2013-02-28 21:48:12 +0530" MODIFIED_BY="Xavier Bosch" ORDER="896" O_E="0.0" SE="0.39287952897438555" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.15435432428713505" WEIGHT="11.704225322001655"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 21:03:33 +0530" MODIFIED_BY="Xavier Bosch" ORDER="799" O_E="0.0" SE="0.0" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="147.36553289489572" CI_START="0.38303737170923763" EFFECT_SIZE="7.513089005235602" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.168395918910134" LOG_CI_START="-0.41675885126556694" LOG_EFFECT_SIZE="0.8758185338222836" MODIFIED="2009-12-17 21:04:05 +0530" MODIFIED_BY="Xavier Bosch" ORDER="802" O_E="0.0" SE="1.518532708723702" STUDY_ID="STD-CLEAR-PLATELETS_x002d_2-2009" TOTAL_1="98" TOTAL_2="102" VAR="2.3059415874637432" WEIGHT="0.5527905353315783"/>
<DICH_DATA CI_END="2.862927770247001" CI_START="0.34575566077574593" EFFECT_SIZE="0.9949238578680203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.45681039120048" LOG_CI_START="-0.4612307008107137" LOG_EFFECT_SIZE="-0.002210154805116882" MODIFIED="2009-12-17 21:03:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="801" O_E="0.0" SE="0.5392618818240714" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.2908033771884388" WEIGHT="8.062001358161979"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-17 21:04:25 +0530" MODIFIED_BY="Xavier Bosch" ORDER="805" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-05 16:22:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1029" O_E="0.0" SE="0.0" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-04-10 21:24:25 +0530" MODIFIED_BY="Xavier Bosch" NO="7">
<NAME>Subgroup of PCI in patients pre-treated with clopidogrel</NAME>
<DICH_OUTCOME CHI2="4.7324201741704535" CI_END="1.1990702995444111" CI_START="0.5733560868471348" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8291527330965057" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.078844645825469" LOG_CI_START="-0.24157557258640153" LOG_EFFECT_SIZE="-0.08136546338046628" METHOD="MH" MODIFIED="2013-04-10 21:21:08 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.8569823841465655" P_Q="0.8887029110237129" P_Z="0.3195410583941818" Q="0.019584795432450477" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4056" TOTAL_2="3992" WEIGHT="100.0" Z="0.9954014674950273">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9968183085423195" CI_END="1.2470851468312674" CI_START="0.5631212630034655" DF="5" EFFECT_SIZE="0.8380096437132961" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.09589610667545316" LOG_CI_START="-0.24939807374098424" LOG_EFFECT_SIZE="-0.07675098353276556" MODIFIED="2013-04-10 21:21:08 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.5498742072200384" P_Z="0.3835848345517443" STUDIES="7" TAU2="0.0" TOTAL_1="2346" TOTAL_2="2288" WEIGHT="85.60022912507576" Z="0.8713101583167386">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:37:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1017" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4783959943434857" CI_START="0.3152530098603363" EFFECT_SIZE="0.6826923076923077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16979077717359825" LOG_CI_START="-0.5013407583330084" LOG_EFFECT_SIZE="-0.16577499057970504" MODIFIED="2013-03-08 16:54:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="835" O_E="0.0" SE="0.3942259861112605" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.15541412812539573" WEIGHT="25.490808097613073"/>
<DICH_DATA CI_END="1.2195597139842589" CI_START="0.27009845721495546" EFFECT_SIZE="0.5739348370927319" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.08620306977393853" LOG_CI_START="-0.5684778964676589" LOG_EFFECT_SIZE="-0.24113741334686023" MODIFIED="2013-03-08 16:55:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="836" O_E="0.0" SE="0.384562840293363" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.14788857813449863" WEIGHT="29.736008061561712"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2013-03-08 16:55:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="837" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="6.118289185121992"/>
<DICH_DATA CI_END="6.10558003083999" CI_START="0.5067747078702879" EFFECT_SIZE="1.759020618556701" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7857269282689927" LOG_CI_START="-0.2951850680318199" LOG_EFFECT_SIZE="0.2452709301185864" MODIFIED="2013-03-08 17:12:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="938" O_E="0.0" SE="0.6349330572277724" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.40313998716060573" WEIGHT="6.243274419851701"/>
<DICH_DATA CI_END="3.0079258897057595" CI_START="0.5647488097940576" EFFECT_SIZE="1.3033505154639176" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.47826713175725805" LOG_CI_START="-0.24814467568058352" LOG_EFFECT_SIZE="0.11506122803833728" MODIFIED="2013-03-08 16:55:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="834" O_E="0.0" SE="0.4266978914854272" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.18207109059810941" WEIGHT="15.608186049629252"/>
<DICH_DATA CI_END="8.196019479828836" CI_START="0.013332642230707504" EFFECT_SIZE="0.330567081604426" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9136029819365901" LOG_CI_START="-1.8750837746293763" LOG_EFFECT_SIZE="-0.48074039634639315" MODIFIED="2013-03-08 17:11:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="939" O_E="0.0" SE="1.6380884050289253" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="2.6833336226902085" WEIGHT="2.403663311298021"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7312585046472837" CI_END="2.0915078021780538" CI_START="0.2882876580421126" DF="3" EFFECT_SIZE="0.7765023413143822" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.32045948901540855" LOG_CI_START="-0.5401739499078029" LOG_EFFECT_SIZE="-0.10985723044619712" MODIFIED="2013-04-05 16:11:01 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8658281815995457" P_Z="0.6168168029975846" STUDIES="6" TAU2="0.0" TOTAL_1="1710" TOTAL_2="1704" WEIGHT="14.399770874924247" Z="0.5003668353515479">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 16:57:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2750" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.9744715717384125" CI_START="0.19987271343101215" EFFECT_SIZE="0.9971264367816092" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6967469532893872" LOG_CI_START="-0.6992464916008017" LOG_EFFECT_SIZE="-0.001249769155707207" MODIFIED="2013-03-08 16:58:33 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2748" O_E="0.0" SE="0.8200134598074966" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.672422074265461" WEIGHT="4.792842694769751"/>
<DICH_DATA CI_END="4.970205306279777" CI_START="0.201573081602601" EFFECT_SIZE="1.0009293680297398" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6963743286815872" LOG_CI_START="-0.6955674647463649" LOG_EFFECT_SIZE="4.0343196761120383E-4" MODIFIED="2013-03-08 16:58:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2746" O_E="0.0" SE="0.8176334996825806" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.6685245398031845" WEIGHT="4.811622846411638"/>
<DICH_DATA CI_END="8.315037261213861" CI_START="0.013362671461425384" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9198641997134829" LOG_CI_START="-1.8741067091528076" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-03-08 17:16:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="941" O_E="0.0" SE="1.6411923422471113" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="2.6935123042505595" WEIGHT="2.3816683157589527"/>
<DICH_DATA CI_END="8.132763947030567" CI_START="0.013252828875088381" EFFECT_SIZE="0.3283018867924528" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910238167112663" LOG_CI_START="-1.877691409749042" LOG_EFFECT_SIZE="-0.48372662131818933" MODIFIED="2013-03-08 17:17:06 +0530" MODIFIED_BY="Xavier Bosch" ORDER="942" O_E="0.0" SE="1.6376436339225422" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="2.6818766717270295" WEIGHT="2.413637017983905"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 17:17:28 +0530" MODIFIED_BY="Xavier Bosch" ORDER="944" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.017048653280126" CI_END="1.205719488273257" CI_START="0.7511521703638122" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9516715875061112" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.08124628055268357" LOG_CI_START="-0.1242720735752619" LOG_EFFECT_SIZE="-0.02151289651128917" METHOD="MH" MODIFIED="2013-04-10 20:50:47 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.6925396871831637" P_Q="0.8436831992123118" P_Z="0.6815686767588636" Q="0.038881750849341055" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3797" TOTAL_2="3729" WEIGHT="100.00000000000003" Z="0.41032347251102097">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.224249793233337" CI_END="1.310680874903242" CI_START="0.7174377663057973" DF="7" EFFECT_SIZE="0.9697071512731614" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="88" I2="24.113069822382602" ID="CMP-007.02.01" LOG_CI_END="0.11749696236919696" LOG_CI_START="-0.14421576556567672" LOG_EFFECT_SIZE="-0.013359401598239872" MODIFIED="2013-04-10 20:50:47 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.23695457363779449" P_Z="0.8414048384651285" STUDIES="8" TAU2="0.0" TOTAL_1="1998" TOTAL_2="1936" WEIGHT="61.08110399903176" Z="0.20009684812939457">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="5.651593953590671" CI_START="0.0406258298685047" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.752170951823081" LOG_CI_START="-1.3911977545390697" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2013-04-04 19:39:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1020" O_E="0.0" SE="1.2590253879633373" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.585144927536232" WEIGHT="1.36479558733008"/>
<DICH_DATA CI_END="1.381299390738275" CI_START="0.6030299390679948" EFFECT_SIZE="0.9126691007323302" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="49" LOG_CI_END="0.1402878202538681" LOG_CI_START="-0.21966112558912065" LOG_EFFECT_SIZE="-0.039686652667626277" MODIFIED="2010-05-27 17:13:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="840" O_E="0.0" SE="0.21143579256418962" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.04470509437724702" WEIGHT="33.31484365441662"/>
<DICH_DATA CI_END="0.8834563410491986" CI_START="0.002881385072286747" EFFECT_SIZE="0.05045372050816697" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.053814907741730686" LOG_CI_START="-2.5403986981256867" LOG_EFFECT_SIZE="-1.2971068029337087" MODIFIED="2013-03-08 19:38:58 +0530" MODIFIED_BY="Xavier Bosch" ORDER="946" O_E="0.0" SE="1.4606316272598117" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="2.1334447505516456" WEIGHT="6.441906255301484"/>
<DICH_DATA CI_END="3.6488654517883754" CI_START="0.1938259998036942" EFFECT_SIZE="0.8409785932721713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5621578494914818" LOG_CI_START="-0.7125879671515286" LOG_EFFECT_SIZE="-0.07521505883002341" MODIFIED="2010-05-27 17:13:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="842" O_E="0.0" SE="0.7487920027896646" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.5606894634417571" WEIGHT="2.70281102868784"/>
<DICH_DATA CI_END="4.318001687357362" CI_START="0.5265163609854081" EFFECT_SIZE="1.5078125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6352828077086909" LOG_CI_START="-0.27858812898888013" LOG_EFFECT_SIZE="0.1783473393599054" MODIFIED="2013-03-08 17:24:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="948" O_E="0.0" SE="0.5368123119502478" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.2881674582613702" WEIGHT="4.09438676199024"/>
<DICH_DATA CI_END="5.541897364276366" CI_START="0.04435592312350596" EFFECT_SIZE="0.4957983193277311" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7436584784037782" LOG_CI_START="-1.3530483779045512" LOG_EFFECT_SIZE="-0.3046949497503866" MODIFIED="2013-03-08 19:37:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="949" O_E="0.0" SE="1.2316159862618397" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="1.5168779376157242" WEIGHT="1.4098148862177042"/>
<DICH_DATA CI_END="3.2595498269126137" CI_START="0.91618733147098" EFFECT_SIZE="1.7281082887700534" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.5131576242434559" LOG_CI_START="-0.03801571770104572" LOG_EFFECT_SIZE="0.2375709532712051" MODIFIED="2013-03-04 22:18:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1570" O_E="0.0" SE="0.32376194941024516" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.10482179988592213" WEIGHT="10.634032284613541"/>
<DICH_DATA CI_END="7.28486338926983" CI_START="0.011522173759729045" EFFECT_SIZE="0.2897196261682243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8624214119958415" LOG_CI_START="-1.9384655796977155" LOG_EFFECT_SIZE="-0.538022083850937" MODIFIED="2013-04-10 20:50:47 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1036" O_E="0.0" SE="1.6452548835350098" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="2.706863631795799" WEIGHT="1.1185135404742537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6583155672303399" CI_END="1.3532840413539644" CI_START="0.6300261236577724" DF="5" EFFECT_SIZE="0.9233657448607041" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="56" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="0.13138896041577883" LOG_CI_START="-0.20064144241117998" LOG_EFFECT_SIZE="-0.03462624099770055" MODIFIED="2013-04-05 16:12:44 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.985177867663922" P_Z="0.6826901060830906" STUDIES="6" TAU2="0.0" TOTAL_1="1799" TOTAL_2="1793" WEIGHT="38.91889600096826" Z="0.408795006105911">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" MODIFIED="2010-05-27 17:10:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="2764" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="1.0988867531914708"/>
<DICH_DATA CI_END="1.5573678239082727" CI_START="0.500577314151068" EFFECT_SIZE="0.8829399766899767" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.19239119768551802" LOG_CI_START="-0.3005288362344995" LOG_EFFECT_SIZE="-0.05406881927449073" ORDER="2761" O_E="0.0" SE="0.2895436679181379" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.08383553563148893" WEIGHT="18.079274570467945"/>
<DICH_DATA CI_END="2.7941731204946523" CI_START="0.44551088293209834" EFFECT_SIZE="1.11572153065929" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4462533104919537" LOG_CI_START="-0.3511416825594777" LOG_EFFECT_SIZE="0.04755581396623803" ORDER="2762" O_E="0.0" SE="0.46839376608728556" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.21939272010943078" WEIGHT="6.142599661601394"/>
<DICH_DATA CI_END="1.853129240597719" CI_START="0.4755874190312977" EFFECT_SIZE="0.9387890884896873" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.26790570886079224" LOG_CI_START="-0.32276964252591284" LOG_EFFECT_SIZE="-0.0274319668325603" ORDER="2763" O_E="0.0" SE="0.3469656252946958" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12038514513613925" WEIGHT="12.19262819636894"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2013-03-08 17:29:08 +0530" MODIFIED_BY="Xavier Bosch" ORDER="953" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="0.71083103506775"/>
<DICH_DATA CI_END="16.508125798938536" CI_START="0.06057622846951526" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2176977697266207" LOG_CI_START="-1.2176977697266207" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-28 22:00:15 +0530" MODIFIED_BY="Xavier Bosch" ORDER="901" O_E="0.0" SE="1.4305633952771812" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="44" VAR="2.046511627906977" WEIGHT="0.6946757842707557"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.189456637188124" CI_END="0.9771362742721217" CI_START="0.6711754500952622" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8098332412842776" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="256" I2="29.525137884478816" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-0.010044864083388973" LOG_CI_START="-0.17316393728535875" LOG_EFFECT_SIZE="-0.09160440068437385" METHOD="MH" MODIFIED="2013-04-05 16:13:08 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.16452412529599236" P_Q="0.40203848248899643" P_Z="0.02771104735829003" Q="0.7022220934864467" RANDOM="NO" SCALE="33.81" SORT_BY="YEAR" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4056" TOTAL_2="3992" WEIGHT="100.0" Z="2.201352945948212">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.818503395697564" CI_END="0.9622840832496096" CI_START="0.6121009951270591" DF="5" EFFECT_SIZE="0.7674731558510798" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="183" I2="36.049142055096574" ID="CMP-007.03.01" LOG_CI_END="-0.016696697635202734" LOG_CI_START="-0.21317691444324152" LOG_EFFECT_SIZE="-0.11493680603922211" MODIFIED="2013-04-04 19:37:52 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.1665260869571158" P_Z="0.021843650053504315" STUDIES="7" TAU2="0.0" TOTAL_1="2346" TOTAL_2="2288" WEIGHT="70.90672286322487" Z="2.293075648985383">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:37:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1018" O_E="0.0" SE="0.0" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9714269034686553" CI_START="0.5408837972671123" EFFECT_SIZE="0.7248648648648649" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="116" LOG_CI_END="-0.012589872999912627" LOG_CI_START="-0.26689602810291707" LOG_EFFECT_SIZE="-0.13974295055141486" MODIFIED="2010-05-27 17:18:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="845" O_E="0.0" SE="0.14938069434327483" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.022314591842478904" WEIGHT="43.71400317391557"/>
<DICH_DATA CI_END="1.2364778498688138" CI_START="0.41829389011617946" EFFECT_SIZE="0.7191739218465276" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" LOG_CI_END="0.09218634086237065" LOG_CI_START="-0.37851847897234026" LOG_EFFECT_SIZE="-0.14316606905498483" MODIFIED="2010-05-27 17:18:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="846" O_E="0.0" SE="0.27649434119734556" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.07644912071415413" WEIGHT="12.848093378392388"/>
<DICH_DATA CI_END="1.1038931784097734" CI_START="0.10118222733826397" EFFECT_SIZE="0.33420707732634336" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.042927049596310406" LOG_CI_START="-0.9948957646381609" LOG_EFFECT_SIZE="-0.4759843575209253" MODIFIED="2010-05-27 17:18:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="847" O_E="0.0" SE="0.6096222583871124" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.37163929792100325" WEIGHT="3.654248688781319"/>
<DICH_DATA CI_END="1.6286850888993347" CI_START="0.06367457549921701" EFFECT_SIZE="0.3220338983050847" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21183712029725427" LOG_CI_START="-1.1960339416758847" LOG_EFFECT_SIZE="-0.49209841068931526" MODIFIED="2013-03-08 17:39:26 +0530" MODIFIED_BY="Xavier Bosch" ORDER="954" O_E="0.0" SE="0.8269904308771744" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6839131727624145" WEIGHT="2.430099324623383"/>
<DICH_DATA CI_END="2.350045571117705" CI_START="0.6032006136699485" EFFECT_SIZE="1.1906086387434556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.3710762840134639" LOG_CI_START="-0.2195382253058275" LOG_EFFECT_SIZE="0.07576902935381821" MODIFIED="2010-05-27 17:18:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="844" O_E="0.0" SE="0.34692988636312394" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12036034605193009" WEIGHT="6.2935453695331"/>
<DICH_DATA CI_END="6.053764570656634" CI_START="0.6816653038207906" EFFECT_SIZE="2.031413612565445" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7820255273485307" LOG_CI_START="-0.16642881065557125" LOG_EFFECT_SIZE="0.30779835834647973" MODIFIED="2013-03-08 17:38:57 +0530" MODIFIED_BY="Xavier Bosch" ORDER="955" O_E="0.0" SE="0.5571267730683014" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.31039024126949855" WEIGHT="1.966732927979094"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.517520068774359" CI_END="1.2796228016325017" CI_START="0.6515234850812442" DF="4" EFFECT_SIZE="0.9130740973814958" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="73" I2="27.50366196876299" ID="CMP-007.03.02" LOG_CI_END="0.10708197018586267" LOG_CI_START="-0.1860699249132344" LOG_EFFECT_SIZE="-0.039493977363685845" MODIFIED="2013-04-05 16:13:08 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.23819397678187348" P_Z="0.59742986039987" STUDIES="6" TAU2="0.0" TOTAL_1="1710" TOTAL_2="1704" WEIGHT="29.093277136775132" Z="0.5281001046430065">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2758" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.636734776341132"/>
<DICH_DATA CI_END="1.5829481218694044" CI_START="0.6647323957684306" EFFECT_SIZE="1.0257859900717043" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.19946668191539413" LOG_CI_START="-0.17735315534557233" LOG_EFFECT_SIZE="0.011056763284910887" ORDER="2754" O_E="0.0" SE="0.2213458376953691" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.04899397986506469" WEIGHT="16.60192364842679"/>
<DICH_DATA CI_END="2.6510797996207787" CI_START="0.6348282227549744" EFFECT_SIZE="1.2972972972972974" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.4234228005408498" LOG_CI_START="-0.19734377392366526" LOG_EFFECT_SIZE="0.11303951330859224" ORDER="2756" O_E="0.0" SE="0.36464135868455794" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.13296332046332043" WEIGHT="5.478431805118214"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-03-08 17:41:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="956" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="0.8071766611193583"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 17:44:26 +0530" MODIFIED_BY="Xavier Bosch" ORDER="959" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9416889999817076" CI_START="0.11495840288142405" EFFECT_SIZE="0.32902137232845896" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.026092502613264228" LOG_CI_START="-0.9394592784907644" LOG_EFFECT_SIZE="-0.4827758905520144" MODIFIED="2013-03-08 17:41:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="957" O_E="0.0" SE="0.5365161653889019" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.2878495957236115" WEIGHT="5.56901024576964"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.90616302391318" CI_END="1.1398838520421257" CI_START="0.6622922797121418" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8688706894446591" ESTIMABLE="YES" EVENTS_1="312" EVENTS_2="357" I2="40.65596980261237" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.056860601347871124" LOG_CI_START="-0.1789503074594648" LOG_EFFECT_SIZE="-0.061044853055796836" METHOD="MH" MODIFIED="2013-04-10 21:22:48 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.0568329086962962" P_Q="0.4799150992242003" P_Z="0.3102203623090155" Q="0.49905635044170354" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08049654729554619" TOTALS="YES" TOTAL_1="3797" TOTAL_2="3732" WEIGHT="100.0" Z="1.014759783896644">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.033459434175132" CI_END="1.2748251905142838" CI_START="0.4621616767576714" DF="7" EFFECT_SIZE="0.7675775841053458" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="220" I2="58.904413827084774" ID="CMP-007.04.01" LOG_CI_END="0.10545063653472062" LOG_CI_START="-0.3352060698104139" LOG_EFFECT_SIZE="-0.11487771663784666" MODIFIED="2013-04-10 20:51:02 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.01718171486165565" P_Z="0.3068225683233071" STUDIES="8" TAU2="0.2356218788816685" TOTAL_1="1998" TOTAL_2="1936" WEIGHT="52.02264807578974" Z="1.0219119963195502">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="3.159193437595083" CI_START="0.029553175319944055" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4995762185952884" LOG_CI_START="-1.5293958498134126" LOG_EFFECT_SIZE="-0.5149098156090622" MODIFIED="2013-04-04 19:38:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1019" O_E="0.0" SE="1.1918282365569903" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="1.4204545454545454" WEIGHT="1.2783107665511164"/>
<DICH_DATA CI_END="0.9404987851447159" CI_START="0.5614014133321323" EFFECT_SIZE="0.7266342595951535" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="154" LOG_CI_END="-0.02664176109742685" LOG_CI_START="-0.2507264983606934" LOG_EFFECT_SIZE="-0.13868412972906016" MODIFIED="2010-05-27 17:22:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="850" O_E="0.0" SE="0.13162848390578177" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.017326057775334653" WEIGHT="19.613891293723537"/>
<DICH_DATA CI_END="1.4311007059550747" CI_START="0.15874593051244992" EFFECT_SIZE="0.4766355140186916" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.15567019595523704" LOG_CI_START="-0.7992973991297837" LOG_EFFECT_SIZE="-0.3218136015872733" MODIFIED="2010-05-27 17:22:55 +0530" MODIFIED_BY="Xavier Bosch" ORDER="852" O_E="0.0" SE="0.5609526925187756" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.31466792324406395" WEIGHT="4.855400940547823"/>
<DICH_DATA CI_END="0.6122631719676019" CI_START="0.009801003503232143" EFFECT_SIZE="0.07746478873239436" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.21306186287730208" LOG_CI_START="-2.008729455572361" LOG_EFFECT_SIZE="-1.1108956592248316" MODIFIED="2013-03-08 17:51:49 +0530" MODIFIED_BY="Xavier Bosch" ORDER="961" O_E="0.0" SE="1.0547840326470164" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="1.112569355527102" WEIGHT="1.6081944320005614"/>
<DICH_DATA CI_END="4.858291695424427" CI_START="0.7404466913695666" EFFECT_SIZE="1.8966565349544073" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6864835866136397" LOG_CI_START="-0.1305062031487403" LOG_EFFECT_SIZE="0.2779886917324497" MODIFIED="2013-03-08 17:50:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="960" O_E="0.0" SE="0.47990384667110486" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.2303077020497233" WEIGHT="6.173280918684158"/>
<DICH_DATA CI_END="1.6286850888993347" CI_START="0.06367457549921701" EFFECT_SIZE="0.3220338983050847" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21183712029725427" LOG_CI_START="-1.1960339416758847" LOG_EFFECT_SIZE="-0.49209841068931526" MODIFIED="2013-03-08 17:47:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="963" O_E="0.0" SE="0.8269904308771744" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6839131727624145" WEIGHT="2.5100177190101967"/>
<DICH_DATA CI_END="2.475775806656468" CI_START="0.8899366852164702" EFFECT_SIZE="1.4843462246777164" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="27" LOG_CI_END="0.39371131468559334" LOG_CI_START="-0.05064089025310598" LOG_EFFECT_SIZE="0.17153521221624368" MODIFIED="2013-03-04 22:19:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1571" O_E="0.0" SE="0.26101468475988077" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.06812866566029994" WEIGHT="12.90953199508021"/>
<DICH_DATA CI_END="3.723005569583228" CI_START="0.20684787573541472" EFFECT_SIZE="0.8775510204081632" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5708936859195615" LOG_CI_START="-0.6843489348174159" LOG_EFFECT_SIZE="-0.05672762444892715" MODIFIED="2013-04-10 20:51:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1037" O_E="0.0" SE="0.737335728972084" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.5436639772187946" WEIGHT="3.07402001019214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.1563497072037165" CI_END="1.2143931429293309" CI_START="0.7303644684854245" DF="5" EFFECT_SIZE="0.9417800180338957" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="137" I2="0.0" ID="CMP-007.04.02" LOG_CI_END="0.0843593063146123" LOG_CI_START="-0.13646036296015213" LOG_EFFECT_SIZE="-0.02605052832276991" MODIFIED="2013-04-05 16:15:37 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.527132335472446" P_Z="0.643764695848831" STUDIES="6" TAU2="0.0" TOTAL_1="1799" TOTAL_2="1796" WEIGHT="47.97735192421027" Z="0.462441570160477">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="1.490417290079542" CI_START="0.018790038269107676" EFFECT_SIZE="0.1673469387755102" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.17330788009442707" LOG_CI_START="-1.7260723353840213" LOG_EFFECT_SIZE="-0.7763822276447969" ORDER="2771" O_E="0.0" SE="1.115705340655742" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2447984071677451" WEIGHT="1.4477395657981056"/>
<DICH_DATA CI_END="1.3325825657155022" CI_START="0.662004293235404" EFFECT_SIZE="0.9392419175027871" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="69" LOG_CI_END="0.12469412705977545" LOG_CI_START="-0.17913919406120712" LOG_EFFECT_SIZE="-0.027222533500715847" ORDER="2768" O_E="0.0" SE="0.17847319682566087" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.03185268198517109" WEIGHT="17.077838043152582"/>
<DICH_DATA CI_END="1.6375543683499472" CI_START="0.5635675410031722" EFFECT_SIZE="0.9606625258799172" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.21419572788971358" LOG_CI_START="-0.24905402828297613" LOG_EFFECT_SIZE="-0.017429150196631278" ORDER="2770" O_E="0.0" SE="0.27211519989911404" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.07404668201613479" WEIGHT="12.415179561568047"/>
<DICH_DATA CI_END="2.55497240607456" CI_START="0.684418996161148" EFFECT_SIZE="1.3223734908810685" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.40738621407767245" LOG_CI_START="-0.16467794504929822" LOG_EFFECT_SIZE="0.12135413451418711" ORDER="2769" O_E="0.0" SE="0.3360333188344404" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.11291839136688867" WEIGHT="9.920029730887341"/>
<DICH_DATA CI_END="15.53753977894483" CI_START="0.05365382197279375" EFFECT_SIZE="0.9130434782608695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1913822535244636" LOG_CI_START="-1.2703993360918107" LOG_EFFECT_SIZE="-0.039508541283673634" MODIFIED="2013-03-08 19:35:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="965" O_E="0.0" SE="1.4460626917560016" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="2.091097308488613" WEIGHT="0.8835362730551991"/>
<DICH_DATA CI_END="1.5974377473368826" CI_START="0.24645388119281297" EFFECT_SIZE="0.6274509803921569" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.20342394256447882" LOG_CI_START="-0.6082643381205396" LOG_EFFECT_SIZE="-0.2024201977780304" MODIFIED="2013-02-28 22:03:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="906" O_E="0.0" SE="0.47678971399616943" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.22732843137254904" WEIGHT="6.233028749748985"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.933339340174718" CI_END="1.2799022881583921" CI_START="0.6155079356264439" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8875753574699637" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.1071768154811302" LOG_CI_START="-0.21076634342062905" LOG_EFFECT_SIZE="-0.05179476396974941" METHOD="MH" MODIFIED="2013-04-05 16:13:30 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.4358535099541466" P_Q="0.43013778097222233" P_Z="0.523097014845705" Q="0.6224519739460561" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3899" TOTAL_2="3838" WEIGHT="100.0" Z="0.6385787467113198">
<NAME>30-day urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.93557584472972" CI_END="1.2433534578325722" CI_START="0.5403491754782287" DF="5" EFFECT_SIZE="0.8196615251235323" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" I2="15.7621748791304" ID="CMP-007.05.01" LOG_CI_END="0.09459460648975368" LOG_CI_START="-0.2673255068879559" LOG_EFFECT_SIZE="-0.08636545019910112" MODIFIED="2013-04-04 19:41:01 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.3125384926705934" P_Z="0.3495732837445641" STUDIES="6" TAU2="0.0" TOTAL_1="2321" TOTAL_2="2265" WEIGHT="80.4981311268138" Z="0.9354173235581841">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="1.9298648416669453" CI_START="0.35697372673348626" EFFECT_SIZE="0.8300066533599467" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.28552689420276856" LOG_CI_START="-0.4473637467857298" LOG_EFFECT_SIZE="-0.08091842629148066" MODIFIED="2010-05-27 17:26:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="855" O_E="0.0" SE="0.4305035903838263" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.18533334133336532" WEIGHT="19.520236344005234"/>
<DICH_DATA CI_END="2.0902129935917557" CI_START="0.0046596722490235415" EFFECT_SIZE="0.09868995633187773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32019054315814804" LOG_CI_START="-2.3316446295431223" LOG_EFFECT_SIZE="-1.0057270431924872" MODIFIED="2010-05-27 17:26:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="857" O_E="0.0" SE="1.5577011072405373" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="2.426432739498396" WEIGHT="5.400245483802209"/>
<DICH_DATA CI_END="1.7313461317694077" CI_START="0.4719660121165727" EFFECT_SIZE="0.903956043956044" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.2383839009719388" LOG_CI_START="-0.3260892752678133" LOG_EFFECT_SIZE="-0.04385268714793728" MODIFIED="2010-05-27 17:26:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="856" O_E="0.0" SE="0.3315743379105168" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.10994154156079758" WEIGHT="31.44380123760944"/>
<DICH_DATA CI_END="3.3473104987492195" CI_START="0.16552156130414566" EFFECT_SIZE="0.7443467336683417" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5246959996714731" LOG_CI_START="-0.7811454257825281" LOG_EFFECT_SIZE="-0.12822471305552757" MODIFIED="2010-05-27 17:26:02 +0530" MODIFIED_BY="Xavier Bosch" ORDER="854" O_E="0.0" SE="0.7670577173309867" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.5883775417170239" WEIGHT="6.532363323044026"/>
<DICH_DATA CI_END="1.3450633984541422" CI_START="0.05565626122334936" EFFECT_SIZE="0.2736077481840194" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12874275493314666" LOG_CI_START="-1.254485971279109" LOG_EFFECT_SIZE="-0.5628716081729812" MODIFIED="2013-03-08 19:51:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="967" O_E="0.0" SE="0.8125154008697023" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.6601812766504531" WEIGHT="11.297596534410316"/>
<DICH_DATA CI_END="6.890840025883355" CI_START="0.6047914710086019" EFFECT_SIZE="2.0414507772020727" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8382721676795183" LOG_CI_START="-0.21839434204391756" LOG_EFFECT_SIZE="0.3099389128178004" MODIFIED="2013-03-08 19:50:12 +0530" MODIFIED_BY="Xavier Bosch" ORDER="966" O_E="0.0" SE="0.6206911383951271" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3852574892822388" WEIGHT="6.303888203942584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.49580844949028424" CI_END="2.5341759261777996" CI_START="0.538242130946349" DF="1" EFFECT_SIZE="1.167904212981046" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-007.05.02" LOG_CI_END="0.40383676094842846" LOG_CI_START="-0.2690223108060265" LOG_EFFECT_SIZE="0.06740722507120096" MODIFIED="2013-04-05 16:13:30 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.48134771562789" P_Z="0.694541390609781" STUDIES="5" TAU2="0.0" TOTAL_1="1578" TOTAL_2="1573" WEIGHT="19.50186887318619" Z="0.39269956810674306">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2779" O_E="0.0" SE="0.0" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.987023368566935" CI_START="0.21179738528757835" EFFECT_SIZE="0.7953890489913544" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47523862026063" LOG_CI_START="-0.674079405711942" LOG_EFFECT_SIZE="-0.09942039272565603" ORDER="2777" O_E="0.0" SE="0.6751150976722718" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.45578039510504115" WEIGHT="8.124538789153604"/>
<DICH_DATA CI_END="3.781031937907338" CI_START="0.5437980021108695" EFFECT_SIZE="1.4339168782573835" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.577610345809597" LOG_CI_START="-0.2645623923237646" LOG_EFFECT_SIZE="0.15652397674291624" ORDER="2775" O_E="0.0" SE="0.4946964352018243" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.24472456300139275" WEIGHT="11.377330084032588"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 20:10:05 +0530" MODIFIED_BY="Xavier Bosch" ORDER="968" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 20:11:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="971" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.714816049578682" CI_END="0.9819514868457679" CI_START="0.7634256412676568" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8658215425472846" ESTIMABLE="YES" EVENTS_1="561" EVENTS_2="628" I2="0.0" I2_Q="57.917717232528744" ID="CMP-007.06" LOG_CI_END="-0.007909967931613755" LOG_CI_START="-0.11723325744162334" LOG_EFFECT_SIZE="-0.06257161268661857" METHOD="MH" MODIFIED="2013-04-10 20:51:24 +0530" MODIFIED_BY="Xavier Bosch" NO="6" P_CHI2="0.5535042053404619" P_Q="0.12318942536793942" P_Z="0.02485904331023634" Q="2.3762969454997807" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3747" TOTAL_2="3688" WEIGHT="100.00000000000001" Z="2.2435861172862577">
<NAME>6-month urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.8967492590905195" CI_END="0.9362432799543993" CI_START="0.6364250721018729" DF="7" EFFECT_SIZE="0.7719123635166576" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="269" I2="0.0" ID="CMP-007.06.01" LOG_CI_END="-0.028611286503901896" LOG_CI_START="-0.19625271956441043" LOG_EFFECT_SIZE="-0.11243200303415617" MODIFIED="2013-04-10 20:51:24 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.43970905173998" P_Z="0.008564233098002284" STUDIES="8" TAU2="0.0" TOTAL_1="1998" TOTAL_2="1938" WEIGHT="45.16379849467184" Z="2.6289762934334555">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="5.77937573192896" CI_START="0.418687622791419" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7618809299740814" LOG_CI_START="-0.378109877496255" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2013-04-04 19:41:32 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1022" O_E="0.0" SE="0.6696362433535825" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.44841269841269843" WEIGHT="0.6899717852653725"/>
<DICH_DATA CI_END="1.032685386096504" CI_START="0.6316987638578053" EFFECT_SIZE="0.8076794425087108" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="164" LOG_CI_END="0.013968031206493012" LOG_CI_START="-0.1994899729556546" LOG_EFFECT_SIZE="-0.09276097087458082" MODIFIED="2010-05-27 17:29:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="860" O_E="0.0" SE="0.12538628827900727" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.015721721288386316" WEIGHT="27.20380019386223"/>
<DICH_DATA CI_END="2.0166422415625695" CI_START="0.053146902198584145" EFFECT_SIZE="0.3273809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.3046288598904091" LOG_CI_START="-1.2745220443536471" LOG_EFFECT_SIZE="-0.484946592231619" MODIFIED="2010-05-27 17:29:23 +0530" MODIFIED_BY="Xavier Bosch" ORDER="862" O_E="0.0" SE="0.9276010580760043" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.8604437229437228" WEIGHT="0.7488065886600941"/>
<DICH_DATA CI_END="3.464326476266973" CI_START="0.03578858328997774" EFFECT_SIZE="0.352112676056338" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5396188129527141" LOG_CI_START="-1.4462554930467892" LOG_EFFECT_SIZE="-0.4533183400470377" MODIFIED="2013-03-08 20:16:36 +0530" MODIFIED_BY="Xavier Bosch" ORDER="973" O_E="0.0" SE="1.166512397580463" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="1.3607511737089202" WEIGHT="0.5443110750426827"/>
<DICH_DATA CI_END="0.9484297050211324" CI_START="0.44173922377133823" EFFECT_SIZE="0.6472701149425287" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="76" LOG_CI_END="-0.02299485228480921" LOG_CI_START="-0.35483403630615146" LOG_EFFECT_SIZE="-0.18891444429548035" MODIFIED="2013-03-04 22:20:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1572" O_E="0.0" SE="0.19492397932458935" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.03799535771573294" WEIGHT="12.67248178937401"/>
<DICH_DATA CI_END="3.955226875555563" CI_START="0.4588393732155589" EFFECT_SIZE="1.3471502590673574" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.597171400090559" LOG_CI_START="-0.3383393221644707" LOG_EFFECT_SIZE="0.12941603896304418" MODIFIED="2013-03-08 20:14:21 +0530" MODIFIED_BY="Xavier Bosch" ORDER="972" O_E="0.0" SE="0.5495236291053651" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.3019762189451308" WEIGHT="1.104183702787868"/>
<DICH_DATA CI_END="1.387435875521921" CI_START="0.0928782314732757" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.14221292004658065" LOG_CI_START="-1.0320860627431032" LOG_EFFECT_SIZE="-0.4449365713482612" MODIFIED="2013-03-08 20:14:12 +0530" MODIFIED_BY="Xavier Bosch" ORDER="974" O_E="0.0" SE="0.6897890353643739" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.47580891330891334" WEIGHT="1.4949388680749738"/>
<DICH_DATA CI_END="5.984006774904314" CI_START="0.4472035769791267" EFFECT_SIZE="1.6358695652173914" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.77699207655124" LOG_CI_START="-0.3494947313826262" LOG_EFFECT_SIZE="0.2137486725843069" MODIFIED="2013-04-10 20:51:24 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1038" O_E="0.0" SE="0.6617039271799842" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.4378520872454138" WEIGHT="0.7053044916046031"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5022471185337485" CI_END="1.1138012638455363" CI_START="0.7986727843480954" DF="4" EFFECT_SIZE="0.9431663462008927" ESTIMABLE="YES" EVENTS_1="343" EVENTS_2="359" I2="0.0" ID="CMP-007.06.02" LOG_CI_END="0.04680770635391175" LOG_CI_START="-0.09763111437662372" LOG_EFFECT_SIZE="-0.02541170401135599" MODIFIED="2013-04-05 16:16:06 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8262434509616652" P_Z="0.49041511958712314" STUDIES="5" TAU2="0.0" TOTAL_1="1749" TOTAL_2="1750" WEIGHT="54.83620150532818" Z="0.6896487301148453">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="1.1688860250620519" CI_START="0.5927735955328928" EFFECT_SIZE="0.8323970037453183" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="96" LOG_CI_END="0.06777216633738355" LOG_CI_START="-0.2271111497820314" LOG_EFFECT_SIZE="-0.07966949172232393" ORDER="2798" O_E="0.0" SE="0.17321591958450078" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.030003754797504244" WEIGHT="14.01597463934223"/>
<DICH_DATA CI_END="1.2710449219595512" CI_START="0.8273272660180548" EFFECT_SIZE="1.025460930640913" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="204" LOG_CI_END="0.10416089989656532" LOG_CI_START="-0.08232266250200475" LOG_EFFECT_SIZE="0.010919118697280301" ORDER="2796" O_E="0.0" SE="0.10954136766144161" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.011999311229139125" WEIGHT="31.546741468038817"/>
<DICH_DATA CI_END="1.269607706872106" CI_START="0.5309487402340985" EFFECT_SIZE="0.8210338680926916" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="55" LOG_CI_END="0.10366955004316035" LOG_CI_START="-0.27494740529905853" LOG_EFFECT_SIZE="-0.08563892762794909" ORDER="2797" O_E="0.0" SE="0.22240147375217478" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.049462415527139286" WEIGHT="8.567378741342939"/>
<DICH_DATA CI_END="5.034588321726299" CI_START="0.16259404980062087" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7019639640828441" LOG_CI_START="-0.7888953516450247" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2013-03-08 20:18:46 +0530" MODIFIED_BY="Xavier Bosch" ORDER="977" O_E="0.0" SE="0.875738141931184" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.7669172932330826" WEIGHT="0.5249785322671313"/>
<DICH_DATA CI_END="17.641513452415772" CI_START="0.0648698527340903" EFFECT_SIZE="1.069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2465358401970499" LOG_CI_START="-1.1879570879930745" LOG_EFFECT_SIZE="0.029289376101987508" MODIFIED="2013-02-28 22:06:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="911" O_E="0.0" SE="1.4300331969532285" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="2.044994944388271" WEIGHT="0.1811281243370636"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.672828442971774" CI_END="1.202285697397393" CI_START="0.6504803298847961" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.884343370563057" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="269" I2="46.44624926244701" I2_Q="5.962272166948407" ID="CMP-007.07" LOG_CI_END="0.08000768069493962" LOG_CI_START="-0.18676583169524955" LOG_EFFECT_SIZE="-0.05337907550015495" METHOD="MH" MODIFIED="2013-04-10 21:24:25 +0530" MODIFIED_BY="Xavier Bosch" NO="7" P_CHI2="0.044620572572995454" P_Q="0.30244071649745663" P_Z="0.4328384549121512" Q="1.0634029798926388" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09942429660276317" TOTALS="YES" TOTAL_1="3899" TOTAL_2="3838" WEIGHT="100.0" Z="0.784343727163789">
<NAME>30-day mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.060697866468457" CI_END="1.2629002194272494" CI_START="0.5004593601249743" DF="5" EFFECT_SIZE="0.7950032928964827" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="204" I2="66.80100720211556" ID="CMP-007.07.01" LOG_CI_END="0.10136903870735196" LOG_CI_START="-0.30063118369929126" LOG_EFFECT_SIZE="-0.09963107249596967" MODIFIED="2013-03-08 20:22:20 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.010106125916134578" P_Z="0.33129514150975403" STUDIES="6" TAU2="0.19640563529332683" TOTAL_1="2321" TOTAL_2="2265" WEIGHT="66.35246571120847" Z="0.971508486558353">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="0.9659913924620098" CI_START="0.542584572743223" EFFECT_SIZE="0.7239696312364425" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="120" LOG_CI_END="-0.015026743380476264" LOG_CI_START="-0.2655325586535567" LOG_EFFECT_SIZE="-0.1402796510170165" MODIFIED="2010-05-27 17:31:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="865" O_E="0.0" SE="0.14714835591519188" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.021652638648543984" WEIGHT="20.281459205507364"/>
<DICH_DATA CI_END="0.7840334509694098" CI_START="0.07955354949249081" EFFECT_SIZE="0.24974515800203873" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="-0.10566540764526376" LOG_CI_START="-1.0993404383855683" LOG_EFFECT_SIZE="-0.6025029230154161" MODIFIED="2010-05-27 17:31:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="867" O_E="0.0" SE="0.5836896318275859" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.34069358630302277" WEIGHT="5.579452729379109"/>
<DICH_DATA CI_END="1.3640756923992228" CI_START="0.5201194130751116" EFFECT_SIZE="0.8423076923076923" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" LOG_CI_END="0.1348384699386668" LOG_CI_START="-0.283896936200066" LOG_EFFECT_SIZE="-0.07452923313069962" MODIFIED="2010-05-27 17:31:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="866" O_E="0.0" SE="0.24596725033958133" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.06049988823961427" WEIGHT="15.354881598724534"/>
<DICH_DATA CI_END="0.8972843645247331" CI_START="0.08977486378926258" EFFECT_SIZE="0.2838196286472148" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.04706989990731927" LOG_CI_START="-1.046845245133847" LOG_EFFECT_SIZE="-0.5469575725205833" MODIFIED="2013-03-08 20:20:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="979" O_E="0.0" SE="0.5872729867538373" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.3448895609707727" WEIGHT="5.526761952547984"/>
<DICH_DATA CI_END="4.79000015643427" CI_START="0.9192311686322996" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6803355275979743" LOG_CI_START="-0.03657525832377156" LOG_EFFECT_SIZE="0.32188013463710136" MODIFIED="2013-03-08 20:21:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="978" O_E="0.0" SE="0.4211169444160576" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.17733948087431695" WEIGHT="8.872609506244368"/>
<DICH_DATA CI_END="2.767396850752258" CI_START="0.676043157306895" EFFECT_SIZE="1.367801047120419" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.44207144238401824" LOG_CI_START="-0.17002557864125237" LOG_EFFECT_SIZE="0.1360229318713829" MODIFIED="2010-05-27 17:31:39 +0530" MODIFIED_BY="Xavier Bosch" ORDER="864" O_E="0.0" SE="0.359548820079364" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.12927535402046286" WEIGHT="10.737300718805109"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4699838290366176" CI_END="1.5247365322884325" CI_START="0.7618548039234474" DF="4" EFFECT_SIZE="1.077788407732019" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="65" I2="0.0" ID="CMP-007.07.02" LOG_CI_END="0.1831948060050468" LOG_CI_START="-0.11812778963587994" LOG_EFFECT_SIZE="0.03253350818458343" MODIFIED="2013-04-05 16:13:43 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8319449101618452" P_Z="0.672126865038075" STUDIES="5" TAU2="0.0" TOTAL_1="1578" TOTAL_2="1573" WEIGHT="33.64753428879154" Z="0.42323081809973573">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="7.558780009576709" CI_START="0.011932895071623408" EFFECT_SIZE="0.30033003300330036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8784517058366139" LOG_CI_START="-1.9232541781990369" LOG_EFFECT_SIZE="-0.5224012361812114" ORDER="2786" O_E="0.0" SE="1.6457359049503382" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.7084466688427082" WEIGHT="0.8745476388505111"/>
<DICH_DATA CI_END="1.6082015976438466" CI_START="0.6849581893064272" EFFECT_SIZE="1.0495479285682157" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.2063404892236446" LOG_CI_START="-0.16433593756989562" LOG_EFFECT_SIZE="0.02100227582687446" ORDER="2782" O_E="0.0" SE="0.2177371679764307" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.0474094743183964" WEIGHT="16.723788455625463"/>
<DICH_DATA CI_END="2.6809347848852267" CI_START="0.6792424973440371" EFFECT_SIZE="1.34944612286002" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.42828624967517337" LOG_CI_START="-0.1679751499363205" LOG_EFFECT_SIZE="0.13015554986942643" ORDER="2784" O_E="0.0" SE="0.35024689767332146" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.12267288932978612" WEIGHT="11.05649723888447"/>
<DICH_DATA CI_END="5.635756745545849" CI_START="0.044359615094740276" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7509522395212357" LOG_CI_START="-1.353012230849198" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-03-08 20:25:13 +0530" MODIFIED_BY="Xavier Bosch" ORDER="982" O_E="0.0" SE="1.2358791446876887" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="1.5273972602739727" WEIGHT="1.5094568378732787"/>
<DICH_DATA CI_END="4.136431592337159" CI_START="0.195820958697962" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6166258464281339" LOG_CI_START="-0.7081408275494842" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2013-03-08 20:25:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="983" O_E="0.0" SE="0.7781745019952502" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.6055555555555556" WEIGHT="3.483244117557815"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.873771309906058" CI_END="0.9765326514790212" CI_START="0.7856993092048645" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8759343752148683" ESTIMABLE="YES" EVENTS_1="828" EVENTS_2="906" I2="24.403597823591067" I2_Q="47.694455019431985" ID="CMP-007.08" LOG_CI_END="-0.010313231003782638" LOG_CI_START="-0.10474362869123541" LOG_EFFECT_SIZE="-0.05752842984750904" METHOD="MH" MODIFIED="2013-04-10 20:51:45 +0530" MODIFIED_BY="Xavier Bosch" NO="8" P_CHI2="0.19708631066068327" P_Q="0.16675890075193" P_Z="0.01693667553382944" Q="1.9118431905670978" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3725" TOTAL_2="3656" WEIGHT="100.00000000000001" Z="2.3880795453483237">
<NAME>6-month mortality, myocardial infarction or urgent revascularisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.684747837838378" CI_END="0.9461864899759567" CI_START="0.6912748635301691" DF="6" EFFECT_SIZE="0.808748994887919" ESTIMABLE="YES" EVENTS_1="381" EVENTS_2="439" I2="38.046915619651365" ID="CMP-007.08.01" LOG_CI_END="-0.024023257271156968" LOG_CI_START="-0.16034923485576652" LOG_EFFECT_SIZE="-0.09218624606346174" MODIFIED="2013-04-10 20:51:45 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.13857128193163004" P_Z="0.008031787066462986" STUDIES="7" TAU2="0.0" TOTAL_1="1926" TOTAL_2="1860" WEIGHT="49.95443130511814" Z="2.650730628976326">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="3.2818350259814215" CI_START="0.3047075773411107" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5161167457887658" LOG_CI_START="-0.5161167457887657" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-04 19:42:11 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1023" O_E="0.0" SE="0.6063390625908325" STUDY_ID="STD-Kurowski-2005" TOTAL_1="25" TOTAL_2="25" VAR="0.36764705882352944" WEIGHT="0.7829544517322153"/>
<DICH_DATA CI_END="0.953751578729526" CI_START="0.6383805812228086" EFFECT_SIZE="0.7802925651135771" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="281" LOG_CI_END="-0.020564730155853063" LOG_CI_START="-0.19492033217744956" LOG_EFFECT_SIZE="-0.10774253116665135" MODIFIED="2010-05-27 17:33:53 +0530" MODIFIED_BY="Xavier Bosch" ORDER="870" O_E="0.0" SE="0.10241734370163527" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.01048931229089889" WEIGHT="31.122348346277974"/>
<DICH_DATA CI_END="1.0778788344356367" CI_START="0.15704313321671678" EFFECT_SIZE="0.4114285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.03256994406638623" LOG_CI_START="-0.8039810485764382" LOG_EFFECT_SIZE="-0.385705552255026" MODIFIED="2010-05-27 17:34:04 +0530" MODIFIED_BY="Xavier Bosch" ORDER="872" O_E="0.0" SE="0.49139419407259377" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="0.24146825396825397" WEIGHT="1.7572293397717726"/>
<DICH_DATA CI_END="0.9071379885371758" CI_START="0.1290167676353862" EFFECT_SIZE="0.34210526315789475" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.042326645572642096" LOG_CI_START="-0.8893538430473046" LOG_EFFECT_SIZE="-0.4658402443099734" MODIFIED="2013-03-08 20:28:27 +0530" MODIFIED_BY="Xavier Bosch" ORDER="986" O_E="0.0" SE="0.49754796864886575" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.24755398110661267" WEIGHT="2.1876668504282484"/>
<DICH_DATA CI_END="3.4705248704498204" CI_START="0.8202144425463485" EFFECT_SIZE="1.6871794871794872" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.5403951609874541" LOG_CI_START="-0.08607258781254147" LOG_EFFECT_SIZE="0.2271612865874563" MODIFIED="2013-03-08 20:28:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="984" O_E="0.0" SE="0.3679902567104873" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="201" VAR="0.13541682903385033" WEIGHT="1.6755500229124451"/>
<DICH_DATA CI_END="1.198304705792229" CI_START="0.6271970198850383" EFFECT_SIZE="0.8669331810394061" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="102" LOG_CI_END="0.07856726481289066" LOG_CI_START="-0.20259601386085985" LOG_EFFECT_SIZE="-0.06201437452398457" MODIFIED="2013-03-04 22:21:18 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1573" O_E="0.0" SE="0.16515670167363683" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.027276736107714677" WEIGHT="11.340605886808806"/>
<DICH_DATA CI_END="2.95874555117806" CI_START="0.41329613692164313" EFFECT_SIZE="1.1058201058201058" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4711076179247954" LOG_CI_START="-0.38373865404917573" LOG_EFFECT_SIZE="0.043684481937809855" MODIFIED="2013-04-10 20:51:45 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1039" O_E="0.0" SE="0.5021409317148026" STUDY_ID="STD-ITTI-2012" TOTAL_1="53" TOTAL_2="47" VAR="0.25214551530341" WEIGHT="1.0880764071866815"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.167385890419188" CI_END="1.0965397920284647" CI_START="0.8109547071489426" DF="5" EFFECT_SIZE="0.9429974050450012" ESTIMABLE="YES" EVENTS_1="447" EVENTS_2="467" I2="0.0" ID="CMP-007.08.02" LOG_CI_END="0.04002439629153637" LOG_CI_START="-0.09100340101027811" LOG_EFFECT_SIZE="-0.02548950235937087" MODIFIED="2013-04-05 16:17:38 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.5255770833346559" P_Z="0.445723777076903" STUDIES="6" TAU2="0.0" TOTAL_1="1799" TOTAL_2="1796" WEIGHT="50.04556869488187" Z="0.7625634809862414">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="1.1771634974207843" CI_START="0.015724923278181254" EFFECT_SIZE="0.1360544217687075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07083678662964918" LOG_CI_START="-1.8034114647980388" LOG_EFFECT_SIZE="-0.8662873390841949" ORDER="2805" O_E="0.0" SE="1.100942700567097" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="1.2120748299319728" WEIGHT="0.8815433854521726"/>
<DICH_DATA CI_END="1.3912058332074704" CI_START="0.638564961241306" EFFECT_SIZE="0.94253663003663" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="72" LOG_CI_END="0.1433913899582164" LOG_CI_START="-0.19479491535660595" LOG_EFFECT_SIZE="-0.025701762699194778" ORDER="2803" O_E="0.0" SE="0.19865230979113668" STUDY_ID="STD-ISAR_x002d_SMART_x002d_2-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.039462740185353735" WEIGHT="7.513940660518917"/>
<DICH_DATA CI_END="1.249540537688291" CI_START="0.6583788979122845" EFFECT_SIZE="0.9070121951219512" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="112" LOG_CI_END="0.09675035010532974" LOG_CI_START="-0.18152409739955114" LOG_EFFECT_SIZE="-0.042386873647110725" ORDER="2804" O_E="0.0" SE="0.16345978794509788" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.026719102275056365" WEIGHT="11.31364912211861"/>
<DICH_DATA CI_END="1.2205425601562463" CI_START="0.8213024295341018" EFFECT_SIZE="1.0012165450121655" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="257" LOG_CI_END="0.08655292780789149" LOG_CI_START="-0.08549689246345253" LOG_EFFECT_SIZE="5.280176722194622E-4" ORDER="2802" O_E="0.0" SE="0.1010629160877332" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.010213713008156202" WEIGHT="28.1656573962342"/>
<DICH_DATA CI_END="4.136431592337159" CI_START="0.195820958697962" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6166258464281339" LOG_CI_START="-0.7081408275494842" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2013-03-08 20:32:30 +0530" MODIFIED_BY="Xavier Bosch" ORDER="988" O_E="0.0" SE="0.7781745019952502" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.6055555555555556" WEIGHT="0.5006102632558921"/>
<DICH_DATA CI_END="1.6058163716198053" CI_START="0.25974370533021174" EFFECT_SIZE="0.6458333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.20569588132137684" LOG_CI_START="-0.5854549684040059" LOG_EFFECT_SIZE="-0.1898795435413145" MODIFIED="2013-02-28 22:09:01 +0530" MODIFIED_BY="Xavier Bosch" ORDER="916" O_E="0.0" SE="0.46472592538855656" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.21597018572825025" WEIGHT="1.6701678673020752"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2157116126107437" CI_END="1.8266745859548632" CI_START="0.9252039349348166" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3000178901733876" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-007.09" LOG_CI_END="0.2616611865908248" LOG_CI_START="-0.03376252882311792" LOG_EFFECT_SIZE="0.11394932888385344" METHOD="MH" MODIFIED="2013-04-05 16:23:30 +0530" MODIFIED_BY="Xavier Bosch" NO="9" P_CHI2="0.9736741597549964" P_Q="0.8039182649271398" P_Z="0.13054031794012283" Q="0.06164264412706631" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4147" TOTAL_2="4092" WEIGHT="100.0" Z="1.5119746250698052">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.039362773807716" CI_END="1.86406083242283" CI_START="0.8669910075884164" DF="5" EFFECT_SIZE="1.2712686495420122" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="48" I2="0.0" ID="CMP-007.09.01" LOG_CI_END="0.2704600811694994" LOG_CI_START="-0.06198540699320471" LOG_EFFECT_SIZE="0.10423733708814732" MODIFIED="2013-04-05 16:06:38 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.8436721215757994" P_Z="0.2190409876383257" STUDIES="7" TAU2="0.0" TOTAL_1="2393" TOTAL_2="2341" WEIGHT="79.7393616360502" Z="1.2290822634785865">
<NAME>Patients with ACS</NAME>
<DICH_DATA CI_END="2.1042808924914613" CI_START="0.47331893929655383" EFFECT_SIZE="0.9979959919839679" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.32310371167784774" LOG_CI_START="-0.32484611740519254" LOG_EFFECT_SIZE="-8.712028636723787E-4" MODIFIED="2010-05-27 17:36:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="875" O_E="0.0" SE="0.3806089370067602" STUDY_ID="STD-ISAR_x002d_REACT-2-2006" TOTAL_1="1012" TOTAL_2="1010" VAR="0.14486316292941592" WEIGHT="23.533027245253155"/>
<DICH_DATA CI_END="15.145884842133626" CI_START="0.1566937278201711" EFFECT_SIZE="1.5405405405405406" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1802946504539946" LOG_CI_START="-0.8049483872430017" LOG_EFFECT_SIZE="0.18767313160549642" MODIFIED="2013-03-08 20:47:20 +0530" MODIFIED_BY="Xavier Bosch" ORDER="877" O_E="0.0" SE="1.1661415874547418" STUDY_ID="STD-Shen-2008" TOTAL_1="114" TOTAL_2="58" VAR="1.3598862019914653" WEIGHT="2.1978340821922537"/>
<DICH_DATA CI_END="2.793753964807843" CI_START="0.6856670030823098" EFFECT_SIZE="1.3840465701699183" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.4461881568135316" LOG_CI_START="-0.16388674994265123" LOG_EFFECT_SIZE="0.14115070343544017" MODIFIED="2013-03-08 20:42:00 +0530" MODIFIED_BY="Xavier Bosch" ORDER="876" O_E="0.0" SE="0.35836102014807486" STUDY_ID="STD-On_x002d_TIME-2-2008" TOTAL_1="473" TOTAL_2="477" VAR="0.1284226207615689" WEIGHT="22.78560976143387"/>
<DICH_DATA CI_END="8.887695683575577" CI_START="0.014285508586923415" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9487891758600732" LOG_CI_START="-1.8451042934287647" LOG_EFFECT_SIZE="-0.4481575587843458" MODIFIED="2013-04-05 16:06:38 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1026" O_E="0.0" SE="1.6411468538559837" STUDY_ID="STD-Fu-2008" TOTAL_1="72" TOTAL_2="78" VAR="2.693362995921394" WEIGHT="2.436610153355032"/>
<DICH_DATA CI_END="3.853603594794696" CI_START="0.8260906671731362" EFFECT_SIZE="1.7842157842157842" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5858670384337318" LOG_CI_START="-0.08297228428731374" LOG_EFFECT_SIZE="0.25144737707320897" MODIFIED="2013-03-08 20:37:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="989" O_E="0.0" SE="0.39287952897438555" STUDY_ID="STD-ASSIST-2009" TOTAL_1="201" TOTAL_2="199" VAR="0.15435432428713505" WEIGHT="17.0452923242885"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 20:37:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="990" O_E="0.0" SE="0.0" STUDY_ID="STD-Yan-2009" TOTAL_1="120" TOTAL_2="120" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.862927770247001" CI_START="0.34575566077574593" EFFECT_SIZE="0.9949238578680203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.45681039120048" LOG_CI_START="-0.4612307008107137" LOG_EFFECT_SIZE="-0.002210154805116882" MODIFIED="2010-05-27 17:36:40 +0530" MODIFIED_BY="Xavier Bosch" ORDER="874" O_E="0.0" SE="0.5392618818240714" STUDY_ID="STD-BRAVE_x002d_3-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.2908033771884388" WEIGHT="11.740988069527392"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11635176452700194" CI_END="2.969306170345907" CI_START="0.6725602126947499" DF="2" EFFECT_SIZE="1.413165662434407" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" ID="CMP-007.09.02" LOG_CI_END="0.4726549807675597" LOG_CI_START="-0.17226882824680292" LOG_EFFECT_SIZE="0.1501930762603784" MODIFIED="2013-04-05 16:23:30 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.9434839960334015" P_Z="0.36129914826162146" STUDIES="7" TAU2="0.0" TOTAL_1="1754" TOTAL_2="1751" WEIGHT="20.260638363949802" Z="0.9128923946768532">
<NAME>Patients without ACS</NAME>
<DICH_DATA CI_END="15.120249715113221" CI_START="0.0557794083969631" EFFECT_SIZE="0.9183673469387755" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1795589637181094" LOG_CI_START="-1.2535260962244492" LOG_EFFECT_SIZE="-0.036983566253169974" ORDER="2793" O_E="0.0" SE="1.429206208175548" STUDY_ID="STD-TOPSTAR-2002" TOTAL_1="50" TOTAL_2="46" VAR="2.042630385487528" WEIGHT="1.7383019561483026"/>
<DICH_DATA CI_END="6.001482304785" CI_START="0.2962231141397101" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7782585299305445" LOG_CI_START="-0.5283810567139446" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="2792" O_E="0.0" SE="0.7675265611652409" STUDY_ID="STD-ISAR_x002d_SWEET-2004" TOTAL_1="351" TOTAL_2="350" VAR="0.5890970220941403" WEIGHT="5.057467300056385"/>
<DICH_DATA CI_END="3.7015192534081667" CI_START="0.6135687571429665" EFFECT_SIZE="1.507029053420806" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.568380012701654" LOG_CI_START="-0.21213676272572884" LOG_EFFECT_SIZE="0.17812162498796255" ORDER="2790" O_E="0.0" SE="0.4584794175063947" STUDY_ID="STD-ISAR_x002d_REACT-2004" TOTAL_1="1079" TOTAL_2="1080" VAR="0.21020337627700297" WEIGHT="13.464869107745116"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 20:49:10 +0530" MODIFIED_BY="Xavier Bosch" ORDER="993" O_E="0.0" SE="0.0" STUDY_ID="STD-Cuisset-2008" TOTAL_1="74" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 20:49:22 +0530" MODIFIED_BY="Xavier Bosch" ORDER="994" O_E="0.0" SE="0.0" STUDY_ID="STD-OPTIMIZE_x002d_IT-2009" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 20:49:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="991" O_E="0.0" SE="0.0" STUDY_ID="STD-_x0033_T_x002f_2R-2009" TOTAL_1="132" TOTAL_2="131" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-05 16:23:30 +0530" MODIFIED_BY="Xavier Bosch" ORDER="1030" O_E="0.0" SE="0.0" STUDY_ID="STD-INSTANT-2012" TOTAL_1="44" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-03-04 21:32:25 +0530" MODIFIED_BY="Xavier Bosch" NO="8">
<NAME>As initial medical treatment in patients with NSTEACS</NAME>
<DICH_OUTCOME CHI2="11.01963519031979" CI_END="1.0157645777498387" CI_START="0.7937950048269329" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8979470184247847" ESTIMABLE="YES" EVENTS_1="586" EVENTS_2="502" I2="9.252894244770362" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.006793063822356059" LOG_CI_START="-0.10029163833755392" LOG_EFFECT_SIZE="-0.046749287257598915" METHOD="MH" MODIFIED="2013-03-01 15:47:48 +0530" MODIFIED_BY="Xavier Bosch" NO="1" P_CHI2="0.3559903810951637" P_Q="1.0" P_Z="0.08702611190491681" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17630" TOTAL_2="13860" WEIGHT="100.0" Z="1.7112980188521103">
<NAME>30-day mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2606629969925407" CI_START="0.06961001188058982" EFFECT_SIZE="0.29623430962343095" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.10059900559987443" LOG_CI_START="-1.157328292116612" LOG_EFFECT_SIZE="-0.5283646432583687" ORDER="5" O_E="0.0" SE="0.7389127215192128" STUDY_ID="STD-CANADIAN-1996" TOTAL_1="242" TOTAL_2="123" VAR="0.5459920100229299" WEIGHT="1.2332788655278648"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Schulman-1996" TOTAL_1="153" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1726882149178903" CI_START="0.7604005891979254" EFFECT_SIZE="0.9443054641211324" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="175" LOG_CI_END="0.06918256067519181" LOG_CI_START="-0.11895755529251159" LOG_EFFECT_SIZE="-0.024887497308659887" ORDER="4" O_E="0.0" SE="0.11051443542802299" STUDY_ID="STD-PURSUIT-1998" TOTAL_1="4722" TOTAL_2="4739" VAR="0.01221344043797466" WEIGHT="31.751648861031736"/>
<DICH_DATA CI_END="1.924486788666794" CI_START="0.6971563564341068" EFFECT_SIZE="1.158304017774486" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="22" LOG_CI_END="0.2843149340698387" LOG_CI_START="-0.15666980852864265" LOG_EFFECT_SIZE="0.06382256277059804" ORDER="6" O_E="0.0" SE="0.2590366207120293" STUDY_ID="STD-PARAGON-A-1998" TOTAL_1="1524" TOTAL_2="758" VAR="0.06709997086990774" WEIGHT="5.349288682557705"/>
<DICH_DATA CI_END="1.5047418737292335" CI_START="0.6239345786373648" EFFECT_SIZE="0.9689481342895749" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="36" LOG_CI_END="0.17746200662112926" LOG_CI_START="-0.20486094497508686" LOG_EFFECT_SIZE="-0.013699469176978772" ORDER="2" O_E="0.0" SE="0.22457839429675006" STUDY_ID="STD-PRISM-Plus-1998" TOTAL_1="1118" TOTAL_2="797" VAR="0.05043545518490654" WEIGHT="7.570031313788146"/>
<DICH_DATA CI_END="0.9563424962856215" CI_START="0.4142901931469935" EFFECT_SIZE="0.629446834530803" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.01938654537165699" LOG_CI_START="-0.38269534696372476" LOG_EFFECT_SIZE="-0.2010409461676909" ORDER="1" O_E="0.0" SE="0.21340938846275287" STUDY_ID="STD-PRISM-1998" TOTAL_1="1616" TOTAL_2="1616" VAR="0.04554356708404615" WEIGHT="10.673946452812904"/>
<DICH_DATA CI_END="1.1899031803227311" CI_START="0.6332183155843703" EFFECT_SIZE="0.8680256260920209" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="85" LOG_CI_END="0.07551162528982845" LOG_CI_START="-0.19844653183528904" LOG_EFFECT_SIZE="-0.0614674532727303" ORDER="7" O_E="0.0" SE="0.1609243776100429" STUDY_ID="STD-PARAGON-B-2002" TOTAL_1="2600" TOTAL_2="2569" VAR="0.025896655309179683" WEIGHT="15.64083823300964"/>
<DICH_DATA CI_END="1.267016444224494" CI_START="0.7785543459790792" EFFECT_SIZE="0.9931974421422658" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="102" LOG_CI_END="0.10278225149718416" LOG_CI_START="-0.10871106667318975" LOG_EFFECT_SIZE="-0.0029644075880028067" ORDER="8" O_E="0.0" SE="0.12423222200208693" STUDY_ID="STD-GUSTO_x002d_IV-2001" TOTAL_1="5102" TOTAL_2="2598" VAR="0.015433644983575813" WEIGHT="24.465696736199813"/>
<DICH_DATA CI_END="16.930336813038373" CI_START="0.06320929050031218" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.228665598072844" LOG_CI_START="-1.1992190844314314" LOG_EFFECT_SIZE="0.014723256820706378" MODIFIED="2013-03-01 15:32:05 +0530" MODIFIED_BY="Xavier Bosch" ORDER="914" O_E="0.0" SE="1.4261514807260172" STUDY_ID="STD-Kim-2005" TOTAL_1="59" TOTAL_2="61" VAR="2.0339080459770114" WEIGHT="0.1820677376793926"/>
<DICH_DATA CI_END="16.22523758734072" CI_START="0.062400376793060104" EFFECT_SIZE="1.0062111801242235" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.210191064924831" LOG_CI_START="-1.2048127879032688" LOG_EFFECT_SIZE="0.002689138510781192" MODIFIED="2009-12-18 20:55:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="818" O_E="0.0" SE="1.4185852176130964" STUDY_ID="STD-ELISA_x002d_2-2006" TOTAL_1="162" TOTAL_2="163" VAR="2.0123840196303964" WEIGHT="0.1866073576639716"/>
<DICH_DATA CI_END="1.6462983034698992" CI_START="0.06542025529170384" EFFECT_SIZE="0.3281786941580756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21650853064117076" LOG_CI_START="-1.1842877654454926" LOG_EFFECT_SIZE="-0.48388961740216097" MODIFIED="2009-12-10 19:11:19 +0530" MODIFIED_BY="Xavier Bosch" ORDER="688" O_E="0.0" SE="0.8228346783748027" STUDY_ID="STD-PRACTICE-2007" TOTAL_1="196" TOTAL_2="197" VAR="0.6770569079361651" WEIGHT="1.1156980608518714"/>
<DICH_DATA CI_END="1.155845982642182" CI_START="0.08627705869755325" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.06289996786918378" LOG_CI_START="-1.0641046690075546" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2013-03-01 15:47:48 +0530" MODIFIED_BY="Xavier Bosch" ORDER="913" O_E="0.0" SE="0.6620081024643217" STUDY_ID="STD-Bhattacharya-2010" TOTAL_1="136" TOTAL_2="165" VAR="0.43825472772841195" WEIGHT="1.8308976988769712"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2268939799502716" CI_END="1.1474715618201776" CI_START="0.8715045608880472" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0000133497187003" ESTIMABLE="YES" EVENTS_1="477" EVENTS_2="408" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.05974193107412251" LOG_CI_START="-0.05973033573318661" LOG_EFFECT_SIZE="5.797670467935523E-6" METHOD="MH" MODIFIED="2013-03-04 21:32:25 +0530" MODIFIED_BY="Xavier Bosch" NO="2" P_CHI2="0.8736511807473795" P_Q="1.0" P_Z="0.9998482234877524" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7619" TOTAL_2="6552" WEIGHT="100.0" Z="1.9022364963933072E-4">
<NAME>6-month mortality</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4167507726114241" CI_START="0.6951674527861413" EFFECT_SIZE="0.9924107142857143" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="56" LOG_CI_END="0.15129345815192197" LOG_CI_START="-0.15791056942226644" LOG_EFFECT_SIZE="-0.003308555635172214" ORDER="1" O_E="0.0" SE="0.18162797638169972" STUDY_ID="STD-PRISM-Plus-1998" TOTAL_1="1118" TOTAL_2="797" VAR="0.032988721804511276" WEIGHT="14.978375528860807"/>
<DICH_DATA CI_END="1.2194228582158084" CI_START="0.8751124960690099" EFFECT_SIZE="1.0330209006679596" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="294" LOG_CI_END="0.08615433166010819" LOG_CI_START="-0.05793611465584022" LOG_EFFECT_SIZE="0.01410910850213399" ORDER="2" O_E="0.0" SE="0.08463944142520065" STUDY_ID="STD-PURSUIT-1998" TOTAL_1="4722" TOTAL_2="4739" VAR="0.007163835044769971" WEIGHT="67.64639917941639"/>
<DICH_DATA CI_END="1.2986448106987438" CI_START="0.6372733262542137" EFFECT_SIZE="0.9097206703910614" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="50" LOG_CI_END="0.11349038444728085" LOG_CI_START="-0.19567425899234342" LOG_EFFECT_SIZE="-0.04109193727253129" ORDER="3" O_E="0.0" SE="0.18160484194610216" STUDY_ID="STD-PARAGON-A-1998" TOTAL_1="1524" TOTAL_2="758" VAR="0.03298031861826875" WEIGHT="15.452882736311144"/>
<DICH_DATA CI_END="16.930336813038373" CI_START="0.06320929050031218" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.228665598072844" LOG_CI_START="-1.1992190844314314" LOG_EFFECT_SIZE="0.014723256820706378" MODIFIED="2013-03-01 15:51:30 +0530" MODIFIED_BY="Xavier Bosch" ORDER="916" O_E="0.0" SE="1.4261514807260172" STUDY_ID="STD-Kim-2005" TOTAL_1="59" TOTAL_2="61" VAR="2.0339080459770114" WEIGHT="0.23804489611815619"/>
<DICH_DATA CI_END="1.9633456226387218" CI_START="0.16286654693314026" EFFECT_SIZE="0.5654761904761905" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2929967584855103" LOG_CI_START="-0.7881681113595405" LOG_EFFECT_SIZE="-0.2475856764370151" MODIFIED="2009-12-10 19:12:49 +0530" MODIFIED_BY="Xavier Bosch" ORDER="690" O_E="0.0" SE="0.6350815963994021" STUDY_ID="STD-PRACTICE-2007" TOTAL_1="196" TOTAL_2="197" VAR="0.403328634085213" WEIGHT="1.6842976592935084"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.227230793116064" CI_END="0.9793028646492505" CI_START="0.8482473912728041" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9114225695058855" ESTIMABLE="YES" EVENTS_1="1852" EVENTS_2="1648" I2="27.760995091944842" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-0.009082975097160228" LOG_CI_START="-0.0714774673239506" LOG_EFFECT_SIZE="-0.04028022121055543" METHOD="MH" MODIFIED="2013-03-01 15:58:49 +0530" MODIFIED_BY="Xavier Bosch" NO="3" P_CHI2="0.17232882947721717" P_Q="1.0" P_Z="0.011386728987090517" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17630" TOTAL_2="13860" WEIGHT="100.0" Z="2.530601020841296">
<NAME>30-day mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.104216263781352" CI_START="0.17253448994272974" EFFECT_SIZE="0.43648068669527895" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.04305413948812511" LOG_CI_START="-0.7631240756946739" LOG_EFFECT_SIZE="-0.3600349681032744" ORDER="5" O_E="0.0" SE="0.47355307424490156" STUDY_ID="STD-CANADIAN-1996" TOTAL_1="242" TOTAL_2="123" VAR="0.22425251412679725" WEIGHT="0.8210447144412429"/>
<DICH_DATA CI_END="7.7865860690326905" CI_START="0.02962180072064345" EFFECT_SIZE="0.48026315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.891347088435317" LOG_CI_START="-1.5283885440839504" LOG_EFFECT_SIZE="-0.3185207278243167" ORDER="3" O_E="0.0" SE="1.4213646884263755" STUDY_ID="STD-Schulman-1996" TOTAL_1="153" TOTAL_2="74" VAR="2.0202775775054076" WEIGHT="0.08612346289009502"/>
<DICH_DATA CI_END="1.1200274334386295" CI_START="0.6285511575442893" EFFECT_SIZE="0.8390438247011952" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="95" LOG_CI_END="0.04922866021045383" LOG_CI_START="-0.2016593694735947" LOG_EFFECT_SIZE="-0.07621535463157043" ORDER="2" O_E="0.0" SE="0.1473728705521864" STUDY_ID="STD-PRISM-Plus-1998" TOTAL_1="1118" TOTAL_2="797" VAR="0.02171876297479149" WEIGHT="6.406079040586088"/>
<DICH_DATA CI_END="0.9942515275193536" CI_START="0.7928703207332715" EFFECT_SIZE="0.8878696568268425" ESTIMABLE="YES" EVENTS_1="670" EVENTS_2="744" LOG_CI_END="-0.0025037331126969717" LOG_CI_START="-0.10079783865387279" LOG_EFFECT_SIZE="-0.051650785883284867" ORDER="4" O_E="0.0" SE="0.057738444158556286" STUDY_ID="STD-PURSUIT-1998" TOTAL_1="4722" TOTAL_2="4739" VAR="0.0033337279338507228" WEIGHT="40.983503615368186"/>
<DICH_DATA CI_END="1.2475029006569502" CI_START="0.7234812590964894" EFFECT_SIZE="0.9500236677545529" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="89" LOG_CI_END="0.09604156410532158" LOG_CI_START="-0.14057271427043921" LOG_EFFECT_SIZE="-0.022265575082558806" ORDER="6" O_E="0.0" SE="0.13898839837748964" STUDY_ID="STD-PARAGON-A-1998" TOTAL_1="1524" TOTAL_2="758" VAR="0.01931777488353976" WEIGHT="6.786969792194929"/>
<DICH_DATA CI_END="1.0684051275620157" CI_START="0.6082136216693818" EFFECT_SIZE="0.8061132377306748" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="115" LOG_CI_END="0.028735963649733336" LOG_CI_START="-0.21594385754012663" LOG_EFFECT_SIZE="-0.09360394694519664" ORDER="1" O_E="0.0" SE="0.14372613815157237" STUDY_ID="STD-PRISM-1998" TOTAL_1="1616" TOTAL_2="1616" VAR="0.020657202787964863" WEIGHT="6.965381269727288"/>
<DICH_DATA CI_END="1.3123387507916016" CI_START="0.9316212580029183" EFFECT_SIZE="1.105713650968663" ESTIMABLE="YES" EVENTS_1="450" EVENTS_2="209" LOG_CI_END="0.11804595288289293" LOG_CI_START="-0.030760610167379444" LOG_EFFECT_SIZE="0.04364267135775675" ORDER="8" O_E="0.0" SE="0.0874097117400969" STUDY_ID="STD-GUSTO_x002d_IV-2001" TOTAL_1="5102" TOTAL_2="2598" VAR="0.007640457706486833" WEIGHT="16.24048594746284"/>
<DICH_DATA CI_END="1.0894736157180462" CI_START="0.7692474906910677" EFFECT_SIZE="0.9154642784211908" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="295" LOG_CI_END="0.03721671720108229" LOG_CI_START="-0.11393391176012714" LOG_EFFECT_SIZE="-0.038358597279522434" ORDER="7" O_E="0.0" SE="0.08878662765949469" STUDY_ID="STD-PARAGON-B-2002" TOTAL_1="2600" TOTAL_2="2569" VAR="0.007883065251145746" WEIGHT="17.059070365360597"/>
<DICH_DATA CI_END="5.7638552676157335" CI_START="0.04488228693020505" EFFECT_SIZE="0.5086206896551724" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7607130669953509" LOG_CI_START="-1.3479250221648995" LOG_EFFECT_SIZE="-0.2936059775847743" MODIFIED="2013-03-01 15:53:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="918" O_E="0.0" SE="1.2386244514996132" STUDY_ID="STD-Kim-2005" TOTAL_1="59" TOTAL_2="61" VAR="1.5341905318527176" WEIGHT="0.12433130618541569"/>
<DICH_DATA CI_END="1.322552557752" CI_START="0.5042511843375372" EFFECT_SIZE="0.8166386554621848" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="50" LOG_CI_END="0.12141293975306802" LOG_CI_START="-0.2973530730841546" LOG_EFFECT_SIZE="-0.08797006666554333" MODIFIED="2009-12-18 20:55:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="819" O_E="0.0" SE="0.24598522886577984" STUDY_ID="STD-ELISA_x002d_2-2006" TOTAL_1="162" TOTAL_2="163" VAR="0.06050873282015008" WEIGHT="2.3547096184717984"/>
<DICH_DATA CI_END="1.9634422648108392" CI_START="0.515080770370231" EFFECT_SIZE="1.0056497175141244" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.29301813532748966" LOG_CI_START="-0.28812466343331483" LOG_EFFECT_SIZE="0.002446735947087378" MODIFIED="2009-12-10 19:11:56 +0530" MODIFIED_BY="Xavier Bosch" ORDER="689" O_E="0.0" SE="0.34136615669534526" STUDY_ID="STD-PRACTICE-2007" TOTAL_1="196" TOTAL_2="197" VAR="0.11653085293695102" WEIGHT="1.1006216970296208"/>
<DICH_DATA CI_END="0.7020661588310605" CI_START="0.07723116576473" EFFECT_SIZE="0.23285486443381181" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.1536219604322684" LOG_CI_START="-1.11220740966029" LOG_EFFECT_SIZE="-0.6329146850462793" MODIFIED="2013-03-01 15:58:49 +0530" MODIFIED_BY="Xavier Bosch" ORDER="917" O_E="0.0" SE="0.5630778379510413" STUDY_ID="STD-Bhattacharya-2010" TOTAL_1="136" TOTAL_2="165" VAR="0.3170566515916191" WEIGHT="1.0716791702818969"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.790178412217367" CI_END="0.9588237769301431" CI_START="0.8136033303909354" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8832339543792345" ESTIMABLE="YES" EVENTS_1="1358" EVENTS_2="1329" I2="0.0" I2_Q="100.0" ID="CMP-008.04" LOG_CI_END="-0.01826120486207781" LOG_CI_START="-0.08958728234754691" LOG_EFFECT_SIZE="-0.053924243604812384" METHOD="MH" MODIFIED="2013-03-01 16:00:16 +0530" MODIFIED_BY="Xavier Bosch" NO="4" P_CHI2="0.8773486781548481" P_Q="0.0" P_Z="0.00304102208818012" Q="1.0971565483532095E-31" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10247" TOTAL_2="9149" WEIGHT="100.00000000000001" Z="2.963560568167462">
<NAME>6-month mortality or myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1101196740575505" CI_START="0.6621400973215907" EFFECT_SIZE="0.8573533396558732" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="122" LOG_CI_END="0.045369799490495" LOG_CI_START="-0.17905011168336646" LOG_EFFECT_SIZE="-0.0668401560964357" ORDER="1" O_E="0.0" SE="0.13182536672000283" STUDY_ID="STD-PRISM-Plus-1998" TOTAL_1="1118" TOTAL_2="797" VAR="0.01737792731086323" WEIGHT="10.188779222503744"/>
<DICH_DATA CI_END="0.9964490387137054" CI_START="0.7831904015089739" EFFECT_SIZE="0.8834077895929026" ESTIMABLE="YES" EVENTS_1="576" EVENTS_2="644" LOG_CI_END="-0.0015449074716434167" LOG_CI_START="-0.10613264372436619" LOG_EFFECT_SIZE="-0.053838775598004804" ORDER="2" O_E="0.0" SE="0.061435353992493454" STUDY_ID="STD-PURSUIT-1998" TOTAL_1="4722" TOTAL_2="4739" VAR="0.0037743027201829816" WEIGHT="46.6266125336327"/>
<DICH_DATA CI_END="1.0206823265964349" CI_START="0.6408314030333926" EFFECT_SIZE="0.8087553940495117" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="136" LOG_CI_END="0.008890594904087645" LOG_CI_START="-0.19325621441765065" LOG_EFFECT_SIZE="-0.09218280975678146" ORDER="3" O_E="0.0" SE="0.11874203643843337" STUDY_ID="STD-PARAGON-A-1998" TOTAL_1="1524" TOTAL_2="758" VAR="0.014099671217546237" WEIGHT="12.751133091658138"/>
<DICH_DATA CI_END="1.0746339208655096" CI_START="0.792315495600812" EFFECT_SIZE="0.92274" ESTIMABLE="YES" EVENTS_1="378" EVENTS_2="400" LOG_CI_END="0.0312605449728643" LOG_CI_START="-0.10110185033604273" LOG_EFFECT_SIZE="-0.034920652681589226" ORDER="4" O_E="0.0" SE="0.07775032620887579" STUDY_ID="STD-PARAGON-B-2002" TOTAL_1="2628" TOTAL_2="2597" VAR="0.0060451132255865975" WEIGHT="28.45849680964315"/>
<DICH_DATA CI_END="3.2990598084519496" CI_START="0.03367962921631568" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5183901889146093" LOG_CI_START="-1.4726326983539342" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-03-01 16:00:16 +0530" MODIFIED_BY="Xavier Bosch" ORDER="920" O_E="0.0" SE="1.1695366997037855" STUDY_ID="STD-Kim-2005" TOTAL_1="59" TOTAL_2="61" VAR="1.3678160919540228" WEIGHT="0.23956520717117655"/>
<DICH_DATA CI_END="1.8398213195057012" CI_START="0.5498695434748571" EFFECT_SIZE="1.005813953488372" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.26477564707433693" LOG_CI_START="-0.259740334631844" LOG_EFFECT_SIZE="0.002517656221246502" MODIFIED="2009-12-10 19:13:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="691" O_E="0.0" SE="0.3081032840501942" STUDY_ID="STD-PRACTICE-2007" TOTAL_1="196" TOTAL_2="197" VAR="0.09492763364251466" WEIGHT="1.7354131353910973"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.884713063776132" CI_END="1.453950267838981" CI_START="1.1362763634692514" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2853362684547658" ESTIMABLE="YES" EVENTS_1="649" EVENTS_2="493" I2="24.272467061645425" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.1625495517964134" LOG_CI_START="0.055483972688897376" LOG_EFFECT_SIZE="0.10901676224265541" METHOD="MH" MODIFIED="2013-03-01 16:02:14 +0530" MODIFIED_BY="Xavier Bosch" NO="5" P_CHI2="0.21988712203484462" P_Q="1.0" P_Z="6.569395093942984E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17263" TOTAL_2="13836" WEIGHT="100.0" Z="3.991365469423234">
<NAME>30-day major bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="25.21172058298405" CI_START="0.35213651858128103" EFFECT_SIZE="2.979591836734694" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4016024852717346" LOG_CI_START="-0.45328893375988766" LOG_EFFECT_SIZE="0.47415677575592347" ORDER="3" O_E="0.0" SE="1.0895724013997823" STUDY_ID="STD-Schulman-1996" TOTAL_1="153" TOTAL_2="74" VAR="1.1871680178920885" WEIGHT="0.28791671861347556"/>
<DICH_DATA CI_END="29.87491130394044" CI_START="0.4420520330269448" EFFECT_SIZE="3.6340425531914895" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4753066245748916" LOG_CI_START="-0.3545266077403537" LOG_EFFECT_SIZE="0.5603900084172688" ORDER="5" O_E="0.0" SE="1.0748530984825575" STUDY_ID="STD-CANADIAN-1996" TOTAL_1="242" TOTAL_2="123" VAR="1.1553091833175544" WEIGHT="0.2862532355686488"/>
<DICH_DATA CI_END="1.3584929560029237" CI_START="1.0344911805923542" EFFECT_SIZE="1.1854741590949427" ESTIMABLE="YES" EVENTS_1="496" EVENTS_2="427" LOG_CI_END="0.13305739087537305" LOG_CI_START="0.014726792501607272" LOG_EFFECT_SIZE="0.07389209168849012" ORDER="4" O_E="0.0" SE="0.06950797923065875" STUDY_ID="STD-PURSUIT-1998" TOTAL_1="4679" TOTAL_2="4696" VAR="0.0048313591767296885" WEIGHT="84.70711092544227"/>
<DICH_DATA CI_END="3.978356218357007" CI_START="0.6293086707683264" EFFECT_SIZE="1.582281284606866" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.5997036668579446" LOG_CI_START="-0.2011362843960139" LOG_EFFECT_SIZE="0.19928369123096537" ORDER="6" O_E="0.0" SE="0.47041735158826803" STUDY_ID="STD-PARAGON-A-1998" TOTAL_1="1524" TOTAL_2="758" VAR="0.22129248467532017" WEIGHT="1.7593308441130178"/>
<DICH_DATA CI_END="5.171534069357465" CI_START="0.7003360845194951" EFFECT_SIZE="1.9031058617672791" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.7136193901019826" LOG_CI_START="-0.15469349623666764" LOG_EFFECT_SIZE="0.2794629469326575" ORDER="2" O_E="0.0" SE="0.5100512876534313" STUDY_ID="STD-PRISM-Plus-1998" TOTAL_1="773" TOTAL_2="797" VAR="0.2601523160369234" WEIGHT="1.294738242179834"/>
<DICH_DATA CI_END="3.107107776492913" CI_START="0.3218427141683287" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49235631792325485" LOG_CI_START="-0.49235631792325485" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.5784250767024006" STUDY_ID="STD-PRISM-1998" TOTAL_1="1616" TOTAL_2="1616" VAR="0.33457556935817806" WEIGHT="1.3288659723134333"/>
<DICH_DATA CI_END="6.848217963043382" CI_START="1.3783474863551217" EFFECT_SIZE="3.0723320158102765" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="7" LOG_CI_END="0.8355775744846015" LOG_CI_START="0.1393587185747371" LOG_EFFECT_SIZE="0.4874681465296693" ORDER="8" O_E="0.0" SE="0.4089624023003729" STUDY_ID="STD-GUSTO_x002d_IV-2001" TOTAL_1="5102" TOTAL_2="2598" VAR="0.16725024649529205" WEIGHT="2.0451880107223883"/>
<DICH_DATA CI_END="2.4968459210354315" CI_START="0.8616163142371246" EFFECT_SIZE="1.4667389609949506" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.39739174310877245" LOG_CI_START="-0.06468608650199428" LOG_EFFECT_SIZE="0.1663528283033891" ORDER="7" O_E="0.0" SE="0.2714268044355104" STUDY_ID="STD-PARAGON-B-2002" TOTAL_1="2600" TOTAL_2="2569" VAR="0.07367251016607282" WEIGHT="5.076371092584299"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-01 16:01:34 +0530" MODIFIED_BY="Xavier Bosch" ORDER="922" O_E="0.0" SE="0.0" STUDY_ID="STD-Kim-2005" TOTAL_1="80" TOTAL_2="80" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5971612691665915" CI_START="0.644731796512553" EFFECT_SIZE="1.2940140845070423" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.41449891772118314" LOG_CI_START="-0.19062091097483108" LOG_EFFECT_SIZE="0.11193900337317603" MODIFIED="2009-12-18 20:56:54 +0530" MODIFIED_BY="Xavier Bosch" ORDER="820" O_E="0.0" SE="0.35545038276749985" STUDY_ID="STD-ELISA_x002d_2-2006" TOTAL_1="162" TOTAL_2="163" VAR="0.12634497460956215" WEIGHT="3.1081385688035232"/>
<DICH_DATA CI_END="310.7517191103948" CI_START="1.0209295956227975" EFFECT_SIZE="17.811671087533156" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4924135398819627" LOG_CI_START="0.008995793715919846" LOG_EFFECT_SIZE="1.2507046667989412" MODIFIED="2013-03-01 15:56:52 +0530" MODIFIED_BY="Xavier Bosch" ORDER="692" O_E="0.0" SE="1.458771877214038" STUDY_ID="STD-PRACTICE-2007" TOTAL_1="196" TOTAL_2="197" VAR="2.1280153897505683" WEIGHT="0.10608638965910024"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-01 16:02:14 +0530" MODIFIED_BY="Xavier Bosch" ORDER="921" O_E="0.0" SE="0.0" STUDY_ID="STD-Bhattacharya-2010" TOTAL_1="136" TOTAL_2="165" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-10-03 16:31:19 +0530" MODIFIED_BY="Nicole Ackermann">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-09-05 16:40:45 +0530" MODIFIED_BY="Xavier Bosch" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-10-03 16:31:19 +0530" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-10-03 16:31:19 +0530" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-09-05 16:35:48 +0530" MODIFIED_BY="Nicole Ackermann" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 During PCI (all patients), outcome: 1.1 30-day mortality.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-09-05 16:36:00 +0530" MODIFIED_BY="Nicole Ackermann" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 During PCI (all patients), outcome: 1.2 6-month mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAAj60lEQVR42u1dC3wU1bk/yWZfIa8ZjALBNsFcFaj+RBQJj5obQKoBTFqp3h/CBesNteiNt9aW1t56UaOsgBXhqklaAsSoKRQoELEKITaLgRjBcoUoBkiAsNGQGUgg+5iQ3HltdhP2Mbs7s5nH9/9lszNnz5w5881/vu8735xHDIYAAPERCyIAALEAQCyAthEnNCNJfzDui91AJEZi1+ThcmDIk5FOI8GPA2L55RXG/8O8EwYD49LZ3zAuFwbMAlMYBkiS5L54FcVxigTBgsYKAdggDdavn5i/QMeBygJi+eUG8vKdMD8ZBjtlCAgFxBKgrbx9LCEHgKICH0tIozBkgK8FxIoYpBeXQFMB4vyxBAvsY/H+OMblZGMKnozYIK8diAbE8m7r+WoRYoOSrk0ekAKMAmKF7D9hA+0g5ls1kaCwwMcKjVne2zTYLx/ZMHWoLRtwJSTEYAFMIemLRNrEupUPrQW2hACd2Ueiw8x9zDQcGP1P61Kqj/t8f9rMN0uBL9EPN6gZ1mfXlo+tWnvrRhCF9M67ljBurwEfhQxfZIIoIjOFZtLhwLzMopZBvFi3waJDKKkLlVqQNXEd2MPwnffBjryWreCKcav1nl3qV18UTQPWhKuxBjvy2lVXzopHfq/zFtehFdm/qdUBb8B5jww3bS8YlLK4p68L5AKmMBJ1ddzb6KW1ehtIBPYQNFa43lX+JO/dRu+d47eXgICAWOGAKnxuicE7Yaz3TsG2LbltICQgVujIQ9sXD0joG+hpVWb+DIQExAoR9QiVr8UHOaMDd/G15Ww+ADjvglGypRIXlHHW/AJgkB9AHGsw2npqnr9FWNb393S0Q0wLiCUI+x7MfUEgr1Bpg4Uq3QwkAh9LAIzlT/m0g2k+cy8tN4LIwMcKBiIhRu/vt84k/0ddxoFIYAr9w/rkzX/x23dhjN8XOT9JfGbbJmASaCx/iqfiteXz/aueUecD+GUr5y0ApQUayzde0p+utPj/OSnAq+fNDTuyVgOXQGP5UFcoYo1TP0EPdIJW4UBUT9wacRlH0l0gSNBYg7yr4yIY/NQ7Mt8ApQUay4P8v58Izqu0oDnaK9fOJECaQKx+bN8tQNE0Bs+CG7ZD2xBahRyK0QlkEZKRiWMRwXLSvxc+WmEBWmmdWITjk10C3yIndiHbvvVrguazxlW+DyPENE6sjePrjwiKP5EOxw1nZv77dc0fBaWh7puvXo+BLg/aJtYzv9gkzGw5MHPXxevrDn7vf94OfoDuysZuIJZmiUWM2Wwp2yAwMy0E++S8HlSz9NRbwZlloXlVvFnjnpZWW4X1D+8MKb9tRzbzhGX1tQuj7ZJ8q7aJpc0AKZHgeOnVEPKTX577VSsrjLbNP00X5r+VTVg+Akyhxkzh3JSSxaHkHzYr6VUjK4zVu17SCXLNdxypGblBw8TSoMaqzww5jEne/AavsVqSL6YLP45omgQ+llZgfW5n6Ae1z+6rYl7XnG8IhVfo+LOaHTGtNVNIvLiuaHHIRzkcK25I+8x1dM7iN0LhFdpQ8WbmVzoglvqJRTycV5Ib+mFms7lr/9uZf1kfGq9oZjUcO09oklla87GoCDq2NKdcTA/9qDZttg21RKyNzqUR6rswOy+sW6q9cTzaMYXUM3seCaf9TzpYZJ4xo3CD6SsS39q8AYilTmLtO5BbdEs4B7IT3ZvNrX3hC6L0UGnRf+0BU6hKU1gyLsxJ+EhuXbMffBnRAh1UWQEQS33EskYwsyPJLUc16ljEK1uXLNFQl3gtBEip+1ZE3hc9JvJ6HLu5BIilIuyz/6Qy8kZZa+QVWXt5S6FmRluof8mT4teOThMSZojCUmftlSu3uk80vEPda6qp3MdiIk8Co0/uCx18wWT/+sMiicLficAUKshpn2hFEQ+eJxFJI02sOqXqNOFpqTqOVfzMn7IFZ3Zf6OAL5pdsbO1zIDZSGkgefDA1YKbu7pib2HE86h5Yp2KNVT+r8cQMcYwXScYy87zzKxQHAMYhcKbKqmfV329ZxcSaVPS6OHEjhiq9fUH5Ihi4Ye841RNLrc77vrOLxfWp3Wvp+JWHd6syoNC4H0uOVap6bQt1aiyicOVNIhf5pRDFhoSrtSVNsVYglsJQkh9TOT0cT4r2pUjpq8ee5/I7fberOVyqygCps2ja66F7Uuz/XuktP8afx/bVEfCxFASrNEsJBvexsIEfYahOmATEUkSM4TlDlQTGCyHd1QGazQ+xUJBM18Dl2LZYlcRSl49FuG6tKpfEfGFjMQHOuTuP8IfRcLRsDqVGYqkr8v5i4Vv+54+hwh8tQwshsSuIMPxF7oNgw5HuXWocxqMujXW5yL+D1XKlJSKfQVirkgy5VYk/ZWCmAwcfS7beVVlRoNfNzSltx7NGhutjSdwhgXh4/kM4EEuW3lWCw2QI8Dsz54Ljg7l6eRILWVeg8hFALPmBemDc84Ee+fN1E9MROno2C5cnsRAq/je9qno7qMR5v/Qvvwg06K8l8Y10RDr+OOG9miAdX/wKIa1LWmHsHt1mAWLJCxsPdFsCruvGjY13YOa/xvxvsTkcYjkcHd30PyShMLot6LqLlyxALNl4V8cOlQQeZky9WJ3FXYnliTHdlnCIhZnHUGazWWJh1Bh/vVstI6YV72Pte3zegmBvRWx1429hr8RWM3p6OFdEH8KuVyi5MPDkec/jQCw5IPeZHAG+/a6Ye3ESq73NaEZhEiut1YcwxB/Z07byD+oglrIDpPUIVQngFdLPNdRQyHbOGL4p8z2uUFBX5FAw4nUcUWoIlyrZx6J+dKZB6GW+u2nb3yYt6wnzivy9rgnzNU4QXP2rCtaYVrDG2nfzvCLhuU33bhmtEE1guPxKYT34WEOFwuO/zQnpgAgcIr8+lkSBU2KF6y2FEytuoOQxzz2Qe8R9QaizakdyQSTqvBrFa8MR8VbY8wfKTmN5dX0kMXlrLOsrO6I9I1BaawB1LomQMr42qM3HknmIgSheOK8r2ifti6jG4Rx0In+WgrsA+tRY3pZQfiSzPmd4flrUz+pbYwkzs7W3ZV4I55wux/sF6iIWFm4X7qhEGSrmKcv7sNUkdT4Ulumun6BXFbEkdx8iUFcGxY1qqT23jNjbmR3mw0C9fY8ix/F4BUiZKJ8n0idN7C9S78qx9TWlrV5qO5rXgzYvOrs+vI4LvbeWVyjxxbRv512mlS3JjylvH6Jzhzs/Vq05j11B01UX3vH6tUtuf1qB73i8NJaZdDgYa2h2b8lNYxErFi0Psja4kAmqwkOrMUx9tZWtiuWdn24Kc9T5jis1o0uV7GP5uVVy8bEExQul8wzTwprdlog94F4TyrFqWQRtDqpLYeFSpbwrrC9MGNoKhBfHwv+l08FtNTsWRkKNsjyFzU2jEI21sezjy0rUWExXMOPEEQi1lC/8fmTN4RXjfqukcTzK0Fi5FUWGITYF4c7zrs++8VMbak5+NDJeoWmVmQuV5MMrQ2MJ9jBkGX1zfDD+yOT0KHmZoLEEk6qQQHpFv+g33XmDGLxi5hUvdBFALHHagr+2j5dFRSKZ5z29N12kWswvfFghTrzMTWHqHagolDca0r3d7EySxw0rXrl8qRKIJfOpIlc554dkBaV7Csa2ykMiS9uaQGNFCOs4GblW7LhCuaB4vuydTvn6WEThc8fl9ATKqC71xydWg8YKE/Z5mUtUOu+rCNi36KEFk4BY4Xjthj/Mx4FA/vX5C+9cAGKFLjZc4WNUoiMlJGMZyXEkdFtPrg7JbT6ftC7Z3bvZs1bvBmKF4D88k/qR/KaJCrM/lpTYZCTnrpNrTy35tQqfePz5tTJU8WNlePMuVMbcKtex+PLzsWQVvfJAVnEsr8jDJCCWAFBlsh1Hl9Yq15q5iuU4jkdWprD45j653j0kW16hmJ3PydAeysh5t549fvADCCKEfgtPLc+Okd2qKTLSWMfmV+qBJuGgoEd+nZbl4mOltsv85snXx3L7EfJ6UyEPU0g4TrfLfAksGcaxBmLc6hU7wBQO8q7yG0/I3QqOlXn90KuP/fjpNiDWAF79bsH7sveu+uReQbT4q76dYAq9sfquebJd6aPNPaY/qUv2zCo9tAuh+lIgFuddPbHDIt+ZCZoTiDXclvx5xaL+1k27oFXIjHCeIOeVGFrqErvuHYmUBOsK9IEc/Ioh1ViEo/qFAhmvd9WcUjKx6PBbilqRa0MDapRDC3toNVbxY3J22rn5FrYb2NUzZR/H8vILDbiWiVXfNUPe94db5RARNQ+YkHzGFQrDvukGrRKr5BGTvKcxb6njx8VTW1NnKkpjMZ5WRdMQzCztjSGKY1G5W47Km1cdyQkcr5A+tZ1QQhzLG9PeWr6wmNAgsX6VWTRN3rdmuP1yFbdlbx+Ny2tcoRDMOLFEc6ZQIQNwbHWImUPbVrNMsesHDmFv3OhrLMKVr4wbNTLbWEMhe02ectel3DJ0I6ajrrGoBxQ0wtmxPX979kikXKTeMW/B0CitaGusfTdXFSln5LzpesdonldpiiRWe/nJFdrQWESisnqJ9vuDyopjDb1TG01iES+sUm7fY2XFsQZ6H+l/iP5cbVE0hdaHb+pS7lPfp9yq651bn4j6OJ6ovYSuj1+56hGLcu9OkoIfiu6GB19/L8r9lqM2VWTm+OcVPX9Mq5Irjxu+yFSlj0UdmoYAQwzrpMtRfLSjYgqLG2/ZDTd2qFGc//7XOjURqz7OuvbHir8taV1KvwLdN185YtpXq8fHeq7qsgpm52uMOI5FDXmsxfDFoah1KZFaYxEW1LDaonxeoTGRaqyW1HfXDPVFlO6xIOvPozJ2RWLnvXjrxyrxUCKdH6s55YAzSw6vHV2zliyOwmkkDZDWz9parhbXN8L+WC3vXModXyeHfhKGorJojJiWUmOVVCx4COY+5vUV039+d0yWHORBrGiqUrTGGreqAHjF6auD7LiMKc7DcqgNvracmctbmc47MbrCsqEUKMXrq5IbmW/LW0cLy+RQIbo11fkf0oYWJdJY1vyTieoiRwT9sdrK94/idUXq7XLpjrpga66knpYkGot48fyi5Tp1ESuC+bFWv3v2hfXslu34n66XyfVsOPWfi3ZsVhixfpL4dK7azFkkcaw1rx9+hBmob5+ct1Y+V7RnT7yEvor4rUJZr/ASPiKLYxF1jnl6GY73IRKkeisiusYquX3cLjUSK7L+WJZ3C+Y+9nVej9yu6ifGX+/eoASNRf3qiyLoIeMT2JuyHO9TvPKXkozjEblVeDPaDrzy84TOluU4sqV1H0rSfhdZY8Eqg4qEBH6xiD6W65eHkEW1sld+f6xATd5F2zbJ1RRSubnz1fxQN6r54pb+6WeFIo/jEUtjFTcuXJSlZtmPUbPGQpvbD5w9JUuNNf7EU+pec75P1VeH9IZK+TnvbTsLkOqR1qr+a5yzTbyeyyKYwtRyfJ36+zF0qZ9X6Fh+eoNFWmKRZqHEIhynl/8e+seoArpvHsoWa/0B36aQRJhQU3jdguchdqUe1Oe2S0gsEiOFEUulL5y16mO5W/gTRGiH+WwVCg22F088ohlpN2rmSomdz1olaxVyeooMyLT6iq3lOZoRt4Y0Fip55A8Rz2QWMI6F0eD++SL2szHN2uGV2uNYA1DQ03dIUo0V2Meqn6QhWWtKY4nhP/sJNziChBuK5+5G2ooxdGmMV2huQURrTIf1Ssf6xNbx0DJXOaYtqYhkxLQfjWVGATSW6/R7R24ByasdOxrOPX4q7EB8OO8KS+6YpD0xa87HYtA2AkWLWITZrM3nV8nzvEeCdcbw5t8I0ceyPjyP0KaAx2rUIN5z5GFKRB8L+fSxiBebF71m0aaAE7u0ed2lDb9ptIQxzUNIptD17IJJGn1wtelj8Z5WOP3thBMLBuBoGRvnhXj7BftYJflWEK92cWRirSQ+FuH8+8swElXDOPTXJf++JxT3WpjGst7mXK1xXqUpvP6RNuZnnDi5VQIfi9Jr/ZFVeBzLVvPUBRGKEc4DARqrhHauNM8rhcexas1J66jIi7GmF4vnYy1vvQvGSig8jmU7uvUvFbvfjjgEucFIzv5IWCnBNBahW1U0CWgV8TzvQ6yv8szIZPok8pcmFyqNccKiA1FfxR4wBP5VHmOXqF3jxeiTYh2HA7EAjL46x89QSf11crooJZY4nxLBxzLDrVF2nOFI0p/5e/3OS92ivOnddmvS+8H8btBYAqHcd4WpbyQ/wG60lD+aLlKZJRUfGyIONwAYKHdcYftsRxUTamhOFo1XqGB7sBU2QGOpXmPR1rAGZY1sqZucLm6xAd14IJZARLpe4dDC8cH4G7pHiVyoa1aAGbLBFApEjKJrb7rzLxfF5hUyLLndRYDG0nrjUIrudMSKVQYgFkAavvqmrOpNYQfcfClB8yp/oxaJ1fxmi0itQiCRH2oVleX68LRUHnlvTtn4z9fXiFFSBOsVqhwbjtiX6Ls1RSxSnxq73Ni8TYxrkHKed3IY4aD/HAqVtWVP+z9KNWUKn778swO9myZ8KkZZks6P1YthvX6mIVME9JM05WN9nfkdE7uZ4hRjeasYBAgFKibW1zegL22Md5l9ea8IPhZwBYjF4psbqp8cX8e0V/DCdgLuNBBLHJxPJfuevsXAMMu2NhtGcQOxRIozbLiUMTVz+xTnQVRbM1yEtU0hjgXEYniV8uj30YgnDfvnXuo7t0yMEXWNwJXQGjuqfFdIrRz/Y6buKPEV9NTwvg4RrkHK/lgkQsM7mI+K3suqU2PpH0dfI2ae+rhnMy9e7RXjfkkZx8K4MFavmt73q7V3Q9unMffizAgVxxJxCkyDeANoLBojsg37KWQ7t0wkXkEcK0So9l2h5d2CORWT83rgFg8N4tR7aTPx7dkwKBJMofggZo8UrzCIY4HzLgm0Os87aCyJMRZEAMSSAn0gAiCWJD4DiACIJQUgjgXEAgCxAEAsjQPiWEAsSQD9sYBYkgDiWEAsSQBxLCCWJIA4FhBLEkAcC4glOWCUYnDAPO+hPYfM7B0zh7e1gssFGkscpHGLZ2GoY07Vhz+KIUkQCRBLDDRe4adNdjw5ZtOzHaCxgFiioGXs/oPMDCNoTk0egUyFn4BIgFgi4HxDX/4DdR0I2arYfvTlfU+DUIITay/IIYi+ip8Yg0zoIBHjngdiSmYziCUYsRztIIeAaG64mN6KULYz/p0kfh6IEU0pFAgmcLhh75sVJgg3BNJXKW+kM9+Wd7YtzL3un8xmTPPZ99YBewJqLFpf7QE5BACVfCad29Lnly/IfJEkY0lXw2/TQTIBibXXcT9qAjkEgN7+YRXXH6vWkdf7JFo/p2POK691gWACE2sara8yQQ6BMPK/nEeJRrpFeM5oRth///QZc9XCAzDcMoiPlYju2gM+VhAhvfNg4+Gu2rQ6diaI9ZaXLoIdDIYYDDkce/6N2+kf9cy8r8AGpWkbjjGntue5nzECpjQVQixUdfi/eTr1E8vDJiAWh7RjRtDdIRILOUwchUgfWgqIBWoqbGINJpGXJQRiAcKC7/mxMI5Q5GCWAQCREAvz+gaNxftY0Dc5JEDvBoGAcYUiEAt6R14LGFcYqSmkbR9Ggls1GNBlNAJisT4Vr6/AtxrUfAYRRKixMDCHvgC+OzjvACAWAIilccD8WEAsSQBxLCCWJIA4FhBLEkAcKzT4CJCCUHwB4lgREgvior4BcSwNmEKYnwqIJSqHOrgv299tcOOAWBGhNvY6z07Lmy1sWk2SOfrD2yGOFRrkPaOf7egvZryv43eaU35/9vU1dNqyP6Pdb1ui7WMZgSyq0Vj2mrzcD1fGkrEkjZaDF3PH11F2dn4q0yfR9rMgjqUejWWbvKwH1fz+N6+tNJvN+hdKbkTrFy7Kz15L/7S+edj66FYmEcbUq0VjsboJoaymOsa/euXSKPoreep37PxU+JS/NUe3NhDHClFesl0T2lazjGDPb6u7M705JYGJuBF/T+pMnclpUscwPdw+MIWhxxn2Jf2ZO/+aTS+NNv+6hKmH5R85xs5Sxm9veekizE8FpjAM4NmdDm7rfFX3hcf5OT/bs52JbFoDzMsBpjBMULuMWTgiO5MZDrWV/uBeHKHac46UvqyRLclR5xWMK1QNsRBRg7JGTv3lRJZD5KeOeXrW7/r62AOO6OurziQgi1rCDZbKFw5v+sXjK4YRtKdu31Ywp2JyXs9QzU81BsINagk30LjlTsfP4rBeDKM/aOay7ewc6yi9dwj8K+iPpR5TyJpD3N8O+FhALACYQgAAiAUAYike0B8LiCUJYFwhEEsSQH8sIJYkgDgWEEsSQH8sIJYkgPgoEAsAxAIAsTQOiGMBsSQBxLGAWJIA4lhALEkAcSwgliSAOBYQSxJAHAuIBQBiAYBYGgfEsYBYkgDiWEAsSQBxLCCWJIA4FhBLEkAcC4glCSCOBcQCALEAQCyNA+JYQCxJAHEsIJYkgDgWEEsSQBwLiCUJII4FxJIEEMcKDXEgAkBYILlFU7kFeTEgFkAkXmH8bI+Yew9MYViAONY1vEIYCT5WxIA4FvhYkmAseO9+fS3wsSIAxLH8APM9szaYQoGAOFYAbpFArLABlvBaLgVaAwBMISBsZmGenWsoBitTACSBb1NIkqTU7YioNlpEQJq0F6BImQQqM86flgJNNRCNsF5h5BoLOHUtoD+WGKYQcA0gjhUa/DnvJBZtwy9z/OBLkEHgZqIAH8s7rwS+VlTdN7FO1opJegGKlEkg5z0WggyAKIYbgFeAyOA73IBIaBoCJHHeAQDxNVa/O4aJbBo9RUZBJQ44mahnE99TiKqFEFscvDwGXkNcwNy8BEkRK0BigwqXsunjPgUm+o2Rrq7RjwyII49B1xA7JA9odB04kesP4hBSXpzcLltao6g4FshfHH7KGrr+WNFV/bIPoKhNHFp4VwgN3yEQR6wGnlBFmCe1iSNWA4IkgVfRF0eAACnpscbixrHo0sgo6GRP/UlJ4jZi32ssisySop08sFiIvAPAeQcAsQBALAAAiAUAYgGAWAAAEAsAxAIAsQAAIBYAiAUAYgUAlVRgKEiwuXdzckByADGIlXLXItfCSY+BvAACoTMLy/f91c6y000oJ+M088lAF/tM3ToqacmpKRmnczK+i+tByX1xw5zuDDkZF5H+O0tqn05nSukGMYPG8gM9mmhK9U64Ouye36K4e7ZS7J7xE5Q8cVj8XV6Tk101ZX0PdWZdTr7nCkgZiOUPl+rQlNsSKE9CcxPqREtR0xl2r2kSehidPIlcXhlOISZ70ntbQWFpEdd09Lum4yqXgdhSOAUdupKDqhH9Yb+sLuPU/j3Ebltd3hlqKax7KjowjPBdMEBNGMyjuKA5OOCIOPwyhWqnI+IhlmjI+wvx27HowFTE6TWqi94jCXPqVGugcgHqABlcY/kkwP3OKnPqbYeu3O/8P+ddjEJqiLujoTPpri86ZvAaK3niETShodM0ZcWciWwG3YR9Measo7bZxj0gd/UTCwvPx9pZX2jI33cGbfs038gmfPtQ3Wl0+mA3hg5wOU5/Pr+7oRN9nHmfnt3f1n2QRK0Pdi07uAHEDj5WaCNQZnx+KnH2QV/OOavEVAsCB+IEo01ExMIdVKzukt5XeCLWqV4h2mryzEAlcUyhnye3m3J2++IVolTMq1pz0o5UoFIQwEvokPXVOWNu6hsUCCIsH4sMFn7QLGpvG0Mg9EHnfeBnhWUKMTcisZSSHzAk+oqp5QOJNZJUlpC6oKiJWKgpzMnJMZpTmeYeyhnU/vO7lzb4p4CdbXLYA3ICZgghWSr/ahnnt2fF8Ctj5qT4rUSOnwsPsDc6JJH5k0EAUaZFS6KCfazqapspn9sSekjWNWUEPIGPA2Sqr5gG8Q+/cXBbrg4BwhN6gslhHylQlFETcQjOO05u6n+OUoxGO0L18QbmeaUSDMMoZs/IG85ag8F0HZ0vhyU//aGGGcr4LS6v3WA01TJZTfUoNScVUSZ39jKjgfNerjMbTFx5OWWGeMqdNoNOqzcZ6TxEvJF9DUmZ2LMPM8TXc9o+3pTC1tHEnJf5ja+Fp5yw9ZUnzjB8yo5mdiP++3xDmD9XislQy+epNw+jPCJj0+lcGOqvOy8XRrhGg9nuLbL6eOZKmS0+r92gv58ruPZ+g5GWe07y/Qa7Vxn3U7Qoa71Eic3gf/fIgCse5dgNfM34sijTDNwjQ67e9P2MJ6JBLISZ+jd7bRfp6tzd0dbLyJh0GYbTtTXZrnK/zkhwfXyZfm76H7fhf2sr5LdIl5HOm5TgTJjJ7Btmo/c+daFPDOyDRh9QaEvg+tlcIVzxfOz1qbadw91pR2hZ/au5mf7/vUvODxnZY+c/pH+92+gycTocM57vZdsl5+nzsjVzo7+cMP2Wcwe84lcj8lJYsV/osvPXyJ2r7/y+GXyWu1sveM7HpQ83tDFH8XX3yOVKvMuMe4vs7v/dwkuTz5vyAbVtFptw3zZXPHvOin1JbImL2eQPrkc9mXPR9Xa3KHu3sL97y8B9gtQ2Po0vK8X8T1rWd591dczsr3eO0Wn6nvTEop2sCZ6V3Jtx81Ra3dhxxg449Yh0ItTThPNWQe+sHe/wPth5J97Mb+kRQec1umpPsKGubymUZ+xBeXGekomp7IbdjPgtROJ3OvvTptBnOjmSFkaPHk1nbnQ1Pp0+makJNXEPofkkV4+TOHLciU56VaS/nPCAZ3fu9ey17LjIqdbPcIK7Ru5cp/Hp0/rPZ/acj0t3nsQ/Q/1198gljsKb7N4nMz/o/onPq5thtzvcUiCnciVOZ0vk2vBWCrkqXchl9TrjdE+9BhpL/OSAsnpOXmBkiCOzq7/ePSfdEg0H1/QgdZg9/722MqpPn37f9TnKOM3+/RwxX7GvIB39dW9GRsaZqyj2ZXaPRtsfy9acW8PnZT66l5GF2+PzXjH1LcQYfdT17ecxZ7/7+NudlgElM/rhbX3sjexWxhlkibvKJPNp9/6cSf4hXVQLnfw7+iquMmmWWFZT8fVgSmISuSPZsrlywsea9U3/sdbCbZ9PLLmRrdzp0v37qzLYSlnoenAXkJPB14A7u+fC4l5GpfQXX3deLswDtsZ54Uy3l8ge+6lbZHzeb9f/aBnezUumoN27RK6MNat6Ys+ual9lGShKd714GXAS/Z2XRJmyOIkyN6e5113vH3IHCoPDHIEpvGfToIQfEmwfGWt1dTVN9BiC7zGDhl9pMz/q3cClf+L8H3de/ZWV8ZdZLfBuih5/N70C99F+MfzD7au4W8l82gF29wBXFEpFRAx7CoK7GE89kJVO7PM0s+sjbW2PnNdVxxXRsuHiKHfq9MbruEoRXk0dxuRQPs7H5TrQLzJeLni3bUsn6r9ehDb3XwWfF+9+t5jLMSqm/Y8DSuTKwHWYHte9HDdIlJ56EdceQ5dl+CMnM+Y/fSaqv97MgdOj42PpBiV8dhNiRGqiEBZPk5bbY9R4Lb6rlq1ZbS2RTicYD6OZ3E903r3xrBHdyT0McY4dSDc1zs0DD3q/auKPoY89bHKn3c2Y2kwb/YDoKVTGPCeX0TEjQoeOoZu4t0uOMWg47z6bMtFN9JHWWiJjQDlhQ5/trGFE35z8aLqXJmOMmJE7lzeSkdk4qADjGDbiTNfdbvKWixnHGUejlkBWnGDS7P3S5K+TzvEI95D06e1e3eg8ZRjsemRYp3fTyf17vwzSPekYus/Il9XElHXwplQ6z956hJv76/2qGWUeEp1YpBseH8vovDQoU7PTxBzfkaKfPIymmcvEO2HDZhln0Hn1I1D1jJHbmBx5Rp6UdN41dN5E3JDDuZHtU5Jon+wCJ5kRXoXHPzbSXTmdIe80V/BjI9kpUbszaPlUJxue+ITe+8T8I9qnOnOf0cn1k/7MZYzlj+xwGphowL4crqj+ciLxs8bvsqGWg5fSvemm95zLG5dMqc2Dju+gmLYLqk4xYF3ecvnIrr9Cy8U4AiVcGcmkkZxsUf91fnSPITmBk8LlEV5ayVPGd1Pi0C7+GdX3i9IjA50nHTdQHd5l7bd30o87mW20d/bXO2u4wRF+H5WIejdECTkhXx7u6BalHN/uRNUPbugepegXMDmid2q6hjZ+nHdZoTU0hzupL673ki7ycvwh7tX33rtR0bwSSxKBaKMEjSU7QEe/4BoLiAWQhFjQHwsgCYBYACAWAIgF0DiuHQkNQ+EBIgAWaQKAKQQAsQBALAAAiAUAYgGAWAAAEAsAxAIAsQAAIBYAiAUAYgEAQCwAEAsAxAIAxMH/AyPZCeXDozVpAAAAAElFTkSuQmCC</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-09-05 16:36:10 +0530" MODIFIED_BY="Nicole Ackermann" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 During PCI (all patients), outcome: 1.3 30-day mortality or myocardial infarction.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-10-02 18:19:59 +0530" MODIFIED_BY="Nicole Ackermann">
<APPENDIX ID="APP-01" MODIFIED="2013-10-02 18:19:59 +0530" MODIFIED_BY="Xavier Bosch" NO="1">
<TITLE MODIFIED="2013-02-28 17:35:38 +0530" MODIFIED_BY="Xavier Bosch">Search strategies for 2013 update</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-02 18:19:59 +0530" MODIFIED_BY="Xavier Bosch">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor: [Platelet Glycoprotein GPIIb-IIIa Complex] explode all trees<BR/>#2 glycoprotein near/6 inhibit*<BR/>#3 glycoprotein near/6 block*<BR/>#4 glycoprotein near/6 antagonist*<BR/>#5 gpiib*<BR/>#6 abciximab<BR/>#7 sibrafiban<BR/>#8 tirofiban<BR/>#9 lamifiban<BR/>#10 aggrastat<BR/>#11 eptifibatide<BR/>#12 xemilofiban<BR/>#13 lotrafiban<BR/>#14 orbofiban<BR/>#15 fradafiban<BR/>#16 fibrinogen next receptor next antagonist*<BR/>#17 roxifiban<BR/>#18 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17)<BR/>#19 MeSH descriptor: [Angioplasty, Balloon, Coronary] this term only<BR/>#20 ptca<BR/>#21 coronary near/6 angioplasty<BR/>#22 pci<BR/>#23 percutaneous next coronary next intervention*<BR/>#24 MeSH descriptor: [Angina, Unstable] explode all trees<BR/>#25 angina<BR/>#26 stent*<BR/>#27 MeSH descriptor: [Myocardial Infarction] explode all trees<BR/>#28 myocardial next infarction<BR/>#29 heart next infarction<BR/>#30 coronary next syndrome*<BR/>#31 non next st next segment<BR/>#32 non next st next elevation<BR/>#33 without next st next segment<BR/>#34 MeSH descriptor: [Acute Coronary Syndrome] this term only<BR/>#35 #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34<BR/>#36 #18 and #35<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE OVID</HEADING>
<P>Sensitivity maximising Cochrane RCT filter (Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011).<I> </I>The Cochrane Collaboration, 2011. <A HREF="http://www.cochrane-handbook.org">www.cochrane-handbook.org</A>)</P>
<P>1. Platelet Glycoprotein GPIIb-IIIa Complex/<BR/>2. (glycoprotein adj5 (inhibit$ or block$ or antagonist$)).tw.<BR/>3. gpIIb$.tw.<BR/>4. abciximab.tw.<BR/>5. sibrafiban.tw.<BR/>6. tirofiban.tw.<BR/>7. lamifiban.tw.<BR/>8. aggrastat.tw.<BR/>9. eptifibatide.tw.<BR/>10. xemilofiban.tw.<BR/>11. lotrafiban.tw.<BR/>12. orbofiban.tw.<BR/>13. roxifiban.tw.<BR/>14. or/1-13<BR/>15. Angioplasty, Balloon, Coronary/<BR/>16. ptca.tw.<BR/>17. (coronary adj5 angioplasty).tw.<BR/>18. exp Angina, Unstable/<BR/>19. angina.tw.<BR/>20. exp Stents/<BR/>21. stent$.tw.<BR/>22. exp Myocardial Infarction/<BR/>23. myocardial infarction.tw.<BR/>24. coronary syndrome$.tw.<BR/>25. Acute Coronary Syndrome/<BR/>26. pci.tw.<BR/>27. percutaneous coronary intervention$.tw.<BR/>28. or/15-27<BR/>29. 14 and 28<BR/>30. randomized controlled trial.pt.<BR/>31. controlled clinical trial.pt.<BR/>32. randomized.ab.<BR/>33. placebo.ab.<BR/>34. drug therapy.fs.<BR/>35. randomly.ab.<BR/>36. trial.ab.<BR/>37. groups.ab.<BR/>38. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37<BR/>39. exp animals/ not humans.sh.<BR/>40. 38 not 39<BR/>41. 29 and 40<BR/>42. 29 and 41<BR/>43. (200910* or 200911* or 200912* or 2010* or 2011* or 2012* or 2013*).ed.<BR/>44. 42 and 43 </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE OVID</HEADING>
<P>Cochrane RCT filter (Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011).<I> </I>The Cochrane Collaboration, 2011. Available from <A HREF="http://www.cochrane-handbook.org">www.cochrane-handbook.org</A>)</P>
<P>1. fibrinogen receptor/<BR/>2. (glycoprotein adj5 (inhibit$ or block$ or antagonist$)).tw.<BR/>3. gpIIb$.tw.<BR/>4. abciximab.tw.<BR/>5. sibrafiban.tw.<BR/>6. tirofiban.tw.<BR/>7. lamifiban.tw.<BR/>8. aggrastat.tw.<BR/>9. eptifibatide.tw.<BR/>10. xemilofiban.tw.<BR/>11. lotrafiban.tw.<BR/>12. orbofiban.tw.<BR/>13. roxifiban.tw.<BR/>14. or/1-13<BR/>15. exp transluminal coronary angioplasty/<BR/>16. ptca.tw.<BR/>17. (coronary adj5 angioplasty).tw.<BR/>18. exp unstable angina pectoris/<BR/>19. angina.tw.<BR/>20. coronary stent/<BR/>21. stent$.tw.<BR/>22. exp heart infarction/<BR/>23. myocardial infarction.tw.<BR/>24. coronary syndrome$.tw.<BR/>25. pci.tw.<BR/>26. percutaneous coronary intervention$.tw.<BR/>27. acute coronary syndrome/<BR/>28. or/15-27<BR/>29. 28 and 14<BR/>30. random$.tw.<BR/>31. factorial$.tw.<BR/>32. crossover$.tw.<BR/>33. cross over$.tw.<BR/>34. cross-over$.tw.<BR/>35. placebo$.tw.<BR/>36. (doubl$ adj blind$).tw.<BR/>37. (singl$ adj blind$).tw.<BR/>38. assign$.tw.<BR/>39. allocat$.tw.<BR/>40. volunteer$.tw.<BR/>41. crossover procedure/<BR/>42. double blind procedure/<BR/>43. randomized controlled trial/<BR/>44. single blind procedure/<BR/>45. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44<BR/>46. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/<BR/>47. human/ or normal human/ or human cell/<BR/>48. 46 and 47<BR/>49. 46 not 48<BR/>50. 45 not 49<BR/>51. 29 and 50<BR/>52. (20094* or 20095* or 2010* or 2011* or 2012* or 2013*).em.<BR/>53. 51 and 52<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-05-21 16:16:13 +0530" MODIFIED_BY="Nicole Ackermann" NO="2">
<TITLE MODIFIED="2010-01-07 16:17:43 +0530" MODIFIED_BY="[Empty name]">Search strategies for 2010 update</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-21 16:16:13 +0530" MODIFIED_BY="Nicole Ackermann">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Platelet Glycoprotein GPIIb-IIIa Complex explode all trees<BR/>#2 (glycoprotein in All Text near/6 inhibit* in All Text)<BR/>#3 (glycoprotein in All Text near/6 block* in All Text)<BR/>#4 (glycoprotein in All Text near/6 antagonist* in All Text)<BR/>#5 gpiib* in All Text<BR/>#6 abciximab in All Text<BR/>#7 sibrafiban in All Text<BR/>#8 tirofiban in All Text<BR/>#9 lamifiban in All Text<BR/>#10 aggrastat in All Text<BR/>#11 eptifibatide in All Text<BR/>#12 xemilofiban in All Text<BR/>#13 lotrafiban in All Text<BR/>#14 orbofiban in All Text<BR/>#15 fradafiban in All Text 1<BR/>#16 fibrinogen next receptor next antagonist* in All Text<BR/>#17 roxifiban in All Text<BR/>#18 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)<BR/>#19 (#11 or #12 or #13 or #14 or #15 or #16 or #17)<BR/>#20 (#18 or #19)<BR/>#21 MeSH descriptor Angioplasty, Transluminal, Percutaneous Coronary explode all trees<BR/>#22 ptca in All Text<BR/>#23 (coronary in All Text near/6 angioplasty in All Text)<BR/>#24 pci in All Text<BR/>#25 percutaneous next coronary next intervention* in All Text<BR/>#26 MeSH descriptor Angina, Unstable explode all trees<BR/>#27 angina in All Text<BR/>#28 stent* in All Text<BR/>#29 MeSH descriptor Myocardial Infarction explode all trees<BR/>#30 myocardial next infarction in All Text<BR/>#31 heart next infarction in All Text<BR/>#32 coronary next syndrome* in All Text<BR/>#33 non next st next segment in All Text<BR/>#34 non next st next elevation in All Text<BR/>#35 without next st next segment in All Text<BR/>#36 MeSH descriptor acute coronary syndrome this term only<BR/>#37 (#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30)<BR/>#38 (#31 or #32 or #33 or #34 or #35 or #36)<BR/>#39 (#37 or #38)<BR/>#40 (#20 and #39)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (on Ovid)</HEADING>
<P>1 Platelet Glycoprotein GPIIb-IIIa Complex/<BR/>2 (glycoprotein adj5 (inhibit$ or block$ or antagonist$)).tw.<BR/>3 gpIIb$.tw.<BR/>4 abciximab.tw.<BR/>5 sibrafiban.tw.<BR/>6 tirofiban.tw.<BR/>7 lamifiban.tw.<BR/>8 aggrastat.tw.<BR/>9 eptifibatide.tw.<BR/>10 xemilofiban.tw.<BR/>11 lotrafiban.tw.<BR/>12 orbofiban.tw.<BR/>13 roxifiban.tw.<BR/>14 or/1-13<BR/>15 exp Angioplasty, Transluminal, Percutaneous Coronary/<BR/>16 ptca.tw.<BR/>17 (coronary adj5 angioplasty).tw.<BR/>18 exp Angina, Unstable/<BR/>19 angina.tw.<BR/>20 exp Stents/<BR/>21 stent$.tw.<BR/>22 exp Myocardial Infarction/<BR/>23 myocardial infarction.tw.<BR/>24 coronary syndrome$.tw.<BR/>25 Acute Coronary Syndrome/<BR/>26 pci.tw.<BR/>27 percutaneous coronary intervention$.tw.<BR/>28 or/15-27<BR/>29 14 and 28<BR/>30 randomized controlled trial.pt.<BR/>31 controlled clinical trial.pt.<BR/>32 Randomized controlled trials/<BR/>33 random allocation/<BR/>34 double blind method/<BR/>35 single-blind method/<BR/>36 or/30-35<BR/>37 exp animal/ not humans/<BR/>38 36 not 37<BR/>39 clinical trial.pt.<BR/>40 exp Clinical Trials as Topic/<BR/>41 (clin$ adj25 trial$).ti,ab.<BR/>42 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.<BR/>43 placebos/<BR/>44 placebo$.ti,ab.<BR/>45 random$.ti,ab.<BR/>46 research design/<BR/>47 or/39-46<BR/>48 47 not 37<BR/>49 38 or 48<BR/>50 29 and 49<BR/>51 (2006$ or 2007$ or 2008$ or 2009$).em.<BR/>52 51 and 50<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (on Ovid)</HEADING>
<P>1 exp Fibrinogen Receptor/<BR/>2 (glycoprotein adj5 (inhibit$ or block$ or antagonist$)).tw.<BR/>3 gpIIb$.tw.<BR/>4 abciximab.tw.<BR/>5 sibrafiban.tw.<BR/>6 tirofiban.tw.<BR/>7 lamifiban.tw.<BR/>8 aggrastat.tw.<BR/>9 eptifibatide.tw.<BR/>10 xemilofiban.tw.<BR/>11 lotrafiban.tw.<BR/>12 orbofiban.tw.<BR/>13 roxifiban.tw.<BR/>14 or/1-13<BR/>15 exp Transluminal Coronary Angioplasty/<BR/>16 ptca.tw.<BR/>17 (coronary adj5 angioplasty).tw.<BR/>18 exp Unstable Angina Pectoris/<BR/>19 angina.tw.<BR/>20 exp coronary stent/<BR/>21 stent$.tw.<BR/>22 exp Heart Infarction/<BR/>23 myocardial infarction.tw.<BR/>24 coronary syndrome$.tw.<BR/>25 pci.tw.<BR/>26 percutaneous coronary intervention$.tw.<BR/>27 acute coronary syndrome/<BR/>28 or/15-27<BR/>29 28 and 14<BR/>30 controlled clinical trial/<BR/>31 random$.tw.<BR/>32 randomized controlled trial/<BR/>33 follow-up.tw.<BR/>34 double blind procedure/<BR/>35 placebo$.tw.<BR/>36 placebo/<BR/>37 factorial$.ti,ab.<BR/>38 (crossover$ or cross-over$).ti,ab.<BR/>39 (double$ adj blind$).ti,ab.<BR/>40 (singl$ adj blind$).ti,ab.<BR/>41 assign$.ti,ab.<BR/>42 allocat$.ti,ab.<BR/>43 volunteer$.ti,ab.<BR/>44 Crossover Procedure/<BR/>45 Single Blind Procedure/<BR/>46 or/30-45<BR/>47 (exp animals/ or nonhuman/) not human/<BR/>48 46 not 47<BR/>49 29 and 48<BR/>50 (2006$ or 2007$ or 2008$ or 2009$).em.<BR/>51 50 and 49<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-09-04 15:53:06 +0530" MODIFIED_BY="Nicole Ackermann" NO="3">
<TITLE MODIFIED="2010-01-07 16:14:16 +0530" MODIFIED_BY="[Empty name]">Search strategies for 2007 update</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-04 15:53:06 +0530" MODIFIED_BY="Nicole Ackermann">
<SUBSECTION>
<HEADING LEVEL="3">Database: Ovid MEDLINE(R) &lt;1966 to June 2006&gt;</HEADING>
<P>1 Platelet Glycoprotein GPIIb-IIIa Complex/<BR/>2 (glycoprotein adj5 (inhibit$ or block$ or antagonist$)).tw.<BR/>3 gpIIb$.tw.<BR/>4 abciximab.tw.<BR/>5 sibrafiban.tw.<BR/>6 tirofiban.tw.<BR/>7 lamifiban.tw.<BR/>8 aggrastat.tw.<BR/>9 eptifibatide.tw.<BR/>10 xemilofiban.tw.<BR/>11 lotrafiban.tw.<BR/>12 orbofiban.tw.<BR/>13 roxifiban.tw.<BR/>14 or/1-13<BR/>15 exp Angioplasty, Transluminal, Percutaneous Coronary/<BR/>16 ptca.tw.<BR/>17 (coronary adj5 angioplasty).tw.<BR/>18 exp Angina, Unstable/<BR/>19 angina.tw.<BR/>20 exp Stents/<BR/>21 stent$.tw.<BR/>22 exp Myocardial Infarction/<BR/>23 myocardial infarction.tw.<BR/>24 coronary syndrome$.tw.<BR/>25 pci.tw.<BR/>26 percutaneous coronary intervention$.tw.<BR/>27 or/15-26<BR/>28 14 and 27<BR/>29 randomized controlled trial.pt.<BR/>30 controlled clinical trial.pt.<BR/>31 Randomized controlled trials/<BR/>32 random allocation.sh.<BR/>33 double blind method.sh.<BR/>34 single-blind method.sh.<BR/>35 or/29-34<BR/>36 exp animal/ not human/<BR/>37 35 not 36<BR/>38 clinical trial.pt.<BR/>39 exp Clinical trials/<BR/>40 (clin$ adj25 trial$).ti,ab.<BR/>41 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.<BR/>42 placebos.sh.<BR/>43 placebo$.ti,ab.<BR/>44 random$.ti,ab.<BR/>45 research design.sh.<BR/>46 or/38-45<BR/>47 46 not 36<BR/>48 37 or 47<BR/>49 28 and 48<BR/>50 limit 49 to yr=2001 - 2005</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Database: EMBASE &lt;1980 to 2006 Week 15&gt;</HEADING>
<P>1 exp Fibrinogen Receptor/<BR/>2 (glycoprotein adj5 (inhibit$ or block$ or antagonist$)).tw.<BR/>3 gpIIb$.tw.<BR/>4 abciximab.tw.<BR/>5 sibrafiban.tw.<BR/>6 tirofiban.tw.<BR/>7 lamifiban.tw.<BR/>8 aggrastat.tw.<BR/>9 eptifibatide.tw.<BR/>10 xemilofiban.tw.<BR/>11 lotrafiban.tw.<BR/>12 orbofiban.tw.<BR/>13 roxifiban.tw.<BR/>14 or/1-13<BR/>15 exp Transluminal Coronary Angioplasty/<BR/>16 ptca.tw.<BR/>17 (coronary adj5 angioplasty).tw.<BR/>18 exp Unstable Angina Pectoris/<BR/>19 angina.tw.<BR/>20 exp coronary stent/<BR/>21 stent$.tw.<BR/>22 exp Heart Infarction/<BR/>23 myocardial infarction.tw.<BR/>24 coronary syndrome$.tw.<BR/>25 pci.tw.<BR/>26 percutaneous coronary intervention$.tw.<BR/>27 or/15-26<BR/>28 14 and 27<BR/>29 random$.ti,ab.<BR/>30 factorial$.ti,ab.<BR/>31 (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>32 placebo$.ti,ab.<BR/>33 (double$ adj blind$).ti,ab.<BR/>34 (singl$ adj blind$).ti,ab.<BR/>35 assign$.ti,ab.<BR/>36 allocat$.ti,ab.<BR/>37 volunteer$.ti,ab.<BR/>38 Crossover Procedure/<BR/>39 Double Blind Procedure/<BR/>40 Randomized Controlled Trial/<BR/>41 Single Blind Procedure/<BR/>42 or/29-41<BR/>43 exp animal/<BR/>44 nonhuman/<BR/>45 exp animal experiment/<BR/>46 or/43-45<BR/>47 exp human/<BR/>48 46 not 47<BR/>49 42 not 48<BR/>50 49 and 28<BR/>51 limit 50 to yr=2000 - 2005<BR/>52 from 51 keep 1-569</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-09-05 16:46:03 +0530" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-01-07 16:17:05 +0530" MODIFIED_BY="[Empty name]">MEDLINE search strategy for original review (2001)</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-05 16:46:03 +0530" MODIFIED_BY="[Empty name]" NOTES="&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;/h1&gt;&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;&lt;h1 id=&quot;f3&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Title&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s0&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Review information&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s45&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bosch, Xavier&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s47&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Marrugat, Jaume&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s49&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sanchis, Juan&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contact person&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s6&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dates&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s10&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;What's new&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s51&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;New citation: conclusions changed, 12 July 2010&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s52&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Updated, 12 July 2010&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s11&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;History&lt;/h2&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s43&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abstract&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f180&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f180&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f182&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f182&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f184&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f184&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f186&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f186&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection criteria&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f188&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f188&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f190&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f190&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f192&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f192&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s42&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language summary&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f175&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f175&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language title&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f177&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f177&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary text&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f205&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f205&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f207&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f207&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of the condition&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f209&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f209&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of the intervention&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f211&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f211&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;How the intervention might work&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f213&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f213&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Why it is important to do this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f215&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f215&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f217&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f217&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Methods&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f219&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f219&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Criteria for considering studies for this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f221&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f221&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f223&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f223&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of participants&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f225&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f225&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of interventions&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f227&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f227&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of outcome measures&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 id=&quot;f229&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f229&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Primary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 id=&quot;f231&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f231&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Secondary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f233&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f233&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods for identification of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f235&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Electronic searches&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f237&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f237&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Searching other resources&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f239&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f239&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f241&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f241&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f243&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f243&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data extraction and management&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f245&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of risk of bias in included studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f257&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f257&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data synthesis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f259&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f259&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Subgroup analysis and investigation of heterogeneity&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f261&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f261&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sensitivity analysis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f263&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f265&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f265&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f267&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f267&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results of the search&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f269&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f271&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Excluded studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f273&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f273&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f275&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f275&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Allocation (selection bias)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f277&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f277&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blinding (performance bias and detection bias)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f279&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f279&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Incomplete outcome data (attrition bias)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f281&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f281&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selective reporting (reporting bias)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f283&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f283&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other potential sources of bias&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f285&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f285&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Effects of interventions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f287&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f287&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Discussion&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f299&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f299&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f301&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f301&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for practice&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 id=&quot;f303&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for research&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f194&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f194&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Acknowledgements&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f198&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f198&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contributions of authors&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f196&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f196&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Declarations of interest&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f200&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f200&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Differences between protocol and review&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 id=&quot;f202&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f202&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Published notes&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s19&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s20&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1016&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3T/2R 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f7992&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7992&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f7994&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7994&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f7996&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7996&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f7998&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7998&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8000&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8000&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s69&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2395&quot; doc_sec_id=&quot;s2395&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13182&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13182&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2456&quot; doc_sec_id=&quot;s2456&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13367&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13367&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2519&quot; doc_sec_id=&quot;s2519&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13558&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13558&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2520&quot; doc_sec_id=&quot;s2520&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13561&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13561&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2644&quot; doc_sec_id=&quot;s2644&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13939&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13939&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2645&quot; doc_sec_id=&quot;s2645&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13942&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13942&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2765&quot; doc_sec_id=&quot;s2765&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14304&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14304&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2826&quot; doc_sec_id=&quot;s2826&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14489&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14489&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1017&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ACE 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8003&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8003&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8005&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8005&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8007&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8007&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8009&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8009&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8011&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8011&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s77&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2396&quot; doc_sec_id=&quot;s2396&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13185&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13185&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2457&quot; doc_sec_id=&quot;s2457&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13370&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13370&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2521&quot; doc_sec_id=&quot;s2521&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13564&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13564&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2522&quot; doc_sec_id=&quot;s2522&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13567&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13567&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2646&quot; doc_sec_id=&quot;s2646&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13945&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13945&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2647&quot; doc_sec_id=&quot;s2647&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13948&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13948&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2766&quot; doc_sec_id=&quot;s2766&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14307&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14307&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2827&quot; doc_sec_id=&quot;s2827&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14492&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14492&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1018&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ADMIRAL 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8014&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8014&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8016&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8016&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8018&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8018&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8020&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8020&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8022&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8022&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s87&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2397&quot; doc_sec_id=&quot;s2397&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13188&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13188&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2458&quot; doc_sec_id=&quot;s2458&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13373&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13373&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2523&quot; doc_sec_id=&quot;s2523&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13570&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13570&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2524&quot; doc_sec_id=&quot;s2524&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13573&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13573&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2648&quot; doc_sec_id=&quot;s2648&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13951&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13951&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2649&quot; doc_sec_id=&quot;s2649&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13954&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13954&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2767&quot; doc_sec_id=&quot;s2767&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14310&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14310&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2828&quot; doc_sec_id=&quot;s2828&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14495&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14495&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1019&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ADVANCE 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8025&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8025&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8027&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8027&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8029&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8029&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8031&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8031&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8033&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8033&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s93&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2398&quot; doc_sec_id=&quot;s2398&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13191&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13191&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2459&quot; doc_sec_id=&quot;s2459&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13376&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13376&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2525&quot; doc_sec_id=&quot;s2525&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13576&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13576&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2526&quot; doc_sec_id=&quot;s2526&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13579&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13579&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2650&quot; doc_sec_id=&quot;s2650&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13957&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13957&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2651&quot; doc_sec_id=&quot;s2651&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13960&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13960&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2768&quot; doc_sec_id=&quot;s2768&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14313&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14313&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2829&quot; doc_sec_id=&quot;s2829&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14498&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14498&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1020&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ASIAD 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8036&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8036&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8038&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8038&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8040&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8040&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8042&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8042&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8044&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8044&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s99&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2399&quot; doc_sec_id=&quot;s2399&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13194&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13194&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2460&quot; doc_sec_id=&quot;s2460&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13379&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13379&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2527&quot; doc_sec_id=&quot;s2527&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13582&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13582&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2528&quot; doc_sec_id=&quot;s2528&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13585&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13585&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2652&quot; doc_sec_id=&quot;s2652&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13963&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13963&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2653&quot; doc_sec_id=&quot;s2653&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13966&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13966&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2769&quot; doc_sec_id=&quot;s2769&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14316&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14316&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2830&quot; doc_sec_id=&quot;s2830&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14501&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14501&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1021&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ASSIST 2009&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8047&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8047&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8049&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8049&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8051&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8051&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8053&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8053&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8055&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8055&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s105&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2400&quot; doc_sec_id=&quot;s2400&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13197&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13197&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2461&quot; doc_sec_id=&quot;s2461&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13382&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13382&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2529&quot; doc_sec_id=&quot;s2529&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13588&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13588&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2530&quot; doc_sec_id=&quot;s2530&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13591&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13591&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2654&quot; doc_sec_id=&quot;s2654&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13969&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13969&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2655&quot; doc_sec_id=&quot;s2655&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13972&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13972&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2770&quot; doc_sec_id=&quot;s2770&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14319&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14319&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2831&quot; doc_sec_id=&quot;s2831&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14504&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14504&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1022&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bhattacharya 2010&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8058&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8058&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8060&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8060&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8062&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8062&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8064&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8064&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8066&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8066&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s111&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2402&quot; doc_sec_id=&quot;s2402&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13203&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13203&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2463&quot; doc_sec_id=&quot;s2463&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13388&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13388&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2533&quot; doc_sec_id=&quot;s2533&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13600&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13600&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2534&quot; doc_sec_id=&quot;s2534&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13603&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13603&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2658&quot; doc_sec_id=&quot;s2658&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13981&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13981&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2659&quot; doc_sec_id=&quot;s2659&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13984&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13984&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2772&quot; doc_sec_id=&quot;s2772&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14325&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14325&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2833&quot; doc_sec_id=&quot;s2833&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14510&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14510&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1023&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;BRAVE-3 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8069&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8069&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8071&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8071&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8073&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8073&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8075&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8075&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8077&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8077&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s119&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2401&quot; doc_sec_id=&quot;s2401&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13200&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13200&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2462&quot; doc_sec_id=&quot;s2462&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13385&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13385&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2531&quot; doc_sec_id=&quot;s2531&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13594&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13594&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2532&quot; doc_sec_id=&quot;s2532&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13597&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13597&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2656&quot; doc_sec_id=&quot;s2656&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13975&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13975&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2657&quot; doc_sec_id=&quot;s2657&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13978&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13978&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2771&quot; doc_sec_id=&quot;s2771&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14322&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14322&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2832&quot; doc_sec_id=&quot;s2832&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14507&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14507&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1024&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CADILLAC 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8080&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8080&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8082&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8082&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8084&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8084&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8086&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8086&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8088&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8088&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s127&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2403&quot; doc_sec_id=&quot;s2403&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13206&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13206&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2464&quot; doc_sec_id=&quot;s2464&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13391&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13391&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2535&quot; doc_sec_id=&quot;s2535&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13606&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13606&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2536&quot; doc_sec_id=&quot;s2536&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13609&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13609&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2660&quot; doc_sec_id=&quot;s2660&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13987&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13987&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2661&quot; doc_sec_id=&quot;s2661&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13990&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13990&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2773&quot; doc_sec_id=&quot;s2773&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14328&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14328&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2834&quot; doc_sec_id=&quot;s2834&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14513&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14513&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1025&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CANADIAN 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8091&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8091&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8093&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8093&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8095&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8095&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8097&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8097&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8099&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8099&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s133&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2404&quot; doc_sec_id=&quot;s2404&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13209&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13209&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2465&quot; doc_sec_id=&quot;s2465&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13394&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13394&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2537&quot; doc_sec_id=&quot;s2537&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13612&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13612&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2538&quot; doc_sec_id=&quot;s2538&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13615&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13615&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2662&quot; doc_sec_id=&quot;s2662&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13993&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13993&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2663&quot; doc_sec_id=&quot;s2663&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13996&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13996&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2774&quot; doc_sec_id=&quot;s2774&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14331&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14331&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2835&quot; doc_sec_id=&quot;s2835&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14516&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14516&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1026&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CAPTURE 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8102&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8102&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8104&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8104&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8106&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8106&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8108&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8108&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8110&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8110&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s139&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2405&quot; doc_sec_id=&quot;s2405&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13212&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13212&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2466&quot; doc_sec_id=&quot;s2466&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13397&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13397&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2539&quot; doc_sec_id=&quot;s2539&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13618&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13618&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2540&quot; doc_sec_id=&quot;s2540&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13621&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13621&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2664&quot; doc_sec_id=&quot;s2664&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13999&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13999&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2665&quot; doc_sec_id=&quot;s2665&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14002&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14002&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2775&quot; doc_sec_id=&quot;s2775&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14334&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14334&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2836&quot; doc_sec_id=&quot;s2836&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14519&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14519&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1027&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chen 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8113&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8113&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8115&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8115&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8117&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8117&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8119&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8119&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8121&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8121&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s145&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2407&quot; doc_sec_id=&quot;s2407&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13218&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13218&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2468&quot; doc_sec_id=&quot;s2468&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13403&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13403&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2543&quot; doc_sec_id=&quot;s2543&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13630&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13630&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2544&quot; doc_sec_id=&quot;s2544&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13633&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13633&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2668&quot; doc_sec_id=&quot;s2668&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14011&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14011&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2669&quot; doc_sec_id=&quot;s2669&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14014&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14014&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2777&quot; doc_sec_id=&quot;s2777&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14340&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14340&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2838&quot; doc_sec_id=&quot;s2838&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14525&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14525&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1028&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Claeys 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8124&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8124&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8126&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8126&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8128&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8128&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8130&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8130&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8132&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8132&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2408&quot; doc_sec_id=&quot;s2408&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13221&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13221&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2469&quot; doc_sec_id=&quot;s2469&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13406&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13406&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2545&quot; doc_sec_id=&quot;s2545&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13636&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13636&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2546&quot; doc_sec_id=&quot;s2546&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13639&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13639&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2670&quot; doc_sec_id=&quot;s2670&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14017&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14017&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2671&quot; doc_sec_id=&quot;s2671&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14020&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14020&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2778&quot; doc_sec_id=&quot;s2778&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14343&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14343&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2839&quot; doc_sec_id=&quot;s2839&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14528&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14528&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1029&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CLEAR PLATELETS-2 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8135&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8135&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8137&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8137&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8139&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8139&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8141&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8141&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8143&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8143&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s157&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2406&quot; doc_sec_id=&quot;s2406&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13215&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13215&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2467&quot; doc_sec_id=&quot;s2467&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13400&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13400&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2541&quot; doc_sec_id=&quot;s2541&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13624&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13624&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2542&quot; doc_sec_id=&quot;s2542&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13627&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13627&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2666&quot; doc_sec_id=&quot;s2666&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14005&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14005&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2667&quot; doc_sec_id=&quot;s2667&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14008&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14008&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2776&quot; doc_sec_id=&quot;s2776&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14337&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14337&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2837&quot; doc_sec_id=&quot;s2837&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14522&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14522&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1030&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cuisset 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8146&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8146&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8148&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8148&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8150&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8150&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8152&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8152&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8154&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8154&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s163&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2409&quot; doc_sec_id=&quot;s2409&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13224&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13224&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2470&quot; doc_sec_id=&quot;s2470&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13409&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13409&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2547&quot; doc_sec_id=&quot;s2547&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13642&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13642&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2548&quot; doc_sec_id=&quot;s2548&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13645&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13645&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2672&quot; doc_sec_id=&quot;s2672&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14023&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14023&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2673&quot; doc_sec_id=&quot;s2673&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14026&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14026&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2779&quot; doc_sec_id=&quot;s2779&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14346&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14346&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2840&quot; doc_sec_id=&quot;s2840&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14531&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14531&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1031&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;DANTE 2004&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8157&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8157&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8159&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8159&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8161&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8161&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8163&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8163&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8165&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8165&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s169&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2410&quot; doc_sec_id=&quot;s2410&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13227&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13227&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2471&quot; doc_sec_id=&quot;s2471&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13412&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13412&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2549&quot; doc_sec_id=&quot;s2549&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13648&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13648&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2550&quot; doc_sec_id=&quot;s2550&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13651&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13651&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2674&quot; doc_sec_id=&quot;s2674&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14029&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14029&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2675&quot; doc_sec_id=&quot;s2675&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14032&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14032&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2780&quot; doc_sec_id=&quot;s2780&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14349&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14349&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2841&quot; doc_sec_id=&quot;s2841&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14534&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14534&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1032&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Luca 2005&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8168&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8168&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8170&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8170&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8172&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8172&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8174&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8174&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8176&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8176&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s175&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2411&quot; doc_sec_id=&quot;s2411&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13230&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13230&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2472&quot; doc_sec_id=&quot;s2472&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13415&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13415&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2551&quot; doc_sec_id=&quot;s2551&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13654&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13654&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2552&quot; doc_sec_id=&quot;s2552&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13657&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13657&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2676&quot; doc_sec_id=&quot;s2676&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14035&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14035&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2677&quot; doc_sec_id=&quot;s2677&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14038&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14038&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2781&quot; doc_sec_id=&quot;s2781&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14352&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14352&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2842&quot; doc_sec_id=&quot;s2842&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14537&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14537&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1033&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Luca 2008&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8179&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8179&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8181&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8181&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8183&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8183&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8185&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8185&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8187&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8187&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s181&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2412&quot; doc_sec_id=&quot;s2412&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13233&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13233&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2473&quot; doc_sec_id=&quot;s2473&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13418&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13418&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2553&quot; doc_sec_id=&quot;s2553&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13660&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13660&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2554&quot; doc_sec_id=&quot;s2554&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13663&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13663&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2678&quot; doc_sec_id=&quot;s2678&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14041&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14041&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2679&quot; doc_sec_id=&quot;s2679&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14044&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14044&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2782&quot; doc_sec_id=&quot;s2782&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14355&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14355&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2843&quot; doc_sec_id=&quot;s2843&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14540&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14540&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1034&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ELISA-2 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8190&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8190&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8192&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8192&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8194&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8194&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8196&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8196&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8198&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8198&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s187&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2413&quot; doc_sec_id=&quot;s2413&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13236&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13236&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2474&quot; doc_sec_id=&quot;s2474&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13421&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13421&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2555&quot; doc_sec_id=&quot;s2555&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13666&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13666&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2556&quot; doc_sec_id=&quot;s2556&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13669&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13669&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2680&quot; doc_sec_id=&quot;s2680&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14047&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14047&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2681&quot; doc_sec_id=&quot;s2681&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14050&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14050&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2783&quot; doc_sec_id=&quot;s2783&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14358&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14358&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2844&quot; doc_sec_id=&quot;s2844&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14543&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14543&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1035&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EPIC 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8201&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8201&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8203&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8203&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8205&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8205&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8207&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8207&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8209&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8209&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s197&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2414&quot; doc_sec_id=&quot;s2414&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13239&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13239&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2475&quot; doc_sec_id=&quot;s2475&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13424&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13424&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2557&quot; doc_sec_id=&quot;s2557&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13672&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13672&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2558&quot; doc_sec_id=&quot;s2558&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13675&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13675&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2682&quot; doc_sec_id=&quot;s2682&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14053&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14053&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2683&quot; doc_sec_id=&quot;s2683&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14056&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14056&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2784&quot; doc_sec_id=&quot;s2784&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14361&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14361&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2845&quot; doc_sec_id=&quot;s2845&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14546&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14546&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1036&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EPILOG 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8212&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8212&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8214&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8214&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8216&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8216&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8218&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8218&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8220&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8220&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s205&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2415&quot; doc_sec_id=&quot;s2415&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13242&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13242&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2476&quot; doc_sec_id=&quot;s2476&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13427&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13427&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2559&quot; doc_sec_id=&quot;s2559&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13678&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13678&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2560&quot; doc_sec_id=&quot;s2560&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13681&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13681&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2684&quot; doc_sec_id=&quot;s2684&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14059&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14059&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2685&quot; doc_sec_id=&quot;s2685&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14062&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14062&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2785&quot; doc_sec_id=&quot;s2785&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14364&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14364&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2846&quot; doc_sec_id=&quot;s2846&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14549&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14549&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1037&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EPISTENT 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8223&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8223&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8225&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8225&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8227&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8227&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8229&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8229&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8231&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8231&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s215&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2416&quot; doc_sec_id=&quot;s2416&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13245&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13245&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2477&quot; doc_sec_id=&quot;s2477&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13430&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13430&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2561&quot; doc_sec_id=&quot;s2561&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13684&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13684&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2562&quot; doc_sec_id=&quot;s2562&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13687&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13687&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2686&quot; doc_sec_id=&quot;s2686&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14065&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14065&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2687&quot; doc_sec_id=&quot;s2687&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14068&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14068&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2786&quot; doc_sec_id=&quot;s2786&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14367&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14367&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2847&quot; doc_sec_id=&quot;s2847&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14552&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14552&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1038&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ERASER 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8234&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8234&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8236&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8236&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8238&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8238&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8240&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8240&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8242&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8242&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s221&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2417&quot; doc_sec_id=&quot;s2417&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13248&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13248&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2478&quot; doc_sec_id=&quot;s2478&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13433&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13433&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2563&quot; doc_sec_id=&quot;s2563&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13690&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13690&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2564&quot; doc_sec_id=&quot;s2564&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13693&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13693&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2688&quot; doc_sec_id=&quot;s2688&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14071&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14071&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2689&quot; doc_sec_id=&quot;s2689&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14074&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14074&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2787&quot; doc_sec_id=&quot;s2787&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14370&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14370&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2848&quot; doc_sec_id=&quot;s2848&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14555&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14555&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1039&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ESPRIT 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8245&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8245&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8247&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8247&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8249&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8249&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8251&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8251&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8253&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8253&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s231&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2418&quot; doc_sec_id=&quot;s2418&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13251&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13251&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2479&quot; doc_sec_id=&quot;s2479&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13436&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13436&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2565&quot; doc_sec_id=&quot;s2565&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13696&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13696&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2566&quot; doc_sec_id=&quot;s2566&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13699&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13699&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2690&quot; doc_sec_id=&quot;s2690&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14077&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14077&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2691&quot; doc_sec_id=&quot;s2691&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14080&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14080&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2788&quot; doc_sec_id=&quot;s2788&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14373&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14373&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2849&quot; doc_sec_id=&quot;s2849&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14558&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14558&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1040&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fu 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8256&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8256&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8258&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8258&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8260&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8260&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8262&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8262&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8264&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8264&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s237&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2419&quot; doc_sec_id=&quot;s2419&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13254&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13254&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2480&quot; doc_sec_id=&quot;s2480&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13439&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13439&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2567&quot; doc_sec_id=&quot;s2567&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13702&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13702&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2568&quot; doc_sec_id=&quot;s2568&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13705&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13705&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2692&quot; doc_sec_id=&quot;s2692&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14083&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14083&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2693&quot; doc_sec_id=&quot;s2693&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14086&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14086&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2789&quot; doc_sec_id=&quot;s2789&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14376&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14376&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2850&quot; doc_sec_id=&quot;s2850&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14561&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14561&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Galassi 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8267&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8267&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8269&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8269&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8271&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8271&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8273&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8273&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8275&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8275&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s243&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2421&quot; doc_sec_id=&quot;s2421&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13260&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13260&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2482&quot; doc_sec_id=&quot;s2482&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13445&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13445&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2571&quot; doc_sec_id=&quot;s2571&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13714&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13714&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2572&quot; doc_sec_id=&quot;s2572&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13717&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13717&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2696&quot; doc_sec_id=&quot;s2696&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14095&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14095&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2697&quot; doc_sec_id=&quot;s2697&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14098&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14098&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2791&quot; doc_sec_id=&quot;s2791&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14382&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14382&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2852&quot; doc_sec_id=&quot;s2852&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14567&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14567&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1042&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;GUSTO-IV 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8278&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8278&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8280&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8280&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8282&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8282&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8284&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8284&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8286&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8286&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2420&quot; doc_sec_id=&quot;s2420&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13257&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13257&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2481&quot; doc_sec_id=&quot;s2481&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13442&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13442&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2569&quot; doc_sec_id=&quot;s2569&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13708&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13708&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2570&quot; doc_sec_id=&quot;s2570&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13711&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13711&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2694&quot; doc_sec_id=&quot;s2694&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14089&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14089&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2695&quot; doc_sec_id=&quot;s2695&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14092&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14092&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2790&quot; doc_sec_id=&quot;s2790&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14379&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14379&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2851&quot; doc_sec_id=&quot;s2851&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14564&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14564&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1043&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;IMPACT 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8289&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8289&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8291&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8291&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8293&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8293&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8295&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8295&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8297&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8297&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s257&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2422&quot; doc_sec_id=&quot;s2422&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13263&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13263&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2483&quot; doc_sec_id=&quot;s2483&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13448&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13448&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2573&quot; doc_sec_id=&quot;s2573&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13720&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13720&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2574&quot; doc_sec_id=&quot;s2574&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13723&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13723&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2698&quot; doc_sec_id=&quot;s2698&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14101&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14101&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2699&quot; doc_sec_id=&quot;s2699&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14104&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14104&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2792&quot; doc_sec_id=&quot;s2792&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14385&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14385&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2853&quot; doc_sec_id=&quot;s2853&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14570&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14570&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1044&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;IMPACT-II 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8300&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8300&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8302&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8302&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8304&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8304&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8306&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8306&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8308&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8308&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s265&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2423&quot; doc_sec_id=&quot;s2423&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13266&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13266&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2484&quot; doc_sec_id=&quot;s2484&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13451&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13451&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2575&quot; doc_sec_id=&quot;s2575&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13726&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13726&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2576&quot; doc_sec_id=&quot;s2576&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13729&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13729&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2700&quot; doc_sec_id=&quot;s2700&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14107&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14107&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2701&quot; doc_sec_id=&quot;s2701&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14110&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14110&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2793&quot; doc_sec_id=&quot;s2793&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14388&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14388&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2854&quot; doc_sec_id=&quot;s2854&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14573&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14573&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1045&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;INSTANT 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8311&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8311&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8313&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8313&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8315&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8315&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8317&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8317&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8319&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8319&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2424&quot; doc_sec_id=&quot;s2424&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13269&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13269&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2485&quot; doc_sec_id=&quot;s2485&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13454&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13454&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2577&quot; doc_sec_id=&quot;s2577&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13732&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13732&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2578&quot; doc_sec_id=&quot;s2578&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13735&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13735&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2702&quot; doc_sec_id=&quot;s2702&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14113&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14113&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2703&quot; doc_sec_id=&quot;s2703&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14116&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14116&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2794&quot; doc_sec_id=&quot;s2794&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14391&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14391&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2855&quot; doc_sec_id=&quot;s2855&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14576&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14576&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1046&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-2 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8322&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8322&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8324&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8324&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8326&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8326&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8328&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8328&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8330&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8330&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s277&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2425&quot; doc_sec_id=&quot;s2425&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13272&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13272&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2486&quot; doc_sec_id=&quot;s2486&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13457&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13457&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2579&quot; doc_sec_id=&quot;s2579&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13738&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13738&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2580&quot; doc_sec_id=&quot;s2580&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13741&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13741&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2704&quot; doc_sec_id=&quot;s2704&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14119&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14119&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2705&quot; doc_sec_id=&quot;s2705&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14122&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14122&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2795&quot; doc_sec_id=&quot;s2795&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14394&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14394&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2856&quot; doc_sec_id=&quot;s2856&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14579&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14579&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1047&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-REACT 2 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8333&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8333&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8335&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8335&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8337&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8337&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8339&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8339&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8341&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8341&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s293&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2426&quot; doc_sec_id=&quot;s2426&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13275&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13275&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2487&quot; doc_sec_id=&quot;s2487&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13460&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13460&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2581&quot; doc_sec_id=&quot;s2581&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13744&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13744&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2582&quot; doc_sec_id=&quot;s2582&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13747&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13747&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2706&quot; doc_sec_id=&quot;s2706&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14125&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14125&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2707&quot; doc_sec_id=&quot;s2707&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14128&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14128&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2796&quot; doc_sec_id=&quot;s2796&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14397&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14397&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2857&quot; doc_sec_id=&quot;s2857&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14582&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14582&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1048&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-REACT 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8344&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8344&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8346&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8346&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8348&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8348&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8350&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8350&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8352&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8352&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s285&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2427&quot; doc_sec_id=&quot;s2427&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13278&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13278&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2488&quot; doc_sec_id=&quot;s2488&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13463&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13463&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2583&quot; doc_sec_id=&quot;s2583&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13750&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13750&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2584&quot; doc_sec_id=&quot;s2584&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13753&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13753&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2708&quot; doc_sec_id=&quot;s2708&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14131&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14131&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2709&quot; doc_sec_id=&quot;s2709&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14134&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14134&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2797&quot; doc_sec_id=&quot;s2797&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14400&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14400&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2858&quot; doc_sec_id=&quot;s2858&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14585&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14585&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1049&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-SMART-2 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8355&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8355&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8357&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8357&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8359&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8359&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8361&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8361&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8363&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8363&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s299&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2428&quot; doc_sec_id=&quot;s2428&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13281&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13281&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2489&quot; doc_sec_id=&quot;s2489&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13466&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13466&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2585&quot; doc_sec_id=&quot;s2585&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13756&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13756&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2586&quot; doc_sec_id=&quot;s2586&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13759&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13759&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2710&quot; doc_sec_id=&quot;s2710&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14137&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14137&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2711&quot; doc_sec_id=&quot;s2711&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14140&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14140&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2798&quot; doc_sec_id=&quot;s2798&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14403&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14403&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2859&quot; doc_sec_id=&quot;s2859&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14588&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14588&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1050&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-SWEET 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8366&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8366&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8368&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8368&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8370&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8370&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8372&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8372&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8374&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8374&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s305&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2429&quot; doc_sec_id=&quot;s2429&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13284&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13284&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2490&quot; doc_sec_id=&quot;s2490&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13469&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13469&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2587&quot; doc_sec_id=&quot;s2587&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13762&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13762&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2588&quot; doc_sec_id=&quot;s2588&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13765&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13765&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2712&quot; doc_sec_id=&quot;s2712&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14143&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14143&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2713&quot; doc_sec_id=&quot;s2713&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14146&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14146&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2799&quot; doc_sec_id=&quot;s2799&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14406&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14406&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2860&quot; doc_sec_id=&quot;s2860&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14591&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14591&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1051&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ITTI 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8377&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8377&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8379&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8379&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8381&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8381&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8383&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8383&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8385&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8385&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s311&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2430&quot; doc_sec_id=&quot;s2430&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13287&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13287&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2491&quot; doc_sec_id=&quot;s2491&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13472&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13472&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2589&quot; doc_sec_id=&quot;s2589&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13768&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13768&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2590&quot; doc_sec_id=&quot;s2590&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13771&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13771&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2714&quot; doc_sec_id=&quot;s2714&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14149&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14149&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2715&quot; doc_sec_id=&quot;s2715&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14152&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14152&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2800&quot; doc_sec_id=&quot;s2800&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14409&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14409&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2861&quot; doc_sec_id=&quot;s2861&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14594&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14594&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1052&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;JEPPORT 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8388&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8388&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8390&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8390&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8392&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8392&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8394&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8394&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8396&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8396&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2431&quot; doc_sec_id=&quot;s2431&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13290&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13290&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2492&quot; doc_sec_id=&quot;s2492&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13475&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13475&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2591&quot; doc_sec_id=&quot;s2591&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13774&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13774&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2592&quot; doc_sec_id=&quot;s2592&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13777&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13777&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2716&quot; doc_sec_id=&quot;s2716&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14155&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14155&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2717&quot; doc_sec_id=&quot;s2717&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14158&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14158&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2801&quot; doc_sec_id=&quot;s2801&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14412&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14412&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2862&quot; doc_sec_id=&quot;s2862&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14597&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14597&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1053&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Juergens 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8399&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8399&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8401&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8401&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8403&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8403&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8405&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8405&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8407&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8407&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s323&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2432&quot; doc_sec_id=&quot;s2432&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13293&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13293&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2493&quot; doc_sec_id=&quot;s2493&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13478&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13478&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2593&quot; doc_sec_id=&quot;s2593&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13780&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13780&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2594&quot; doc_sec_id=&quot;s2594&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13783&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13783&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2718&quot; doc_sec_id=&quot;s2718&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14161&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14161&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2719&quot; doc_sec_id=&quot;s2719&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14164&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14164&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2802&quot; doc_sec_id=&quot;s2802&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14415&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14415&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2863&quot; doc_sec_id=&quot;s2863&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14600&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14600&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1054&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8410&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8410&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8412&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8412&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8414&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8414&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8416&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8416&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8418&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8418&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2433&quot; doc_sec_id=&quot;s2433&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13296&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13296&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2494&quot; doc_sec_id=&quot;s2494&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13481&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13481&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2595&quot; doc_sec_id=&quot;s2595&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13786&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13786&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2596&quot; doc_sec_id=&quot;s2596&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13789&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13789&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2720&quot; doc_sec_id=&quot;s2720&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14167&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14167&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2721&quot; doc_sec_id=&quot;s2721&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14170&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14170&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2803&quot; doc_sec_id=&quot;s2803&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14418&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14418&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2864&quot; doc_sec_id=&quot;s2864&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14603&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14603&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1055&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kim 2005&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8421&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8421&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8423&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8423&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8425&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8425&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8427&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8427&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8429&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8429&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s335&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2434&quot; doc_sec_id=&quot;s2434&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13299&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13299&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2495&quot; doc_sec_id=&quot;s2495&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13484&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13484&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2597&quot; doc_sec_id=&quot;s2597&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13792&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13792&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2598&quot; doc_sec_id=&quot;s2598&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13795&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13795&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2722&quot; doc_sec_id=&quot;s2722&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14173&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14173&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2723&quot; doc_sec_id=&quot;s2723&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14176&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14176&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2804&quot; doc_sec_id=&quot;s2804&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14421&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14421&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2865&quot; doc_sec_id=&quot;s2865&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14606&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14606&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1056&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurowski 2005&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8432&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8432&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8434&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8434&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8436&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8436&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8438&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8438&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8440&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8440&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s341&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2435&quot; doc_sec_id=&quot;s2435&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13302&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13302&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2496&quot; doc_sec_id=&quot;s2496&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13487&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13487&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2599&quot; doc_sec_id=&quot;s2599&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13798&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13798&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2600&quot; doc_sec_id=&quot;s2600&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13801&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13801&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2724&quot; doc_sec_id=&quot;s2724&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14179&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14179&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2725&quot; doc_sec_id=&quot;s2725&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14182&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14182&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2805&quot; doc_sec_id=&quot;s2805&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14424&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14424&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2866&quot; doc_sec_id=&quot;s2866&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14609&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14609&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1057&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;On-TIME 2 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8443&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8443&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8445&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8445&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8447&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8447&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8449&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8449&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8451&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8451&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s347&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2437&quot; doc_sec_id=&quot;s2437&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13308&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13308&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2498&quot; doc_sec_id=&quot;s2498&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13493&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13493&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2603&quot; doc_sec_id=&quot;s2603&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13810&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13810&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2604&quot; doc_sec_id=&quot;s2604&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13813&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13813&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2728&quot; doc_sec_id=&quot;s2728&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14191&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14191&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2729&quot; doc_sec_id=&quot;s2729&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14194&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14194&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2807&quot; doc_sec_id=&quot;s2807&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14430&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14430&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2868&quot; doc_sec_id=&quot;s2868&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14615&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14615&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1058&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;OPTIMIZE-IT 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8454&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8454&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8456&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8456&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8458&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8458&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8460&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8460&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8462&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8462&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s353&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2436&quot; doc_sec_id=&quot;s2436&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13305&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13305&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2497&quot; doc_sec_id=&quot;s2497&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13490&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13490&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2601&quot; doc_sec_id=&quot;s2601&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13804&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13804&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2602&quot; doc_sec_id=&quot;s2602&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13807&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13807&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2726&quot; doc_sec_id=&quot;s2726&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14185&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14185&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2727&quot; doc_sec_id=&quot;s2727&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14188&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14188&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2806&quot; doc_sec_id=&quot;s2806&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14427&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14427&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2867&quot; doc_sec_id=&quot;s2867&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14612&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14612&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1059&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARAGON A 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8465&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8465&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8467&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8467&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8469&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8469&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8471&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8471&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8473&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8473&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s359&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2438&quot; doc_sec_id=&quot;s2438&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13311&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13311&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2499&quot; doc_sec_id=&quot;s2499&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13496&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13496&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2605&quot; doc_sec_id=&quot;s2605&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13816&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13816&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2606&quot; doc_sec_id=&quot;s2606&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13819&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13819&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2730&quot; doc_sec_id=&quot;s2730&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14197&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14197&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2731&quot; doc_sec_id=&quot;s2731&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14200&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14200&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2808&quot; doc_sec_id=&quot;s2808&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14433&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14433&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2869&quot; doc_sec_id=&quot;s2869&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14618&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14618&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1060&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARAGON B 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8476&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8476&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8478&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8478&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8480&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8480&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8482&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8482&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8484&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8484&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s367&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2439&quot; doc_sec_id=&quot;s2439&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13314&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13314&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2500&quot; doc_sec_id=&quot;s2500&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13499&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13499&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2607&quot; doc_sec_id=&quot;s2607&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13822&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13822&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2608&quot; doc_sec_id=&quot;s2608&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13825&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13825&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2732&quot; doc_sec_id=&quot;s2732&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14203&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14203&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2733&quot; doc_sec_id=&quot;s2733&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14206&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14206&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2809&quot; doc_sec_id=&quot;s2809&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14436&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14436&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2870&quot; doc_sec_id=&quot;s2870&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14621&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14621&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1061&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRACTICE 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8487&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8487&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8489&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8489&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8491&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8491&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8493&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8493&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8495&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8495&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s373&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2440&quot; doc_sec_id=&quot;s2440&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13317&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13317&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2501&quot; doc_sec_id=&quot;s2501&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13502&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13502&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2609&quot; doc_sec_id=&quot;s2609&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13828&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13828&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2610&quot; doc_sec_id=&quot;s2610&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13831&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13831&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2734&quot; doc_sec_id=&quot;s2734&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14209&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14209&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2735&quot; doc_sec_id=&quot;s2735&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14212&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14212&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2810&quot; doc_sec_id=&quot;s2810&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14439&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14439&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2871&quot; doc_sec_id=&quot;s2871&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14624&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14624&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1062&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Prati 2005&lt;/h3&gt;&lt;p&gt;2005&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8498&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8498&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8500&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8500&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8502&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8502&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8504&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8504&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8506&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8506&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s379&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2445&quot; doc_sec_id=&quot;s2445&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13332&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13332&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2506&quot; doc_sec_id=&quot;s2506&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13517&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13517&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2619&quot; doc_sec_id=&quot;s2619&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13858&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13858&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2620&quot; doc_sec_id=&quot;s2620&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13861&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13861&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2744&quot; doc_sec_id=&quot;s2744&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14239&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14239&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2745&quot; doc_sec_id=&quot;s2745&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14242&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14242&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2815&quot; doc_sec_id=&quot;s2815&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14454&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14454&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2876&quot; doc_sec_id=&quot;s2876&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14639&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14639&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1063&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRIDE 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8509&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8509&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8511&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8511&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8513&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8513&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8515&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8515&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8517&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8517&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s385&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2441&quot; doc_sec_id=&quot;s2441&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13320&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13320&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2502&quot; doc_sec_id=&quot;s2502&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13505&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13505&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2611&quot; doc_sec_id=&quot;s2611&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13834&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13834&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2612&quot; doc_sec_id=&quot;s2612&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13837&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13837&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2736&quot; doc_sec_id=&quot;s2736&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14215&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14215&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2737&quot; doc_sec_id=&quot;s2737&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14218&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14218&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2811&quot; doc_sec_id=&quot;s2811&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14442&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14442&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2872&quot; doc_sec_id=&quot;s2872&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14627&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14627&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1064&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRISM 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8520&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8520&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8522&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8522&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8524&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8524&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8526&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8526&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8528&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8528&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s391&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2442&quot; doc_sec_id=&quot;s2442&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13323&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13323&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2503&quot; doc_sec_id=&quot;s2503&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13508&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13508&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2613&quot; doc_sec_id=&quot;s2613&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13840&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13840&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2614&quot; doc_sec_id=&quot;s2614&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13843&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13843&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2738&quot; doc_sec_id=&quot;s2738&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14221&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14221&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2739&quot; doc_sec_id=&quot;s2739&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14224&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14224&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2812&quot; doc_sec_id=&quot;s2812&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14445&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14445&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2873&quot; doc_sec_id=&quot;s2873&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14630&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14630&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1065&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRISM Plus 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8531&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8531&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8533&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8533&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8535&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8535&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8537&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8537&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8539&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8539&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s397&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2443&quot; doc_sec_id=&quot;s2443&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13326&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13326&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2504&quot; doc_sec_id=&quot;s2504&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13511&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13511&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2615&quot; doc_sec_id=&quot;s2615&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13846&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13846&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2616&quot; doc_sec_id=&quot;s2616&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13849&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13849&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2740&quot; doc_sec_id=&quot;s2740&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14227&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14227&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2741&quot; doc_sec_id=&quot;s2741&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14230&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14230&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2813&quot; doc_sec_id=&quot;s2813&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14448&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14448&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2874&quot; doc_sec_id=&quot;s2874&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14633&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14633&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1066&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PURSUIT 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8542&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8542&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8544&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8544&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8546&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8546&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8548&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8548&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8550&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8550&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s407&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2444&quot; doc_sec_id=&quot;s2444&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13329&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13329&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2505&quot; doc_sec_id=&quot;s2505&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13514&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13514&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2617&quot; doc_sec_id=&quot;s2617&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13852&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13852&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2618&quot; doc_sec_id=&quot;s2618&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13855&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13855&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2742&quot; doc_sec_id=&quot;s2742&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14233&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14233&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2743&quot; doc_sec_id=&quot;s2743&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14236&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14236&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2814&quot; doc_sec_id=&quot;s2814&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14451&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14451&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2875&quot; doc_sec_id=&quot;s2875&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14636&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14636&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1067&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;RAPPORT 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8553&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8553&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8555&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8555&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8557&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8557&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8559&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8559&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8561&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8561&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s413&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2446&quot; doc_sec_id=&quot;s2446&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13335&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13335&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2507&quot; doc_sec_id=&quot;s2507&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13520&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13520&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2621&quot; doc_sec_id=&quot;s2621&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13864&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13864&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2622&quot; doc_sec_id=&quot;s2622&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13867&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13867&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2746&quot; doc_sec_id=&quot;s2746&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14245&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14245&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2747&quot; doc_sec_id=&quot;s2747&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14248&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14248&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2816&quot; doc_sec_id=&quot;s2816&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14457&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14457&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2877&quot; doc_sec_id=&quot;s2877&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14642&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14642&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1068&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;RESTORE 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8564&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8564&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8566&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8566&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8568&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8568&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8570&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8570&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8572&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8572&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s421&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2447&quot; doc_sec_id=&quot;s2447&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13338&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13338&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2508&quot; doc_sec_id=&quot;s2508&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13523&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13523&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2623&quot; doc_sec_id=&quot;s2623&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13870&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13870&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2624&quot; doc_sec_id=&quot;s2624&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13873&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13873&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2748&quot; doc_sec_id=&quot;s2748&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14251&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14251&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2749&quot; doc_sec_id=&quot;s2749&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14254&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14254&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2817&quot; doc_sec_id=&quot;s2817&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14460&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14460&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2878&quot; doc_sec_id=&quot;s2878&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14645&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14645&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1069&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schulman 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8575&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8575&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8577&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8577&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8579&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8579&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8581&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8581&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8583&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8583&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s427&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2448&quot; doc_sec_id=&quot;s2448&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13341&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13341&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2509&quot; doc_sec_id=&quot;s2509&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13526&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13526&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2625&quot; doc_sec_id=&quot;s2625&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13876&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13876&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2626&quot; doc_sec_id=&quot;s2626&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13879&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13879&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2750&quot; doc_sec_id=&quot;s2750&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14257&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14257&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2751&quot; doc_sec_id=&quot;s2751&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14260&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14260&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2818&quot; doc_sec_id=&quot;s2818&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14463&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14463&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2879&quot; doc_sec_id=&quot;s2879&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14648&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14648&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1070&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shen 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8586&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8586&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8588&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8588&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8590&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8590&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8592&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8592&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8594&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8594&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s433&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2449&quot; doc_sec_id=&quot;s2449&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13344&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13344&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2510&quot; doc_sec_id=&quot;s2510&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13529&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13529&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2627&quot; doc_sec_id=&quot;s2627&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13882&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13882&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2628&quot; doc_sec_id=&quot;s2628&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13885&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13885&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2752&quot; doc_sec_id=&quot;s2752&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14263&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14263&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2753&quot; doc_sec_id=&quot;s2753&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14266&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14266&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2819&quot; doc_sec_id=&quot;s2819&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14466&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14466&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2880&quot; doc_sec_id=&quot;s2880&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14651&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14651&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1071&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simoons 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8597&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8597&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8599&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8599&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8601&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8601&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8603&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8603&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8605&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8605&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s441&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2450&quot; doc_sec_id=&quot;s2450&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13347&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13347&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2511&quot; doc_sec_id=&quot;s2511&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13532&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13532&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2629&quot; doc_sec_id=&quot;s2629&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13888&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13888&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2630&quot; doc_sec_id=&quot;s2630&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13891&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13891&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2754&quot; doc_sec_id=&quot;s2754&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14269&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14269&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2755&quot; doc_sec_id=&quot;s2755&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14272&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14272&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2820&quot; doc_sec_id=&quot;s2820&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14469&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14469&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2881&quot; doc_sec_id=&quot;s2881&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14654&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14654&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1072&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tamburino 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8608&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8608&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8610&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8610&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8612&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8612&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8614&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8614&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8616&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8616&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s447&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2452&quot; doc_sec_id=&quot;s2452&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13353&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13353&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2513&quot; doc_sec_id=&quot;s2513&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13538&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13538&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2633&quot; doc_sec_id=&quot;s2633&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13900&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13900&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2634&quot; doc_sec_id=&quot;s2634&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13903&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13903&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2758&quot; doc_sec_id=&quot;s2758&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14281&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14281&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2759&quot; doc_sec_id=&quot;s2759&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14284&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14284&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2822&quot; doc_sec_id=&quot;s2822&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14475&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14475&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2883&quot; doc_sec_id=&quot;s2883&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14660&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14660&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1073&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TOPSTAR 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8619&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8619&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8621&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8621&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8623&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8623&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8625&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8625&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8627&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8627&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s455&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2451&quot; doc_sec_id=&quot;s2451&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13350&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13350&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2512&quot; doc_sec_id=&quot;s2512&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13535&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13535&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2631&quot; doc_sec_id=&quot;s2631&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13894&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13894&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2632&quot; doc_sec_id=&quot;s2632&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13897&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13897&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2756&quot; doc_sec_id=&quot;s2756&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14275&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14275&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2757&quot; doc_sec_id=&quot;s2757&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14278&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14278&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2821&quot; doc_sec_id=&quot;s2821&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14472&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14472&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2882&quot; doc_sec_id=&quot;s2882&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14657&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14657&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1074&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yan 2009&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8630&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8630&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8632&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8632&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8634&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8634&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8636&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8636&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8638&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8638&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s461&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2453&quot; doc_sec_id=&quot;s2453&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13356&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13356&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2514&quot; doc_sec_id=&quot;s2514&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13541&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13541&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2635&quot; doc_sec_id=&quot;s2635&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13906&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13906&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2636&quot; doc_sec_id=&quot;s2636&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13909&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13909&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2760&quot; doc_sec_id=&quot;s2760&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14287&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14287&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2761&quot; doc_sec_id=&quot;s2761&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14290&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14290&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2823&quot; doc_sec_id=&quot;s2823&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14478&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14478&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2884&quot; doc_sec_id=&quot;s2884&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14663&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14663&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1075&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zhang 2011&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8641&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8641&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8643&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8643&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8645&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8645&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8647&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8647&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8649&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8649&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s467&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Bias&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr id=&quot;s2454&quot; doc_sec_id=&quot;s2454&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13181&quot; class=&quot;fixedcell&quot;&gt;Random sequence generation (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13359&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13359&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2515&quot; doc_sec_id=&quot;s2515&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13366&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment (selection bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13544&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13544&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2637&quot; doc_sec_id=&quot;s2637&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13912&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13912&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2638&quot; doc_sec_id=&quot;s2638&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13551&quot; class=&quot;fixedcell&quot;&gt;Blinding (performance bias and detection bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13915&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13915&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2762&quot; doc_sec_id=&quot;s2762&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Primary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14293&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14293&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2763&quot; doc_sec_id=&quot;s2763&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f13932&quot; class=&quot;fixedcell&quot;&gt;Incomplete outcome data (attrition bias) (Secondary)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14296&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14296&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2824&quot; doc_sec_id=&quot;s2824&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14303&quot; class=&quot;fixedcell&quot;&gt;Selective reporting (reporting bias)&lt;/td&gt;&lt;td doc_fld_id=&quot;f14481&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14481&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr id=&quot;s2885&quot; doc_sec_id=&quot;s2885&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f14488&quot; class=&quot;fixedcell&quot;&gt;Other bias&lt;/td&gt;&lt;td doc_fld_id=&quot;f14666&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f14666&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s21&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1076&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ACUITY 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8652&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8652&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1077&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ADVANCE MI 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8655&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8655&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1078&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alexander 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8658&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8658&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1079&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Azar 2010&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8661&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8661&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1080&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Batyraliev 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8664&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8664&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1081&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bellandi 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8667&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8667&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1082&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bertrand 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8670&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8670&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1083&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blankenship 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8673&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8673&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1084&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;BOCHUM 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8676&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8676&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1085&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Boehrer 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8679&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8679&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1086&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brener 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8682&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8682&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1087&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cannon 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8685&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8685&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1088&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Claeys 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8688&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8688&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1089&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CLEAR PLATELETS 1b 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8691&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8691&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1090&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CLOTILDA 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8694&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8694&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1091&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Costantini 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8697&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8697&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1092&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cutlip 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8700&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8700&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1093&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EARLY-ACS 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8703&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8703&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1094&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ELISA 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8706&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8706&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1095&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ellis 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8709&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8709&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1096&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Emre 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8712&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8712&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1097&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ERAMI 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8715&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8715&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1098&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ercan 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8718&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8718&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1099&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EVEREST 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8721&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8721&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1100&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ghaffari 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8724&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8724&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1101&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;GRAPE 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8727&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8727&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1102&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gunasekara 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8730&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8730&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1103&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;GUSTO V 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8733&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8733&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1104&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hamm 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8736&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8736&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1105&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hamza 2011&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8739&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8739&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1106&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanefeld 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8742&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8742&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1107&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Heeschen 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8745&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8745&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1108&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;HORIZONS-AMI 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8748&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8748&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1109&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;IMPACT-AMI 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8751&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8751&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1110&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;INTAMI 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8754&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8754&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1111&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-REACT 4&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8757&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8757&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1112&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ji 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8760&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8760&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1113&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8763&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8763&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1114&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1998a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8766&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8766&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1115&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1998b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8769&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8769&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1116&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kleiman 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8772&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8772&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1117&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Klootwijk 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8775&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8775&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1118&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Krause 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8778&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8778&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1119&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lefkovits 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8781&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8781&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1120&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lenderink 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8784&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8784&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1121&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lincoff 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8787&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8787&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1122&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahaffey 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8790&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8790&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1123&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mak 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8793&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8793&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1124&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McClure 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8796&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8796&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1125&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McElwee 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8799&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8799&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1126&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Miller 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8802&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8802&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1127&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mockel 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8805&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8805&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1128&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morrow 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8808&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8808&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1129&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Muller 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8811&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8811&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1130&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Murdock 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8814&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8814&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1131&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Narins 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8817&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8817&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1132&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Neumann 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8820&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8820&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1133&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Newby 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8823&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8823&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1134&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Newby 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8826&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8826&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1135&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okmen 2004&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8829&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8829&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1136&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okmen 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8832&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8832&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1137&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;On-TIME 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8835&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8835&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1138&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARADIGM 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8838&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8838&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1139&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARAGON-B 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8841&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8841&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1140&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pels 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8844&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8844&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1141&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peng 2009&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8847&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8847&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1142&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Petronio 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8850&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8850&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1143&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PROLOG 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8853&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8853&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1144&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rakowski 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8856&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8856&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1145&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;RELAx-AMI 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8859&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8859&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1146&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ren 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8862&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8862&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1147&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ReoPro-BRIDGING 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8865&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8865&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1148&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;REPLACE-2 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8868&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8868&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1149&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roe 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8871&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8871&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1150&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shen 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8874&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8874&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simpfendorfer 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8877&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8877&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1152&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SPEED P-St 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8880&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8880&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1153&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steen 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8883&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8883&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1154&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;STOPAMI 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8886&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8886&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1155&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;STOPAMI-2 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8889&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8889&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1156&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Svensson 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8892&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8892&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1157&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SYMPHONY 2 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8895&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8895&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1158&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TAMI-8 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8898&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8898&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1159&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TARGET 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8901&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8901&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1160&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thiele 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8904&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8904&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1161&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TIGER-PA 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8907&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8907&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1162&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TIMI 14 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8910&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8910&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1163&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TIMI 15A 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8913&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8913&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1164&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TITAN-TIMI 34 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8916&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8916&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1165&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valgimigli 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8919&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8919&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1166&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van den Brand 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8922&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8922&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1167&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van den Merkhof 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8925&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8925&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1168&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wong 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8928&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8928&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1169&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zajdel 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8931&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8931&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1170&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zeymer 2008&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8934&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8934&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1171&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zhao 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f8937&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8937&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s22&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1172&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gasior 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f8940&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8940&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f8942&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8942&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f8944&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8944&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8946&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8946&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th readonly=&quot;true&quot; width=&quot;25%&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f8948&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f8948&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s23&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s25&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of findings tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1173&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Main results for the primary outcomes&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1174&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Main results for the secondary outcomes&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1175&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 Main results for safety outcomes&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s26&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1176&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Summary assessment of the risk of bias (allocation concealment and blinding) for major endpoints within and across PCI studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1177&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Summary assessment of the risk of bias (allocation concealment and blinding) for major endpoints within and across studies on initial treatment of patients with NSTEACS&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s28&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;References to studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s29&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s62&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3T/2R 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s65&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119(25):3215-22.&lt;/h4&gt;&lt;p&gt;19528337&lt;br&gt;English&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s67&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valgimigli M, Campo G, de Cesare N, Vranckx P, Hamon M, Angiolillo DJ, et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. Cardiovascular Drugs and Therapy 2008;22(4):313-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s70&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ACE 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s73&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antoniucci D, Migliorini A, Parodi G, Valenti R, Rodriguez A, Hempel A, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004;109(14):1704-6.&lt;/h4&gt;&lt;p&gt;One-year results of the ACE trial&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s75&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. Journal of the American College of Cardiology 2003;42:1879-85.&lt;/h4&gt;&lt;p&gt;C10. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.[see comment]. Journal of the American College of Cardiology 2003;42:1879-1885.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s78&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ADMIRAL 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s81&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Montalescot G, Barragan P, Wittemberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. New England Journal of Medicine 2001;344(25):1895-903.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s83&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Montalescot G. The ADMIRAL study: abciximab with percutaneous transluminal coronary angioplasty and stent in acute myocardial infarction. American Heart Journal 1999;138:178-9.&lt;/h4&gt;&lt;p&gt;1999;138:178-179.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s85&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Montalescot G. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. European Heart Journal 2005;26:2520-3.&lt;/h4&gt;&lt;p&gt;3-year results of the ADMIRAL study&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s88&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ADVANCE 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s91&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. Journal of the American College of Cardiology 2004;44(1):14-9.&lt;/h4&gt;&lt;p&gt;Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004;44:14-19.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s94&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ASIAD 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s97&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chen WH, Kaul U, Leung SK, Lau YK, Tan HC, Leung AW, et al. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. The Journal of Invasive Cardiology 2005;17(10):534-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s100&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ASSIST 2009&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s103&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Le May M R, Wells G A, Glover C A, So D Y, Froeschl M, Marquis J F, et al. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circulation: Cardiovascular Interventions 2009;2:330-8.&lt;/h4&gt;&lt;p&gt;INCLUDED&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s106&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bhattacharya 2010&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s109&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bhattacharya R, Pani A, Dutta D, Basak S, Gangopadhyay S, Das Baksi S, Sarkar RN. Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective. Singapore Med J 2010;51(7):558-564.&lt;/h4&gt;&lt;p&gt;New study 2013&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s112&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;BRAVE-3 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s115&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mehilli J, Kastrati A, Schulz S, Fr&amp;#252;ngel S, Nekolla SG, Moshage W, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009;119(14):1933-40.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s117&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schulz S, Birkmeier K A, Ndrepepa G, Moshage W, Dotzer F, Huber K, et al. One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clinical Research in Cardiology 2010;99:795-802.&lt;/h4&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s120&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CADILLAC 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s123&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stone G, Grines CL, Cox DA, Garc&amp;#237;a E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. New England Journal of Medicine 2002;346(13):957-66.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s125&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003;108(11):1316-23.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s128&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CANADIAN 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s131&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94(5):899-905.&lt;/h4&gt;&lt;p&gt;Unstable angina, Events at 30 days.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s134&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CAPTURE 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s137&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simoons ML, Rutsch W, Vahanian A, Adgey J, Maseri A, Vassanelli C, et al. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349(9063):1429-35.&lt;/h4&gt;&lt;p&gt;Unstable angina, Events at 30 days.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s140&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chen 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s143&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chinese Medical Journal (Taipei) 2000;63(1):8-15.&lt;/h4&gt;&lt;p&gt;C55. Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chin Med J 2000;63:8-15.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s146&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Claeys 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s149&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Claeys MJ, Van Der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, Van Der GP, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. European Heart Journal 2005;26(6):567-75.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s152&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CLEAR PLATELETS-2 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s155&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, DiChiara J, Antonino MJ, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. Journal of the American College of Cardiology 2009;53(8):648-57.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s158&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cuisset 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s161&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.[see comment]. JACC: Cardiovascular Interventions 2008;1(6):649-53.&lt;/h4&gt;&lt;p&gt;19463379&lt;br&gt;English&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s164&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;DANTE 2004&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s167&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Staico R, Feres F, Centemero M, Tanajura LF, Abizaid A, Pinto I, Maldonado G, Seixas A, Costa MA, Paes A, Mintz G, Sousa E. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial. Circulation 2004;109:861-866.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s170&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Luca 2005&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s173&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Luca L, De Persio G, Minati M, Iacoboni C, Fedele F. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting. American Heart Journal 2005;149:1135.e11-1135.e18.&lt;/h4&gt;&lt;p&gt;This is not a RCT on the effects of abciximab in diabetic patients with or without metabolic control identified retrospectively&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s176&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Luca 2008&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s179&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Luca L, Sardella G, De Persio G, Petrolini A, Fedele F. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study. Acute Card Care 2008;10:93-99.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s182&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ELISA-2 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s185&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rasoul S, Ottervanger JP, de Boer M, Miedema K, Hoorntje JCA, Gosselink M, et al. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial. European Heart Journal 2006;27:1401-07.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s188&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EPIC 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s191&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine 1994;330(14):956-61.&lt;/h4&gt;&lt;p&gt;PTCA-STENT&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s193&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343(8902):881-6.&lt;/h4&gt;&lt;p&gt;Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343(8902):881-6.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s195&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-84.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s198&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EPILOG 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s201&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999;99:1951-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s203&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Topol EJ, Califf RM, Lincoff AM, Tcheng JE, Cabot CF, Weisman HF, et al. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. New England Journal of Medicine 1997;336(24):1689-96.&lt;/h4&gt;&lt;p&gt;PTCA-STENT. Events at 30 days&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s206&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EPISTENT 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s209&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. New England Journal of Medicine 1999;341(5):319-27.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s211&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Topol EJ, Lincoff AM, Califf RM, Tcheng JE, Cohen EA, Kleiman NS, et al. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352(9122):87-92.&lt;/h4&gt;&lt;p&gt;Stent Events at 30 days&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s213&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. Lancet 1999;354(9195):2019-24.&lt;/h4&gt;&lt;p&gt;One-year results of the EPISTENT trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s216&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ERASER 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s219&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999;100(8):799-806.&lt;/h4&gt;&lt;p&gt;PTCA-STENT in-hospital and 6-month&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s222&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ESPRIT 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s225&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287(5):618-21.&lt;/h4&gt;&lt;p&gt;ESPIT study. Results at 12 months.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s227&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Shea JE, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kit MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial. JAMA 2001;285(19):2468-73.&lt;/h4&gt;&lt;p&gt;Secondary reference. Events at 6 months&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s229&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tcheng J.E. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356(9247):2037-44.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fu 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chinese Medical Journal 2008;121(6):522-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s238&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Galassi 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s241&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Galassi AR, Russo G, Nicosia A, Tamburino C, Foti R, Rodi G, et al. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome. Cardiologia 1999;44(7):639-45.&lt;/h4&gt;&lt;p&gt;C99. Galassi AR, Russo G, Nicosia A, et al. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome. Cardiologia 1999;44:639-645.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s244&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;GUSTO-IV 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s247&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. Circulation 2003;107(3):437-42.&lt;/h4&gt;&lt;p&gt;One-year results of the GUSTO-IV trial&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s249&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simoons ML, The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet 2001;357(9272):1915-24.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s252&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;IMPACT 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s255&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995;91(8):2151-7.&lt;/h4&gt;&lt;p&gt;PTCA-Stent Events at 30 days&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s258&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;IMPACT-II 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s261&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kleiman NS. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology 1997;80(4A):29B-33B.&lt;/h4&gt;&lt;p&gt;Safety endpoints of the IMPACT II trial&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tcheng JE, Lincoff AM, Sigmon KN, Lee KL, Kitt MM, Califf RM, et al. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349(9063):1422-8.&lt;/h4&gt;&lt;p&gt;PTCA-Stent. Events at 30 days&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s266&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;INSTANT 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Biondi-Zoccai G, Valgimigli M, Margheri M, Marzocchi A, Lettieri C, Stabile A, et al. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. American Heart Journal 2012;163:835.e1-7.&lt;/h4&gt;&lt;p&gt;INCLUDED&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s272&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-2 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s275&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, et al. Effect of glycoprotein IIb/IIIa receptor blockade with Abciximab on clinical and angiographic reestenosis after replacement of coronary stent following an acute myocardial infarction. Journal of the American College of Cardiology 2000;35:915-21.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s278&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-REACT 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s281&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kastrati A, Mehilli J, Sch&amp;#252;hlen H, Dirschinger J, Dotzer F, Ten Berg JM, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. New England Journal of Medicine 2004;350(3):232-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s283&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sch&amp;#246;mig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Sxh&amp;#252;hlen H, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. European Heart Journal 2005;26:1379-84.&lt;/h4&gt;&lt;p&gt;Secondary reference. Outcomes at 1 year&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s286&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-REACT 2 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s289&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kastrati A, Mehilli J, Neumann FJ, Dotzer F, Ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s291&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ndrepepa G, Kastrati A, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. European Heart Journal 2008;29:455-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s294&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-SMART-2 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hausleiter J, Kastrati A, Mehilli J, Sch&amp;#252;hlen H, Pache J, Dotzer F, et al. A randomized trial comparing phosphorylcholine-coated atenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. Journal of Internal Medicine 2004;256:388-97.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s300&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-SWEET 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-35.&lt;/h4&gt;&lt;p&gt;E114. Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-3635.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s306&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ITTI 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s309&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Liu CP, Lin MS, Chiu YW, Lee JK, Hsu CN, Hung CS, Kao HL. Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: Results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial. Int J Cardiol 2012;156:174-179.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s312&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;JEPPORT 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s315&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nakagawa Y, Nobuyoshi M, Yamaguchi T, Meguro T, Yokoi H, Kimura T, et al. Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circulation Journal : Official Journal of the Japanese Circulation Society 2009;73(1):145-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s318&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Juergens 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s321&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Juergens CP, White HD, Belardi JA, Macaya C. Soler-Soler J. Meyer BJ, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clinical Therapeutics 2002;24(8):1332-44.&lt;/h4&gt;&lt;p&gt;C149. Juergens CP, White HD, Belardi JA, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clinical Therapeutics 2002;24:1332-1344.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s324&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s327&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Journal of the American College of Cardiology 1996;27(3):536-42.&lt;/h4&gt;&lt;p&gt;Dose-ranging study, in-hospital events, low statistical power&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s330&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kim 2005&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s333&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kim J H, Jeong M H, Rhew J Y, Lim J H, Yun K H, Kim K H, et al. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. Circulation Journal 2005;69:159-64.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s336&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurowski 2005&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s339&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurowski V, Toelg R, Jain D, Richter C, Wiegand UKH, Richardt G, Khattab AA. Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts. Am J Cardiol 2005;96:681-684.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s342&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;On-TIME 2 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s345&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van't Hof AW, ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008;372(9638):537-46.&lt;/h4&gt;&lt;p&gt;Comment in: Lancet. 2008 Aug 16;372(9638):509-10. PMID: 18707968&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s348&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;OPTIMIZE-IT 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s351&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, et al. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study. Journal of cardiovascular medicine (Hagerstown, Md.) 2009;10(3):245-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s354&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARAGON A 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s357&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Moliterno DJ. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998;97(24):2386-95.&lt;/h4&gt;&lt;p&gt;Unstable angina. Events at 30 days&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s360&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARAGON B 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s363&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Global Organization Network (PARAGON-B) Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002;105(3):316-21.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s365&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. American Heart Journal 2000;139:563-6.&lt;/h4&gt;&lt;p&gt;Design of the PARAGON B study&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s368&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRACTICE 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s371&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Durand E, Hamm C, Macaya CM, Georges JL, Coste P, Wolf JE, Slama MS, Husted SE, Mosseri M, Lafont A. A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy. Eurointervention 2007;3(2):228-34.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s374&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Prati 2005&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s377&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Prati F, Kwiatkowski P, Caroselli C, Imola F, Manzoli A, Fouad T, et al. Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study. Catheterization &amp;amp; Cardiovascular Interventions 2005;66:165-9.&lt;/h4&gt;&lt;p&gt;Small study on the effects of abciximab on coronary microcirculation&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s380&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRIDE 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s383&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (The PRIDE Study). American Journal of Cardiology 2001;88:1097-1102.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s386&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRISM 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s389&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bazzino O, Aylward P, Hains A, Slany J, Steinbach K, Van de WF, et al. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. New England Journal of Medicine 1998;338(21):1498-505.&lt;/h4&gt;&lt;p&gt;Unstable angina&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s392&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PRISM Plus 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s395&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bazzino O, Barrero C, Garre L, Sosa A, Aylward P, Slany J, et al. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine 1998;338(21):1488-97.&lt;/h4&gt;&lt;p&gt;Bazzino O, Barrero C, Garre L, Sosa A, Aylward P, Slany J et al. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338(21):1488-97.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s398&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PURSUIT 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s401&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harrington RA, Lincoff AM, Berdan LG, MacAulay C, Kint PP, Mahaffey KW, et al. Glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. In: Circulation. Vol. 98. 1998:I-359.&lt;/h4&gt;&lt;p&gt;Secondary reference. Events at 6 months.&lt;br&gt;Abstract from the Congress of the American Heart Association&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s403&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology 1997;80:34B-38B.&lt;/h4&gt;&lt;p&gt;Design of the PURSUIT trial&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s405&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Topol E, Califf R, Simoons M, Diaz R, Paolasso E, Klein W, et al. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine 1998;339(7):436-43.&lt;/h4&gt;&lt;p&gt;Primary reference. Events at 30 days&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s408&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;RAPPORT 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s411&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98(8):734-41.&lt;/h4&gt;&lt;p&gt;PTCA-STENT&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s414&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;RESTORE 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s417&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial.Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Journal of the American College of Cardiology 1998;32(1):28-34.&lt;/h4&gt;&lt;p&gt;Secondary publication. Six-minth outcomes&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s419&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanrath P, vom DJ, Paulus O, Heyndrickx G, Sosa JA, Muller D, et al. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96(5):1445-53.&lt;/h4&gt;&lt;p&gt;PCI-STENT&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s422&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schulman 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s425&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996;94(9):2083-9.&lt;/h4&gt;&lt;p&gt;Unstable angina. Events at 30 days&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s428&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shen 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s431&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, et al. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coronary Artery Disease 2008;19(4):271-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s434&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simoons 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s437&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simoons ML, de Boer MJ, van Den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation 1994;89(2):596-603.&lt;/h4&gt;&lt;p&gt;PTCA-STENT. EVENTS in-hospital&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s439&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van Den Brand MJ, Simoons ML, de Boer MJ, van Miltenburg A, van der Wieken LR, de Feyter PJ. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3). European Heart Journal 1995;16(Suppl L):36-42.&lt;/h4&gt;&lt;p&gt;Duplicate publication of Simoons 1994&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s442&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tamburino 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s445&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tamburino C, Russo G, Nicosia A, Galassi A, Foti R, Scriffignano V, et al. Prophylactic abciximab in elective coronary stenting: results of a randomized trial. Journal of Invasive Cardiology 2002;14(2):72-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s448&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TOPSTAR 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s451&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR Trial). Journal of the American College of Cardiology 2002;40(4):662-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s453&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lengenfelder B, Stoerk S, Boes L, Strotmann J, Ertl G, Voelker W, Bonz AW. Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial. J Invasive Cardiol 2011;23(4):128-32.&lt;/h4&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s456&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yan 2009&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s459&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yan Z, Zhou Y, Zhao Y, Li Y, Nie X, Zhou Z, et al. Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes. Clin Cardiol 2009;32:E40-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s462&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zhang 2011&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s465&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zhang Y X, Lu C Y, Zhou S H, Xue Q, Gao L, Tian J W, et al. [Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue 2011;23:727-30.&lt;/h4&gt;&lt;p&gt;NOT FOUND&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s30&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s468&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ACUITY 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s471&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. New England Journal of Medicine 2006;355:2203-16.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s473&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ADVANCE MI 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s476&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roe MT. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. American Heart Journal 2005;150(1):116-122.&lt;/h4&gt;&lt;p&gt;Facilitated thombolysis (eptifibatide + tenecteplase) vs. facilitated PCI (eptifibatide) in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s478&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alexander 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s481&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology 1999;83(8):1147-51.&lt;/h4&gt;&lt;p&gt;Substudy of the PURSUIT trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s483&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Azar 2010&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s486&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Azar R R, Badaoui G, Sarkis A, Kassab R, Salame E, Aboujaoude S, et al. Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention. Clinical Cardiology 2010;33:E14-9.&lt;/h4&gt;&lt;p&gt;EXCLUDED&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s488&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Batyraliev 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s491&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Batyraliev TA, Fettser DV, Vural A, Pershukov IV, Preobrazhenskii DV, Avsar O, et al. [Safety and efficacy of the use of glycoprotein IIb/IIIa inhibitors in the invasive treatment of patients with ST-elevation acute coronary syndrome]. [Russian]. Kardiologiia 2009;49(6):4-9.&lt;/h4&gt;&lt;p&gt;19656087&lt;br&gt;Russian&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s493&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bellandi 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s496&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Internal Journal of Cardiology 2006;108:36-42.&lt;/h4&gt;&lt;p&gt;Comparison of Abciximab administered in the emergency room vs. in the catheterization laboratory&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s498&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bertrand 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s501&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bertrand OF, De Larochelli&amp;#352;re R, Rod&amp;#8218;s-Cabau J, Proulx G, Gleeton O, Nguyen CM, et al. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006;114(24):2636-43.&lt;/h4&gt;&lt;p&gt;Comment in: Circulation. 2006 Dec 12;114(24):2578-80. PMID: 17159072&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s503&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bertrand OF, Faurie B, Larose E, Nguyen CM, Gleeton O, Dery JP, et al. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents. Journal of Invasive Cardiology 2008;20(3):99-104.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s505&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blankenship 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s508&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology 1998;81(1):36-40.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s510&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;BOCHUM 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s513&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanefeld C, Sirtl C, Spiecker M, Bojara W, Grewe PH, Lawo T, et al. Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study. Chest 2004;126(3):935-41.&lt;/h4&gt;&lt;p&gt;M214. Open-label study. Pre-hospital Eptifibatide vs Control in even/uneven days. 365 patients with chest pain suggestive of ACS. No ECG performed; 60% had a confirmed MI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s515&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Boehrer 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s518&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology 1994;74(11):1166-70.&lt;/h4&gt;&lt;p&gt;A substudy of the EPIC trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s520&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brener 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s523&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brener SJ, Barr LA, Burchenal JE, Wolski KE, Effron MB, Topol EJ. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology 1999;84(6):728-30.&lt;/h4&gt;&lt;p&gt;A substudy of the RAPPORT trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s525&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cannon 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s528&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation 1998;97(4):340-9.&lt;/h4&gt;&lt;p&gt;Trial with an oral GP IIb/IIIa antagonist (TIMI 12)&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s530&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Claeys 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s533&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Claeys MJ, Van Der Planken MG, Michiels JJ, Vertessen F, Dilling D, Bosmans JM, et al. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagulation &amp;amp; Fibrinolysis 2002;13(4):283-8.&lt;/h4&gt;&lt;p&gt;C60&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s535&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CLEAR PLATELETS 1b 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s538&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. Journal of the American College of Cardiology 2006;48(11):2186-91.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s540&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CLOTILDA 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s543&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leoncini M, Toso A, Maioli M, Bellandi F, Badia T, Politi A, et al. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. American Heart Journal 2005;150(3):401.e9-401.e14.&lt;/h4&gt;&lt;p&gt;Comparison of Tirofiban vs. provisional abciximab.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s545&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Costantini 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s548&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Journal of the American College of Cardiology 2004;44(2):305-312.&lt;/h4&gt;&lt;p&gt;C68. Substudy of the CADILLAC Trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s550&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cutlip 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s553&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. American Journal of Cardiology 2003;92(8):977-80.&lt;/h4&gt;&lt;p&gt;C75. Tirofiban vs Control in the e,ergency room followed by any IIb/IIIa inhibitor during PCI a median of 90 min later&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s555&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EARLY-ACS 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s558&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-90.&lt;/h4&gt;&lt;p&gt;Study design and rationale of the EARLY-ACS trial&lt;br&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s560&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ELISA 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s563&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van 't Hof AW, de Vries ST, Dambrink JH, Miedema K, Suryapranata H, Hoorntje JCA, et al. A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes. European Heart Journal 2003;24(15):1401-1405.&lt;/h4&gt;&lt;p&gt;C337. The ELISA pilot study. Early (&amp;lt;6 h) angiography without Tirofiban vs late angiography with Tirofiban&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s565&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ellis 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s568&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ellis SG, Tendera M, de Belder MA, Van Boven AJ, Widimsky P, Janssens L, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. The New England Journal of Medicine 2008;358(21):2205-17.&lt;/h4&gt;&lt;p&gt;Comment in: N Engl J Med. 2008 May 22;358(21):2277-9. PMID: 18499572&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s570&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Emre 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s573&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Emre A, Ucer E, Yesilcimen K, Bilsel T, Oz D, Sayar N, et al. Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting. Cardiology 2006;106(4):264-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s575&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ERAMI 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s578&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp;amp; Interventions 2006;68(2):218-24.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s580&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ercan 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s583&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ercan E, Tengiz I, Duman C, Onbasili OA, Baris N. Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction. American Heart Journal 2004;147:E1.&lt;/h4&gt;&lt;p&gt;C93. Small study looking at differences in CRP at 48-72 h. No clinical events reported.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s585&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EVEREST 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s588&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. Journal of the American College of Cardiology 2006;47:522-8.&lt;/h4&gt;&lt;p&gt;Comparison of Tirofiban administered in the CCU vs. in the catheterization laboratory&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s590&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ghaffari 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s593&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, et al. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology 1998;82(1):7-12.&lt;/h4&gt;&lt;p&gt;Substudy of the EPILOG trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s595&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;GRAPE 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s598&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van den Merkhof LF, Zijlstra F, Olsson H, Grip L, Veen G, Bar FW, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. Journal of the American College of Cardiology 1999;33(6):1528-32.&lt;/h4&gt;&lt;p&gt;The GRAPE pilot study performed in 60 patients with STEMI treated with primary PCI without a control group. Not a randomized study&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s600&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gunasekara 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s603&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gunasekara AP, Walters DL, Aroney CN. Comparison of abciximab with 'high-dose' tirofiban in patients undergoing percutaneous coronary intervention. International Journal of Cardiology 2006;109:16-20.&lt;/h4&gt;&lt;p&gt;A non-randomized comparison of Abciximab vs. high-dose Tirofiban&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s605&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;GUSTO V 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s608&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;The GUSTO Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein iib/IIIa inhibition:the GUSTO V randomised trial. Lancet 2001;357:1905-14.&lt;/h4&gt;&lt;p&gt;Trial comparing the addition of a GP IIb/IIIa antagonist to the fibrinolytic treatment in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s610&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hamm 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s613&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. New England Journal of Medicine 1999;340(21):1623-9.&lt;/h4&gt;&lt;p&gt;Substudy of the CAPTURE trial. Differential effects of Abciximab in patients with refractory angina according to basal troponin levels&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s615&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hamza 2011&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s618&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hamza M. Effect of high loading dose of clopidogrel vs glycoprotein llb/llla receptor antagonist in management of patients with non-ST-segment elevation acute coronary syndrome. EuroIntervention 2011;7:M174.&lt;/h4&gt;&lt;p&gt;AsiaPCR/SingLIVE 2011 Singapore Singapore. Conference Start: 20110113 Conference End: 20110115. Conference Publication: (var.pagings)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;NOT FOUND&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s620&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanefeld 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s623&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanefeld C, Segbers S, Sirtl C, Lemke B, Mugg A. Pre-hospital therapy of acute coronary syndrome with the glycoprotein-IIb/IIIa receptor antagonist Eptifibatide - Pilot study Bochum [Prahospitale Therapie des akuten Koronarsyndroms mit dem Glykoprotein-IIb/IIIa-Rezeptor-Antagonisten Eptifibatide - Pilotstudie Bochum]. Zeitschrift F&amp;#252;r Kardiologie 2002;91(Suppl 5):V/10.&lt;/h4&gt;&lt;p&gt;C127. Pilot study of the Bochum trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s625&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Heeschen 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s628&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354(9192):1757-62.&lt;/h4&gt;&lt;p&gt;Substudy of the PRISM trial. Effects of Tirofiban in patients with US/NSTEMI according to baseline troponon levels&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s630&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;HORIZONS-AMI 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2900&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s633&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. The New England Journal of Medicine 2008;358(21):2218-30.&lt;/h4&gt;&lt;p&gt;Comment in: ACP J Club. 2008 Sep 16;149(3):11. PMID: 18783187. Comment in: N Engl J Med. 2008 May 22;358(21):2280-2. PMID: 18499573&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s635&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;IMPACT-AMI 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s638&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997;95:846-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s640&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;INTAMI 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s643&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. European Heart Journal 2005;26:1971-7.&lt;/h4&gt;&lt;p&gt;Comparison of eptifibatide administered in the emergency room vs. in the cath lab in patients with STEMI submitted to primary PCI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s645&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ISAR-REACT 4&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s648&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Sch&amp;#246;mig A, Berger PB, Mehilli J, for the ISAR-REACT 4 Trial Investigators. Abciximab and Heparin versus Bivalirudin for Non-ST-Elevation Myocardial Infarction. N Engl J Med 2011;365:1980-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s650&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ji 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s653&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ji Z G, Liu H B. Clinical efficacy and short-term prognosis of tirofiban treatment in different duration combined with percutaneous coronary intervention in acute st segment elevation myocardial infarction. American Journal of Cardiology 2012;1):7S.&lt;/h4&gt;&lt;p&gt;17th Annual Interventional Vascular Therapeutics Angioplasty Summit-Transcatheter Cardiovascular Therapeutics Asia Pacific Symposium, TCTAP 2012 Seoul South Korea. Conference Start: 20120424 Conference End: 20120427. Conference Publication: (var.pagings). 109 (7 SUPPL&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;NOT FOUND&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s655&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s658&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96(4):1117-21.&lt;/h4&gt;&lt;p&gt;Study with an oral GP IIb/IIIa antagonist&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s660&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1998a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s663&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998;98(13):1268-78.&lt;/h4&gt;&lt;p&gt;Study with an oral GP IIb/IIIa antagonist&lt;br&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s665&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes 1998b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s668&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation 1998;97(9):857-64.&lt;/h4&gt;&lt;p&gt;Substudy of the EPILOG trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s670&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kleiman 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s673&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998;97(19):1912-20.&lt;/h4&gt;&lt;p&gt;Substudy of the EPILOG trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s675&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Klootwijk 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s678&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998;98(14):1358-64.&lt;/h4&gt;&lt;p&gt;Substudy of the CAPTURE trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s680&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Krause 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s683&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Krause M, Rutsch W, Franke O, Langemann C, Dreysse S, Riess H. Fradafiban, a non-peptide GP IIB/IIA antagonist during elective coronary angioplasty: safety and antiplatelet effects. Annals of Hematology 1996;72:A53.&lt;/h4&gt;&lt;p&gt;C175. Abstract from a Congress. A phase II RCT with 3 escalating doses of i.v. Fradafiban in 65 patients with stable angina submitted to elective PTCA.&lt;br&gt;Aim: Safety and antiplatelet effects. No clinical events reported&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s685&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lefkovits 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s688&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology 1996;77(12):1045-51.&lt;/h4&gt;&lt;p&gt;Substudy of the EPIC trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s690&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lenderink 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s693&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, et al. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.[see comment]. European Heart Journal 2003;24(1):77-85.&lt;/h4&gt;&lt;p&gt;C186. Substudy of the CAPTURE trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s695&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lincoff 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s698&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology 1997;30(1):149-56.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s700&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahaffey 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s703&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999;99(18):2371-7.&lt;/h4&gt;&lt;p&gt;Substudy of the PURSUIT trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s705&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mak 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s708&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology 1997;80(8):985-8.&lt;/h4&gt;&lt;p&gt;Substudy of the EPIC trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s710&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McClure 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s713&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999;99(22):2892-900.&lt;/h4&gt;&lt;p&gt;Substudy of the PURSUIT trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s715&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McElwee 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s718&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McElwee NE, Johnson ER. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. American Journal of Cardiology 1997;80(4A):39B-43B.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s720&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Miller 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s723&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Miller JM, Smalling R, Ohman EM, Bode C, Betriu A, Kleiman NS, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. American Journal of Cardiology 1999;84(7):779-84.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s725&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mockel 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s728&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mockel M, Bocksch W, Strohm S, Kuhnle Y, Vollert J, Nibbe L, et al. Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: Comparison of prehospital tirofiban versus fibrinolysis before direct PCI. International Journal of Cardiology 2005;103:193-200.&lt;/h4&gt;&lt;p&gt;Comparison of prehospital tirofiban versus fibrinolysis before direct PCI in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s730&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morrow 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s733&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.[see comment]. JAMA 2001;286(19):2405-12.&lt;/h4&gt;&lt;p&gt;C229. Substudy of the TACTICS trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s735&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Muller 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s738&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation 1997;96(4):1130-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s740&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Murdock 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s743&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Murdock DK, Logemann T, Hoffmann MT, Olson KJ, Engelmeier RS. Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with Abciximab: early and six-month outcome. Catheterization &amp;amp; Cardiovascular Diagnosis 1997;42(2):173-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s745&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Narins 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s748&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Narins CR, Miller DP, Califf RM, Topol EJ. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology 1999;33(3):647-53.&lt;/h4&gt;&lt;p&gt;Substudy of the EPIC trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s750&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Neumann 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s753&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98(24):2695-701.&lt;/h4&gt;&lt;p&gt;Small study on primary PCI with stent implantation. Events at 14 days&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s755&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Newby 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s758&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Newby LK. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. American Heart Journal 1999;138(2 Pt 1):210-8.&lt;/h4&gt;&lt;p&gt;Design of the SYMPHONY trial on an oral GP IIb/IIIa antagonist&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s760&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Newby 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s763&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrigton RA, White HD, et al. Benefit of glycoproteoin IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin substudy. Circulation 2001;103:2891-6.&lt;/h4&gt;&lt;p&gt;A substudy of the PARAGON-B study&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s765&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okmen 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s768&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N. Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty. Cardiology 2004;102:18-23.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s770&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okmen 2006&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s773&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N. Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention. Angiology 2006;57(3):273-81.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s775&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;On-TIME 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s778&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.[see comment]. European Heart Journal 2004;25(10):837-46.&lt;/h4&gt;&lt;p&gt;C336. Pre-hospital Tirofiban vs hospital (median delay 59 m) Tirofiban during primary PCI in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s780&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARADIGM 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s783&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harrington RA, Van de WF, Luyten A, Potkin B, McIntosh-Yellin N, Morgan C, et al. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. Journal of the American College of Cardiology 1998;32(7):2003-10.&lt;/h4&gt;&lt;p&gt;Trial on GP IIb/IIIa blockers in STEMI patients trerated with thrombolytics&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s785&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PARAGON-B 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s788&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrigton RA, White HD, et al. Benefit of glycoproteoin IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin substudy. Circulation 2001;103:2891-6.&lt;/h4&gt;&lt;p&gt;A substudy of the PARAGON-B study&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s790&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pels 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s793&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pels K, Schr&amp;#8221;der J, Witzenbichler B, Mller D, Morguet A, Pauschinger M, et al. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention. European journal of emergency medicine : official journal of the European Society for Emergency Medicine 2008;15(6):324-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s795&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peng 2009&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s798&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peng J J, Ma Z M, Ren L H, Ma Z M, Ren L H, Fu G Q, et al. [Effect of tirofiban in acute anterior myocardial infarction patients without ST segment resolution after primary percutaneous coronary intervention]. Zhonghua xin xue guan bing za zhi 2009;37(8):725-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s800&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Petronio 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s803&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. American Heart Journal 2002;143:334-41.&lt;/h4&gt;&lt;p&gt;C263. Rescue PCI in STEMI after thrombolysis&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s805&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PROLOG 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s808&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. American Journal of Cardiology 1997;79(3):286-91.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s810&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rakowski 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s813&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rakowski T, Zalewski J, Legutko J, Bartus S, Rzeszutko L, Dziewierz A, et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. American Heart Journal 2007;153(3):360-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s815&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;RELAx-AMI 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s818&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). Journal of the American College of Cardiology 2007;49(14):1517-24.&lt;/h4&gt;&lt;p&gt;Comment in: Nat Clin Pract Cardiovasc Med. 2007 Oct;4(10):536-7. PMID: 17684480&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s820&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ren 2012&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s823&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ren X N, Wang L F, Wang M S, Xu L. Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. [Chinese]. Chinese Journal of Cardiology 2012;40:131-5.&lt;/h4&gt;&lt;p&gt;EXCLUDED&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s825&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ReoPro-BRIDGING 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s828&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - Results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. European Heart Journal 2004;25(23):2125-33.&lt;/h4&gt;&lt;p&gt;E73. Abciximab at admission versus Abciximab immediately before primary PCI (mean difference 62 min) in patients with ST elevation myocardial infarction&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s830&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;REPLACE-2 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s833&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s835&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roe 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s838&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roe MT, Christenson RH, Ohman EM, Bahr R, Fesmire FM, Storrow A, et al. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. American Heart Journal 2003;146(6):993-998.&lt;/h4&gt;&lt;p&gt;C275. Treatment with Eptifibatide vs Placebo in the Emergency department followed by open-label Eptifibatide 12-24 h later.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s840&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shen 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s843&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shen J, Zhang Q, Zhang RY. [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction]. [Chinese]. Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2007;35(11):1005-9.&lt;/h4&gt;&lt;p&gt;18269820&lt;br&gt;Chinese&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s845&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simpfendorfer 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s848&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96(1):76-81.&lt;/h4&gt;&lt;p&gt;Study on an oral GP IIb/IIIa antagonist&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s850&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SPEED P-St 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s853&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hermann HC, Moliterno DJ, Ohman EM, Sebbins AL, Bode C, Betriu A. Facilitation of early percutaneous coronary intervention after Reteplase with or without abciximab in acute myocardial infarction. Journal of the American College of Cardiology 2000;36:1489-96.&lt;/h4&gt;&lt;p&gt;Thrombolysis in patients with STEMI with or without GP IIb/IIIa antagonist, followed by primary PCI (facilitated PCI)&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s855&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steen 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s858&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Steen H, Lehrke S, Wiegand UK, Merten C, Schuster L, Richardt G, et al. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction. American Heart Journal 2005;149(3):564.&lt;/h4&gt;&lt;p&gt;Comparison of myocardial tissue perfusion with and without Tirofiban in patients with STEMI. No clinical events reported.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s860&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;STOPAMI 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s863&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sch&amp;#246;mic A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. New England Journal of Medicine 2000;343:385-91.&lt;/h4&gt;&lt;p&gt;Primary PCI with stent and abciximab vs. thrombolysis in patients with STEMI&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s865&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schomig A, Schwaiger M, Mehilli J, Neverve J, Pache J, Schricke U, et al. 1-year mortality after stenting with Abciximab or thrombolysis in acute myocardial infarction and prognostic value of myocardial salvage. Results of the STOPAMI study. Zeitschrift Fur Kardiologie 2001;90(Suppl 2):109.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s867&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schricke U, Mehilli J, Neverve J, Ibrahim T, Nekolla S, Blasini R, et al. Myocardial salvage and clinical one-year results in patients with acute anterior myocardial infarction and stent placement with Abciximab or thrombolysis: a STOPAMI sub-group analysis. Zeitschrift Fur Kardiologie 2001;90(Suppl 2):74.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s869&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;STOPAMI-2 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s872&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 2002;359:920-25.&lt;/h4&gt;&lt;p&gt;Primary PCI with stent and abciximab vs. thrombolysis and abciximab in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s874&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Svensson 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s877&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summers KM, Holdford DA, Crouch MA. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention. Pharmacotherapy 2006;26:609-18.&lt;/h4&gt;&lt;p&gt;Thrombolysis vs Facilitated PCI with Abciximab in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s879&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SYMPHONY 2 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s882&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Second SYMPHONY Investigators. Randomized trial of apirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727-33.&lt;/h4&gt;&lt;p&gt;Study on an oral GP IIb/IIIa antagonist&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s884&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TAMI-8 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s887&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. Journal of the American College of Cardiology 1993;22(2):381-9.&lt;/h4&gt;&lt;p&gt;TAMI-8 pilot study on the effects of abciximab in patients with STEMI treated with thrombolytics&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s889&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TARGET 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s892&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine 2001;344:1888-94.&lt;/h4&gt;&lt;p&gt;Trial comparing Abciximab with tirofiban in patients submitted to PCI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s894&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thiele 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s897&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thiele H, Engelmann L, Elsner K, Kappl MJ, Storch WH, Rahimi K, et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. European Heart Journal 2005;26:1956-63.&lt;/h4&gt;&lt;p&gt;Patients with STEMI were randomized to either pre-hospital facilitated fibrinolysis (half-dose reteplase+abciximab) or pre-hospital facilitated fibrinolysis (half-dose reteplase+abciximab) plus PCI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s899&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TIGER-PA 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s902&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107(11):1497-1501.&lt;/h4&gt;&lt;p&gt;C183. Open-label randomization of patients (n=100) with ST segment elevation MI to &amp;quot;early&amp;quot; administration of Tirofiban in the emergency room versus &amp;quot;late&amp;quot; administration in the catheterization laboratory immediately before primary PCI.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s904&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TIMI 14 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s907&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99(21):2720-32.&lt;/h4&gt;&lt;p&gt;Thrombolysis with or without abciximab in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s909&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TIMI 15A 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s912&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giugliano RP, McCabe CH, Sequeira RF, et al.. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. American Heart Journal 2000;140:81-93.&lt;/h4&gt;&lt;p&gt;Study on an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with acute coronary syndromes&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s914&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TITAN-TIMI 34 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s917&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. American Heart Journal 2006;152(4):668-75.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s919&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valgimigli 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s922&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-17.&lt;/h4&gt;&lt;p&gt;Comparison of Tirofiban and an eluting stent vs. Abciximab + bare metal stent durinf primary PCI in patients with STEMI&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s924&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van den Brand 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s927&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van den Brand M, Laarman GJ, Steg PG, De S, I, Heyndrickx G, Beatt K, et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. European Heart Journal 1999;20(21):1572-8.&lt;/h4&gt;&lt;p&gt;Substudy of the CAPTURE trial&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s929&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van den Merkhof 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s932&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van den Merkhof LF, Zijlstra F, Olsson H, Grip L, Veen G, Bar FW, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. Journal of the American College of Cardiology 1999;33(6):1528-32.&lt;/h4&gt;&lt;p&gt;Study on the TIMI perffusion grade of 60 patients with STEMI treated with Abciximab in the emergency department. Not a RCT&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s934&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wong 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s937&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wong P, Harding S, Inglessis I, Choi CJ, Walters D, Chang Y, et al. The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study. Journal of Thrombosis &amp;amp; Thrombolysis 2003;16:163-6.&lt;/h4&gt;&lt;p&gt;M528. Small study (n=32) on the coronary flow reserve before and after stenting in patients receiving Tirofiban vs. control. No data on clinical events&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s939&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zajdel 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s942&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zajdel W, Zalewski J, Czunko P, et al. Randomised trial assessing efficacy and safety of cornaroplasty in coronary arteries of reference size of &amp;lt; 2,9 mm with the use of integrillin - eptifibatide -- preliminary results. Kardiologia Polska 2002;57:II-166.&lt;/h4&gt;&lt;p&gt;C351. Abstract from a congress&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s944&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zeymer 2008&lt;/h3&gt;&lt;p&gt;2013&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s947&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zeymer U. Eptifibatide versus abciximab in primary PCI for acute St-elevation myocardial infarction: EVA-AMI Study. Clinical research in cardiology 2008;97(1):2-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s949&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zhao 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s952&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation 1999;100(15):1609-15.&lt;/h4&gt;&lt;p&gt;Substudy of the PRISM PLUS trial&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s31&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s954&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gasior 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s957&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gasior M, Piegza J, Dziobek B, Wasilewski J, Lekston A, Zebik T, Gierlotka M, Polo&amp;#324;ski L. Stenting in chronic total occlusion of left anterior descending artery. Randomised comparison of the impact of adjunctive abciximab therapy on immediate and long-term results [Angioplastyka przewleklego zamkni&amp;#234;cia gal&amp;#234;zimi&amp;#234;dzykomorowej przedniej z uzyciem stentu. Badanie por&amp;#243;wnawcze oceniajace wplyw zastosowania abciximabu na wyniki wczesne i odlegle]. Folia Cardiologica 2003;10(3):279-87.&lt;/h4&gt;&lt;p&gt;Gasior M, Piegza J, Dziobek B, et al. Stenting in chronic total occlusion of left anterior descending artery. Randomised comparison of the impact of adjunctive abciximab therapy on immediate and long-term results. Folia Cardiologica 2003;10:279-287.&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s32&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s33&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other references&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s34&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional references&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s959&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ACCF/AHA Guideline NSTEACS 2012&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s961&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ACCF/AHA Guideline revascularization 2012&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s963&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Als-Nielsen 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s965&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ATC 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s967&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Boersma 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s969&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Boersma 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s971&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bovill 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s973&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CRUSADE 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s975&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CURE 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s977&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Luca 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s979&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ESC 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s982&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ESC Guidelines CV Prevention 2012&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s984&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ESC Guidelines NSTEACS 2011&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s986&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ESC Guidelines revascularization 2010&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s988&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Falk 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s990&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;GRACE 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s992&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gurbel 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s994&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Higgins 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s996&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hochholzer 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s998&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mehta 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1000&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NICE 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1002&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;OASIS-5 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1004&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Patrono 2011&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1006&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PCI-CURE 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1008&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Phillips 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1010&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;PLATO 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1012&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Quinn 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1014&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;TRITON TIMI-38 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s35&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other published versions of this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s36&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Classification pending references&lt;/h2&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s40&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data and analyses&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1178&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 During PCI (all patients)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1179&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1180&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.1 Blinded studies with a placebo group&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1209&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.2 No blinded studies and without placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1225&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.1 Blinded studies with a placebo group&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1247&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.2 No blinded studies and without placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1262&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3.1 Blinded studies with a placebo group&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1292&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3.2 No blinded studies and without placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1309&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1310&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4.1 Blinded studies with a placebo group&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1331&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4.2 No blinded studies and without placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1346&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.5 30-day urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1390&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.6 6-month urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1424&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.7 30-day mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1466&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.8 6-month mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1500&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.9 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1501&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.9.1 Blinded studies with a placebo group&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1529&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.9.2 No blinded studies and without placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1543&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Subgroup of PCI in patients with stable CAD&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1544&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1560&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1573&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1589&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1602&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.5 30-day urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1617&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.6 6-month urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1630&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.7 30-day mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1645&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.8 6-month mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1658&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.9 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1675&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 Subgroup of PCI in patients with NSTEACS&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1676&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1685&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1693&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1703&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1711&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.5 30-day urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1719&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.6 6-month urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1727&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.7 30-day mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1734&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.8 6-month mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1741&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.9 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1749&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4 Subgroup of primary PCI in patients with STEMI&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1750&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1761&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1772&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1783&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1794&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.5 30-day urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1805&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.6 6-month urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1816&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.7 30-day mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1827&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.8 6-month mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1838&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.9 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1850&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5 Subgroup of balloon angioplasty&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1851&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1864&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1870&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1883&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1889&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.5 30-day urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1902&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.6 6-month urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1908&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.7 30-day mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1921&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.8 6-month mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1928&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.9 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1940&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6 Subgroup of stent implantation&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1941&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1971&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1998&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2029&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2056&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.5 30-day urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2084&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.6 6-month urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2110&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.7 30-day mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2137&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.8 6-month mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2163&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.9 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2192&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7 Subgroup of PCI in patients pre-treated with clopidogrel&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2193&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2194&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.1.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2202&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.1.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2209&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.2.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2219&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.2.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2227&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2242&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2243&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.4.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2252&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.4.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2259&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.5 30-day urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2260&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.5.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2267&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.5.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2273&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.6 6-month urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2274&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.6.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2283&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.6.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2289&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.7 30-day mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2290&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.7.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.7.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.8 6-month mortality, myocardial infarction or urgent revascularisation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2304&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.8.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2312&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.8.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2319&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.9 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2320&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.9.1 Patients with ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2328&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.9.2 Patients without ACS&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2336&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8 As initial medical treatment in patients with NSTEACS&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2337&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.1 30-day mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2351&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.2 6-month mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2358&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.3 30-day mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2372&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.4 6-month mortality or myocardial infarction&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2380&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.5 30-day major bleeding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s37&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figures&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2886&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 1&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2887&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 2&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2888&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 3&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2889&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 4 (Analysis 1.1)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2890&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 5 (Analysis 1.2)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2891&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 6 (Analysis 1.3)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2892&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 7 (Analysis 1.9)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s12&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sources of support&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s13&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Internal sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s55&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;University of Barcelona, Spain&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s56&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Institut d&amp;#8217;Investigacions Biom&amp;#232;diques August Pi i Sunyer (IDIBAPS), Not specified&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s57&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Institut Municipal d'Investigacio Medica, Barcelona, Spain&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s14&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;External sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s58&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FIS PI050120, Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Spain&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s59&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FIS PI07/0640, Spain&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s60&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Red HERACLES RD06/0009, Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Spain&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s61&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;EUPHORIC Project (Ref. 2003/134), Not specified&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s38&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feedback&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s17&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendices&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2893&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Search strategies for 2013 update&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14692&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14692&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14694&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14694&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2894&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Search strategies for 2010 update&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14697&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14697&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14699&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14699&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2895&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 Search strategies for 2007 update&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14702&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14702&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14704&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14704&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2896&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4 MEDLINE search strategy for original review (2001)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14707&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14707&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 id=&quot;f14709&quot; readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;f14709&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 16:46:03 +0530" NOTES_MODIFIED_BY="[Empty name]">
<P>1 Clinical trial/ or Phase 1 clinical trial/ or Phase 2<BR/>clinical trial/ or Phase 3 clinical trial/ or Phase 4<BR/>clinical trial/ or Randomized controlled trial/<BR/>2 Randomization/<BR/>3 Double blind procedure/ or Meta analysis/ or Single blind<BR/>procedure/<BR/>4 exp controlled study/<BR/>5 Placebo/<BR/>6 ["150".tg.]<BR/>7 ["197".tg.]<BR/>8 (clinic$ adj10 trial).ti,ab.<BR/>9 (clinic$ adj10 trial$).ti,ab.<BR/>10 (controlled adj trial$).ti,ab.<BR/>11 ((singl$ or doubl$ or trebl$ or tripl$) adj10 (blind$ or<BR/>mask$)).ti,ab.<BR/>12 (placebo$ or random$).ti,ab.<BR/>13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 9 or 10 or 11 or 12<BR/>14 limit 13 to human<BR/>15 ("glycoprotein IIb/IIIa" or "glycoprotein IIb-IIIa" or "glycoprotein-IIb/IIIa" or "Platelet IIb/IIIa" or "GP IIb-IIIa" or "GP IIb/IIIa" or "IIb" or "IIIa").mp. [mp=Title, Abstract, registry number word, mesh subject heading]<BR/>16 (Abciximab or 7E3 or Sibrafiban or Tirofiban or MK-383 or lamifiban or Aggrastat or Eptifibatide or Xemilofiban or Sibrafiban or Orbofiban or Lefradafiban or Integrilin or Integrelin or Fradafiban or Lefradafiban).mp. [mp=Title, Abstract, registry number word, mesh subject heading]<BR/>17 (Inhibitor$ or block$ or antagonist$).mp. [mp=Title, Abstract, registry number word, mesh subject heading]<BR/>18 14 and (15 or 16) and 17</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;60 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;1. During PCI: 48&lt;/p&gt;&lt;p&gt;2. Initial medical treatment of NSTEACS: 12&lt;/p&gt;" WIDTH="290">
<FLOWCHARTBOX TEXT="&lt;p&gt;60 studies included in qualitative synthesis (81 references)&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;184 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;4106 records screened&lt;/p&gt;" WIDTH="90">
<OUT TEXT="&lt;p&gt;3922 records excluded on the basis of title and abstract&lt;/p&gt;" WIDTH="160"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;102 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;Not a RCT: 10&lt;/p&gt;&lt;p&gt;Substudy of a RCT: 24&lt;/p&gt;&lt;p&gt;No appropriate control: 12&lt;/p&gt;&lt;p&gt;No clinical events reported: 15&lt;/p&gt;&lt;p&gt;Oral GP IIb/IIIa blocker: 7&lt;/p&gt;&lt;p&gt;Facilitated thrombolysis: 10&lt;/p&gt;&lt;p&gt;Rescue PCI: 2&lt;/p&gt;&lt;p&gt;Comparing different timing: 15&lt;/p&gt;&lt;p&gt;Comparing different agents: 7&lt;/p&gt;&lt;p&gt;Comparing different doses: 1&lt;/p&gt;" WIDTH="270"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>